[
  {
    "spl_product_data_elements": [
      "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE norethindrone acetate and ethinyl estradiol and ferrous fumarate NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL .ALPHA.-TOCOPHEROL, DL- ANHYDROUS LACTOSE MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K25 White to Off-White 242 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL .ALPHA.-TOCOPHEROL, DL- ANHYDROUS LACTOSE MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM FD&C BLUE NO. 1 FD&C BLUE NO. 2 LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K25 Light Purple 243 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL .ALPHA.-TOCOPHEROL, DL- ANHYDROUS LACTOSE MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM FD&C BLUE NO. 1 FD&C BLUE NO. 2 LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K25 244 FERROUS FUMARATE ferrous fumarate MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM FERROUS FUMARATE LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K90 SILICON DIOXIDE 291"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS: Cigarette smoking increases the risk of serious cardiovascular side effects from combined oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke."
    ],
    "spl_unclassified_section": [
      "Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Each white to off white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol; each light purple tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; each purple tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol; each brown tablet contains 75 mg ferrous fumarate. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases."
    ],
    "description": [
      "DESCRIPTION Norethindrone acetate and ethinyl estradiol tablets are graduated estrophasic combined oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets provide for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each white to off white tablet contains 1 mg norethindrone acetate [(17 alpha)- 17-(acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)- 19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each light purple tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each purple tablet contains 1 mg norethindrone acetate, 35 mcg ethinyl estradiol. Norethindrone acetate and ethinyl estradiol tablets (1 mg and 20 mcg) also contain: Lactose anhydrous, lactose monohydrate, povidone K-25, dl-\u03b1-tocopherol, magnesium stearate, microcrystalline cellulose, croscarmellose sodium. Norethindrone acetate and ethinyl estradiol tablets (1 mg and 30 mcg) also contain: Lactose anhydrous, lactose monohydrate, povidone K-25, dl-\u03b1-tocopherol, magnesium stearate, microcrystalline cellulose, croscarmellose sodium, aluminium lake of FD and C Blue No. 1, aluminium lake of FD and C Blue No. 2, caramine. Norethindrone acetate and ethinyl estradiol tablets (1 mg and 35 mcg) also contain: Lactose anhydrous, lactose monohydrate, povidone K-25, dl-\u03b1-tocopherol, magnesium stearate, microcrystalline cellulose, croscarmellose sodium, aluminium lake of FD and C Blue No. 1, aluminium lake of FD and C Blue No. 2, caramine. The structural formulas are as follows: Each brown tablet contains ferrous fumarate, microcrystalline cellulose, lactose monohydrate, polyvinyl pyrrolidone K-90, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate. Each norethindrone acetate and ethinyl estradiol tablet and ferrous fumarate tablet blister contains five white to off white tablets, seven light purple tablets, nine purple tablets, and seven brown tablets. These tablets are to be taken in the following order: one white to off white each day for five days, then light purple tablet each day for seven days, followed by one purple tablet each day for nine days, and then one brown tablet each day for seven days. Structural Formula"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY ORAL CONTRACEPTION Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). In vitro and animal studies have shown that norethindrone combines high progestational activity with low intrinsic androgenicity. In humans, norethindrone acetate in combination with ethinyl estradiol does not counteract estrogen-induced increases in sex hormone binding globulin (SHBG). Following multiple-dose administration of norethindrone acetate and ethinyl estradiol tablets, serum SHBG concentrations increase two- to three-fold and free testosterone concentrations decrease by 47% to 64%, indicating minimal androgenic activity. ACNE Acne is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. While the combination of norethindrone acetate and ethinyl estradiol increases sex hormone binding globulin (SHBG) and decreases free testosterone, the relationship between these changes and a decrease in the severity of facial acne in otherwise healthy women with this skin condition has not been established. Pharmacokinetics Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed, with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring 1 to 2 hours post-dose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. Administration of norethindrone acetate and ethinyl estradiol with a high fat meal decreases rate, but not extent, of ethinyl estradiol absorption. The extent of norethindrone absorption is increased by 27% following administration with food. Plasma concentrations of norethindrone and ethinyl estradiol following chronic administration of norethindrone acetate and ethinyl estradiol tablets to 17 women are shown below (Figure 1). Mean steady-state concentrations of norethindrone for the 1/20, 1/30, and 1/35 tablet strengths increased as ethinyl estradiol dose increased over the 21-day dose regimen, due to dose-dependent effects of ethinyl estradiol on serum SHBG concentrations (Table 1). Mean steady-state plasma concentrations of ethinyl estradiol for the 1/20, 1/30, and 1/35 tablet strengths were proportional to ethinyl estradiol dose (Table 1). Figure 1. Mean Steady-State Plasma Ethinyl Estradiol and Norethindrone Concentrations Following Chronic Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets Table 1. Mean (SD) Steady-State Pharmacokinetic Parameters Following Chronic Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets * Norethindrone Acetate / Ethinyl Estradiol Dose Cycle Day Cmax AUC CL/F SHBG \u2020 Norethindrone mg/\u00b5g ng/mL ng\u00b7hr/mL mL/min nmol/L 1/20 5 10.8 (3.9) 81.1 (28.5) 220 (137) 120 (33) 1/30 12 12.7 (4.1) 102 (32) 166 (85) 139 (42) 1/35 21 12.7 (4.1) 109 (32) 152 (73) 163 (40) Ethinyl Estradiol mg/\u00b5g pg/mL pg\u00b7hr/mL mL/min nmol/L 1/20 5 61.0 (16.8) 661 (190) 549 (171) 1/30 12 92.4 (26.9) 973 (293) 546 (199) 1/35 21 113 (44) 1149 (372) 568 (219) * Cmax = Maximum plasma concentration; AUC (0-24) = Area under the plasma concentration-time curve over the dosing interval; CL/F = Apparent oral clearance \u2020 Mean (SD) baseline value = 55 (29) nmol/L No age-related differences were seen in plasma concentrations of ethinyl estradiol and norethindrone following administration of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets to 119 postmenarchal women ages 15 to 48 years. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (> 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets increase serum SHBG concentrations two- to three-fold (Table 1). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are approximately 13 hours and 19 hours, respectively. Concentrations SPECIAL POPULATION Race The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of a combined oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function. Drug-Drug Interactions Numerous drug-drug interactions have been reported for combined oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions ."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"100%\"><caption>Table 1. Mean (SD) Steady-State Pharmacokinetic Parameters Following Chronic Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets<sup>*</sup></caption><col width=\"34%\"/><col width=\"11%\"/><col width=\"19%\"/><col width=\"13%\"/><col width=\"12%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Norethindrone Acetate / Ethinyl Estradiol Dose </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cycle Day </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cmax </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">AUC </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">CL/F </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">SHBG<sup>&#x2020;</sup> </content></paragraph></td></tr><tr><td styleCode=\"Lrule Botrule\" valign=\"top\"/><td styleCode=\"Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Norethindrone</content> </paragraph></td><td styleCode=\"Botrule\" valign=\"top\"/><td styleCode=\"Botrule\" valign=\"top\"/><td styleCode=\"Rrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>mg/&#xB5;g </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>ng/mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>ng&#xB7;hr/mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>mL/min </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>nmol/L </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1/20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>10.8 (3.9) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>81.1 (28.5) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>220 (137) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>120 (33) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1/30 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>12 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>12.7 (4.1) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>102 (32) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>166 (85) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>139 (42) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1/35 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>21 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>12.7 (4.1) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>109 (32) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>152 (73) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>163 (40) </paragraph></td></tr><tr><td styleCode=\"Lrule Botrule\" valign=\"top\"/><td styleCode=\"Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Ethinyl Estradiol</content> </paragraph></td><td styleCode=\"Botrule\" valign=\"top\"/><td styleCode=\"Botrule\" valign=\"top\"/><td styleCode=\"Rrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>mg/&#xB5;g </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>pg/mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>pg&#xB7;hr/mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>mL/min </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>nmol/L </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1/20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>61.0 (16.8) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>661 (190) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>549 (171) </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1/30 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>12 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>92.4 (26.9) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>973 (293) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>546 (199) </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1/35 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>21 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>113 (44) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1149 (372) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>568 (219) </paragraph></td><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"/></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "Pharmacokinetics"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the treatment of moderate acne vulgaris in females, \u2265 15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be used for the treatment of acne only if the patient desires a combined oral contraceptive for birth control and plans to stay on it for at least 6 months. Combined oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2. Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. Emergency Contraceptives Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. \u00e8 Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. \u00f0 Source: Trussell J, The Essentials of Contraception. In Hatcher RA, Trussell J, Stewart F, Cates W, Stweart GK, Kowel D, Guest F, Contraceptive Technology : Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year \u2021 Method (1) Typical Use * (2) Perfect Use \u2020 (3) (4) Chance \u00a7 85 85 Spermicides \u00b6 26 6 40 Periodic Abstinence 25 63 Calendar 9 Ovulation Method 3 Symptothermal #\u00de 2 Post-ovulation 1 Cap \u00df Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm \u00df 20 6 56 Withdrawal 19 4 Condom \u00e0 Female (Reality \u00ae ) 21 5 56 Male 14 3 61 Pill 5 71 Progestin only 0.5 Combined 0.1 IUD Progesterone T 2.0 1.5 81 Copper T380A 0.8 0.6 78 LNG 20 0.1 0.1 81 Depo-Provera \u00ae 0.3 0.3 70 Norplant \u00ae and Norplant-2 \u00ae 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 \u2021 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year. * Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. \u2020 Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. \u00a7 The percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. \u00b6 Foams, creams, gels, vaginal suppositories, and vaginal film. #\u00de Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. \u00df With spermicidal cream or jelly. \u00e0 Without spermicides. \u00e8 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of combined oral contraceptives to be safe and effective for emergency contraception: Ovral (1 dose is 2 white pills), Alesse \u00ae (1 dose is 5 pink pills), Nordette \u00ae or Levlen \u00ae (1 dose is 4 light-orange pills), Lo/Ovral \u00ae (1 dose is 4 white pills), Triphasil \u00ae or Tri-Levlen \u00ae (1 dose is 4 yellow pills). \u00f0 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28-day) cycle studies. A total of 296 patients received norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and 295 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator\u2019s global evaluation. Patients with severe androgen excess were not studied. Table 3. Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline*Intent To Treat Population Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets N=296 Placebo N=295 Difference in Counts Between Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets and Placebo at Six Months (95% CI) \u2020 Number of Lesions Counts % reduction Counts % reduction INFLAMMATORY LESIONS Baseline Mean 29 29 Six Month Mean 14 52% 17 41% 3 (\u00b12) NON-INFLAMMATORY LESIONS Baseline Mean 44 43 Six Month Mean 27 38% 32 25% 5 (\u00b13.5) TOTAL LESIONS Baseline Mean 74 72 Six Month Mean 42 43% 49 32% 7 (\u00b15) *Numbers rounded to nearest integer \u2020 Limits for 95% Confidence Interval; not adjusted for baseline differences Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment. Figure 2. Mean Percent Reduction in Total Lesion Counts From Baseline to Each 28-Day Cycle and Mean Total Lesion Counts at Each Cycle Following Administration of Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and Placebo (Statistically significant differences were not found in both studies individually until cycle 6) Figure 2. Mean Percent Reduction in Total Lesion Counts From Baseline to Each 28-Day Cycle and Mean Total Lesion Counts at Each Cycle Following Administration of Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and Placebo (Statistically significant differences were not found in both studies individually until cycle 6)"
    ],
    "indications_and_usage_table": [
      "<table width=\"100%\"><caption>Table 2. Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States.</caption><col width=\"16%\"/><col width=\"27%\"/><col width=\"27%\"/><col width=\"29%\"/><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">Emergency Contraceptives Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.<sup>&#xE8;</sup></td></tr><tr><td align=\"left\" colspan=\"4\" valign=\"top\">Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.<sup> &#xF0;</sup></td></tr><tr><td align=\"left\" colspan=\"4\" valign=\"top\">Source: Trussell J, The Essentials of Contraception. In Hatcher RA, Trussell J, Stewart F, Cates W, Stweart GK, Kowel D, Guest F, <content styleCode=\"underline\">Contraceptive Technology</content>: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998.</td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"/><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>% of Women Experiencing an Unintended Pregnancy within the First Year of Use </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>% of Women Continuing Use at One Year<sup>&#x2021;</sup> </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Method (1) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Typical Use<sup>*</sup> (2) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Perfect Use<sup>&#x2020;</sup> (3) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph> (4) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Chance<sup>&#xA7;</sup> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>85 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>85 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides<sup>&#xB6;</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Periodic Abstinence </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>25 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>63 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Calendar </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Ovulation Method </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Symptothermal<sup>#&#xDE;</sup> </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Post-ovulation </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Cap<sup>&#xDF;</sup> </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Parous Women </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>42 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Nulliparous Women </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>56 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Sponge </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Parous Women </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>42 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Nulliparous Women </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>56 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm<sup>&#xDF;</sup> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>56 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Withdrawal </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>19 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>4 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom<sup>&#xE0;</sup> </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Female (Reality<sup>&#xAE;</sup>) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>21 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>56 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Male </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>14 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>61 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Pill </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>5 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>71 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Progestin only </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Combined </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1 </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Progesterone T </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>81 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Copper T380A </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>78 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> LNG 20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>81 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Depo-Provera<sup>&#xAE;</sup> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>70 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Norplant<sup>&#xAE; </sup>and  Norplant-2<sup>&#xAE;</sup> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> 0.05 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> 0.05 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> 88 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Female Sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>100 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Male Sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.15 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.10 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>100 </paragraph></td></tr></tbody></table>",
      "<table width=\"463.9pt\"><caption>Table 3. Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline*Intent To Treat Population </caption><col width=\"16%\"/><col width=\"21%\"/><col width=\"9%\"/><col width=\"12%\"/><col width=\"9%\"/><col width=\"11%\"/><col width=\"19%\"/><tbody><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"/><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets</paragraph><paragraph>N=296</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Placebo</paragraph><paragraph>N=295</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Difference in Counts</paragraph><paragraph>Between Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets and Placebo at Six Months (95% CI)<sup> &#x2020;</sup></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Number of Lesions</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Counts</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>% reduction</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Counts</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>% reduction</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>INFLAMMATORY LESIONS</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> Baseline Mean </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>29</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>29</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Six Month Mean</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>52%</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>41%</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>3 (&#xB1;2)</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>NON-INFLAMMATORY LESIONS</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Baseline Mean </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>44</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>43</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Six Month Mean</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>38%</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>25%</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>5 (&#xB1;3.5)</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>TOTAL LESIONS</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Baseline Mean </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>74</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>72</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"/><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Six Month Mean</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>43%</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>32%</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>7 (&#xB1;5)</paragraph></td></tr></tbody></table>"
    ],
    "contraindications": [
      "CONTRAINDICATIONS Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in females who are known to have or develop the following conditions: \u2022 A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: \u2022 Smoke, if over age 35 \u2022 Have cerebrovascular disease \u2022 Have coronary artery disease \u2022 Have current or history of deep vein thrombosis or pulmonary embolism \u2022 Have thrombogenic valvular or thrombogenic rhythm diseases of the heart \u2022 Have inherited or acquired hypercoagulopathies \u2022 Have uncontrolled hypertension or hypertension with vascular disease \u2022 Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches \u2022 Have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or with vascular disease or end-organ damage, or diabetes mellitus of > 20 years duration \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive \u2022 Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \u2022 Undiagnosed abnormal genital bleeding \u2022 Cholestatic jaundice of pregnancy or jaundice with prior pill use \u2022 Hepatic adenomas or carcinomas \u2022 Known or suspected pregnancy \u2022 Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT )."
    ],
    "warnings": [
      "WARNINGS The use of combined oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing combined oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used combined oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the combined oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among combined oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between combined oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author's permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial infarction An increased risk of myocardial infarction has been attributed to combined oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current combined oral contraceptive users has been estimated to be two to six. The risk is very low under the age of 30. Smoking in combination with combined oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases. Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Figure 3) among women who use combined oral contraceptives. Figure 3. Circulatory Disease Mortality Rates per 100,000 Woman Years by Age, Smoking Status and Combined Oral Contraceptive Use Adapted from P.M. Layde and V. Beral Combined oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity. In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism. Combined oral contraceptives have been shown to increase blood pressure among users (see Section 10 in WARNINGS ). Similar effects on risk factors have been associated with an increased risk of heart disease. Combined oral contraceptives must be used with caution in women with cardiovascular disease risk factors. Figure 3. Circulatory Disease Mortality Rates per 100,000 Woman Years by Age, Smoking Status and Oral Contraceptive Use b. Thromboembolism An increased risk of thromboembolic and thrombotic disease associated with the use of combined oral contraceptives is well established. Case control studies have found the relative risk of users compared to nonusers to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease. Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization. The risk of thromboembolic disease due to combined oral contraceptives is not related to length of use and disappears after combined oral contraceptive pill use is stopped. A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of combined oral contraceptives. The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions. If feasible, combined oral contraceptives should be discontinued at least 4 weeks prior to and for 2 weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, combined oral contraceptives should be started no earlier than 4 to 6 weeks after delivery in women who elect not to breastfeed. c. Cerebrovascular disease Combined oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (> 35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes. In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension. The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used combined oral contraceptives, 2.6 for smokers who did not use combined oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension. The attributable risk is also greater in older women. d. Dose-related risk of vascular disease from combined oral contraceptives A positive association has been observed between the amount of estrogen and progestogen in combined oral contraceptives and the risk of vascular disease. A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents. A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of a combined oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of a combined oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular combined oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of combined oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. e. Persistence of risk of vascular disease There are two studies which have shown persistence of risk of vascular disease for ever-users of combined oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing combined oral contraceptives persists for at least 9 years for women 40-49 years who had used combined oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups. In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of combined oral contraceptives, although excess risk was very small. However, both studies were performed with combined oral contraceptive formulations containing 50 mcg or higher of estrogens. 2. Estimates of Mortality from Combined Oral Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table 4). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of combined oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for combined oral contraceptive users is based on data gathered in the 1970\u2019s but not reported until 1983. However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of combined oral contraceptive use to women who do not have the various risk factors listed in this labeling. Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of combined oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4; and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with combined oral contraceptive use after age 40 in healthy nonsmoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. Therefore, the Committee recommended that the benefits of combined oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take combined oral contraceptives, should take the lowest possible dose formulation that is effective. Table 4. Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility Per 100,000 Nonsterile Women by Fertility Control Method According to Age Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods* 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker** 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker** 2.2 3.4 6.6 13.5 51.1 117.2 IUD** 0.8 0.8 1.0 1.0 1.4 1.4 Condom* 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide* 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence* 2.5 1.6 1.6 1.7 2.9 3.6 ** Deaths are method-related. Adapted from H.W. Ory, Reference 41. 3. Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see Contraindications ) . Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see Post Marketing Experience) . Cervical Cancer Some studies suggest that combined oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. 4. Hepatic Neoplasia Benign hepatic adenomas are associated with combined oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after 4 or more years of use. Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage. Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) combined oral contraceptive users. However, these cancers are extremely rare in the US, and the attributable risk (the excess incidence) of liver cancers in combined oral contraceptive users approaches less than one per million users. 5. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see Contraindications ). Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of combined oral contraceptives. Combined oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. Oral Contraceptive Use Before and During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used combined oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned, when taken inadvertently during early pregnancy. The administration of combined oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Combined oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Combined oral contraceptive use should be discontinued if pregnancy is confirmed. 8. Gallbladder Disease Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of combined oral contraceptives and estrogens. More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal. The recent findings of minimal risk may be related to the use of combined oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. Carbohydrate and Lipid Metabolic Effects Combined oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users. Combined oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance. Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents. However, in the non-diabetic woman, combined oral contraceptives appear to have no effect on fasting blood glucose. Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking combined oral contraceptives. A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a. and 1d. ), changes in serum triglycerides and lipoprotein levels have been reported in combined oral contraceptive users. 10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking combined oral contraceptives and this increase is more likely in older combined oral contraceptive users and with continued use. Data from the Royal College of General Practitioners and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal disease should be encouraged to use another method of contraception. If women elect to use combined oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, combined oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping combined oral contraceptives, and there is no difference in the occurrence of hypertension among ever and never users. 11. Headache The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of combined oral contraceptives and evaluation of the cause. 12. Bleeding Irregularities Breakthrough bleeding and spotting are sometimes encountered in patients on combined oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of prolonged breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. 13. Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 14. Chloasma Chloasma may occur with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, especially in women with a history of chloasma gravidarum. Advise women with a history of chloasma to avoid exposure to the sun or ultraviolet radiation while taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets."
    ],
    "warnings_table": [
      "<table width=\"102%\"><caption>Table 4. Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility Per 100,000 Nonsterile Women by Fertility Control Method According to Age</caption><col width=\"32%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">15-19 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">20-24 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">25-29 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">30-34 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">35-39 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">40-44 </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>No fertility control methods* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>9.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>14.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>25.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>28.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives non-smoker** </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>31.6 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives smoker** </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>3.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>6.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>51.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>117.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD** </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm/spermicide* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.8 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Periodic abstinence* </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>3.6 </paragraph></td></tr></tbody></table>"
    ],
    "precautions": [
      "PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. 2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using combined oral contraceptives. The physical examination, however, may be deferred until after initiation of combined oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. 3. Lipid Disorders Women who are being treated for hyperlipidemia should be followed closely if they elect to use combined oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. 4. Liver Function If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function. 5. Fluid Retention Combined oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. 6. Emotional Disorders Women with a history of depression should be carefully observed and the drug discontinued if depression recurs to a serious degree. 7. Contact Lenses Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 8. Drug Interactions Effects of Other Drugs on Combined Oral Contraceptives Rifampin: Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants: Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Antibiotics: Pregnancy while taking combined oral contraceptives has been reported when the combined oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin: Coadministration of atorvastatin and an combined oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. St. John\u2019s Wort: Herbal products containing St. John\u2019s Wort (hypericum perforatum) may induce hepatic enzymes (cytochrome P450) and p-glycoprotein transporter and may reduce the effectiveness of combined oral contraceptives. This may also result in breakthrough bleeding. Human immunodeficiency virus (HIV)/Hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors Significant changes (increase or decrease) in the plasma concentrations of estrogen and progestin have been noted in some cases of co-administration with HIV/HCV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors (decrease [e.g., boceprevir and telaprevir]) or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]). Concomitant Use with HCV Combination Therapy \u2013 Liver Enzyme Elevation: Do not co-administer norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Other: Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Combined Oral Contraceptives on Other Drugs COCs containing ethinyl estradiol may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. Significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because the serum concentration of thyroid-binding globulin increase with use of COCs. 9. Interactions with Laboratory Tests Certain endocrine and liver function tests and blood components may be affected by combined oral contraceptives: a. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T 4 by column or by radioimmunoassay. Free T 3 resin uptake is decreased, reflecting the elevated TBG; free T 4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged. e. Triglycerides may be increased. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by combined oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing combined oral contraceptives. 10. Carcinogenesis See WARNINGS section. 11. Pregnancy See CONTRAINDICATIONS and WARNINGS sections. 12. Nursing Mothers Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, combined oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use combined oral contraceptives but to use other forms of contraception until she has completely weaned her child. 13. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated. 14. Geriatric Use This product has not been studied in women over 65 years of age and is not indicated in this population. INFORMATION FOR THE PATIENT See patient labeling printed below."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of combined oral contraceptives (see WARNINGS section): \u2022 Thrombophlebitis \u2022 Arterial thromboembolism \u2022 Pulmonary embolism \u2022 Myocardial infarction \u2022 Cerebral hemorrhage \u2022 Cerebral thrombosis \u2022 Hypertension \u2022 Gallbladder disease \u2022 Hepatic adenomas or benign liver tumors There is evidence of an association between the following conditions and the use of combined oral contraceptives, although additional confirmatory studies are needed: \u2022 Mesenteric thrombosis \u2022 Retinal thrombosis The following adverse reactions have been reported in patients receiving combined oral contraceptives and are believed to be drug-related: \u2022 Nausea \u2022 Vomiting \u2022 Gastrointestinal symptoms (such as abdominal cramps and bloating) \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Temporary infertility after discontinuation of treatment \u2022 Edema \u2022 Melasma which may persist \u2022 Breast changes: tenderness, enlargement, secretion \u2022 Change in weight (increase or decrease) \u2022 Change in cervical erosion and secretion \u2022 Diminution in lactation when given immediately postpartum \u2022 Cholestatic jaundice \u2022 Migraine \u2022 Rash (allergic) \u2022 Mental depression \u2022 Mood swings \u2022 Reduced tolerance to carbohydrates \u2022 Vaginal candidiasis \u2022 Change in corneal curvature (steepening) \u2022 Intolerance to contact lenses The following adverse reactions have been reported in users of combined oral contraceptives and the association has been neither confirmed nor refuted: \u2022 Pre-menstrual syndrome \u2022 Cataracts \u2022 Changes in appetite \u2022 Cystitis-like syndrome \u2022 Headache \u2022 Nervousness \u2022 Dizziness \u2022 Hirsutism \u2022 Loss of scalp hair \u2022 Erythema multiforme \u2022 Erythema nodosum \u2022 Hemorrhagic eruption \u2022 Vaginitis \u2022 Porphyria \u2022 Impaired renal function \u2022 Hemolytic uremic syndrome \u2022 Budd-Chiari syndrome \u2022 Acne \u2022 Changes in libido \u2022 Colitis Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 4). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 4). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use. Figure 4. Risk of Breast Cancer with Combined Oral Contraceptive Use RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. Figure 4. Risk of Breast Cancer with Combined Oral Contraceptive Use"
    ],
    "overdosage": [
      "OVERDOSAGE Serious ill effects have not been reported following acute ingestion of large doses of combined oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females. NON-CONTRACEPTIVE HEALTH BENEFITS The following non-contraceptive health benefits related to the use of combined oral contraceptives are supported by epidemiological studies which largely utilized combined oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol. Effects on menses: \u2022 Increased menstrual cycle regularity \u2022 Decreased blood loss and decreased incidence of iron deficiency anemia \u2022 Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation: \u2022 Decreased incidence of functional ovarian cysts \u2022 Decreased incidence of ectopic pregnancies Effects from long-term use: \u2022 Decreased incidence of fibroadenomas and fibrocystic disease of the breast \u2022 Decreased incidence of acute pelvic inflammatory disease \u2022 Decreased incidence of endometrial cancer Decreased incidence of ovarian cancer"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION The tablet blister has been designed to make norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the tablet blister above the first row of tablets. Note: Each tablet blister has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days. Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen. The possibility of ovulation and conception prior to initiation of use should be considered. Dosage and Administration for 28-Day Dosage Regimen To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken exactly as directed and at intervals not exceeding 24 hours. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets provide a continuous administration regimen. These tablets are to be taken in the following order: one white to off white each day for five days, then light purple tablet each day for seven days, followed by one purple tablet each day for nine days, and then one brown non-hormone tablet each day for seven days. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen and do not serve any therapeutic purpose. There is no need for the patient to count days between cycles because there are no \u201coff-tablet days\u201d. A. Sunday-Start Regimen: The patient begins taking the first white to off white tablet from the top row of the blister (labeled Sunday) on the first Sunday after menstrual flow begins. When menstrual flow begins on Sunday, the first white to off white tablet is taken on the same day. The patient takes one white to off white tablet daily for 5 days. The last purple tablet in the blister will be taken on a Saturday. Upon completion of all 21 tablets, and without interruption, the patient takes one brown tablet daily for 7 days. Upon completion of this first course of tablets, the patient begins a second course of 28-day tablets, without interruption, the next day (Sunday), starting with the Sunday white to off white tablet in the top row. Adhering to this regimen of one tablet daily for 21 days, followed without interruption by one brown tablet daily for 7 days, the patient will start all subsequent cycles on a Sunday. B. Day-1 Start Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the tablet blister. She starts taking one tablet daily, beginning with the first white to off white tablet in the top row. After the last purple tablet (at the end of the third row) has been taken, the patient will then take the brown tablets for a week (7 days). For all subsequent cycles, the patient begins a new 28 tablet regimen on the eighth day after taking her last purple tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the tablet blister. Following this regimen of 21 tablets and 7 brown tablets, the patient will start all subsequent cycles on the same day of the week as the first course. Tablets should be taken regularly at the same time each day and can be taken without regard to meals. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule. Special Notes on Administration Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after the brown tablets have been started. In any event, the next course of tablets should be started without interruption. If spotting occurs while the patient is taking white to off white tablets, continue medication without interruption. If the patient forgets to take one or more active tablets, the following is suggested: One tablet is missed \u2022 take tablet as soon as remembered \u2022 take next tablet at the regular time Two consecutive tablets are missed (Week 1 or Week 2) \u2022 take two tablets as soon as remembered \u2022 take two tablets the next day \u2022 use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (Week 3) Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets The possibility of ovulation occurring increases with each successive day that scheduled active tablets are missed. While there is little likelihood of ovulation occurring if only one active tablet is missed, the possibility of spotting or bleeding is increased. This is particularly likely to occur if two or more consecutive active tablets are missed. If the patient forgets to take any of the seven brown tablets in week four, those brown tablets that were missed are discarded and one brown tablet is taken each day until the pack is empty. A back-up birth control method is not required during this time. A new pack of tablets should be started no later than the eighth day after the last active tablet was taken. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet blister on the next Sunday or the first day (Day 1) depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered. Use of Combined Oral Contraceptives in the Event of a Missed Menstrual Period 1. If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and combined oral contraceptives should be withheld until pregnancy has been ruled out. 2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy. Acne The timing of initiation of dosing with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets for acne should follow the guidelines for use of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets as a combined oral contraceptive. Consult the DOSAGE AND ADMINISTRATION section for norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets oral contraceptives."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets are available in blister packs each containing 28 tablets. The first five white to off white tablets each contain 1 mg of norethindrone acetate and 20 mcg of ethinyl estradiol; the next seven light purple tablets each contain 1 mg of norethindrone acetate and 30 mcg of ethinyl estradiol; the next nine purple tablets each contain 1 mg of norethindrone acetate and 35 mcg of ethinyl estradiol; and the last seven (brown) tablets each contain 75 mg ferrous fumarate. Carton of 3 tri-laminated aluminium pouches (NDC 0378-7303-53), Carton of 6 tri-laminated aluminium pouches (NDC 0378-7303-56) each pouch containing blister of 28 tablets. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP for Controlled Room Temperature.] Protect from light. Store tablets in blister sleeve when not in use. Keep this and all medication out of the reach of children. REFERENCES AVAILABLE UPON REQUEST The brands listed are trademarks of their respective owners."
    ],
    "spl_patient_package_insert": [
      "BRIEF SUMMARY PATIENT PACKAGE INSERT Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (like all oral contraceptives) are intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases. Combined oral contraceptives, also known as \u201cbirth control pills\u201d or \u201cthe pill\u201d, are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women combined oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may also be taken to treat moderate acne in females who are at least 15 years of age, have started having menstrual periods, are able to use the pill and want the pill for birth control, plan to stay on the pill for at least 6 months, and have not improved with acne medicines that are put on the skin. For the majority of women, combined oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you: \u2022 Smoke \u2022 Have high blood pressure, diabetes, high cholesterol, migraine headaches \u2022 Have or have had blood clots in your arm, legs, lungs, or eyes, clotting disorders, heart attack, heart problems, stroke, angina pectoris, cancer of the breast or sex organs, jaundice, or malignant or benign liver tumors. \u2022 Are receiving Hepatitis C medication You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea, vomiting, and breakthrough bleeding, may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill: 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack or angina pectoris), or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences. 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease combined oral contraceptive effectiveness. Do not take the pill if you take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. There may be slight increases in the risk of breast cancer among current users of hormonal birth control pills with longer duration of use of 8 years or more. Some studies have found an increase in the incidence of precancerous lesions of the cervix in women who use combined oral contraceptives. However, this finding may be related to factors other than the use of combined oral contraceptives. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. INSTRUCTIONS TO PATIENT TABLET BLISTER The norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets blister has been designed to make combined oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing above the first row of tablets. Each white to off white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each light purple tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each purple tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn\u2019t go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or spermicide) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK: The pill pack has 21 \u201cactive\u201c pills (with hormones) to take for 3 weeks, followed by 1 week of \u201creminder\u201d brown pills (without hormones). 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following pictures: Each norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets blister contains five white to off white tablets, seven light purple tablets, nine purple tablets, and seven brown tablets. These tablets are to be taken in the following order: one white to off white tablet each day for five days, then one light purple tablet each day for seven days, followed by one purple tablet each day for nine days, and then one brown tablet each day for seven days. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets will contain : 5 WHITE TO OFF WHITE, 7 LIGHT PURPLE, 9 PURPLE PILLS for Weeks 1, 2, and 3. Week 4 will contain BROWN PILLS ONLY . 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or spermicide) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first \"active\" white to off white pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d white to off white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or spermicide are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: 21 pills : Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. 28 pills : Start the next pack on the day after your last \u201creminder\u201d pill. Do not wait any days between packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off white \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off white \u201cactive\u201d pills in a row in Week 1 OR light purple \u201cactive\u201d pills in Week 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills.You MUST use another birth control method (such as condoms or spermicide) as a back-up method of birth control until you have taken a white to off white \u201cactive\u201d pill every day for 7 days. If you MISS 2 purple \u201cactive\u201d pills in a row in THE 3rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or spermicide) as a back-up method of birth control until you have taken a white to off white \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE \u201c active\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 1. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 2. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or spermicide) as a back-up method of birth control until you have taken a white to off white \u201cactive\u201d pill every day for 7 days. REMINDER: IF YOU FORGET ANY OF THE 7 BROWN \u201cREMINDER\u201d PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic. Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP for Controlled Room Temperature.] Protect from light. Store tablets in blister sleeve when not in use. Keep this and all medication out of the reach of children. Rx only Blister DETAILED PATIENT PACKAGE INSERT What is the most important information I should know about norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (like all oral contraceptives) are intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases. What You Should Know About Combined Oral Contraceptives Any woman who considers using oral contraceptives (the \u201cbirth control pill\u201d or \u201cthe pill\u201d) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider\u2019s advice with regard to regular check-ups while you are on the pill. EFFECTIVENESS OF COMBINED ORAL CONTRACEPTIVES Oral contraceptives or \u201cbirth control pills\u201d' or \u201cthe pill\u201d are used to prevent pregnancy and are more effective than other nonsurgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 5% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: Implant: < 1% Injection: < 1% IUD: < 1 to 2% Diaphragm with spermicides: 20% Spermicides alone: 26% Vaginal Sponge: 20 to 40% Female sterilization: < 1% Male sterilization: < 1% Cervical Cap: 20 to 40% Condom alone (male): 14% Condom alone (female): 21% Periodic abstinence: 25% Withdrawal: 19% No method: 85% Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may also be taken to treat moderate acne if all of the following are true: \u2022 Your doctor says it is safe for you to use the pill \u2022 You are at least 15 years old \u2022 You have started having menstrual periods \u2022 You want to use the pill for birth control \u2022 You plan to stay on the pill for at least 6 months \u2022 Your acne has not improved with acne medicines that you put on your skin Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets users who started with about 74 acne pimples had about 42 pimples after 6 months of treatment. Placebo users who started with about 72 acne pimples had about 49 pimples after six months of treatment. Use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets to treat acne only if you want the pill for birth control and plan to stay on it for at least 6 months. WHO SHOULD NOT TAKE COMBINED ORAL CONTRACEPTIVES? Do not take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you have: \u2022 Smoke and are over age 35 years old \u2022 History of heart attack or stroke \u2022 History or current blood clots in your arms, legs, lungs, or eyes \u2022 Chest pain (angina pectoris) \u2022 Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart \u2022 Problem with your blood that makes it clot more than normal \u2022 High blood pressure that medicine cannot control \u2022 Diabetes with kidney, eye, nerve or blood vessel damage \u2022 Certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or have any migraine headache if you are over age 35 \u2022 Known or suspected breast cancer or cancer of the lining of the uterus, cervix, or vagina \u2022 Unexplained vaginal bleeding \u2022 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill \u2022 Liver problems, including liver tumors \u2022 Known or suspected pregnancy \u2022 Are receiving Hepatitis C drug combination containing ombitasvir/paritaprevir/ ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. If any of these conditions happen while you are taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, stop taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets right away and talk with your healthcare provider. Your healthcare provider can recommend a safer method of birth control. Before you use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets tell your healthcare provider if you: \u2022 Are pregnant or think you are pregnant \u2022 Have any medical conditions, including conditions listed above \u2022 Elevated cholesterol or triglycerides \u2022 Are depressed now or have been depressed in the past \u2022 Are breastfeeding or plan to breastfeed \u2022 Gallbladder disease \u2022 History of scanty or irregular menstrual periods RISKS OF TAKING COMBINED ORAL CONTRACEPTIVES 1. Risk of Developing Blood Clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives; in particular, a clot in the leg can cause thrombophlebitis, and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in GENERAL PRECAUTIONS. ) 2. Heart Attacks and Strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder Disease Oral contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver Tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Risk of Cancer It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Some studies have found an increase in the incidence of precancerous lesions of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility Per 100,000 Nonsterile Women by Fertility Control Method According to Age Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods* 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker** 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker** 2.2 3.4 6.6 13.5 51.1 117.2 IUD** 0.8 0.8 1.0 1.0 1.4 1.4 Condom* 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide* 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence* 2.5 1.6 1.6 1.7 2.9 3.6 * Deaths are birth - related ** Deaths are method - related In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7 to 26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. The suggestion that women over 40 who don\u2019t smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: \u2022 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung) \u2022 Pain in the calf (indicating a possible clot in the leg) \u2022 Crushing chest pain or heaviness in the chest (indicating a possible heart attack) \u2022 Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) \u2022 Sudden partial or complete loss of vision (indicating a possible clot in the eye) \u2022 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts) \u2022 Severe pain or tenderness in the stomach area (indicating a possible ruptured liver tumor) \u2022 Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression) \u2022 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark colored urine, or light colored bowel movements (indicating possible liver problems) SIDE EFFECTS OF COMBINED ORAL CONTRACEPTIVES 1. Vaginal Bleeding Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider. 2. Contact Lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider. 3. Fluid Retention Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or healthcare provider. 4. Chloasma A spotty darkening of the skin is possible, particularly of the face. 5. Other Side Effects Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections. If any of these side effects bother you, call your doctor or healthcare provider. GENERAL PRECAUTIONS 1. Missed Periods and Use of Combined Oral Contraceptives Before or During Early Pregnancy There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception. There is no conclusive evidence that oral contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy. 2. While Breastfeeding If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant, and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely. 3. Laboratory Tests If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills. 4. Drug Interactions Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin \u00ae is one brand of this drug); phenylbutazone; and possibly St. John\u2019s Wort and certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective. Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your healthcare provider may need to adjust the dose of lamotrigine. Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications. 5. Sexually Transmitted Diseases Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (like all oral contraceptives) are intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis. INSTRUCTIONS TO PATIENT TABLET BLISTER The norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets blister has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing above the first row of tablets. Each white to off white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each light purple tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each purple tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet dispenser. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn\u2019t go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or spermicide) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK. The pill pack has 21 \u201cactive\u201d pills (with hormones) to take for 3 weeks, followed by 1 week of \u201creminder\u201d brown pills (without hormones). 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following pictures: Each norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets blister contains five white to off white tablets, seven light purple tablets, nine purple tablets, and seven brown tablets. These tablets are to be taken in the following order: one white to off white tablet each day for five days, then one light purple tablet each day for seven days, followed by one purple tablet each day for nine days, and then one brown tablet each day for seven days. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets will contain : 5 WHITE TO OFF WHITE, 7 LIGHT PURPLE, 9 PURPLE PILLS for Weeks 1, 2, and 3. Week 4 will contain BROWN PILLS ONLY . 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or spermicide) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first \u201cactive\u201d white to off white pill of the first pack during the first 24 hours of your period . 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d white to off white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or spermicide are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: 21 pills : Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. 28 pills : Start the next pack on the day after your last \u201creminder\u201d pill. Do not wait any days between packs WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off white \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off white \u201cactive\u201d pills in a row in Week 1 OR light purple \u201cactive\u201d pills in Week 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or spermicide) as a back-up method of birth control until you have taken a white to off white \u201cactive\u201d pill every day for 7 days. If you MISS 2 purple \u201cactive\u201d pills in a row in THE 3rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or spermicide) as a back-up method of birth control until you have taken a white to off white \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE \u201cactive\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or spermicide) as a back-up method of birth control until you have taken a white to off white \u201cactive\u201d pill every day for 7 days. REMINDER: IF YOU FORGET ANY OF THE 7 BROWN \u201cREMINDER\u201d PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic. PREGNANCY DUE TO PILL FAILURE The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 5%. If failure does occur, the risk to the fetus is minimal. PREGNANCY AFTER STOPPING THE PILL There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. OVERDOSAGE Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. OTHER INFORMATION Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. HEALTH BENEFITS FROM COMBINED ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: \u2022 Menstrual cycles may become more regular. \u2022 Blood flow during menstruation may be lighter and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur. \u2022 Pain or other symptoms during menstruation may be encountered less frequently. \u2022 Ectopic (tubal) pregnancy may occur less frequently. \u2022 Noncancerous cysts or lumps in the breast may occur less frequently. \u2022 Acute pelvic inflammatory disease may occur less frequently. \u2022 Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the \u201cPhysician Insert\u201d, which you may wish to read. Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection. MISSED MENSTRUAL PERIODS At times there may be no menstrual period after a cycle of pills. Therefore, if you miss one menstrual period but have taken the pills exactly as you were supposed to , continue as usual into the next cycle. If you have not taken the pills correctly and miss a menstrual period, you may be pregnant and should stop taking oral contraceptives until your doctor or healthcare provider determines whether or not you are pregnant. Until you can get to your doctor or healthcare provider, use another form of contraception. If two consecutive menstrual periods are missed, you should stop taking pills until it is determined whether or not you are pregnant. Although there does not appear to be any increase in birth defects in newborn babies, if you become pregnant while using oral contraceptives, you should discuss the situation with your doctor or healthcare provider. Periodic Examination Your doctor or healthcare provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaou smear, i.e., test for cancer). Rx only Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP for Controlled Room Temperature.] Protect from light. Store tablets in blister sleeve when not in use. Keep this and all medication out of the reach of children. To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited Ahmedabad - 382 213, India Code No.: GUJ-DRUGS/G/28/1297 75083624 Revised: 11/2021 FC:OT:7303:R5 Blister"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">REMINDER:</content> IF YOU FORGET ANY OF THE 7 BROWN &#x201C;REMINDER&#x201D; PILLS IN WEEK 4:  THROW AWAY THE PILLS YOU MISSED. </paragraph><paragraph>KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY.  YOU DO NOT NEED A BACK-UP METHOD. </paragraph></td></tr><tr><td styleCode=\"Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</content> Use a BACK-UP METHOD anytime you have sex.  KEEP TAKING ONE &#x201C;ACTIVE&#x201D; PILL EACH DAY until you can reach your doctor or clinic. </paragraph></td></tr></tbody></table>",
      "<table width=\"98%\"><caption>Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility Per 100,000 Nonsterile Women by Fertility Control Method According to Age</caption><col width=\"30%\"/><col width=\"12%\"/><col width=\"12%\"/><col width=\"12%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control </content> <content styleCode=\"bold\">and outcome</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">15-19</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">20-24</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">25-29</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">30-34</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">35-39</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">40-44</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>No fertility control methods* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>9.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>14.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>25.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>28.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives non-smoker** </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>31.6 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives smoker** </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>3.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>6.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>51.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>117.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD** </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm/spermicide* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.8 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Periodic abstinence* </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>3.6 </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">REMINDER:</content> IF YOU FORGET ANY OF THE 7 BROWN &#x201C;REMINDER&#x201D; PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. </paragraph></td></tr><tr><td styleCode=\"Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS</content> <content styleCode=\"bold\">YOU HAVE MISSED:</content> Use a BACK-UP METHOD anytime you have sex.  KEEP TAKING ONE &#x201C;ACTIVE&#x201D; PILL EACH DAY until you can reach your doctor or clinic. </paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 0378-7303-53 Rx only Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets* 1 mg/20 mcg 1 mg/30 mcg 1 mg/35 mcg *Ferrous fumarate tablets are not USP for dissolution and assay. Pharmacist: Each pouch contains Detailed Patient Labeling and a carrier sleeve. The Detailed Patient Labeling and the carrier sleeve should be included with each package dispensed to the patient. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. 28-Day Regimen An Oral Contraceptive with Acne Indication 3 pouches each containing 28 tablets 3s carton"
    ],
    "set_id": "054917fa-573b-4b16-a719-ece6c0909656",
    "id": "931f0bbe-68fa-5010-6d73-7f97e3d9eddf",
    "effective_time": "20211129",
    "version": "4",
    "openfda": {
      "application_number": [
        "ANDA205069"
      ],
      "brand_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"
      ],
      "manufacturer_name": [
        "Mylan Pharmaceuticals Inc."
      ],
      "product_ndc": [
        "0378-7303"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "259176",
        "1358762",
        "1359130",
        "1359131",
        "1359132"
      ],
      "spl_id": [
        "931f0bbe-68fa-5010-6d73-7f97e3d9eddf"
      ],
      "spl_set_id": [
        "054917fa-573b-4b16-a719-ece6c0909656"
      ],
      "package_ndc": [
        "0378-7303-85",
        "0378-7303-53",
        "0378-7190-98",
        "0378-7191-71",
        "0378-7192-59",
        "0378-7193-71"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol ETHINYL ESTRADIOL ETHINYL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE .ALPHA.-TOCOPHEROL, DL- ANHYDROUS LACTOSE CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K25 SODIUM LAURYL SULFATE SUCROSE white to off-white 239 FERROUS FUMARATE ferrous fumarate MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM FERROUS FUMARATE LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K90 SILICON DIOXIDE 291"
    ],
    "spl_unclassified_section": [
      "Rx only Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg* *Ferrous Fumarate Tablets are not USP for dissolution and assay. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS ).",
      "PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( PATIENT PACKAGE INSERT BRIEF SUMMARY and DETAILED PATIENT PACKAGE INSERT ). \u2022 Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs (see BOXED WARNING and CONTRAINDICATIONS ). \u2022 Counsel patients that the increased risk of venous thromboembolism compared to non-users of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or greater interruption in intake) the same or a different CHC (see WARNINGS ). \u2022 Counsel patients that this product does not protect against HIV-infection (AIDS) and other sexually transmitted infections. \u2022 Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs (see PRECAUTIONS ). \u2022 Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established (see PRECAUTIONS ). \u2022 Counsel any patient who starts norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a white-to-off-white tablet for 7 consecutive days (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients that amenorrhea may occur. Pregnancy should be considered in the event of amenorrhea, and should be ruled out if amenorrhea is associated with symptoms of pregnancy, such as morning sickness or unusual breast tenderness (see WARNINGS ). \u2022 Counsel patients with a history of depression that depression may reoccur. Women should contact their healthcare provider if depression occurs (see WARNINGS )."
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS )."
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets are a progestogen-estrogen combination. Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg provide a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each white to off-white tablet contains norethindrone acetate (19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)), 1 mg; ethinyl estradiol (19-Norpregna-1,3,5(10)-trien-20-yne-3, 17-diol, (17\u03b1)-), 0.02 mg. Also contains compressible sugar, croscarmellose sodium, dl -\u03b1-tocopherol, lactose anhydrous, lactose monohydrate, magnesium stearate, povidone K-25, sodium lauryl sulphate. The structural formulas are as follows: Each brown placebo tablet contains colloidal silicon dioxide, croscarmellose sodium, ferrous fumarate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone K-90. The ferrous fumarate tablets do not serve any therapeutic purpose. Structural Formula"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1-3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1-3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3). Special Population Race: The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function. Drug-Drug Interactions Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions."
    ],
    "pharmacokinetics": [
      "Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1-3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1-3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3)."
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD Adapted from RA Hatcher et al, Reference 7. % Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use Method Lowest Expected The authors\u2019 best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. Typical This term represents \u201ctypical\u201d couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (No contraception) (85) (85) Oral contraceptives 3 Combined 0.1 N/A N/A - Data not available. progestin only 0.5 N/A Diaphragm with spermicidal cream or jelly 6 20 Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film) 6 26 Vaginal Sponge nulliparous 9 20 parous 20 40 Implant 0.05 0.05 Injection: depot medroxyprogesterone acetate 0.3 0.3 IUD progesterone T 1.5 2.0 copper T 380A 0.6 0.8 LNg 20 0.1 0.1 Condom without spermicides female 5 21 male 3 14 Cervical Cap with spermicidal cream or jelly nulliparous 9 20 parous 26 40 Periodic abstinence (all methods) 1-9 25 Withdrawal 4 19 Female sterilization 0.5 0.5 Male sterilization 0.10 0.15"
    ],
    "indications_and_usage_table": [
      "<table ID=\"_RefID29\" width=\"100%\"><caption>TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD</caption><col width=\"62%\"/><col width=\"21%\"/><col width=\"17%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Adapted from RA Hatcher et al, Reference 7. </td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">% Of Women Experiencing an Unintended Pregnancy</content> <content styleCode=\"bold\">in the First Year of Continuous Use</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Lowest Expected</content><footnote ID=\"_Ref156543007\">The authors&#x2019; best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. </footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Typical</content><footnote ID=\"_Ref156543014\">This term represents &#x201C;typical&#x201D; couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason. </footnote> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(No contraception)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(85) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(85) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives  </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Combined  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>N/A <footnote ID=\"_Ref156543024\">N/A - Data not available.</footnote> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progestin only  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>N/A <footnoteRef IDREF=\"_Ref156543024\"/> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicidal cream or jelly  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone (foam, creams, gels, vaginal suppositories,</paragraph><paragraph>and vaginal film)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Implant  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.05 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.05 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: depot medroxyprogesterone acetate  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progesterone T  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.0 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> copper T 380A  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> LNg 20  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom without spermicides </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> female  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>21 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> male  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>14 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Cervical Cap with spermicidal cream or jelly </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Periodic abstinence (all methods)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1-9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>25 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Withdrawal  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>19 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Female sterilization  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Male sterilization  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.10 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.15 </paragraph></td></tr></tbody></table>"
    ],
    "contraindications": [
      "CONTRAINDICATIONS \u2022 Oral contraceptives are contraindicated in women who currently have the following conditions: \u2022 Thrombophlebitis or thromboembolic disorders \u2022 A past history of deep vein thrombophlebitis or thromboembolic disorders \u2022 Cerebral vascular or coronary artery disease \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone sensitive \u2022 Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \u2022 Undiagnosed abnormal genital bleeding \u2022 Cholestatic jaundice of pregnancy or jaundice with prior pill use \u2022 Hepatic adenomas or carcinomas \u2022 Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT )."
    ],
    "warnings": [
      "WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author\u2019s permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial Infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10-16). The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases (17). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives. TABLE II: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity (19). In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism (20-24). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS ). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. Graph b. Thromboembolism An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (9, 10, 25-30). Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8). A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives (15,32). The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions (15,32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. c. Cerebrovascular Disease Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (greater than 35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes (33-35). In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk is also greater in older women (9). d. Dose-related Risk of Vascular Disease from Oral Contraceptives A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (37-39). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (20-22). A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. e. Persistence of Risk of Vascular Disease There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40-49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (40). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens. 2. Estimates of Mortality from Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970's but not reported until 1983 (41). However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling. Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4; and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective. TABLE III: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Adapted from H.W. Ory, Reference 41. Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker Deaths are method related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom Deaths are birth related. 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/ spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 3. Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ). Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS , Postmarketing Experience ). Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women (42-45). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. 4. Hepatic Neoplasia Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (46). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (47,48). Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (49- 51) in long-term (greater than 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users. 5. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see Contraindications) . Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. Oral Contraceptive Use Before and During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy (52-54). Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned (52, 53, 55, 56), when taken inadvertently during early pregnancy. The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed. 8. Gallbladder Disease Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (57, 58). More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal (59-61). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance (62). Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (23, 63). However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (64). Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives. A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a . and 1d .), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking oral contraceptives (65) and this increase is more likely in older oral contraceptive users (66) and with continued use (65). Data from the Royal College of General Practitioners (18) and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal disease (67) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (66), and there is no difference in the occurrence of hypertension among ever and never users (65,67,68). 11. Headache The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause. 12. Bleeding Irregularities Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. 13. Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 14. Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if depression recurs to a serious degree."
    ],
    "warnings_table": [
      "<table ID=\"_RefID53\" width=\"100%\"><caption>TABLE III: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"33%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><tfoot><tr><td align=\"left\" colspan=\"7\" valign=\"top\">Adapted from H.W. Ory, Reference 41.</td></tr></tfoot><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">15-19</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">20-24</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">25-29</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">30-34</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">35-39</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">40-44</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>No fertility control methods </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>7.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>7.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>14.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>25.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>28.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives non-smoker<footnote ID=\"_Ref156536611\">Deaths are method related.  </footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>13.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>31.6 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives smoker<footnoteRef IDREF=\"_Ref156536611\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>13.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>51.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>117.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD<footnoteRef IDREF=\"_Ref156536611\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom<footnote ID=\"_Ref156536631\">Deaths are birth related.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm/ spermicide<footnoteRef IDREF=\"_Ref156536631\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.8 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref156536631\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>2.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>2.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>3.6 </paragraph></td></tr></tbody></table>"
    ],
    "precautions": [
      "PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections. 2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. 3. Lipid Disorders Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. 4. Liver Function If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function. 5. Fluid Retention Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. 6. Contact Lenses Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 7. Drug Interactions Effects of Other Drugs on Oral Contraceptives (69) Rifampin: Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants: Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Troglitazone: Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness. Antibiotics: Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. Concomitant Use with HCV Combination Therapy Liver Enzyme Elevation Co-administration of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Co-administration of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations. Other: Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Oral Contraceptives on Other Drugs Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. 8. Interactions with Laboratory Tests Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: a. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged. e. Triglycerides may be increased. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives. 9. Carcinogenesis See WARNINGS section. 10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS section. 11. Lactation Small amounts of oral contraceptive steroids have been identified in human milk, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child. 12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): \u2022 Thrombophlebitis \u2022 Arterial thromboembolism \u2022 Pulmonary embolism \u2022 Myocardial infarction \u2022 Cerebral hemorrhage \u2022 Cerebral thrombosis \u2022 Hypertension \u2022 Gallbladder disease \u2022 Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1) (70-74). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1) (70,73,75). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use. FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: \u2022 Mesenteric thrombosis \u2022 Retinal thrombosis The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related: \u2022 Nausea \u2022 Vomiting \u2022 Gastrointestinal symptoms (such as abdominal cramps and bloating) \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Temporary infertility after discontinuation of treatment \u2022 Edema \u2022 Melasma which may persist \u2022 Breast changes: tenderness, enlargement, secretion \u2022 Change in weight (increase or decrease) \u2022 Change in cervical erosion and secretion \u2022 Diminution in lactation when given immediately postpartum \u2022 Cholestatic jaundice \u2022 Migraine \u2022 Rash (allergic) \u2022 Depression \u2022 Reduced tolerance to carbohydrates \u2022 Vaginal candidiasis \u2022 Change in corneal curvature (steepening) \u2022 Intolerance to contact lenses The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted: \u2022 Pre-menstrual syndrome \u2022 Cataracts \u2022 Changes in appetite \u2022 Cystitis-like syndrome \u2022 Headache \u2022 Nervousness \u2022 Dizziness \u2022 Hirsutism \u2022 Loss of scalp hair \u2022 Erythema multiforme \u2022 Erythema nodosum \u2022 Hemorrhagic eruption \u2022 Vaginitis \u2022 Porphyria \u2022 Impaired renal function \u2022 Hemolytic uremic syndrome \u2022 Budd-Chiari syndrome \u2022 Acne \u2022 Changes in libido \u2022 Colitis Figure 1"
    ],
    "overdosage": [
      "OVERDOSAGE Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females. NON-CONTRACEPTIVE HEALTH BENEFITS The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (76-81). Effects on menses: \u2022 Increased menstrual cycle regularity \u2022 Decreased blood loss and decreased incidence of iron deficiency anemia \u2022 Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation: \u2022 Decreased incidence of functional ovarian cysts \u2022 Decreased incidence of ectopic pregnancies Effects from long-term use: \u2022 Decreased incidence of fibroadenomas and fibrocystic disease of the breast \u2022 Decreased incidence of acute pelvic inflammatory disease \u2022 Decreased incidence of endometrial cancer \u2022 Decreased incidence of ovarian cancer"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION The tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the tablet blister above the first row of tablets. Note: Each blister card has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days. Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen. The possibility of ovulation and conception prior to initiation of use should be considered. Dosage and Administration for 28-Day Dosage Regimen To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken exactly as directed and at intervals not exceeding 24 hours. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets provide a continuous administration regimen consisting of 21 white to off-white tablets of norethindrone acetate and ethinyl estradiol tablets and 7 brown non-hormone containing tablets of ferrous fumarate. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen and do not serve any therapeutic purpose. There is no need for the patient to count days between cycles because there are no \u201coff-tablet days..\u201d A. Sunday-Start Regimen: The patient begins taking the first white to off-white tablet from the top row of the blister (labeled Sunday) on the first Sunday after menstrual flow begins. When the menstrual flow begins on Sunday, the first white to off-white tablet is taken on the same day. The patient takes one white to off-white tablet daily for 21 days. The last white to off-white tablet in the blister pack will be taken on a Saturday. Upon completion of all 21 white to off-white tablets, and without interruption, the patient takes one brown tablet daily for 7 days. Upon completion of this first course of tablets, the patient begins a second course of 28-day tablets, without interruption, the next day (Sunday), starting with the Sunday white to off-white tablet in the top row. Adhering to this regimen of one white to off-white tablet daily for 21 days, followed without interruption by one brown tablet daily for seven days, the patient will start all subsequent cycles on a Sunday. B. Day-1 Start Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the blister card. She starts taking one white to off-white tablet daily, beginning with the first white to off-white tablet in the top row. After the last white to off-white tablet (at the end of the third row) has been taken, the patient will then take the brown tablets for a week (7 days). For all subsequent cycles, the patient begins a new 28 tablet regimen on the eighth day after taking her last white to off-white tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the tablet blister. Following this regimen of 21 white to off-white tablets and 7 brown tablets, the patient will start all subsequent cycles on the same day of the week as the first course. Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule. Special Notes on Administration Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after the brown tablets have been started. In any event, the next course of tablets should be started without interruption. If spotting occurs while the patient is taking white to off-white tablets, continue medication without interruption. If the patient forgets to take one or more white to off-white tablets, the following is suggested: One tablet is missed \u2022 take tablet as soon as remembered \u2022 take next tablet at the regular time Two consecutive tablets are missed (week 1 or week 2) \u2022 take two tablets as soon as remembered \u2022 take two tablets the next day \u2022 use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (week 3) Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets The possibility of ovulation occurring increases with each successive day that scheduled white to off-white tablets are missed. While there is little likelihood of ovulation occurring if only one white to off-white tablet is missed, the possibility of spotting or bleeding is increased. This is particularly likely to occur if two or more consecutive white to off-white tablets are missed. If the patient forgets to take any of the seven brown tablets in week four, those brown tablets that were missed are discarded and one brown tablet is taken each day until the pack is empty. A back-up birth control method is not required during this time. A new pack of tablets should be started no later than the eighth day after the last white to off-white tablet was taken. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet blister pack on the next Sunday or the first day (Day-1), depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered. Use of Oral Contraceptives in the Event of a Missed Menstrual Period 1. If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out. 2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg are packaged in a carton of three pouches (NDC 0378-7283-53); each pouch contains a blister pack of 28 tablets. Each blister pack contains 21 white to off-white, round, flat-faced, unscored tablet debossed with 239 on one side and plain on the other side and 7 brown, round, flat-faced, unscored tablets debossed with 291 on one side and plain on the other side. Each brown tablet contains 75 mg ferrous fumarate. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]"
    ],
    "references": [
      "REFERENCES 1. Back DJ, Breckenridge AM, Crawford FE, Mclver M, Orme ML\u2019E, Rowe PH and Smith E: Kinetics of norethindrone in women II. Single-dose kinetics. Clin Pharmacol Ther 1978; 24:448-453. 2. Humpel M, Nieuweboer B, Wendt H and Speck U: Investigations of pharmacokinetics of ethinyl estradiol to specific consideration of a possible first-pass effect in women. Contraception 1979;19:421-432. 3. Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML\u2019E, Rowe PH and Watts MJ. An investigation of the pharmacokinetics of ethinyl estradiol in women using radioimmunoassay. Contraception 1979;20:263-273. 4. Hammond GL, Lahteenmaki PLA, Lahteenmaki P and Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steriod Biochem 1982;17:375-380. 5. Fotherby K. Pharmacokinetics and metabolism of progestins in humans, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994;99-126. 6. Goldzieher JW. Pharmacokinetics and metabolism of ethynyl estrogens, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press Ltd., New York, 1994;127-151. 7. Hatcher RA, et al. 1998. Contraceptive Technology, Seventeenth Edition. New York: Irvington Publishers. 8. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 1). New England Journal of Medicine, 305:612-618, 1981. 9. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 2). New England Journal of Medicine, 305:672-677, 1981. 10. Adam, S.A., and M. Thorogood: Oral contraception and myocardial infarction revisited: The effects of new preparations and prescribing patterns. Brit. J. Obstet. and Gynec., 88:838-845, 1981. 11. Mann, J.I., and W.H. Inman: Oral contraceptives and death from myocardial infarction. Brit. Med. J., 2(5965): 245-248, 1975. 12. Mann, J.I., M.P. Vessey, M. Thorogood, and R. Doll: Myocardial infarction in young women with special reference to oral contraceptive practice. Brit. Med. J., 2(5956):241-245, 1975. 13. Royal College of General Practitioners\u2019 Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet, 1:541-546, 1981. 14. Slone, D., S. Shapiro, D.W. Kaufman, L. Rosenberg, O.S. Miettinen, and P.D. Stolley: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N.E.J.M., 305:420-424, 1981. 15. Vessey, M.P.: Female hormones and vascular disease: An epidemiological overview. Brit. J. Fam. Plann., 6:1-12, 1980. 16. Russell-Briefel, R.G., T.M. Ezzati, R. Fulwood, J.A. Perlman, and R.S. Murphy: Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Preventive Medicine , 15:352-362, 1986. 17. Goldbaum, G.M., J.S. Kendrick, G.C. Hogelin, and E.M. Gentry: The relative impact of smoking and oral contraceptive use on women in the United States. J.A.M.A., 258:1339-1342, 1987. 18. Layde, P.M., and V. Beral: Further analyses of mortality in oral contraceptive users: Royal College General Practitioners\u2019 Oral Contraception Study. (Table 5) Lancet, 1:541-546, 1981. 19. Knopp, R.H.: Arteriosclerosis risk: The roles of oral contraceptives and postmenopausal estrogens. J. of Reprod. Med., 31(9)(Supplement): 913-921, 1986. 20. Krauss, R.M., S. Roy, D.R. Mishell, J. Casagrande, and M.C. Pike: Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am. J. Obstet. Gyn., 145:446-452, 1983. 21. Wahl, P., C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss, and B. Rifkind: Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N.E.J.M., 308:862-867, 1983. 22. Wynn, V., and R. Niththyananthan: The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am. J. Obstet. and Gyn., 142:766-771, 1982. 23. Wynn, V., and I. Godsland: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Medicine, 31 (9)(Supplement): 892-897, 1986. 24. LaRosa, J.C.: Atherosclerotic risk factors in cardiovascular disease. J. Reprod. Med., 31(9)(Supplement): 906-912, 1986. 25. Inman, W.H., and M.P. Vessey: Investigations of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Brit. Med. J., 2(5599): 193-199, 1968. 26. Maguire, M.G., J. Tonascia, P.E. Sartwell, P.D. Stolley, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives: A further report. Am. J. Epidemiology, 110(2): 188-195, 1979. 27. Pettiti, D.B., J. Wingerd, F. Pellegrin, and S. Ramacharan: Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J.A.M.A., 242:1150-1154, 1979. 28. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit. Med. J., 2(5599): 199-205, 1968. 29. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease: A further report. Brit. Med. J., 2(5658): 651-657, 1969. 30. Porter, J.B., J.R. Hunter, D.A. Danielson, H. Jick, and A. Stergachis: Oral contraceptives and non-fatal vascular disease: Recent experience. Obstet. and Gyn., 59(3):299-302, 1982. 31. Vessey, M., R. Doll, R. Peto, B. Johnson, and P. Wiggins: A long-term follow-up study of women using different methods of contraception: An interim report. J. Biosocial. Sci., 8:375-427, 1976. 32. Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J. of Royal College of General Practitioners, 28:393-399, 1978. 33. Collaborative Group for the study of stroke in young women: Oral contraception and increased risk of cerebral ischemia or thrombosis. N.E.J.M., 288:871-878, 1973. 34. Petitti, D.B., and J.Wingerd: Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet, 2:234-236, 1978. 35. Inman, W.H.: Oral contraceptives and fatal subarachnoid hemorrhage. Brit. Med. J., 2(6203): 1468-70, 1979. 36. Collaborative Group for the study of stroke in young women: Oral contraceptives and stroke in young women: Associated risk factors. J.A.M.A., 231:718-722, 1975. 37. Inman, W.H., M.P. Vessey, B. Westerholm, and A. Engelund: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Brit. Med. J., 2:203-209, 1970. 38. Meade, T.W., G. Greenberg, and S.G. Thompson: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Brit. Med. J., 280(6224): 1157-1161, 1980. 39. Kay, C.R.: Progestogens and arterial disease: Evidence from the Royal College of General Practitioners\u2019 study. Amer. J. Obstet. Gyn., 142:762-765, 1982. 40. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J. Coll. Gen. Pract., 33:75-82, 1983. 41. Ory, H.W: Mortality associated with fertility and fertility control:1983. Family Planning Perspectives, 15:50-56, 1983. 42. Ory, H., Z. Naib, S.B. Conger, R.A. Hatcher, and C.W. Tyler: Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Am. J. Obstet. Gynec., 124:573-577, 1976. 43. Vessey, M.P., M. Lawless, K. McPherson, D. Yeates: Neoplasia of the cervix uteri and contraception: A possible adverse effect of the pill. Lancet, 2:930, 1983. 44. Brinton, L.A., G.R. Huggins, H.F. Lehman, K. Malli, D.A. Savitz, E. Trapido, J. Rosenthal, and R. Hoover: Long-term use of oral contraceptives and risk of invasive cervical cancer. Int. J. Cancer, 38:339-344, 1986. 45. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Brit. Med. J., 290:961-965, 1985. 46. Rooks, J.B., H.W. Ory, K.G. Ishak, L.T. Strauss, J.R. Greenspan, A.P. Hill, and C.W. Tyler: Epidemiology of hepatocellular adenoma: The role of oral contraceptive use. J.A.M.A., 242:644-648, 1979. 47. Bein, N.N., and H.S. Goldsmith: Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Brit. J. Surg., 64:433-435, 1977. 48. Klatskin, G.: Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology, 73:386-394, 1977. 49. Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike: Hepatocellular carcinoma and oral contraceptives. Brit. J. Cancer, 48:437-440, 1983. 50. Neuberger, J., D. Forman, R. Doll, and R. Williams: Oral contraceptives and hepatocellular carcinoma. Brit. Med. J., 292:1355-1357, 1986. 51. Forman, D., T.J. Vincent, and R. Doll: Cancer of the liver and oral contraceptives. Brit. Med. J., 292:1357-1361, 1986. 52. Harlap, S., and J. Eldor: Births following oral contraceptive failures. Obstet. Gynec., 55:447-452, 1980. 53. Savolainen, E., E. Saksela, and L. Saxen: Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Amer. J. Obstet. Gynec., 140:521-524, 1981. 54. Janerich, D.T., J.M. Piper, and D.M. Glebatis: Oral contraceptives and birth defects. Am. J. Epidemiology, 112:73-79, 1980. 55. Ferencz, C., G.M. Matanoski, P.D. Wilson, J.D. Rubin, C.A. Neill, and R. Gutberlet: Maternal hormone therapy and congenital heart disease. Teratology, 21:225-239, 1980. 56. Rothman, K.J., D.C. Fyler, A. Goldbatt, and M.B. Kreidberg: Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiology, 109:433-439, 1979. 57. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet, 1:1399-1404, 1973. 58. Royal College of General Practitioners: Oral Contraceptives and Health. New York, Pittman, 1974, 100p. 59. Layde, P.M., M.P. Vessey, and D. Yeates: Risk of gallbladder disease: A cohort study of young women attending family planning clinics. J. of Epidemiol. and Comm. Health, 36:274-278, 1982. 60. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am. J. Epidemiol., 119:796-805, 1984. 61. Strom, B.L., R.T. Tamragouri, M.L. Morse, E.L. Lazar, S.L. West, P.D. Stolley, and J.K. Jones: Oral contraceptives and other risk factors for gallbladder disease. Clin. Pharmacol. Ther., 39:335-341, 1986. 62. Wynn, V., P.W. Adams, I.F. Godsland, J. Melrose, R. Niththyananthan, N.W. Oakley, and A. Seedj: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet, 1:1045-1049, 1979. 63. Wynn, V.: Effect of progesterone and progestins on carbohydrate metabolism. In Progesterone and Progestin. Edited by C.W. Bardin, E. Milgrom, P. Mauvis-Jarvis. New York, Raven Press, pp. 395-410, 1983. 64. Perlman, J.A., R. G. Roussell-Briefel, T.M. Ezzati, and G. Lieberknecht: Oral glucose tolerance and the potency of oral contraceptive progestogens. J. Chronic Dis., 38:857-864, 1985. 65. Royal College of General Practitioners\u2019 Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet, 1:624, 1977. 66. Fisch, I.R., and J. Frank: Oral contraceptives and blood pressure. J.A.M.A., 237:2499-2503, 1977. 67. Laragh, A.J.: Oral contraceptive induced hypertension: Nine years later. Amer. J. Obstet. Gynecol., 126:141-147, 1976. 68. Ramcharan, S., E. Peritz, F.A. Pellegrin, and W.T. Williams: Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort. In Pharmacology of Steroid Contraceptive Drugs. Edited by S. Garattini and H.W. Berendes. New York, Raven Press , pp. 277-288, 1977. (Monographs of the Mario Negri Institute for Pharmacological Research, Milan.) 69. Back DJ, Orme ML\u2019E. Drug interactions, in Pharmacology of the contraceptive steroids. Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994, 407-425. 70. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med . 2002;346(26):2025-2032. 71. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control . 2005;16(5):537-544. 72. Dorjgochoo T, Shu XO, Li HL, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer . 2009;124(10):2442-2449. 73. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology . 2010;19(10):2496-2502. 74. Vessey M, Yeates D. Oral contraceptive use and cancer. Final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-683. 75. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med . 2017;377(23):2228-2239. 76. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. J.A.M.A., 249:1596-1599, 1983. 77. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. J.A.M.A., 257:796-800, 1987. 78. Ory, H.W.: Functional ovarian cysts and oral contraceptives: Negative association confirmed surgically. J.A.M.A., 228:68-69, 1974. 79. Ory, H.W., P. Cole, B. Macmahon, and R. Hoover: Oral contraceptives and reduced risk of benign breast disease. N.E.J.M., 294:41-422, 1976. 80. Ory, H.W.: The noncontraceptive health benefits from oral contraceptive use. Fam. Plann. Perspectives, 14:182-184, 1982. 81. Ory, H.W., J.D. Forrest, and R. Lincoln: Making Choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, p.1, 1983."
    ],
    "spl_patient_package_insert": [
      "BRIEF SUMMARY PATIENT PACKAGE INSERT This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Oral contraceptives, also known as \u201cbirth control pills\u201d or \u201cthe pill\u201d, are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you: \u2022 Smoke \u2022 Have high blood pressure, diabetes, high cholesterol \u2022 Have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast, jaundice, or malignant or benign liver tumors. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea, vomiting, and breakthrough bleeding may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill: 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack or angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences. 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. There may be slight increases in the risk of breast cancer among current users of hormonal birth control pills with longer duration of use of 8 years or more. Some studies have found an increase in the risk of developing cancer of the cervix in women taking the pill, but this finding may be related to differences in sexual behavior or other factors not related to use of the pill. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis.",
      "DETAILED PATIENT PACKAGE INSERT Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. What You Should Know About Oral Contraceptives Any woman who considers using oral contraceptives (the \u201cbirth control pill\u201d or \u201cthe pill\u201d) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider's advice with regard to regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES Oral contraceptives or \u201cbirth control pills\u201d or \u201cthe pill\u201d are used to prevent pregnancy and are more effective than other non-surgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 3% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: Implant: <1% Male sterilization: <1% Injection: <1% Cervical Cap: 20 to 40% IUD: <1 to 2% Condom alone (male): 14% Diaphragm with spermicides: 20% Condom alone (female): 21% Spermicides alone: 26% Periodic abstinence: 25% Vaginal Sponge: 20 to 40% Withdrawal: 19% Female sterilization: <1% No method: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions: \u2022 A history of heart attack or stroke \u2022 Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), or eyes \u2022 A history of blood clots in the deep veins of your legs \u2022 Chest pain (angina pectoris) \u2022 Known or suspected breast cancer \u2022 Unexplained vaginal bleeding (until a diagnosis is reached by your doctor) \u2022 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill \u2022 Liver tumor (benign or cancerous) \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend a safer method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your healthcare provider if you have: \u2022 Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram \u2022 Diabetes \u2022 Elevated cholesterol or triglycerides \u2022 High blood pressure \u2022 Migraine or other headaches or epilepsy \u2022 Depression \u2022 Gallbladder, heart, or kidney disease \u2022 History of scanty or irregular menstrual periods Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. RISKS OF TAKING ORAL CONTRACEPTIVES 1. Risk of Developing Blood Clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives; in particular, a clot in the legs can cause thrombophlebitis, and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in GENERAL PRECAUTIONS.) 2. Heart Attacks and Strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder Disease Oral contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver Tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Risk of Cancer It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods Deaths are birth related. 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker Deaths are method related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/ spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7-26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: \u2022 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung) \u2022 Pain in the calf (indicating a possible clot in the leg) \u2022 Crushing chest pain or heaviness in the chest (indicating a possible heart attack) \u2022 Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) \u2022 Sudden partial or complete loss of vision (indicating a possible clot in the eye) \u2022 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts) \u2022 Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor) \u2022 Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression) \u2022 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark colored urine, or light-colored bowel movements (indicating possible liver problems) SIDE EFFECTS OF ORAL CONTRACEPTIVES 1. Vaginal Bleeding Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider. 2. Contact Lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider. 3. Fluid Retention Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or healthcare provider. 4. Melasma A spotty darkening of the skin is possible, particularly of the face. 5. Other Side Effects Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections. If any of these side effects bother you, call your doctor or healthcare provider. GENERAL PRECAUTIONS 1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception. There is no conclusive evidence that oral contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy. 2. While Breastfeeding If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely. 3. Laboratory Tests If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills. 4. Drug Interactions Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin\u00ae is one brand of this drug); troglitazone; phenylbutazone; and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective. Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications. 5. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis."
    ],
    "spl_patient_package_insert_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Implant: &lt;1%</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Male sterilization: &lt;1%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: &lt;1%</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Cervical Cap: 20 to 40%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD: &lt;1 to 2%</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Condom alone (male): 14%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicides: 20%</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Condom alone (female): 21%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone: 26%</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Periodic abstinence: 25%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge: 20 to 40%</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Withdrawal: 19%</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Female sterilization: &lt;1%</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>No method: 85%</paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><caption>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"33%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">15-19</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">20-24</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">25-29</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">30-34</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">35-39</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">40-44</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>No fertility control methods<footnote ID=\"_Ref156545718\">Deaths are birth related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>7.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>7.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>9.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>14.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>25.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>28.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives non-smoker<footnote ID=\"_Ref156545724\">Deaths are method related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>13.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>31.6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives smoker<footnoteRef IDREF=\"_Ref156545724\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>3.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>6.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>13.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>51.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>117.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD<footnoteRef IDREF=\"_Ref156545724\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom<footnoteRef IDREF=\"_Ref156545718\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm/ spermicide<footnoteRef IDREF=\"_Ref156545718\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>2.8</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref156545718\"/></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>2.5</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>1.6</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>1.6</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>1.7</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>2.9</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>3.6</paragraph></td></tr></tbody></table>"
    ],
    "information_for_patients": [
      "INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet and ferrous fumarate tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each with the days of the week appearing above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 white to off-white tablets and 7 brown tablets Norethindrone Acetate and Ethinyl Estradiol Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg Each white to off-white tablet contains 1 mg norethindrone acetate and 0.02 mg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS: The 28-Day pill pack has 21 \u201cactive\u201d white to off-white pills (with hormones) to take for 3 weeks, followed by 1 week of reminder brown pills (without hormones). 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone acetate and ethinyl estradiol tablets, 1 mg/0.02 mg and ferrous fumarate tablets, 75 mg will contain: 21 WHITE TO OFF-WHITE PILLS for WEEKS 1, 2, and 3 . WEEK 4 will contain BROWN PILLS ONLY . 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \u201cactive\u201d white to off-white pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Start the next pack on the day after your last \u201creminder\u201d pill. Do not wait any days between packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \u201cactive\u201d pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \u201cactive\u201d pill every day for 7 days. If you MISS 2 white to off-white \u201cactive\u201d pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE white to off-white \u201cactive\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \u201cactive\u201d pill every day for 7 days. A REMINDER FOR THOSE ON 28-DAY PACKS: IF YOU FORGET ANY OF THE 7 BROWN \u201cREMINDER\u201d PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic. Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Figure 2 Figure 3"
    ],
    "information_for_patients_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains:</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking:</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>21 white to off-white tablets and 7 brown tablets</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl Estradiol Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg</paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE</content> YOU START TAKING YOUR PILLS</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST</content> PACK OF PILLS</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">A REMINDER FOR THOSE ON 28-DAY PACKS:</content></paragraph><paragraph>IF YOU FORGET ANY OF THE 7 BROWN &#x201C;REMINDER&#x201D; PILLS IN WEEK 4:</paragraph><paragraph>THROW AWAY THE PILLS YOU MISSED.</paragraph><paragraph>KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY.</paragraph><paragraph>YOU DO NOT NEED A BACK-UP METHOD.</paragraph></td></tr></tbody></table>"
    ],
    "instructions_for_use": [
      "INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet and ferrous fumarate tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 white to off-white tablets and 7 brown tablets Norethindrone Acetate and Ethinyl Estradiol Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg Each white to off-white tablet contains 1 mg norethindrone acetate and 0.02 mg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS: The 28-Day pill pack has 21 \u201cactive\u201d white to off-white pills (with hormones) to take for 3 weeks, followed by 1 week of reminder brown pills (without hormones). 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone acetate and ethinyl estradiol tablets, 1 mg/0.02 mg and ferrous fumarate tablets, 75 mg will contain: 21 WHITE TO OFF-WHITE PILLS for WEEKS 1, 2, and 3 . WEEK 4 will contain BROWN PILLS ONLY . 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \u201cactive\u201d white to off-white pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Start the next pack on the day after your last \u201creminder\u201d pill. Do not wait any days between packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \u201cactive\u201d pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \u201cactive\u201d pill every day for 7 days. If you MISS 2 white to off-white \u201cactive\u201d pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE white to off-white \u201cactive\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \u201cactive\u201d pill every day for 7 days. A REMINDER FOR THOSE ON 28-DAY PACKS: IF YOU FORGET ANY OF THE 7 BROWN \u201cREMINDER\u201d PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic. PREGNANCY DUE TO PILL FAILURE The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 3%. If failure does occur, the risk to the fetus is minimal. PREGNANCY AFTER STOPPING THE PILL There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. OVERDOSAGE Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. OTHER INFORMATION Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: \u2022 Menstrual cycles may become more regular \u2022 Blood flow during menstruation may be lighter and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur \u2022 Pain or other symptoms during menstruation may be encountered less frequently \u2022 Ectopic (tubal) pregnancy may occur less frequently \u2022 Noncancerous cysts or lumps in the breast may occur less frequently \u2022 Acute pelvic inflammatory disease may occur less frequently \u2022 Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the \"Physician Insert\", which you may wish to read. Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection. MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS At times there may be no menstrual period after a cycle of pills. Therefore, if you miss one menstrual period but have taken the pills exactly as you were supposed to, continue as usual into the next cycle. If you have not taken the pills correctly and miss a menstrual period, you may be pregnant and should stop taking oral contraceptives until your doctor or healthcare provider determines whether or not you are pregnant. Until you can get to your doctor or healthcare provider, use another form of contraception. If two consecutive menstrual periods are missed, you should stop taking pills until it is determined whether or not you are pregnant. Although there does not appear to be any increase in birth defects in newborn babies if you become pregnant while using oral contraceptives, you should discuss the situation with your doctor or healthcare provider. Periodic Examination Your doctor or healthcare provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaou smear, i.e., test for cancer). Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited Ahmedabad - 382 213, India Code No.: GUJ-DRUGS/G/28/1297 75101349 Revised: 1/2024 FC:OT:7283:R9 Figure 4 Figure 5"
    ],
    "instructions_for_use_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains:</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking:</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>21 white to off-white tablets and 7 brown tablets</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl Estradiol Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg</paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE</content> YOU START TAKING YOUR PILLS</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST</content> PACK OF PILLS</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">A REMINDER FOR THOSE ON 28-DAY PACKS:</content></paragraph><paragraph>IF YOU FORGET ANY OF THE 7 BROWN &#x201C;REMINDER&#x201D; PILLS IN WEEK 4:</paragraph><paragraph>THROW AWAY THE PILLS YOU MISSED.</paragraph><paragraph>KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY.</paragraph><paragraph>YOU DO NOT NEED A BACK-UP METHOD.</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 1 mg/0.02 mg NDC 0378-7283-53 Rx only Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets* 1 mg /0.02 mg Each white to off-white tablet contains norethindrone acetate 1 mg and ethinyl estradiol 0.02 mg. Each brown tablet contains ferrous fumarate USP, 75 mg. Each blister pack contains 21 white to off-white tablets and 7 brown tablets. * Ferrous fumarate tablets are not USP for dissolution and assay. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. 3 pouches, each pouch contains one blister pack of 28 tablets Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Made in India Code No.: GUJ-DRUGS/G/28/1297 Mylan.com Carton"
    ],
    "set_id": "2376cab5-3d34-4a0a-9ba1-df19a96eb5dd",
    "id": "024ab85d-682d-b3cb-9886-57dd821426c8",
    "effective_time": "20240119",
    "version": "12",
    "openfda": {
      "application_number": [
        "ANDA202772"
      ],
      "brand_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "Mylan Pharmaceuticals Inc."
      ],
      "product_ndc": [
        "0378-7283"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "259176",
        "1358762",
        "1358763"
      ],
      "spl_id": [
        "024ab85d-682d-b3cb-9886-57dd821426c8"
      ],
      "spl_set_id": [
        "2376cab5-3d34-4a0a-9ba1-df19a96eb5dd"
      ],
      "package_ndc": [
        "0378-7283-85",
        "0378-7283-53"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate Norethindrone Acetate ANHYDROUS LACTOSE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE NORETHINDRONE ACETATE NORETHINDRONE b;211;5"
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate Tablets, USP (17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white, or creamy white, crystalline powder. The structural formula is as follows: C 22 H 28 O 3 M.W. 340.46 Each Norethindrone Acetate Tablet, USP for oral administration, contains norethindrone acetate, USP 5 mg. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose. Norethindrone Acetate structural formula"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone. Pharmacokinetics Absorption Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n = 29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf)(ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Figure 1 Effect of Food The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. Special Populations Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted."
    ],
    "clinical_pharmacology_table": [
      "<table><col/><col/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Table 1</content></paragraph><paragraph>Pharmacokinetic Parameters after a Single Dose of   Norethindrone Acetate in Healthy Women </paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>Norethindrone Acetate (n = 29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>Norethindrone (NET)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>AUC (0-inf)(ng/ml*h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>C <sub>max</sub>(ng/ml) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>26.19 &#xB1; 6.19</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>t <sub>max</sub>(h) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>1.83 &#xB1; 0.58</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>t <sub>1/2</sub>(h) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>8.51 &#xB1; 2.19</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Toprule\" valign=\"top\"><paragraph>AUC = area under the curve,   C <sub>max</sub>= maximum plasma concentration,   t <sub>max</sub>= time at maximum plasma concentration,   t <sub>1/2</sub>= half-life,   SD = standard deviation </paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "Pharmacokinetics Absorption Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n = 29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf)(ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Figure 1 Effect of Food The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours."
    ],
    "pharmacokinetics_table": [
      "<table><col/><col/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Table 1</content></paragraph><paragraph>Pharmacokinetic Parameters after a Single Dose of   Norethindrone Acetate in Healthy Women </paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>Norethindrone Acetate (n = 29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>Norethindrone (NET)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>AUC (0-inf)(ng/ml*h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>C <sub>max</sub>(ng/ml) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>26.19 &#xB1; 6.19</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>t <sub>max</sub>(h) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>1.83 &#xB1; 0.58</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>t <sub>1/2</sub>(h) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\" valign=\"top\"><paragraph>8.51 &#xB1; 2.19</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Toprule\" valign=\"top\"><paragraph>AUC = area under the curve,   C <sub>max</sub>= maximum plasma concentration,   t <sub>max</sub>= time at maximum plasma concentration,   t <sub>1/2</sub>= half-life,   SD = standard deviation </paragraph></td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone Acetate Tablets, USP are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone Acetate Tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."
    ],
    "contraindications": [
      "CONTRAINDICATIONS Known or suspected pregnancy. There is no indication for norethindrone acetate in pregnancy. (See PRECAUTIONS .) Undiagnosed vaginal bleeding Known, suspected or history of cancer of the breast Active deep vein thrombosis, pulmonary embolism or history of these conditions Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) Impaired liver function or liver disease As a diagnostic test for pregnancy Hypersensitivity to any of the drug components"
    ],
    "warnings": [
      "WARNINGS Cardiovascular Disorders Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. Visual Abnormalities Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued."
    ],
    "precautions": [
      "PRECAUTIONS General Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation. In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated. Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree. Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy. The pathologist should be advised of progestin therapy when relevant specimens are submitted. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate tablets. Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test. Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established. Pregnancy Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "general_precautions": [
      "General Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation. In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated. Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree. Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy. The pathologist should be advised of progestin therapy when relevant specimens are submitted."
    ],
    "information_for_patients": [
      "Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate tablets."
    ],
    "drug_and_or_laboratory_test_interactions": [
      "Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established."
    ],
    "pregnancy": [
      "Pregnancy Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses."
    ],
    "nursing_mothers": [
      "Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman."
    ],
    "pediatric_use": [
      "Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See WARNINGS and PRECAUTIONS . The following adverse reactions have been observed in women taking progestins: Breakthrough bleeding Spotting Change in menstrual flow Amenorrhea Edema Changes in weight (decreases, increases) Changes in the cervical squamo-columnar junction and cervical secretions Cholestatic jaundice Rash (allergic) with and without pruritus Melasma or chloasma Clinical depression Acne Breast enlargement/tenderness Headache/migraine Urticaria Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) Decreased HDL cholesterol and increased LDL/HDL ratio Mood swings Nausea Insomnia Anaphylactic/anaphylactoid reactions Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) Optic neuritis (which may lead to partial or complete loss of vision) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch."
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Therapy with norethindrone acetate tablets must be adapted to the specific indications and therapeutic response of the individual patient. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology 2.5 to 10 mg norethindrone acetate tablets may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate tablets therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate tablets. Endometriosis Initial daily dosage of 5 mg norethindrone acetate tablets for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate tablets is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate Tablets, USP are available as: 5 mg: White, oval, flat-faced, beveled-edge, scored tablet. Debossed with stylized b on one side and 211/5 on the scored side. Available in bottles of 50 tablets (NDC 51407-599-50). Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [See USP Controlled Room Temperature]. Keep this and all medications out of the reach of children. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. B 11/2022 Marketed by: GSMS, Inc. Camarillo, CA 93012 USA"
    ],
    "how_supplied_table": [
      "<table><colgroup><col width=\"9%\"/><col width=\"91%\"/></colgroup><tbody><tr><td styleCode=\"Toprule\" valign=\"top\"><paragraph>5 mg:</paragraph></td><td styleCode=\"Toprule\" valign=\"top\"><paragraph>White, oval, flat-faced, beveled-edge, scored tablet. Debossed with stylized b on one side and 211/5 on the scored side. Available in bottles of 50 tablets (NDC 51407-599-50).</paragraph></td></tr></tbody></table>"
    ],
    "spl_patient_package_insert": [
      "PATIENT INFORMATION Norethindrone Acetate (nor eth\u2032 in drone as\u2032 e tate) Tablets, USP Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition. What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets? Do not use norethindrone acetate tablets if you are pregnant, breastfeeding or are trying to conceive. Do not use norethindrone acetate tablets if you have had a previous blood clot, stroke, or heart attack. Do not use norethindrone acetate tablets if you are postmenopausal. What are norethindrone acetate tablets? Norethindrone acetate tablets are similar to the progesterone hormones naturally produced by the body. Your healthcare provider may provide norethindrone acetate tablets as individual tablets. What are norethindrone acetate tablets used for? Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. Who should not take norethindrone acetate tablets? You should not take norethindrone acetate tablets if you are postmenopausal, pregnant, or breastfeeding. You should not take norethindrone acetate tablets if you have the following conditions: Known or suspected pregnancy . Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate tablets during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate tablets and later find out you were pregnant, talk with your healthcare provider right away. History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions Liver impairment or disease Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate tablets. Undiagnosed vaginal bleeding Hypersensitivity to norethindrone acetate tablets . See the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets. What are the risks associated with norethindrone acetate tablets? Risk to the Fetus Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. You should avoid using norethindrone acetate tablets during pregnancy. If you take Norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. Abnormal Blood Clotting Use of progestational drugs, such as norethindrone acetate tablets, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug. Eye Abnormalities Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. These are some of the warning signs of serious side effects with progestin therapy Breast lumps Dizziness and faintness Changes in speech Severe headaches Chest pain Shortness of breath Pains in your legs Changes in vision Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. Common side effects include Headache Breast pain Irregular vaginal bleeding or spotting Stomach/abdominal cramps/bloating Nausea and vomiting Hair loss Other side effects include High blood pressure Liver problems High blood sugar Fluid retention Enlargements of benign tumors of the uterus (\u201cfibroids\u201d) Vaginal yeast infections Mental depression These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist. What can I do to lower my chances of getting a serious side effect with norethindrone acetate tablets? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate tablets. Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks. General information about the safe and effective use of norethindrone acetate tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. Keep norethindrone acetate tablets out of the reach of children. This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate tablets that is written for health professionals. What are the ingredients in norethindrone acetate tablets? Norethindrone acetate tablets contain the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. B 11/2022 Marketed by: GSMS, Inc. Camarillo, CA 93012 USA"
    ],
    "package_label_principal_display_panel": [
      "Package/Label Display Panel NDC 51407-599-50 Norethindrone Acetate Tablets, USP 5 mg ORALLY ACTIVE PROGESTIN PHARMACIST: Dispense the accompanying Patient Information Leaflet to each patient. Rx only 50 TABLETS 51407-599-50OL - Norethindrone Acetate 5 mg - Rev. 0125.jpg"
    ],
    "set_id": "2bb29135-6e9b-a9e2-e063-6394a90ae9e4",
    "id": "2bb2a27e-11f5-a9fb-e063-6394a90a1ea8",
    "effective_time": "20250114",
    "version": "1",
    "openfda": {
      "application_number": [
        "ANDA075951"
      ],
      "brand_name": [
        "Norethindrone Acetate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "Golden State Medical Supply, Inc."
      ],
      "product_ndc": [
        "51407-599"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1000405"
      ],
      "spl_id": [
        "2bb2a27e-11f5-a9fb-e063-6394a90a1ea8"
      ],
      "spl_set_id": [
        "2bb29135-6e9b-a9e2-e063-6394a90ae9e4"
      ],
      "package_ndc": [
        "51407-599-50"
      ],
      "original_packager_product_ndc": [
        "0555-0211"
      ],
      "unii": [
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate NORETHINDRONE Ethinyl Estradiol Ethinyl Estradiol Lactose monohydrate STARCH, CORN POLYETHYLENE GLYCOL 300 Magnesium Stearate HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) .ALPHA.-TOCOPHEROL Titanium Dioxide Hypromellose, Unspecified Triacetin Polydextrose N2 Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate NORETHINDRONE Ethinyl Estradiol Ethinyl Estradiol Lactose monohydrate STARCH, CORN POLYETHYLENE GLYCOL 300 Magnesium Stearate HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) .ALPHA.-TOCOPHEROL FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE Talc Polyvinyl Alcohol, Unspecified Titanium Dioxide LECITHIN, SOYBEAN Light N1"
    ],
    "boxed_warning": [
      "WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER AND PROBABLE DEMENTIA WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER AND PROBABLE DEMENTIA See full prescribing information for complete boxed warning. Estrogen Plus Progestin Therapy Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI) ( 5.1 ) The WHI estrogen plus progestin substudy reported an increased risk of invasive breast cancer ( 5.2 ) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Estrogen-Alone Therapy There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 ) Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) The WHI estrogen-alone substudy reported increased risks of stroke and DVT ( 5.1 ) The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1 , 5.3) , and Clinical Studies (14.5 , 14.6) ] . The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [ see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ] . The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ] . Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2) , and Clinical Studies (14.5) ] . In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2) ] . Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1 , 5.3) , and Clinical Studies (14.5 , 14.6) ] . The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [ see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ] . The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ] . In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman."
    ],
    "recent_major_changes": [
      "Warnings and Precautions, Malignant Neoplasms (5.2) 11/2017"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Norethindrone acetate and Ethinyl estradiol tablets are an estrogen plus progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Prevention of Postmenopausal Osteoporosis ( 1.2 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be condisered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. One tablet taken orally once daily ( 2.1 , 2.2 ) 2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Norethindrone acetate and ethinyl estradiol tablets therapy consists of a single tablet to be taken orally once daily. 2.2 Prevention of Postmenopausal Osteoporosis Norethindrone acetate and ethinyl estradiol tablets therapy consists of a single tablet taken orally once daily."
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS The following two strengths of norethindrone acetate and ethinyl estradiol tablets are available: 0.5 mg/2.5 mcg: Each round light yellow tablet contains 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol; debossed with N1 on one side. 1 mg/5 mcg: Each round white tablet contains 1 mg norethindrone acetate and 5 mcg ethinyl estradiol; debossed with N2 on one side. Round light yellow tablet contains 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol ( 3 ) Round white tablet contains 1 mg norethindrone acetate and 5 mcg ethinyl estradiol ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Norethindrone acetate and ethinyl estradiol tablets are contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding Known, suspected, or history of breast cancer Known or suspected estrogen-dependent neoplasia Active DVT, PE or a history of these conditions Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions Known anaphylactic reaction or angioedema to Norethindrone acetate and Ethinyl estradiol tablets. Known liver impairment or disease Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders Known or suspected pregnancy Undiagnosed abnormal genital bleeding ( 4 ) Known, suspected, or history of breast cancer ( 4 , 5.2 ) Known or suspected estrogen-dependent neoplasia ( 4 , 5.2 ) Active DVT, PE, or history of these conditions ( 4 , 5.1 ) Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions ( 4 , 5.1 ) Known anaphylactic reaction or angioedema to norethindrone acetate and ethinyl estradiol tablets. ( 4 ) Known liver impairment or disease ( 4 , 5.10 ) Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders ( 4 ) Known or suspected pregnancy ( 4 , 8.1 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Estrogens increase the risk of gallbladder disease ( 5.4 ) Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs ( 5.5 , 5.6 , 5.9 , 5.10 ) Monitor thyroid function in women on thyroid replacement therapy ( 5.11 , 5.18 ) 5.1 Cardiovascular Disorders An increased risk of PE, DVT, stroke, and MI has been reported with estrogen plus progestin therapy. An increased risk of stroke and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately. Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. Stroke In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years) [see Clinical Studies (14.5) ]. The increase in risk was demonstrated after the first year and persisted. 1 Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily conjugated estrogens CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted [see Clinical Studies (14.5) ] . Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately. Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 Coronary Heart Disease In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). 1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies (14.5) ]. In the WHI estrogen-alone substudy, no overall effect on CHD events was reported in women receiving estrogen-alone compared to placebo 2 [see Clinical Studies (14.5) ]. Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 woman-years). 1 In postmenopausal women with documented heart disease (n = 2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall. Venous Thromboembolism In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE (DVT and PE) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted 3 [see Clinical Studies (14.5) ]. Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg) alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years 4 [see Clinical Studies (14.5) ]. Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately. If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism or during periods of prolonged immobilization. 5.2 Malignant Neoplasms Breast Cancer The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years for CE plus MPA compared with placebo [see Clinical Studies (14.5) ]. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86 and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups 5 [see Clinical Studies (14.5) ]. The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80 [see Clinical Studies (14.5) ]. Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors and prior mammogram results. Endometrial Cancer Endometrial hyperplasia (a possible precursor of endometrial cancer) has been reported to occur at a rate of approximately 1 percent or less with norethindrone acetate and ethinyl estradiol tablets. An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Ovarian Cancer The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77-3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. 7 A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. 5.3 Probable Dementia In the WHIMS estrogen plus progestin ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years 8 [see Use in Specific Populations (8.5) , and Clinical Studies (14.6) ]. In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8 [see Use in Specific Populations (8.5) , and Clinical Studies (14.6) ]. When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60). Since both ancillary substudies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Use in Specific Populations (8.5) , and Clinical Studies (14.6) ]. 5.4 Gallbladder Disease A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. 5.5 Hypercalcemia Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level. 5.6 Visual Abnormalities Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued. 5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. 5.8 Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen. 5.9 Hypertriglyceridemia In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Consider discontinuation of treatment if pancreatitis occurs. 5.10 Hepatic Impairment and/or a Past History of Cholestatic Jaundice Estrogens may be poorly metabolized in women with impaired liver function. For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued. 5.11 Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range. 5.12 Fluid Retention Estrogens plus progestins may cause some degree of fluid retention. Women with conditions that might be influenced by this factor, such as cardiac or renal impairment, warrant careful observation when estrogens plus progestins are prescribed. 5.13 Hypocalcemia Estrogen therapy should be used with caution in women with hypoparathyroidism as estrogen-induced hypocalcemia may occur. 5.14 Exacerbation of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual endometriosis post- hysterectomy, the addition of progestin should be considered. 5.15 Hereditary Angioedema Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. 5.16 Exacerbation of Other Conditions Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus and hepatic hemangiomas, and should be used with caution in women with these conditions. 5.17 Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms. 5.18 Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased TBG levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Norethindrone acetate and ethinyl estradiol tablets 1/5 was associated with an SHBG increase of 22 percent. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels. Impaired glucose tolerance."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Cardiovascular Disorders [see Boxed Warning , Warnings and Precautions (5.1) ]. Malignant Neoplasms [ see Boxed Warning , Warnings and Precautions (5.2) ]. Most common adverse reactions (incidence greater than or equal to 5 percent) are headache, abdominal pain, breast pain, and edema (generalized). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Nivagen Pharmaceuticals Toll-free at 1-877-977-0687 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported by \u22655 percent of subjects in controlled clinical studies of norethindrone acetate and ethinyl estradiol tablets are shown in Table 1. Table 1. Associated Adverse Reactions Reported by \u2265 5 Percent of Subjects by Body System The total number of subjects for each body system may be less than the number of subjects with AEs in that body system because a subject may have had more than one AE per body system BODY SYSTEM/ Adverse Reaction Number (Percent) of Subjects Placebo N = 247 NDAc-EE 0.5/2.5 NDAc-EE 0.5/2.5 = Norethindrone Acetate - Ethinyl Estradiol 0.5 mg/2.5 mcg NDAc-EE 1/5 = Norethindrone Acetate - Ethinyl Estradiol 1 mg/5 mcg N = 244 NDAc-EE 1/5 N = 258 BODY AS A WHOLE 23 (12.8) 30 (16.9) 30 (15.7) Edema \u2013 Generalized 10 (4.0) 12 (4.9) 11 (4.3) Headache 12 (4.9) 14 (5.7) 16 (6.2) DIGESTIVE SYSTEM 8 (4.4) 17 (9.6) 25 (13.1) Abdominal Pain 3 (1.2) 13 (5.3) 14 (6.8) UROGENITAL SYSTEM 20 (11.1) 34 (19.2) 45 (23.6) Breast Pain 9 (3.6) 22 (9.0) 20 (7.8) 6.2 Postmarketing Experience The following additional adverse reactions have been identified during post-approval use of norethindrone acetate and ethinyl estradiol tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; increase in size of uterine leiomyomata, vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer; uterine cancer; vaginal hemorrhage; ovarian cyst; irregular menstruation; metrorrhagia; menorrhagia; dysmenorrhea; uterine enlargement. Breasts Tenderness, enlargement, breast pain, nipple pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer; breast disorder; breast mass; breast enlargement. Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; thrombosis; chest pain; myocardial infarction; cerebrovascular accident (stroke); transient ischemic attack; hemiparesis; increase in blood pressure; irregular heart rate; palpitations; dyspnea. Gastrointestinal Nausea, vomiting; cholestatic jaundice; pancreatitis, enlargement of hepatic hemangiomas; bloating, abdominal cramps; abdominal pain; increased incidence of gallbladder disease; cholecystitis; cholelithiasis. Skin Chloasma or melasma that may persist when drug is discontinued; generalized erythema; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; rash, pruritus. Eyes Retinal vascular thrombosis; visual impairment; intolerance to contact lenses. Central Nervous System (CNS) Headache; migraine; dizziness; depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy, dementia; paresthesia; insomnia. Miscellaneous Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthralgias; leg cramps; back pain; changes in libido; urticaria, angioedema, anaphylactoid/anaphylactic reactions; hypocalcemia; exacerbation of asthma; increased triglycerides; blood glucose abnormal; fatigue; myalgia; hypersensitivity."
    ],
    "adverse_reactions_table": [
      "<table width=\"100%\"><caption>Table 1. Associated Adverse Reactions Reported by &#x2265; 5 Percent of Subjects by Body System<footnote>The total number of subjects for each body system may be less than the number of subjects with AEs in that body system because a subject may have had more than one AE per body system</footnote></caption><colgroup><col width=\"27%\" align=\"left\" valign=\"top\"/><col width=\"19%\" align=\"center\" valign=\"top\"/><col width=\"27%\" align=\"center\" valign=\"top\"/><col width=\"27%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr><th styleCode=\"Botrule Lrule Rrule\" rowspan=\"2\" align=\"left\">BODY SYSTEM/  Adverse Reaction</th><th styleCode=\"Botrule Rrule\" colspan=\"3\" align=\"center\">Number (Percent) of Subjects</th></tr><tr><th styleCode=\"Rrule\" align=\"center\">Placebo N = 247</th><th styleCode=\"Rrule\" align=\"center\">NDAc-EE 0.5/2.5<footnote ID=\"ft1b\">NDAc-EE 0.5/2.5 = Norethindrone Acetate - Ethinyl Estradiol 0.5 mg/2.5 mcg NDAc-EE 1/5 = Norethindrone Acetate - Ethinyl Estradiol 1 mg/5 mcg</footnote> N = 244</th><th styleCode=\"Rrule\" align=\"center\">NDAc-EE 1/5<footnoteRef IDREF=\"ft1b\"/> N = 258</th></tr></thead><tbody><tr><td styleCode=\"Lrule Rrule\" align=\"left\">BODY AS A WHOLE</td><td styleCode=\"Rrule\" align=\"center\">23 (12.8)</td><td styleCode=\"Rrule\" align=\"center\">30 (16.9)</td><td styleCode=\"Rrule\" align=\"center\">30 (15.7)</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">Edema &#x2013; Generalized</td><td styleCode=\"Rrule\" align=\"center\">10 (4.0)</td><td styleCode=\"Rrule\" align=\"center\">12 (4.9)</td><td styleCode=\"Rrule\" align=\"center\">11 (4.3)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Headache</td><td styleCode=\"Rrule\" align=\"center\">12 (4.9)</td><td styleCode=\"Rrule\" align=\"center\">14 (5.7)</td><td styleCode=\"Rrule\" align=\"center\">16 (6.2)</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">DIGESTIVE SYSTEM</td><td styleCode=\"Rrule\" align=\"center\">8 (4.4)</td><td styleCode=\"Rrule\" align=\"center\">17 (9.6)</td><td styleCode=\"Rrule\" align=\"center\">25 (13.1)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Abdominal Pain</td><td styleCode=\"Rrule\" align=\"center\">3 (1.2)</td><td styleCode=\"Rrule\" align=\"center\">13 (5.3)</td><td styleCode=\"Rrule\" align=\"center\">14 (6.8)</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">UROGENITAL SYSTEM</td><td styleCode=\"Rrule\" align=\"center\">20 (11.1)</td><td styleCode=\"Rrule\" align=\"center\">34 (19.2)</td><td styleCode=\"Rrule\" align=\"center\">45 (23.6)</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">Breast Pain</td><td styleCode=\"Rrule\" align=\"center\">9 (3.6)</td><td styleCode=\"Rrule\" align=\"center\">22 (9.0)</td><td styleCode=\"Rrule\" align=\"center\">20 (7.8)</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS No drug-drug interaction studies have been conducted for norethindrone acetate and ethinyl estradiol tablets . Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism ( 7.1 ) 7.1 Effect of Other Drugs on Combined Hormonal Products Substances decreasing or increasing the plasma concentration of estrogen: In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine and rifampin may decrease the plasma concentration of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase the plasma concentration of estrogens and may result in side effects. Co-administration of atorvastatin and certain hormonal products containing ethinyl estradiol increase AUC values for ethinyl estradiol approximately 20 percent. Ascorbic acid and acetaminophen may increase the plasma ethinyl estradiol concentration, possibly by inhibition of conjugation. 7.2 Effect of Combined Hormonal Products on Other Drugs Combination hormonal products containing some synthetic estrogens (for example, ethinyl estradiol) may inhibit the metabolism of other compounds. Combination hormonal products have been shown to significantly decrease the plasma concentration of lamotrigine likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Nursing Mothers: Estrogen administration to nursing women has been shown to decrease the quantity and quality of breast milk ( 8.3 ) Geriatric Use: An increased risk of probable dementia in women over 65 years of age was reported in the Women's Health Initiative Memory ancillary studies of the Women's Health Initiative ( 5.3 , 8.5 ) 8.1 Pregnancy Norethindrone acetate and ethinyl estradiol tablets should not be used during pregnancy [see Contraindications (4) ]. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. 8.3 Nursing Mothers Norethindrone acetate and ethinyl estradiol tablets should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogen and progestin have been identified in the breast milk of women receiving estrogen plus progestin therapy. Caution should be exercised when norethindrone acetate and ethinyl estradiol tablets are administered to a nursing woman. 8.4 Pediatric Use Norethindrone acetate and ethinyl estradiol tablets are not indicated in children. Clinical studies have not been conducted in the pediatric population. 8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing norethindrone acetate and ethinyl estradiol tablets to determine whether those over 65 years of age differ from younger subjects in their response to norethindrone acetate and ethinyl estradiol tablets. The Women's Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies (14.5) ]. In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [ see Clinical Studies (14.5) ] . The Women's Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo [see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ]. Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [ see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ]. 8.6 Renal Impairment The effect of renal impairment on the pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been studied. 8.7 Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been studied."
    ],
    "pregnancy": [
      "8.1 Pregnancy Norethindrone acetate and ethinyl estradiol tablets should not be used during pregnancy [see Contraindications (4) ]. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy."
    ],
    "nursing_mothers": [
      "8.3 Nursing Mothers Norethindrone acetate and ethinyl estradiol tablets should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogen and progestin have been identified in the breast milk of women receiving estrogen plus progestin therapy. Caution should be exercised when norethindrone acetate and ethinyl estradiol tablets are administered to a nursing woman."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Norethindrone acetate and ethinyl estradiol tablets are not indicated in children. Clinical studies have not been conducted in the pediatric population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing norethindrone acetate and ethinyl estradiol tablets to determine whether those over 65 years of age differ from younger subjects in their response to norethindrone acetate and ethinyl estradiol tablets. The Women's Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies (14.5) ]. In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [ see Clinical Studies (14.5) ] . The Women's Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo [see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ]. Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [ see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ]."
    ],
    "overdosage": [
      "10 OVERDOSAGE Overdosage of estrogen plus progestin may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of norethindrone acetate and ethinyl estradiol tablets with institution of appropriate symptomatic care."
    ],
    "description": [
      "11 DESCRIPTION Norethindrone acetate and ethinyl estradiol tablets are a continuous dosage regimen of a progestin-estrogen combination for oral administration. The following two strengths of norethindrone acetate and ethinyl estradiol tablets are available: 0.5 mg/2.5 mcg: Each round light yellow tablet contains 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol; debossed with N1 on one side. 1 mg/5 mcg: Each round white tablet contains 1 mg norethindrone acetate and 5 mcg ethinyl estradiol; debossed with N2 on one side. Each white tablet also contains lactose monohydrate, pregelatinized starch, polyethylene glycol, magnesium stearate, ethyl cellulose, vitamin E, titanium dioxide, hypromelloses, macrogol/PEG, triacetin, polydextrose. Each light yellow tablet also contains lactose monohydrate, pregelatinized starch, polyethylene glycol, magnesium stearate, ethyl cellulose, vitamin E, iron oxide yellow, iron oxide black, talc, polyvinyl alcohol, titanium dioxide, lecithin (soya). The structural formulas are as follows. Norethindrone Acetate [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)-]; Molecular Weight: 340.47 Molecular Formula: C22H28O3 Ethinyl Estradiol [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17\u03b1)-]; Molecular Weight: 296.41 Molecular Formula: C20H24O2 Chemical Structure Chemical Structure"
    ],
    "description_table": [
      "<table width=\"90%\" styleCode=\"Noautorules\"><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"50%\" align=\"left\" valign=\"top\"/><tbody><tr><td><paragraph><renderMultiMedia referencedObject=\"MM1\"/> Norethindrone Acetate [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17&#x3B1;)-]; Molecular Weight: 340.47 Molecular Formula: C22H28O3 </paragraph></td><td><paragraph><renderMultiMedia referencedObject=\"MM2\"/> Ethinyl Estradiol [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17&#x3B1;)-]; Molecular Weight: 296.41 Molecular Formula: C20H24O2 </paragraph></td></tr></tbody></table>"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. The pharmacologic effects of ethinyl estradiol are similar to those of endogenous estrogens.Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, bone, skeletal tissue and central nervous system. Progestins produce similar endometrial changes to those of the naturally occurring hormone progesterone. 12.2 Pharmacodynamics Currently, there are no pharmacodynamic data known for norethindrone acetate and ethinyl estradiol tablets. 12.3 Pharmacokinetics Absorption Norethindrone acetate (NA) is completely deacetylated to norethindrone after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol (EE) are absorbed from norethindrone acetate and ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol generally occurring 1 to 2 hours postdose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64 percent for norethindrone and 55 percent for ethinyl estradiol. Bioavailability of norethindrone acetate and ethinyl estradiol tablets is similar to that from solution for norethindrone and slightly less for ethinyl estradiol. Administration of norethindrone acetate and ethinyl estradiol tablets with a high fat meal decreases rate but not extent of ethinyl estradiol absorption. The extent of norethindrone absorption is increased by 27 percent following administration of norethindrone acetate and ethinyl estradiol tablets with food. The full pharmacokinetic profile of norethindrone acetate and ethinyl estradiol tablets was not characterized due to assay sensitivity limitations. However, the multiple-dose pharmacokinetics were studied at a dose of 1 mg NA/10 mcg EE in 18 postmenopausal women. Mean plasma concentrations are shown below (Figure 1) and pharmacokinetic parameters are found in Table 2. Based on a population pharmacokinetic analysis, mean steady-state concentrations of norethindrone for 1 mg NA/5 mcg EE and 1/10 are slightly more than proportional to dose when compared to 0.5 mg NA/2.5 mcg EE tablets. It can be explained by higher SHBG concentrations. Mean steady-state plasma concentrations of ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 0.5/2.5 tablets and norethindrone acetate and ethinyl estradiol 1/5 tablets are proportional to dose, but there is a less than proportional increase in steady-state concentrations for the NA/EE 1/10 tablet. Figure 1. Mean Steady-State (Day 87) Plasma Norethindrone and Ethinyl Estradiol Concentrations Following Continuous Oral Administration of 1 mg NA/10 mcg EE Tablets Table 2: Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters C max = Maximum plasma concentration; T max = Time of Cmax; AUC (0-24) = Area under the plasma concentration-time curve over the dosing interval; and CL/F = Apparent oral clearance; t\u00bd = Elimination half-life Following Administration of 1 mg NA/10 mcg EE Tablets C max t max AUC (0-24) CL/F t\u00bd Norethindrone ng/mL hr ng.hr/mL mL/min hr Day 1 6.0 (3.3) 1.8 (0.8) 29.7 (16.5) 588 (416) 10.3 (3.7) Day 87 10.7 (3.6) 1.8 (0.8) 81.8 (36.7) 226 (139) 13.3 (4.5) Ethinyl Estradiol pg/mL hr pg.hr/mL mL/min hr Day 1 33.5 (13.7) 2.2 (1.0) 339 (113) ND ND = Not determined ND Day 87 38.3 (11.9) 1.8 (0.7) 471 (132) 383 (119) 23.9 (7.1) Based on a population pharmacokinetic analysis, average steady-state concentrations (C ss ) of norethindrone acetate and ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 1/5 tablets are estimated to be 2.6 ng/mL and 11.4 pg/mL, respectively. C ss values of norethindrone and ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 0.5/2.5 tablets are estimated to be 1.1 ng/mL and 5.4 ng/mL, respectively. The pharmacokinetics of ethinyl estradiol and norethindrone acetate were not affected by age, (age range 40-62 years), in the postmenopausal population studied. Figure 1 Distribution The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin. Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95 percent); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol, such that exposure to ethinyl estradiol following administration of 1 mg of norethindrone acetate is equivalent to oral administration of 2.8 mcg ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of 1 mg NA/10 mcg EE tablets are approximately 13 hours and 24 hours, respectively. Use in Specific Populations No pharmacokinetic studies were conducted in specific populations, including women with renal or hepatic impairment."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"90%\"><caption>Table 2: Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters<footnote>C<sub>max</sub> = Maximum plasma concentration; T<sub>max</sub> = Time of Cmax; AUC<sub>(0-24)</sub> = Area under the plasma concentration-time curve over the dosing interval; and CL/F = Apparent oral clearance; t&#xBD; = Elimination half-life</footnote> Following Administration of 1 mg NA/10 mcg EE Tablets</caption><colgroup><col width=\"17%\" align=\"left\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th styleCode=\"Lrule Rrule\" align=\"left\"/><th styleCode=\"Rrule\" align=\"center\">C<sub>max</sub></th><th styleCode=\"Rrule\" align=\"center\">t<sub>max</sub></th><th styleCode=\"Rrule\" align=\"center\">AUC<sub>(0-24)</sub></th><th styleCode=\"Rrule\" align=\"center\">CL/F</th><th styleCode=\"Rrule\" align=\"center\">t&#xBD;</th></tr></thead><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" align=\"left\">Norethindrone</td><td styleCode=\"Rrule\" align=\"center\">ng/mL</td><td styleCode=\"Rrule\" align=\"center\">hr</td><td styleCode=\"Rrule\" align=\"center\">ng.hr/mL</td><td styleCode=\"Rrule\" align=\"center\">mL/min</td><td styleCode=\"Rrule\" align=\"center\">hr</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Day 1</td><td styleCode=\"Rrule\" align=\"center\">6.0 (3.3)</td><td styleCode=\"Rrule\" align=\"center\">1.8 (0.8)</td><td styleCode=\"Rrule\" align=\"center\">29.7 (16.5)</td><td styleCode=\"Rrule\" align=\"center\">588 (416)</td><td styleCode=\"Rrule\" align=\"center\">10.3 (3.7)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Day 87</td><td styleCode=\"Rrule\" align=\"center\">10.7 (3.6)</td><td styleCode=\"Rrule\" align=\"center\">1.8 (0.8)</td><td styleCode=\"Rrule\" align=\"center\">81.8 (36.7)</td><td styleCode=\"Rrule\" align=\"center\">226 (139)</td><td styleCode=\"Rrule\" align=\"center\">13.3 (4.5)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Ethinyl Estradiol</td><td styleCode=\"Rrule\" align=\"center\">pg/mL</td><td styleCode=\"Rrule\" align=\"center\">hr</td><td styleCode=\"Rrule\" align=\"center\">pg.hr/mL</td><td styleCode=\"Rrule\" align=\"center\">mL/min</td><td styleCode=\"Rrule\" align=\"center\">hr</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Day 1</td><td styleCode=\"Rrule\" align=\"center\">33.5 (13.7)</td><td styleCode=\"Rrule\" align=\"center\">2.2 (1.0)</td><td styleCode=\"Rrule\" align=\"center\">339 (113)</td><td styleCode=\"Rrule\" align=\"center\">ND <footnote ID=\"ft1\">ND = Not determined</footnote></td><td styleCode=\"Rrule\" align=\"center\">ND <footnoteRef IDREF=\"ft1\"/></td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">Day 87</td><td styleCode=\"Rrule\" align=\"center\">38.3 (11.9)</td><td styleCode=\"Rrule\" align=\"center\">1.8 (0.7)</td><td styleCode=\"Rrule\" align=\"center\">471 (132)</td><td styleCode=\"Rrule\" align=\"center\">383 (119)</td><td styleCode=\"Rrule\" align=\"center\">23.9 (7.1)</td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. The pharmacologic effects of ethinyl estradiol are similar to those of endogenous estrogens.Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, bone, skeletal tissue and central nervous system. Progestins produce similar endometrial changes to those of the naturally occurring hormone progesterone."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Currently, there are no pharmacodynamic data known for norethindrone acetate and ethinyl estradiol tablets."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption Norethindrone acetate (NA) is completely deacetylated to norethindrone after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol (EE) are absorbed from norethindrone acetate and ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol generally occurring 1 to 2 hours postdose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64 percent for norethindrone and 55 percent for ethinyl estradiol. Bioavailability of norethindrone acetate and ethinyl estradiol tablets is similar to that from solution for norethindrone and slightly less for ethinyl estradiol. Administration of norethindrone acetate and ethinyl estradiol tablets with a high fat meal decreases rate but not extent of ethinyl estradiol absorption. The extent of norethindrone absorption is increased by 27 percent following administration of norethindrone acetate and ethinyl estradiol tablets with food. The full pharmacokinetic profile of norethindrone acetate and ethinyl estradiol tablets was not characterized due to assay sensitivity limitations. However, the multiple-dose pharmacokinetics were studied at a dose of 1 mg NA/10 mcg EE in 18 postmenopausal women. Mean plasma concentrations are shown below (Figure 1) and pharmacokinetic parameters are found in Table 2. Based on a population pharmacokinetic analysis, mean steady-state concentrations of norethindrone for 1 mg NA/5 mcg EE and 1/10 are slightly more than proportional to dose when compared to 0.5 mg NA/2.5 mcg EE tablets. It can be explained by higher SHBG concentrations. Mean steady-state plasma concentrations of ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 0.5/2.5 tablets and norethindrone acetate and ethinyl estradiol 1/5 tablets are proportional to dose, but there is a less than proportional increase in steady-state concentrations for the NA/EE 1/10 tablet. Figure 1. Mean Steady-State (Day 87) Plasma Norethindrone and Ethinyl Estradiol Concentrations Following Continuous Oral Administration of 1 mg NA/10 mcg EE Tablets Table 2: Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters C max = Maximum plasma concentration; T max = Time of Cmax; AUC (0-24) = Area under the plasma concentration-time curve over the dosing interval; and CL/F = Apparent oral clearance; t\u00bd = Elimination half-life Following Administration of 1 mg NA/10 mcg EE Tablets C max t max AUC (0-24) CL/F t\u00bd Norethindrone ng/mL hr ng.hr/mL mL/min hr Day 1 6.0 (3.3) 1.8 (0.8) 29.7 (16.5) 588 (416) 10.3 (3.7) Day 87 10.7 (3.6) 1.8 (0.8) 81.8 (36.7) 226 (139) 13.3 (4.5) Ethinyl Estradiol pg/mL hr pg.hr/mL mL/min hr Day 1 33.5 (13.7) 2.2 (1.0) 339 (113) ND ND = Not determined ND Day 87 38.3 (11.9) 1.8 (0.7) 471 (132) 383 (119) 23.9 (7.1) Based on a population pharmacokinetic analysis, average steady-state concentrations (C ss ) of norethindrone acetate and ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 1/5 tablets are estimated to be 2.6 ng/mL and 11.4 pg/mL, respectively. C ss values of norethindrone and ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 0.5/2.5 tablets are estimated to be 1.1 ng/mL and 5.4 ng/mL, respectively. The pharmacokinetics of ethinyl estradiol and norethindrone acetate were not affected by age, (age range 40-62 years), in the postmenopausal population studied. Figure 1 Distribution The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin. Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95 percent); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol, such that exposure to ethinyl estradiol following administration of 1 mg of norethindrone acetate is equivalent to oral administration of 2.8 mcg ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of 1 mg NA/10 mcg EE tablets are approximately 13 hours and 24 hours, respectively. Use in Specific Populations No pharmacokinetic studies were conducted in specific populations, including women with renal or hepatic impairment."
    ],
    "pharmacokinetics_table": [
      "<table width=\"90%\"><caption>Table 2: Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters<footnote>C<sub>max</sub> = Maximum plasma concentration; T<sub>max</sub> = Time of Cmax; AUC<sub>(0-24)</sub> = Area under the plasma concentration-time curve over the dosing interval; and CL/F = Apparent oral clearance; t&#xBD; = Elimination half-life</footnote> Following Administration of 1 mg NA/10 mcg EE Tablets</caption><colgroup><col width=\"17%\" align=\"left\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th styleCode=\"Lrule Rrule\" align=\"left\"/><th styleCode=\"Rrule\" align=\"center\">C<sub>max</sub></th><th styleCode=\"Rrule\" align=\"center\">t<sub>max</sub></th><th styleCode=\"Rrule\" align=\"center\">AUC<sub>(0-24)</sub></th><th styleCode=\"Rrule\" align=\"center\">CL/F</th><th styleCode=\"Rrule\" align=\"center\">t&#xBD;</th></tr></thead><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" align=\"left\">Norethindrone</td><td styleCode=\"Rrule\" align=\"center\">ng/mL</td><td styleCode=\"Rrule\" align=\"center\">hr</td><td styleCode=\"Rrule\" align=\"center\">ng.hr/mL</td><td styleCode=\"Rrule\" align=\"center\">mL/min</td><td styleCode=\"Rrule\" align=\"center\">hr</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Day 1</td><td styleCode=\"Rrule\" align=\"center\">6.0 (3.3)</td><td styleCode=\"Rrule\" align=\"center\">1.8 (0.8)</td><td styleCode=\"Rrule\" align=\"center\">29.7 (16.5)</td><td styleCode=\"Rrule\" align=\"center\">588 (416)</td><td styleCode=\"Rrule\" align=\"center\">10.3 (3.7)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Day 87</td><td styleCode=\"Rrule\" align=\"center\">10.7 (3.6)</td><td styleCode=\"Rrule\" align=\"center\">1.8 (0.8)</td><td styleCode=\"Rrule\" align=\"center\">81.8 (36.7)</td><td styleCode=\"Rrule\" align=\"center\">226 (139)</td><td styleCode=\"Rrule\" align=\"center\">13.3 (4.5)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Ethinyl Estradiol</td><td styleCode=\"Rrule\" align=\"center\">pg/mL</td><td styleCode=\"Rrule\" align=\"center\">hr</td><td styleCode=\"Rrule\" align=\"center\">pg.hr/mL</td><td styleCode=\"Rrule\" align=\"center\">mL/min</td><td styleCode=\"Rrule\" align=\"center\">hr</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Day 1</td><td styleCode=\"Rrule\" align=\"center\">33.5 (13.7)</td><td styleCode=\"Rrule\" align=\"center\">2.2 (1.0)</td><td styleCode=\"Rrule\" align=\"center\">339 (113)</td><td styleCode=\"Rrule\" align=\"center\">ND <footnote ID=\"ft1\">ND = Not determined</footnote></td><td styleCode=\"Rrule\" align=\"center\">ND <footnoteRef IDREF=\"ft1\"/></td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">Day 87</td><td styleCode=\"Rrule\" align=\"center\">38.3 (11.9)</td><td styleCode=\"Rrule\" align=\"center\">1.8 (0.7)</td><td styleCode=\"Rrule\" align=\"center\">471 (132)</td><td styleCode=\"Rrule\" align=\"center\">383 (119)</td><td styleCode=\"Rrule\" align=\"center\">23.9 (7.1)</td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Effects on Vasomotor Symptoms A 12-week placebo-controlled, multicenter, randomized clinical trial was conducted in 266 symptomatic women who had at least 56 moderate to severe hot flushes during the week prior to randomization. On average, patients had 12 hot flushes per day upon study entry. A total of 66 women were randomized to receive norethindrone acetate and ethinyl estradiol 1/5 and 66 women were randomized to the placebo group. Norethindrone acetate and ethinyl estradiol 1/5 was shown to be statistically better than placebo at weeks 4, and 12 for relief of the frequency of moderate to severe vasomotor symptoms (see Table 3 ). In Table 4, norethindrone acetate and ethinyl estradiol 1/5 was shown to be statistically better than placebo at weeks 4 and 12 for relief of the severity of moderate to severe vasomotor symptoms. Table 3: Mean Change from Baseline in the Number of Moderate to Severe Vasomotor Symptoms per Week-ITT Population, LOCF Visit Placebo (N=66) Norethindrone Acetate and Ethinyl Estradiol 0.5/2.5 (N=67) Norethindrone Acetate and Ethinyl Estradiol 1/5 (N=66) ITT = intent to treat; LOCF = last observation carried forward; CI = confidence interval 2 randomized subjects (1 in Placebo and 1 in norethindrone acetate and ethinyl estradiol) did not return diaries. Baseline The baseline number of moderate to severe vasomotor symptoms (MSVS) is the weekly average number of MSVS during the two week prerandomization observation period. Mean (SD) 76.5 (21.4) 77.6 (26.5) 70.0 (16.6) Week 4 Mean (SD) 39.4 (27.6) 30.2 (26.1) 20.4 (22.7) Mean Change from Baseline (SD) -37.0 (26.6) -47.4 Denotes statistical significance at the 0.05 level (26.1) -49.6 (22.1) p-Value vs. Placebo (95% CI) ANCOVA - Analysis of Covariance model where the observation variable is change from baseline; independent variables include treatment, center and baseline as covariate. The 95% CI -Mann-Whitney confidence interval for the difference between means (not stratified by center). 0.041 ( -20.0, -1.0) <0.001 ( -22.0, -6.0) Week 12 Mean (SD) 31.1 (27.0) 13.8 (20.4) 11.3 (18.9) Mean Change from Baseline (SD) -45.3 (30.2) -63.8 (27.5) -58.7 (23.1) p-Value vs. Placebo (95% CI) <0.001 ( -27.0, -7.0) <0.001 ( -25.0, -5.0) Table 4: Mean Change from Baseline in the Daily Severity Score of Moderate to Severe Vasomotor Symptoms per Week - ITT Population, LOCF Visit Placebo (N=66) Norethindrone Acetate and Ethinyl Estradiol 0.5/2.5 (N=67) Norethindrone Acetate and Ethinyl Estradiol 1/5 (N=66) ITT = intent to treat; LOCF = last observation carried forward; CI = confidence interval 2 randomized subjects (1 in Placebo and 1 in norethindrone acetate and ethinyl estradiol) did not return diaries. Baseline The baseline severity of moderate to severe vasomotor symptoms (MSVS) is the daily severity score of MSVS during the two week pre-randomization observation period. Mean (SD) 2.49 (0.26) 2.48 (0.22) 2.47 (0.23) Week 4 Mean (SD) 2.13 (0.74) 1.88 (0.89) 1.45 (1.03) Mean Change from Baseline (SD) -0.36 (0.68) -0.59 (0.83) -1.02 Denotes statistical significance at the 0.05 level (1.06) p-Value vs. Placebo (95% CI) ANCOVA - Analysis of Covariance model where the observation variable is change from baseline; independent variables include treatment, center and baseline as covariate. The 95% CI - Mann-Whitney confidence interval for the difference between means (not stratified by center). - 0.130 ( -0.3, 0.0) <0.001 ( -0.9, -0.2) Week 5 Mean (SD) 2.06 (0.79) 1.68 (0.99) 1.23 (1.03) Mean Change from Baseline (SD) -0.44 (0.74) -0.80 (0.94) -1.24 (1.07) p-Value vs. Placebo (95% CI) - 0.041 ( -0.4, -0.0) <0.001 ( -1.2, -0.3) Week 12 Mean (SD) 1.82 (1.03) 1.22 (1.11) 1.02 (1.16) Mean Change from Baseline (SD) -0.67 (1.02) -1.26 (1.08) -1.45 (1.19) p-Value vs. Placebo (95% CI) - 0.002 ( -0.9, -0.2) <0.001 ( -1.4, -0.3) 14.2 Effects on the Endometrium A 2-year, placebo-controlled, multicenter, randomized clinical trial was conducted to determine the safety and efficacy of norethindrone acetate and ethinyl estradiol on maintaining bone mineral density, protecting the endometrium, and to determine effects on lipids. A total of 1265 women were enrolled and randomized to either placebo, 0.2 mg NA/1 mcg EE, norethindrone acetate and ethinyl estradiol 0.5/2.5, norethindrone acetate and ethinyl estradiol 1/5 and 1 mg NA/10 mcg EE or matching unopposed EE doses (1, 2.5, 5, or 10 mcg) for a total of 9 treatment groups. All participants received 1000 mg of calcium supplementation daily. Of the 1265 women randomized to the various treatment arms of this study, 137 were randomized to placebo, 146 to norethindrone acetate and ethinyl estradiol 1/5, 136 to norethindrone acetate and ethinyl estradiol 0.5/2.5 and 141 to EE 5 mcg and 137 to EE 2.5 mcg. Of these, 134 placebo, 143 norethindrone acetate and ethinyl estradiol 1/5, 136 norethindrone acetate and ethinyl estradiol 0.5/2.5,139 EE 5 mcg and 137 EE 2.5 mcg had a baseline endometrial result. Baseline biopsies were classified as normal (in approximately 95% of subjects), or insufficient tissue (in approximately 5% of subjects). Follow-up biopsies were obtained in approximately 70-80% of patients in each arm after 12 and 24 months of therapy. Results for norethindrone acetate and ethinyl estradiol 1/5 and appropriate comparators are shown in Table 5. Table 5: Endometrial Biopsy Results After 12 and 24 Months of Treatment (CHART Study, 376 -359) Endometrial Status Placebo Norethindrone Acetate and Ethinyl Estradiol EE Alone 0.5/2.5 1/5 2.5 mcg 5 mcg Number of Patients Biopsied at Baseline N= 134 N=136 N= 143 N=137 N=139 MONTH 12 (% Patients) Patients Biopsied (%) 113 (84) 103 (74) 110 (77) 100 (73) 114 (82) Insufficient Tissue 30 34 45 20 20 Atrophic Tissue 60 41 41 15 2 Proliferative Tissue 23 28 24 65 91 Endometrial Hyperplasia All patients with endometrial hyperplasia were carried forward for all time points 0 0 0 0 1 MONTH 24 (% Patients) Patients Biopsied (%) 94 (70) 99 (73) 102 (71) 89 (65) 107 (77) Insufficient Tissue 35 42 37 23 17 Atrophic Tissue 38 30 33 6 2 Proliferative Tissue 20 27 32 60 86 Endometrial Hyperplasia 1 0 0 0 2 14.3 Effects on Uterine Bleeding or Spotting The cumulative incidence of amenorrhea, defined as no bleeding or spotting obtained from subject recall, was evaluated over 12 months for norethindrone acetate and ethinyl estradiol (NA/EE) 1/5 and placebo arms. Results are shown in Figure 2. Figure 2. Patients With Cumulative Amenorrhea Over Time: Intent-to-Treat Population, Last Observation Carried Forward Figure 2 14.4 Effect on Bone Mineral Density In the 2 year study, trabecular bone mineral density (BMD) was assessed at lumbar spine using quantitative computed tomography. A total of 419 postmenopausal primarily Caucasian women, aged 40 to 64 years, with intact uteri and non-osteoporotic bone mineral densities were randomized (1:1:1) to norethindrone acetate and ethinyl estradiol 1/5, norethindrone acetate and ethinyl estradiol 0.5/2.5 or placebo. Approximately 75 percent of the subjects in each group completed the two-year study. All patients received 1000 mg calcium in divided doses. Vitamin D was not supplemented. As shown in Figure 3, women treated with norethindrone acetate and ethinyl estradiol 1/5 had an average increase of 3.1percent in lumbar spine BMD from baseline to Month 24. Women treated with placebo had average decreases of \u20136.3 percent in spinal BMD from baseline to Month 24. The differences in the changes from baseline to Month 24 in the norethindrone acetate and ethinyl estradiol 1/5 group compared with the placebo group were statistically significant. Figure 3: Mean Percent Change (+ SE) From Baseline in Volumetric Bone Mineral Density* at Lumbar Spine Measured by Quantitative Computed Tomography after 12 and 24 Months of Treatment (Intent-to-Treat Population) *It should be noted that when measured by QCT, BMD gains and losses are greater than when measured by dual X-ray absorptiometry (DXA). Therefore, the differences in the changes in BMD between the placebo and active drug treated groups will be larger when measured by QCT compared with DXA. Changes in BMD measured by DXA should not be compared with changes in BMD measured by QCT. Figure 3 14.5 Women's Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome. A \"global index\" included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other cause. The study did not evaluate the effects of CE plus MPA or CE-alone on menopausal symptoms. WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the \"global index\". The absolute excess risk of events included in the \"global index\" was 19 per 10,000 women-years. For those outcomes included in the WHI \"global index\" that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other), are presented in Table 6. These results reflect centrally adjudicated data after an average follow-up of 5.6 years. Table 6. Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 years Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi , Results are based on centrally adjudicated data. Event Relative Risk CE/MPA vs placebo (95 pecent nCI Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. ) CE/MPA n = 8506 Placebo n = 8102 Absolute Risk per 10,000 Women -years CHD events 1.23 (0.99 -1.53) 41 34 Non-fatal MI 1.28 (1.00 -1.63) 31 25 CHD death 1.10 (0.70 -1.75) 8 8 All strokes 1.31 (1.03 -1.68) 33 25 Ischemic stroke 1.44 (1.09 - 1.90) 26 18 Deep vein thrombosis Not included in \"global index\". 1.95 (1.43 -2.67) 26 13 Pulmonary embolism 2.13 (1.45 -3.11) 18 8 Invasive breast cancer Includes metastatic and non -metastatic breast cancer with the exception of in situ cancer. 1.24 (1.01 -1.54) 41 33 Colorectal cancer 0.61 (0.42 -0.87) 10 16 Endometrial cancer 0.81 (0.48 -1.36) 6 7 Cervical cancer 1.44 (0.47 -4.42) 2 1 Hip fracture 0.67 (0.47 -0.96) 11 16 Vertebral fractures 0.65 (0.46 -0.92) 11 17 Lower arm/wrist fractures 0.71 (0.59 -0.85) 44 62 Total fractures 0.76 (0.69 -0.83) 152 199 Overall Mortality , All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. 1.00 (0.83 -1.19) 52 52 Global Index A subset of the events was combined in a \"global index\" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other uses. 1.13 (1.02 -1.25) 184 165 Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age, a non-significant trend toward reduced risk for overall mortality [hazard ratio (HR) 0.69 (95 percent CI, 0.44-1.07)]. WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was also stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years, are presented in Table 7. Table 7. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI Adapted from numerous WHI publications. WHI publications can be viewed at www.nblbi.nih.gov/whi. Event Relative Risk CE vs placebo (95 percent nCI Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. ) CE n = 5,310 Placebo n = 5,429 Absolute Risk per 10,000 Women -years CHD events Results are based on centrally adjudicated data for an average follow -up of 7.1 years. 0.95 (0.78 -1.16) 54 57 Non - fatal MI 0.91 (0.73 - 1.14) 40 43 CHD death 1.01 (0.71 - 1.43) 16 16 All strokes 1.33 (1.05 -1.68) 45 33 Ischemic stroke 1.55 (1.19 - 2.01) 38 25 Deep vein thrombosis , Not included in \"global index\". 1.47 (1.06 -2.06) 23 15 Pulmonary embolism 1.37 (0.90 -2.07) 14 10 Invasive breast cancer 0.80 (0.62 -1.04) 28 34 Colorectal cancer Results are based on an average follow -up of 6.8 years. 1.08 (0.75 -1.55) 17 16 Hip fracture 0.65 (0.45 -0.94) 12 19 Vertebral fractures , 0.64 (0.44 -0.93) 11 18 Lower arm/wrist fractures , 0.58 (0.47 -0.72) 35 59 Total fractures , 0.71 (0.64 -0.80) 144 197 Deaths due to other causes , All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. 1.08 (0.88 -1.32) 53 50 Overall Mortality , 1.04 (0.88 -1.22) 79 75 Global Index A subset of the events was combined in a \"global index\" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. 1.02 (0.92 -1.13) 206 201 For those outcomes included in the WHI \"global index\" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone were 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. 9 The absolute excess risk of events included in the \"global index\" was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years (see Table 7 ). Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone therapy increased the risk of ischemic stroke, and this excess was present in all subgroups of women examined 10 (see Table 7 ). Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [HR 0.63 (95 percent CI, 0.36-1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46-1.11)]. 14.6 Women's Health Initiative Memory Study The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, and 18 percent were 75 years of age and older) to evaluate the effects of CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 per 10,000 women-years. Probable dementia as defined in this study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger post-menopausal women [see Warnings and Precautions (5.3) , and Use in Specific Populations (8.5) ]. The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) , and Use in Specific Populations (8.5) ]. When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) , and Use in Specific Populations (8.5) ]."
    ],
    "clinical_studies_table": [
      "<table ID=\"table3\" width=\"90%\"><caption>Table 3: Mean Change from Baseline in the Number of Moderate to Severe Vasomotor Symptoms per Week-ITT Population, LOCF</caption><colgroup><col width=\"30%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"left\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th styleCode=\"Lrule Rrule\" align=\"left\">Visit</th><th styleCode=\"Rrule\" align=\"left\">Placebo (N=66)</th><th styleCode=\"Rrule\" align=\"left\">Norethindrone Acetate and Ethinyl Estradiol 0.5/2.5 (N=67)</th><th styleCode=\"Rrule\" align=\"left\">Norethindrone Acetate and Ethinyl Estradiol 1/5 (N=66)</th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"4\">ITT = intent to treat; LOCF = last observation carried forward; CI = confidence interval 2 randomized subjects (1 in Placebo and 1 in norethindrone acetate and ethinyl estradiol) did not return diaries.</td></tr></tfoot><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" align=\"left\"><content styleCode=\"bold\">Baseline <footnote>The baseline number of moderate to severe vasomotor symptoms (MSVS) is the weekly average number of MSVS during the two week prerandomization observation period.</footnote></content></td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean (SD)</td><td styleCode=\"Rrule\" align=\"left\">76.5 (21.4)</td><td styleCode=\"Rrule\" align=\"left\">77.6 (26.5)</td><td styleCode=\"Rrule\" align=\"left\">70.0 (16.6)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Week 4</td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean (SD)</td><td styleCode=\"Rrule\" align=\"left\">39.4 (27.6)</td><td styleCode=\"Rrule\" align=\"left\">30.2 (26.1)</td><td styleCode=\"Rrule\" align=\"left\">20.4 (22.7)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean Change from Baseline (SD)</td><td styleCode=\"Rrule\" align=\"left\">-37.0 (26.6)</td><td styleCode=\"Rrule\" align=\"left\">-47.4<footnote ID=\"ft2\">Denotes statistical significance at the 0.05 level</footnote> (26.1)</td><td styleCode=\"Rrule\" align=\"left\">-49.6<footnoteRef IDREF=\"ft2\"/> (22.1)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">p-Value vs. Placebo (95% CI) <footnote ID=\"ft4\">ANCOVA - Analysis of Covariance model where the observation variable is change from baseline; independent variables include treatment, center and baseline as covariate. The 95% CI -Mann-Whitney confidence interval for the difference between means (not stratified by center).</footnote></td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\">0.041 ( -20.0, -1.0)</td><td styleCode=\"Rrule\" align=\"left\">&lt;0.001 ( -22.0, -6.0)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Week 12</td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean (SD)</td><td styleCode=\"Rrule\" align=\"left\">31.1 (27.0)</td><td styleCode=\"Rrule\" align=\"left\">13.8 (20.4)</td><td styleCode=\"Rrule\" align=\"left\">11.3 (18.9)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean Change from Baseline (SD)</td><td styleCode=\"Rrule\" align=\"left\">-45.3 (30.2)</td><td styleCode=\"Rrule\" align=\"left\">-63.8<footnoteRef IDREF=\"ft2\"/> (27.5)</td><td styleCode=\"Rrule\" align=\"left\">-58.7<footnoteRef IDREF=\"ft2\"/> (23.1)</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">p-Value vs. Placebo (95% CI) <footnoteRef IDREF=\"ft4\"/></td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\">&lt;0.001 ( -27.0, -7.0)</td><td styleCode=\"Rrule\" align=\"left\">&lt;0.001 ( -25.0, -5.0)</td></tr></tbody></table>",
      "<table width=\"90%\"><caption>Table 4: Mean Change from Baseline in the Daily Severity Score of Moderate to Severe Vasomotor Symptoms per Week - ITT Population, LOCF</caption><colgroup><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"left\" valign=\"top\"/></colgroup><thead><tr styleCode=\"Botrule First Last\"><th styleCode=\"Lrule Rrule\" align=\"left\">Visit</th><th styleCode=\"Rrule\" align=\"left\">Placebo (N=66)</th><th styleCode=\"Rrule\" align=\"left\">Norethindrone Acetate and Ethinyl Estradiol 0.5/2.5 (N=67)</th><th styleCode=\"Rrule\" align=\"left\">Norethindrone Acetate and Ethinyl Estradiol 1/5 (N=66)</th></tr></thead><tfoot><tr><td colspan=\"4\" align=\"left\" valign=\"top\">ITT = intent to treat; LOCF = last observation carried forward; CI = confidence interval 2 randomized subjects (1 in Placebo and 1 in norethindrone acetate and ethinyl estradiol) did not return diaries.</td></tr></tfoot><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" align=\"left\">Baseline <footnote ID=\"ft5\">The baseline severity of moderate to severe vasomotor symptoms (MSVS) is the daily severity score of MSVS during the two week pre-randomization observation period.</footnote></td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean (SD)</td><td styleCode=\"Rrule\" align=\"left\">2.49 (0.26)</td><td styleCode=\"Rrule\" align=\"left\">2.48 (0.22)</td><td styleCode=\"Rrule\" align=\"left\">2.47 (0.23)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Week 4</td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean (SD)</td><td styleCode=\"Rrule\" align=\"left\">2.13 (0.74)</td><td styleCode=\"Rrule\" align=\"left\">1.88 (0.89)</td><td styleCode=\"Rrule\" align=\"left\">1.45 (1.03)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean Change from Baseline (SD)</td><td styleCode=\"Rrule\" align=\"left\">-0.36 (0.68)</td><td styleCode=\"Rrule\" align=\"left\">-0.59 (0.83)</td><td styleCode=\"Rrule\" align=\"left\">-1.02<footnote ID=\"ft7\">Denotes statistical significance at the 0.05 level</footnote> (1.06)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">p-Value vs. Placebo (95% CI) <footnote ID=\"ft6\">ANCOVA - Analysis of Covariance model where the observation variable is change from baseline; independent variables include treatment, center and baseline as covariate. The 95% CI - Mann-Whitney confidence interval for the difference between means (not stratified by center).</footnote></td><td styleCode=\"Rrule\" align=\"left\">-</td><td styleCode=\"Rrule\" align=\"left\">0.130 ( -0.3, 0.0)</td><td styleCode=\"Rrule\" align=\"left\">&lt;0.001 ( -0.9, -0.2)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Week 5</td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean (SD)</td><td styleCode=\"Rrule\" align=\"left\">2.06 (0.79)</td><td styleCode=\"Rrule\" align=\"left\">1.68 (0.99)</td><td styleCode=\"Rrule\" align=\"left\">1.23 (1.03)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean Change from Baseline (SD)</td><td styleCode=\"Rrule\" align=\"left\">-0.44 (0.74)</td><td styleCode=\"Rrule\" align=\"left\">-0.80<footnoteRef IDREF=\"ft7\"/> (0.94)</td><td styleCode=\"Rrule\" align=\"left\">-1.24<footnoteRef IDREF=\"ft7\"/> (1.07)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">p-Value vs. Placebo (95% CI) <footnoteRef IDREF=\"ft6\"/></td><td styleCode=\"Rrule\" align=\"left\">-</td><td styleCode=\"Rrule\" align=\"left\">0.041 ( -0.4, -0.0)</td><td styleCode=\"Rrule\" align=\"left\">&lt;0.001 ( -1.2, -0.3)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Week 12</td><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/><td styleCode=\"Rrule\" align=\"left\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean (SD)</td><td styleCode=\"Rrule\" align=\"left\">1.82 (1.03)</td><td styleCode=\"Rrule\" align=\"left\">1.22 (1.11)</td><td styleCode=\"Rrule\" align=\"left\">1.02 (1.16)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Mean Change from Baseline (SD)</td><td styleCode=\"Rrule\" align=\"left\">-0.67 (1.02)</td><td styleCode=\"Rrule\" align=\"left\">-1.26<footnoteRef IDREF=\"ft7\"/> (1.08)</td><td styleCode=\"Rrule\" align=\"left\">-1.45<footnoteRef IDREF=\"ft7\"/> (1.19)</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">p-Value vs. Placebo (95% CI) <footnoteRef IDREF=\"ft6\"/></td><td styleCode=\"Rrule\" align=\"left\">-</td><td styleCode=\"Rrule\" align=\"left\">0.002 ( -0.9, -0.2)</td><td styleCode=\"Rrule\" align=\"left\">&lt;0.001 ( -1.4, -0.3)</td></tr></tbody></table>",
      "<table width=\"90%\"><caption>Table 5: Endometrial Biopsy Results After 12 and 24 Months of Treatment (CHART Study, 376 -359)</caption><colgroup><col width=\"30%\" align=\"left\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr styleCode=\"Botrule First\"><th styleCode=\"Lrule Rrule\" align=\"left\">Endometrial Status</th><th styleCode=\"Rrule\" align=\"center\">Placebo</th><th styleCode=\"Rrule\" colspan=\"2\" align=\"center\">Norethindrone Acetate and Ethinyl Estradiol</th><th styleCode=\"Rrule\" colspan=\"2\" align=\"center\">EE Alone</th></tr><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" align=\"left\"/><th styleCode=\"Rrule\" align=\"center\"/><th styleCode=\"Rrule\" align=\"center\">0.5/2.5</th><th styleCode=\"Rrule\" align=\"center\">1/5</th><th styleCode=\"Rrule\" align=\"center\">2.5 mcg</th><th styleCode=\"Rrule\" align=\"center\">5 mcg</th></tr><tr styleCode=\"Botrule Last\"><th styleCode=\"Lrule Rrule\" align=\"left\">Number of Patients Biopsied at Baseline</th><th styleCode=\"Rrule\" align=\"center\">N= 134</th><th styleCode=\"Rrule\" align=\"center\">N=136</th><th styleCode=\"Rrule\" align=\"center\">N= 143</th><th styleCode=\"Rrule\" align=\"center\">N=137</th><th styleCode=\"Rrule\" align=\"center\">N=139</th></tr></thead><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" align=\"left\">MONTH 12 (% Patients)</td><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Patients Biopsied (%)</td><td styleCode=\"Rrule\" align=\"center\">113 (84)</td><td styleCode=\"Rrule\" align=\"center\">103 (74)</td><td styleCode=\"Rrule\" align=\"center\">110 (77)</td><td styleCode=\"Rrule\" align=\"center\">100 (73)</td><td styleCode=\"Rrule\" align=\"center\">114 (82)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Insufficient Tissue</td><td styleCode=\"Rrule\" align=\"center\">30</td><td styleCode=\"Rrule\" align=\"center\">34</td><td styleCode=\"Rrule\" align=\"center\">45</td><td styleCode=\"Rrule\" align=\"center\">20</td><td styleCode=\"Rrule\" align=\"center\">20</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Atrophic Tissue</td><td styleCode=\"Rrule\" align=\"center\">60</td><td styleCode=\"Rrule\" align=\"center\">41</td><td styleCode=\"Rrule\" align=\"center\">41</td><td styleCode=\"Rrule\" align=\"center\">15</td><td styleCode=\"Rrule\" align=\"center\">2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Proliferative Tissue</td><td styleCode=\"Rrule\" align=\"center\">23</td><td styleCode=\"Rrule\" align=\"center\">28</td><td styleCode=\"Rrule\" align=\"center\">24</td><td styleCode=\"Rrule\" align=\"center\">65</td><td styleCode=\"Rrule\" align=\"center\">91</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Endometrial Hyperplasia<footnote ID=\"ft8\">All patients with endometrial hyperplasia were carried forward for all time points</footnote></td><td styleCode=\"Rrule\" align=\"center\">0</td><td styleCode=\"Rrule\" align=\"center\">0</td><td styleCode=\"Rrule\" align=\"center\">0</td><td styleCode=\"Rrule\" align=\"center\">0</td><td styleCode=\"Rrule\" align=\"center\">1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">MONTH 24 (% Patients)</td><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/><td styleCode=\"Rrule\" align=\"center\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Patients Biopsied (%)</td><td styleCode=\"Rrule\" align=\"center\">94 (70)</td><td styleCode=\"Rrule\" align=\"center\">99 (73)</td><td styleCode=\"Rrule\" align=\"center\">102 (71)</td><td styleCode=\"Rrule\" align=\"center\">89 (65)</td><td styleCode=\"Rrule\" align=\"center\">107 (77)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Insufficient Tissue</td><td styleCode=\"Rrule\" align=\"center\">35</td><td styleCode=\"Rrule\" align=\"center\">42</td><td styleCode=\"Rrule\" align=\"center\">37</td><td styleCode=\"Rrule\" align=\"center\">23</td><td styleCode=\"Rrule\" align=\"center\">17</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Atrophic Tissue</td><td styleCode=\"Rrule\" align=\"center\">38</td><td styleCode=\"Rrule\" align=\"center\">30</td><td styleCode=\"Rrule\" align=\"center\">33</td><td styleCode=\"Rrule\" align=\"center\">6</td><td styleCode=\"Rrule\" align=\"center\">2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\">Proliferative Tissue</td><td styleCode=\"Rrule\" align=\"center\">20</td><td styleCode=\"Rrule\" align=\"center\">27</td><td styleCode=\"Rrule\" align=\"center\">32</td><td styleCode=\"Rrule\" align=\"center\">60</td><td styleCode=\"Rrule\" align=\"center\">86</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\">Endometrial Hyperplasia<footnoteRef IDREF=\"ft8\"/></td><td styleCode=\"Rrule\" align=\"center\">1</td><td styleCode=\"Rrule\" align=\"center\">0</td><td styleCode=\"Rrule\" align=\"center\">0</td><td styleCode=\"Rrule\" align=\"center\">0</td><td styleCode=\"Rrule\" align=\"center\">2</td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\"><caption>Figure 2. Patients With Cumulative Amenorrhea Over Time: Intent-to-Treat Population, Last Observation Carried Forward</caption><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><renderMultiMedia referencedObject=\"MM4\"/></td></tr></tbody></table>",
      "<table width=\"90%\"><caption>Table 6. Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 years<footnote>Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi</footnote><sup>,</sup><footnote>Results are based on centrally adjudicated data.</footnote></caption><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Rrule Lrule\">Event</th><th styleCode=\"Rrule\">Relative Risk CE/MPA vs placebo (95 pecent nCI <footnote ID=\"ft10\">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote>)</th><th styleCode=\"Botrule Rrule\">CE/MPA n = 8506</th><th styleCode=\"Botrule Rrule\">Placebo n = 8102</th></tr><tr><th styleCode=\"Rrule Lrule\"/><th styleCode=\"Rrule\"/><th styleCode=\"Rrule\" colspan=\"2\">Absolute Risk per 10,000 Women -years</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">CHD events</td><td styleCode=\"Rrule\">1.23 (0.99 -1.53)</td><td styleCode=\"Rrule\">41</td><td styleCode=\"Rrule\">34</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\"><content styleCode=\"italics\">Non-fatal MI</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">1.28 (1.00 -1.63)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">31</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">25</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\"><content styleCode=\"italics\">CHD death</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">1.10 (0.70 -1.75)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">8</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">8</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">All strokes</td><td styleCode=\"Rrule\">1.31 (1.03 -1.68)</td><td styleCode=\"Rrule\">33</td><td styleCode=\"Rrule\">25</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\"><content styleCode=\"italics\">Ischemic stroke</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">1.44 (1.09</content> -<content styleCode=\"italics\">1.90)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">26</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">18</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Deep vein thrombosis <footnote ID=\"ft9\">Not included in &quot;global index&quot;.</footnote></td><td styleCode=\"Rrule\">1.95 (1.43 -2.67)</td><td styleCode=\"Rrule\">26</td><td styleCode=\"Rrule\">13</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Pulmonary embolism</td><td styleCode=\"Rrule\">2.13 (1.45 -3.11)</td><td styleCode=\"Rrule\">18</td><td styleCode=\"Rrule\">8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Invasive breast cancer <footnote>Includes metastatic and non -metastatic breast cancer with the exception of <content styleCode=\"italics\">in situ</content> cancer.</footnote></td><td styleCode=\"Rrule\">1.24 (1.01 -1.54)</td><td styleCode=\"Rrule\">41</td><td styleCode=\"Rrule\">33</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Colorectal cancer</td><td styleCode=\"Rrule\">0.61 (0.42 -0.87)</td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">16</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Endometrial cancer <footnoteRef IDREF=\"ft9\"/></td><td styleCode=\"Rrule\">0.81 (0.48 -1.36)</td><td styleCode=\"Rrule\">6</td><td styleCode=\"Rrule\">7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Cervical cancer <footnoteRef IDREF=\"ft9\"/></td><td styleCode=\"Rrule\">1.44 (0.47 -4.42)</td><td styleCode=\"Rrule\">2</td><td styleCode=\"Rrule\">1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Hip fracture</td><td styleCode=\"Rrule\">0.67 (0.47 -0.96)</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">16</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Vertebral fractures <footnoteRef IDREF=\"ft9\"/></td><td styleCode=\"Rrule\">0.65 (0.46 -0.92)</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">17</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Lower arm/wrist fractures <footnoteRef IDREF=\"ft9\"/></td><td styleCode=\"Rrule\">0.71 (0.59 -0.85)</td><td styleCode=\"Rrule\">44</td><td styleCode=\"Rrule\">62</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Total fractures <footnoteRef IDREF=\"ft9\"/></td><td styleCode=\"Rrule\">0.76 (0.69 -0.83)</td><td styleCode=\"Rrule\">152</td><td styleCode=\"Rrule\">199</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Overall Mortality <footnoteRef IDREF=\"ft10\"/><sup>, </sup><footnote> All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote></td><td styleCode=\"Rrule\">1.00 (0.83 -1.19)</td><td styleCode=\"Rrule\">52</td><td styleCode=\"Rrule\">52</td></tr><tr><td styleCode=\"Rrule Lrule\">Global Index <footnote>A subset of the events was combined in a &quot;global index&quot; defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other uses.</footnote></td><td styleCode=\"Rrule\">1.13 (1.02 -1.25)</td><td styleCode=\"Rrule\">184</td><td styleCode=\"Rrule\">165</td></tr></tbody></table>",
      "<table width=\"90%\" ID=\"table7\"><caption>Table 7. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI<footnote>Adapted from numerous WHI publications. WHI publications can be viewed at <content styleCode=\"italics\">www.nblbi.nih.gov/whi.</content></footnote></caption><col width=\"27%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"24%\" align=\"center\" valign=\"top\"/><col width=\"24%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Rrule Lrule\">Event</th><th styleCode=\"Rrule\">Relative Risk CE vs placebo (95 percent nCI <footnote>Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote> )</th><th styleCode=\"Botrule Rrule\">CE n = 5,310</th><th styleCode=\"Botrule Rrule\">Placebo n = 5,429</th></tr><tr><th styleCode=\"Rrule Lrule\"/><th styleCode=\"Rrule\"/><th styleCode=\"Rrule\" colspan=\"2\" align=\"center\">Absolute Risk per 10,000 Women -years</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">CHD events <footnote ID=\"ft11\">Results are based on centrally adjudicated data for an average follow -up of 7.1 years.</footnote></td><td styleCode=\"Rrule\">0.95 (0.78 -1.16)</td><td styleCode=\"Rrule\">54</td><td styleCode=\"Rrule\">57</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\"><content styleCode=\"italics\">Non</content> -<content styleCode=\"italics\">fatal MI </content><footnoteRef IDREF=\"ft11\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">0.91 (0.73</content> -<content styleCode=\"italics\">1.14)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">40</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">43</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\"><content styleCode=\"italics\">CHD death </content><footnoteRef IDREF=\"ft11\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">1.01 (0.71</content> -<content styleCode=\"italics\">1.43)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">16</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">16</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">All strokes <footnoteRef IDREF=\"ft11\"/></td><td styleCode=\"Rrule\">1.33 (1.05 -1.68)</td><td styleCode=\"Rrule\">45</td><td styleCode=\"Rrule\">33</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\"><content styleCode=\"italics\">Ischemic stroke </content><footnoteRef IDREF=\"ft11\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">1.55 (1.19</content> -<content styleCode=\"italics\">2.01)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">38</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">25</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Deep vein thrombosis <footnoteRef IDREF=\"ft11\"/><sup>,</sup><footnote ID=\"ft12\">Not included in &quot;global index&quot;.</footnote></td><td styleCode=\"Rrule\">1.47 (1.06 -2.06)</td><td styleCode=\"Rrule\">23</td><td styleCode=\"Rrule\">15</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Pulmonary embolism <footnoteRef IDREF=\"ft11\"/></td><td styleCode=\"Rrule\">1.37 (0.90 -2.07)</td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">10</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Invasive breast cancer <footnoteRef IDREF=\"ft11\"/></td><td styleCode=\"Rrule\">0.80 (0.62 -1.04)</td><td styleCode=\"Rrule\">28</td><td styleCode=\"Rrule\">34</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Colorectal cancer <footnote ID=\"ft13\">Results are based on an average follow -up of 6.8 years.</footnote></td><td styleCode=\"Rrule\">1.08 (0.75 -1.55)</td><td styleCode=\"Rrule\">17</td><td styleCode=\"Rrule\">16</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Hip fracture <footnoteRef IDREF=\"ft11\"/></td><td styleCode=\"Rrule\">0.65 (0.45 -0.94)</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">19</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Vertebral fractures <footnoteRef IDREF=\"ft11\"/><sup>,</sup><footnoteRef IDREF=\"ft12\"/></td><td styleCode=\"Rrule\">0.64 (0.44 -0.93)</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">18</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Lower arm/wrist fractures <footnoteRef IDREF=\"ft11\"/><sup>,</sup><footnoteRef IDREF=\"ft12\"/></td><td styleCode=\"Rrule\">0.58 (0.47 -0.72)</td><td styleCode=\"Rrule\">35</td><td styleCode=\"Rrule\">59</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Total fractures <footnoteRef IDREF=\"ft11\"/><sup>,</sup><footnoteRef IDREF=\"ft12\"/></td><td styleCode=\"Rrule\">0.71 (0.64 -0.80)</td><td styleCode=\"Rrule\">144</td><td styleCode=\"Rrule\">197</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Deaths due to other causes<footnoteRef IDREF=\"ft13\"/><sup>,</sup><footnote>All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote></td><td styleCode=\"Rrule\">1.08 (0.88 -1.32)</td><td styleCode=\"Rrule\">53</td><td styleCode=\"Rrule\">50</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Lrule\">Overall Mortality <footnoteRef IDREF=\"ft11\"/><sup>,</sup><footnoteRef IDREF=\"ft12\"/></td><td styleCode=\"Rrule\">1.04 (0.88 -1.22)</td><td styleCode=\"Rrule\">79</td><td styleCode=\"Rrule\">75</td></tr><tr><td styleCode=\"Rrule Lrule\">Global Index <footnote>A subset of the events was combined in a &quot;global index&quot; defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</footnote></td><td styleCode=\"Rrule\">1.02 (0.92 -1.13)</td><td styleCode=\"Rrule\">206</td><td styleCode=\"Rrule\">201</td></tr></tbody></table>"
    ],
    "references": [
      "15 REFERENCES Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA. 2007;297:1465-1477. Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365. Cushman M, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2004;292:1573-1580. Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med. 2006;166:772-780. Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA. 2003;289:3234-3253. Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA. 2006;295:1647-1657. Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. JAMA. 2003;290:1739-1748. Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA. 2004;291:2947-2958. Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. J Bone Miner Res. 2006;21:817-828. Hendrix SL, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Norethindrone acetate and ethinyl estradiol tablets are available in the following strength and package sizes: 1. 75834-129-84 Blister card of 28 round light yellow tablets with 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol 2. 75834-129-29 Carton containing 3 \u00d7 28 tablet blister cards each in a plastic compact. Each blister card contains 28 round light yellow tablets with 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol 3. 75834-129-90 Bottle of 90 round light yellow tablets with 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol 4. 75834-130-84 Blister card of 28 round white tablets with 1 mg norethindrone acetate and 5 mcg ethinyl estradiol 5. 75834-130-29 Carton containing 3 \u00d7 28 tablet blister cards each in a plastic compact. Each blister card contains 28 round white tablets with 1 mg norethindrone acetate and 5 mcg ethinyl estradiol 6. 75834-130-90 Bottle of 90 round white tablets with 1 mg norethindrone acetate and 5 mcg ethinyl estradiol. 16.2 Storage and Handling Store at 20\u00ba-25\u00ba C (68\u00ba-77\u00ba F); excursions permitted to 15 to 30\u00ba C (59 to 86\u00ba F) [see USP Controlled Room Temperature]."
    ],
    "how_supplied_table": [
      "<table width=\"100%\"><colgroup><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"80%\" align=\"left\" valign=\"top\"/></colgroup><tbody><tr><td align=\"left\">1. 75834-129-84</td><td align=\"left\">Blister card of 28 round light yellow tablets with 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol</td></tr><tr><td align=\"left\">2. 75834-129-29</td><td align=\"left\">Carton containing 3 &#xD7; 28 tablet blister cards each in a plastic compact. Each blister card contains 28 round light yellow tablets with 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol</td></tr><tr><td align=\"left\">3. 75834-129-90</td><td align=\"left\">Bottle of 90 round light yellow tablets with 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol</td></tr><tr><td align=\"left\">4. 75834-130-84</td><td align=\"left\">Blister card of 28 round white tablets with 1 mg norethindrone acetate and 5 mcg ethinyl estradiol</td></tr><tr><td align=\"left\">5. 75834-130-29</td><td align=\"left\">Carton containing 3 &#xD7; 28 tablet blister cards each in a plastic compact. Each blister card contains 28 round white tablets with 1 mg norethindrone acetate and 5 mcg ethinyl estradiol</td></tr><tr><td align=\"left\">6. 75834-130-90</td><td align=\"left\">Bottle of 90 round white tablets with 1 mg norethindrone acetate and 5 mcg ethinyl estradiol.</td></tr></tbody></table>"
    ],
    "storage_and_handling": [
      "16.2 Storage and Handling Store at 20\u00ba-25\u00ba C (68\u00ba-77\u00ba F); excursions permitted to 15 to 30\u00ba C (59 to 86\u00ba F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) 17.1 Abnormal Vaginal Bleeding Inform postmenopausal women of the importance of reporting abnormal vaginal bleeding to their healthcare provider as soon as possible [ see Warnings and Precautions (5.2) ]. 17.2 Possible Serious Adverse Reactions with Estrogen Plus Progestin Therapy Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestin therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia [see Warnings and Precautions (5.1 , 5.2 , 5.3) ]. 17.3 Possible Less Serious but Common Adverse Reactions with Estrogen Plus Progestin Therapy Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestin therapy such as headache, breast pain and tenderness, nausea and vomiting."
    ],
    "spl_unclassified_section": [
      "Distributed by: Nivagen Pharmaceuticals, Inc. Sacramento, CA 95827, USA Toll Free 1-877-977-0687 Manufactured by: Novast Laboratories Ltd. Nantong, China 226009 Iss. 08/2022 Rev D I0058"
    ],
    "spl_patient_package_insert": [
      "Patient Information Norethindrone Acetate and Ethinyl Estradiol Tablets USP 0.5 mg/2.5 mc g and 1 mg/5 mcg Read this Patient Information before you start taking norethindrone acetate and ethinyl estradiol tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. What is the most important information I should know about norethindrone acetate and ethinyl estradiol tablets (a combination of estrogen and progestin)? Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia (decline of brain function). Using estrogens with progestins may increase your chances of getting a heart attack, strokes, breast cancer, or blood clots. Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older. Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Using estrogen-alone may increase your chances of getting strokes or blood clots. Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older. You and your healthcare provider should talk regularly about whether you still need treatment with norethindrone acetate and ethinyl estradiol tablets . What are norethindrone acetate and ethinyl estradiol tablets ? Norethindrone acetate and ethinyl estradiol tablets are a prescription medicine that contains two kinds of hormones, an estrogen and a progestin. What are norethindrone acetate and ethinyl estradiol tablets used for? Norethindrone acetate and ethinyl estradiol tablets are used after menopause to: Reduce moderate to severe hot flushes Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the \"change of life\" or menopause, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes \"surgical menopause\". When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden intense episodes of heat and sweating (\"hot flashes\" or \"hot flushes\"). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. Help reduce your chances of getting osteoporosis (thin weak bones) If you use norethindrone acetate and ethinyl estradiol tablets only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you still need treatment with norethindrone acetate and ethinyl estradiol tablets. Who should not take norethindrone acetate and ethinyl estradiol tablets ? Do not take norethindrone acetate and ethinyl estradiol tablets if you have had your uterus (womb) removed (hysterectomy). Norethindrone acetate and ethinyl estradiol tablets contain a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not take norethindrone acetate and ethinyl estradiol tablets. Do not take norethindrone acetate and ethinyl estradiol tablets if you: have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. currently have or have had certain cancers. Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should take norethindrone acetate and ethinyl estradiol tablets had a stroke or heart attack currently have or have had blood clots currently have or have had liver problems have been diagnosed with a bleeding disorder are allergic to norethindrone acetate and ethinyl estradiol tablets or any of its ingredients. See the list of ingredients in norethindrone acetate and ethinyl estradiol tablets at the end of this leaflet. think you may be pregnant Norethindrone acetate and ethinyl estradiol tablets are not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results. Do not take norethindrone acetate and ethinyl estradiol tablets if the test is positive and talk to your healthcare provider. What should I tell my healthcare provider before I take norethindrone acetate and ethinyl estradiol tablets ? Before you take norethindrone acetate and ethinyl estradiol tablets, tell your healthcare provider if you: have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. have any other medical conditions Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop taking norethindrone acetate and ethinyl estradiol tablets . are breastfeeding The hormones in norethindrone acetate and ethinyl estradiol tablets can pass into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how norethindrone acetate and ethinyl estradiol tablets work. Norethindrone acetate and ethinyl estradiol tablets may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take norethindrone acetate and ethinyl estradiol tablets? Take norethindrone acetate and ethinyl estradiol tablets exactly as your healthcare provider tells you to take it. Take 1 norethindrone acetate and ethinyl estradiol tablet at the same time each day. You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether or not you still need treatment with norethindrone acetate and ethinyl estradiol tablets. What are the possible side effects of norethindrone acetate and ethinyl estradiol tablets ? Side effects are grouped by how serious they are and how often they happen when you are treated. Serious, but less common side effects include: heart attack stroke blood clots dementia breast cancer cancer of the lining of the uterus (womb) cancer of the ovary high blood pressure high blood sugar gallbladder disease liver problems changes in your thyroid hormone levels enlargement of benign tumors of the uterus (\"fibroids\") Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: new breast lumps unusual vaginal bleeding changes in vision or speech sudden new severe headaches severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Less serious, but common side effects include: headache breast pain irregular vaginal bleeding or spotting stomach or abdominal cramps, bloating hair loss fluid retention vaginal yeast infection These are not all the possible side effects of norethindrone acetate and ethinyl estradiol tablets. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or does not go away. To report SUSPECTED ADVERSE REACTIONS, contact Nivagen Pharmaceuticals Toll-free at 1-877-977-0687 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. What can I do to lower my chances of a serious side effect with norethindrone acetate and ethinyl estradiol tablets ? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate and ethinyl estradiol tablets. If you have a uterus, talk with your healthcare provider about whether the addition of a progestin is right for you. The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). See your healthcare provider right away if you develop vaginal bleeding while taking norethindrone acetate and ethinyl estradiol tablets. Have a pelvic exam, breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram (breast x-ray), you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or use tobacco, you may have a higher chance for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart disease. How should I store norethindrone acetate and ethinyl estradiol tablets? Store norethindrone acetate and ethinyl estradiol tablets at room temperature between 68\u00b0 to 77\u00b0 F (20\u00b0 to 25\u00b0 C). Keep norethindrone acetate and ethinyl estradiol tablets out of the reach of children. General information about the safe and effective use of norethindrone acetate and ethinyl estradiol tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate and ethinyl estradiol tablets for conditions for which it was not prescribed. Do not give norethindrone acetate and ethinyl estradiol tablets to other people, even if they have the same symptoms you have. It may harm them. This leaflet summarizes the most important information about norethindrone acetate and ethinyl estradiol tablets . If you would like more information, talk with your healthcare provider or pharmacist. You can ask your pharmacist or healthcare provider for information about norethindrone acetate and ethinyl estradiol tablets that is written for health professionals. For more information call 1-877-977-0687. What are the ingredients in norethindrone acetate and ethinyl estradiol tablets? Active Ingredients: norethindrone acetate and ethinyl estradiol Inactive Ingredients: Each white tablet also contains lactose monohydrate, pregelatinized starch, polyethylene glycol, magnesium stearate, ethyl cellulose, vitamin E, titanium dioxide, hypromelloses, macrogol/PEG, triacetin, polydextrose. Each light yellow tablet also contains lactose monohydrate, pregelatinized starch, polyethylene glycol, magnesium stearate, ethyl cellulose, vitamin E, iron oxide yellow, iron oxide black, talc, polyvinyl alcohol, titanium dioxide, lecithin (soya). This Patient Information has been approved by the U.S Food and Drug Administration. Distributed by: Nivagen Pharmaceuticals, Inc. Sacramento, CA 95827, USA Toll Free 1-877-977-0687 Manufactured by: Novast Laboratories Ltd. Nantong, China 226009 I0058 Iss. 08/2022 Rev D",
      "FDA-Approved Patient Labeling Patient Information Norethindrone Acetate and Ethinyl Estradiol Tablets, USP (0.5 mg/2.5 mcg and 1 mg/5 mcg) Read this Patient Information before you start taking norethindrone acetate and ethinyl estradiol tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. What is the most important information I should know about norethindrone acetate and ethinyl estradiol tablets (a combination of estrogen and progestin)? Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia (decline of brain function). Using estrogens with progestins may increase your chances of getting a heart attack, strokes, breast cancer, or blood clots. Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older. Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Using estrogen-alone may increase your chances of getting strokes or blood clots. Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older. You and your healthcare provider should talk regularly about whether you still need treatment with norethindrone acetate and ethinyl estradiol tablets. What are norethindrone acetate and ethinyl estradiol tablets ? Norethindrone acetate and ethinyl estradiol tablets are a prescription medicine that contains two kinds of hormones, an estrogen and a progestin. What are norethindrone acetate and ethinyl estradiol tablets used for? Norethindrone acetate and ethinyl estradiol tablets are used after menopause to: Reduce moderate to severe hot flushes Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the \"change of life\" or menopause, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes \"surgical menopause\". When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden intense episodes of heat and sweating (\"hot flashes\" or \"hot flushes\"). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. Help reduce your chances of getting osteoporosis (thin weak bones) If you use norethindrone acetate and ethinyl estradiol tablets only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you still need treatment with norethindrone acetate and ethinyl estradiol tablets. Who should not take norethindrone acetate and ethinyl estradiol tablets ? Do not take norethindrone acetate and ethinyl estradiol tablets if you have had your uterus (womb) removed (hysterectomy). Norethindrone acetate and ethinyl estradiol tablets contain a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not take norethindrone acetate and ethinyl estradiol tablets. Do not take norethindrone acetate and ethinyl estradiol tablets if you: have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. currently have or have had certain cancers. Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should take norethindrone acetate and ethinyl estradiol tablets had a stroke or heart attack currently have or have had blood clots currently have or have had liver problems have been diagnosed with a bleeding disorder are allergic to norethindrone acetate and ethinyl estradiol tablets or any of its ingredients. See the list of ingredients in norethindrone acetate and ethinyl estradiol tablets at the end of this leaflet. think you may be pregnant Norethindrone acetate and ethinyl estradiol tablets are not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results. Do not take norethindrone acetate and ethinyl estradiol tablets if the test is positive and talk to your healthcare provider. What should I tell my healthcare provider before I take norethindrone acetate and ethinyl estradiol tablets ? Before you take norethindrone acetate and ethinyl estradiol tablets , tell your healthcare provider if you: have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. have any other medical conditions Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop taking norethindrone acetate and ethinyl estradiol tablets. are breastfeeding The hormones in norethindrone acetate and ethinyl estradiol tablets can pass into your breast milk. Tell your healthcare provider about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how norethindrone acetate and ethinyl estradiol tablets work. Norethindrone acetate and ethinyl estradiol tablets may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take norethindrone acetate and ethinyl estradiol tablets ? Take norethindrone acetate and ethinyl estradiol tablets exactly as your healthcare provider tells you to take it. Take 1 norethindrone acetate and ethinyl estradiol tablet at the same time each day. You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether or not you still need treatment with norethindrone acetate and ethinyl estradiol tablets . What are the possible side effects of norethindrone acetate and ethinyl estradiol tablets ? Side effects are grouped by how serious they are and how often they happen when you are treated. Serious, but less common side effects include: heart attack stroke blood clots dementia breast cancer cancer of the lining of the uterus (womb) cancer of the ovary high blood pressure high blood sugar gallbladder disease liver problems changes in your thyroid hormone levels enlargement of benign tumors of the uterus (\"fibroids\") Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: new breast lumps unusual vaginal bleeding changes in vision or speech sudden new severe headaches severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Less serious, but common side effects include: headache breast pain irregular vaginal bleeding or spotting stomach or abdominal cramps, bloating hair loss fluid retention vaginal yeast infection These are not all the possible side effects of norethindrone acetate and ethinyl estradiol tablets . For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or does not go away. To report SUSPECTED ADVERSE REACTIONS, contact Nivagen Pharmaceuticals Toll-free at 1-877-977-0687 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. What can I do to lower my chances of a serious side effect with norethindrone acetate and ethinyl estradiol tablets ? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate and ethinyl estradiol tablets . If you have a uterus, talk with your healthcare provider about whether the addition of a progestin is right for you. The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). See your healthcare provider right away if you develop vaginal bleeding while taking norethindrone acetate and ethinyl estradiol tablets. Have a pelvic exam, breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram (breast x-ray), you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or use tobacco, you may have a higher chance for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart disease. How should I store norethindrone acetate and ethinyl estradiol tablets ? Store norethindrone acetate and ethinyl estradiol tablets at room temperature between 68\u00b0 to 77\u00b0 F (20\u00b0 to 25\u00b0 C). Keep norethindrone acetate and ethinyl estradiol tablets out of the reach of children. General information about the safe and effective use of norethindrone acetate and ethinyl estradiol tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate and ethinyl estradiol tablets for conditions for which it was not prescribed. Do not give norethindrone acetate and ethinyl estradiol tablets to other people, even if they have the same symptoms you have. It may harm them. This leaflet summarizes the most important information about norethindrone acetate and ethinyl estradiol tablets. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your pharmacist or healthcare provider for information about norethindrone acetate and ethinyl estradiol tablets that is written for health professionals. For more information call 1-877-977-0687. What are the ingredients in norethindrone acetate and ethinyl estradiol tablets? Active Ingredients: norethindrone acetate and ethinyl estradiol Inactive Ingredients: Each white tablet also contains lactose monohydrate, pregelatinized starch, polyethylene glycol, magnesium stearate, ethyl cellulose, vitamin E, titanium dioxide, hypromelloses, macrogol/PEG, triacetin, polydextrose. Each light yellow tablet also contains lactose monohydrate, pregelatinized starch, polyethylene glycol, magnesium stearate, ethyl cellulose, vitamin E, iron oxide yellow, iron oxide black, talc, polyvinyl alcohol, titanium dioxide, lecithin (soya). This Patient Information has been approved by the U.S Food and Drug Administration. Distributed by: Nivagen Pharmaceuticals, Inc. Sacramento, CA 95827, USA Toll Free 1-877-977-0687 Manufactured by: Novast Laboratories Ltd. Nantong, China 226009 I 0059 Rx only Iss. 08/2022 Rev. B"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><colgroup><col width=\"100%\" align=\"left\" valign=\"top\"/></colgroup><tbody><tr><td styleCode=\"Lrule Rrule\" align=\"left\"><content styleCode=\"bold\">What is the most important information I should know about <content styleCode=\"italics\">norethindrone acetate and ethinyl estradiol tablets </content>(a combination of estrogen and progestin)?</content></td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\"><list listType=\"unordered\"><item>Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia (decline of brain function).</item><item>Using estrogens with progestins may increase your chances of getting a heart attack, strokes, breast cancer, or blood clots.</item><item>Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.</item><item>Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia.</item><item>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).</item><item>Using estrogen-alone may increase your chances of getting strokes or blood clots.</item><item>Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.</item><item>You and your healthcare provider should talk regularly about whether you still need treatment with <content styleCode=\"italics\">norethindrone acetate and ethinyl estradiol tablets.</content></item></list></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 1 mg/5 mcg Tablet Blister Pack Carton 3 Blister Cards of 28 Tablets each. NDC 75834-130-29 Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1 mg/5 mcg Each light yellow tablet contains norethindrone acetate 1 mg and ethinyl estradiol 5 mcg. Each tablet dispenser contains 28 white tablets This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. Rx Only NIVAGEN PHARMACEUTICALS PRINCIPAL DISPLAY PANEL - 1 mg/5 mcg Tablet Blister Pack Carton",
      "PRINCIPAL DISPLAY PANEL - 0.5 mg/2.5 mcg Tablet Blister Pack Carton 3 Blister Cards of 28 Tablets each. NDC 75834-129-29 Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 0.5 mg/2.5 mcg Each light yellow tablet contains norethindrone acetate 0.5 mg and ethinyl estradiol 2.5 mcg. Each tablet dispenser contains 28 light yellow tablets This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. Rx Only NIVAGEN PHARMACEUTICALS PRINCIPAL DISPLAY PANEL - 0.5 mg/2.5 mcg Tablet Blister Pack Carton"
    ],
    "set_id": "2c2a37e1-adaf-4947-abb1-736bfa58bf98",
    "id": "4ffa902e-2cf8-4160-ba1e-f27e48b8e502",
    "effective_time": "20231124",
    "version": "5",
    "openfda": {
      "application_number": [
        "ANDA203435"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "Nivagen Pharmaceuticals, Inc."
      ],
      "product_ndc": [
        "75834-129",
        "75834-130"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ETHINYL ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1090992",
        "1251323",
        "1251334",
        "1251336"
      ],
      "spl_id": [
        "4ffa902e-2cf8-4160-ba1e-f27e48b8e502"
      ],
      "spl_set_id": [
        "2c2a37e1-adaf-4947-abb1-736bfa58bf98"
      ],
      "package_ndc": [
        "75834-130-84",
        "75834-130-29",
        "75834-130-90",
        "75834-129-84",
        "75834-129-29",
        "75834-129-90"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "423D2T571U",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone acetate norethindrone acetate NORETHINDRONE ACETATE NORETHINDRONE LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE white to off-white flat, beveled-edge P658"
    ],
    "description": [
      "DESCRIPTION Norethindrone acetate tablets, USP - 5 mg oral tablets. Norethindrone acetate, USP (17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white to yellowish-white, crystalline powder. Norethindrone acetate tablets, USP contain the following inactive ingredients: lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Meets USP dissolution Test 2. structure"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone. PHARMACOKINETICS Absorption: Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate tablets in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of norethindrone acetate tablets in Healthy Women Norethindrone acetate tablets (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC(0-inf)(ng/mL*h) 166.90\u00b156.28 C max (ng/mL) 26.19\u00b16.19 t max (h) 1.83\u00b10.58 t 1/2 (h) 8.51\u00b12.19 AUC= area under the curve C max = maximum plasma concentration t max = time at maximum plasma concentration t 1/2 = half-life SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Effect of Food: The effect of food administration on the pharmacokinetics of norethindrone acetate tablets has not been studied. Distribution: Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism: Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion: Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate tablets is approximately 9 hours. figure 1 SPECIAL POPULATIONS Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate tablets administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate tablets administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate tablets administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate tablets administration has not been evaluated. However, norethindrone acetate tablets are contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate tablets have been conducted."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"1042.72\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Table 1</content> Pharmacokinetic Parameters after a Single Dose of norethindrone acetate tablets in Healthy Women</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" valign=\"top\">Norethindrone acetate tablets (n=29) Arithmetic Mean &#xB1; SD</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" valign=\"top\">Norethindrone (NET)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">AUC(0-inf)(ng/mL*h)</td><td styleCode=\"Rrule\" valign=\"top\">166.90&#xB1;56.28</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">C<sub>max</sub>(ng/mL)</td><td styleCode=\"Rrule\" valign=\"top\">26.19&#xB1;6.19</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">t<sub>max</sub>(h)</td><td styleCode=\"Rrule\" valign=\"top\">1.83&#xB1;0.58</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">t<sub>1/2</sub>(h)</td><td styleCode=\"Rrule\" valign=\"top\">8.51&#xB1;2.19</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"2\" valign=\"top\">AUC= area under the curve C<sub>max</sub>= maximum plasma concentration t<sub>max</sub>= time at maximum plasma concentration t<sub>1/2</sub>= half-life SD = standard deviation</td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "PHARMACOKINETICS Absorption: Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate tablets in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of norethindrone acetate tablets in Healthy Women Norethindrone acetate tablets (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC(0-inf)(ng/mL*h) 166.90\u00b156.28 C max (ng/mL) 26.19\u00b16.19 t max (h) 1.83\u00b10.58 t 1/2 (h) 8.51\u00b12.19 AUC= area under the curve C max = maximum plasma concentration t max = time at maximum plasma concentration t 1/2 = half-life SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Effect of Food: The effect of food administration on the pharmacokinetics of norethindrone acetate tablets has not been studied. Distribution: Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism: Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion: Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate tablets is approximately 9 hours. figure 1"
    ],
    "pharmacokinetics_table": [
      "<table width=\"1042.72\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Table 1</content> Pharmacokinetic Parameters after a Single Dose of norethindrone acetate tablets in Healthy Women</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" valign=\"top\">Norethindrone acetate tablets (n=29) Arithmetic Mean &#xB1; SD</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" valign=\"top\">Norethindrone (NET)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">AUC(0-inf)(ng/mL*h)</td><td styleCode=\"Rrule\" valign=\"top\">166.90&#xB1;56.28</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">C<sub>max</sub>(ng/mL)</td><td styleCode=\"Rrule\" valign=\"top\">26.19&#xB1;6.19</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">t<sub>max</sub>(h)</td><td styleCode=\"Rrule\" valign=\"top\">1.83&#xB1;0.58</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">t<sub>1/2</sub>(h)</td><td styleCode=\"Rrule\" valign=\"top\">8.51&#xB1;2.19</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"2\" valign=\"top\">AUC= area under the curve C<sub>max</sub>= maximum plasma concentration t<sub>max</sub>= time at maximum plasma concentration t<sub>1/2</sub>= half-life SD = standard deviation</td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."
    ],
    "contraindications": [
      "CONTRAINDICATIONS Known or suspected pregnancy. There is no indication for norethindrone acetate tablets in pregnancy. (See PRECAUTIONS .) Undiagnosed vaginal bleeding Known, suspected or history of cancer of the breast Active deep vein thrombosis, pulmonary embolism or history of these conditions Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) Impaired liver function or liver disease As a diagnostic test for pregnancy Hypersensitivity to any of the drug components"
    ],
    "warnings": [
      "WARNINGS 1 Cardiovascular disorders Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. 2 Visual abnormalities Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued."
    ],
    "precautions": [
      "PRECAUTIONS 1 General Precautions Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy The pathologist should be advised of progestin therapy when relevant specimens are submitted 2 Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate tablets. 3 Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radio immunoassay) or T 3 levels by radio immunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test. 4 Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established. 5 Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses. 6 Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman. 7 Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "general_precautions": [
      "1 General Precautions Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy The pathologist should be advised of progestin therapy when relevant specimens are submitted"
    ],
    "information_for_patients": [
      "2 Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate tablets."
    ],
    "drug_and_or_laboratory_test_interactions": [
      "3 Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radio immunoassay) or T 3 levels by radio immunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "4 Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established."
    ],
    "pregnancy": [
      "5 Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses."
    ],
    "nursing_mothers": [
      "6 Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman."
    ],
    "pediatric_use": [
      "7 Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See WARNINGS and PRECAUTIONS The following adverse reactions have been observed in women taking progestins: Breakthrough bleeding Spotting Change in menstrual flow Amenorrhea Edema Changes in weight (decreases, increases) Changes in the cervical squamo-columnar junction and cervical secretions Cholestatic jaundice Rash (allergic) with and without pruritus Melasma or chloasma Clinical depression Acne Breast enlargement/tenderness Headache/migraine Urticaria Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) Decreased HDL cholesterol and increased LDL/HDL ratio Mood swings Nausea Insomnia Anaphylactic/anaphylactoid reactions Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) Optic neuritis (which may lead to partial or complete loss of vision) To report SUSPECTED ADVERSE REACTIONS, please call Ingenus Pharmaceuticals, LLC toll-free at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Therapy with norethindrone acetate tablets must be adapted to the specific indications and therapeutic response of the individual patient. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg norethindrone acetate tablets may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate tablets therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate tablets. Endometriosis: Initial daily dosage of 5 mg norethindrone acetate tablets for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate tablets is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone acetate tablets, USP are available as: 5 mg: White to off-white, oval, flat beveled edged tablet. 'P658' is engraved on one side, and a breakline on the reverse. Available as follows: Bottle of 50 NDC 50742-267-50 Bottle of 500 NDC 50742-267-05 Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [See USP Controlled Room Temperature]. Rx Only Revised: 05/2019 I0093 Rev B Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32839-6408 Made in China ingenus"
    ],
    "spl_patient_package_insert": [
      "PATIENT INFORMATION Norethindrone acetate (nor-eth-IN-drone as-i-teyt) tablets, USP Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition. What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets? Do not use norethindrone acetate tablets if you are pregnant, breast-feeding or are trying to conceive. Do not use norethindrone acetate tablets if you have had a previous blood clot, stroke, or heart attack. Do not use norethindrone acetate tablets if you are postmenopausal. What are norethindrone acetate tablets? Norethindrone acetate tablets are similar to the progesterone hormones naturally produced by the body. What are norethindrone acetate tablets used for? Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. Who should not take norethindrone acetate tablets? You should not take norethindrone acetate tablets if you are post-menopausal, pregnant or breastfeeding. You should not take norethindrone acetate tablets if you have the following conditions: Known or suspected pregnancy. Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate tablets during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate tablets and later find out you were pregnant, talk with your healthcare provider right away History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions Liver impairment or disease Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate tablets Undiagnosed vaginal bleeding Hypersensitivity to norethindrone acetate tablets. See the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets What are the risks associated with norethindrone acetate tablets? Risk to the Fetus: Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. You should avoid using norethindrone acetate tablets during pregnancy. If you take norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. Abnormal Blood Clotting: Use of progestational drugs, such as norethindrone acetate tablets, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug. Eye Abnormalities: Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. These are some of the warning signs of serious side effects with progestin therapy: Breast lumps Dizziness and faintness Changes in speech Severe headaches Chest pain Shortness of breath Pains in your legs Changes in vision Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. Common side effects include: Headache Breast pain Irregular vaginal bleeding or spotting Stomach/abdominal cramps/bloating Nausea and vomiting Hair loss Other side effects include: High blood pressure Liver problems High blood sugar Fluid retention Enlargements of benign tumors of the uterus (\u201cfibroids\u201d) Vaginal yeast infections Mental depression These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist. What can I do to lower my chances of getting a serious side effect with norethindrone acetate tablets? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate tablets Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks General information about the safe and effective use of norethindrone acetate tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. Keep norethindrone acetate tablets out of the reach of children. This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate tablets that is written for health professionals. What are the ingredients in norethindrone acetate tablets? Norethindrone acetate tablets contain the following inactive ingredients: lactose monohydrate, magnesium stearate, and microcrystalline cellulose Rx Only Revised: 05/2019 I0094 Rev B Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32839-6408 Made in China"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL ingenus NDC 50742-267-50 Norethindrone Acetate Tablets, USP 5 mg ORALLY ACTIVE PROGESTIN PHARMACIST: PLEASE DISPENSE WITH ATTACHED PATIENT INFORMATION LEAFLET Rx only 50 Tablets 50's Count Container Label"
    ],
    "set_id": "2f39b608-cc62-4ff0-a52a-bc3343275269",
    "id": "ec08066e-8299-493e-b502-e56db778b15e",
    "effective_time": "20231204",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA206490"
      ],
      "brand_name": [
        "Norethindrone acetate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "Ingenus Pharmaceuticals, LLC"
      ],
      "product_ndc": [
        "50742-267"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1000405"
      ],
      "spl_id": [
        "ec08066e-8299-493e-b502-e56db778b15e"
      ],
      "spl_set_id": [
        "2f39b608-cc62-4ff0-a52a-bc3343275269"
      ],
      "package_ndc": [
        "50742-267-50"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0350742267507"
      ],
      "unii": [
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol ETHINYL ESTRADIOL ETHINYL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE .ALPHA.-TOCOPHEROL, DL- ANHYDROUS LACTOSE CROSCARMELLOSE SODIUM FD&C BLUE NO. 1 LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K25 SODIUM LAURYL SULFATE SUCROSE light blue 237"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS )."
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are a progestogen-estrogen combination. Each blue tablet contains norethindrone acetate (19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)), 1.5 mg; ethinyl estradiol (19-Norpregna-1,3,5(10)-trien-20-yne-3, 17-diol, (17\u03b1)-), 0.03 mg. Also contains lactose anhydrous, dl -\u03b1-tocopherol, compressible sugar, croscarmellose sodium, FD & C Blue No. 1 Aluminum Lake, lactose monohydrate, magnesium stearate, povidone K-25, sodium lauryl sulphate. The structural formulas are as follows: Ethinyl Estradiol and Norethindrone Acetate Structural Formulas"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1-3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1-3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3). Special Population Race The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function. Drug-Drug Interactions Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions."
    ],
    "pharmacokinetics": [
      "Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature."
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD Adapted from RA Hatcher et al, Reference 7. % Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use Method Lowest Expected The authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. Typical This term represents \u201ctypical\u201d couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (No contraception) (85) (85) Oral contraceptives 3 Combined 0.1 N/A N/A - Data not available. progestin only 0.5 N/A Diaphragm with spermicidal cream or jelly 6 20 Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film) 6 26 Vaginal Sponge nulliparous 9 20 parous 20 40 Implant 0.05 0.05 Injection: depot medroxyprogesterone acetate 0.3 0.3 IUD progesterone T 1.5 2.0 copper T 380A 0.6 0.8 LNg 20 0.1 0.1 Condom without spermicides female 5 21 male 3 14 Cervical Cap with spermicidal cream or jelly nulliparous 9 20 parous 26 40 Periodic abstinence (all methods) 1-9 25 Withdrawal 4 19 Female sterilization 0.5 0.5 Male sterilization 0.10 0.15"
    ],
    "indications_and_usage_table": [
      "<table width=\"100%\"><col width=\"69%\"/><col width=\"19%\"/><col width=\"10%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Adapted from RA Hatcher et al, Reference 7.</td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>% Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Method</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Lowest Expected<footnote ID=\"_Ref126757270\">The authors&apos; best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Typical<footnote ID=\"_Ref126757284\">This term represents &#x201C;typical&#x201D; couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(No contraception) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(85)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(85)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Combined </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>N/A <footnote ID=\"_Ref126757294\">N/A - Data not available.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progestin only </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>N/A <footnoteRef IDREF=\"_Ref126757294\"/></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicidal cream or jelly </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone (foam, creams, gels, vaginal   suppositories, and vaginal film) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Implant </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.05</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.05</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: depot medroxyprogesterone acetate </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progesterone T </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> copper T 380A </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> LNg 20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom without spermicides</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> female </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>21</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> male </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>14</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Cervical Cap with spermicidal cream or jelly</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Periodic abstinence (all methods) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1-9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>25</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Withdrawal </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>19</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Female sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Male sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.15</paragraph></td></tr></tbody></table>"
    ],
    "contraindications": [
      "CONTRAINDICATIONS Oral contraceptives are contraindicated in women who currently have the following conditions: \u2022 Thrombophlebitis or thromboembolic disorders \u2022 A past history of deep vein thrombophlebitis or thromboembolic disorders \u2022 Cerebral vascular or coronary artery disease \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone sensitive \u2022 Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \u2022 Undiagnosed abnormal genital bleeding \u2022 Cholestatic jaundice of pregnancy or jaundice with prior pill use \u2022 Hepatic adenomas or carcinomas \u2022 Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT )."
    ],
    "warnings": [
      "WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author's permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial Infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10-16). The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases (17). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives. TABLE II CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity (19). In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism (20-24). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS ). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. TABLE II CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE b. Thromboembolism An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (9, 10, 25-30). Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8). A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives (15, 32). The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions (15, 32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. c. Cerebrovascular Disease Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (greater than 35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes (33-35). In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk is also greater in older women (9). d. Dose-related Risk of Vascular Disease from Oral Contraceptives A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (37-39). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (20-22). A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. e. Persistence of Risk of Vascular Disease There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40-49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (40). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens. 2. Estimates of Mortality from Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970's but not reported until 1983 (41). However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling. Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4; and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective. TABLE III ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Adapted from H.W. Ory, Reference 41. Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non- smoker Deaths are method related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom Deaths are birth related. 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/ spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 3. Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ). Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS, Postmarketing Experience ). Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women (42-45). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors 4. Hepatic Neoplasia Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (46). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (47,48). Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (49- 51) in long-term (greater than 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users. 5. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see Contraindications ). Norethindrone acetate and ethinyl estradiol tablets can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. Oral Contraceptive Use Before and During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy (52-54). Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned (52, 53, 55, 56), when taken inadvertently during early pregnancy. The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed. 8. Gallbladder Disease Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (57, 58). More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal (59-61). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance (62). Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (23, 63). However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (64). Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives. A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a . and 1d .), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking oral contraceptives (65) and this increase is more likely in older oral contraceptive users (66) and with continued use (65). Data from the Royal College of General Practitioners (18) and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal disease (67) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (66), and there is no difference in the occurrence of hypertension among ever and never users (65,67,68). 11. Headache The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause. 12. Bleeding Irregularities Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. 13. Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 14. Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets if depression recurs to a serious degree."
    ],
    "warnings_table": [
      "<table ID=\"_RefID34\" width=\"100%\"><caption>TABLE III ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"34%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><tfoot><tr><td align=\"left\" colspan=\"7\" valign=\"top\">Adapted from H.W. Ory, Reference 41.</td></tr></tfoot><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and  outcome</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">15-19</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">20-24</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">25-29</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">30-34</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">35-39</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">40-44</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>No fertility control methods</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>7.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>7.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>14.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>25.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>28.2</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives non- smoker<footnote ID=\"_Ref155757614\">Deaths are method related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>13.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>31.6</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives  smoker<footnoteRef IDREF=\"_Ref155757614\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>13.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>51.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>117.2</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD<footnoteRef IDREF=\"_Ref155757614\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom<footnote ID=\"_Ref155757641\">Deaths are birth related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm/ spermicide<footnoteRef IDREF=\"_Ref155757641\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.8</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref155757641\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>3.6</paragraph></td></tr></tbody></table>"
    ],
    "precautions": [
      "PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections. 2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. 3. Lipid Disorders Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. 4. Liver Function If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function. 5. Fluid Retention Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. 6. Contact Lenses Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 7. Drug Interactions Effects of Other Drugs on Oral Contraceptives (69) Rifampin Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Troglitazone Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness. Antibiotics Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation Co-administration of norethindrone acetate and ethinyl estradiol tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Co-administration of norethindrone acetate and ethinyl estradiol tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations. Other Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Oral Contraceptives on Other Drugs Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. 8. Interactions with Laboratory Tests Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: a. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T 4 by column or by radioimmunoassay. Free T 3 resin uptake is decreased, reflecting the elevated TBG; free T 4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged. e. Triglycerides may be increased. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives. 9. Carcinogenesis See WARNINGS section. 10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS section. 11. Lactation Small amounts of oral contraceptive steroids have been identified in human milk, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child. 12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."
    ],
    "drug_interactions": [
      "7. Drug Interactions Effects of Other Drugs on Oral Contraceptives (69) Rifampin Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Troglitazone Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness. Antibiotics Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation Co-administration of norethindrone acetate and ethinyl estradiol tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Co-administration of norethindrone acetate and ethinyl estradiol tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations. Other Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Oral Contraceptives on Other Drugs Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives."
    ],
    "pregnancy": [
      "10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS section."
    ],
    "nursing_mothers": [
      "11. Lactation Small amounts of oral contraceptive steroids have been identified in human milk, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child."
    ],
    "pediatric_use": [
      "12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."
    ],
    "spl_unclassified_section": [
      "PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( PATIENT PACKAGE INSERT BRIEF SUMMARY and DETAILED PATIENT PACKAGE INSERT ). \u2022 Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs (see BOXED WARNING and CONTRAINDICATIONS ). \u2022 Counsel patients that the increased risk of venous thromboembolism compared to non-users of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or greater interruption in intake) the same or a different CHC (see WARNINGS ). \u2022 Counsel patients that this product does not protect against HIV-infection (AIDS) and other sexually transmitted infections. \u2022 Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs (see PRECAUTIONS ). \u2022 Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established (see PRECAUTIONS ). \u2022 Counsel any patient who starts norethindrone acetate and ethinyl estradiol tablets postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a blue tablet for 7 consecutive days (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients that amenorrhea may occur. Pregnancy should be considered in the event of amenorrhea, and should be ruled out if amenorrhea is associated with symptoms of pregnancy, such as morning sickness or unusual breast tenderness (see WARNINGS ). \u2022 Counsel patients with a history of depression that depression may reoccur. Women should contact their healthcare provider if depression occurs (see WARNINGS )."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): \u2022 Thrombophlebitis \u2022 Arterial thromboembolism \u2022 Pulmonary embolism \u2022 Myocardial infarction \u2022 Cerebral hemorrhage \u2022 Cerebral thrombosis \u2022 Hypertension \u2022 Gallbladder disease \u2022 Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1) (70-74). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1) (70,73,75). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use. FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: \u2022 Mesenteric thrombosis \u2022 Retinal thrombosis The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related: \u2022 Nausea \u2022 Vomiting \u2022 Gastrointestinal symptoms (such as abdominal cramps and bloating) \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Temporary infertility after discontinuation of treatment \u2022 Edema \u2022 Melasma which may persist \u2022 Breast changes: tenderness, enlargement, secretion \u2022 Change in weight (increase or decrease) \u2022 Change in cervical erosion and secretion \u2022 Diminution in lactation when given immediately postpartum \u2022 Cholestatic jaundice \u2022 Migraine \u2022 Rash (allergic) \u2022 Depression \u2022 Reduced tolerance to carbohydrates \u2022 Vaginal candidiasis \u2022 Change in corneal curvature (steepening) \u2022 Intolerance to contact lenses The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted: \u2022 Pre-menstrual syndrome \u2022 Cataracts \u2022 Changes in appetite \u2022 Cystitis-like syndrome \u2022 Headache \u2022 Nervousness \u2022 Dizziness \u2022 Hirsutism \u2022 Loss of scalp hair \u2022 Erythema multiforme \u2022 Erythema nodosum \u2022 Hemorrhagic eruption \u2022 Vaginitis \u2022 Porphyria \u2022 Impaired renal function \u2022 Hemolytic uremic syndrome \u2022 Budd-Chiari syndrome \u2022 Acne \u2022 Changes in libido \u2022 Colitis FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES"
    ],
    "overdosage": [
      "OVERDOSAGE Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females. NON-CONTRACEPTIVE HEALTH BENEFITS The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (76-81). Effects on menses: \u2022 Increased menstrual cycle regularity \u2022 Decreased blood loss and decreased incidence of iron deficiency anemia \u2022 Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation: \u2022 Decreased incidence of functional ovarian cysts \u2022 Decreased incidence of ectopic pregnancies Effects from long-term use: \u2022 Decreased incidence of fibroadenomas and fibrocystic disease of the breast \u2022 Decreased incidence of acute pelvic inflammatory disease \u2022 Decreased incidence of endometrial cancer \u2022 Decreased incidence of ovarian cancer"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION The tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing on the tablet blister above the first row of tablets. Note: Each blister card has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days. Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen. The possibility of ovulation and conception prior to initiation of use should be considered. Dosage and Administration for 21-Day Dosage Regimen To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets must be taken exactly as directed and at intervals not exceeding 24 hours. Norethindrone acetate and ethinyl estradiol tablets provide the patient with a convenient tablet schedule of \u201c3 weeks on - 1 week off.\u201d Two dosage regimens are described, one of which may be more convenient or suitable than the other for an individual patient. For the initial cycle of therapy, the patient begins her tablets according to the Day-1 Start or Sunday-Start regimen. With either regimen, the patient takes one tablet daily for 21 consecutive days followed by one week of no tablets. A. Sunday-Start Regimen: The patient begins taking tablets from the top row on the first Sunday after menstrual flow begins. When menstrual flow begins on Sunday, the first tablet is taken on the same day. The last tablet in the blister pack will then be taken on a Saturday, followed by no tablets for a week (7 days). For all subsequent cycles, the patient then begins a new 21-tablet regimen on the eighth day, Sunday, after taking her last tablet. Following this regimen, of 21 days on \u2013 7 days off, the patient will start all subsequent cycles on a Sunday. B. Day-1 Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the blister pack. She starts taking one tablet daily, beginning with the first tablet in the top row. The patient completes her 21-tablet regimen when she has taken the last tablet in the tablet blister pack. She will then take no tablets for a week (7 days). For all subsequent cycles, the patient begins a new 21-tablet regimen on the eighth day after taking her last tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the tablet blister pack. Following this regimen of 21 days on \u2013 7 days off, the patient will start all subsequent cycles on the same day of the week as the first course. Likewise, the interval of no tablets will always start on the same day of the week. Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule. Special Notes on Administration Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after discontinuing medication. If spotting occurs while on the usual regimen of one tablet daily, the patient should continue medication without interruption. If the patient forgets to take one or more tablets, the following is suggested: One tablet is missed \u2022 take tablet as soon as remembered \u2022 take next tablet at the regular time Two consecutive tablets are missed (week 1 or week 2) \u2022 take two tablets as soon as remembered \u2022 take two tablets the next day \u2022 use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (week 3) Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets The possibility of ovulation occurring increases with each successive day that scheduled tablets are missed. While there is little likelihood of ovulation occurring if only one tablet is missed, the possibility of spotting or bleeding is increased. This is particularly likely to occur if two or more consecutive tablets are missed. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet blister pack on the next Sunday or the first day (Day 1), depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered. Use of Oral Contraceptives in the Event of a Missed Menstrual Period 1. If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out. 2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg are packaged in a carton of three pouches (NDC 0378-7274-53); each pouch contains a blister pack of 21 tablets. Each blister pack contains 21 blue, round, flat-faced, unscored tablet debossed with 237 on one side and plain on the other side. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]"
    ],
    "references": [
      "REFERENCES 1. Back DJ, Breckenridge AM, Crawford FE, Mclver M, Orme ML'E, Rowe PH and Smith E: Kinetics of norethindrone in women II. Single-dose kinetics. Clin Pharmacol Ther 1978; 24:448-453. 2. Humpel M, Nieuweboer B, Wendt H and Speck U: Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception 1979;19:421-432. 3. Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML'E, Rowe PH and Watts MJ. An investigation of the pharmacokinetics of ethinyl estradiol in women using radioimmunoassay. Contraception 1979;20:263-273. 4. Hammond GL, Lahteenmaki PLA, Lahteenmaki P and Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steriod Biochem 1982;17:375-380. 5. Fotherby K. Pharmacokinetics and metabolism of progestins in humans, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994;99-126. 6. Goldzieher JW. Pharmacokinetics and metabolism of ethynyl estrogens, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press Ltd., New York, 1994;127-151. 7. Hatcher RA, et al. 1998. Contraceptive Technology, Seventeenth Edition. New York: Irvington Publishers. 8. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 1). New England Journal of Medicine, 305:612-618, 1981. 9. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 2). New England Journal of Medicine, 305:672-677, 1981. 10. Adam, S.A., and M. Thorogood: Oral contraception and myocardial infarction revisited: The effects of new preparations and prescribing patterns. Brit. J. Obstet. and Gynec., 88:838-845, 1981. 11. Mann, J.I., and W.H. Inman: Oral contraceptives and death from myocardial infarction. Brit. Med. J., 2(5965): 245-248, 1975. 12. Mann, J.I., M.P. Vessey, M. Thorogood, and R. Doll: Myocardial infarction in young women with special reference to oral contraceptive practice. Brit. Med. J., 2(5956):241-245, 1975. 13. Royal College of General Practitioners' Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet, 1:541-546, 1981. 14. Slone, D., S. Shapiro, D.W. Kaufman, L. Rosenberg, O.S. Miettinen, and P.D. Stolley: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N.E.J.M., 305:420-424, 1981. 15. Vessey, M.P.: Female hormones and vascular disease: An epidemiological overview. Brit. J. Fam. Plann., 6:1-12, 1980. 16. Russell-Briefel, R.G., T.M. Ezzati, R. Fulwood, J.A. Perlman, and R.S. Murphy: Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Preventive Medicine , 15:352-362, 1986. 17. Goldbaum, G.M., J.S. Kendrick, G.C. Hogelin, and E.M. Gentry: The relative impact of smoking and oral contraceptive use on women in the United States. J.A.M.A., 258:1339-1342, 1987. 18. Layde, P.M., and V. Beral: Further analyses of mortality in oral contraceptive users: Royal College General Practitioners' Oral Contraception Study. (Table 5) Lancet, 1:541-546, 1981. 19. Knopp, R.H.: Arteriosclerosis risk: The roles of oral contraceptives and postmenopausal estrogens. J. of Reprod. Med., 31(9)(Supplement): 913-921, 1986. 20. Krauss, R.M., S. Roy, D.R. Mishell, J. Casagrande, and M.C. Pike: Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am. J. Obstet Gyn., 145:446-452, 1983. 21. Wahl, P., C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss, and B. Rifkind: Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N.E.J.M., 308:862-867, 1983. 22. Wynn, V., and R. Niththyananthan: The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am. J. Obstet. and Gyn., 142:766-771, 1982. 23. Wynn, V., and I. Godsland: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Medicine, 31 (9)(Supplement): 892-897, 1986. 24. LaRosa, J.C.: Atherosclerotic risk factors in cardiovascular disease. J. Reprod. Med., 31(9)(Supplement): 906-912, 1986. 25. Inman, W.H., and M.P. Vessey: Investigations of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Brit. Med. J., 2(5599): 193-199, 1968. 26. Maguire, M.G., J. Tonascia, P.E. Sartwell, P.D. Stolley, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives: A further report. Am. J. Epidemiology, 110(2): 188-195, 1979. 27. Pettiti, D.B., J. Wingerd, F. Pellegrin, and S. Ramacharan: Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J.A.M.A., 242:1150-1154, 1979. 28. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit. Med. J., 2(5599): 199-205, 1968. 29. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease: A further report. Brit. Med. J., 2(5658): 651-657, 1969. 30. Porter, J.B., J.R. Hunter, D.A. Danielson, H. Jick, and A. Stergachis: Oral contraceptives and non-fatal vascular disease: Recent experience. Obstet. and Gyn., 59(3):299-302, 1982. 31. Vessey, M., R. Doll, R. Peto, B. Johnson, and P. Wiggins: A long-term follow-up study of women using different methods of contraception: An interim report. J.Biosocial. Sci., 8:375-427, 1976. 32. Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J. of Royal College of General Practitioners, 28:393-399, 1978. 33. Collaborative Group for the study of stroke in young women: Oral contraception and increased risk of cerebral ischemia or thrombosis. N.E.J.M., 288:871-878, 1973. 34. Petitti, D.B., and J.Wingerd: Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet, 2:234-236, 1978. 35. Inman, W.H.: Oral contraceptives and fatal subarachnoid hemorrhage. Brit. Med. J., 2(6203): 1468-70, 1979. 36. Collaborative Group for the study of stroke in young women: Oral contraceptives and stroke in young women: Associated risk factors. J.A.M.A., 231:718-722, 1975. 37. Inman, W.H., M.P. Vessey, B. Westerholm, and A. Engelund: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Brit. Med. J., 2:203-209, 1970. 38. Meade, T.W., G. Greenberg, and S.G. Thompson: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Brit. Med. J., 280(6224): 1157-1161, 1980. 39. Kay, C.R.: Progestogens and arterial disease: Evidence from the Royal College of General Practitioners' study. Amer. J. Obstet. Gyn., 142:762-765, 1982. 40. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J. Coll. Gen. Pract., 33:75-82, 1983. 41. Ory, H.W: Mortality associated with fertility and fertility control: 1983. Family Planning Perspectives, 15:50-56, 1983. 42. Ory, H., Z. Naib, S.B. Conger, R.A. Hatcher, and C.W. Tyler: Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Am. J. Obstet. Gynec., 124:573-577, 1976. 43. Vessey, M.P., M. Lawless, K. McPherson, D. Yeates: Neoplasia of the cervix uteri and contraception: A possible adverse effect of the pill. Lancet, 2:930, 1983. 44. Brinton, L.A., G.R. Huggins, H.F. Lehman, K. Malli, D.A. Savitz, E. Trapido, J. Rosenthal, and R. Hoover: Long-term use of oral contraceptives and risk of invasive cervical cancer. Int. J. Cancer, 38:339-344, 1986. 45. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Brit. Med. J., 290:961-965, 1985. 46. Rooks, J.B., H.W. Ory, K.G. Ishak, L.T. Strauss, J.R. Greenspan, A.P. Hill, and C.W. Tyler: Epidemiology of hepatocellular adenoma: The role of oral contraceptive use. J.A.M.A., 242:644-648, 1979. 47. Bein, N.N., and H.S. Goldsmith: Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Brit. J. Surg., 64:433-435, 1977. 48. Klatskin, G.: Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology, 73:386-394, 1977. 49. Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike: Hepatocellular carcinoma and oral contraceptives. Brit. J. Cancer, 48:437-440, 1983. 50. Neuberger, J., D. Forman, R. Doll, and R. Williams: Oral contraceptives and hepatocellular carcinoma. Brit. Med. J., 292:1355-1357, 1986. 51. Forman, D., T.J. Vincent, and R. Doll: Cancer of the liver and oral contraceptives. Brit. Med. J., 292:1357-1361, 1986. 52. Harlap, S., and J. Eldor: Births following oral contraceptive failures. Obstet. Gynec., 55:447-452, 1980. 53. Savolainen, E., E. Saksela, and L. Saxen: Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Amer. J. Obstet. Gynec., 140:521-524, 1981. 54. Janerich, D.T., J.M. Piper, and D.M. Glebatis: Oral contraceptives and birth defects. Am. J. Epidemiology, 112:73-79, 1980. 55. Ferencz, C., G.M. Matanoski, P.D. Wilson, J.D. Rubin, C.A. Neill, and R. Gutberlet: Maternal hormone therapy and congenital heart disease. Teratology, 21:225-239, 1980. 56. Rothman, K.J., D.C. Fyler, A. Goldbatt, and M.B. Kreidberg: Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiology, 109:433-439, 1979. 57. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet, 1:1399-1404, 1973. 58. Royal College of General Practitioners: Oral Contraceptives and Health. New York, Pittman, 1974, 100p. 59. Layde, P.M., M.P. Vessey, and D. Yeates: Risk of gallbladder disease: A cohort study of young women attending family planning clinics. J. of Epidemiol. and Comm. Health, 36:274-278, 1982. 60. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am. J. Epidemiol., 119:796-805, 1984. 61. Strom, B.L., R.T. Tamragouri, M.L. Morse, E.L. Lazar, S.L. West, P.D. Stolley, and J.K. Jones: Oral contraceptives and other risk factors for gallbladder disease. Clin. Pharmacol. Ther., 39:335-341, 1986. 62. Wynn, V., P.W. Adams, I.F. Godsland, J. Melrose, R. Niththyananthan, N.W. Oakley, and A. Seedj: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet, 1:1045-1049, 1979. 63. Wynn, V.: Effect of progesterone and progestins on carbohydrate metabolism. In Progesterone and Progestin. Edited by C.W. Bardin, E. Milgrom, P. Mauvis-Jarvis. New York, Raven Press, pp. 395-410, 1983. 64. Perlman, J.A., R. G. Roussell-Briefel, T.M. Ezzati, and G. Lieberknecht: Oral glucose tolerance and the potency of oral contraceptive progestogens. J. Chronic Dis., 38:857-864, 1985. 65. Royal College of General Practitioners' Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet, 1:624, 1977. 66. Fisch, I.R., and J. Frank: Oral contraceptives and blood pressure. J.A.M.A., 237:2499-2503, 1977. 67. Laragh, A.J.: Oral contraceptive induced hypertension: Nine years later. Amer. J. Obstet. Gynecol., 126:141-147, 1976. 68. Ramcharan, S., E. Peritz, F.A. Pellegrin, and W.T. Williams: Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort. In Pharmacology of Steroid Contraceptive Drugs. Edited by S. Garattini and H.W. Berendes. New York, Raven Press , pp. 277-288, 1977. (Monographs of the Mario Negri Institute for Pharmacological Research, Milan.) 69. Back DJ, Orme ML'E. Drug interactions, in Pharmacology of the contraceptive steroids. Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994, 407-425. 70. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med . 2002;346(26):2025-2032. 71. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control . 2005;16(5):537-544. 72. Dorjgochoo T, Shu XO, Li HL, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer . 2009;124(10):2442-2449. 73. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(10):2496-2502. 74. Vessey M, Yeates D. Oral contraceptive use and cancer. Final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-683. 75. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med . 2017;377(23):2228-2239. 76. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. J.A.M.A., 249:1596-1599, 1983. 77. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. J.A.M.A., 257:796-800, 1987. 78. Ory, H.W.: Functional ovarian cysts and oral contraceptives: Negative association confirmed surgically. J.A.M.A., 228:68-69, 1974. 79. Ory, H.W., P. Cole, B. Macmahon, and R. Hoover: Oral contraceptives and reduced risk of benign breast disease. N.E.J.M., 294:41-422, 1976. 80. Ory, H.W.: The noncontraceptive health benefits from oral contraceptive use. Fam. Plann. Perspectives, 14:182-184, 1982. 81. Ory, H.W., J.D. Forrest, and R. Lincoln: Making Choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, p.1, 1983."
    ],
    "spl_patient_package_insert": [
      "Patient Package Insert BRIEF SUMMARY PATIENT PACKAGE INSERT This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Oral contraceptives, also known as \u201cbirth control pills\u201d or \u201cthe pill\u201d, are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you: \u2022 Smoke \u2022 Have high blood pressure, diabetes, high cholesterol \u2022 Have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast, jaundice, or malignant or benign liver tumors. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea, vomiting, and breakthrough bleeding may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill: 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack or angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences. 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. There may be slight increases in the risk of breast cancer among current users of hormonal birth control pills with longer duration of use of 8 years or more. Some studies have found an increase in the risk of developing cancer of the cervix in women taking the pill, but this finding may be related to differences in sexual behavior or other factors not related to use of the pill. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis. INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing on the tablet blister pack above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 blue tablets Norethindrone Acetate and Ethinyl Estradiol Tablets, 1.5 mg/0.03 mg Each blue tablet contains 1.5 mg norethindrone acetate and 0.03 mg ethinyl estradiol. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 21 PILLS: The 21-Day pill pack has 21 \u201cactive\u201d blue pills (with hormones) to take for 3 weeks, followed by 1 week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone Acetate and Ethinyl Estradiol Tablets, 1.5 mg/0.03 mg will contain: ALL BLUE PILLS. 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \u201cactive\u201d blue pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d blue pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 blue \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 blue \u201cactive\u201d pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 2 blue \u201cactive\u201d pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE blue \u201cactive\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE BLUE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic. Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] DETAILED PATIENT PACKAGE INSERT Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. What You Should Know About Oral Contraceptives Any woman who considers using oral contraceptives (the \u201cbirth control pill\u201d or \u201cthe pill\u201d) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider's advice with regard to regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES Oral contraceptives or \u201cbirth control pills\u201d or \u201cthe pill\u201d are used to prevent pregnancy and are more effective than other non-surgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 3% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: Implant: < 1% Male sterilization: < 1% Injection: < 1% Cervical Cap: 20 to 40% IUD: < 1 to 2% Condom alone (male): 14% Diaphragm with spermicides: 20% Condom alone (female): 21% Spermicides alone: 26% Periodic abstinence: 25% Vaginal Sponge: 20 to 40% Withdrawal: 19% Female sterilization: < 1% No method: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions: \u2022 A history of heart attack or stroke \u2022 Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), or eyes \u2022 A history of blood clots in the deep veins of your legs \u2022 Chest pain (angina pectoris) \u2022 Known or suspected breast cancer or cancer \u2022 Unexplained vaginal bleeding (until a diagnosis is reached by your doctor) \u2022 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill \u2022 Liver tumor (benign or cancerous) \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend a safer method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your healthcare provider if you have: \u2022 Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram \u2022 Diabetes \u2022 Elevated cholesterol or triglycerides \u2022 High blood pressure \u2022 Migraine or other headaches or epilepsy \u2022 Depression \u2022 Gallbladder, heart, or kidney disease \u2022 History of scanty or irregular menstrual periods Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. RISKS OF TAKING ORAL CONTRACEPTIVES 1. Risk of Developing Blood Clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives; in particular, a clot in the legs can cause thrombophlebitis, and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in GENERAL PRECAUTIONS .) 2. Heart Attacks and Strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder Disease Oral contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver Tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Risk of Cancer It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods Deaths are birth related. 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non- smoker Deaths are method related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/ spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7-26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: \u2022 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung) \u2022 Pain in the calf (indicating a possible clot in the leg) \u2022 Crushing chest pain or heaviness in the chest (indicating a possible heart attack) \u2022 Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) \u2022 Sudden partial or complete loss of vision (indicating a possible clot in the eye) \u2022 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts) \u2022 Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor) \u2022 Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression) \u2022 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark colored urine, or light-colored bowel movements (indicating possible liver problems) SIDE EFFECTS OF ORAL CONTRACEPTIVES 1. Vaginal Bleeding Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider. 2. Contact Lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider. 3. Fluid Retention Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or healthcare provider. 4. Melasma A spotty darkening of the skin is possible, particularly of the face. 5. Other Side Effects Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections. If any of these side effects bother you, call your doctor or healthcare provider. GENERAL PRECAUTIONS 1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception. There is no conclusive evidence that oral contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy. 2. While Breastfeeding If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely. 3. Laboratory Tests If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills. 4. Drug Interactions Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin \u00ae is one brand of this drug); troglitazone; phenylbutazone; and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective. Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications. 5. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis. INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing on the tablet blister pack above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 blue tablets Norethindrone Acetate and Ethinyl Estradiol Tablets, 1.5 mg/0.03 mg Each blue tablet contains 1.5 mg norethindrone acetate and 0.03 mg ethinyl estradiol. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 21 PILLS: The 21-Day pill pack has 21 \u201cactive\u201d blue pills (with hormones) to take for 3 weeks, followed by 1 week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone Acetate and Ethinyl Estradiol Tablets, 1.5 mg/0.03 mg will contain: ALL BLUE PILLS. 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. AN EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \u201cactive\u201d blue pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d blue pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 blue \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 blue \u201cactive\u201d pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 2 blue \u201cactive\u201d pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE blue \u201cactive\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE BLUE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic PREGNANCY DUE TO PILL FAILURE The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 3%. If failure does occur, the risk to the fetus is minimal. PREGNANCY AFTER STOPPING THE PILL There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. OVERDOSAGE Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. OTHER INFORMATION Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: \u2022 Menstrual cycles may become more regular \u2022 Blood flow during menstruation may be lighter and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur \u2022 Pain or other symptoms during menstruation may be encountered less frequently \u2022 Ectopic (tubal) pregnancy may occur less frequently \u2022 Noncancerous cysts or lumps in the breast may occur less frequently \u2022 Acute pelvic inflammatory disease may occur less frequently \u2022 Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the \u201cPhysician Insert\u201d, which you may wish to read. Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection. MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS At times there may be no menstrual period after a cycle of pills. Therefore, if you miss one menstrual period but have taken the pills exactly as you were supposed to, continue as usual into the next cycle. If you have not taken the pills correctly and miss a menstrual period, you may be pregnant and should stop taking oral contraceptives until your doctor or healthcare provider determines whether or not you are pregnant. Until you can get to your doctor or healthcare provider, use another form of contraception. If two consecutive menstrual periods are missed, you should stop taking pills until it is determined whether or not you are pregnant. Although there does not appear to be any increase in birth defects in newborn babies if you become pregnant while using oral contraceptives, you should discuss the situation with your doctor or healthcare provider. Periodic Examination Your doctor or healthcare provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaou smear, i.e., test for cancer). Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited, India Ahmedabad - 382 213, India Code No.: GUJ-DRUGS/G/28/1297 75101205 Revised: 1/2024 FC:OT:7274:R7 Brief Summary Patient Package Insert Figure 1 Brief Summary Patient Package Insert Figure 2 Detailed Patient Package Insert Figure 1 Detailed Patient Package Insert Figure 2"
    ],
    "spl_patient_package_insert_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"53%\"/><col width=\"45%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains:</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking:</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>21 blue tablets</paragraph></td><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl  Estradiol Tablets, 1.5 mg/0.03 mg</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</content> Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE BLUE &#x201C;ACTIVE&#x201D; PILL EACH DAY until you can reach your doctor or clinic. </paragraph></td></tr><tr><td styleCode=\"Botrule\" valign=\"bottom\"><paragraph> </paragraph><paragraph>Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. </paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"49%\"/><col width=\"49%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Implant: &lt; 1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Male sterilization: &lt; 1% </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: &lt; 1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Cervical Cap: 20 to 40% </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD: &lt; 1 to 2% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom alone (male): 14% </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicides: 20% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom alone (female): 21% </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone: 26% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Periodic abstinence: 25% </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge: 20 to 40% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Withdrawal: 19% </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Female sterilization: &lt; 1% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>No method: 85% </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"97%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID111\" width=\"100%\"><caption>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"34%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Method of control and  outcome</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">15-19</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">20-24</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">25-29</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">30-34</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">35-39</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">40-44</content> </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>No fertility control methods<footnote ID=\"_Ref126761654\">Deaths are birth related.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>9.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>14.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>25.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>28.2 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Oral contraceptives non- smoker<footnote ID=\"_Ref126761703\">Deaths are method related.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>31.6 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Oral contraceptives smoker<footnoteRef IDREF=\"_Ref126761703\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>3.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>6.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>51.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>117.2 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>IUD<footnoteRef IDREF=\"_Ref126761703\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Condom<footnoteRef IDREF=\"_Ref126761654\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.4 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Diaphragm/ spermicide<footnoteRef IDREF=\"_Ref126761654\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.8 </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref126761654\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>3.6 </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"44%\"/><col width=\"54%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains: </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking: </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>21 blue tablets </paragraph></td><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl  Estradiol Tablets, 1.5 mg/0.03 mg </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</content> Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE BLUE &#x201C;ACTIVE&#x201D; PILL EACH DAY until you can reach your doctor or clinic </paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 1.5 mg/0.03 mg NDC 0378-7274-53 Rx only Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1.5 mg/0.03 mg This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. 3 pouches, each contains one blister pack of 21 tablets Each blue tablet contains norethindrone acetate 1.5 mg and ethinyl estradiol 0.03 mg. Each blister pack contains 21 blue tablets. DOSAGE: One tablet daily as prescribed. See prescribing information. IMPORTANT: The \u201cPatient Instructions\u201d which are packaged inside each pouch provides important instructions to the patient. Please supply these instructions and the carrier sleeve to the patient when dispensing. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Keep this and all medications out of the reach of children. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Made in India Code No.: GUJ-DRUGS/G/28/1297 Mylan.com FC:7274:3C:R4 Norethindrone Acetate and Ethinyl Estradiol Tablets Label"
    ],
    "set_id": "3108a9bc-3378-459d-8f6b-bd5eff2ad657",
    "id": "8a7faa9f-224f-fb2e-fde2-986d2142dc2f",
    "effective_time": "20240115",
    "version": "6",
    "openfda": {
      "application_number": [
        "ANDA202770"
      ],
      "brand_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "Mylan Pharmaceuticals Inc."
      ],
      "product_ndc": [
        "0378-7274"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ETHINYL ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1359022",
        "1359028"
      ],
      "spl_id": [
        "8a7faa9f-224f-fb2e-fde2-986d2142dc2f"
      ],
      "spl_set_id": [
        "3108a9bc-3378-459d-8f6b-bd5eff2ad657"
      ],
      "package_ndc": [
        "0378-7274-85",
        "0378-7274-53"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "423D2T571U",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL LACTOSE MONOHYDRATE STARCH, CORN SUCROSE ACACIA TALC MAGNESIUM STEARATE off-white G;16"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS )."
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are progestogen-estrogen combinations. Each white to off-white tablet contains norethindrone acetate, USP (19-Norpregn-4-en-20-yn-3-one,17-(acetyloxy)-, (17\u03b1), 1 mg; ethinyl estradiol 19-Norpregna-1,3,5(10)-triene-20-yne-3,17-diol, (17 \u03b1), 20 mcg. Also contains acacia, lactose monohydrate, magnesium stearate, corn starch, sucrose and talc. The structural formulas are as follows: structure1 structure2"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1 to 3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1 to 3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1 to 3). Special Population Race: The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function. Drug-Drug Interactions Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions."
    ],
    "pharmacokinetics": [
      "Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature."
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE 1 LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD % Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use Method Lowest Expected* Typical** (No contraception) (85) (85) Oral contraceptives 3 combined 0.1 N/A*** progestin only 0.5 N/A*** Diaphragm with spermicidal cream or jelly 6 20 Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film) 6 26 Vaginal Sponge nulliparous 9 20 parous 20 40 Implant 0.05 0.05 Injection: depot medroxyprogesterone acetate 0.3 0.3 IUD progesterone T 1.5 2 copper T 380A 0.6 0.8 LNg 20 0.1 0.1 Condom without spermicides female 5 21 male 3 14 Cervical Cap with spermicidal cream or jelly nulliparous 9 20 parous 26 40 Periodic abstinence (all methods) 1 to 9 25 Withdrawal 4 19 Female sterilization 0.5 0.5 Male sterilization 0.1 0.15 Adapted from RA Hatcher et al, Reference 7. *The authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. **This term represents \u201ctypical\u201d couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason. ***N/A-Data not available."
    ],
    "indications_and_usage_table": [
      "<table width=\"100%\"><col width=\"56%\"/><col width=\"23%\"/><col width=\"20%\"/><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TABLE 1</content></paragraph><paragraph><content styleCode=\"bold\">LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD</content></paragraph><paragraph>% Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Method</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lowest Expected*</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Typical**</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>(No contraception)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>(85)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>(85)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Oral contraceptives</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> combined</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>N/A***</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> progestin only</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>N/A***</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Diaphragm with spermicidal cream or jelly</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Vaginal Sponge</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> nulliparous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> parous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Implant</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.05</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.05</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Injection: depot medroxyprogesterone acetate</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>IUD</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> progesterone T</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> copper T 380A</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> LNg 20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Condom without spermicides</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> female</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> male</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Cervical Cap with spermicidal cream or jelly</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> nulliparous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> parous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Periodic abstinence (all methods)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1 to 9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>25</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Withdrawal</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Female sterilization</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Male sterilization</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.15</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Adapted from RA Hatcher et al, Reference 7.</paragraph><paragraph>*The authors&apos; best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.</paragraph><paragraph>**This term represents &#x201C;typical&#x201D; couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</paragraph><paragraph>***N/A-Data not available.</paragraph></td></tr></tbody></table>"
    ],
    "contraindications": [
      "CONTRAINDICATIONS Oral contraceptives are contrainditaded in women who currently have the following conditions: \u2022 Thrombophlebitis or thromboembolic disorders \u2022 A past history of deep vein thrombophlebitis or thromboembolic disorders \u2022 Cerebral vascular or coronary artery disease \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone sensitive \u2022 Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \u2022 Undiagnosed abnormal genital bleeding \u2022 Cholestatic jaundice of pregnancy or jaundice with prior pill use \u2022 Hepatic adenomas or carcinomas \u2022 Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see WARNINGS , RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT )."
    ],
    "warnings": [
      "WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author\u2019s permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10 to 16). The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases (17). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives. Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity (19). In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism (20 to 24). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS ). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. b. Thromboembolism An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (9, 10, 25 to 30). Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8). A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives (15, 32). The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions (15, 32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. c. Cerebrovascular disease Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (greater than 35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes (33 to 35). In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk is also greater in older women (9). d. Dose-related risk of vascular disease from oral contraceptives A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (37 to 39). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (20 to 22). A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. e. Persistence of risk of vascular disease There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40 to 49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (40). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens. 2. Estimates of Mortality from Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970\u2019s but not reported until 1983 (41). However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling. Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4; and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective. TABLE III ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 No fertility control methods 7 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker** 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker** 2.2 3.4 6.6 13.5 51.1 117.2 IUD** 0.8 0.8 1 1 1.4 1.4 Condom* 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide* 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence* 2.5 1.6 1.6 1.7 2.9 3.6 *Deaths are birth related. **Deaths are method related. Adapted from H.W. Ory, Reference 41. 3. Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ). Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS ,Postmarketing Experience ). Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women (42 to 45). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. 4. Hepatic Neoplasia Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (46). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (47, 48). Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (49 to 51) in long-term (greater than 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users. 5. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see CONTRAINDICATIONS ). Norethindrone acetate and ethinyl estradiol tablets can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. Oral Contraceptive Use Before and During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy (52 to 54). Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned (52, 53, 55, 56), when taken inadvertently during early pregnancy. The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed. 8. Gallbladder Disease Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (57, 58). More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal (59 to 61). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance (62). Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (23, 63). However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (64). Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives. A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a . and 1d .), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking oral contraceptives (65) and this increase is more likely in older oral contraceptive users (66) and with continued use (65). Data from the Royal College of General Practitioners (18) and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal disease (67) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (66), and there is no difference in the occurrence of hypertension among ever and never users (65,67,68). 11. Headache The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause. 12. Bleeding Irregularities Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. 13. Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 14. Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets if depression recurs to a serious degree. table"
    ],
    "warnings_table": [
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"38%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"11%\"/><col width=\"10%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">15 to 19</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">20 to 24</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">25 to 29</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">30 to 34</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">35 to 39</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">40 to 44</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>No fertility control methods</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>9.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>14.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>25.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>28.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives non-smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>31.6</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>51.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>117.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>IUD**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Condom*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Diaphragm/spermicide*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.8</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Periodic abstinence*</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>3.6</paragraph></td></tr><tr><td colspan=\"7\" styleCode=\"Botrule \" valign=\"top\"><paragraph>*Deaths are birth related. **Deaths are method related.</paragraph></td></tr><tr><td colspan=\"7\" styleCode=\"Botrule \" valign=\"top\"><paragraph>Adapted from H.W. Ory, Reference 41.</paragraph></td></tr></tbody></table>"
    ],
    "precautions": [
      "PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections. 2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. 3. Lipid Disorders Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. 4. Liver Function If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function. 5. Fluid Retention Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. 6. Contact Lenses Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 7. Drug Interactions Effects of Other Drugs on Oral Contraceptives (69) Rifampin: Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants: Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Troglitazone: Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness. Antibiotics: Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. Concomitant Use with HCV Combination Therapy: Liver Enzyme Elevation Co-administeration of norethindrone acetate and ethinyl estradiol tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations (see WARNINGS, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Co-administration of norethindrone acetate and ethinyl estradiol tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations. Other: Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Oral Contraceptives on Other Drugs Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. 8. Interactions with Laboratory Tests Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: a. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged. e. Triglycerides may be increased. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives. 9. Carcinogenesis See WARNINGS section. 10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS sections. 11. Lactation Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child. 12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."
    ],
    "spl_unclassified_section": [
      "PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (PATIENT PACKAGE INSERT BRIEF SUMMARY and DETAILED PATIENT PACKAGE INSERT). \u2022 Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs (see BOXED WARNING and CONTRAINDICATIONS ). \u2022 Counsel patients that the increased risk of venous thromboembolism compared to non-users of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or greater interruption in intake) the same or a different CHC (see WARNINGS ). \u2022 Counsel patients that this product does not protect against HIV-infection (AIDS) and other sexually transmitted infections. \u2022 Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs (see PRECAUTIONS ). \u2022 Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established (see PRECAUTIONS ). \u2022 Counsel any patient who starts norethindrone acetate and ethinyl estradiol tablets postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a light-orange tablet for 7 consecutive days (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients that amenorrhea may occur. Pregnancy should be considered in the event of amenorrhea, and should be ruled out if amenorrhea is associated with symptoms of pregnancy, such as morning sickness or unusual breast tenderness (see WARNINGS ). Counsel patients with a history of depression that depression may reoccur. Women should contact their healthcare provider if depression occurs (see WARNINGS ).",
      "NON-CONTRACEPTIVE HEALTH BENEFITS The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (76 to 81). Effects on menses: \u2022 Increased menstrual cycle regularity \u2022 Decreased blood loss and decreased incidence of iron deficiency anemia \u2022 Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation: \u2022 Decreased incidence of functional ovarian cysts \u2022 Decreased incidence of ectopic pregnancies Effects from long-term use: \u2022 Decreased incidence of fibroadenomas and fibrocystic disease of the breast \u2022 Decreased incidence of acute pelvic inflammatory disease \u2022 Decreased incidence of endometrial cancer \u2022 Decreased incidence of ovarian cancer",
      "BRIEF SUMMARY PATIENT PACKAGE INSERT This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Oral contraceptives, also known as \"birth control pills\" or \"the pill,\" are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you: \u2022 Smoke \u2022 Have high blood pressure, diabetes, high cholesterol \u2022 Have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast or sex organs, jaundice, or malignant or benign liver tumors. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea, vomiting, and breakthrough bleeding may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill: 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack or angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences. 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. There may be slight increases in the risk of breast cancer among current users of hormonal birth control pills with longer duration of use of 8 years or more. Some studies have found an increase in the risk of developing cancer of the cervix in women taking the pill, but this finding may be related to differences in sexual behavior or other factors not related to use of the pill. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis.",
      "INSTRUCTIONS TO PATIENT TABLET DISPENSER The norethindrone acetate and ethinyl estradiol tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each with the days of the week appearing above the first row of tablets. Each white to off-white tablet contains 1 mg norethindrone acetate, USP and 0.02 mg ethinyl estradiol, USP. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet dispenser. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1 TO 3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK. IT HAS 21 PILLS: The 21-pill pack has 21 \"active\" white to off-white pills (with hormones) to take for 3 weeks, followed by 1week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following pictures: 4) the day label strips, if your period starts on a day other than Sunday 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the tablet blister over the area that has the days of the week (starting with Sunday) imprinted in the plastic. 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first \"active\" white to off-white pill of the first pack during the first 24 hours of your period . 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \"active\" white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: 21 pills: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \"active\" pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \"active\" pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 2 white to off-white \"active\" pills in a row in THE 3rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 3 OR MORE white to off-white \"active\" pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \"ACTIVE\" PILL EACH DAY until you can reach your doctor or clinic. Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. Keep this and all drugs out of the reach of children. Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture. blister1"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): \u2022 Thrombophlebitis \u2022 Arterial thromboembolism \u2022 Pulmonary embolism \u2022 Myocardial infarction \u2022 Cerebral hemorrhage \u2022 Cerebral thrombosis \u2022 Hypertension \u2022 Gallbladder disease \u2022 Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 1) (70-74). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1) (70, 73, 75). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 to 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8 to 10 years of COC use. FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: \u2022 Mesenteric thrombosis \u2022 Retinal thrombosis The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related: \u2022 Nausea \u2022 Vomiting \u2022 Gastrointestinal symptoms (such as abdominal cramps and bloating) \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Temporary infertility after discontinuation of treatment \u2022 Edema \u2022 Melasma which may persist \u2022 Breast changes: tenderness, enlargement, secretion \u2022 Change in weight (increase or decrease) \u2022 Change in cervical erosion and secretion \u2022 Diminution in lactation when given immediately postpartum \u2022 Cholestatic jaundice \u2022 Migraine \u2022 Rash (allergic) \u2022 Depression \u2022 Reduced tolerance to carbohydrates \u2022 Vaginal candidiasis \u2022 Change in corneal curvature (steepening) \u2022 Intolerance to contact lenses The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted: \u2022 Pre-menstrual syndrome \u2022 Cataracts \u2022 Changes in appetite \u2022 Cystitis-like syndrome \u2022 Headache \u2022 Nervousness \u2022 Dizziness \u2022 Hirsutism \u2022 Loss of scalp hair \u2022 Erythema multiforme \u2022 Erythema nodosum \u2022 Hemorrhagic eruption \u2022 Vaginitis \u2022 Porphyria \u2022 Impaired renal function \u2022 Hemolytic uremic syndrome \u2022 Budd-Chiari syndrome \u2022 Acne \u2022 Changes in libido \u2022 Colitis figure1"
    ],
    "overdosage": [
      "OVERDOSAGE Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females."
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION The tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing on the tablet dispenser above the first row of tablets. Note: Each tablet dispenser has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days. Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen. The possibility of ovulation and conception prior to initiation of use should be considered. Dosage and Administration for 21-Day Dosage Regimen To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets must be taken exactly as directed and at intervals not exceeding 24 hours. Norethindrone acetate and ethinyl estradiol tablets provides the patient with a convenient tablet schedule of \u201c3 weeks on-1 week off\u201d. Two dosage regimens are described, one of which may be more convenient or suitable than the other for an individual patient. For the initial cycle of therapy, the patient begins her tablets according to the Day-1 Start or Sunday-Start regimen. With either regimen, the patient takes one tablet daily for 21 consecutive days followed by one week of no tablets. A. Sunday-Start Regimen: The patient begins taking tablets from the top row on the first Sunday after menstrual flow begins. When menstrual flow begins on Sunday, the first tablet is taken on the same day. The last tablet in the dispenser will then be taken on a Saturday, followed by no tablets for a week (7 days). For all subsequent cycles, the patient then begins a new 21-tablet regimen on the eighth day, Sunday, after taking her last tablet. Following this regimen, of 21 days on -7 days off, the patient will start all subsequent cycles on a Sunday. B. Day-1 Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the tablet dispenser. She starts taking one tablet daily, beginning with the first tablet in the top row. The patient completes her 21-tablet regimen when she has taken the last tablet in the tablet dispenser. She will then take no tablets for a week (7 days). For all subsequent cycles, the patient begins a new 21-tablet regimen on the eighth day after taking her last tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the tablet dispenser. Following this regimen of 21 days on-7 days off, the patient will start all subsequent cycles on the same day of the week as the first course. Likewise, the interval of no tablets will always start on the same day of the week. Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule. Special Notes on Administration Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after discontinuing medication. If spotting occurs while on the usual regimen of one tablet daily, the patient should continue medication without interruption. If the patient forgets to take one or more tablets, the following is suggested: One tablet is missed \u2022 take tablet as soon as remembered \u2022 take next tablet at the regular time Two consecutive tablets are missed (week 1 or week 2) \u2022 take two tablets as soon as remembered \u2022 take two tablets the next day \u2022 use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (week 3) Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets The possibility of ovulation occurring increases with each successive day that scheduled tablets are missed. While there is little likelihood of ovulation occurring if only one tablet is missed, the possibility of spotting or bleeding is increased. This is particularly likely to occur if two or more consecutive tablets are missed. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet dispenser on the next Sunday or the first day (Day 1), depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered. Use of Oral Contraceptives in the Event of a Missed Menstrual Period 1. If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out. 2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy."
    ],
    "how_supplied": [
      "HOW SUPPLIED Product: 50090-6782 NDC: 50090-6782-0 21 TABLET in a BLISTER PACK / 1 in a CARTON"
    ],
    "references": [
      "REFERENCES 1. Back DJ, Breckenridge AM, Crawford FE, McIver M, Orme ML\u2019E, Rowe PH and Smith E: Kinetics of norethindrone in women II. Single-dose kinetics. Clin Pharmacol Ther 1978; 24:448-453. 2. H\u00fcmpel M, Nieuweboer B, Wendt H and Speck U: Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception 1979;19:421-432. 3. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML\u2019E, Rowe PH and Watts MJ. An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception 1979; 20:263-273. 4. Hammond GL, L\u00e4hteenm\u00e4ki PLA, L\u00e4hteenm\u00e4ki P and Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steriod Biochem 1982;17:375-380. 5. Fotherby K. Pharmacokinetics and metabolism of progestins in humans, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994; 99-126. 6. Goldzieher JW. Pharmacokinetics and metabolism of ethynyl estrogens, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press Ltd., New York, 1994; 127-151. 7. Hatcher RA, et al. 1998. Contraceptive Technology, Seventeenth Edition. New York: Irvington Publishers. 8. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 1). New England Journal of Medicine, 305:612-618, 1981. 9. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 2). New England Journal of Medicine , 305:672-677, 1981. 10. Adam, S.A., and M. Thorogood: Oral contraception and myocardial infarction revisited: The effects of new preparations and prescribing patterns. Brit. J. Obstet. and Gynec., 88:838-845, 1981. 11. Mann, J.I., and W.H. Inman: Oral contraceptives and death from myocardial infarction. Brit. Med. J., 2(5965): 245-248, 1975. 12. Mann, J.I., M.P. Vessey, M. Thorogood, and R. Doll: Myocardial infarction in young women with special reference to oral contraceptive practice. Brit. Med. J., 2(5956):241-245, 1975. 13. Royal College of General Practitioners\u2019 Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet, 1:541-546, 1981. 14. Slone, D., S. Shapiro, D.W. Kaufman, L. Rosenberg, O.S. Miettinen, and P.D. Stolley: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N.E.J.M., 305:420-424, 1981. 15. Vessey, M.P.: Female hormones and vascular disease: An epidemiological overview. Brit. J. Fam. Plann., 6:1-12, 1980. 16. Russell-Briefel, R.G., T.M. Ezzati, R. Fulwood, J.A. Perlman, and R.S. Murphy: Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Preventive Medicine, 15:352-362, 1986. 17. Goldbaum, G.M., J.S. Kendrick, G.C. Hogelin, and E.M. Gentry: The relative impact of smoking and oral contraceptive use on women in the United States. J.A.M.A., 258:1339-1342, 1987. 18. Layde, P.M., and V. Beral: Further analyses of mortality in oral contraceptive users: Royal College General Practitioners\u2019 Oral Contraception Study. (Table 5) Lancet, 1:541-546, 1981. 19. Knopp, R.H.: Arteriosclerosis risk: The roles of oral contraceptives and postmenopausal estrogens. J. of Reprod. Med. , 31(9)(Supplement): 913-921, 1986. 20. Krauss, R.M., S. Roy, D.R. Mishell, J. Casagrande, and M.C. Pike: Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am. J. Obstet. Gyn., 145:446-452, 1983. 21. Wahl, P., C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss, and B. Rifkind: Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N.E.J.M., 308:862-867, 1983. 22. Wynn, V., and R. Niththyananthan: The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am. J. Obstet. and Gyn., 142:766-771, 1982. 23. Wynn, V., and I. Godsland: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Medicine, 31 (9)(Supplement): 892-897, 1986. 24. LaRosa, J.C.: Atherosclerotic risk factors in cardiovascular disease. J. Reprod. Med., 31(9)(Supplement): 906-912, 1986. 25. Inman, W.H., and M.P. Vessey: Investigations of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Brit. Med. J., 2(5599): 193-199, 1968. 26. Maguire, M.G., J. Tonascia, P.E. Sartwell, P.D. Stolley, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives: A further report. Am. J. Epidemiology, 110(2): 188-195, 1979. 27. Pettiti, D.B., J. Wingerd, F. Pellegrin, and S. Ramacharan: Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J.A.M.A., 242:1150-1154, 1979. 28. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit. Med. J., 2(5599): 199-205, 1968. 29. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease: A further report. Brit. Med. J., 2(5658): 651-657, 1969. 30. Porter, J.B., J.R. Hunter, D.A. Danielson, H. Jick, and A. Stergachis: Oral contraceptives and non-fatal vascular disease: Recent experience. Obstet. and Gyn., 59(3):299-302, 1982. 31. Vessey, M., R. Doll, R. Peto, B. Johnson, and P. Wiggins: A long-term follow-up study of women using different methods of contraception: An interim report. J . Biosocial. Sci., 8:375-427, 1976. 32. Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J. of Royal College of General Practitioners, 28:393-399, 1978. 33. Collaborative Group for the study of stroke in young women: Oral contraception and increased risk of cerebral ischemia or thrombosis. N.E.J.M., 288:871-878, 1973. 34. Petitti, D.B., and J. Wingerd: Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet, 2:234-236, 1978. 35. Inman, W.H.: Oral contraceptives and fatal subarachnoid hemorrhage. Brit. Med. J. , 2(6203): 1468-70, 1979. 36. Collaborative Group for the study of stroke in young women: Oral contraceptives and stroke in young women: Associated risk factors. J.A.M.A. , 231:718-722, 1975. 37. Inman, W.H., M.P. Vessey, B. Westerholm, and A. Engelund: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Brit. Med. J., 2:203-209, 1970. 38. Meade, T.W., G. Greenberg, and S.G. Thompson: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Brit. Med. J., 280(6224): 1157-1161, 1980. 39. Kay, C.R.: Progestogens and arterial disease: Evidence from the Royal College of General Practitioners\u2019 study. Amer. J. Obstet. Gyn. , 142:762-765, 1982. 40. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J. Coll. Gen. Pract. , 33:75-82, 1983. 41. Ory, H.W: Mortality associated with fertility and fertility control: 1983. Family Planning Perspectives, 15:50-56, 1983. 42. Ory, H., Z. Naib, S.B. Conger, R.A. Hatcher, and C.W. Tyler: Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Am. J. Obstet. Gynec. , 124:573-577, 1976. 43. Vessey, M.P., M. Lawless, K. McPherson, D. Yeates: Neoplasia of the cervix uteri and contraception: A possible adverse effect of the pill. Lancet , 2:930, 1983. 44. Brinton, L.A., G.R. Huggins, H.F. Lehman, K. Malli, D.A. Savitz, E. Trapido, J. Rosenthal, and R. Hoover: Long-term use of oral contraceptives and risk of invasive cervical cancer. Int. J. Cancer , 38:339-344, 1986. 45. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Brit. Med. J ., 290:961-965, 1985. 46. Rooks, J.B., H.W. Ory, K.G. Ishak, L.T. Strauss, J.R. Greenspan, A.P. Hill, and C.W. Tyler: Epidemiology of hepatocellular adenoma: The role of oral contraceptive use. J.A.M.A. , 242:644-648, 1979. 47. Bein, N.N., and H.S. Goldsmith: Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Brit. J. Surg ., 64:433-435, 1977. 48. Klatskin, G.: Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology , 73:386-394, 1977. 49. Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike: Hepatocellular carcinoma and oral contraceptives. Brit. J. Cancer , 48:437-440, 1983. 50. Neuberger, J., D. Forman, R. Doll, and R. Williams: Oral contraceptives and hepatocellular carcinoma. Brit. Med. J. , 292:1355-1357, 1986. 51. Forman, D., T.J. Vincent, and R. Doll: Cancer of the liver and oral contraceptives. Brit. Med. J ., 292: 1357-1361, 1986. 52. Harlap, S., and J. Eldor: Births following oral contraceptive failures. Obstet. Gynec ., 55:447-452, 1980. 53. Savolainen, E., E. Saksela, and L. Saxen: Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Amer. J. Obstet. Gynec. , 140:521-524, 1981. 54. Janerich, D.T., J.M. Piper, and D.M. Glebatis: Oral contraceptives and birth defects. Am. J. Epidemiology , 112:73-79, 1980. 55. Ferencz, C., G.M. Matanoski, P.D. Wilson, J.D. Rubin, C.A. Neill, and R. Gutberlet: Maternal hormone therapy and congenital heart disease. Teratology , 21:225-239, 1980. 56. Rothman, K.J., D.C. Fyler, A. Goldbatt, and M.B. Kreidberg: Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiology , 109:433-439, 1979. 57. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet , 1:1399-1404, 1973. 58. Royal College of General Practitioners: Oral Contraceptives and Health . New York, Pittman, 1974, 100p. 59. Layde, P.M., M.P. Vessey, and D. Yeates: Risk of gallbladder disease: A cohort study of young women attending family planning clinics. J. of Epidemiol. and Comm. Health , 36: 274-278, 1982. 60. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am. J. Epidemiol ., 119:796-805, 1984. 61. Strom, B.L., R.T. Tamragouri, M.L. Morse, E.L. Lazar, S.L. West, P. D. Stolley, and J.K. Jones: Oral contraceptives and other risk factors for gallbladder disease. Clin. Pharmacol. Ther. , 39:335-341, 1986. 62. Wynn, V., P.W. Adams, I.F. Godsland, J. Melrose, R. Niththyananthan, N.W. Oakley, and A. Seedj: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet , 1:1045-1049, 1979. 63. Wynn, V.: Effect of progesterone and progestins on carbohydrate metabolism. In Progesterone and Progestin. Edited by C.W. Bardin, E. Milgrom, P. Mauvis-Jarvis. New York, Raven Press , pp. 395-410, 1983. 64. Perlman, J.A., R. G. Roussell-Briefel, T.M. Ezzati, and G. Lieberknecht: Oral glucose tolerance and the potency of oral contraceptive progestogens. J. Chronic Dis. , 38:857- 864, 1985. 65. Royal College of General Practitioners\u2019 Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet , 1:624, 1977. 66. Fisch, I.R., and J. Frank: Oral contraceptives and blood pressure. J.A.M.A. , 237:2499- 2503, 1977. 67. Laragh, A.J.: Oral contraceptive induced hypertension: Nine years later. Amer. J. Obstet. Gynecol ., 126:141-147, 1976. 68. Ramcharan, S., E. Peritz, F.A. Pellegrin, and W.T. Williams: Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort. In Pharmacology of Steroid Contraceptive Drugs. Edited by S. Garattini and H.W. Berendes. New York, Raven Press , pp. 277-288, 1977. (Monographs of the Mario Negri Institute for Pharmacological Research, Milan.) 69. Back DJ, Orme ML\u2019E. Drug interactions, in Pharmacology of the contraceptive steroids. Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994, 407-425. 70. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med . 2002;346(26):2025-2032. 71. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control . 2005;16(5):537-544. 72. Dorjgochoo T, Shu XO, Li HL, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer . 2009;124(10):2442-2449. 73. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology . 2010;19(10):2496-2502. 74. Vessey M, Yeates D. Oral contraceptive use and cancer. Final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-683. 75. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med . 2017;377(23):2228-2239. 76. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. J.A.M.A. , 249:1596-1599, 1983. 77. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. J.A.M.A. , 257:796-800, 1987. 78. Ory, H.W.: Functional ovarian cysts and oral contraceptives: Negative association confirmed surgically. J.A.M.A. , 228:68-69, 1974. 79. Ory, H.W., P. Cole, B. Macmahon, and R. Hoover: Oral contraceptives and reduced risk of benign breast disease. N.E.J.M. , 294:41-422, 1976. 80. Ory, H.W.: The noncontraceptive health benefits from oral contraceptive use. Fam. Plann. Perspectives , 14:182-184, 1982. 81. Ory, H.W., J.D. Forrest, and R. Lincoln: Making Choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, p.1, 1983. Manufactured by: Glenmark Pharmaceuticals Limited Colvale-Bardez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com March 2023 logo"
    ],
    "spl_unclassified_section_table": [
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td align=\"justify\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>"
    ],
    "spl_patient_package_insert": [
      "DETAILED PATIENT PACKAGE INSERT Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. What You Should Know About Oral Contraceptives Any woman who considers using oral contraceptives (the \"birth control pill\" or \"the pill\") should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider's advice with regard to regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES Oral contraceptives or \"birth control pills'' or \"the pill\" are used to prevent pregnancy and are more effective than other non-surgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 3% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: Implant: <1% Male sterilization: <1% Injection: <1% Cervical Cap: 20 to 40% IUD: <1 to 2% Condom alone (male): 14% Diaphragm with spermicides: 20% Condom alone (female): 21% Spermicides alone: 26% Periodic abstinence: 25% Vaginal Sponge: 20 to 40% Withdrawal: 19% Female sterilization: <1% No method: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions: \u2022 A history of heart attack or stroke \u2022 Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), or eyes \u2022 A history of blood clots in the deep veins of your legs \u2022 Chest pain (angina pectoris) \u2022 Known or suspected breast cancer \u2022 Unexplained vaginal bleeding (until a diagnosis is reached by your doctor) \u2022 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill \u2022 Liver tumor (benign or cancerous) \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend a safer method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your healthcare provider if you have: \u2022 Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram \u2022 Diabetes \u2022 Elevated cholesterol or triglycerides \u2022 High blood pressure \u2022 Migraine or other headaches or epilepsy \u2022 Depression \u2022 Gallbladder, heart, or kidney disease \u2022 History of scanty or irregular menstrual periods Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. RISKS OF TAKING ORAL CONTRACEPTIVES 1. Risk of Developing Blood Clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives; in particular, a clot in the legs can cause thrombophlebitis, and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in GENERAL PRECAUTIONS .) 2. Heart Attacks and Strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder Disease Oral contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver Tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Risk of Cancer It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 No fertility control methods* 7 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker** 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker** 2.2 3.4 6.6 13.5 51.1 117.2 IUD** 0.8 0.8 1 1 1.4 1.4 Condom* 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide* 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence* 2.5 1.6 1.6 1.7 2.9 3.6 *Deaths are birth related. **Deaths are method related. In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7 to 26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: \u2022 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung) \u2022 Pain in the calf (indicating a possible clot in the leg) \u2022 Crushing chest pain or heaviness in the chest (indicating a possible heart attack) \u2022 Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) \u2022 Sudden partial or complete loss of vision (indicating a possible clot in the eye) \u2022 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts) \u2022 Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor) \u2022 Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression) \u2022 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark colored urine, or light colored bowel movements (indicating possible liver problems) SIDE EFFECTS OF ORAL CONTRACEPTIVES 1. Vaginal Bleeding Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider. 2. Contact Lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider. 3. Fluid Retention Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or healthcare provider. 4. Melasma A spotty darkening of the skin is possible, particularly of the face. 5. Other Side Effects Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections. If any of these side effects bother you, call your doctor or healthcare provider. GENERAL PRECAUTIONS 1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception. There is no conclusive evidence that oral contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy. 2. While Breastfeeding If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely. 3. Laboratory Tests If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills. 4. Drug Interactions Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin \u00ae is one brand of this drug); troglitazone; phenylbutazone; and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective. Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications. 5. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis. INSTRUCTIONS TO PATIENT TABLET DISPENSER The norethindrone acetate and ethinyl estradiol tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing above the first row of tablets. Each white to off-white tablet contains 1 mg norethindrone acetate, USP and 0.02 mg ethinyl estradiol, USP. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet dispenser. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1 TO 3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK IT HAS 21 PILLS: The 21-pill pack has 21 \"active\" white to off-white pills (with hormones) to take for 3 weeks, followed by 1week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following pictures: 4) the day label strips, if your period starts on a day other than Sunday 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the tablet blister over the area that has the days of the week (starting with Sunday) imprinted in the plastic. Norethindrone acetate and ethinyl estradiol tablets will contain: ALL WHITE TO OFF-WHITE PILLS 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first \"active\" white to off-white pill of the first pack during the first 24 hours of your period . 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \"active\" white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: 21 pills: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \"active\" pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \"active\" pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 2 white to off-white \"active\" pills in a row in THE 3rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 3 OR MORE white to off-white \"active\" pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \"ACTIVE\" PILL EACH DAY until you can reach your doctor or clinic. PREGNANCY DUE TO PILL FAILURE The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 3%. If failure does occur, the risk to the fetus is minimal. PREGNANCY AFTER STOPPING THE PILL There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. OVERDOSAGE Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. OTHER INFORMATION Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: \u2022 Menstrual cycles may become more regular \u2022 Blood flow during menstruation may be lighter and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur \u2022 Pain or other symptoms during menstruation may be encountered less frequently \u2022 Ectopic (tubal) pregnancy may occur less frequently \u2022 Noncancerous cysts or lumps in the breast may occur less frequently \u2022 Acute pelvic inflammatory disease may occur less frequently \u2022 Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the \"Physician Insert,\" which you may wish to read. Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection. MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS At times there may be no menstrual period after a cycle of pills. Therefore, if you miss one menstrual period but have taken the pills exactly as you were supposed to , continue as usual into the next cycle. If you have not taken the pills correctly and miss a menstrual period, you may be pregnant and should stop taking oral contraceptives until your doctor or healthcare provider determines whether or not you are pregnant. Until you can get to your doctor or healthcare provider, use another form of contraception. If two consecutive menstrual periods are missed, you should stop taking pills until it is determined whether or not you are pregnant. Although there does not appear to be any increase in birth defects in newborn babies if you become pregnant while using oral contraceptives, you should discuss the situation with your doctor or healthcare provider. Periodic Examination Your doctor or healthcare provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaou smear, i.e., test for cancer). Keep this and all drugs out of the reach of children. Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture. Trademarks are the property of their respective owners. Manufactured by: Glenmark Pharmaceuticals Limited Colvale-Bardez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com March 2023 blister2 logo1"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"39%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><tbody><tr><td align=\"center\" colspan=\"7\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</content></paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">15 to 19</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">20 to 24</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">25 to 29</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">30 to 34</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">35 to 39</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">40 to 44</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>No fertility control methods*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>9.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>14.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>25.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>28.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives non-smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>31.6</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>51.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>117.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>IUD**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Condom*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Diaphragm/spermicide*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.8</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Periodic abstinence*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.6</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/></tr><tr><td colspan=\"7\" styleCode=\"Botrule \" valign=\"top\"><paragraph>*Deaths are birth related.</paragraph><paragraph>**Deaths are method related.</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL Label Image"
    ],
    "set_id": "38924c83-53aa-4279-8f0e-1a5d8f5fd8ad",
    "id": "0c0d4259-230e-46dd-b857-928cfc6808fd",
    "effective_time": "20231213",
    "version": "5",
    "openfda": {
      "application_number": [
        "ANDA206969"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "A-S Medication Solutions"
      ],
      "product_ndc": [
        "50090-6782"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ETHINYL ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1358762",
        "1358776"
      ],
      "spl_id": [
        "0c0d4259-230e-46dd-b857-928cfc6808fd"
      ],
      "spl_set_id": [
        "38924c83-53aa-4279-8f0e-1a5d8f5fd8ad"
      ],
      "package_ndc": [
        "50090-6782-0"
      ],
      "original_packager_product_ndc": [
        "68462-132"
      ],
      "nui": [
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "423D2T571U",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL SESAME OIL CORN OIL PEG-6 ESTERS .ALPHA.-TOCOPHEROL, DL- ALCOHOL GELATIN, UNSPECIFIED SORBITOL GLYCERIN FD&C RED NO. 40 TITANIUM DIOXIDE Pale Pink G3 Ferrous Fumarate Ferrous Fumarate FERROUS FUMARATE SOYBEAN OIL SOYBEAN LECITHIN YELLOW WAX GELATIN, UNSPECIFIED SORBITOL GLYCERIN FD&C BLUE NO. 1 FD&C RED NO. 40 TITANIUM DIOXIDE Maroon G3"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 ) and Warnings & Precautions ( 5.1 )]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See Full Prescribing Information for complete boxed warning. \u2022 Women over 35 years old who smoke should not use Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules. ( 4 ) \u2022 Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are indicated for use by females of reproductive age to prevent pregnancy [see Clinical Studies ( 14 )] . The efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. \u2022 Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy ( 1 ) \u2022 The efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in females of reproductive potential with a body mass index (BMI) of > 35 kg/m 2 has not been evaluated ( 1 , 8.8 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION \u2022 Take one capsule by mouth at the same time every day ( 2.1 ) \u2022 Take capsules in the order directed on the blister pack ( 2.1 ) \u2022 Capsules may be administered without regard to meals ( 2.1 ) 2.1 How to Take Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules must be taken exactly as directed. Instruct patients to take one capsule by mouth at the same time every day. Capsules must be taken in the order directed on the blister pack. Capsules should not be skipped or taken at intervals exceeding 24 hours. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be administered without regard to meals [see Clinical Pharmacology ( 12.3 )] . 2.2 How to Start Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules Instruct the patient to begin taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start). Day 1 Start During the first cycle of Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules use, instruct the patient to take one pink capsule daily, beginning on Day one (1) of her menstrual cycle (the first day of menstruation is Day one). She should take one pink capsule daily for 24 consecutive days, followed by one maroon capsule daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be taken in the order directed on the package at the same time each day. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days if she starts taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules on a day other than the first day of her menstrual cycle. The possibility of ovulation and conception prior to initiation of medication should be considered. Sunday Start During the first cycle of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules use, instruct the patient to take one pink capsule daily, beginning on the first Sunday after the onset of her menstrual period. She should take one pink capsule daily for 24 consecutive days, followed by one maroon capsule daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be taken in the order directed on the package at the same time each day. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should begin her next and all subsequent 28-day regimens of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules on the same day of the week that she began her first regimen, following the same schedule. She should begin taking her pink capsules on the next day after ingestion of the last maroon capsule, regardless of whether or not a menstrual period has occurred or is still in progress. Anytime a subsequent cycle of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are started later than the day following administration of the last maroon capsule, the patient should use another method of contraception until she has taken a pink capsule daily for 7 consecutive days. For postpartum women who do not breastfeed or after a second trimester abortion, start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules no earlier than 4 weeks postpartum due to the increased risk of thromboembolism. If the patient starts norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules for 7 consecutive days. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be initiated immediately after a first-trimester abortion or miscarriage; if the patient starts norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules immediately, additional contraceptive measures are not needed. Switching from another Hormonal Method of Contraception If the patient is switching from a combination hormonal method such as: \u2022 Another pill \u2022 Vaginal ring \u2022 Patch \u2022 Instruct her to take the first pink capsule on the day she would have taken her next COC pill. She should not continue taking the tablet from her previous birth control pack and should not skip any days between packs. If she does not have a withdrawal bleed, rule out pregnancy before starting norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. \u2022 If she previously used a vaginal ring or transdermal patch, she should start using norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules on the day she would have resumed the previous product. If the patient is switching from a progestin-only method such as a: \u2022 Progestin-only pill \u2022 Implant \u2022 Intrauterine system \u2022 Injection \u2022 She may switch any day from a progestin-only pill; instruct her to take the first pink capsule on the day she would have taken her next progestin-only pill. She should use a non-hormonal method of contraception for 7 consecutive days. \u2022 If switching from an implant or injection, start the first pink capsule on the day her next injection would have been due or on the day of removal of her implant. \u2022 If switching from an IUD, depending on the timing of removal, back-up contraception may be needed. 2.3Missed Doses Table 1. Instructions for Missed Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules If one pink capsule is missed Take the missed capsule as soon as possible. Take the next capsule at the regular time. Continue taking one capsule a day until the pack is finished. Additional nonhormonal contraception (such as condoms) is not needed. If two pink capsules in a row are missed in Week 1 or Week 2 of the capsule pack Take the two missed capsules as soon as possible, and the next two capsules the next day. Continue taking one capsule a day until the pack is finished. Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules. If two pink capsules in a row are missed in Week 3 or Week 4 of the capsule pack Day 1 Starter: Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day. Sunday Starter: Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules. If three or more pink capsules in a row are missed Day 1 Starter: Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day. Sunday Starter: Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. Bleeding may occur during the week following the missed capsules. Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules. If any of the four maroon capsules are missed Throw away the missed capsules. Continue taking the remaining capsules until the pack is finished. Additional nonhormonal contraception (such as condoms) is not needed. 2.4 Advice in Case of Gastrointestinal Disturbances If the patient vomits or has diarrhea (within 3 to 4 hours after she takes a pink capsule), she should follow the instructions in the \u201cWhat to Do if You Miss Capsules\u201d section [see Dosage and Administration ( 2.3 )] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"38%\"/><col width=\"62%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>If one pink capsule is missed</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Take the missed capsule as soon as possible. Take the next capsule at the regular time. Continue taking one capsule a day until the pack is finished. </paragraph><paragraph>Additional nonhormonal contraception (such as condoms) is not needed.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>If two pink capsules in a row are missed in Week 1 or Week 2 of the capsule pack</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Take the two missed capsules as soon as possible, and the next two capsules the next day. Continue taking one capsule a day until the pack is finished.</paragraph><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>If two pink capsules in a row are missed in Week 3 or Week 4 of the capsule pack</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Day 1 Starter:</content></paragraph><list listType=\"unordered\"><item><caption> </caption>Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day.</item></list><paragraph><content styleCode=\"bold\">Sunday Starter:</content></paragraph><list listType=\"unordered\"><item><caption> </caption>Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day.</item></list><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>If three or more pink capsules in a row are missed</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Day 1 Starter:</content></paragraph><list listType=\"unordered\"><item><caption> </caption>Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day. </item></list><paragraph><content styleCode=\"bold\">Sunday Starter: </content></paragraph><list listType=\"unordered\"><item><caption> </caption>Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day.</item></list><paragraph>Bleeding may occur during the week following the missed capsules.</paragraph><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules.</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>If any of the four maroon capsules are missed</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Throw away the missed capsules. Continue taking the remaining capsules until the pack is finished. </paragraph><paragraph>Additional nonhormonal contraception (such as condoms) is not needed.</paragraph></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules are available in blister packs. Each blister pack contains 28 soft gelatin capsules in the following order: \u2022 24 oval, opaque, pale pink (active) soft gelatin capsule with \u201cG3\u201d printed on the outer shell and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. \u2022 4 oval, opaque, maroon, (non-hormonal placebo) capsules imprinted with \u201cG3\u201d on one side, lightly marked and each containing 75 mg ferrous fumarate, USP. The ferrous fumarate capsules do not serve any therapeutic purpose. Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules consists of 28 soft gelatin capsules in the following order (3): \u2022 24 pink capsules (active), each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP \u2022 4 maroon capsules (non-hormonal placebo) each containing 75 mg ferrous fumarate, USP which does not serve any therapeutic purpose"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are contraindicated in females who are known to have or develop the following conditions: \u2022 A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: \u2022 Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] \u2022 Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ( 5.1 )] \u2022 Have cerebrovascular disease [see Warnings and Precautions ( 5.1 )] \u2022 Have coronary artery disease [see Warnings and Precautions ( 5.1 )] \u2022 Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ( 5.1 )] \u2022 Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ( 5.1 )] \u2022 Have uncontrolled hypertension [see Warnings and Precautions ( 5.4 )] \u2022 Have diabetes mellitus with vascular disease [see Warnings and Precautions ( 5.6 )] \u2022 Have headaches with focal neurological symptoms or have migraine headaches with aura \u2022 Women over age 35 with any migraine headaches [see Warnings and Precautions ( 5.7 )] \u2022 Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions ( 5.2 )] \u2022 Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.8 )] \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions ( 5.11 )] \u2022 Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions ( 5.3 )] \u2022 A high risk of arterial or venous thrombotic diseases ( 4 ) \u2022 Liver tumors or liver disease ( 4 ) \u2022 Undiagnosed abnormal uterine bleeding ( 4 ) \u2022 Breast cancer ( 4 ) \u2022 Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS \u2022 Vascular risks: Stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding ( 5.1 ) \u2022 Liver disease: Discontinue if jaundice occurs ( 5.2 ) \u2022 High blood pressure: Do not prescribe norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules for women with uncontrolled hypertension or hypertension with vascular disease ( 5.4 ) \u2022 Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia ( 5.6 ) \u2022 Headache: Evaluate significant change in headaches and discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if indicated ( 5.7 ) \u2022 Uterine bleeding: Evaluate irregular bleeding or amenorrhea ( 5.8 ) 5.1 Thromboembolic Disorders and Other Vascular Problems Stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if an arterial or deep venous thrombotic event (VTE) occurs. Stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. If feasible, stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE. Start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use of a COC. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest in older (> 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with underlying risk factors. Use COCs with caution in women with cardiovascular disease risk factors. 5.2 Liver Disease Impaired Liver Function Do not use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in women with acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications ( 4 )] . Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if jaundice develops. Liver Tumors Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are contraindicated in women with benign and malignant liver tumors [see Contraindications ( 4 )]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users. 5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [see Contraindications (4)] . Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen. 5.4 High Blood Pressure Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are contraindicated in women with uncontrolled hypertension or hypertension with vascular disease [see Contraindications (4)] . For women with well-controlled hypertension, monitor blood pressure and stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if blood pressure rises significantly. An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin. 5.5 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may also worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC-related cholestasis. 5.6 Carbohydrate and Lipid Metabolic Effects Carefully monitor prediabetic and diabetic women who are taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. COCs may decrease glucose tolerance in a dose-related fashion. Consider alternative contraception for women with uncontrolled dyslipidemias. A small proportion of women will have adverse lipid changes while on COCs. Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. 5.7 Headache If a woman taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if indicated. Consider discontinuation of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) [see Contraindications ( 4 )] . 5.8 Bleeding Irregularities and Amenorrhea Unscheduled Bleeding and Spotting Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC. Based on patient diaries from a clinical trial evaluating the safety and efficacy of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets, 24 to 35% of women experienced unscheduled bleeding per cycle. A total of 10 subjects out of 743 (1.3%) discontinued due to bleeding or spotting. Amenorrhea and Oligomenorrhea Women who are not pregnant and use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may experience amenorrhea. In the clinical trial with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets, 22 to 36% of the women using norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets experienced amenorrhea in at least one of 6 cycles of use. Some women may experience post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active capsules or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. 5.9 COC Use before or during Early Pregnancy Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned when oral contraceptives are taken inadvertently during early pregnancy. Discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if pregnancy is confirmed. Administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy [see Use in Specific Populations ( 8.1 )]. 5.10 Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if depression recurs to a serious degree. 5.11 Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive [see Contraindications ( 4 )] . Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use [see Adverse Reactions ( 6.2 )] . Cervical Cancer Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors. 5.12 Effect on Binding Globulins The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased. 5.13 Monitoring A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare. 5.14 Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 5.15 Chloasma Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: \u2022 Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ( 5.1 )] \u2022 Vascular events [see Warnings and Precautions ( 5.1 )] \u2022 Liver disease [see Warnings and Precautions ( 5.2 )] Adverse reactions commonly reported by COC users are: \u2022 Irregular uterine bleeding \u2022 Nausea \u2022 Breast tenderness \u2022 Headache The most common adverse reactions in clinical trials (\u2265 2%) are headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data presented in Section 6.1 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. Common Adverse Reactions (\u2265 2% of all Treated Subjects) : The most common adverse reactions reported by at least 2% of the 743 women using norethindrone acetate/ethinyl estradiol tablets were the following, in order of decreasing incidence: headache (6.3%), vaginal candidiasis (6.1%), nausea (4.6%), menstrual cramps (4.4%), breast tenderness (3.4%), bacterial vaginitis (3.1%), abnormal cervical smear (3.1%), acne (2.7%), mood swings (2.2%), and weight gain (2%). Adverse Reactions Leading to Study Discontinuation : Among the 743 women using norethindrone acetate/ethinyl estradiol tablets, 46 women (6.2%) withdrew because of an adverse event. Adverse events occurring in 3 or more subjects leading to discontinuation of treatment were, in decreasing order: abnormal or irregular bleeding (1.3%), nausea (0.8%), menstrual cramps (0.5%), and increased blood pressure (0.4%). 6.2 Postmarketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 1). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 to 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8 to 10 years of COC use. Figure 1. RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. The following adverse reactions have been identified during post approval use of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Vascular disorders: thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein). Hepatobiliary disorders: cholelithiasis, cholecystitis, hepatic adenoma, hemangioma of liver. Immune system disorders: hypersensitivity reaction. Skin and subcutaneous disorders: alopecia, rash (generalized and allergic), pruritus, skin discoloration. GI disorders: nausea, vomiting, abdominal pain. Musculoskeletal and connective tissue disorders: myalgia. Eye disorders: blurred vision, visual impairment, corneal thinning, change in corneal curvature (steepening). Infections and infestations: fungal infection, vaginal infection. Investigations: change in weight or appetite (increase or decrease), fatigue, malaise, peripheral edema, blood pressure increased. Nervous system disorders: headache, dizziness, migraine, loss of consciousness. Psychiatric disorders: mood swings, depression, insomnia, anxiety, suicidal ideation, panic attack, changes in libido. Renal and urinary disorders: cystitis-like syndrome. Reproductive system and breast disorders: breast changes (tenderness, pain, enlargement, and secretion), premenstrual syndrome, dysmenorrhea. Cardiovascular: chest pain, palpitations, tachycardia, myocardial infarction. figure1"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations. \u2022 Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate and products containing St. John\u2019s wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin and certain COCs containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone concentrations. Human immunodeficiency virus (HIV)/ Hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors: Significant changes (increase or decrease) in the plasma concentrations of estrogen and progestin have been noted in some cases of co-administration with HIV/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors. Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids. 7.2 Effects of Combined Oral Contraceptives on Other Drugs COCs containing ethinyl estradiol may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs. 7.3 Concomitant Use with HCV Combination Therapy \u2013 Liver Enzyme Elevation Do not co-administer norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with HCV drug combinations containing ombitasvir/ paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions (5.3)] . 7.4 Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS \u2022 Lactation: Not recommended; Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can decrease milk production ( 8.2 ) 8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. 8.2 Lactation Risk Summary Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breastfeeding [see Dosage and Administration ( 2.2 )] . The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules and any potential adverse effects on the breastfed child from norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules or from the underlying maternal condition. 8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated. 8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in postmenopausal women and is not indicated in this population. 8.6 Renal Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in subjects with renal impairment [ see Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in subjects with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded [see Contraindications ( 4 ) and Warnings and Precautions ( 5.2 )]. 8.8 Body Mass Index The safety and efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in women with a body mass index (BMI) >35 kg/m 2 has not been evaluated [see Clinical Studies ( 14 )]."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in postmenopausal women and is not indicated in this population."
    ],
    "overdosage": [
      "10 OVERDOSAGE There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea."
    ],
    "description": [
      "11 DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules contain norethindrone acetate, USP a progestin, and ethinyl estradiol, USP an estrogen. Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules provides an oral contraceptive regimen consisting of 24 pink active soft gelatin capsules that contain the active ingredients, followed by 4 maroon non-hormonal placebo soft gelatin capsules as specified below: \u2022 24 oval, opaque, pale pink soft gelatin capsules each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. \u2022 4 oval, opaque, maroon, capsules each containing 75 mg ferrous fumarate, USP. Each pink active capsule also contains the following inactive ingredients: sesame oil, corn oil PEG-6 esters, DL-\u03b1-tocopherol, dehydrated alcohol, bovine 150 bloom gelatin, sorbitol sorbitan solution, glycerin, FD&C Red #40, and titanium dioxide. Each maroon non-hormonal placebo capsule contains ferrous fumarate, soybean oil, soybean lecithin, yellow beeswax, bovine 150 bloom gelatin, sorbitol sorbitan solution, glycerin, FD&C Blue #1, FD&C Red #40 and titanium dioxide. The ferrous fumarate capsules do not serve any therapeutic purpose. The chemical name of ethinyl estradiol, USP is [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17\u03b1)-]. The empirical formula of ethinyl estradiol is C 20 H 24 O 2 and the structural formula is: The chemical name of norethindrone acetate, USP is [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)]. The empirical formula of norethindrone acetate is C 22 H 28 O 3 and the structural formula is: ethinylestradiol norethindroneacetate"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action CHCs lower the risk of becoming pregnant primarily by suppressing ovulation. 12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. 12.3 Pharmacokinetics Absorption In a single-dose, crossover clinical study conducted in 39 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules were bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets (24-day regimen tablets) based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed from norethindrone acetate/ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring 1 to 4 hours post-dose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single- and multiple-dose administrations of norethindrone acetate/ethinyl estradiol tablets in 17 healthy female volunteers are provided in Figures 2 and 3, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean Plasma Norethindrone Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers under Fasting Condition (n = 17) Figure 3. Mean Plasma Ethinyl Estradiol Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Regimen Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC( 0 to 24 ) (pg/mL\u2022h) C min (pg/mL) t \u00bd (hr) C avg (pg/mL) Day 1 (Single Dose) NE 8420 (31) 1 (0.7 to 4) 33390 (40) -\u2011 -\u2011 -\u2011 EE 64.5 (27) 1.3 (0.7 to 4) 465.4 (26) -\u2011 -\u2011 -\u2011 SHBG -\u2011 -\u2011 -\u2011 57.5 (37) b -\u2011 -\u2011 Day 24 (Multiple Dose) NE 16400 (26) 1.3 (0.7 to 4) 88160 (30) 880 (51) 8.4 3670 (30) EE 81.9 (24) 1.7 (1 to 2) 701.3 (28) 11.4 (43) 14.5 29.2 (28) SHBG -\u2011 -\u2011 -\u2011 144 (24) -\u2011 -- C max = Maximum plasma concentration t max = Time of C max C min = minimum plasma concentration at steady-state AUC (0 to 24) = Area under plasma concentration versus time curve from 0 to 24 hours t \u00bd = Apparent first-order terminal elimination half-life C avg = Average plasma concentration = AUC (0 to 24)/24 % CV = Coefficient of Variation (%) SHBG = Sex Hormone Binding Globulin (nmol/L) a The harmonic mean (0.693/mean apparent elimination rate constant) is reported for t \u00bd , and the median (range) is reported for t max . b The SHBG concentration reported here is the pre-dose concentration. Food Effect Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be administered without regard to meals. A single-dose administration of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with food in 38 healthy, non-smoking premenopausal women decreased the maximum concentration of norethindrone and ethinyl estradiol by 38% and 33%, respectively. Food intake did not affect the extent of ethinyl estradiol absorption, but increased the extent of norethindrone absorption by 19%. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (>95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. Drug Interactions No drug-drug interaction studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. figure2 figure3"
    ],
    "clinical_pharmacology_table": [
      "<table cellpadding=\"1.95pt\" width=\"100%\"><col width=\"13%\"/><col width=\"14%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"10%\"/><col width=\"10%\"/><thead><tr><th align=\"left\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Regimen</content></th><th align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Analyte</content></th><th align=\"center\" colspan=\"6\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Arithmetic Mean<sup>a </sup>(% CV) by Pharmacokinetic Parameter</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">C<sub>max</sub></content> <content styleCode=\"bold\">(pg/mL)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">t<sub>max</sub> (hr)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">AUC(<sub>0 to 24</sub>) </content> <content styleCode=\"bold\">(pg/mL&#x2022;h)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">C<sub>min</sub></content> <content styleCode=\"bold\">(pg/mL)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">t<sub>&#xBD;</sub></content> <content styleCode=\"bold\">(hr)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">C<sub>avg</sub></content> <content styleCode=\"bold\">(pg/mL)</content></th></tr></thead><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 1 </item></list><paragraph>(Single </paragraph><list listType=\"unordered\"><item><caption> </caption>Dose) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>NE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8420</paragraph><paragraph>(31)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph><list listType=\"unordered\"><item><caption> </caption>(0.7 to 4)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>33390</paragraph><paragraph>(40)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>EE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>64.5</paragraph><paragraph>(27)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.3</paragraph><list listType=\"unordered\"><item><caption> </caption>(0.7 to 4)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>465.4</paragraph><paragraph>(26)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>SHBG</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>57.5</paragraph><paragraph>(37)<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Day 24 </paragraph><paragraph>(Multiple </paragraph><list listType=\"unordered\"><item><caption> </caption>Dose) </item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>NE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16400</paragraph><paragraph>(26)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.3</paragraph><list listType=\"unordered\"><item><caption> </caption>(0.7 to 4)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>88160</paragraph><paragraph>(30)</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>880</item><item><caption> </caption>(51)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>8.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3670</paragraph><paragraph>(30)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>EE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>81.9</paragraph><paragraph>(24)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.7</paragraph><list listType=\"unordered\"><item><caption> </caption>(1 to 2)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>701.3</paragraph><paragraph>(28)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11.4</paragraph><paragraph>(43)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>14.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29.2</paragraph><paragraph>(28)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>SHBG</item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>144</item><item><caption> </caption>(24)</item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>--</paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action CHCs lower the risk of becoming pregnant primarily by suppressing ovulation."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption In a single-dose, crossover clinical study conducted in 39 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules were bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets (24-day regimen tablets) based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed from norethindrone acetate/ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring 1 to 4 hours post-dose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single- and multiple-dose administrations of norethindrone acetate/ethinyl estradiol tablets in 17 healthy female volunteers are provided in Figures 2 and 3, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean Plasma Norethindrone Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers under Fasting Condition (n = 17) Figure 3. Mean Plasma Ethinyl Estradiol Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Regimen Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC( 0 to 24 ) (pg/mL\u2022h) C min (pg/mL) t \u00bd (hr) C avg (pg/mL) Day 1 (Single Dose) NE 8420 (31) 1 (0.7 to 4) 33390 (40) -\u2011 -\u2011 -\u2011 EE 64.5 (27) 1.3 (0.7 to 4) 465.4 (26) -\u2011 -\u2011 -\u2011 SHBG -\u2011 -\u2011 -\u2011 57.5 (37) b -\u2011 -\u2011 Day 24 (Multiple Dose) NE 16400 (26) 1.3 (0.7 to 4) 88160 (30) 880 (51) 8.4 3670 (30) EE 81.9 (24) 1.7 (1 to 2) 701.3 (28) 11.4 (43) 14.5 29.2 (28) SHBG -\u2011 -\u2011 -\u2011 144 (24) -\u2011 -- C max = Maximum plasma concentration t max = Time of C max C min = minimum plasma concentration at steady-state AUC (0 to 24) = Area under plasma concentration versus time curve from 0 to 24 hours t \u00bd = Apparent first-order terminal elimination half-life C avg = Average plasma concentration = AUC (0 to 24)/24 % CV = Coefficient of Variation (%) SHBG = Sex Hormone Binding Globulin (nmol/L) a The harmonic mean (0.693/mean apparent elimination rate constant) is reported for t \u00bd , and the median (range) is reported for t max . b The SHBG concentration reported here is the pre-dose concentration. Food Effect Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be administered without regard to meals. A single-dose administration of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with food in 38 healthy, non-smoking premenopausal women decreased the maximum concentration of norethindrone and ethinyl estradiol by 38% and 33%, respectively. Food intake did not affect the extent of ethinyl estradiol absorption, but increased the extent of norethindrone absorption by 19%. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (>95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. Drug Interactions No drug-drug interaction studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. figure2 figure3"
    ],
    "pharmacokinetics_table": [
      "<table cellpadding=\"1.95pt\" width=\"100%\"><col width=\"13%\"/><col width=\"14%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"10%\"/><col width=\"10%\"/><thead><tr><th align=\"left\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Regimen</content></th><th align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Analyte</content></th><th align=\"center\" colspan=\"6\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Arithmetic Mean<sup>a </sup>(% CV) by Pharmacokinetic Parameter</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">C<sub>max</sub></content> <content styleCode=\"bold\">(pg/mL)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">t<sub>max</sub> (hr)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">AUC(<sub>0 to 24</sub>) </content> <content styleCode=\"bold\">(pg/mL&#x2022;h)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">C<sub>min</sub></content> <content styleCode=\"bold\">(pg/mL)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">t<sub>&#xBD;</sub></content> <content styleCode=\"bold\">(hr)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">C<sub>avg</sub></content> <content styleCode=\"bold\">(pg/mL)</content></th></tr></thead><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 1 </item></list><paragraph>(Single </paragraph><list listType=\"unordered\"><item><caption> </caption>Dose) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>NE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8420</paragraph><paragraph>(31)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph><list listType=\"unordered\"><item><caption> </caption>(0.7 to 4)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>33390</paragraph><paragraph>(40)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>EE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>64.5</paragraph><paragraph>(27)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.3</paragraph><list listType=\"unordered\"><item><caption> </caption>(0.7 to 4)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>465.4</paragraph><paragraph>(26)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>SHBG</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>57.5</paragraph><paragraph>(37)<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Day 24 </paragraph><paragraph>(Multiple </paragraph><list listType=\"unordered\"><item><caption> </caption>Dose) </item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>NE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16400</paragraph><paragraph>(26)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.3</paragraph><list listType=\"unordered\"><item><caption> </caption>(0.7 to 4)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>88160</paragraph><paragraph>(30)</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>880</item><item><caption> </caption>(51)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>8.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3670</paragraph><paragraph>(30)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>EE</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>81.9</paragraph><paragraph>(24)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.7</paragraph><list listType=\"unordered\"><item><caption> </caption>(1 to 2)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>701.3</paragraph><paragraph>(28)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11.4</paragraph><paragraph>(43)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>14.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29.2</paragraph><paragraph>(28)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>SHBG</item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>144</item><item><caption> </caption>(24)</item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>-&#x2011;</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>--</paragraph></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [See Warnings and Precautions ( 5.2 , 5.11 )]"
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [See Warnings and Precautions ( 5.2 , 5.11 )]"
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES The data presented in Section 14 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules capsules are bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. In a clinical study, 743 women 18 to 45 years of age were studied to assess the efficacy of norethindrone acetate/ethinyl estradiol tablets, for up to six 28-day cycles providing a total of 3,823 treatment-cycles of exposure. The racial demographic of all enrolled women was: 70% Caucasian, 16% African-American, 10% Hispanic, 2% Asian and 2% Other. Women with body mass index (BMI) greater than 35 mg/m 2 were excluded from the study. The weight range for those women treated was 90 to 260 pounds, with a mean weight of 147 pounds. Among the women in the study, about 40% had not used hormonal contraception immediately prior to enrolling in this study. A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies in 3,565 treatment cycles during which no backup contraception was used. The Pearl Index for norethindrone acetate/ethinyl estradiol tablets was 1.82 (95% confidence interval 0.59 to 4.25)."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules are available in blisters (dispensers) containing 28 soft gelatin capsules: Each blister contains 28 capsules in the following order: \u2022 24 oval, opaque, pale pink (active) soft gelatin capsules with \u201cG3\u201d printed on the outer shell and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. \u2022 4 oval, opaque, maroon, (non-hormonal placebo) capsules imprinted with \u201cG3\u201d on one side, lightly marked and each containing 75 mg ferrous fumarate, USP. The ferrous fumarate capsules do not serve any therapeutic purpose. Each blister is packed in a carton (NDC 68462-849-84). Cartons of 3 blisters packed individually in 3 cartons are provided for dispensing (NDC 68462-849-29). 3 cartons - each carton contains 1 blister (28): NDC 68462-849-84. 16.2 Storage Conditions Store at 25\u00baC (77\u00baF); excursions permitted to 15\u00b0C to 30\u00baC (59\u00b0F to 86\u00baF) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information). Counsel patients on the following information: \u2022 Cigarette smoking increases the risk of serious cardiovascular events from COC use, and women who are over 35 years old and smoke should not use COCs. \u2022 Increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC. \u2022 Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules does not protect against HIV infection (AIDS) and other sexually transmitted infections. \u2022 The Warnings and Precautions associated with COCs. \u2022 Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are not to be used during pregnancy; if pregnancy occurs during use of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, instruct the patient to stop further intake. \u2022 Take one capsule daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed. See \u201c What to Do if You Miss Capsules \u201d section in FDA-approved patient labeling . \u2022 Use a back-up or alternative method of contraception when enzyme inducers are used with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. \u2022 COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established. \u2022 Women who start COCs postpartum, and who have not yet had a period, should use an additional method of contraception until they have taken a pink capsule for 7 consecutive days. \u2022 Amenorrhea may occur. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles. Manufactured by: Cyndea Pharma S.L Poligono Industrial Emiliano Revilla Sanz Avenida \u00c1greda 31 42110 \u00d3lvega, Soria, Spain Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com July 2025 logo"
    ],
    "spl_patient_package_insert": [
      "Patient Package Insert FDA-Approved Patient Labeling Guide for Using Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules WARNING TO WOMEN WHO SMOKE Do not use Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. Birth control pills help to lower the chances of becoming pregnant when taken as directed. They do not protect against HIV infection (AIDS) and other sexually transmitted infections. What is Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules? Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate. How well does Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules work? Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant. Based on the results of one clinical study of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets lasting six months, about 1 to 4 out of 100 women may get pregnant during the first year they use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Women with a BMI above 35 kg/m 2 were not studied in the clinical trial, so it is not known how well norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules protects against pregnancy in such women. If you are overweight, discuss with your healthcare provider whether norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are the best choice for you. The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant. How do I take Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules? 1. Be sure to read these directions before you start taking your capsules or anytime you are not sure what to do. 2. The right way to take the capsule is to take one capsule every day at the same time in the order directed on the package. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can be taken without regard to meals. If you miss capsules you could get pregnant. This includes starting the pack late. The more capsules you miss, the more likely you are to get pregnant. See \"WHAT TO DO IF YOU MISS CAPSULES\u201d below. 3. Many women have spotting or light bleeding at unexpected times, or may feel sick to their stomach during the first 1 to 3 packs of capsules. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the capsules. The problem will usually go away. If it does not go away, check with your healthcare provider. 4. Missing capsules can also cause spotting or light bleeding, even when you make up these missed capsules. On the days you take two capsules, to make up for missed capsules, you could also feel a little sick to your stomach. 5. If you have vomiting (within 3 to 4 hours after you take your capsule), you should follow the instructions for \"WHAT TO DO IF YOU MISS CAPSULES.\" If you have diarrhea or if you take certain medicines, including some antibiotics and some herbal products such as St. John's Wort, your capsules may not work as well. Use a back-up method (such as condoms and spermicides) until you check with your healthcare provider. 6. If you have trouble remembering to take norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, talk to your healthcare provider about how to make capsule-taking easier or about using another method of birth control. 7. If you have any questions or are unsure about the information in this leaflet, call your healthcare provider. Before You Start Taking Your Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules 1. Decide What Time of Day You Want to Take Your Capsule. It is important to take norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in the order directed on the package at the same time every day. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can be taken without regard to meals. 2. Look at Your Capsule Pack \u2013 It has 28 Capsules The norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules -pill pack has 24 \"active\" pink capsules (with hormones) to be taken for 24 days, followed by 4 \"reminder\" maroon capsules (without hormones) to be taken for the next four days. 3. Also look for: 4. Be sure you have ready at all times a) Where on the pack to start taking capsules, b) In what order to take the capsules (follow the arrows shown in the picture above) o c) The week numbers as shown in the picture above. 4. Be sure you have ready at all times a) another kind of birth control (such as a condoms and spermicide) to use as a back-up in case you miss capsules, and b) an extra, full pill pack. When to Start the First Pack of Capsules You have a choice for which day to start taking your first pack of capsules. Decide with your healthcare provider which is the best day for you. Pick a time of day which will be easy to remember. Day 1 Start: 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the capsule dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first pink pill of the pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the capsule at the beginning of your period. However, if you start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules later than the first day of your period, you should use another method of birth control (such as a condom and spermicide) as a back-up method until you have taken 7 pink capsules. Sunday Start: 1. Take the first pink capsule of the pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control (such as a condom and spermicide) as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). This also applies if you start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules after having been pregnant, and you have not had a period since your pregnancy. When You Switch From a Different Birth Control Tablet When switching from another birth control pill, finish all the tablets, then norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started on the same day that a new pack of the previous birth control tablet would have been started. When You Switch From Another Type of Birth Control Method When switching from a transdermal patch or vaginal ring, finish the 21 days of use, wait 7 days, then norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started when the next application would have been due. When switching from an injection, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started when the next injection would have been due. When switching from an intrauterine device or an implant, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started on the day of removal. What to Do During the Month 1. Take one capsule at the same time every day until the pack is empty. Do not skip capsules even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). 2. Do not skip capsules even if you do not have sex very often. When you finish a pack of capsules, start the next pack on the day after your last maroon capsule. Do not wait any days between packs. What to Do if You Miss Capsules Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may not be as effective if you miss any pink capsules, especially if you miss the first few or the last few pink capsules in a pack. If you miss 1 pink capsule: 1. Take the capsule as soon as you remember. Take the next capsule at your regular time. This means you may take two capsules in one day. 2. You do not need to use a back-up birth control method if you have sex. 1. Take two capsules on the day you remember and two capsules the next day. 2. Then take one capsule a day until you finish the pack. 3 . You could become pregnant if you have sex in the 7 days after you restart your capsules. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. 1. If you are a Day 1 Starter: 2. You could become pregnant if you have sex in the 7 days after you restart your capsules. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. 1 . If you are a Day 1 Starter: Throw out the rest of the capsule pack and start a new pack that same day. If you are a Sunday Starter: 2 . You could become pregnant if you have sex on the days when you missed capsules or during the first 7 days after you restart your capsules. You must use another birth control method (such as a condom and spermicide) as a back-up the next time you have sex and for the first 7 days after you restart your capsules. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss any of the 4 maroon capsules in Week 4: 1. Throw away the capsules you missed. 2. Keep taking one capsule each day until the pack is empty. 3. You do not need a back-up method. 4. Start the next pack of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules as scheduled. 1. Use a back-up method (such as a condom and spermicide) anytime you have sex. 2. Contact your healthcare provider and continue taking one active pink capsule each day until otherwise directed. 1. Finally, if you are still not sure what to do about the capsules you have missed: 1. Use a back-up method (such as a condom and spermicide) anytime you have sex. 2. Contact your healthcare provider and continue taking one active pink capsule each day until otherwise directed. Who should not take Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules? Your healthcare provider will not give you norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if you have: \u2022 Ever had blood clots in your arms, legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis) \u2022 Ever had a stroke \u2022 Ever had a heart attack \u2022 Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart \u2022 An inherited problem with your blood that makes it clot more than normal \u2022 High blood pressure that medicine cannot control \u2022 Diabetes with kidney, eye, nerve, or blood vessel damage \u2022 Ever had certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or have any migraine headaches if you are over age 35 \u2022 Ever had breast cancer, which may be sensitive to female hormones \u2022 Liver disease, including liver tumors \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Also, do not take birth control pills if you: \u2022 Smoke and are over 35 years old \u2022 Are or suspect you are pregnant \u2022 Have any unexplained bleeding from the vagina Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy, also called cholestasis of pregnancy. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). What else should I know about taking Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules? Birth control pills do not protect you against any sexually transmitted infection, including HIV, the virus that causes AIDS. Do not skip any pills, even if you do not have sex often. If you miss a period, you could be pregnant. However, some women miss periods or have light periods on birth control pills, even when they are not pregnant. Contact your healthcare provider for advice if you: \u2022 Think you are pregnant \u2022 Miss one period and have not taken your birth control pills every day \u2022 Miss two periods in a row Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects. You should stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules at least four weeks before you have surgery and not restart it until at least two weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, may decrease the amount of milk you make. A small amount of the pill's hormones pass into breast milk. Tell your healthcare provider about all medicines and herbal products that you take. Some medicines and herbal products may make birth control pills less effective, including: \u2022 barbiturates \u2022 bosentan \u2022 carbamazepine \u2022 felbamate \u2022 griseofulvin \u2022 oxcarbazepine \u2022 phenytoin \u2022 rifampin \u2022 St. John\u2019s wort \u2022 topiramate Use a back-up or alternative birth control method when you take medicines that may make birth control pills less effective. Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your healthcare provider may need to adjust the dose of lamotrigine. If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like a condom and spermicide, until you check with your healthcare provider. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone. If you are scheduled for any laboratory tests, tell your healthcare provider that you are taking birth control pills. Certain blood tests may be affected by birth control pills. What are the most serious risks of taking Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules? Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke. Some examples of serious blood clots are blood clots in the: \u2022 Legs (deep vein thrombosis) \u2022 Lungs (pulmonary embolus) \u2022 Eyes (loss of eyesight) \u2022 Heart (heart attack) \u2022 Brain (stroke) Women who take birth control pills may get: \u2022 High blood pressure \u2022 Gallbladder problems \u2022 Rare cancerous or noncancerous liver tumors All of these events are uncommon in healthy women. Call your healthcare provider right away if you have: \u2022 Persistent leg pain \u2022 Sudden shortness of breath \u2022 Sudden blindness, partial or complete \u2022 Severe pain or pressure in your chest \u2022 Sudden, severe headache unlike your usual headaches \u2022 Weakness or numbness in an arm or leg, or trouble speaking \u2022 Yellowing of the skin or eyeballs What are the common side effects of birth control pills? The most common side effects of birth control pills are: \u2022 Spotting or bleeding between menstrual periods \u2022 Nausea \u2022 Breast tenderness \u2022 Headache These side effects are usually mild and usually disappear with time. Less common side effects are: \u2022 Acne \u2022 Less sexual desire \u2022 Bloating or fluid retention \u2022 Blotchy darkening of the skin, especially on the face \u2022 High blood sugar, especially in women who already have diabetes \u2022 High fat (cholesterol, triglyceride) levels in the blood \u2022 Depression, especially if you have had depression in the past. Call your healthcare provider immediately if you have any thoughts of harming yourself \u2022 Problems tolerating contact lenses \u2022 Weight gain This is not a complete list of possible side effects. Talk to your healthcare provider if you develop any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088. No serious problems have been reported from a birth control pill overdose, even when accidentally taken by children. Do birth control pills cause cancer? It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners. What should I know about my period when taking Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules? Irregular vaginal bleeding or spotting may occur while you are taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding, which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle, is unusually heavy, or lasts for more than a few days, call your healthcare provider. Some women may not have a menstrual period but this should not be cause for alarm as long has you have taken the pills according to direction. What if I miss my scheduled period when taking Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules? It is not uncommon to miss your period. However, if you go two or more months in a row without a period, or you miss your period after a month where you did not take all your pills correctly, call your healthcare provider because you may be pregnant. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. Stop taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if you are pregnant. What if I want to become pregnant? You may stop taking the capsule whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the capsule. General Advice about Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules Your healthcare provider prescribed norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules for you. Please do not share norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with anyone else. Keep norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules out of the reach of children. If you have concerns or questions, ask your healthcare provider. You may also ask your pharmacist for a more detailed label written for healthcare professionals. This Patient Information has been approved by the U.S. Food and Drug Administration. Manufactured by: Cyndea Pharma S.L Poligono Industrial Emiliano Revilla Sanz Avenida \u00c1greda 31 42110 \u00d3lvega, Soria, Spain Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com July 2025 flowchart blisterimage logo1"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Do not use Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</content></paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 68462-849-84 Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules 1 mg/20 mcg This package contains 1 blister of 28 soft gelatin capsules. PROVIDES 28 DAYS OF ACTIVE THERAPY. Rx Only This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. carton"
    ],
    "set_id": "3e608414-5e64-4c69-a9e0-365904cf7df8",
    "id": "920756d5-a617-404c-968d-ccf58740fa1e",
    "effective_time": "20260131",
    "version": "3",
    "openfda": {
      "application_number": [
        "ANDA213418"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"
      ],
      "manufacturer_name": [
        "Glenmark Pharmaceuticals Inc., USA"
      ],
      "product_ndc": [
        "68462-849"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "1421459",
        "1421460",
        "1421461"
      ],
      "spl_id": [
        "920756d5-a617-404c-968d-ccf58740fa1e"
      ],
      "spl_set_id": [
        "3e608414-5e64-4c69-a9e0-365904cf7df8"
      ],
      "package_ndc": [
        "68462-849-84",
        "68462-849-29",
        "68462-821-40",
        "68462-822-40"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0368462849842"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Estradiol / Norethindrone Acetate Estradiol and Norethindrone Acetate Estradiol Estradiol Norethindrone Acetate Norethindrone lactose monohydrate starch, corn COPOVIDONE K25-31 talc magnesium stearate hypromellose, unspecified triacetin round, convex B;474 Estradiol / Norethindrone Acetate Estradiol and Norethindrone Acetate Estradiol Estradiol Norethindrone Acetate Norethindrone lactose monohydrate starch, corn COPOVIDONE K25-31 talc magnesium stearate hypromellose, unspecified triacetin round, convex B;623"
    ],
    "boxed_warning": [
      "WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER See full prescribing information for complete boxed warning Estrogen Plus Progestin Therapy The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) ( 5.1 ) The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer ( 5.2 ) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) Estrogen-Alone Therapy There is an increased risk of endometrial cancer in a woman with a uterus who use unopposed estrogens ( 5.2 ) The WHI estrogen-alone substudy reported increased risks of stroke and DVT ( 5.1 ) The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia ( 5.2 , 5.3 ) Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ] . The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ]. Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1 , 5.3) , and Clinical Studies (14.5 , 14.6) ] . Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2) , and Clinical Studies (14.5) ] . Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2) ] . Cardiovascular Disorders and Probable Dementia The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ] . The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ] . Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1 , 5.3) , and Clinical Studies (14.5 , 14.6) ] . Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman."
    ],
    "recent_major_changes": [
      "Boxed Warning 08/2021"
    ],
    "recent_major_changes_table": [
      "<table width=\"100%\"><col width=\"85%\" align=\"left\" valign=\"top\"/><col width=\"15%\" align=\"left\" valign=\"top\"/><tbody><tr><td><linkHtml href=\"#BOX\">Boxed Warning</linkHtml></td><td>08/2021</td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Estradiol/Norethindrone Acetate Tablets are indicated for: Estradiol/Norethindrone Acetate Tablets are an estrogen and progestin combination indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Limitations of Use : When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. Prevention of Postmenopausal Osteoporosis ( 1.3 ) Limitations of Use : When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. 1.3 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Reevaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary. Take a single Estradiol/Norethindrone Acetate 1 mg/0.5 mg or 0.5 mg/0.1 mg tablet orally once daily for the Treatment of Moderate to severe Vasomotor Symptoms due to Menopause and for the Prevention of Postmenopausal Osteoporosis ( 2.1 , 2.3 ) Estradiol/Norethindrone Acetate 1 mg/0.5 mg tablets are taken orally once daily for the Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause ( 2.2 ) 2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Take a single Estradiol/Norethindrone Acetate tablet orally once daily for the treatment of moderate to severe vasomotor symptoms due to menopause. Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg 2.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Take a single Estradiol/Norethindrone Acetate tablet orally once daily for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg 2.3 Prevention of Postmenopausal Osteoporosis Take a single Estradiol/Norethindrone Acetate tablet orally once daily for the prevention of postmenopausal osteoporosis. Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Estradiol/Norethindrone Acetate Tablets are available in two strengths: Each tablet of Estradiol/Norethindrone Acetate 1 mg/ 0.5 mg contains 1 mg of estradiol and 0.5 mg of norethindrone acetate. The tablets are white, convex, coated tablets debossed with \"B\" on one side and \"474\" on the other side. Each tablet of Estradiol/Norethindrone Acetate 0.5 mg/ 0.1 mg contains 0.5 mg of estradiol and 0.1 mg of norethindrone acetate. The tablets are white, convex, coated tablets debossed with \"B\" on one side and \"623\" on the other side. Estradiol/Norethindrone Acetate 1 mg/0.5 mg tablet ( 3 ) Estradiol/Norethindrone Acetate 0.5 mg/0.1 mg tablet ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Estradiol/Norethindrone Acetate Tablets are contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.2) ] Breast cancer or history of breast cancer [see Warnings and Precautions (5.2) ] Estrogen-dependent neoplasia [see Warnings and Precautions (5.2) ] Active DVT, PE, or history of these conditions [see Warnings and Precautions (5.1) ] Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions [see Warnings and Precautions (5.1) ] Known anaphylactic reaction, angioedema, or hypersensitivity to Estradiol/Norethindrone Acetate Tablets Hepatic impairment or disease Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders Undiagnosed abnormal genital bleeding ( 4 ) Breast cancer or a history of breast cancer ( 4 , 5.2 ) Estrogen-dependent neoplasia ( 4 , 5.2 ) Active DVT, PE, or history of these conditions ( 4 , 5.1 ) Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions ( 4 , 5.1 ) Known anaphylactic reaction, angioedema, or hypersensitivity to Estradiol/Norethindrone Acetate Tablets ( 4 ) Hepatic impairment or disease ( 4 , 5.10 ) Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Estrogens increase the risk of gall bladder disease ( 5.4 ) Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs ( 5.5 , 5.6 , 5.9 , 5.10 ) Monitor thyroid function in women on thyroid replacement therapy ( 5.11 , 5.18 ) 5.1 Cardiovascular Disorders Increased risks of PE, DVT, stroke and MI are reported with estrogen plus progestin therapy. Increased risks of stroke and DVT are reported with estrogen-alone therapy. Immediately discontinue estrogen with or without progestogen therapy if any of these occur or is suspected. Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). Stroke The WHI estrogen plus progestin substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 strokes per 10,000 women-years) [see Clinical Studies (14.5) ] . The increase in risk was demonstrated after the first year and persisted. 1 Immediately discontinue estrogen with or without progestogen therapy if a stroke occurs or is suspected. The WHI estrogen-alone substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 strokes per 10,000 women-years, respectively). The increase in risk was demonstrated in year 1 and persisted [see Clinical Studies (14.5) ] . Immediately discontinue estrogen-alone therapy if a stroke occurs or is suspected. Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 Coronary Heart Disease The WHI estrogen plus progestin substudy reported an increased risk (not statistically significant) of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) in those women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). 1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies (14.5) ] . The WHI estrogen-alone substudy reported no overall effect on CHD events in women receiving estrogen-alone compared to placebo 2 [see Clinical Studies (14.5) ]. Subgroup analyses of women 50 to 59 years of age, who were less than 10 years since menopause, suggest a reduction (not statistically significant) in CHD events in those women receiving daily CE (0.625 mg)-alone compared to placebo (8 versus 16 per 10,000 women-years). 1 In postmenopausal women with documented heart disease (n=2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall. Venous Thromboembolism The WHI estrogen plus progestin substudy reported a statistically significant 2-fold greater rate of VTE (DVT and PE) in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted 3 [see Clinical Studies (14.5) ]. Immediately discontinue estrogen plus progestogen therapy if a VTE occurs or is suspected. In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years 4 [see Clinical Studies (14.5) ]. Immediately discontinue estrogen-alone therapy if a VTE occurs or is suspected. If feasible, discontinue estrogens at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. 5.2 Malignant Neoplasms Breast Cancer After a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA compared to placebo. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years, for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups 5 [see Clinical Studies (14.5) ] . The WHI substudy of daily CE (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80] compared to placebo 6 [see Clinical Studies (14.5) ] . Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer with estrogen plus progestin therapy, and a smaller increase in the risk for breast cancer with estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. These studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. The use of estrogen-alone and estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation. In a one-year trial among 1,176 women who received either unopposed 1 mg estradiol or a combination of 1 mg estradiol plus one of three different doses of NETA (0.1, 0.25, 0.5 mg), seven new cases of breast cancer were diagnosed, two of which occurred among the group of 295 women treated with Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and two of which occurred among the group of 294 women treated with 1 mg estradiol/0.1 mg NETA. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. Endometrial Cancer An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears to be associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. Clinical surveillance of all women using estrogen-alone or estrogen plus progestogen therapy is important. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding with unknown etiology. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestogen to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Endometrial hyperplasia occured at a rate of approximately 1 percent or less with Estradiol/Norethindrone Acetate Tablets in a clinical trial. Ovarian Cancer The CE plus MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent confidence interval [CI], 0.77-3.24), but it was not statistically significant. The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. 7 A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% CI 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. 5.3 Probable Dementia In the WHI Memory Study (WHIMS) estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for the CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years 8 [see Use in Specific Populations (8.5) , and Clinical Studies (14.6) ]. In the WHIMS estrogen-alone ancillary study, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8 [see Use in Specific Populations (8.5) , and Clinical Studies (14.6) ]. When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk of probable dementia was 1.76 (95 percent CI, 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Use in Specific Populations (8.5) , and Clinical Studies (14.6) ]. 5.4 Gallbladder Disease A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. 5.5 Hypercalcemia Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. Discontinue estrogens, including Estradiol/Norethindrone Acetate Tablets if hypercalcemia occurs, and take appropriate measures to reduce the serum calcium level. 5.6 Vision Abnormalities Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue Estradiol/Norethindrone Acetate Tablets pending examination if there is a sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. Permanently discontinue estrogens, including Estradiol/Norethindrone Acetate Tablets, if examination reveals papilledema or retinal vascular lesions. 5.7 Addition of a Progestogen When a Woman Has Not Had a Hysterectomy Studies of the addition of a progestogen for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestogens with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. 5.8 Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen. 5.9 Exacerbation of Hypertriglyceridemia In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Discontinue Estradiol/Norethindrone Acetate Tablets if pancreatitis occurs. 5.10 Hepatic Impairment and/or Past History of Cholestatic Jaundice Estrogens may be poorly metabolized in women with hepatic impairment. Exercise caution in any woman with a history of cholestatic jaundice associated with past estrogen use or with pregnancy. In the case of recurrence of cholestatic jaundice, discontinue Estradiol/Norethindrone Acetate Tablets. 5.11 Exacerbation of Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T 4 and T 3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy. Monitor thyroid function in these women during treatment with Estradiol/Norethindrone Acetate Tablets to maintain their free thyroid hormone levels in an acceptable range. 5.12 Fluid Retention Estrogens plus progestogens may cause some degree of fluid retention. Monitor any woman with a condition(s) that might predispose her to fluid retention, such as a cardiac or renal impairment. Discontinue estrogen plus progestogen therapy, including Estradiol/Norethindrone Acetate Tablets, with evidence of medically concerning fluid retention. 5.13 Hypocalcemia Estrogen-induced hypocalcemia may occur in women with hypoparathyroidism. Consider whether the benefits of estrogen therapy, including Estradiol/Norethindrone Acetate Tablets, outweigh the risks in such women. 5.14 Exacerbation of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. 5.15 Hereditary Angioedema Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. Consider whether the benefits of estrogen therapy, including Estradiol/Norethindrone Acetate Tablets, outweigh the risks in such women. 5.16 Exacerbation of Other Conditions Estrogen therapy, including Estradiol/Norethindrone Acetate Tablets, may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas. Consider whether the benefits of estrogen therapy outweigh the risks in such women. 5.17 Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy. 5.18 Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay), or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/rennin substrate, alpha-1 antitrypsin, ceruloplasmin). Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentration, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglyceride levels. Impaired glucose tolerance."
    ],
    "drug_and_or_laboratory_test_interactions": [
      "5.18 Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay), or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/rennin substrate, alpha-1 antitrypsin, ceruloplasmin). Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentration, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglyceride levels. Impaired glucose tolerance."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Cardiovascular Disorders [see Boxed Warning , Warnings and Precautions (5.1) ] Malignant Neoplasms [see Boxed Warning , Warnings and Precautions (5.2) ] The most common adverse reactions (incidence \u2265 5 percent) with Estradiol/Norethindrone Acetate Tablets are: back pain, headache, pain in the extremity, nausea, diarrhea, gastroenteritis, insomnia, emotional lability, upper respiratory tract infection, sinusitis, nasopharyngitis, weight increase, breast pain, post-menopausal bleeding, uterine fibroid vaginal hemorrhage, ovarian cyst, endometrial thickening, viral infection, moniliasis genital, and accidental injury. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc. at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported with Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg by investigators during clinical trials regardless of causality assessment are shown in Table 1. TABLE 1 ALL TREATMENT-EMERGENT ADVERSE REACTIONS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF \u2265 5 PERCENT WITH ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG Endometrial Hyperplasia Study (12-Months) Vasomotor Symptoms Study (3-Months) Osteoporosis Study (2-Years) Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg 1 mg E 2 Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg Placebo Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg Placebo (n=295) (n=296) (n=29) (n=34) (n=47) (n=48) Body as a Whole Back Pain 6% 5% 3% 3% 6% 4% Headache 16% 16% 17% 18% 11% 6% Digestive System Nausea 3% 5% 10% 0% 11% 0% Gastroenteritis 2% 2% 0% 0% 6% 4% Nervous System Insomnia 6% 4% 3% 3% 0% 8% Emotional Lability 1% 1% 0% 0% 6% 0% Respiratory System Upper Respiratory Tract Infection 18% 15% 10% 6% 15% 19% Sinusitis 7% 11% 7% 0% 15% 10% Metabolic and Nutritional Weight Increase 0% 0% 0% 0% 9% 6% Urogenital System Breast Pain 24% 10% 21% 0% 17% 8% Post-Menopausal Bleeding 5% 15% 10% 3% 11% 0% Uterine Fibroid 5% 4% 0% 0% 4% 8% Ovarian Cyst 3% 2% 7% 0% 0% 8% Resistance Mechanism Infection Viral 4% 6% 0% 3% 6% 6% Moniliasis Genital 4% 7% 0% 0% 6% 0% Secondary Terms Injury Accidental 4% 3% 3% 0% 17% including one upper extremity fracture in each group 4% Other Events 2% 3% 3% 0% 6% 4% Adverse reactions reported with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg by investigators during clinical trials regardless of causality assessment are shown in Table 2. TABLE 2 ALL TREATMENT-EMERGENT ADVERSE REACTIONS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF \u2265 5 PERCENT WITH ESTRADIOL/NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg (n=194) Placebo (n=200) Body as a Whole Back Pain 10% 4% Headache 22% 19% Pain in extremity 5% 4% Digestive System Nausea 5% 4% Diarrhea 6% 6% Respiratory System Nasopharyngitis 21% 18% Urogenital System Endometrial thickening 10% 4% Vaginal hemorrhage 26% 12% 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Estradiol/Norethindrone Acetate Tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; pre-menstrual-like syndrome; cystitis-like syndrome; ovarian cancer; endometrial hyperplasia; endometrial cancer. Breast Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer. Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction, stroke; increase in blood pressure. Gastrointestinal Nausea, vomiting; changes in appetite; cholestatic jaundice; abdominal pain/cramps, flatulence, bloating; increased incidence of gallbladder disease and pancreatitis. Skin Chloasma or melasma that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; seborrhea; hirsutism; itching; skin rash; pruritus. Eyes Retinal vascular thrombosis, intolerance to contact lenses. Central Nervous System Headache; migraine; dizziness; mental depression; chorea; insomnia; nervousness; mood disturbances; irritability; exacerbation of epilepsy; dementia. Miscellaneous Increase or decrease in weight; edema; leg cramps; changes in libido; fatigue; exacerbation of asthma; increased triglycerides; hypersensitivity; anaphylactoid/anaphylactic reactions."
    ],
    "adverse_reactions_table": [
      "<table width=\"100%\"><caption>TABLE 1 ALL TREATMENT-EMERGENT ADVERSE REACTIONS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF &#x2265; 5 PERCENT WITH ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG</caption><col width=\"21%\" align=\"left\" valign=\"top\"/><col width=\"13%\" align=\"center\" valign=\"top\"/><col width=\"13%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"13%\" align=\"center\" valign=\"top\"/><col width=\"13%\" align=\"center\" valign=\"top\"/><col width=\"13%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th/><th colspan=\"2\" align=\"center\" valign=\"top\">Endometrial Hyperplasia Study  (12-Months)</th><th colspan=\"2\" align=\"center\" valign=\"top\">Vasomotor Symptoms Study  (3-Months)</th><th colspan=\"2\" align=\"center\" valign=\"top\">Osteoporosis Study  (2-Years)</th></tr><tr><th/><th>Estradiol/Norethindrone Acetate Tablets  1 mg/0.5 mg</th><th>1 mg E<sub>2</sub></th><th>Estradiol/Norethindrone Acetate Tablets  1 mg/0.5 mg</th><th>Placebo</th><th>Estradiol/Norethindrone Acetate Tablets  1 mg/0.5 mg</th><th>Placebo</th></tr><tr><th/><th>(n=295)</th><th>(n=296)</th><th>(n=29)</th><th>(n=34)</th><th>(n=47)</th><th>(n=48)</th></tr></thead><tbody><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Body as a Whole</content></td></tr><tr><td> Back Pain</td><td>6%</td><td>5%</td><td>3%</td><td>3%</td><td>6%</td><td>4%</td></tr><tr><td> Headache</td><td>16%</td><td>16%</td><td>17%</td><td>18%</td><td>11%</td><td>6%</td></tr><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Digestive System</content></td></tr><tr><td> Nausea</td><td>3%</td><td>5%</td><td>10%</td><td>0%</td><td>11%</td><td>0%</td></tr><tr><td> Gastroenteritis</td><td>2%</td><td>2%</td><td>0%</td><td>0%</td><td>6%</td><td>4%</td></tr><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Nervous System</content></td></tr><tr><td> Insomnia</td><td>6%</td><td>4%</td><td>3%</td><td>3%</td><td>0%</td><td>8%</td></tr><tr><td> Emotional Lability</td><td>1%</td><td>1%</td><td>0%</td><td>0%</td><td>6%</td><td>0%</td></tr><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Respiratory System</content></td></tr><tr><td> Upper Respiratory Tract Infection</td><td>18%</td><td>15%</td><td>10%</td><td>6%</td><td>15%</td><td>19%</td></tr><tr><td> Sinusitis</td><td>7%</td><td>11%</td><td>7%</td><td>0%</td><td>15%</td><td>10%</td></tr><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Metabolic and Nutritional</content></td></tr><tr><td> Weight Increase</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>9%</td><td>6%</td></tr><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Urogenital System</content></td></tr><tr><td> Breast Pain</td><td>24%</td><td>10%</td><td>21%</td><td>0%</td><td>17%</td><td>8%</td></tr><tr><td> Post-Menopausal Bleeding</td><td>5%</td><td>15%</td><td>10%</td><td>3%</td><td>11%</td><td>0%</td></tr><tr><td> Uterine Fibroid</td><td>5%</td><td>4%</td><td>0%</td><td>0%</td><td>4%</td><td>8%</td></tr><tr><td> Ovarian Cyst</td><td>3%</td><td>2%</td><td>7%</td><td>0%</td><td>0%</td><td>8%</td></tr><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Resistance Mechanism</content></td></tr><tr><td> Infection Viral</td><td>4%</td><td>6%</td><td>0%</td><td>3%</td><td>6%</td><td>6%</td></tr><tr><td> Moniliasis Genital</td><td>4%</td><td>7%</td><td>0%</td><td>0%</td><td>6%</td><td>0%</td></tr><tr><td colspan=\"7\"><content styleCode=\"bold italics\">Secondary Terms</content></td></tr><tr><td> Injury Accidental</td><td>4%</td><td>3%</td><td>3%</td><td>0%</td><td>17%<footnote ID=\"fn1\">including one upper extremity fracture in each group</footnote></td><td>4%<footnoteRef IDREF=\"fn1\"/></td></tr><tr><td> Other Events</td><td>2%</td><td>3%</td><td>3%</td><td>0%</td><td>6%</td><td>4%</td></tr></tbody></table>",
      "<table width=\"85%\"><caption>TABLE 2 ALL TREATMENT-EMERGENT ADVERSE REACTIONS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF &#x2265; 5 PERCENT WITH ESTRADIOL/NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG</caption><col width=\"34%\" align=\"left\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><thead><tr><th/><th>Estradiol/Norethindrone Acetate Tablets  0.5 mg/0.1 mg (n=194)</th><th>Placebo (n=200)</th></tr></thead><tbody><tr><td colspan=\"3\"><content styleCode=\"bold italics\">Body as a Whole</content></td></tr><tr><td> Back Pain</td><td>10%</td><td>4%</td></tr><tr><td> Headache</td><td>22%</td><td>19%</td></tr><tr><td> Pain in extremity</td><td>5%</td><td>4%</td></tr><tr><td colspan=\"3\"><content styleCode=\"bold italics\">Digestive System</content></td></tr><tr><td> Nausea</td><td>5%</td><td>4%</td></tr><tr><td> Diarrhea</td><td>6%</td><td>6%</td></tr><tr><td colspan=\"3\"><content styleCode=\"bold italics\">Respiratory System</content></td></tr><tr><td> Nasopharyngitis</td><td>21%</td><td>18%</td></tr><tr><td colspan=\"3\"><content styleCode=\"bold italics\">Urogenital System</content></td></tr><tr><td> Endometrial thickening</td><td>10%</td><td>4%</td></tr><tr><td> Vaginal hemorrhage</td><td>26%</td><td>12%</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Co-administration of estradiol with norethindrone acetate did not elicit any apparent influence on the pharmacokinetics of norethindrone acetate. Similarly, no relevant interaction of norethindrone acetate on the pharmacokinetics of estradiol was found within the NETA dose range investigated in a single dose study. Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. ( 7 ) Estradiol In-vitro and in-vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's wort ( Hypericum perforatum ) preparations, phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and result in adverse reactions. Norethindrone Acetate Drugs or herbal products that induce or inhibit cytochrome P-450 enzymes, including CYP3A4, may decrease or increase the serum concentrations of norethindrone."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Estradiol/Norethindrone Acetate Tablets are not indicated for use in pregnancy. There are no data with the use of Estradiol/Norethindrone Acetate Tablets in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalities and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary Estrogens plus progestogens are present in human milk and can reduce milk production in breast-feeding women. This reduction can occur at any time but is less likely to occur once breast-feeding is well established. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Estradiol/Norethindrone Acetate Tablets and any potential adverse effects on the breastfed child from Estradiol/Norethindrone Acetate Tablets or from the underlying maternal condition. 8.4 Pediatric Use Estradiol/Norethindrone Acetate Tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population. 8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Estradiol/Norethindrone Acetate Tablets to determine whether those over 65 years of age differ from younger subjects in their response to Estradiol/Norethindrone Acetate Tablets. The Women's Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies (14.5) ] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies (14.5) ] . The Women's Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Estradiol/Norethindrone Acetate Tablets are not indicated for use in pregnancy. There are no data with the use of Estradiol/Norethindrone Acetate Tablets in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalities and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Estradiol/Norethindrone Acetate Tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Estradiol/Norethindrone Acetate Tablets to determine whether those over 65 years of age differ from younger subjects in their response to Estradiol/Norethindrone Acetate Tablets. The Women's Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies (14.5) ] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies (14.5) ] . The Women's Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Warnings and Precautions (5.3) , and Clinical Studies (14.6) ] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE Overdosage of estrogen plus progestogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of Estradiol/Norethindrone Acetate Tablets therapy with institution of appropriate symptomatic care."
    ],
    "description": [
      "11 DESCRIPTION Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin. Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin. Estradiol is a white or almost white crystalline powder. Its chemical name is estra-1, 3, 5 (10)-triene-3, 17\u03b2-diol hemihydrate with the empirical formula of C 18 H 24 O 2 , \u00bd H 2 O and a molecular weight of 281.4. The structural formula of E 2 is as follows: Estradiol Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder. Its chemical name is 17\u03b2-acetoxy-19-nor-17\u03b1 -pregn-4-en-20-yn-3-one with the empirical formula of C 22 H 28 O 3 and molecular weight of 340.5. The structural formula of NETA is as follows: Norethindrone Acetate Chemical Structure Chemical Structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system. 12.2 Pharmacodynamics Generally, a serum estrogen concentration does not predict an individual woman's therapeutic response to Estradiol/Norethindrone Acetate tablets nor her risk for adverse outcomes. Likewise, exposure comparisions across different estrogen products to infer efficacy or safety for the individual woman may not be valid. 12.3 Pharmacokinetics Absorption Estradiol Estradiol is absorbed through the gastrointestinal tract. Following oral administration of Estradiol/Norethindrone Acetate tablets, peak plasma estradiol concentrations are reached within 5 to 8 hours. The oral bioavailability of estradiol following administration of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg when compared to a combination oral solution is 53%. Administration of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg with food did not modify the bioavailability of estradiol. Norethindrone Acetate After oral administration, norethindrone acetate is absorbed and transformed to norethindrone. Norethindrone reaches a peak plasma concentration within 0.5 to 1.5 hours after the administration of Estradiol/Norethindrone Acetate Tablets. The oral bioavailability of norethindrone following administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg when compared to a combination oral solution is 100%. Administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg with food increases norethindrone AUC 0-72 by 19% and decreases C max by 36%. The pharmacokinetic parameters of estradiol (E 2 ), estrone (E 1 ), and norethindrone (NET) following oral administration of 1 Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg or 2 Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg tablet(s) to healthy postmenopausal women are summarized in Table 3. TABLE 3 PHARMACOKINETIC PARAMETERS AFTER ADMINISTRATION OF 1 TABLET OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG OR 2 TABLETS OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG TO HEALTHY POSTMENOPAUSAL WOMEN 1 \u00d7 Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (n=24) Mean geometric mean; (%CV) geometric % coefficient of variation; 2 \u00d7 Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg (n=24) Mean (%CV) AUC = area under the curve, 0 \u2013 last quantifiable sample C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, Estradiol baseline unadjusted data; (E 2 ) AUC 0-t (pg/mL*h) 766.5 (48) 697.3 (53) C max (pg/mL) 26.8 (36) 26.5 (37) t max (h): median (range) 6.0 (0.5-16.0) 6.5 (0.5-16.0) t 1/2 (h) baseline unadjusted data ; 14.0 n=18; (29) 14.5 n=16; (27) Estrone (E 1 ) AUC 0-t (pg/mL*h) 4469.1 (48) 4506.4 (44) C max (pg/mL) 195.5 (37) 199.5 (30) t max (h): median (range) 6.0 (1.0-9.0) 6.0 (2.0-9.0) t 1/2 (h) 10.7 (44) n=13; 11.8 (25) Norethindrone (NET) AUC 0-t (pg/mL*h) 21043 (41) 8407.2 (43) C max (pg/mL) 5249.5 (47) 2375.4 (41) t max (h) : median (range) 0.7 (0.7-1.25) 0.8 (0.7-1.3) t 1/2 (h) 9.8 (32) n=22; 11.4 (36) n=21 Following continuous dosing with once-daily administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg, serum concentrations of estradiol, estrone, and norethindrone reached steady-state within two weeks with an accumulation of 33 to 47% above concentrations following single dose administration. Unadjusted circulating concentrations of E 2 , E 1 , and NET during Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg treatment at steady-state (dosing at time 0) are provided in Figures 1a and 1b. Figure 1a: Mean Baseline-Uncorrected Estradiol and Estrone Serum Concentration-Time Profiles Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Figure 1b: Mean Baseline-Uncorrected Norethindrone Serum Concentration-Time Profile Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Figure 1a Figure 1b Distribution Estradiol The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estradiol circulates in the blood bound to SHBG (37%) and to albumin (61%), while only approximately 1 to 2% is unbound. Norethindrone Acetate Norethindrone also binds to a similar extent to SHBG (36%) and to albumin (61%). Metabolism Estradiol Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone Acetate The most important metabolites of norethindrone are isomers of 5\u03b1-dihydro-norethindrone and tetrahydro-norethindrone, which are excreted mainly in the urine as sulfate or glucuronide conjugates. Excretion Estradiol Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. The half-life of estradiol following single dose administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg is 12 to 14 hours. Norethindrone Acetate The terminal half-life of norethindrone is about 8 to 11 hours."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"95%\"><caption>TABLE 3 PHARMACOKINETIC PARAMETERS AFTER ADMINISTRATION OF 1 TABLET OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG OR 2 TABLETS OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG TO HEALTHY POSTMENOPAUSAL WOMEN</caption><col width=\"34%\" align=\"left\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><thead><tr><th/><th>1 &#xD7; Estradiol/Norethindrone Acetate Tablets  1 mg/0.5 mg  (n=24)  Mean<footnote ID=\"fn3a\">geometric mean;</footnote> (%CV)<footnote ID=\"fn3b\">geometric % coefficient of variation;</footnote></th><th>2 &#xD7; Estradiol/Norethindrone Acetate Tablets  0.5 mg/0.1 mg  (n=24)  Mean<footnoteRef IDREF=\"fn3a\"/> (%CV)<footnoteRef IDREF=\"fn3b\"/></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"3\">AUC = area under the curve, 0 &#x2013; last quantifiable sample</td></tr><tr><td align=\"left\" colspan=\"3\">C<sub>max</sub> = maximum plasma concentration,</td></tr><tr><td align=\"left\" colspan=\"3\">t<sub>max</sub> = time at maximum plasma concentration,</td></tr><tr><td align=\"left\" colspan=\"3\">t<sub>1/2</sub> = half-life,</td></tr></tfoot><tbody><tr><td colspan=\"3\"><content styleCode=\"bold\">Estradiol<footnote ID=\"fn3c\">baseline unadjusted data;</footnote> (E<sub>2</sub>)</content></td></tr><tr><td>AUC<sub>0-t</sub> (pg/mL*h)</td><td>766.5 (48)</td><td>697.3 (53)</td></tr><tr><td>C<sub>max</sub> (pg/mL)</td><td>26.8 (36)</td><td>26.5 (37)</td></tr><tr><td>t<sub>max</sub> (h): median (range)</td><td>6.0 (0.5-16.0)</td><td>6.5 (0.5-16.0)</td></tr><tr><td>t<sub>1/2</sub> (h)<footnote ID=\"fn3d\">baseline unadjusted data ;</footnote></td><td>14.0<footnote ID=\"fn3e\">n=18;</footnote> (29)</td><td>14.5<footnote ID=\"fn3f\">n=16;</footnote> (27)</td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Estrone<footnoteRef IDREF=\"fn3c\"/> (E<sub>1</sub>)</content></td></tr><tr><td>AUC<sub>0-t</sub> (pg/mL*h)</td><td>4469.1 (48)</td><td>4506.4 (44)</td></tr><tr><td>C<sub>max</sub> (pg/mL)</td><td>195.5 (37)</td><td>199.5 (30)</td></tr><tr><td>t<sub>max</sub> (h): median (range)</td><td>6.0 (1.0-9.0)</td><td>6.0 (2.0-9.0)</td></tr><tr><td>t<sub>1/2</sub> (h)<footnoteRef IDREF=\"fn3d\"/></td><td>10.7 (44)<footnote ID=\"fn3g\">n=13;</footnote></td><td>11.8 (25)<footnoteRef IDREF=\"fn3g\"/></td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Norethindrone (NET)</content></td></tr><tr><td>AUC<sub>0-t</sub> (pg/mL*h)</td><td>21043 (41)</td><td>8407.2 (43)</td></tr><tr><td>C<sub>max</sub> (pg/mL)</td><td>5249.5 (47)</td><td>2375.4 (41)</td></tr><tr><td>t<sub>max</sub> (h) : median (range)</td><td>0.7 (0.7-1.25)</td><td>0.8 (0.7-1.3)</td></tr><tr><td>t<sub>1/2</sub> (h)</td><td>9.8 (32)<footnote ID=\"fn3h\">n=22;</footnote></td><td>11.4 (36)<footnote>n=21</footnote></td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 1a: Mean Baseline-Uncorrected Estradiol and Estrone Serum Concentration-Time Profiles Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24)</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM3\"/></td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 1b: Mean Baseline-Uncorrected Norethindrone Serum Concentration-Time Profile Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24)</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM4\"/></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Generally, a serum estrogen concentration does not predict an individual woman's therapeutic response to Estradiol/Norethindrone Acetate tablets nor her risk for adverse outcomes. Likewise, exposure comparisions across different estrogen products to infer efficacy or safety for the individual woman may not be valid."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption Estradiol Estradiol is absorbed through the gastrointestinal tract. Following oral administration of Estradiol/Norethindrone Acetate tablets, peak plasma estradiol concentrations are reached within 5 to 8 hours. The oral bioavailability of estradiol following administration of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg when compared to a combination oral solution is 53%. Administration of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg with food did not modify the bioavailability of estradiol. Norethindrone Acetate After oral administration, norethindrone acetate is absorbed and transformed to norethindrone. Norethindrone reaches a peak plasma concentration within 0.5 to 1.5 hours after the administration of Estradiol/Norethindrone Acetate Tablets. The oral bioavailability of norethindrone following administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg when compared to a combination oral solution is 100%. Administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg with food increases norethindrone AUC 0-72 by 19% and decreases C max by 36%. The pharmacokinetic parameters of estradiol (E 2 ), estrone (E 1 ), and norethindrone (NET) following oral administration of 1 Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg or 2 Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg tablet(s) to healthy postmenopausal women are summarized in Table 3. TABLE 3 PHARMACOKINETIC PARAMETERS AFTER ADMINISTRATION OF 1 TABLET OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG OR 2 TABLETS OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG TO HEALTHY POSTMENOPAUSAL WOMEN 1 \u00d7 Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (n=24) Mean geometric mean; (%CV) geometric % coefficient of variation; 2 \u00d7 Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg (n=24) Mean (%CV) AUC = area under the curve, 0 \u2013 last quantifiable sample C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, Estradiol baseline unadjusted data; (E 2 ) AUC 0-t (pg/mL*h) 766.5 (48) 697.3 (53) C max (pg/mL) 26.8 (36) 26.5 (37) t max (h): median (range) 6.0 (0.5-16.0) 6.5 (0.5-16.0) t 1/2 (h) baseline unadjusted data ; 14.0 n=18; (29) 14.5 n=16; (27) Estrone (E 1 ) AUC 0-t (pg/mL*h) 4469.1 (48) 4506.4 (44) C max (pg/mL) 195.5 (37) 199.5 (30) t max (h): median (range) 6.0 (1.0-9.0) 6.0 (2.0-9.0) t 1/2 (h) 10.7 (44) n=13; 11.8 (25) Norethindrone (NET) AUC 0-t (pg/mL*h) 21043 (41) 8407.2 (43) C max (pg/mL) 5249.5 (47) 2375.4 (41) t max (h) : median (range) 0.7 (0.7-1.25) 0.8 (0.7-1.3) t 1/2 (h) 9.8 (32) n=22; 11.4 (36) n=21 Following continuous dosing with once-daily administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg, serum concentrations of estradiol, estrone, and norethindrone reached steady-state within two weeks with an accumulation of 33 to 47% above concentrations following single dose administration. Unadjusted circulating concentrations of E 2 , E 1 , and NET during Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg treatment at steady-state (dosing at time 0) are provided in Figures 1a and 1b. Figure 1a: Mean Baseline-Uncorrected Estradiol and Estrone Serum Concentration-Time Profiles Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Figure 1b: Mean Baseline-Uncorrected Norethindrone Serum Concentration-Time Profile Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Figure 1a Figure 1b Distribution Estradiol The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estradiol circulates in the blood bound to SHBG (37%) and to albumin (61%), while only approximately 1 to 2% is unbound. Norethindrone Acetate Norethindrone also binds to a similar extent to SHBG (36%) and to albumin (61%). Metabolism Estradiol Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone Acetate The most important metabolites of norethindrone are isomers of 5\u03b1-dihydro-norethindrone and tetrahydro-norethindrone, which are excreted mainly in the urine as sulfate or glucuronide conjugates. Excretion Estradiol Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. The half-life of estradiol following single dose administration of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg is 12 to 14 hours. Norethindrone Acetate The terminal half-life of norethindrone is about 8 to 11 hours."
    ],
    "pharmacokinetics_table": [
      "<table width=\"95%\"><caption>TABLE 3 PHARMACOKINETIC PARAMETERS AFTER ADMINISTRATION OF 1 TABLET OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG OR 2 TABLETS OF ESTRADIOL/NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG TO HEALTHY POSTMENOPAUSAL WOMEN</caption><col width=\"34%\" align=\"left\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><thead><tr><th/><th>1 &#xD7; Estradiol/Norethindrone Acetate Tablets  1 mg/0.5 mg  (n=24)  Mean<footnote ID=\"fn3a\">geometric mean;</footnote> (%CV)<footnote ID=\"fn3b\">geometric % coefficient of variation;</footnote></th><th>2 &#xD7; Estradiol/Norethindrone Acetate Tablets  0.5 mg/0.1 mg  (n=24)  Mean<footnoteRef IDREF=\"fn3a\"/> (%CV)<footnoteRef IDREF=\"fn3b\"/></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"3\">AUC = area under the curve, 0 &#x2013; last quantifiable sample</td></tr><tr><td align=\"left\" colspan=\"3\">C<sub>max</sub> = maximum plasma concentration,</td></tr><tr><td align=\"left\" colspan=\"3\">t<sub>max</sub> = time at maximum plasma concentration,</td></tr><tr><td align=\"left\" colspan=\"3\">t<sub>1/2</sub> = half-life,</td></tr></tfoot><tbody><tr><td colspan=\"3\"><content styleCode=\"bold\">Estradiol<footnote ID=\"fn3c\">baseline unadjusted data;</footnote> (E<sub>2</sub>)</content></td></tr><tr><td>AUC<sub>0-t</sub> (pg/mL*h)</td><td>766.5 (48)</td><td>697.3 (53)</td></tr><tr><td>C<sub>max</sub> (pg/mL)</td><td>26.8 (36)</td><td>26.5 (37)</td></tr><tr><td>t<sub>max</sub> (h): median (range)</td><td>6.0 (0.5-16.0)</td><td>6.5 (0.5-16.0)</td></tr><tr><td>t<sub>1/2</sub> (h)<footnote ID=\"fn3d\">baseline unadjusted data ;</footnote></td><td>14.0<footnote ID=\"fn3e\">n=18;</footnote> (29)</td><td>14.5<footnote ID=\"fn3f\">n=16;</footnote> (27)</td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Estrone<footnoteRef IDREF=\"fn3c\"/> (E<sub>1</sub>)</content></td></tr><tr><td>AUC<sub>0-t</sub> (pg/mL*h)</td><td>4469.1 (48)</td><td>4506.4 (44)</td></tr><tr><td>C<sub>max</sub> (pg/mL)</td><td>195.5 (37)</td><td>199.5 (30)</td></tr><tr><td>t<sub>max</sub> (h): median (range)</td><td>6.0 (1.0-9.0)</td><td>6.0 (2.0-9.0)</td></tr><tr><td>t<sub>1/2</sub> (h)<footnoteRef IDREF=\"fn3d\"/></td><td>10.7 (44)<footnote ID=\"fn3g\">n=13;</footnote></td><td>11.8 (25)<footnoteRef IDREF=\"fn3g\"/></td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Norethindrone (NET)</content></td></tr><tr><td>AUC<sub>0-t</sub> (pg/mL*h)</td><td>21043 (41)</td><td>8407.2 (43)</td></tr><tr><td>C<sub>max</sub> (pg/mL)</td><td>5249.5 (47)</td><td>2375.4 (41)</td></tr><tr><td>t<sub>max</sub> (h) : median (range)</td><td>0.7 (0.7-1.25)</td><td>0.8 (0.7-1.3)</td></tr><tr><td>t<sub>1/2</sub> (h)</td><td>9.8 (32)<footnote ID=\"fn3h\">n=22;</footnote></td><td>11.4 (36)<footnote>n=21</footnote></td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 1a: Mean Baseline-Uncorrected Estradiol and Estrone Serum Concentration-Time Profiles Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24)</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM3\"/></td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 1b: Mean Baseline-Uncorrected Norethindrone Serum Concentration-Time Profile Following Multiple Doses of Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24)</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM4\"/></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Effects on Vasomotor Symptoms in Postmenopausal Women In a 12-week randomized clinical trial involving 92 subjects, Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg was compared to 1 mg of estradiol and to placebo. The mean number and intensity of hot flushes were significantly reduced from baseline to week 4 and 12 in both the Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and the 1 mg estradiol group compared to placebo (see Figure 2 ). Figure 2 Mean Weekly Number of Moderate and Severe Hot Flushes in a 12-Week Study In a study conducted in Europe a total of 577 postmenopausal women were randomly assigned to either Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg, 0.5 mg E 2 /0.25 mg NETA, or placebo for 24 weeks of treatment. The mean number and severity of hot flushes were significantly reduced at week 4 and week 12 in the Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg (see Figure 3 ) and 0.5 mg E 2 /0.25 mg NETA groups compared to placebo. Figure 3 Mean Number of Moderate to Severe Hot Flushes for Weeks 0 Through 12 Figure 2 Figure 3 14.2 Effects on the Endometrium in Postmenopausal Women Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg reduced the incidence of estrogen-induced endometrial hyperplasia at 1 year in a randomized, controlled clinical trial. This trial enrolled 1,176 postmenopausal women who were randomized to one of 4 arms: 1 mg estradiol unopposed (n=296), 1 mg E 2 + 0.1 mg NETA (n=294), 1 mg E 2 + 0.25 mg NETA (n=291), and Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (n=295). At the end of the study, endometrial biopsy results were available for 988 women. The results of the 1 mg estradiol unopposed arm compared to Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg are shown in Table 4. TABLE 4 INCIDENCE OF ENDOMETRIAL HYPERPLASIA WITH UNOPPOSED ESTRADIOL AND ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG IN A 12-MONTH STUDY 1 mg E 2 (n=296) Estradiol/Norethindrone Acetate Tablets 1 mg E 2 /0.5 mg NETA (n=295) 1 mg E 2 /0.25 mg NETA (n=291) 1 mg E 2 /0.1 mg NETA (n=294) No. of subjects with histological evaluation at the end of the study 247 241 251 249 No. (%) of subjects with endometrial hyperplasia at the end of the study 36 (14.6%) 1 (0.4%) 1 (0.4%) 2 (0.8%) 14.3 Effects on Uterine Bleeding or Spotting in Postmenopausal Women During the initial months of therapy, irregular bleeding or spotting occurred with Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg treatment. However, bleeding tended to decrease over time, and after 12 months of treatment with Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg, about 86 percent of women were amenorrheic (see Figure 4 ). Figure 4 Patients Treated with Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg with Cumulative Amenorrhea over Time Percentage of Women with no Bleeding or Spotting at any Cycle Through Cycle 13 Intent to Treat Population, LOCF Note: the percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown. If data were missing, the bleeding value from the last reported day was carried forward (LOCF). In the clinical trial with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg, 88 percent of women were amenorrheic after 6 months of treatment (See Figure 5 ). Figure 5 Patients Treated with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg with Cumulative Amenorrhea over Time Percentage of Women with no Bleeding or Spotting at any Cycle Through Cycle 6, Intent to Treat Population, LOCF Figure 4 Figure 5 14.4 Effects on Bone Mineral Density in Postmenopausal Women The results of two randomized, multicenter, calcium-supplemented (500 to 1,000 mg per day), placebo-controlled, 2 year clinical trials have shown that Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and estradiol 0.5 mg are effective in preventing bone loss in postmenopausal women. A total of 462 postmenopausal women with intact uteri and baseline BMD values for lumbar spine within 2 standard deviations of the mean in healthy young women (T-score > -2.0) were enrolled. In a US trial, 327 postmenopausal women (mean time from menopause 2.5 to 3.1 years) with a mean age of 53 years were randomized to 7 groups (0.25 mg, 0.5 mg, and 1 mg of estradiol alone, 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and 2 mg estradiol with 1 mg norethindrone acetate, and placebo). In a European trial (EU trial), 135 postmenopausal women (mean time from menopause 8.4 to 9.3 years) with a mean age of 58 years were randomized to 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and placebo. Approximately 58 percent and 67 percent of the randomized subjects in the two clinical trials, respectively, completed the two clinical trials. BMD was measured using dual-energy x-ray absorptiometry (DXA). A summary of the results comparing Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and estradiol 0.5 mg to placebo from the two prevention trials is shown in Table 5. TABLE 5 PERCENTAGE CHANGE (MEAN \u00b1 SD) IN BONE MINERAL DENSITY (BMD) FOR ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG AND 0.5 MG E 2 While Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg was not directly studied in these trials, the US trial showed that addition of NETA to estradiol enhances the effect on BMD; therefore the BMD changes expected from treatment with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg should be at least as great as observed with estradiol 0.5 mg. (Intent to Treat Analysis, Last Observation Carried Forward) US Trial EU Trial Placebo (n=37) 0.5 mg E 2 (n=31) Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (n=37) Placebo (n=40) Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (n=38) US= United States, EU = European Lumbar spine -2.1 \u00b1 2.9 2.3 \u00b1 2.8 Significantly (p<0.001) different from placebo 3.8 \u00b1 3.0 -0.9 \u00b1 4.0 5.4 \u00b1 4.8 Femoral neck -2.3 \u00b1 3.4 0.3 \u00b1 2.9 Significantly (p<0.007) different from placebo 1.8 \u00b1 4.1 -1.0 \u00b1 4.6 0.7 \u00b1 6.1 Femoral trochanter -2.0 \u00b1 4.3 1.7 \u00b1 4.1 Significantly (p<0.002) different from placebo 3.7 \u00b1 4.3 0.8 \u00b1 6.9 6.3 \u00b1 7.6 The overall difference in mean percentage change in BMD at the lumbar spine in the US trial (1000 mg per day calcium) between Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and placebo was 5.9 percent and between estradiol 0.5 mg and placebo was 4.4 percent. In the European trial (500 mg per day calcium), the overall difference in mean percentage change in BMD at the lumbar spine was 6.3 percent. Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and estradiol 0.5 mg also increased BMD at the femoral neck and femoral trochanter compared to placebo. The increase in lumbar spine BMD in the US and European clinical trials for Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and estradiol 0.5 mg is displayed in Figure 6. Figure 6 Percentage Change in Bone Mineral Density (BMD) \u00b1 SEM of the Lumbar Spine (L1-L4) for Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and Estradiol 0.5 mg (Intent to Treat Analysis with Last Observation Carried Forward) Figure 6 14.5 Women's Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome. A \"global index\" included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other cause. These substudies did not evaluate the effects of CE plus MPA or CE-alone on menopausal symptoms. WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the \"global index.\" The absolute excess risk of events included in the \"global index\" was 19 per 10,000 women-years. For those outcomes included in the WHI \"global index,\" that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 6. These results reflect centrally adjudicated data after an average follow-up of 5.6 years. Table 6: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi . , Results are based on centrally adjudicated data. Event Relative Risk CE/MPA versus Placebo (95% nCI Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. ) CE/MPA n = 8,506 Placebo n = 8,102 Absolute Risk per 10,000 Women-Years CHD events 1.23 (0.99-1.53) 41 34 Non-fatal MI 1.28 (1.00-1.63) 31 25 CHD death 1.10 (0.70-1.75) 8 8 All strokes 1.31 (1.03\u20131.68) 33 25 Ischemic stroke 1.44 (1.09\u20131.90) 26 18 Deep vein thrombosis Not included in \"global index\". 1.95 (1.43\u20132.67) 26 13 Pulmonary embolism 2.13 (1.45\u20133.11) 18 8 Invasive breast cancer Includes metastatic and non-metastatic breast cancer, with the exception of in situ breast cancer. 1.24 (1.01\u20131.54) 41 33 Colorectal cancer 0.61 (0.42\u20130.87) 10 16 Endometrial cancer 0.81 (0.48\u20131.36) 6 7 Cervical cancer 1.44 (0.47\u20134.42) 2 1 Hip fracture 0.67 (0.47\u20130.96) 11 16 Vertebral fractures 0.65 (0.46\u20130.92) 11 17 Lower arm/wrist fractures 0.71 (0.59\u20130.85) 44 62 Total fractures 0.76 (0.69\u20130.83) 152 199 Overall Mortality All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. 1.00 (0.83-1.19) 52 52 Global Index A subset of the events was combined in a \"global index\" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. 1.13 (1.02-1.25) 184 165 Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [hazard ratio (HR) 0.69 (95 percent CI, 0.44-1.07)]. WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years, are presented in Table 7. Table 7: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi . Event Relative Risk CE versus Placebo (95% nCI Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. ) CE n = 5,310 Placebo n = 5,429 Absolute Risk per 10,000 Women-Years CHD events Results are based on centrally adjudicated data for an average follow-up of 7.1 years. 0.95 (0.78\u20131.16) 54 57 Non-fatal MI 0.91 (0.73\u20131.14) 40 43 CHD death 1.01(0.71\u20131.43) 16 16 All strokes 1.33 (1.05-1.68) 45 33 Ischemic stroke 1.55 (1.19 \u2013 2.01) 38 25 Deep vein thrombosis , Not included in \"global index\". 1.47 (1.06\u20132.06) 23 15 Pulmonary embolism 1.37 (0.90\u20132.07) 14 10 Invasive breast cancer 0.80 (0.62\u20131.04) 28 34 Colorectal cancer Results are based on an average follow-up of 6.8 years. 1.08 (0.75\u20131.55) 17 16 Hip fracture 0.65 (0.45\u20130.94) 12 19 Vertebral fractures , 0.64 (0.44-0.93) 11 18 Lower arm/wrist fractures , 0.58 (0.47-0.72) 35 59 Total fractures , 0.71 (0.64-0.80) 144 197 Death due to other causes , All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. 1.08 (0.88\u20131.32) 53 50 Overall Mortality , 1.04 (0.88-1.22) 79 75 Global Index A subset of the events was combined in a \"global index,\" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. 1.02 (0.92-1.13) 206 201 For those outcomes included in the WHI \"global index\" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. 9 The absolute excess risk of events included in the \"global index\" was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years. Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for ischemic stroke, and this excess risk was present in all subgroups of women examined. 10 Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [HR 0.63 (95 percent CI, 0.36-1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46-1.11)] . 14.6 Women's Health Initiative Memory Study The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. Probable dementia as defined in this study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) , and Use in Specific Populations (8.5) ]. The WHIMS estrogen-alone ancillary study of WHI study enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age, 36 percent were 70 to 74 years of age, 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) , and Use in Specific Populations (8.5) ] . When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions (5.3) , and Use in Specific Populations (8.5) ]."
    ],
    "clinical_studies_table": [
      "<table width=\"100%\" styleCode=\"Noautorules\" ID=\"fig2\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 2  Mean Weekly Number of Moderate and Severe Hot Flushes in a 12-Week Study</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM5\"/></td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\" ID=\"fig3\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 3  Mean Number of Moderate to Severe Hot Flushes for Weeks 0 Through 12</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM6\"/></td></tr></tbody></table>",
      "<table width=\"95%\"><caption>TABLE 4 INCIDENCE OF ENDOMETRIAL HYPERPLASIA WITH UNOPPOSED ESTRADIOL AND ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG IN A 12-MONTH STUDY</caption><col width=\"28%\" align=\"left\" valign=\"top\"/><col width=\"18%\" align=\"center\" valign=\"top\"/><col width=\"18%\" align=\"center\" valign=\"top\"/><col width=\"18%\" align=\"center\" valign=\"top\"/><col width=\"18%\" align=\"center\" valign=\"top\"/><thead><tr><th/><th valign=\"bottom\">1 mg E<sub>2</sub> (n=296)</th><th valign=\"bottom\">Estradiol/Norethindrone Acetate Tablets  1 mg E<sub>2</sub>/0.5 mg NETA (n=295)</th><th valign=\"bottom\">1 mg E<sub>2</sub>/0.25 mg NETA  (n=291)</th><th valign=\"bottom\">1 mg E<sub>2</sub>/0.1 mg NETA  (n=294)</th></tr></thead><tbody><tr><td>No. of subjects with histological evaluation at the end of the study</td><td>247</td><td>241</td><td>251</td><td>249</td></tr><tr><td>No. (%) of subjects with endometrial hyperplasia at the end of the study</td><td>36 (14.6%)</td><td>1 (0.4%)</td><td>1 (0.4%)</td><td>2 (0.8%)</td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\" ID=\"fig4\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 4  Patients Treated with Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg with Cumulative Amenorrhea over Time Percentage of Women with no Bleeding or Spotting at any Cycle Through Cycle 13 Intent to Treat Population, LOCF</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM7\"/></td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\" ID=\"fig5\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 5  Patients Treated with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg with Cumulative Amenorrhea over Time Percentage of Women with no Bleeding or Spotting at any Cycle Through Cycle 6, Intent to Treat Population, LOCF</content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM8\"/></td></tr></tbody></table>",
      "<table width=\"90%\"><caption>TABLE 5 PERCENTAGE CHANGE (MEAN &#xB1; SD) IN BONE MINERAL DENSITY (BMD) FOR ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG AND 0.5 MG E<sub>2</sub><footnote ID=\"fn5a\">While Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg was not directly studied in these trials, the US trial showed that addition of NETA to estradiol enhances the effect on BMD; therefore the BMD changes expected from treatment with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg should be at least as great as observed with estradiol 0.5 mg.</footnote> (Intent to Treat Analysis, Last Observation Carried Forward)</caption><col width=\"16%\" align=\"left\" valign=\"bottom\"/><col width=\"12%\" align=\"center\" valign=\"bottom\"/><col width=\"12%\" align=\"center\" valign=\"bottom\"/><col width=\"25%\" align=\"center\" valign=\"bottom\"/><col width=\"10%\" align=\"center\" valign=\"bottom\"/><col width=\"25%\" align=\"center\" valign=\"bottom\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\"/><th colspan=\"3\" align=\"center\" styleCode=\"Rrule\">US Trial</th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule\">EU Trial</th></tr><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">Placebo  (n=37)</th><th styleCode=\"Rrule\">0.5 mg E<sub>2</sub><footnoteRef IDREF=\"fn5a\"/> (n=31)</th><th styleCode=\"Rrule\">Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (n=37)</th><th styleCode=\"Rrule\">Placebo  (n=40)</th><th styleCode=\"Rrule\">Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg (n=38)</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"6\">US= United States, EU = European</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Lumbar spine</td><td styleCode=\"Rrule\">-2.1 &#xB1; 2.9</td><td styleCode=\"Rrule\">2.3 &#xB1; 2.8 <footnote ID=\"fn5b\">Significantly (p&lt;0.001) different from placebo</footnote></td><td styleCode=\"Rrule\">3.8 &#xB1; 3.0 <footnoteRef IDREF=\"fn5b\"/></td><td styleCode=\"Rrule\">-0.9 &#xB1; 4.0</td><td styleCode=\"Rrule\">5.4 &#xB1; 4.8 <footnoteRef IDREF=\"fn5b\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Femoral neck</td><td styleCode=\"Rrule\">-2.3 &#xB1; 3.4</td><td styleCode=\"Rrule\">0.3 &#xB1; 2.9 <footnote>Significantly (p&lt;0.007) different from placebo</footnote></td><td styleCode=\"Rrule\">1.8 &#xB1; 4.1 <footnoteRef IDREF=\"fn5b\"/></td><td styleCode=\"Rrule\">-1.0 &#xB1; 4.6</td><td styleCode=\"Rrule\">0.7 &#xB1; 6.1</td></tr><tr><td styleCode=\"Lrule Rrule\">Femoral trochanter</td><td styleCode=\"Rrule\">-2.0 &#xB1; 4.3</td><td styleCode=\"Rrule\">1.7 &#xB1; 4.1<footnote>Significantly (p&lt;0.002) different from placebo</footnote></td><td styleCode=\"Rrule\">3.7 &#xB1; 4.3 <footnoteRef IDREF=\"fn5b\"/></td><td styleCode=\"Rrule\">0.8 &#xB1; 6.9</td><td styleCode=\"Rrule\">6.3 &#xB1; 7.6 <footnoteRef IDREF=\"fn5b\"/></td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" valign=\"top\" align=\"center\"/><thead><tr><th>Figure 6  Percentage Change in Bone Mineral Density (BMD) &#xB1; SEM of the Lumbar Spine (L1-L4) for Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg and Estradiol 0.5 mg (Intent to Treat Analysis with Last Observation Carried Forward)</th></tr></thead><tbody><tr><td><paragraph><renderMultiMedia referencedObject=\"MM9\"/></paragraph></td></tr></tbody></table>",
      "<table width=\"90%\"><caption>Table 6: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years<footnote ID=\"foot61\">Adapted from numerous WHI publications. WHI publications can be viewed at <content styleCode=\"underline\">www.nhlbi.nih.gov/whi</content>.</footnote><sup>,</sup><footnote ID=\"foot62\">Results are based on centrally adjudicated data.</footnote></caption><col width=\"34%\" align=\"left\" valign=\"top\"/><col width=\"22%\" align=\"center\" valign=\"top\"/><col width=\"22%\" align=\"center\" valign=\"top\"/><col width=\"22%\" align=\"right\" valign=\"top\"/><thead><tr><th>Event</th><th>Relative Risk CE/MPA versus Placebo (95% nCI<footnote ID=\"foot63\">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote>)</th><th>CE/MPA n = 8,506</th><th>Placebo n = 8,102</th></tr><tr><th/><th/><th colspan=\"2\" align=\"center\">Absolute Risk per 10,000 Women-Years</th></tr></thead><tbody><tr><td>CHD events</td><td>1.23 (0.99-1.53)</td><td>41</td><td>34</td></tr><tr><td><content styleCode=\"italics\"> Non-fatal MI</content></td><td><content styleCode=\"italics\">1.28 (1.00-1.63)</content></td><td><content styleCode=\"italics\">31</content></td><td><content styleCode=\"italics\">25</content></td></tr><tr><td><content styleCode=\"italics\"> CHD death</content></td><td><content styleCode=\"italics\">1.10 (0.70-1.75)</content></td><td><content styleCode=\"italics\">8</content></td><td><content styleCode=\"italics\">8</content></td></tr><tr><td>All strokes</td><td>1.31 (1.03&#x2013;1.68)</td><td>33</td><td>25</td></tr><tr><td><content styleCode=\"italics\"> Ischemic stroke</content></td><td><content styleCode=\"italics\">1.44 (1.09&#x2013;1.90)</content></td><td><content styleCode=\"italics\">26</content></td><td><content styleCode=\"italics\">18</content></td></tr><tr><td>Deep vein thrombosis<footnote ID=\"foot64\">Not included in &quot;global index&quot;.</footnote></td><td>1.95 (1.43&#x2013;2.67)</td><td>26</td><td>13</td></tr><tr><td>Pulmonary embolism</td><td>2.13 (1.45&#x2013;3.11)</td><td>18</td><td>8</td></tr><tr><td>Invasive breast cancer<footnote ID=\"foot65\">Includes metastatic and non-metastatic breast cancer, with the exception of <content styleCode=\"italics\">in situ</content> breast cancer.</footnote></td><td>1.24 (1.01&#x2013;1.54)</td><td>41</td><td>33</td></tr><tr><td>Colorectal cancer</td><td>0.61 (0.42&#x2013;0.87)</td><td>10</td><td>16</td></tr><tr><td>Endometrial cancer<footnoteRef IDREF=\"foot64\"/></td><td>0.81 (0.48&#x2013;1.36)</td><td>6</td><td>7</td></tr><tr><td>Cervical cancer<footnoteRef IDREF=\"foot64\"/></td><td>1.44 (0.47&#x2013;4.42)</td><td>2</td><td>1</td></tr><tr><td>Hip fracture</td><td>0.67 (0.47&#x2013;0.96)</td><td>11</td><td>16</td></tr><tr><td>Vertebral fractures<footnoteRef IDREF=\"foot64\"/></td><td>0.65 (0.46&#x2013;0.92)</td><td>11</td><td>17</td></tr><tr><td>Lower arm/wrist fractures<footnoteRef IDREF=\"foot64\"/></td><td>0.71 (0.59&#x2013;0.85)</td><td>44</td><td>62</td></tr><tr styleCode=\"Botrule\"><td>Total fractures<footnoteRef IDREF=\"foot64\"/></td><td>0.76 (0.69&#x2013;0.83)</td><td>152</td><td>199</td></tr><tr styleCode=\"Botrule\"><td>Overall Mortality<footnote ID=\"foot66\">All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote></td><td>1.00 (0.83-1.19)</td><td>52</td><td>52</td></tr><tr><td>Global Index<footnote ID=\"foot67\">A subset of the events was combined in a &quot;global index&quot; defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</footnote></td><td>1.13 (1.02-1.25)</td><td>184</td><td>165</td></tr></tbody></table>",
      "<table width=\"90%\" ID=\"Table7\"><caption>Table 7: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI<footnote ID=\"foot71\">Adapted from numerous WHI publications. WHI publications can be viewed at <content styleCode=\"underline\">www.nhlbi.nih.gov/whi</content>.</footnote></caption><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><thead><tr><th valign=\"top\">Event</th><th>Relative Risk CE versus Placebo (95% nCI<footnote ID=\"foot72\">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote>)</th><th>CE n = 5,310</th><th>Placebo n = 5,429</th></tr><tr><th/><th/><th colspan=\"2\" align=\"center\">Absolute Risk per 10,000 Women-Years</th></tr></thead><tbody><tr><td>CHD events<footnote ID=\"foot73\">Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</footnote></td><td>0.95 (0.78&#x2013;1.16)</td><td>54</td><td>57</td></tr><tr><td><content styleCode=\"italics\"> Non-fatal MI</content><footnoteRef IDREF=\"foot73\"/></td><td><content styleCode=\"italics\">0.91 (0.73&#x2013;1.14)</content></td><td><content styleCode=\"italics\">40</content></td><td><content styleCode=\"italics\">43</content></td></tr><tr><td><content styleCode=\"italics\"> CHD death</content><footnoteRef IDREF=\"foot73\"/></td><td><content styleCode=\"italics\">1.01(0.71&#x2013;1.43)</content></td><td><content styleCode=\"italics\">16</content></td><td><content styleCode=\"italics\">16</content></td></tr><tr><td>All strokes<footnoteRef IDREF=\"foot73\"/></td><td>1.33 (1.05-1.68)</td><td>45</td><td>33</td></tr><tr><td><content styleCode=\"italics\"> Ischemic stroke</content><footnoteRef IDREF=\"foot72\"/></td><td><content styleCode=\"italics\">1.55 (1.19 &#x2013; 2.01)</content></td><td><content styleCode=\"italics\">38</content></td><td><content styleCode=\"italics\">25</content></td></tr><tr><td>Deep vein thrombosis<footnoteRef IDREF=\"foot73\"/><sup>,</sup><footnote ID=\"foot74\">Not included in &quot;global index&quot;.</footnote></td><td>1.47 (1.06&#x2013;2.06)</td><td>23</td><td>15</td></tr><tr><td>Pulmonary embolism<footnoteRef IDREF=\"foot73\"/></td><td>1.37 (0.90&#x2013;2.07)</td><td>14</td><td>10</td></tr><tr><td>Invasive breast cancer<footnoteRef IDREF=\"foot73\"/></td><td>0.80 (0.62&#x2013;1.04)</td><td>28</td><td>34</td></tr><tr><td>Colorectal cancer<footnote ID=\"foot75\">Results are based on an average follow-up of 6.8 years.</footnote></td><td>1.08 (0.75&#x2013;1.55)</td><td>17</td><td>16</td></tr><tr><td>Hip fracture<footnoteRef IDREF=\"foot73\"/></td><td>0.65 (0.45&#x2013;0.94)</td><td>12</td><td>19</td></tr><tr><td>Vertebral fractures<footnoteRef IDREF=\"foot73\"/><sup>,</sup><footnoteRef IDREF=\"foot74\"/></td><td>0.64 (0.44-0.93)</td><td>11</td><td>18</td></tr><tr><td>Lower arm/wrist fractures<footnoteRef IDREF=\"foot73\"/><sup>,</sup><footnoteRef IDREF=\"foot74\"/></td><td>0.58 (0.47-0.72)</td><td>35</td><td>59</td></tr><tr><td>Total fractures<footnoteRef IDREF=\"foot73\"/><sup>,</sup><footnoteRef IDREF=\"foot74\"/></td><td>0.71 (0.64-0.80)</td><td>144</td><td>197</td></tr><tr styleCode=\"Botrule\"><td>Death due to other causes<footnoteRef IDREF=\"foot75\"/><sup>,</sup><footnote ID=\"foot76\">All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote></td><td>1.08 (0.88&#x2013;1.32)</td><td>53</td><td>50</td></tr><tr styleCode=\"Botrule\"><td>Overall Mortality<footnoteRef IDREF=\"foot73\"/><sup>,</sup><footnoteRef IDREF=\"foot74\"/></td><td>1.04 (0.88-1.22)</td><td>79</td><td>75</td></tr><tr><td>Global Index<footnote ID=\"foot77\">A subset of the events was combined in a &quot;global index,&quot; defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</footnote></td><td>1.02 (0.92-1.13)</td><td>206</td><td>201</td></tr></tbody></table>"
    ],
    "references": [
      "15 REFERENCES 1. Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA . 2007;297:1465-1477. 2. Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med . 2006;166:357-365. 3. Cushman M, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA . 2004;292:1573-1580. 4. Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med . 2006;166:772-780. 5. Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA . 2003;289:3234-3253. 6. Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA . 2006;295:1647-1657. 7. Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. JAMA . 2003;290:1739-1748. 8. Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA . 2004;291:2947-2958. 9. Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. J Bone Miner Res . 2006;21:817-828. 10. Hendrix SL, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women's Health Initiative. Circulation . 2006;113:2425-2434."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Estradiol/Norethindrone Acetate Tablets 1 mg/0.5 mg are available as white, convex, coated tablets debossed with \"B\" on one side and \"474\" on the other side. (NDC 51991-474-28). It is supplied as 28 tablets in a calendar blister pack dispenser. Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg are available as white, convex, coated tablets debossed with \"B\" on one side and \"623\" on the other side. (NDC 51991-623-28). It is supplied as 28 tablets in a calendar blister pack dispenser. 16.2 Storage and Handling Store in a dry place protected from light. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F), excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "storage_and_handling": [
      "16.2 Storage and Handling Store in a dry place protected from light. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F), excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise women to read the FDA-approved patient labeling (Patient Information) Vaginal Bleeding Inform postmenopausal women to report any vaginal bleeding to their healthcare provider as soon as possible [see Warnings and Precautions (5.2) ] . Possible Serious Adverse Reactions with Estrogen Plus Progestogen Therapy Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestogen therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia [see Warnings and Precautions (5.1 , 5.2 , 5.3) ] . Possible Common Adverse Reactions with Estrogen Plus Progestogen Therapy Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestogen therapy such as headache, breast pain and tenderness, nausea and vomiting."
    ],
    "spl_unclassified_section": [
      "Rx Only Distributed by: Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922 Manufactured by: Pharmaceutics International, Inc. Hunt Valley, MD 21031"
    ],
    "spl_patient_package_insert": [
      "Patient Information Estradiol/Norethindrone Acetate Tablets, for oral use Read this Patient Information before you start using Estradiol/Norethindrone Acetate Tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. What is the most important information I should know about Estradiol/Norethindrone Acetate Tablets (a combination of estrogen and progestogen)? Do not use estrogens with or without progestogens to prevent heart disease, heart attacks, strokes, or dementia (decline of brain function). Using estrogens with progestogens may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots. Using estrogens with progestogens may increase your chance of getting dementia, based on a study of women 65 years of age and older. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Do not use estrogen-alone to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function). Using estrogen-alone may increase your chances of getting strokes or blood clots. Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age and older. Only one estrogen with progestogen product and dose have been shown to increase your chances of getting heart attacks, strokes, breast cancer, blood clots, and dementia. Only one estrogen-alone product and dose have been shown to increase your chances of getting strokes, blood clots, and dementia. Because other products and doses have not been studied in the same way, it is not known how the use of Estradiol/Norethindrone Acetate Tablets will affect your chances of these conditions. You and your healthcare provider should talk regularly about whether you still need treatment with Estradiol/Norethindrone Acetate Tablets. What is Estradiol/Norethindrone Acetate Tablets? Estradiol/Norethindrone Acetate Tablets are a prescription medicine that contains two kinds of hormones, an estrogen and a progestogen. What is Estradiol/Norethindrone Acetate Tablets used for? Estradiol/Norethindrone Acetate Tablets are used after menopause to: Reduce moderate to severe hot flushes Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 yrs old. This drop in body estrogen levels causes the \"change of life\" or menopause, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes \"surgical menopause.\" When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden, intense feelings of heat and sweating (\"hot flashes\" or \"hot flushes\"). In some women, the symptoms are mild, and they will not need to use estrogens. In other women, symptoms can be more severe. Treat moderate to severe menopausal changes in and around the vagina You and your healthcare provider should talk regularly about whether you still need treatment with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg to treat these problems. If you use Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you. Help reduce your chances of getting osteoporosis (thin weak bones) Osteoporosis from menopause is a thinning of the bones that makes them weaker and easier to break. If you use Estradiol/Norethindrone Acetate Tablets to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you still need treatment with Estradiol/Norethindrone Acetate Tablets. Who should not use Estradiol/Norethindrone Acetate Tablets? Do not use Estradiol/Norethindrone Acetate Tablets if you have had your uterus (womb) removed (hysterectomy). Estradiol/Norethindrone Acetate Tablets contains a progestogen to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestogen and you should not use Estradiol/Norethindrone Acetate Tablets. Do not start using Estradiol/Norethindrone Acetate Tablets if you: have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. have been diagnosed with a bleeding disorder currently have or have had certain cancers Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus (womb). If you have or have had cancer, talk with your healthcare provider about whether you should use Estradiol/Norethindrone Acetate Tablets. had a stroke or heart attack currently have or have had blood clots currently have or have had liver problems are allergic to Estradiol/Norethindrone Acetate Tablets or any of the ingredients in it. See the list of ingredients in Estradiol/Norethindrone Acetate Tablets at the end of this leaflet. Before you use Estradiol/Norethindrone Acetate Tablets, tell your healthcare provider about all of your medical conditions, including if you: have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. have any other medical conditions that may become worse while you are using Estradiol/Norethindrone Acetate Tablets Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop using Estradiol/Norethindrone Acetate Tablets. are pregnant or think you may be pregnant Estradiol/Norethindrone Acetate Tablets is not for pregnant women. are breast feeding The hormones in Estradiol/Norethindrone Acetate Tablets can pass into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how Estradiol/Norethindrone Acetate Tablets works. Estradiol/Norethindrone Acetate Tablets may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get new medicine. How should I use Estradiol/Norethindrone Acetate Tablets? Use Estradiol/Norethindrone Acetate Tablets exactly as your healthcare provider tells you to use it. Take 1 tablet at the same time each day. You and your healthcare provider should talk regularly (every 3 to 6 months) about your dose and whether you still need treatment with Estradiol/Norethindrone Acetate Tablets. Follow the instructions below to use your Estradiol/Norethindrone Acetate Tablets Dispenser. What are the possible side effects of Estradiol/Norethindrone Acetate Tablets? Side effects are grouped by how serious they are and how often they happen when you are treated. Serious, but less common side effects include: heart attack stroke blood clots breast cancer cancer of the lining of the uterus (womb) cancer of the ovary dementia high or low blood calcium levels gallbladder disease visual abnormalities high blood pressure high levels of fat (triglycerides) in your blood liver problems changes in your thyroid hormone levels fluid retention cancer changes of endometriosis enlargement of benign tumors of the uterus (\"fibroids\") worsening swelling of face and tongue (angioedema) in women who have a history of angioedema changes in laboratory tests results such as bleeding times and high blood sugar levels Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: new breast lumps unusual vaginal bleeding changes in vision or speech sudden new severe headaches severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Common side effects of Estradiol/Norethindrone Acetate Tablets include: irregular vaginal bleeding or spotting nausea stomach or abdominal cramps, bloating headache vomiting back pain breast pain diarrhea fluid retention vaginal yeast infection These are not all the possible side effects of Estradiol/Norethindrone Acetate Tablets. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or do not go away. You may report side effects to Breckenridge Pharmaceutical, Inc. at 1-800-367-3395 or to FDA at 1-800-FDA-1088. What can I do to lower my chances of a serious side effect with Estradiol/Norethindrone Acetate Tablets? Talk with your healthcare provider regularly about whether you should continue using Estradiol/Norethindrone Acetate Tablets. If you have a uterus, talk with your healthcare provider about whether Estradiol/Norethindrone Acetate Tablets is right for you. In general, the addition of a progestogen is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). See your healthcare provider right away if you get vaginal bleeding while using Estradiol/Norethindrone Acetate Tablets. Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram (breast x-ray), you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances for getting heart disease. How should I store Estradiol/Norethindrone Acetate Tablets? Store Estradiol/Norethindrone Acetate Tablets at room temperature between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Store Estradiol/Norethindrone Acetate Tablets in a dry place protected from light. KEEP Estradiol/Norethindrone Acetate Tablets and all medicines out of the reach of children. General information about the safe and effective use of Estradiol/Norethindrone Acetate Tablets. Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use Estradiol/Norethindrone Acetate Tablets for conditions for which it was not prescribed. Do not give Estradiol/Norethindrone Acetate Tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about Estradiol/Norethindrone Acetate Tablets that is written for health professionals. For more information go to www.bpirx.com or call 1-800-367-3395. What are the ingredients in Estradiol/Norethindrone Acetate Tablets? Active ingredients: estradiol and norethindrone acetate Inactive Ingredients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose, and triacetin. This Patient Information has been approved by the U.S. Food and Drug Administration. Distributed by: Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922 Manufactured by: Pharmaceutics International, Inc. Hunt Valley, MD 21031 Revised: 01/2024 Image"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"100%\" align=\"left\" valign=\"top\"/><tbody><tr><td styleCode=\"Lrule Rrule Toprule\"><content styleCode=\"bold\">What is the most important information I should know about Estradiol/Norethindrone Acetate Tablets (a combination of estrogen and progestogen)?</content></td></tr><tr><td styleCode=\"Lrule Rrule\"><list listType=\"unordered\" styleCode=\"disc\"><item>Do not use estrogens with or without progestogens to prevent heart disease, heart attacks, strokes, or dementia (decline of brain function).</item><item>Using estrogens with progestogens may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.</item><item>Using estrogens with progestogens may increase your chance of getting dementia, based on a study of women 65 years of age and older.</item><item>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).</item><item>Do not use estrogen-alone to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function).</item><item>Using estrogen-alone may increase your chances of getting strokes or blood clots.</item><item>Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age and older.</item><item>Only one estrogen with progestogen product and dose have been shown to increase your chances of getting heart attacks, strokes, breast cancer, blood clots, and dementia. Only one estrogen-alone product and dose have been shown to increase your chances of getting strokes, blood clots, and dementia.</item></list>Because other products and doses have not been studied in the same way, it is not known how the use of Estradiol/Norethindrone Acetate Tablets will affect your chances of these conditions. You and your healthcare provider should talk regularly about whether you still need treatment with Estradiol/Norethindrone Acetate Tablets. </td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 1.0 mg/0.5 mg Tablet Blister Pack Carton NDC 51991-474-28 Estradiol / Norethindrone Acetate Tablets 1.0 mg / 0.5 mg breckenridge A Towa Company Rx Only 28 Tablets PRINCIPAL DISPLAY PANEL - 1.0 mg/0.5 mg Tablet Blister Pack Carton",
      "PRINCIPAL DISPLAY PANEL - 0.5 mg/0.1 mg Tablet Blister Pack Carton NDC 51991-623-28 Estradiol / Norethindrone Acetate Tablets 0.5 mg / 0.1 mg breckenridge A Towa Company Rx Only 28 Tablets PRINCIPAL DISPLAY PANEL - 0.5 mg/0.1 mg Tablet Blister Pack Carton"
    ],
    "set_id": "44125b2f-10ac-435c-bdb4-a29bf8450dbf",
    "id": "d0f8f0e6-e2b1-40ff-8b4b-0ed8a7525689",
    "effective_time": "20240221",
    "version": "10",
    "openfda": {
      "application_number": [
        "ANDA078324"
      ],
      "brand_name": [
        "Estradiol / Norethindrone Acetate"
      ],
      "generic_name": [
        "ESTRADIOL AND NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "Breckenridge Pharmaceutical, Inc."
      ],
      "product_ndc": [
        "51991-474",
        "51991-623"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1359123",
        "1359124",
        "1359126",
        "1359127"
      ],
      "spl_id": [
        "d0f8f0e6-e2b1-40ff-8b4b-0ed8a7525689"
      ],
      "spl_set_id": [
        "44125b2f-10ac-435c-bdb4-a29bf8450dbf"
      ],
      "package_ndc": [
        "51991-474-28",
        "51991-623-28"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "M0447348",
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_cs": [
        "Estradiol Congeners [CS]"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "4TI98Z838E",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol ETHINYL ESTRADIOL ETHINYL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE ANHYDROUS LACTOSE .ALPHA.-TOCOPHEROL, DL- SUCROSE CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE MAGNESIUM STEARATE FD&C BLUE NO. 1 POVIDONE K25 SODIUM LAURYL SULFATE 237 FERROUS FUMARATE ferrous fumarate SILICON DIOXIDE CROSCARMELLOSE SODIUM FERROUS FUMARATE LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE K90 291"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS )."
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets are a progestogen-estrogen combination. Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg provide a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each blue tablet contains norethindrone acetate (19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)), 1.5 mg; ethinyl estradiol (19-Norpregna-1,3,5(10)-trien-20-yne-3, 17-diol, (17\u03b1)-), 0.03 mg. Also contains compressible sugar, croscarmellose sodium, dl -\u03b1-tocopherol, FD & C Blue No. 1 Aluminum Lake, lactose anhydrous, lactose monohydrate, magnesium stearate, povidone K-25, sodium lauryl sulphate. The structural formulas are as follows: Each brown tablet contains colloidal silicon dioxide, croscarmellose sodium, ferrous fumarate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone K-90. Structural Formula"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1-3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1-3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3). Special Population Race: The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function. Drug-Drug Interactions Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions."
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD Adapted from RA Hatcher et al, Reference 7. % of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use Method Lowest Expected The authors\u2019 best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. Typical This term represents \u201ctypical\u201d couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (No contraception) (85) (85) Oral contraceptives 3 Combined 0.1 N/A N/A - Data not available. progestin only 0.5 N/A Diaphragm with spermicidal cream or jelly 6 20 Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film) 6 26 Vaginal Sponge nulliparous 9 20 parous 20 40 Implant 0.05 0.05 Injection: depot medroxyprogesterone acetate 0.3 0.3 IUD progesterone T 1.5 2.0 copper T 380A 0.6 0.8 LNg 20 0.1 0.1 Condom without spermicides female 5 21 male 3 14 Cervical Cap with spermicidal cream or jelly nulliparous 9 20 parous 26 40 Periodic abstinence (all methods) 1- 9 25 Withdrawal 4 19 Female sterilization 0.5 0.5 Male sterilization 0.10 0.15"
    ],
    "indications_and_usage_table": [
      "<table ID=\"_RefID29\" width=\"100%\"><caption>TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD</caption><col width=\"70%\"/><col width=\"18%\"/><col width=\"10%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Adapted from RA Hatcher et al, Reference 7.</td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">% of Women Experiencing an Unintended Pregnancy</content> <content styleCode=\"bold\">in the First Year of Continuous Use</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Lowest Expected</content><footnote ID=\"_Ref494107670\">The authors&#x2019; best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Typical</content><footnote ID=\"_Ref494107676\">This term represents &#x201C;typical&#x201D; couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(No contraception) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(85)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(85)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Combined </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>N/A<footnote ID=\"_Ref494107684\">N/A - Data not available.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progestin only </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>N/A<footnoteRef IDREF=\"_Ref494107684\"/></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicidal cream or jelly </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Implant </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.05</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.05</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: depot medroxyprogesterone acetate </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progesterone T </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> copper T 380A </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> LNg 20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom without spermicides</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> female </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>21</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> male </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>14</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Cervical Cap with spermicidal cream or jelly</paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Periodic abstinence (all methods) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1- 9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>25</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Withdrawal </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>19</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Female sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Male sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>0.15</paragraph></td></tr></tbody></table>"
    ],
    "contraindications": [
      "CONTRAINDICATIONS Oral contraceptives are contraindicated in women who currently have the following conditions: \u2022 Thrombophlebitis or thromboembolic disorders \u2022 A past history of deep vein thrombophlebitis or thromboembolic disorders \u2022 Cerebral vascular or coronary artery disease \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone sensitive \u2022 Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \u2022 Undiagnosed abnormal genital bleeding \u2022 Cholestatic jaundice of pregnancy or jaundice with prior pill use \u2022 Hepatic adenomas or carcinomas \u2022 Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT )."
    ],
    "warnings": [
      "WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author\u2019s permission). For further information, the reader is referred to a text on epidemiological methods. 1.Thromboembolic Disorders and Other Vascular Problems a. Myocardial Infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10-16). The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases (17). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives. TABLE II: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE Adapted from P.M. Layde and V. Beral, Reference 18 Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity (19). In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism (20-24). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS ). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. TABLE II: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE b. Thromboembolism An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (9, 10, 25-30). Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8). A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives (15,32). The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions (15,32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. c. Cerebrovascular Disease Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (greater than 35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes (33-35). In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk is also greater in older women (9). d. Dose-related Risk of Vascular Disease from Oral Contraceptives A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (37-39). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (20-22). A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. e. Persistence of Risk of Vascular Disease There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40-49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (40). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens. 2. Estimates of Mortality from Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970\u2019s but not reported until 1983 (41). However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling. Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4; and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective. TABLE III: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15 -19 20-24 25-29 30 -34 35-39 40-44 No fertility control methods 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker Deaths are method related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom Deaths are birth related. 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/ spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 Adapted from H.W. Ory, Reference 41. 3. Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ). Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS , Postmarketing Experience). Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women (42-45). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. 4. Hepatic Neoplasia Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (46). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (47,48). Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (49- 51) in long-term (greater than 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users. 5. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see Contraindications ). Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. Oral Contraceptive Use Before and During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy (52-54). Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned (52, 53, 55, 56), when taken inadvertently during early pregnancy. The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed. 8. Gallbladder Disease Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (57, 58). More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal (59-61). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance (62). Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (23, 63). However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (64). Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives. A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a . and 1d .), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking oral contraceptives (65) and this increase is more likely in older oral contraceptive users (66) and with continued use (65). Data from the Royal College of General Practitioners (18) and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal disease (67) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (66), and there is no difference in the occurrence of hypertension among ever and never users (65,67,68). 11. Headache The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause. 12. Bleeding Irregularities Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Nonhormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. 13. Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 14. Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if depression recurs to a serious degree."
    ],
    "warnings_table": [
      "<table width=\"100%\"><caption>TABLE II: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE</caption><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph>Adapted from P.M. Layde and V. Beral, Reference 18</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID53\" width=\"101%\"><caption>TABLE III: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"33%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">15 -19</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">20-24</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">25-29</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">30 -34</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">35-39</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">40-44</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>No fertility control methods</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>7.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>7.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>9.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>14.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>25.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>28.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives non-smoker<footnote ID=\"_Ref494107911\">Deaths are method related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>13.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>31.6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives smoker<footnoteRef IDREF=\"_Ref494107911\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>13.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>51.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>117.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD<footnoteRef IDREF=\"_Ref494107911\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom<footnote ID=\"_Ref494107931\">Deaths are birth related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm/ spermicide<footnoteRef IDREF=\"_Ref494107931\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>2.8</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref494107931\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>3.6</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph>Adapted from H.W. Ory, Reference 41. </paragraph></td></tr></tbody></table>"
    ],
    "precautions": [
      "PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections. 2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. 3. Lipid Disorders Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. 4. Liver Function If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function. 5. Fluid Retention Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. 6. Contact Lenses Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 7. Drug Interactions Effects of Other Drugs on Oral Contraceptives (69) Rifampin: Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants: Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Troglitazone: Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness. Antibiotics: Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. Concomitant Use with HCV Combination Therapy \u2013 Liver Enzyme Elevation Co-administration of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Co-administration of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations. Other: Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Oral Contraceptives on Other Drugs Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. 8. Interactions with Laboratory Tests Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: a. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T 4 by column or by radioimmunoassay. Free T 3 resin uptake is decreased, reflecting the elevated TBG; free T 4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged. e. Triglycerides may be increased. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives. 9. Carcinogenesis See WARNINGS section. 10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS section. 11. Lactation Small amounts of oral contraceptive steroids have been identified in human milk, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child. 12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated. PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (PATIENT PACKAGE INSERT BRIEF SUMMARY and DETAILED PATIENT PACKAGE INSERT). \u2022 Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs (see BOXED WARNING and CONTRAINDICATIONS ). \u2022 Counsel patients that the increased risk of venous thromboembolism compared to non-users of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or greater interruption in intake) the same or a different CHC (see WARNINGS ). \u2022 Counsel patients that this product does not protect against HIV-infection (AIDS) and other sexually transmitted infections. \u2022 Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs (see PRECAUTIONS ). \u2022 Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established (see PRECAUTIONS ). \u2022 Counsel any patient who starts norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a blue tablet for 7 consecutive days (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients that amenorrhea may occur. Pregnancy should be considered in the event of amenorrhea, and should be ruled out if amenorrhea is associated with symptoms of pregnancy, such as morning sickness or unusual breast tenderness (see WARNINGS ). \u2022 Counsel patients with a history of depression that depression may reoccur. Women should contact their healthcare provider if depression occurs (see WARNINGS )."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): \u2022 Thrombophlebitis \u2022 Arterial thromboembolism \u2022 Pulmonary embolism \u2022 Myocardial infarction \u2022 Cerebral hemorrhage \u2022 Cerebral thrombosis \u2022 Hypertension \u2022 Gallbladder disease \u2022 Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1) (70-74). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1) (70,73,75). One of these studies reported no association between breast cancer risk and COC use.. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use. RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: \u2022 Mesenteric thrombosis \u2022 Retinal thrombosis The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related: \u2022 Nausea \u2022 Vomiting \u2022 Gastrointestinal symptoms (such as abdominal cramps and bloating) \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Temporary infertility after discontinuation of treatment \u2022 Edema \u2022 Melasma which may persist \u2022 Breast changes: tenderness, enlargement, secretion \u2022 Change in weight (increase or decrease) \u2022 Change in cervical erosion and secretion \u2022 Diminution in lactation when given immediately postpartum \u2022 Cholestatic jaundice \u2022 Migraine \u2022 Rash (allergic) \u2022 Depression \u2022 Reduced tolerance to carbohydrates \u2022 Vaginal candidiasis \u2022 Change in corneal curvature (steepening) \u2022 Intolerance to contact lenses The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted: \u2022 Pre-menstrual syndrome \u2022 Cataracts \u2022 Changes in appetite \u2022 Cystitis-like syndrome \u2022 Headache \u2022 Nervousness \u2022 Dizziness \u2022 Hirsutism \u2022 Loss of scalp hair \u2022 Erythema multiforme \u2022 Erythema nodosum \u2022 Hemorrhagic eruption \u2022 Vaginitis \u2022 Porphyria \u2022 Impaired renal function \u2022 Hemolytic uremic syndrome \u2022 Budd-Chiari syndrome \u2022 Acne \u2022 Changes in libido \u2022 Colitis FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES"
    ],
    "overdosage": [
      "OVERDOSAGE Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females. NON-CONTRACEPTIVE HEALTH BENEFITS The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (76-81). Effects on menses: \u2022 Increased menstrual cycle regularity \u2022 Decreased blood loss and decreased incidence of iron deficiency anemia \u2022 Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation: \u2022 Decreased incidence of functional ovarian cysts \u2022 Decreased incidence of ectopic pregnancies Effects from long-term use: \u2022 Decreased incidence of fibroadenomas and fibrocystic disease of the breast \u2022 Decreased incidence of acute pelvic inflammatory disease \u2022 Decreased incidence of endometrial cancer \u2022 Decreased incidence of ovarian cancer"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION The tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the tablet blister above the first row of tablets. Note: Each blister card has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days. Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen. The possibility of ovulation and conception prior to initiation of use should be considered. Dosage and Administration for 28-Day Dosage Regimen To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken exactly as directed and at intervals not exceeding 24 hours. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets provide a continuous administration regimen consisting of 21 blue tablets of norethindrone acetate and ethinyl estradiol and 7 brown non-hormone containing tablets of ferrous fumarate. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen and do not serve any therapeutic purpose. There is no need for the patient to count days between cycles because there are no \u201coff-tablet days.\u201d A. Sunday-Start Regimen: The patient begins taking the first blue tablet from the top row of the blister (labeled Sunday) on the first Sunday after menstrual flow begins. When the menstrual flow begins on Sunday, the first blue tablet is taken on the same day. The patient takes one blue tablet daily for 21 days. The last blue tablet in the blister pack will be taken on a Saturday. Upon completion of all 21 blue tablets, and without interruption, the patient takes one brown tablet daily for 7 days. Upon completion of this first course of tablets, the patient begins a second course of 28-day tablets, without interruption, the next day (Sunday), starting with the Sunday blue tablet in the top row. Adhering to this regimen of one blue tablet daily for 21 days, followed without interruption by one brown tablet daily for 7 days, the patient will start all subsequent cycles on a Sunday. B. Day-1 Start Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the blister card. She starts taking one blue tablet daily, beginning with the first blue tablet in the top row. After the last blue tablet (at the end of the third row) has been taken, the patient will then take the brown tablets for a week (7 days). For all subsequent cycles, the patient begins a new 28 tablet regimen on the eighth day after taking her last blue tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the tablet blister. Following this regimen of 21 blue tablets and 7 brown tablets, the patient will start all subsequent cycles on the same day of the week as the first course. Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule. Special Notes on Administration Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after the brown tablets have been started. In any event, the next course of tablets should be started without interruption. If spotting occurs while the patient is taking blue tablets, continue medication without interruption. If the patient forgets to take one or more blue tablets, the following is suggested: One tablet is missed \u2022 take tablet as soon as remembered \u2022 take next tablet at the regular time Two consecutive tablets are missed (week 1 or week 2) \u2022 take two tablets as soon as remembered \u2022 take two tablets the next day \u2022 use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (week 3) Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets The possibility of ovulation occurring increases with each successive day that scheduled blue tablets are missed. While there is little likelihood of ovulation occurring if only one blue tablet is missed, the possibility of spotting or bleeding is increased. This is particularly likely to occur if two or more consecutive blue tablets are missed. If the patient forgets to take any of the seven brown tablets in week four, those brown tablets that were missed are discarded and one brown tablet is taken each day until the pack is empty. A back-up birth control method is not required during this time. A new pack of tablets should be started no later than the eighth day after the last blue tablet was taken. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet blister pack on the next Sunday or the first day (Day-1), depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered. Use of Oral Contraceptives in the Event of a Missed Menstrual Period 1. If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out. 2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg are packaged in a carton of three pouches (NDC 0378-7288-53); each pouch contains a blister pack of 28 tablets. Each blister pack contains 21 blue, round, flat-faced, unscored tablet debossed with 237 on one side and plain on the other side and 7 brown, round, flat-faced, unscored tablets debossed with 291 on one side and plain on the other side. Each brown tablet contains 75 mg ferrous fumarate. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]"
    ],
    "references": [
      "REFERENCES 1. Back DJ, Breckenridge AM, Crawford FE, Mclver M, Orme ML\u2019E, Rowe PH and Smith E: Kinetics of norethindrone in women II. Single-dose kinetics. Clin Pharmacol Ther 1978; 24:448-453. 2. Humpel M, Nieuweboer B, Wendt H and Speck U: Investigations of pharmacokinetics of ethinyl estradiol to specific consideration of a possible first-pass effect in women. Contraception 1979;19:421-432. 3. Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML\u2019E, Rowe PH and Watts MJ. An investigation of the pharmacokinetics of ethinyl estradiol in women using radioimmunoassay. Contraception 1979;20:263-273. 4. Hammond GL, Lahteenmaki PLA, Lahteenmaki P and Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steriod Biochem 1982;17:375-380. 5. Fotherby K. Pharmacokinetics and metabolism of progestins in humans, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994;99-126. 6. Goldzieher JW. Pharmacokinetics and metabolism of ethynyl estrogens, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press Ltd., New York, 1994;127-151. 7. Hatcher, RA, et al. 1998. Contraceptive Technology, Seventeenth Edition. New York: Irvington Publishers. 8. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 1). New England Journal of Medicine, 305:612-618, 1981. 9. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 2). New England Journal of Medicine, 305:672-677, 1981. 10. Adam, S.A., and M. Thorogood: Oral contraception and myocardial infarction revisited: The effects of new preparations and prescribing patterns. Brit. J. Obstet. and Gynec., 88:838-845, 1981. 11. Mann, J.I., and W.H. Inman: Oral contraceptives and death from myocardial infarction. Brit. Med. J., 2(5965): 245-248, 1975. 12. Mann, J.I., M.P. Vessey, M. Thorogood, and R. Doll: Myocardial infarction in young women with special reference to oral contraceptive practice. Brit. Med. J., 2(5956):241-245, 1975. 13. Royal College of General Practitioners\u2019 Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet, 1:541-546, 1981. 14. Slone, D., S. Shapiro, D.W. Kaufman, L. Rosenberg, O.S. Miettinen, and P.D. Stolley: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N.E.J.M., 305:420-424, 1981. 15. Vessey, M.P.: Female hormones and vascular disease: An epidemiological overview. Brit. J. Fam. Plann., 6:1-12, 1980. 16. Russell-Briefel, R.G., T.M. Ezzati, R. Fulwood, J.A. Perlman, and R.S. Murphy: Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Preventive Medicine , 15:352-362, 1986. 17. Goldbaum, G.M., J.S. Kendrick, G.C. Hogelin, and E.M. Gentry: The relative impact of smoking and oral contraceptive use on women in the United States. J.A.M.A., 258:1339-1342, 1987. 18. Layde, P.M., and V. Beral: Further analyses of mortality in oral contraceptive users: Royal College General Practitioners\u2019 Oral Contraception Study. (Table 5) Lancet, 1:541-546, 1981. 19. Knopp, R.H.: Arteriosclerosis risk: The roles of oral contraceptives and postmenopausal estrogens. J. of Reprod. Med., 31(9)(Supplement): 913-921, 1986. 20. Krauss, R.M., S. Roy, D.R. Mishell, J. Casagrande, and M.C. Pike: Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am. J. Obstet . Gyn., 145:446-452, 1983. 21. Wahl, P., C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss, and B. Rifkind: Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N.E.J.M., 308:862-867, 1983. 22. Wynn, V., and R. Niththyananthan: The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am. J. Obstet. and Gyn., 142:766-771, 1982. 23. Wynn, V., and I. Godsland: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Medicine, 31 (9)(Supplement): 892-897, 1986. 24. LaRosa, J.C.: Atherosclerotic risk factors in cardiovascular disease. J. Reprod. Med., 31(9)(Supplement): 906-912, 1986. 25. Inman, W.H., and M.P. Vessey: Investigations of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Brit. Med. J., 2(5599): 193-199, 1968. 26. Maguire, M.G., J. Tonascia, P.E. Sartwell, P.D. Stolley, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives: A further report. Am. J. Epidemiology, 110(2): 188-195, 1979. 27. Pettiti, D.B., J. Wingerd, F. Pellegrin, and S. Ramacharan: Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J.A.M.A., 242:1150-1154, 1979. 28. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit. Med. J., 2(5599): 199-205, 1968. 29. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease: A further report. Brit. Med. J., 2(5658): 651-657, 1969. 30. Porter, J.B., J.R. Hunter, D.A. Danielson, H. Jick, and A. Stergachis: Oral contraceptives and non-fatal vascular disease: Recent experience. Obstet. and Gyn., 59(3):299-302, 1982. 31. Vessey, M., R. Doll, R. Peto, B. Johnson, and P. Wiggins: A long-term follow-up study of women using different methods of contraception: An interim report. J.Biosocial . Sci., 8:375-427, 1976. 32. Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J. of Royal College of General Practitioners, 28:393-399, 1978. 33. Collaborative Group for the study of stroke in young women: Oral contraception and increased risk of cerebral ischemia or thrombosis. N.E.J.M., 288:871-878, 1973. 34. Petitti, D.B., and J.Wingerd: Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet, 2:234-236, 1978. 35. Inman, W.H.: Oral contraceptives and fatal subarachnoid hemorrhage. Brit. Med. J., 2(6203): 1468-70, 1979. 36. Collaborative Group for the study of stroke in young women: Oral contraceptives and stroke in young women: Associated risk factors. J.A.M.A., 231:718-722, 1975. 37. Inman, W.H., M.P. Vessey, B. Westerholm, and A. Engelund: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Brit. Med. J., 2:203-209, 1970. 38. Meade, T.W., G. Greenberg, and S.G. Thompson: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Brit. Med. J., 280(6224): 1157-1161, 1980. 39. Kay, C.R.: Progestogens and arterial disease: Evidence from the Royal College of General Practitioners\u2019 study. Amer. J. Obstet. Gyn., 142:762-765, 1982. 40. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J. Coll. Gen. Pract., 33:75-82, 1983. 41. Ory, H.W: Mortality associated with fertility and fertility control: 1983. Family Planning Perspectives, 15:50-56, 1983. 42. Ory, H., Z. Naib, S.B. Conger, R.A. Hatcher, and C.W. Tyler: Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Am. J. Obstet. Gynec., 124:573-577, 1976. 43. Vessey, M.P., M. Lawless, K. McPherson, D. Yeates: Neoplasia of the cervix uteri and contraception: A possible adverse effect of the pill. Lancet, 2:930, 1983. 44. Brinton, L.A., G.R. Huggins, H.F. Lehman, K. Malli, D.A. Savitz, E. Trapido, J. Rosenthal, and R. Hoover: Long-term use of oral contraceptives and risk of invasive cervical cancer. Int. J. Cancer, 38:339-344, 1986. 45. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Brit. Med. J., 290:961-965, 1985. 46. Rooks, J.B., H.W. Ory, K.G. Ishak, L.T. Strauss, J.R. Greenspan, A.P. Hill, and C.W. Tyler: Epidemiology of hepatocellular adenoma: The role of oral contraceptive use. J.A.M.A., 242:644-648, 1979. 47. Bein, N.N., and H.S. Goldsmith: Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Brit. J. Surg., 64:433-435, 1977. 48. Klatskin, G.: Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology, 73:386-394, 1977. 49. Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike: Hepatocellular carcinoma and oral contraceptives. Brit. J. Cancer, 48:437-440, 1983. 50. Neuberger, J., D. Forman, R. Doll, and R. Williams: Oral contraceptives and hepatocellular carcinoma. Brit. Med. J., 292:1355-1357, 1986. 51. Forman, D., T.J. Vincent, and R. Doll: Cancer of the liver and oral contraceptives. Brit. Med. J., 292:1357-1361, 1986. 52. Harlap, S., and J. Eldor: Births following oral contraceptive failures. Obstet. Gynec., 55:447-452, 1980. 53. Savolainen, E., E. Saksela, and L. Saxen: Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Amer. J. Obstet. Gynec., 140:521-524, 1981. 54. Janerich, D.T., J.M. Piper, and D.M. Glebatis: Oral contraceptives and birth defects. Am. J. Epidemiology, 112:73-79, 1980. 55. Ferencz, C., G.M. Matanoski, P.D. Wilson, J.D. Rubin, C.A. Neill, and R. Gutberlet: Maternal hormone therapy and congenital heart disease. Teratology, 21:225-239, 1980. 56. Rothman, K.J., D.C. Fyler, A. Goldbatt, and M.B. Kreidberg: Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiology, 109:433-439, 1979. 57. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet, 1:1399-1404, 1973. 58. Royal College of General Practitioners: Oral Contraceptives and Health. New York, Pittman, 1974, 100p. 59. Layde, P.M., M.P. Vessey, and D. Yeates: Risk of gallbladder disease: A cohort study of young women attending family planning clinics. J of Epidemiol. and Comm. Health, 36:274-278, 1982. 60. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am. J. Epidemiol., 119:796-805, 1984. 61. Strom, B.L., R.T. Tamragouri, M.L. Morse, E.L. Lazar, S.L. West, P.D. Stolley, and J.K. Jones: Oral contraceptives and other risk factors for gallbladder disease. Clin. Pharmacol. Ther., 39:335-341, 1986. 62. Wynn, V., P.W. Adams, I.F. Godsland, J. Melrose, R. Niththyananthan, N.W. Oakley, and A. Seedj: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet, 1:1045-1049, 1979. 63. Wynn, V.: Effect of progesterone and progestins on carbohydrate metabolism. In Progesterone and Progestin. Edited by C.W. Bardin, E. Milgrom, P. Mauvis-Jarvis. New York, Raven Press, pp. 395-410, 1983. 64. Perlman, J.A., R. G. Roussell-Briefel, T.M. Ezzati, and G. Lieberknecht: Oral glucose tolerance and the potency of oral contraceptive progestogens. J. Chronic Dis., 38:857-864, 1985. 65. Royal College of General Practitioners\u2019 Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet, 1:624, 1977. 66. Fisch, I.R., and J. Frank: Oral contraceptives and blood pressure. J.A.M.A., 237:2499-2503, 1977. 67. Laragh, A.J.: Oral contraceptive induced hypertension: Nine years later. Amer. J. Obstet. Gynecol., 126:141-147, 1976. 68. Ramcharan, S., E. Peritz, F.A. Pellegrin, and W.T. Williams: Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort. In Pharmacology of Steroid Contraceptive Drugs. Edited by S. Garattini and H.W. Berendes. New York, Raven Press, pp. 277-288, 1977. (Monographs of the Mario Negri Institute for Pharmacological Research, Milan.) 69. Back DJ, Orme ML\u2019E. Drug interactions, in Pharmacology of the contraceptive steroids. Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994, 407-425. 70. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025-2032. 71. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control. 2005;16(5):537-544. 72. Dorjgochoo T, Shu XO, Li HL, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer. 2009;124(10):2442-2449. 73. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(10):2496-2502. 74. Vessey M, Yeates D. Oral contraceptive use and cancer. Final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-683. 75. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2017;377(23):2228-2239. 76. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. J.A.M.A., 249:1596-1599, 1983. 77. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. J.A.M.A., 257:796-800, 1987. 78. Ory, H.W.: Functional ovarian cysts and oral contraceptives: Negative association confirmed surgically. J.A.M.A., 228:68-69, 1974. 79. Ory, H.W., P. Cole, B. Macmahon, and R. Hoover: Oral contraceptives and reduced risk of benign breast disease. N.E.J.M., 294:41-422, 1976. 80. Ory, H.W.: The noncontraceptive health benefits from oral contraceptive use. Fam. Plann. Perspectives, 14:182-184, 1982. 81. Ory, H.W., J.D. Forrest, and R. Lincoln: Making Choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, p.1, 1983."
    ],
    "spl_patient_package_insert": [
      "BRIEF SUMMARY PATIENT PACKAGE INSERT This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Oral contraceptives, also known as \u201cbirth control pills\u201d or \u201cthe pill\u201d, are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you: \u2022 Smoke \u2022 Have high blood pressure, diabetes, high cholesterol \u2022 Have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast, jaundice, or malignant or benign liver tumors. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea, vomiting, and breakthrough bleeding may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill: 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack or angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences. 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. There may be slight increases in the risk of breast cancer among current users of hormonal birth control pills with longer duration of use of 8 years or more. Some studies have found an increase in the risk of developing cancer of the cervix in women taking the pill, but this finding may be related to differences in sexual behavior or other factors not related to use of the pill. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis. INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet and ferrous fumarate tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the tablet blister pack above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 blue tablets and 7 brown tablets Norethindrone Acetate and Ethinyl Estradiol Tablets 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg Each blue tablet contains 1.5 mg norethindrone acetate and 0.03 mg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn\u2019t go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS: The 28-Day pill pack has 21 \u201cactive\u201d blue pills (with hormones) to take for 3 weeks, followed by 1 week of reminder brown pills (without hormones). 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone acetate and ethinyl estradiol tablets 1.5 mg/0.03 mg and ferrous fumarate tablets, 75 mg will contain: 21 BLUE PILLS for WEEKS 1, 2, and 3. WEEK 4 will contain BROWN PILLS ONLY . 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. AN EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \u201cactive\u201d blue pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d blue pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Start the next pack on the day after your last \u201creminder\u201d pill. Do not wait any days between packs. Blister image with instructions Day label sticker WHAT TO DO IF YOU MISS PILLS If you MISS 1 blue \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 blue \u201cactive\u201d pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 2 blue \u201cactive\u201d pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE blue \u201cactive\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. A REMINDER FOR THOSE ON 28-DAY PACKS: IF YOU FORGET ANY OF THE 7 BROWN \u201cREMINDER\u201d PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE BLUE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] DETAILED PATIENT PACKAGE INSERT Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. What You Should Know About Oral Contraceptives Any woman who considers using oral contraceptives (the \u201cbirth control pill\u201d or \u201cthe pill\u201d) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider\u2019s advice with regard to regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES Oral contraceptives or \u201cbirth control pills\u201d or \u201cthe pill\u201d are used to prevent pregnancy and are more effective than other non-surgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 3% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: Implant: < 1% Male sterilization: < 1% Injection: < 1% Cervical Cap: 20% to 40% IUD: < 1% to 2% Condom alone (male): 14% Diaphragm with spermicides: 20% Condom alone (female): 21% Spermicides alone: 26% Periodic abstinence: 25% Vaginal Sponge: 20% to 40% Withdrawal: 19% Female sterilization: < 1% No method: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions: \u2022 A history of heart attack or stroke \u2022 Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), or eyes \u2022 A history of blood clots in the deep veins of your legs \u2022 Chest pain (angina pectoris) \u2022 Known or suspected breast cancer \u2022 Unexplained vaginal bleeding (until a diagnosis is reached by your doctor) \u2022 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill \u2022 Liver tumor (benign or cancerous) \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend a safer method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your healthcare provider if you have: \u2022 Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram \u2022 Diabetes \u2022 Elevated cholesterol or triglycerides \u2022 High blood pressure \u2022 Migraine or other headaches or epilepsy \u2022 Depression \u2022 Gallbladder, heart, or kidney disease \u2022 History of scanty or irregular menstrual periods Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. RISKS OF TAKING ORAL CONTRACEPTIVES 1. Risk of Developing Blood Clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives; in particular, a clot in the legs can cause thrombophlebitis, and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in GENERAL PRECAUTIONS .) 2. Heart Attacks and Strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder Disease Oral contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver Tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Risk of Cancer It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods Deaths are birth related. 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker Deaths are method related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/ spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7-26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. The suggestion that women over 40 who don\u2019t smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: \u2022 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung) \u2022 Pain in the calf (indicating a possible clot in the leg) \u2022 Crushing chest pain or heaviness in the chest (indicating a possible heart attack) \u2022 Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) \u2022 Sudden partial or complete loss of vision (indicating a possible clot in the eye) \u2022 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts) \u2022 Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor) \u2022 Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression) \u2022 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark colored urine, or light-colored bowel movements (indicating possible liver problems) SIDE EFFECTS OF ORAL CONTRACEPTIVES 1. Vaginal Bleeding Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider. 2. Contact Lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider. 3. Fluid Retention Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or healthcare provider. 4. Melasma A spotty darkening of the skin is possible, particularly of the face. 5. Other Side Effects Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections. If any of these side effects bother you, call your doctor or healthcare provider. GENERAL PRECAUTIONS 1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception. There is no conclusive evidence that oral contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy. 2. While Breastfeeding If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely. 3. Laboratory Tests If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills. 4. Drug Interactions Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin \u00ae is one brand of this drug); troglitazone; phenylbutazone; and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective. Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications. 5. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis. INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet and ferrous fumarate tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 blue tablets and 7 brown tablets Norethindrone Acetate and Ethinyl Estradiol Tablets 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg Each blue tablet contains 1.5 mg norethindrone acetate and 0.03 mg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn\u2019t go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS: The 28-Day pill pack has 21 \u201cactive\u201d blue pills (with hormones) to take for 3 weeks, followed by 1 week of reminder brown pills (without hormones). 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone acetate and ethinyl estradiol tablets 1.5 mg/0.03 mg and ferrous fumarate tablets, 75 mg will contain: 21 BLUE PILLS for WEEKS 1, 2, and 3. WEEK 4 will contain BROWN PILLS ONLY . 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. AN EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \u201cactive\u201d blue pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \u201cactive\u201d blue pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Start the next pack on the day after your last \u201creminder\u201d pill. Do not wait any days between packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 blue \u201cactive\u201d pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 blue \u201cactive\u201d pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 2 blue \u201cactive\u201d pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. If you MISS 3 OR MORE blue \u201cactive\u201d pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a blue \u201cactive\u201d pill every day for 7 days. A REMINDER FOR THOSE ON 28-DAY PACKS: IF YOU FORGET ANY OF THE 7 BROWN \u201dREMINDER\u201d PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE BLUE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic Blister image with instructions Day label sticker PREGNANCY DUE TO PILL FAILURE The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 3%. If failure does occur, the risk to the fetus is minimal. PREGNANCY AFTER STOPPING THE PILL There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. OVERDOSAGE Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. OTHER INFORMATION Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: \u2022 Menstrual cycles may become more regular \u2022 Blood flow during menstruation may be lighter and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur \u2022 Pain or other symptoms during menstruation may be encountered less frequently \u2022 Ectopic (tubal) pregnancy may occur less frequently \u2022 Noncancerous cysts or lumps in the breast may occur less frequently \u2022 Acute pelvic inflammatory disease may occur less frequently \u2022 Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the \u201cPhysician Insert\u201d, which you may wish to read. Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection. MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS At times there may be no menstrual period after a cycle of pills. Therefore, if you miss one menstrual period but have taken the pills exactly as you were supposed to, continue as usual into the next cycle. If you have not taken the pills correctly and miss a menstrual period, you may be pregnant and should stop taking oral contraceptives until your doctor or healthcare provider determines whether or not you are pregnant. Until you can get to your doctor or healthcare provider, use another form of contraception. If two consecutive menstrual periods are missed, you should stop taking pills until it is determined whether or not you are pregnant. Although there does not appear to be any increase in birth defects in newborn babies if you become pregnant while using oral contraceptives, you should discuss the situation with your doctor or healthcare provider. Periodic Examination Your doctor or healthcare provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaou smear, i.e., test for cancer). Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U . S . A. Manufactured by: Mylan Laboratories Limited Ahmedabad - 382 213, India Code No.: GUJ-DRUGS/G/28/1297 75099584 Revised: 11/2023 FC:OT:7288:R10"
    ],
    "spl_patient_package_insert_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"46%\"/><col width=\"52%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains:</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking:</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>21 blue tablets and 7 brown tablets</paragraph></td><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl Estradiol Tablets 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">A REMINDER FOR THOSE ON 28-DAY PACKS:</content></paragraph><paragraph>IF YOU FORGET ANY OF THE 7 BROWN &#x201C;REMINDER&#x201D; PILLS IN WEEK 4:</paragraph><paragraph>THROW AWAY THE PILLS YOU MISSED.</paragraph><paragraph>KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY.</paragraph><paragraph>YOU DO NOT NEED A BACK-UP METHOD.</paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"49%\"/><col width=\"49%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Implant: &lt; 1% </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Male sterilization: &lt; 1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: &lt; 1% </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Cervical Cap: 20% to 40% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD: &lt; 1% to 2% </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom alone (male): 14% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicides: 20% </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom alone (female): 21% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone: 26% </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Periodic abstinence: 25% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge: 20% to 40% </paragraph></td><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Withdrawal: 19% </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Female sterilization: &lt; 1% </paragraph></td><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>No method: 85% </paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID182\" width=\"99%\"><caption>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"38%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"11%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">15-19</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">20-24</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">25-29</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">30-34</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">35-39</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">40-44</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>No fertility control methods<footnote ID=\"_Ref494109934\">Deaths are birth related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>7.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>9.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>14.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>25.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>28.2</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Oral contraceptives non-smoker<footnote ID=\"_Ref494109943\">Deaths are method related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>31.6</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Oral contraceptives smoker<footnoteRef IDREF=\"_Ref494109943\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>3.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>6.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>13.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>51.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>117.2</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>IUD<footnoteRef IDREF=\"_Ref494109943\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.4</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Condom<footnoteRef IDREF=\"_Ref494109934\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>0.4</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Diaphragm/ spermicide<footnoteRef IDREF=\"_Ref494109934\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>1.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>2.8</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref494109934\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>1.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>2.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule\" valign=\"middle\"><paragraph>3.6</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"46%\"/><col width=\"52%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains: </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking: </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>21 blue tablets and 7 brown tablets </paragraph></td><td styleCode=\"Rrule Botrule Lrule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl Estradiol Tablets 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content> </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">A REMINDER FOR THOSE ON 28-DAY PACKS:</content> IF YOU FORGET ANY OF THE 7 BROWN &#x201D;REMINDER&#x201D; PILLS IN WEEK 4: THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD. </paragraph></td></tr><tr><td styleCode=\"Botrule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</content> Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE BLUE &#x201C;ACTIVE&#x201D; PILL EACH DAY until you can reach your doctor or clinic </paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 0378-7288-53 Rx only Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets* 1.5 mg/0.03 mg Each blue tablet contains norethindrone acetate 1.5 mg and ethinyl estradiol 0.03 mg. Each brown tablet contains ferrous fumarate USP, 75 mg. Each blister pack contains 21 blue tablets and 7 brown tablets. *Ferrous fumarate tablets are not USP for dissolution and assay. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. 3 pouches, each pouch contains one blister pack of 28 tablets DOSAGE: One tablet daily as prescribed. See prescribing information. IMPORTANT: The \u201cPatient Instructions\u201d which are packaged inside each pouch provides important instructions to the patient. Please supply these instructions and the carrier sleeve to the patient when dispensing. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Keep this and all medication out of the reach of children. 3s Carton"
    ],
    "set_id": "4423eebd-6397-4330-85a8-baa2e736767a",
    "id": "ef1c54ca-92fb-677c-b2fe-46a2f872046a",
    "effective_time": "20231109",
    "version": "6",
    "openfda": {
      "application_number": [
        "ANDA202741"
      ],
      "brand_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "Mylan Pharmaceuticals Inc."
      ],
      "product_ndc": [
        "0378-7288"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "259176",
        "1359022",
        "1359023"
      ],
      "spl_id": [
        "ef1c54ca-92fb-677c-b2fe-46a2f872046a"
      ],
      "spl_set_id": [
        "4423eebd-6397-4330-85a8-baa2e736767a"
      ],
      "package_ndc": [
        "0378-7288-85",
        "0378-7288-53"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Estradiol and Norethindrone Acetate Estradiol and Norethindrone Acetate ESTRADIOL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE LACTOSE MONOHYDRATE STARCH, CORN POLYSORBATE 80 COPOVIDONE K25-31 MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE TALC POLYETHYLENE GLYCOL 3350 LECITHIN, SOYBEAN D&C YELLOW NO. 10 FD&C BLUE NO. 2 FD&C RED NO. 40 round biconvex J2 Estradiol and Norethindrone Acetate Estradiol and Norethindrone Acetate ESTRADIOL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE LACTOSE MONOHYDRATE STARCH, CORN POLYSORBATE 80 COPOVIDONE K25-31 MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE TALC POLYETHYLENE GLYCOL 3350 LECITHIN, SOYBEAN D&C YELLOW NO. 10 FD&C BLUE NO. 2 FD&C YELLOW NO. 6 pale yellow round biconvex J1"
    ],
    "boxed_warning": [
      "WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER S ee full prescribing information for complete boxed warning Estrogen Plus Progestin Therapy \u25cf The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) ( 5.1 ) \u25cf The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer ( 5.2 ) \u25cf The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) \u25cf Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) Estrogen-Alone Therapy \u25cf There is an increased risk of endometrial cancer in a woman with a uterus who use unopposed estrogens ( 5.2 ) \u25cf The WHI estrogen-alone substudy reported increased risks of stroke and DVT ( 5.1 ) \u25cf The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) \u25cf Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia ( 5.2 , 5.3 ) Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions ( 5.1 ), and Clinical Studies ( 14.5 )] . The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )]. Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [ see Warnings and Precautions ( 5.1 , 5.3 ), and Clinical Studies ( 14.5 , 14.6 ) ]. Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.5 )] . Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progest ogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions ( 5.2 )] . Cardiovascular Disorders and Probable Dementia The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions ( 5.1 ), and Clinical Studies ( 14.5 )] . The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )] . Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions ( 5.1 , 5.3 ), and Clinical Studies ( 14.5 , 14.6 )] . Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman."
    ],
    "recent_major_changes": [
      "RECENT MAJOR CHANGES Warnings and Precautions, Malignant Neoplasms (5.2) 11/2023"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Estradiol and norethindrone acetate tablets are an estrogen and progestin combination indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Limitations of Use: When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. Prevention of Postmenopausal Osteoporosis ( 1.3 ) Limitations of Use: When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. Estradiol and norethindrone acetate tablets are indicated for: 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. 1.3 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Take a single estradiol and norethindrone acetate 1 mg/0.5 mg or 0.5 mg/0.1 mg tablet orally once daily for the Treatment of Moderate to severe Vasomotor Symptoms due to Menopause and for the Prevention of Postmenopausal Osteoporosis ( 2.1 , 2.3 ) Estradiol and norethindrone acetate 1 mg/0.5 mg tablets are taken orally once daily for the Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause ( 2.2 ) Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Reevaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary. 2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Take a single estradiol and norethindrone acetate tablet orally once daily for the treatment of moderate to severe vasomotor symptoms due to menopause. Estradiol and norethindrone acetate tablets 1 mg/0.5 mg Estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg 2.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Take a single estradiol and norethindrone acetate tablet orally once daily for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Estradiol and norethindrone acetate tablets 1 mg/0.5 mg 2.3 Prevention of Postmenopausal Osteoporosis Take a single estradiol and norethindrone acetate tablet orally once daily for the prevention of postmenopausal osteoporosis. Estradiol and norethindrone acetate tablets 1 mg/0.5 mg Estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Estradiol and norethindrone acetate 1 mg/0.5 mg tablet ( 3 ) Estradiol and norethindrone acetate 0.5 mg/0.1 mg tablet ( 3 ) Estradiol and norethindrone acetate tablets, USP are available in two strengths: Each tablet of estradiol and norethindrone acetate 1 mg/ 0.5 mg contains 1 mg of estradiol and 0.5 mg of norethindrone acetate. The tablets are yellow, round, bi-convex tablets debossed \"J2\" on one side. Each tablet of estradiol and norethindrone acetate 0.5 mg/ 0.1 mg contains 0.5 mg of estradiol and 0.1 mg of norethindrone acetate. The tablets are pale yellow, round, bi-convex tablets debossed \"J1\" on one side."
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Undiagnosed abnormal genital bleeding ( 4 ) Breast cancer or a history of breast cancer ( 4 , 5.2 ) Estrogen-dependent neoplasia ( 4 , 5.2 ) Active DVT, PE, or history of these conditions ( 4 , 5.1 ) Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions ( 4 , 5.1 ) Known anaphylactic reaction, angioedema, or hypersensitivity to estradiol and norethindrone acetate tablets ( 4 ) Hepatic impairment or disease ( 4 , 5.10 ) Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders ( 4 ) Estradiol and norethindrone acetate tablets are contraindicated in women with any of the following conditions: \u2022 Undiagnosed abnormal genital bleeding [ see Warnings and Precautions ( 5.2 ) ] \u2022 Breast cancer or history of breast cancer [ see Warnings and Precautions ( 5.2 ) ] \u2022 Estrogen-dependent neoplasia [ see Warnings and Precautions ( 5.2 ) ] \u2022 Active DVT, PE, or history of these conditions [ see Warnings and Precautions ( 5.1 ) ] \u2022 Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions [ see Warnings and Precautions ( 5.1 ) ] \u2022 Known anaphylactic reaction, angioedema, or hypersensitivity to estradiol and norethindrone acetate tablets \u2022 Hepatic impairment or disease \u2022 Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Estrogens increase the risk of gall bladder disease ( 5.4 ) Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs ( 5.5 , 5.6 , 5.9 , 5.10 ) Monitor thyroid function in women on thyroid replacement therapy ( 5.11 , 5.18 ) 5.1 Cardiovascular Disorders Increased risks of PE, DVT, stroke and MI are reported with estrogen plus progestin therapy. Increased risks of stroke and DVT are reported with estrogen-alone therapy. Immediately discontinue estrogen with or without progestogen therapy if any of these occur or is suspected. Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). Stroke The WHI estrogen plus progestin substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 strokes per 10,000 women-years) [see Clinical Studies ( 14.5 )] . The increase in risk was demonstrated after the first year and persisted. 1 Immediately discontinue estrogen with or without progestogen therapy if a stroke occurs or is suspected. The WHI estrogen-alone substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 strokes per 10,000 women-years, respectively). The increase in risk was demonstrated in year 1 and persisted [see Clinical Studies ( 14.5 )] . Immediately discontinue estrogen-alone therapy if a stroke occurs or is suspected. Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 Coronary Heart Disease The WHI estrogen plus progestin substudy reported an increased risk (not statistically significant) of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) in those women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years) 1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies ( 14.5 )] . The WHI estrogen-alone substudy reported no overall effect on CHD events in women receiving estrogen-alone compared to placebo 2 [see Clinical Studies ( 14.5 )]. Subgroup analyses of women 50 to 59 years of age, who were less than 10 years since menopause, suggest a reduction (not statistically significant) in CHD events in those women receiving daily CE (0.625 mg)-alone compared to placebo (8 versus 16 per 10,000 women-years). 1 In postmenopausal women with documented heart disease (n=2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA- treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall. Venous Thromboembolism The WHI estrogen plus progestin substudy reported a statistically significant 2-fold greater rate of VTE (DVT and PE) in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted 3 [see Clinical Studies ( 14.5 )]. Immediately discontinue estrogen plus progestogen therapy if a VTE occurs or is suspected. In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years 4 [see Clinical Studies ( 14.5 )]. Immediately discontinue estrogen-alone therapy if a VTE occurs or is suspected. If feasible, discontinue estrogens at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. 5.2 Malignant Neoplasms Breast Cancer After a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA compared to placebo. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years, for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups 5 [see Clinical Studies ( 14.5 )] . The WHI substudy of daily CE (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80] compared to placebo 6 [see Clinical Studies ( 14.5 )] . Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer with estrogen plus progestin therapy, and a smaller increase in the risk for breast cancer with estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to >10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI Trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. These studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. The use of estrogen-alone and estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation. In a one-year trial among 1,176 women who received either unopposed 1 mg estradiol or a combination of 1 mg estradiol plus one of three different doses of NETA (0.1, 0.25, 0.5 mg), seven new cases of breast cancer were diagnosed, two of which occurred among the group of 295 women treated with estradiol and norethindrone acetate tablets 1 mg/0.5 mg and two of which occurred among the group of 294 women treated with 1 mg estradiol/0.1 mg NETA. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self- examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. Endometrial Cancer An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12- times greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears to be associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. Clinical surveillance of all women using estrogen-alone or estrogen plus progestogen therapy is important. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding with unknown etiology. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestogen to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Endometrial hyperplasia occurred at a rate of approximately 1 percent or less with estradiol and norethindrone acetate tablets in a clinical trial. Ovarian Cancer The CE plus MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent confidence interval [CI], 0.77-3.24), but it was not statistically significant. The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. 7 A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% CI 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. 5.3 Probable Dementia In the WHI Memory Study (WHIMS) estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for the CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )]. In the WHIMS estrogen-alone ancillary study, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83- 2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )]. When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk of probable dementia was 1.76 (95 percent CI, 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )]. 5.4 Gallbladder Disease A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. 5.5 Hypercalcemia Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. Discontinue estrogens, including estradiol and norethindrone acetate tablets if hypercalcemia occurs, and take appropriate measures to reduce the serum calcium level. 5.6 Vision Abnormalities Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue estradiol and norethindrone acetate tablets pending examination if there is a sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. Permanently discontinue estrogens, including estradiol and norethindrone acetate tablets, if examination reveals papilledema or retinal vascular lesions. 5.7 Addition of a Progestogen When a Woman Has Not Had a Hysterectomy Studies of the addition of a progestogen for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestogens with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. 5.8 Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen. 5.9 Exacerbation of Hypertriglyceridemia In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Discontinue estradiol and norethindrone acetate tablets if pancreatitis occurs. 5.10 Hepatic Impairment and/or Past History of Cholestatic Jaundice Estrogens may be poorly metabolized in women with hepatic impairment. Exercise caution in any woman with a history of cholestatic jaundice associated with past estrogen use or with pregnancy. In the case of recurrence of cholestatic jaundice, discontinue estradiol and norethindrone acetate tablets. 5.11 Exacerbation of Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T 4 and T 3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy. Monitor thyroid function in these women during treatment with estradiol and norethindrone acetate tablets to maintain their free thyroid hormone levels in an acceptable range. 5.12 Fluid Retention Estrogens plus progestogens may cause some degree of fluid retention. Monitor any woman with a condition(s) that might predispose her to fluid retention, such as a cardiac or renal impairment. Discontinue estrogen plus progestogen therapy, including estradiol and norethindrone acetate tablets, with evidence of medically concerning fluid retention. 5.13 Hypocalcemia Estrogen-induced hypocalcemia may occur in women with hypoparathyroidism. Consider whether the benefits of estrogen therapy, including estradiol and norethindrone acetate tablets, outweigh the risks in such women. 5.14 Exacerbation of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. 5.15 Hereditary Angioedema Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. Consider whether the benefits of estrogen therapy, including estradiol and norethindrone acetate tablets, outweigh the risks in such women. 5.16 Exacerbation of Other Conditions Estrogen therapy, including estradiol and norethindrone acetate tablets, may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas. Consider whether the benefits of estrogen therapy outweigh the risks in such women. 5.17 Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy. 5.18 Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, and beta- thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein- bound iodine (PBI), T 4 levels (by column or by radioimmunoassay), or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/rennin substrate, alpha-1 antitrypsin, ceruloplasmin). Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentration, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglyceride levels. Impaired glucose tolerance."
    ],
    "laboratory_tests": [
      "5.17 Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions (incidence \u2265 5 percent) with estradiol and norethindrone acetate tablets are: back pain, headache, pain in the extremity, nausea, diarrhea, gastroenteritis, insomnia, emotional lability, upper respiratory tract infection, sinusitis, nasopharyngitis, weight increase, breast pain, post-menopausal bleeding, uterine fibroid vaginal hemorrhage, ovarian cyst, endometrial thickening, viral infection, moniliasis genital, and accidental injury. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals, LLC Toll-Free at 1- 877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The following serious adverse reactions are discussed elsewhere in the labeling: Cardiovascular Disorders [see Boxed Warning, Warnings and Precautions ( 5.1 )] Malignant Neoplasms [see Boxed Warning, Warnings and Precautions, ( 5.2 )] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported with estradiol and norethindrone acetate tablets 1 mg/0.5 mg by investigators during clinical trials regardless of causality assessment are shown in Table 1. Adverse reactions reported with estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg by investigators during clinical trials regardless of causality assessment are shown in Table 2. TABLE 2 ALL TREATMENT-EMERGENT ADVERSE REACTIONS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF \u22655 PERCENT WITH ESTRADIOL AND NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG E 2 /NETA Tablets 0.5 mg/0.1 mg (n=194) Placebo (n=200) Body as a Whole Back Pain 10% 4% Headache 22% 19% Pain in extremity 5% 4% Digestive System Nausea 5% 4% Diarrhea 6% 6% Respiratory System Nasopharyngitis 21% 18% Urogenital System Endometrial thickening 10% 4% Vaginal hemorrhage 26% 12% E 2 /NETA Tablets = Estradiol and Norethindrone Acetate Tablets Image 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of estradiol and norethindrone acetate tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; pre-menstrual-like syndrome; cystitis- like syndrome; ovarian cancer; endometrial hyperplasia; endometrial cancer. Breast Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer. Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction, stroke; increase in blood pressure. Gastrointestinal Nausea, vomiting; changes in appetite; cholestatic jaundice; abdominal pain/cramps, flatulence, bloating; increased incidence of gallbladder disease and pancreatitis. Skin Chloasma or melasma that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; seborrhea; hirsutism; itching; skin rash; pruritus. Eyes Retinal vascular thrombosis, intolerance to contact lenses. Central Nervous System Headache; migraine; dizziness; mental depression; chorea; insomnia; nervousness; mood disturbances; irritability; exacerbation of epilepsy; dementia. Miscellaneous Increase or decrease in weight; edema; leg cramps; changes in libido; fatigue; exacerbation of asthma; increased triglycerides; hypersensitivity; anaphylactoid/anaphylactic reactions."
    ],
    "adverse_reactions_table": [
      "<table ID=\"ID504\" width=\"907\"><colgroup><col width=\"409\"/><col width=\"302\"/><col width=\"196\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"top\"/><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\">E<sub>2</sub>/NETA Tablets  0.5 mg/0.1 mg (n=194)</td><td styleCode=\"Botrule Toprule\" align=\"left\" valign=\"top\">Placebo (n=200)</td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"bold\"><content styleCode=\"italics\">Body as a Whole</content></content>  Back Pain</td><td align=\"center\" valign=\"top\">  10%</td><td align=\"center\" valign=\"top\">  4%</td></tr><tr><td align=\"left\" valign=\"top\">Headache</td><td align=\"center\" valign=\"top\">22%</td><td align=\"center\" valign=\"top\">19%</td></tr><tr><td align=\"left\" valign=\"top\">Pain in extremity</td><td align=\"center\" valign=\"top\">5%</td><td align=\"center\" valign=\"top\">4%</td></tr><tr><td align=\"left\" valign=\"top\"> <content styleCode=\"bold\"><content styleCode=\"italics\">Digestive System</content></content>  Nausea</td><td align=\"center\" valign=\"top\">   5%</td><td align=\"center\" valign=\"top\">   4%</td></tr><tr><td align=\"left\" valign=\"top\">Diarrhea</td><td align=\"center\" valign=\"top\">6%</td><td align=\"center\" valign=\"top\">6%</td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"bold\"><content styleCode=\"italics\">Respiratory System</content></content>  Nasopharyngitis</td><td align=\"center\" valign=\"top\">  21%</td><td align=\"center\" valign=\"top\">  18%</td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"bold\"><content styleCode=\"italics\">Urogenital System</content></content>  Endometrial thickening</td><td align=\"center\" valign=\"top\">  10%</td><td align=\"center\" valign=\"top\">  4%</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">Vaginal hemorrhage</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">26%</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">12%</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. ( 7 ) Co-administration of estradiol with norethindrone acetate did not elicit any apparent influence on the pharmacokinetics of norethindrone acetate. Similarly, no relevant interaction of norethindrone acetate on the pharmacokinetics of estradiol was found within the NETA dose range investigated in a single dose study. Estradiol In-vitro and in-vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's wort ( Hypericum perforatum ) preparations, phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and result in adverse reactions. Norethindrone Acetate Drugs or herbal products that induce or inhibit cytochrome P-450 enzymes, including CYP3A4, may decrease or increase the serum concentrations of norethindrone."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Estradiol and norethindrone acetate tablets are not indicated for use in pregnancy. There are no data with the use of estradiol and norethindrone acetate tablets in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary Estrogens plus progestogens are present in human milk and can reduce milk production in breast-feeding women. This reduction can occur at any time but is less likely to occur once breast-feeding is well established. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for estradiol and norethindrone acetate tablets and any potential adverse effects on the breastfed child from estradiol and norethindrone acetate tablets or from the underlying maternal condition. 8.4 Pediatric Use Estradiol and norethindrone acetate tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population. 8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing estradiol and norethindrone acetate tablets to determine whether those over 65 years of age differ from younger subjects in their response to estradiol and norethindrone acetate tablets. The Women's Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . The Women's Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] ."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Estradiol and norethindrone acetate tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing estradiol and norethindrone acetate tablets to determine whether those over 65 years of age differ from younger subjects in their response to estradiol and norethindrone acetate tablets. The Women's Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . The Women's Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE Overdosage of estrogen plus progestogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of estradiol and norethindrone acetate tablets therapy with institution of appropriate symptomatic care."
    ],
    "description": [
      "11 DESCRIPTION Estradiol and norethindrone acetate tablets USP, 1 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), polysorbate 80, copovidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350, lecithin (soya), D&C Yellow NO.10 Aluminum lake, FD&C Blue NO.2 Aluminum lake and FD&C Red NO.40 Aluminum lake. Estradiol and norethindrone acetate tablets USP, 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), polysorbate 80, copovidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350, lecithin (soya), D&C Yellow NO.10 Aluminum lake, FD&C Blue NO.2 Aluminum lake and FD&C Yellow NO.6 Aluminum lake. Estradiol is a white or almost white crystalline powder. Its chemical name is estra-1, 3, 5 (10)- triene-3, 17b-diol hemihydrate with the empirical formula of C 18 H 24 O 2 , \u00bd H 2 O and a molecular weight of 281.4. The structural formula of E 2 is as follows: Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder. Its chemical name is 17\u03b2 -acetoxy-19-nor-17\u03b1 -pregn-4-en-20-yn-3-one with the empirical formula of C 22 H 28 O 3 and molecular weight of 340.5. The structural formula of NETA is as follows: Product meets USP dissolution test 2. Image Image"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system. 12.2 Pharmacodynamics Generally, a serum estrogen concentration does not predict an individual woman's therapeutic response to estradiol and norethindrone acetate tablets nor her risk for adverse outcomes. Likewise, exposure comparisons across different estrogen products to infer efficacy or safety for the individual woman may not be valid. 12.3 Pharmacokinetics Absorption Estradiol Estradiol is absorbed through the gastrointestinal tract. Following oral administration of estradiol and norethindrone acetate tablets, peak plasma estradiol concentrations are reached within 5 to 8 hours. The oral bioavailability of estradiol following administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg when compared to a combination oral solution is 53%. Administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg with food did not modify the bioavailability of estradiol. Norethindrone Acetate After oral administration, norethindrone acetate is absorbed and transformed to norethindrone. Norethindrone reaches a peak plasma concentration within 0.5 to 1.5 hours after the administration of estradiol and norethindrone acetate tablets. The oral bioavailability of norethindrone following administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg when compared to a combination oral solution is 100%. Administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg with food increases norethindrone AUC 0-72 by 19% and decreases C max by 36%. The pharmacokinetic parameters of estradiol (E 2 ), estrone (E 1 ), and norethindrone (NET) following oral administration of 1 estradiol and norethindrone acetate 1 mg/0.5 mg tablet or 2 estradiol and norethindrone acetate 0.5 mg/0.1 mg tablet(s) to healthy postmenopausal women are summarized in Table 3. Following continuous dosing with once-daily administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg, serum concentrations of estradiol, estrone, and norethindrone reached steady-state within two weeks with an accumulation of 33 to 47% above concentrations following single dose administration. Unadjusted circulating concentrations of E 2 , E 1 , and NET during estradiol and norethindrone acetate tablets 1 mg/0.5 mg treatment at steady-state (dosing at time 0) are provided in Figures 1a and 1b . Distribution Estradiol The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estradiol circulates in the blood bound to SHBG (37%) and to albumin (61%), while only approximately 1 to 2% is unbound. Norethindrone Acetate Norethindrone also binds to a similar extent to SHBG (36%) and to albumin (61%). Metabolism Estradiol Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone Acetate The most important metabolites of norethindrone are isomers of 5\u03b1-dihydro-norethindrone and tetrahydro- norethindrone, which are excreted mainly in the urine as sulfate or glucuronide conjugates. Excretion Estradiol Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. The half- life of estradiol following single dose administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg is 12 to 14 hours. Norethindrone Acetate The terminal half-life of norethindrone is about 8 to 11 hours. Image Image Image"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Generally, a serum estrogen concentration does not predict an individual woman's therapeutic response to estradiol and norethindrone acetate tablets nor her risk for adverse outcomes. Likewise, exposure comparisons across different estrogen products to infer efficacy or safety for the individual woman may not be valid."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Effects on Vasomotor Symptoms in Postmenopausal Women In a 12-week randomized clinical trial involving 92 subjects, estradiol and norethindrone acetate tablets 1 mg/0.5 mg was compared to 1 mg of estradiol and to placebo. The mean number and intensity of hot flushes were significantly reduced from baseline to week 4 and 12 in both the estradiol and norethindrone acetate tablets 1 mg/0.5 mg and the 1 mg estradiol group compared to placebo (see Figure 2 ). In a study conducted in Europe a total of 577 postmenopausal women were randomly assigned to either estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg, 0.5 mg E2/0.25 mg NETA, or placebo for 24 weeks of treatment. The mean number and severity of hot flushes were significantly reduced at week 4 and week 12 in the estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg (see Figure 3 ) and 0.5 mg E 2 /0.25 mg NETA groups compared to placebo. 14.2 Effects on the Endometrium in Postmenopausal Women Estradiol and norethindrone acetate tablets 1 mg/0.5 mg reduced the incidence of estrogen-induced endometrial hyperplasia at 1 year in a randomized, controlled clinical trial. This trial enrolled 1,176 postmenopausal women who were randomized to one of 4 arms: 1 mg estradiol unopposed (n=296), 1 mg E2 + 0.1 mg NETA (n=294), 1 mg E 2 + 0.25 mg NETA (n=291), and estradiol and norethindrone acetate tablets 1 mg/0.5 mg (n=295). At the end of the study, endometrial biopsy results were available for 988 women. The results of the 1 mg estradiol unopposed arm compared to estradiol and norethindrone acetate tablets 1 mg/0.5 mg are shown in Table 4 . TABLE 4 INCIDENCE OF ENDOMETRIAL HYPERPLASIA WITH UNOPPOSED ESTRADIOL AND ESTRADIOL AND NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG IN A 12-MONTH STUDY Estradiol and norethindrone acetate tablets 1 mg E 2 1 mg E 2 /0.5 mg NETA 1 mg E 2 /0.25 mg NETA 1 mg E 2 /0.1 mg NETA (n=296) (n=295) (n=291 ) (n=294 ) No. of subjects with histological evaluation at the end of the study 247 241 251 249 No. (%) of subjects with endometrial hyperplasia at the end 36 (14.6%) 1 (0.4%) 1 (0.4%) 2 (0.8%) of the study E 2 = Estradiol NETA = Norethindrone Acetate 14.3 Effects on Uterine Bleeding or Spotting in Postmenopausal Women During the initial months of therapy, irregular bleeding or spotting occurred with estradiol and norethindrone acetate tablets 1 mg/0.5 mg treatment. However, bleeding tended to decrease over time, and after 12 months of treatment with estradiol and norethindrone acetate tablets 1 mg/0.5 mg, about 86 percent of women were amenorrheic (see Figure 4 ). In the clinical trial with estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg, 88 percent of women were amenorrheic after 6 months of treatment (See Figure 5 ). 14.4 Effects on Bone Mineral Density in Postmenopausal Women The results of two randomized, multicenter, calcium-supplemented (500 to 1,000 mg per day), placebo-controlled, 2 year clinical trials have shown that estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg are effective in preventing bone loss in postmenopausal women. A total of 462 postmenopausal women with intact uteri and baseline BMD values for lumbar spine within 2 standard deviations of the mean in healthy young women (T-score > - 2.0) were enrolled. In a US trial, 327 postmenopausal women (mean time from menopause 2.5 to 3.1 years) with a mean age of 53 years were randomized to 7 groups (0.25 mg, 0.5 mg, and 1 mg of estradiol alone, 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and 2 mg estradiol with 1 mg norethindrone acetate, and placebo.) In a European trial (EU trial), 135 postmenopausal women (mean time from menopause 8.4 to 9.3 years) with a mean age of 58 years were randomized to 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and placebo. Approximately 58 percent and 67 percent of the randomized subjects in the two clinical trials, respectively, completed the two clinical trials. BMD was measured using dual-energy x-ray absorptiometry (DXA). A summary of the results comparing estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg to placebo from the two prevention trials is shown in Table 5 . TABLE 5 PERCENTAGE CHANGE (MEAN SD) IN BONE MINERAL DENSITY (BMD) FOR ESTRADIOL AND NORETHINDRONE ACETATE TABLETS 1 MG/0.5 MG AND 0.5 MG E 2 \u2020 (Intent to Treat Analysis, Last Observation Carried Forward) US Trial EU Trial Placebo (n=37) 0.5 mg E 2 \u2020 (n=31) E 2 /NETA Tablets 1 mg/0.5 mg (n=37) Placebo (n=40) E 2 /NETA Tablets 1 mg/0.5 mg (n=38) Lumbar spine -2.1 \u00b1 2.9 2.3 \u00b1 2.8 * 3.8 \u00b13.0 * -0.9 \u00b1 4.0 5.4 \u00b1 4.8 * Femoral neck -2.3 \u00b1 3.4 0.3 \u00b1 2.9 ** 1.8 \u00b1 4.1 * -1.0 \u00b1 4.6 0.7 \u00b1 6.1 Femoral trochanter -2.0 \u00b1 4.3 1.7 \u00b1 4.1*** 3.7 \u00b1 4.3 * 0.8 \u00b1 6.9 6.3 \u00b1 7.6 * US= United States, EU = European \u2020 While estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg was not directly studied in these trials, the US trial showed that addition of NETA to estradiol enhances the effect on BMD; therefore the BMD changes expected from treatment with estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg should be at least as great as observed with estradiol 0.5 mg. * Significantly (p<0.001) different from placebo ** Significantly (p<0.007) different from placebo ***Significantly (p<0.002) different from placebo E 2 = Estradiol E 2 /NETA Tablets = Estradiol and Norethindrone Acetate Tablets The overall difference in mean percentage change in BMD at the lumbar spine in the US trial (1000 mg per day calcium) between estradiol and norethindrone acetate tablets 1 mg/0.5 mg and placebo was 5.9 percent and between estradiol 0.5 mg and placebo was 4.4 percent. In the European trial (500 mg per day calcium), the overall difference in mean percentage change in BMD at the lumbar spine was 6.3 percent. Estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg also increased BMD at the femoral neck and femoral trochanter compared to placebo. The increase in lumbar spine BMD in the US and European clinical trials for estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg is displayed in Figure 6 . 14.5 Women\u2019s Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome. A \"global index\" included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other cause. These substudies did not evaluate the effects of CE plus MPA or CE-alone on menopausal symptoms. WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the \"global index.\" The absolute excess risk of events included in the \"global index\" was 19 per 10,000 women-years. For those outcomes included in the WHI \"global index,\" that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 6. These results reflect centrally adjudicated data after an average follow-up of 5.6 years. Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [hazard ratio (HR) 0.69 (95 percent CI, 0.44-1.07)]. WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years, are presented in Table 7 . Table 7: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI a Event Relative Risk CE Placebo CE versus Placebo (95% nCI b ) n = 5,310 n = 5,429 Absolute Risk per 10,000 Women-Years CHD events c 0.95(0.78-1.16) 54 57 Non-fatal MI C 0.91(0.73-1.14) 40 43 CHD death c 1.01(0.71-1.43) 16 16 All strokes c 1.33 (1.05-1.68) 45 33 Ischemic stroke b 1.55 (1.19 \u2013 2.01) 38 25 Deep vein thrombosis c,d 1.47 (1.06\u20132.06) 23 15 Pulmonary embolism c 1.37 (0.90\u20132.07) 14 10 Invasive breast cancer c 0.80 (0.62\u20131.04) 28 34 Colorectal cancer e 1.08 (0.75\u20131.55) 17 16 Hip fracture c 0.65 (0.45\u20130.94) 12 19 Vertebral fractures c,d 0.64 (0.44-0.93) 11 18 Lower arm/wrist fractures c,d 0.58 (0.47-0.72) 35 59 Total fractures c,d 0.71 (0.64-0.80) 144 197 Death due to other causes e,f 1.08 (0.88\u20131.32) 53 50 Overall mortality c,d 1.04 (0.88\u20131.22) 79 75 Global Index g 1.02 (0.92\u20131.13) 206 201 a Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi. b Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. c Results are based on centrally adjudicated data for an average follow-up of 7.1 years. d Not included in \"global index\". e Results are based on an average follow-up of 6.8 years. f All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. g A subset of the events was combined in a \"global index,\" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. For those outcomes included in the WHI \"global index\" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. 9 The absolute excess risk of events included in the \"global index\" was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years. Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for ischemic stroke, and this excess risk was present in all subgroups of women examined. 10 Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [HR 0.63 (95 percent CI, 0.36-1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46-1.11)] . 14.6 Women\u2019s Health Initiative Memory Study The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. Probable dementia as defined in this study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Use in Specific Populations ( 8.5 )]. The WHIMS estrogen-alone ancillary study of WHI study enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age, 36 percent were 70 to 74 years of age, 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Use in Specific Populations ( 8.5 )] . When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Use in Specific Populations ( 8.5 )]. Image Image Image Image Image Image"
    ],
    "clinical_studies_table": [
      "<table ID=\"ID552\" width=\"909\"><colgroup><col width=\"255\"/><col width=\"119\"/><col width=\"185\"/><col width=\"179\"/><col width=\"171\"/></colgroup><tbody><tr><td styleCode=\"Toprule\" colspan=\"5\" align=\"center\" valign=\"top\">Estradiol and norethindrone acetate tablets</td></tr><tr><td valign=\"top\"/><td align=\"center\" valign=\"top\">1 mg E<sub>2</sub></td><td align=\"center\" valign=\"top\">1 mg E<sub>2</sub>/0.5 mg NETA</td><td align=\"center\" valign=\"top\">1 mg E<sub>2</sub>/0.25 mg NETA</td><td align=\"center\" valign=\"top\">1 mg E<sub>2</sub>/0.1 mg NETA</td></tr><tr><td styleCode=\"Botrule\" valign=\"top\"/><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">(n=296)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">(n=295)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">(n=291 )</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">(n=294 )</td></tr><tr><td align=\"left\" valign=\"top\">No. of subjects with histological evaluation at the end of the study</td><td align=\"center\" valign=\"top\">247</td><td align=\"center\" valign=\"top\">241</td><td align=\"center\" valign=\"top\">251</td><td align=\"center\" valign=\"top\">249</td></tr><tr><td colspan=\"5\" align=\"left\" valign=\"top\">No. (%) of subjects with</td></tr><tr><td align=\"left\" valign=\"top\">endometrial hyperplasia at the end</td><td align=\"center\" valign=\"top\">36 (14.6%)</td><td align=\"center\" valign=\"top\">1 (0.4%)</td><td align=\"center\" valign=\"top\">1 (0.4%)</td><td align=\"center\" valign=\"top\">2 (0.8%)</td></tr><tr><td styleCode=\"Botrule\" colspan=\"5\" align=\"left\" valign=\"top\">of the study</td></tr></tbody></table>",
      "<table ID=\"ID561\" width=\"918\"><colgroup><col width=\"196\"/><col width=\"146\"/><col width=\"146\"/><col width=\"147\"/><col width=\"131\"/><col width=\"152\"/></colgroup><tbody><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"/><td styleCode=\"Botrule Rrule Toprule\" colspan=\"3\" align=\"center\" valign=\"top\">US Trial</td><td styleCode=\"Botrule Rrule Toprule\" colspan=\"2\" align=\"center\" valign=\"top\">EU Trial</td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">Placebo (n=37)</td><td styleCode=\"Botrule Rrule\" align=\"center\" valign=\"top\">0.5 mg E<sub>2</sub>&#x2020;  (n=31)</td><td styleCode=\"Botrule Rrule\" align=\"center\" valign=\"top\">E<sub>2</sub>/NETA Tablets  1 mg/0.5 mg (n=37)</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">Placebo (n=40)</td><td styleCode=\"Botrule Rrule\" align=\"center\" valign=\"top\">E<sub>2</sub>/NETA Tablets  1 mg/0.5 mg (n=38)</td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">Lumbar spine</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">-2.1 &#xB1; 2.9</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">2.3 &#xB1; 2.8 *</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">3.8 &#xB1;3.0 *</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">-0.9 &#xB1; 4.0</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">5.4 &#xB1; 4.8 *</td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">Femoral neck</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">-2.3 &#xB1; 3.4</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">0.3 &#xB1; 2.9 **</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">1.8 &#xB1; 4.1 *</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">-1.0 &#xB1; 4.6</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">0.7 &#xB1; 6.1</td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">Femoral trochanter</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">-2.0 &#xB1; 4.3</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">1.7 &#xB1; 4.1***</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">3.7 &#xB1; 4.3 *</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">0.8 &#xB1; 6.9</td><td styleCode=\"Botrule Rrule\" align=\"left\" valign=\"top\">6.3 &#xB1; 7.6 *</td></tr></tbody></table>",
      "<table ID=\"ID568\" width=\"920\"><colgroup><col width=\"295\"/><col width=\"273\"/><col width=\"172\"/><col width=\"180\"/></colgroup><tbody><tr><td styleCode=\"Toprule\" align=\"left\" valign=\"top\">Event</td><td styleCode=\"Toprule\" align=\"center\" valign=\"top\">Relative Risk</td><td styleCode=\"Toprule\" align=\"center\" valign=\"top\">CE</td><td styleCode=\"Toprule\" align=\"center\" valign=\"top\">Placebo</td></tr><tr><td styleCode=\"Botrule\" valign=\"top\"/><td styleCode=\"Botrule\" align=\"center\" valign=\"top\"> CE versus Placebo  (95% nCI<sup>b</sup>)</td><td styleCode=\"Botrule\" colspan=\"2\" align=\"center\" valign=\"top\">n = 5,310 n = 5,429  Absolute Risk per 10,000 Women-Years</td></tr><tr><td align=\"left\" valign=\"top\">CHD events<sup>c</sup></td><td align=\"left\" valign=\"top\">0.95(0.78-1.16)</td><td align=\"center\" valign=\"top\">54</td><td align=\"center\" valign=\"top\">57</td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">Non-fatal </content><content styleCode=\"italics\">MI<sup>C</sup></content></td><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">0.91(0.73-1.14)</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"italics\">40</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"italics\">43</content></td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">CHD death</content><content styleCode=\"italics\"><sup>c</sup></content></td><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">1.01(0.71-1.43)</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"italics\">16</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"italics\">16</content></td></tr><tr><td align=\"left\" valign=\"top\">All strokes<sup>c</sup></td><td align=\"left\" valign=\"top\">1.33 (1.05-1.68)</td><td align=\"center\" valign=\"top\">45</td><td align=\"center\" valign=\"top\">33</td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">Ischemic stroke</content><content styleCode=\"italics\"><sup>b</sup></content></td><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">1.55 (1.19 &#x2013; 2.01)</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"italics\">38</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"italics\">25</content></td></tr><tr><td align=\"left\" valign=\"top\">Deep vein thrombosis<sup>c,d</sup></td><td align=\"left\" valign=\"top\">1.47 (1.06&#x2013;2.06)</td><td align=\"center\" valign=\"top\">23</td><td align=\"center\" valign=\"top\">15</td></tr><tr><td align=\"left\" valign=\"top\">Pulmonary embolism<sup>c</sup></td><td align=\"left\" valign=\"top\">1.37 (0.90&#x2013;2.07)</td><td align=\"center\" valign=\"top\">14</td><td align=\"center\" valign=\"top\">10</td></tr><tr><td align=\"left\" valign=\"top\">Invasive breast cancer<sup>c</sup></td><td align=\"left\" valign=\"top\">0.80 (0.62&#x2013;1.04)</td><td align=\"center\" valign=\"top\">28</td><td align=\"center\" valign=\"top\">34</td></tr><tr><td align=\"left\" valign=\"top\">Colorectal cancer<sup>e</sup></td><td align=\"left\" valign=\"top\">1.08 (0.75&#x2013;1.55)</td><td align=\"center\" valign=\"top\">17</td><td align=\"center\" valign=\"top\">16</td></tr><tr><td align=\"left\" valign=\"top\">Hip fracture<sup>c</sup></td><td align=\"left\" valign=\"top\">0.65 (0.45&#x2013;0.94)</td><td align=\"center\" valign=\"top\">12</td><td align=\"center\" valign=\"top\">19</td></tr><tr><td align=\"left\" valign=\"top\">Vertebral fractures<sup>c,d</sup></td><td align=\"left\" valign=\"top\">0.64 (0.44-0.93)</td><td align=\"center\" valign=\"top\">11</td><td align=\"center\" valign=\"top\">18</td></tr><tr><td align=\"left\" valign=\"top\">Lower arm/wrist fractures<sup>c,d</sup></td><td align=\"left\" valign=\"top\">0.58 (0.47-0.72)</td><td align=\"center\" valign=\"top\">35</td><td align=\"center\" valign=\"top\">59</td></tr><tr><td align=\"left\" valign=\"top\">Total fractures<sup>c,d</sup></td><td align=\"left\" valign=\"top\">0.71 (0.64-0.80)</td><td align=\"center\" valign=\"top\">144</td><td align=\"center\" valign=\"top\">197</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">Death due to other causes<sup>e,f</sup></td><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">1.08 (0.88&#x2013;1.32)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">53</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">50</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">Overall mortality<sup>c,d</sup></td><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">1.04 (0.88&#x2013;1.22)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">79</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">75</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">Global Index<sup>g</sup></td><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">1.02 (0.92&#x2013;1.13)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">206</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">201</td></tr></tbody></table>"
    ],
    "references": [
      "15 REFERENCES 1. Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA . 2007; 297:1465-1477. 2. Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med . 2006; 166:357-365. 3. Cushman M, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA . 2004; 292:1573-1580. 4. Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med . 2006; 166:772-780. 5. Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA . 2003; 289:3234-3253. 6. Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA . 2006; 295:1647-1657. 7. Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. JAMA . 2003; 290:1739-1748. 8. Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA . 2004; 291:2947-2958. 9. Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. J Bone Miner Res . 2006; 21:817-828. 10. Hendrix SL, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women's Health Initiative. Circulation . 2006; 113:2425-2434."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Estradiol and Norethindrone Acetate Tablets USP, 1 mg/0.5 mg are yellow round biconvex tablets, debossed \"J2\" on one side. It is supplied as 28 tablets in a blister and are available in the following configurations: Carton of 1 blister cards NDC 50742-657-28 Carton of 3 blister cards NDC 50742-657-84 Carton of 6 blister cards NDC 50742-657-68 Estradiol and Norethindrone Acetate Tablets USP, 0.5 mg/0.1 mg are pale yellow round biconvex tablets, debossed \"J1\" on one side. It is supplied as 28 tablets in a blister and are available in the following configurations: Carton of 1 blister cards NDC 50742-658-28 Carton of 3 blister cards NDC 50742-658-84 Carton of 6 blister cards NDC 50742-657-68 16.2 Storage and Handling Store in a dry place protected from light. Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
      "16.1 How Supplied Estradiol and Norethindrone Acetate Tablets USP, 1 mg/0.5 mg are yellow round biconvex tablets, debossed \"J2\" on one side. It is supplied as 28 tablets in a blister and are available in the following configurations: Carton of 1 blister cards NDC 50742-657-28 Carton of 3 blister cards NDC 50742-657-84 Carton of 6 blister cards NDC 50742-657-68 Estradiol and Norethindrone Acetate Tablets USP, 0.5 mg/0.1 mg are pale yellow round biconvex tablets, debossed \"J1\" on one side. It is supplied as 28 tablets in a blister and are available in the following configurations: Carton of 1 blister cards NDC 50742-658-28 Carton of 3 blister cards NDC 50742-658-84 Carton of 6 blister cards NDC 50742-657-68",
      "16.2 Storage and Handling Store in a dry place protected from light. Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise women to read the FDA-approved patient labeling ( Patient Information ) Vaginal Bleeding Inform postmenopausal women to report any vaginal bleeding to their healthcare provider as soon as possible [see Warnings and Precautions ( 5.2 )] . Possible Serious Adverse Reactions with Estrogen Plus Progestogen Therapy Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestogen therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 )] . Possible Common Adverse Reactions with Estrogen Plus Progest ogen Therapy Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestogen therapy such as headache, breast pain and tenderness, nausea and vomiting. Rx Only Iss: 03/2024 I0115 Rev.D Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32839-6408 Product of China Image"
    ],
    "spl_patient_package_insert": [
      "Patient Information Estradiol and Norethindrone Acetate (ES-tra-DYE-ol/nor-eth-IN-drone as-i-teyt) Tablets , USP Read this Patient Information before you start using estradiol and norethindrone acetate tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. What are estradiol and norethindrone acetate tablets? Estradiol and norethindrone acetate tablets are prescription medicines that contain two kinds of hormones, an estrogen and a progestogen. What are estradiol and norethindrone acetate tablets used for? Estradiol and norethindrone acetate tablets are used after menopause to: \u2022 R educe moderate to severe hot flushes Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 yrs old. This drop in body estrogen levels causes the \"change of life\" or menopause, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes \"surgical menopause.\" When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden, intense feelings of heat and sweating (\"hot flashes\" or \"hot flushes\"). In some women, the symptoms are mild, and they will not need to use estrogens. In other women, symptoms can be more severe. \u2022 T reat moderate to severe menopausal changes in and around the vagina You and your healthcare provider should talk regularly about whether you still need treatment with estradiol and norethindrone acetate tablets 1.0 mg/0.5 mg to treat these problems. If you use estradiol and norethindrone acetate tablets 1.0 mg/0.5 mg only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you. \u2022 H elp reduce your chances of getting osteoporosis (thin weak bones) Osteoporosis from menopause is a thinning of the bones that makes them weaker and easier to break. If you use estradiol and norethindrone acetate tablets to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you still need treatment with estradiol and norethindrone acetate tablets. Who should not use estradiol and norethindrone acetate tablets ? Do not use estradiol and norethindrone acetate tablets if you have had your uterus (womb) removed (hysterectomy). Estradiol and norethindrone acetate tablets contain a progestogen to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestogen and you should not use estradiol and norethindrone acetate tablets. Do not start using estradiol and norethindrone acetate tablets if you: \u2022 have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. \u2022 have been diagnosed with a bleeding disorder \u2022 currently have or have had certain cancers Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus (womb). If you have or have had cancer, talk with your healthcare provider about whether you should use estradiol and norethindrone acetate tablets. \u2022 had a stroke or heart attack \u2022 currently have or have had blood clots \u2022 currently have or have had liver problems \u2022 are allergic to estradiol and norethindrone acetate tablets or any of its ingredients in it See the list of ingredients in estradiol and norethindrone acetate tablets at the end of this leaflet. Before you use estradiol and norethindrone acetate tablets , tell your healthcare provider about all of your medical conditions, including if you: \u2022 have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. \u2022 have any other medical conditions that may become worse while you are using estradiol and norethindrone acetate tablets Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. \u2022 are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop using estradiol and norethindrone acetate tablets. \u2022 are pregnant or think you may be pregnant Estradiol and norethindrone acetate tablets are not for pregnant women. \u2022 are breast feeding The hormones in estradiol and norethindrone acetate tablets can pass into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how estradiol and norethindrone acetate tablets work. Estradiol and norethindrone acetate tablets may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. How should I use estradiol and norethindrone acetate tablets ? \u2022 Use estradiol and norethindrone acetate tablets exactly as your healthcare provider tells you to use it. \u2022 Take 1 tablet at the same time each day. \u2022 You and your healthcare provider should talk regularly (every 3 to 6 months) about your dose and whether you still need treatment with estradiol and norethindrone acetate tablets. Follow the instructions below to use your estradiol and norethindrone acetate tablets compact Estradiol and norethindrone acetate tablets are available as a blister card placed within a white compact with the days of the week imprinted on the white compact preset for a Sunday start. The estradiol and norethindrone acetate tablets blister card and the imprinted days of the week on the compact is shown in the picture below. On the above blister card find where on the card to start taking tablets, in what order to take the tablets and the week numbers. Day 1 stickers are also provided. You will use a Day 1 Start if you take your first tablet not on Sunday. Refer to Day 1 Start instructions below: 1. Pick the day label strip that starts with the first day of you first tablet. 2. Place this day label strip over the area on the plastic compact which already has the days of the week (starting with Sunday) imprinted and press firmly. See the picture below as an example. To remove a tablet, i) ensure the blister is properly placed into the compact with the entire blister locked on the right V notch and placed under the six plastic lips of the compact, ii) press down the tablet with even pressure with your thumb or finger. The tablet will be pushed through the back of the compact tablet dispenser. Do not press with your thumbnail, fingernail, or any other sharp object. \u2022 Take 1 tablet every day in the order on the blister card at the same time each day. \u2022 After taking the last tablet on Day 28 from the blister card, start taking the first tablet from a new pack, on the same day of the week as the first pack. What are the possible side effects of estradiol and norethindrone acetate tablets? Side effects are grouped by how serious they are and how often they happen when you are treated. Serious, but less common side effects include: \u2022 heart attack \u2022 stroke \u2022 blood clots \u2022 dementia \u2022 breast cancer \u2022 cancer of the lining of the uterus (womb) \u2022 cancer of the ovary \u2022 liver problems \u2022 changes in your thyroid hormone levels \u2022 fluid retention \u2022 cancer changes of endometriosis \u2022 enlargement of benign tumors of the uterus (\"fibroids\") \u2022 high or low blood calcium levels \u2022 gallbladder disease \u2022 visual abnormalities \u2022 high blood pressure \u2022 high levels of fat (triglycerides) in your blood \u2022 worsening swelling of face and tongue (angioedema) in women who have a history of angioedema \u2022 changes in laboratory tests results such as bleeding times and high blood sugar levels Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: \u2022 new breast lumps \u2022 unusual vaginal bleeding \u2022 changes in vision or speech \u2022 sudden new severe headaches \u2022 severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Common side effects of estradiol and norethindrone acetate tablets include: \u2022 irregular vaginal bleeding or spotting \u2022 nausea \u2022 stomach or abdominal cramps, bloating \u2022 headache \u2022 vomiting \u2022 back pain \u2022 breast pain \u2022 diarrhea \u2022 fluid retention \u2022 vaginal yeast infection These are not all the possible side effects of estradiol and norethindrone acetate tablets. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or do not go away. You may report side effects to Ingenus Pharmaceuticals, LLC. at 1-877-748-1970 or to FDA at 1-800-FDA-1088. What can I do to lower my chances of a serious side effect with estradiol and norethindrone acetate tablets? \u2022 Talk with your healthcare provider regularly about whether you should continue using estradiol and norethindrone acetate tablets. \u2022 If you have a uterus, talk with your healthcare provider about whether estradiol and norethindrone acetate tablets is right for you. \u2022 In general, the addition of a progestogen is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). \u2022 See your healthcare provider right away if you get vaginal bleeding while using estradiol and norethindrone acetate tablets. \u2022 Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. \u2022 If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram (breast x-ray), you may need to have breast exams more often. \u2022 If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. \u2022 Ask your healthcare provider for ways to lower your chances for getting heart disease. How should I store estradiol and norethindrone acetate tablets? \u2022 Store estradiol and norethindrone acetate tablets at room temperature between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). \u2022 Store estradiol and norethindrone acetate tablets in a dry place protected from light. KEEP estradiol and norethindrone acetate tablets and all medicines out of the reach of children. General information about the safe and effective use of estradiol and norethindrone acetate tablets. Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use estradiol and norethindrone acetate tablets for conditions for which it was not prescribed. Do not give estradiol and norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about estradiol and norethindrone acetate tablets that is written for health professionals. For more information go to www.ingenus.com or call 1-877-748-1970. What are the ingredients in estradiol and norethindrone acetate tablets? Active ingredients: estradiol and norethindrone acetate Inactive Ingredients: lactose monohydrate, starch (corn), polysorbate 80, copovidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350, lecithin (soya), D&C Yellow NO.10 Aluminum lake and FD&C Blue NO.2 Aluminum lake. The 1 mg/0.5 mg tablet also contains FD&C Red No.40 Aluminum lake. The 0.5 mg/0.1 mg tablet also contains FD&C Yellow No.6 Aluminum lake. This Patient Information has been approved by the U.S. Food and Drug Administration. Rx Only Iss: 03/2024 Rev.D Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32839-6408 Product of China Image Image Image Image"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 0.5mg/0.1mg 1mg/0.5mg"
    ],
    "set_id": "50c786d6-91bd-4eea-9455-ff2abc08372f",
    "id": "e285b638-ef6a-40f1-9fc9-206dac35cb9f",
    "effective_time": "20251205",
    "version": "4",
    "openfda": {
      "application_number": [
        "ANDA210612"
      ],
      "brand_name": [
        "Estradiol and Norethindrone Acetate"
      ],
      "generic_name": [
        "ESTRADIOL AND NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "Ingenus Pharmaceuticals, LLC"
      ],
      "product_ndc": [
        "50742-657",
        "50742-658"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1359123",
        "1359124",
        "1359126",
        "1359127"
      ],
      "spl_id": [
        "e285b638-ef6a-40f1-9fc9-206dac35cb9f"
      ],
      "spl_set_id": [
        "50c786d6-91bd-4eea-9455-ff2abc08372f"
      ],
      "package_ndc": [
        "50742-657-01",
        "50742-657-28",
        "50742-657-84",
        "50742-657-68",
        "50742-658-01",
        "50742-658-28",
        "50742-658-84",
        "50742-658-68"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "M0447348",
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_cs": [
        "Estradiol Congeners [CS]"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "4TI98Z838E",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "norethindrone acetate and ethinyl estradiol and ferrous fumarate norethindrone acetate and ethinyl estradiol and ferrous fumarate norethindrone acetate and ethinyl estradiol and ferrous fumarate norethindrone acetate and ethinyl estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL ACACIA LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN TALC SUCRALOSE SPEARMINT SUCROSE to off-white flat faced beveled edge 21;Y norethindrone acetate and ethinyl estradiol and ferrous fumarate ferrous fumarate FERROUS FUMARATE ACACIA STARCH, CORN MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A CORN MAGNESIUM STEARATE SUCRALOSE TALC to dark brown 18;G"
    ],
    "recent_major_changes": [
      "Contraindications ( 4 ) 08/2017 Warnings ( 5.3 ) 08/2017"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications (4) ]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. \u2022 Women over 35 years old who smoke should not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets ( 4 ) \u2022 Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use ( 4 )"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for use by females of reproductive age to prevent pregnancy [see Clinical Studies (14) ] . The efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. \u2022 Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are an estrogen/progestin COC indicated for use by women to prevent pregnancy ( 1 ) \u2022 The efficacy in women with a body mass index of more than 35 kg/m 2 has not been evaluated ( 1 , 8.8 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION \u2022 One tablet daily chewed and swallowed or swallowed whole taken at the same time of day. Follow with 8 ounces of water ( 2.1 ) \u2022 Take one tablet by mouth at the same time every day for 28 days ( 2.1 ) \u2022 Take tablets in the order directed on the blister pack ( 2.1 ) \u2022 Tablets may be administered without regard to meals ( 12.3 ) 2.1 How to Take Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets must be taken exactly as directed. Instruct patients to take one tablet by mouth at the same time every day. The tablet may be chewed and swallowed or swallowed whole. The patient should drink a full glass (8 ounces) of water immediately after the white tablets are chewed or swallowed whole. Tablets must be taken in the order directed on the blister pack. Tablets should not be skipped or taken at intervals exceeding 24 hours. For patient instructions for missed tablets, [ see Error! Hyperlink reference not valid. ] . Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals [ see Clinical Pharmacology (12.3) ]. 2.2 How to Start Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Instruct the patient to begin taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start). Day 1 Start During the first cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets use, instruct the patient to take one white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets daily, beginning on Day one (1) of her menstrual cycle (the first day of menstruation is Day one). She should take one white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets daily for 24 consecutive days, followed by one brown tablet daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken in the order directed on the package at the same time each day. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days if she starts taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on a day other than the first day of her menstrual cycle. The possibility of ovulation and conception prior to initiation of medication should be considered. Sunday Start During the first cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets use, instruct the patient to take one white norethindrone acetate and ethinyl estradiol tablet and ferrous fumarate tablet daily, beginning on the first Sunday after the onset of her menstrual period. She should take one white norethindrone acetate and ethinyl estradiol tablet and ferrous fumarate tablet daily for 24 consecutive days, followed by one brown tablet daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken in the order directed on the package at the same time each day. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should begin her next and all subsequent 28-day regimens of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the same day of the week that she began her first regimen, following the same schedule. She should begin taking her white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the next day after ingestion of the last brown tablet, regardless of whether or not a menstrual period has occurred or is still in progress. Anytime a subsequent cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is started later than the day following administration of the last brown tablet, the patient should use another method of contraception until she has taken a white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets daily for 7 consecutive days. For postpartum women who do not breastfeed or after a second trimester abortion, start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets no earlier than 4 weeks postpartum due to the increased risk of thromboembolism. If the patient starts on norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets for 7 consecutive days. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be initiated immediately after a first-trimester abortion or miscarriage; if the patient starts norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets immediately, additional contraceptive measures are not needed. 2.3 Switching from another Hormonal Method of Contraception If the patient is switching from a combination hormonal method such as: \u2022 Another pill \u2022 Vaginal ring \u2022 Patch \u2022 Instruct her to take the first white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the day she would have taken her next COC pill. She should not continue taking the tablets from her previous birth control pack, and should not skip any days between packs. If she does not have a withdrawal bleed, rule out pregnancy before starting norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. \u2022 If she previously used a vaginal ring or transdermal patch, she should start using norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the day she would have resumed the previous product. If the patient is switching from a progestin-only method such as a: \u2022 Progestin-only pill \u2022 Implant \u2022 Intrauterine system \u2022 Injection \u2022 She may switch any day from a progestin-only pill; instruct her to take the first white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the day she would have taken her next progestin-only pill. She should use a non-hormonal method of contraception for 7 consecutive days. \u2022 If switching from an implant or injection, start the first white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the day her next injection would have been due or on the day of removal of her implant. \u2022 If switching from an IUD, depending on the timing of removal, back-up contraception may be needed. 2.4 Advice in Case of Gastrointestinal Disturbances If the patient vomits or has diarrhea (within 3 to 4 hours after she takes a white norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets), she should follow the instructions in the \u201c Error! Hyperlink reference not valid. \u201d section [see Error! Hyperlink reference not valid. ] ."
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP are available in blister packs. Each blister pack contains 28 tablets in the following order: \u2022 24 white to off-white, round, flat faced beveled edge, uncoated tablets debossed with \u201c21\u201d on one side and \u201cY\u201d on the other side and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. \u2022 4 brown to dark brown, round, flat faced beveled edge, uncoated tablets debossed with \u201c18\u201d on one side and \u201cG\u201d on the other side and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose. Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP consist of 28 tablets in the following order: \u2022 24 white chewable tablets (active), each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP \u2022 4 brown tablets (non-hormonal placebo), each containing 75 mg ferrous fumarate, which do not serve any therapeutic purpose"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Do not prescribe norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets to women who are known to have the following conditions: \u2022 A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: o Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1) ] o Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] o Have cerebrovascular disease [see Warnings and Precautions (5.1) ] o Have coronary artery disease [see Warnings and Precautions (5.1) ] o Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] o Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] o Have uncontrolled hypertension [see Warnings and Precautions (5.3) ] o Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.5) ] o Have headaches with focal neurological symptoms or have migraine headaches with aura \u2022 All women over age 35 with migraine headache [see Warnings and Precautions (5.6) ] \u2022 Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] \u2022 Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.7) ] \u2022 Pregnancy, because there is no reason to use COCs during pregnancy [see Warnings and Precautions (5.8) and Use in Specific Populations (8.1) ] \u2022 Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past [see Warnings and Precautions (5.10) ] \u2022 Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ] \u2022 A high risk of arterial or venous thrombotic diseases ( 4 ) \u2022 Breast cancer or other estrogen- or progestin-sensitive cancer ( 4 ) \u2022 Liver tumors or liver disease ( 4 ) \u2022 Undiagnosed abnormal uterine bleeding ( 4 ) \u2022 Pregnancy ( 4 ) \u2022 Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS \u2022 Vascular risks: Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding ( 5.1 ) \u2022 Liver disease: Discontinue if jaundice occurs ( 5.2 ) \u2022 High blood pressure: Do not prescribe for women with uncontrolled hypertension or hypertension with vascular disease ( 5.3 ) \u2022 Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia ( 5.5 ) \u2022 Headache: Evaluate significant change in headaches and discontinue if indicated ( 5.6 ) \u2022 Uterine bleeding: Evaluate irregular bleeding or amenorrhea ( 5.7 ) 5.1 Thromboembolic Disorders and Other Vascular Problems Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if an arterial or deep venous thrombotic event (VTE) occurs. Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. If feasible, stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE. Start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use of a COC. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest in older (greater than 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with underlying risk factors. Use COCs with caution in women with cardiovascular disease risk factors. 5.2 Liver Disease Impaired Liver Function Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4) ] . Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if jaundice develops. Liver Tumors Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in women with benign and malignant liver tumors [see Contraindications (4) ] . Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (greater than 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users. 5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN),including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [see Contraindications (4) ]. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen. 5.4 High Blood Pressure Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in women with uncontrolled hypertension or hypertension with vascular disease [see Contraindications (4) ] . For women with well-controlled hypertension, monitor blood pressure and stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if blood pressure rises significantly. An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin. 5.5 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may also worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC-related cholestasis. 5.6 Carbohydrate and Lipid Metabolic Effects Carefully monitor prediabetic and diabetic women who are taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. COCs may decrease glucose tolerance in a dose-related fashion. Consider alternative contraception for women with uncontrolled dyslipidemias. A small proportion of women will have adverse lipid changes while on COCs. Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. 5.7 Headache If a woman taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if indicated. Consider discontinuation of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) [see Contraindications (4) ] . 5.8 Bleeding Irregularities and Amenorrhea Unscheduled Bleeding and Spotting Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC. Based on patient diaries from a clinical trial evaluating the safety and efficacy of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets, 24 to 35% of women experienced unscheduled bleeding per cycle. A total of 10 subjects out of 743 (1.3%) discontinued due to bleeding or spotting. Amenorrhea and Oligomenorrhea Women who are not pregnant and use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may experience amenorrhea. In the clinical trial with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets and ferrous fumarate tablets, 22 to 36% of the women using norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets and ferrous fumarate tablets experienced amenorrhea in at least one of 6 cycles of use. Some women may experience post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. 5.9 COC Use before or during Early Pregnancy Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when oral contraceptives are taken inadvertently during early pregnancy. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if pregnancy is confirmed. Administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy [see Use in Specific Populations (8.1) ]. 5.10 Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if depression recurs to a serious degree. 5.11 Carcinoma of the Breast and Cervix Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in women who currently have or have had breast cancer because breast cancer may be hormonally-sensitive [see Contraindications (4) ]. There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings. Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors. 5.12 Effect on Binding Globulins The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormones or cortisol therapy may need to be increased. 5.13 Monitoring A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare. 5.14 Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 5.15 Chloasma Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: \u2022 Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions (5.1) ] \u2022 Vascular events [see Warnings and Precautions (5.1) ] \u2022 Liver disease [see Warnings and Precautions (5.2) ] Adverse reactions commonly reported by COC users are: \u2022 Irregular uterine bleeding \u2022 Nausea \u2022 Breast tenderness \u2022 Headache \u2022 The most common adverse reactions in clinical trials (greater than or equal to 2%) were: headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1-888-721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data presented in Section 6.1 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. Common Adverse Reactions (Greater Than or Equal to 2% of all Treated Subjects) : The most common adverse reactions reported by at least 2% of the 743 women using norethindrone acetate/ethinyl estradiol tablets were the following, in order of decreasing incidence: headache (6.3%), vaginal candidiasis (6.1%), nausea (4.6%), menstrual cramps (4.4%), breast tenderness (3.4%), bacterial vaginitis (3.1%), abnormal cervical smear (3.1%), acne (2.7%), mood swings (2.2%), and weight gain (2%). Adverse Reactions Leading to Study Discontinuation : Among the 743 women using norethindrone acetate/ethinyl estradiol tablets, 46 women (6.2%) withdrew because of an adverse event. Adverse events occurring in 3 or more subjects leading to discontinuation of treatment were, in decreasing order: abnormal or irregular bleeding (1.3%), nausea (0.8%), menstrual cramps (0.5%), and increased blood pressure (0.4%). 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Adverse reactions are grouped into System Organ Classes. Vascular disorders: thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein). Hepatobiliary disorders: cholelithiasis, cholecystitis, hepatic adenoma, hemangioma of liver. Immune system disorders: hypersensitivity reaction. Skin and subcutaneous disorders: alopecia, rash (generalized and allergic), pruritus, skin discoloration. GI disorders: nausea, vomiting, abdominal pain. Musculoskeletal and connective tissue disorders: myalgia. Eye disorders: blurred vision, visual impairment, corneal thinning, change in corneal curvature (steepening). Infections and infestations: fungal infection, vaginal infection. Investigations: change in weight or appetite (increase or decrease), fatigue, malaise, peripheral edema, blood pressure increased. Nervous system disorders: headache, dizziness, migraine, loss of consciousness. Psychiatric disorders: mood swings, depression, insomnia, anxiety, suicidal ideation, panic attack, changes in libido. Renal and urinary disorders: cystitis-like syndrome. Reproductive system and breast disorders: breast changes (tenderness, pain, enlargement, and secretion), premenstrual syndrome, dysmenorrhea. Cardiovascular: chest pain, palpitations, tachycardia, myocardial infarction."
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations. No drug-drug interaction studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. \u2022 Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate and products containing St. John\u2019s wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin and certain COCs containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone concentrations. Human immunodeficiency virus (HIV)/ Hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors : Significant changes (increase or decrease) in the plasma concentrations of the estrogen and progestin have been noted in some cases of co-administration of HIV/HCV protease inhibitors or of non-nucleoside reverse transcriptase inhibitors. Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids. 7.2 Effects of Combined Oral Contraceptives on Other Drugs COCs containing ethinyl estradiol may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs. 7.3 Concomitant Use with HCV Combination Therapy\u2013Liver Enzyme Elevation Do not co-administer norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions (5.3) ]. 7.4 Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS \u2022 Nursing mothers: Not recommended; can decrease milk production ( 8.3 ) 8.1 Pregnancy There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose COCs prior to conception or during early pregnancy. The administration of COCs to induce withdrawal bleeding should not be used as a test for pregnancy. COCs should not be used during pregnancy to treat threatened or habitual abortion. 8.3 Nursing Mothers When possible, advise the nursing mother to use other forms of contraception until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk. 8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated. 8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in postmenopausal women and is not indicated in this population. 8.6 Renal Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in subjects with renal impairment. 8.7 Hepatic Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in subjects with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded [see Contraindications (4) and Warnings and Precautions (5.2) ]. 8.8 Body Mass Index The safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with a body mass index (BMI) greater than 35 kg/m 2 has not been evaluated [see Clinical Studies (14) ]."
    ],
    "pregnancy": [
      "8.1 Pregnancy There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose COCs prior to conception or during early pregnancy. The administration of COCs to induce withdrawal bleeding should not be used as a test for pregnancy. COCs should not be used during pregnancy to treat threatened or habitual abortion."
    ],
    "nursing_mothers": [
      "8.3 Nursing Mothers When possible, advise the nursing mother to use other forms of contraception until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in postmenopausal women and is not indicated in this population."
    ],
    "overdosage": [
      "10 OVERDOSAGE There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea."
    ],
    "description": [
      "11 DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP provides an oral contraceptive regimen consisting of 24 white active chewable tablets that contain the active ingredients, followed by 4 brown non-hormonal placebo tablets as specified below: \u2022 24 white to off-white, round, flat faced beveled edge, uncoated tablets debossed with \u201c21\u201d on one side and \u201cY\u201d on the other side each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP \u2022 4 brown to dark brown, round, flat faced beveled edge, uncoated tablets debossed with \u201c18\u201d on one side and \u201cG\u201d on the other side each containing 75 mg ferrous fumarate Each white active chewable tablet also contains the following inactive ingredients: acacia, corn starch, lactose monohydrate, magnesium stearate, spearmint flavor, sucralose, sucrose and talc. Each brown placebo tablet contains acacia, corn starch, ferrous fumarate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, sucralose and talc. The ferrous fumarate tablets do not serve any therapeutic purpose. The empirical formula of ethinyl estradiol, USP is C 20 H 24 O 2 and the structural formula is: The chemical name of ethinyl estradiol, USP is [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17\u03b1)-]. The molecular weight of ethinyl estradiol, USP is 296.40. The empirical formula of norethindrone acetate, USP is C 22 H 28 O 3 and the structural formula is: The chemical name of norethindrone acetate, USP is [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)-]. The molecular weight of norethindrone acetate, USP is 340.46. EEstructure.jpg NEstructure.jpg"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation. 12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. 12.3 Pharmacokinetics Absorption In a single-dose, two-way, crossover clinical study conducted in 35 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets chewed and swallowed was bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablet (24-day regimen tablets) swallowed whole based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are absorbed from norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (chewed and swallowed), with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring at 1 hr (range: 0.7 to 2.5 hrs) and 1.3 hr (range: 1 to 2.5 hrs) post-dose, respectively. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single-dose administrations of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (chewed and swallowed) in 35 healthy female subjects are provided in Figures 1 and 2, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets (swallowed whole) in 17 healthy female subjects, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 1. Mean (\u00b1 Standard Deviation) Plasma Norethindrone Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Figure 2. Mean (\u00b1 Standard Deviation) Plasma Ethinyl Estradiol Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single-Dose Oral Administration of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets (chewed and swallowed) to Healthy Female Volunteers Under Fasting Conditions (n = 35) Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC (0-tldc) (pg/mL\u2022h) AUC (0-inf) (pg/mL\u2022h) t \u00bd (hr) NE 10200 (36) 1.03 (0.67 to 2.50) 48620 (40) 49250 (40) 8.58 EE 84.7 (24) 1.33 (1.00 to 2.50) 677.5 (33) 741.6 (33) 9.68 C max = Maximum plasma concentration t max = Time of C max AUC (0-tldc) = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC (0-inf) = Area under the plasma concentration versus time curve from time 0 to infinity t \u00bd = Terminal phase half-life % CV = Coefficient of Variation (%) a The harmonic mean (0.693/mean terminal phase rate constant) is reported for t \u00bd , and the median (range) is reported for t max Food Effect Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals. A single-dose administration of norethindrone acetate/ethinyl estradiol tablets with food decreased the maximum concentration of norethindrone by 51% and increased the extent of absorption by 15% and decreased the maximum concentration of ethinyl estradiol by 51% but not the extent of absorption. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. Fig1.jpg Fig2.jpg"
    ],
    "clinical_pharmacology_table": [
      "<table width=\"100%\"><col width=\"13%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"17%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Analyte</paragraph></td><td align=\"center\" colspan=\"5\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Arithmetic Mean<sup>a</sup> (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>C<sub>max</sub> (pg/mL)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>t<sub>max</sub> (hr)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>AUC<sub>(0-tldc)</sub> (pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>AUC<sub>(0-inf)</sub> (pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>t<sub>&#xBD;</sub> (hr)</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>NE</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10200 (36)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.03 (0.67 to 2.50)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>48620 (40)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>49250 (40)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>8.58</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>EE</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>84.7 (24)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.33 (1.00 to 2.50)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>677.5 (33)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>741.6 (33)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>9.68</paragraph></td></tr><tr><td colspan=\"6\" styleCode=\"Botrule \" valign=\"top\"><paragraph>C<sub>max</sub> = Maximum plasma concentration t<sub>max</sub> = Time of C<sub>max</sub> AUC<sub>(0-tldc)</sub> = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC<sub>(0-inf)</sub> = Area under the plasma concentration versus time curve from time 0 to infinity t<sub>&#xBD;</sub> = Terminal phase half-life % CV = Coefficient of Variation (%) <sup>a </sup>The harmonic mean (0.693/mean terminal phase rate constant) is reported for t<sub>&#xBD;</sub>, and the median (range) is reported for t<sub>max</sub></paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption In a single-dose, two-way, crossover clinical study conducted in 35 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets chewed and swallowed was bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablet (24-day regimen tablets) swallowed whole based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are absorbed from norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (chewed and swallowed), with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring at 1 hr (range: 0.7 to 2.5 hrs) and 1.3 hr (range: 1 to 2.5 hrs) post-dose, respectively. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single-dose administrations of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (chewed and swallowed) in 35 healthy female subjects are provided in Figures 1 and 2, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets (swallowed whole) in 17 healthy female subjects, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 1. Mean (\u00b1 Standard Deviation) Plasma Norethindrone Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Figure 2. Mean (\u00b1 Standard Deviation) Plasma Ethinyl Estradiol Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single-Dose Oral Administration of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets (chewed and swallowed) to Healthy Female Volunteers Under Fasting Conditions (n = 35) Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC (0-tldc) (pg/mL\u2022h) AUC (0-inf) (pg/mL\u2022h) t \u00bd (hr) NE 10200 (36) 1.03 (0.67 to 2.50) 48620 (40) 49250 (40) 8.58 EE 84.7 (24) 1.33 (1.00 to 2.50) 677.5 (33) 741.6 (33) 9.68 C max = Maximum plasma concentration t max = Time of C max AUC (0-tldc) = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC (0-inf) = Area under the plasma concentration versus time curve from time 0 to infinity t \u00bd = Terminal phase half-life % CV = Coefficient of Variation (%) a The harmonic mean (0.693/mean terminal phase rate constant) is reported for t \u00bd , and the median (range) is reported for t max Food Effect Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals. A single-dose administration of norethindrone acetate/ethinyl estradiol tablets with food decreased the maximum concentration of norethindrone by 51% and increased the extent of absorption by 15% and decreased the maximum concentration of ethinyl estradiol by 51% but not the extent of absorption. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. Fig1.jpg Fig2.jpg"
    ],
    "pharmacokinetics_table": [
      "<table width=\"100%\"><col width=\"13%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"17%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Analyte</paragraph></td><td align=\"center\" colspan=\"5\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Arithmetic Mean<sup>a</sup> (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>C<sub>max</sub> (pg/mL)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>t<sub>max</sub> (hr)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>AUC<sub>(0-tldc)</sub> (pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>AUC<sub>(0-inf)</sub> (pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>t<sub>&#xBD;</sub> (hr)</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>NE</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10200 (36)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.03 (0.67 to 2.50)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>48620 (40)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>49250 (40)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>8.58</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>EE</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>84.7 (24)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.33 (1.00 to 2.50)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>677.5 (33)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>741.6 (33)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>9.68</paragraph></td></tr><tr><td colspan=\"6\" styleCode=\"Botrule \" valign=\"top\"><paragraph>C<sub>max</sub> = Maximum plasma concentration t<sub>max</sub> = Time of C<sub>max</sub> AUC<sub>(0-tldc)</sub> = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC<sub>(0-inf)</sub> = Area under the plasma concentration versus time curve from time 0 to infinity t<sub>&#xBD;</sub> = Terminal phase half-life % CV = Coefficient of Variation (%) <sup>a </sup>The harmonic mean (0.693/mean terminal phase rate constant) is reported for t<sub>&#xBD;</sub>, and the median (range) is reported for t<sub>max</sub></paragraph></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [See Warnings and Precautions ( 5.2 , 5.10 ) and Use in Specific Populations (8.1) .]"
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [See Warnings and Precautions ( 5.2 , 5.10 ) and Use in Specific Populations (8.1) .]"
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES The data presented in Section 14 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. In a clinical study, 743 women 18 to 45 years of age were studied to assess the efficacy of norethindrone acetate/ethinyl estradiol tablets, for up to six 28-day cycles providing a total of 3,823 treatment-cycles of exposure. The racial demographic of all enrolled women was: 70% Caucasian, 16% African-American, 10% Hispanic, 2% Asian and 2% Other. Women with body mass index (BMI) greater than 35 kg/m 2 were excluded from the study. The weight range for those women treated was 90 to 260 pounds, with a mean weight of 147 pounds. Among the women in the study, about 40% had not used hormonal contraception immediately prior to enrolling in this study. A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies in 3,565 treatment cycles during which no backup contraception was used. The Pearl Index for norethindrone acetate and ethinyl estradiol tablets was 1.82 (95% confidence interval 0.59 to 4.25)."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP are available in blister cards (dispensers) containing 28 tablets: NDC 68462-376-29 Cartons of 3 blister cards (dispensers) Each blister card contains 28 tablets in the following order: \u2022 24 white to off-white, round, flat faced beveled edge, uncoated tablets debossed with \u201c21\u201d on one side and \u201cY\u201d on the other side and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. \u2022 4 brown to dark brown, round, flat faced beveled edge, uncoated tablets debossed with \u201c18\u201d on one side and \u201cG\u201d on the other side and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose. 16.2 Storage Conditions Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF); excursions permitted between 15\u00ba to 30\u00baC (59\u00ba to 86\u00baF) [see USP Controlled Room Temperature]. Keep this drug and all drugs out of the reach of children.",
      "16.1 How Supplied Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP are available in blister cards (dispensers) containing 28 tablets: NDC 68462-376-29 Cartons of 3 blister cards (dispensers) Each blister card contains 28 tablets in the following order: \u2022 24 white to off-white, round, flat faced beveled edge, uncoated tablets debossed with \u201c21\u201d on one side and \u201cY\u201d on the other side and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. \u2022 4 brown to dark brown, round, flat faced beveled edge, uncoated tablets debossed with \u201c18\u201d on one side and \u201cG\u201d on the other side and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION See Error! Hyperlink reference not valid. Counsel patients on the following information: \u2022 Cigarette smoking increases the risk of serious cardiovascular events from COC use, and women who are over 35 years old and smoke should not use COCs. \u2022 Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets do not protect against HIV infection (AIDS) and other sexually transmitted infections. \u2022 The Warnings and Precautions associated with COCs. \u2022 Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are not to be used during pregnancy; if pregnancy occurs during use of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, instruct the patient to stop further intake. \u2022 Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event tablets are missed. See \u201c Error! Hyperlink reference not valid. \u201d section in FDA-approved patient labeling . \u2022 Use a back-up or alternative method of contraception when enzyme inducers are used with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. \u2022 COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established. \u2022 Women who start COCs postpartum, and who have not yet had a period, should use an additional method of contraception until they have taken a white tablet for 7 consecutive days. \u2022 Amenorrhea may occur. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles."
    ],
    "spl_patient_package_insert": [
      "FDA-Approved Patient Labeling Guide for Using Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets WARNING TO WOMEN WHO SMOKE Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. Birth control pills help to lower the chances of becoming pregnant when taken as directed. They do not protect against HIV infection (AIDS) and other sexually transmitted infections. What are norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate. How well do norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets work? Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant. Based on the results of one clinical study of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets lasting six months, about 1 to 4 out of 100 women may get pregnant during the first year they use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Women with a BMI above 35 kg/m 2 were not studied in the clinical trial, so it is not known how well norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets protect against pregnancy in such women. If you are overweight, discuss with your healthcare provider whether norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are the best choice for you. The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant. How do I take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? 1. Be sure to read these directions before you start taking your tablets or anytime you are not sure what to do. 2. The tablets may be chewed and swallowed or swallowed whole. You should drink a full glass (8 ounces) of water immediately after chewing or swallowing. 3. The right way to take the tablet is to take one tablet every day at the same time in the order directed on the package. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be taken without regard to meals. If you miss tablets you could get pregnant. This includes starting the pack late. The more tablets you miss, the more likely you are to get pregnant. See \u201c Error! Hyperlink reference not valid. \u201d below. 4. Many women have spotting or light bleeding at unexpected times, or may feel sick to their stomach during the first 1 to 3 packs of tablets. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the tablets. The problem will usually go away. If it does not go away, check with your healthcare provider. 5. Missing tablets can also cause spotting or light bleeding, even when you make up these missed tablets. On the days you take two tablets, to make up for missed tablets, you could also feel a little sick to your stomach. 6. If you have vomiting (within 3 to 4 hours after you take your tablet), you should follow the instructions for \u201c Error! Hyperlink reference not valid. \u201d. If you have diarrhea or if you take certain medicines, including some antibiotics and some herbal products such as St. John's Wort, your tablets may not work as well. Use a back-up method (such as condoms and spermicides) until you check with your healthcare provider. 7. If you have trouble remembering to take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, talk to your healthcare provider about how to make tablet-taking easier or about using another method of birth control. 8. If you have any questions or are unsure about the information in this leaflet, call your healthcare provider. Before You Start Taking Your Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets 1. Decide What Time of Day You Want to Take Your Tablet. It is important to take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets tablets in the order directed on the package at the same time every day. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be taken without regard to meals. 2. Look at Your Tablet Pack \u2013 It has 28 Tablets The norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets pack has 24 \"active\" white tablets (with hormones) to be taken for 24 days, followed by 4 \"reminder\" brown tablets (without hormones) to be taken for the next four days. 3. Also look for: a) Where on the pack to start taking tablets, b) In what order to take the tablets (follow the arrows shown in the picture above) c) The week numbers as shown in the picture above. 4. Be sure you have ready at all times a) another kind of birth control (such as a condoms and spermicide) to use as a back-up in case you miss tablets, and b) an extra, full tablet pack. When to Start the First Pack of Tablets You have a choice for which day to start taking your first pack of tablets. Decide with your healthcare provider which is the best day for you. Pick a time of day which will be easy to remember. Day 1 Start: 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first white tablet of the pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the tablet at the beginning of your period. However, if you start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets later than the first day of your period, you should use another method of birth control (such as a condom and spermicide) as a back-up method until you have taken 7 white tablets. Sunday Start: 1. Take the first white tablet of the pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control (such as a condom and spermicide) as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). This also applies if you start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets after having been pregnant, and you have not had a period since your pregnancy. When You Switch From a Different Birth Control Tablet or Capsule When switching from another birth control pill, finish all the tablets or capsules, then norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started on the same day that a new pack of the previous birth control tablet or capsule would have been started. When You Switch From Another Type of Birth Control Method When switching from a transdermal patch or vaginal ring, finish the 21 days of use, wait 7 days, then norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started when the next application would have been due. When switching from an injection, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started when the next injection would have been due. When switching from an intrauterine device or an implant, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started on the day of removal. What to Do During the Month 1. Take one tablet at the same time every day until the pack is empty. Do not skip tablets even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). 2. Do not skip tablets even if you do not have sex very often. When you finish a pack of tablets, start the next pack on the day after your last brown tablet. Do not wait any days between packs. What to Do if You Miss Tablets Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may not be as effective if you miss any white tablets, especially if you miss the first few or the last few white tablets in a pack. If you miss 1 white tablet: 1. Take the tablet as soon as you remember. Take the next tablet at your regular time. This means you may take two tablets in one day. 2. You do not need to use a back-up birth control method if you have sex. If you miss 2 white tablets in a row in week 1 OR week 2 of your pack: 1. Take two tablets on the day you remember and two tablets the next day. 2. Then take one tablet a day until you finish the pack. 3. You could become pregnant if you have sex in the 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. If you miss 2 white tablets in a row in week 3 or week 4 of your pack: 1. If you are a Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. If you are a Sunday Starter: Keep taking one tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. 2. You could become pregnant if you have sex in the 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss 3 or more white tablets in a row during any week: 1. If you are a Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. 2. You could become pregnant if you have sex on the days when you missed tablets or during the first 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up the next time you have sex and for the first 7 days after you restart your tablets. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss any of the 4 brown tablets in Week 4: 1. Throw away the tablets you missed. 2. Keep taking one tablet each day until the pack is empty. 3. You do not need a back-up method. 4. Start the next pack of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets as scheduled. Finally, if you are still not sure what to do about the tablets you have missed: 1. Use a back-up method (such as a condom and spermicide) anytime you have sex. 2. Contact your healthcare provider and continue taking one active white tablet each day until otherwise directed. Who should not take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Your healthcare provider will not give you norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you have: \u2022 Ever had blood clots in your arms, legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis) \u2022 Ever had a stroke \u2022 Ever had a heart attack \u2022 Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart \u2022 An inherited problem with your blood that makes it clot more than normal \u2022 High blood pressure that medicine cannot control \u2022 Diabetes with kidney, eye, nerve, or blood vessel damage \u2022 Ever had certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or have any migraine headache if you are over age 35. \u2022 Ever had breast cancer or any cancer that is sensitive to female hormones \u2022 Liver disease, including liver tumors \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood Also, do not take birth control pills if you: \u2022 Smoke and are over 35 years old \u2022 Are or suspect you are pregnant \u2022 Have any unexplained bleeding from the vagina Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy, also called cholestasis of pregnancy. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). What else should I know about taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Birth control pills do not protect you against any sexually transmitted infection, including HIV, the virus that causes AIDS. Do not skip any tablets, even if you do not have sex often. If you miss a period, you could be pregnant. However, some women miss periods or have light periods on birth control pills, even when they are not pregnant. Contact your healthcare provider for advice if you: \u2022 Think you are pregnant \u2022 Miss one period and have not taken your birth control pills every day \u2022 Miss two periods in a row Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects. You should stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets at least four weeks before you have surgery and not restart it until at least two weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, may decrease the amount of milk you make. A small amount of the pill's hormones passes into breast milk. Tell your healthcare provider about all medicines and herbal products that you take. Some medicines and herbal products may make birth control pills less effective, including: \u2022 barbiturates \u2022 bosentan \u2022 carbamazepine \u2022 felbamate \u2022 griseofulvin \u2022 oxcarbazepine \u2022 phenytoin \u2022 rifampin \u2022 St. John\u2019s wort \u2022 topiramate Use a back-up or alternative birth control method when you take medicines that may make birth control pills less effective. Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your healthcare provider may need to adjust the dose of lamotrigine. If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like a condom and spermicide, until you check with your healthcare provider. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone. If you are scheduled for any laboratory tests, tell your healthcare provider that you are taking birth control pills. Certain blood tests may be affected by birth control pills. What are the most serious risks of taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke. Some examples of serious blood clots are blood clots in the: \u2022 Legs (deep vein thrombosis) \u2022 Lungs (pulmonary embolus) \u2022 Eyes (loss of eyesight) \u2022 Heart (heart attack) \u2022 Brain (stroke) Women who take birth control pills may get: \u2022 High blood pressure \u2022 Gallbladder problems \u2022 Rare cancerous or noncancerous liver tumors All of these events are uncommon in healthy women. Call your healthcare provider right away if you have: \u2022 Persistent leg pain \u2022 Sudden shortness of breath \u2022 Sudden blindness, partial or complete \u2022 Severe pain or pressure in your chest \u2022 Sudden, severe headache unlike your usual headaches \u2022 Weakness or numbness in an arm or leg, or trouble speaking \u2022 Yellowing of the skin or eyeballs What are the common side effects of birth control pills? The most common side effects of birth control pills are: \u2022 Spotting or bleeding between menstrual periods \u2022 Nausea \u2022 Breast tenderness \u2022 Headache These side effects are usually mild and usually disappear with time. Less common side effects are: \u2022 Acne \u2022 Less sexual desire \u2022 Bloating or fluid retention \u2022 Blotchy darkening of the skin, especially on the face \u2022 High blood sugar, especially in women who already have diabetes \u2022 High fat (cholesterol, triglyceride) levels in the blood \u2022 Depression, especially if you have had depression in the past. Call your healthcare provider immediately if you have any thoughts of harming yourself \u2022 Problems tolerating contact lenses \u2022 Weight gain This is not a complete list of possible side effects. Talk to your healthcare provider if you develop any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088. No serious problems have been reported from a birth control pill overdose, even when accidentally taken by children. Do birth control pills cause cancer? Birth control pills do not seem to cause breast cancer. However, if you have breast cancer now, or have had it in the past, do not use birth control pills because some breast cancers are sensitive to hormones. Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners. What should I know about my period when taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Irregular vaginal bleeding or spotting may occur while you are taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding, which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your tablets on schedule. If the bleeding occurs in more than one cycle, is unusually heavy, or lasts for more than a few days, call your healthcare provider. Some women may not have a menstrual period but this should not be cause for alarm as long as you have taken the tablets according to direction. What if I miss my scheduled period when taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? It is not uncommon to miss your period. However, if you go two or more months in a row without a period, or you miss your period after a month where you did not take all your tablets correctly, call your healthcare provider because you may be pregnant. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. Stop taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you are pregnant. What if I want to become pregnant? You may stop taking the tablets whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the tablets. General Advice about norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets Your healthcare provider prescribed norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets for you. Please do not share norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with anyone else. Keep norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets out of the reach of children. If you have concerns or questions, ask your healthcare provider. You may also ask your pharmacist for a more detailed label written for healthcare professionals. Manufactured by: Glenmark Pharmaceuticals Limited Colvale-Bardez, Goa - 403 513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Questions? 1 (888)721-7115 www.glenmarkpharma.com/usa December 2017 Pregnancychart.jpg Blister.jpg Logo.jpg"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">WARNING TO WOMEN WHO SMOKE</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</content></paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL Carton.jpg",
      "Package/Label Display Panel Blister.jpg",
      "Package/Label Display Panel Laminate.jpg"
    ],
    "set_id": "570670c0-b88f-4e78-a978-498aff52b410",
    "id": "c38d6eb8-e70a-415a-ae54-daf53998112a",
    "effective_time": "20171226",
    "version": "7",
    "openfda": {
      "application_number": [
        "ANDA210369"
      ],
      "brand_name": [
        "norethindrone acetate and ethinyl estradiol and ferrous fumarate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"
      ],
      "manufacturer_name": [
        "Glenmark Pharmaceuticals Inc., USA"
      ],
      "product_ndc": [
        "68462-376"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "259176",
        "1426288",
        "1426600"
      ],
      "spl_id": [
        "c38d6eb8-e70a-415a-ae54-daf53998112a"
      ],
      "spl_set_id": [
        "570670c0-b88f-4e78-a978-498aff52b410"
      ],
      "package_ndc": [
        "68462-376-29"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL LACTOSE MONOHYDRATE STARCH, CORN SUCROSE ACACIA TALC MAGNESIUM STEARATE off-white G;16"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS )."
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are progestogen-estrogen combinations. Each white to off-white tablet contains norethindrone acetate, USP (19-Norpregn-4-en-20-yn-3-one,17-(acetyloxy)-, (17\u03b1), 1 mg; ethinyl estradiol 19-Norpregna-1,3,5(10)-triene-20-yne-3,17-diol, (17 \u03b1), 20 mcg. Also contains acacia, lactose monohydrate, magnesium stearate, corn starch, sucrose and talc. The structural formulas are as follows: structure1 structure2"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1 to 3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1 to 3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1 to 3). Special Population Race: The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function. Drug-Drug Interactions Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions."
    ],
    "pharmacokinetics": [
      "Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature."
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE 1 LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD % Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use Method Lowest Expected* Typical** (No contraception) (85) (85) Oral contraceptives 3 combined 0.1 N/A*** progestin only 0.5 N/A*** Diaphragm with spermicidal cream or jelly 6 20 Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film) 6 26 Vaginal Sponge nulliparous 9 20 parous 20 40 Implant 0.05 0.05 Injection: depot medroxyprogesterone acetate 0.3 0.3 IUD progesterone T 1.5 2 copper T 380A 0.6 0.8 LNg 20 0.1 0.1 Condom without spermicides female 5 21 male 3 14 Cervical Cap with spermicidal cream or jelly nulliparous 9 20 parous 26 40 Periodic abstinence (all methods) 1 to 9 25 Withdrawal 4 19 Female sterilization 0.5 0.5 Male sterilization 0.1 0.15 Adapted from RA Hatcher et al, Reference 7. *The authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. **This term represents \u201ctypical\u201d couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason. ***N/A-Data not available."
    ],
    "indications_and_usage_table": [
      "<table width=\"100%\"><col width=\"55%\"/><col width=\"23%\"/><col width=\"20%\"/><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TABLE 1</content></paragraph><paragraph><content styleCode=\"bold\">LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD</content></paragraph><paragraph>% Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Method</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lowest Expected*</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Typical**</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>(No contraception)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>(85)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>(85)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Oral contraceptives</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> combined</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>N/A***</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> progestin only</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>N/A***</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Diaphragm with spermicidal cream or jelly</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Vaginal Sponge</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> nulliparous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> parous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Implant</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.05</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.05</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Injection: depot medroxyprogesterone acetate</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>IUD</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> progesterone T</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> copper T 380A</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> LNg 20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Condom without spermicides</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> female</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> male</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Cervical Cap with spermicidal cream or jelly</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> nulliparous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> parous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Periodic abstinence (all methods)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1 to 9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>25</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Withdrawal</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Female sterilization</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Male sterilization</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.15</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Adapted from RA Hatcher et al, Reference 7.</paragraph><paragraph>*The authors&apos; best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.</paragraph><paragraph>**This term represents &#x201C;typical&#x201D; couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</paragraph><paragraph>***N/A-Data not available.</paragraph></td></tr></tbody></table>"
    ],
    "contraindications": [
      "CONTRAINDICATIONS Oral contraceptives are contraindicated in women who currently have the following conditions: \u2022 Thrombophlebitis or thromboembolic disorders \u2022 A past history of deep vein thrombophlebitis or thromboembolic disorders \u2022 Cerebral vascular or coronary artery disease \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone sensitive \u2022 Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \u2022 Undiagnosed abnormal genital bleeding \u2022 Cholestatic jaundice of pregnancy or jaundice with prior pill use \u2022 Hepatic adenomas or carcinomas \u2022 Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see WARNINGS , RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT )."
    ],
    "warnings": [
      "WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author\u2019s permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10 to 16). The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases (17). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives. Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity (19). In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism (20 to 24). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS ) Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. b. Thromboembolism An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (9, 10, 25 to 30). Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8). A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives (15, 32). The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions (15, 32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. c. Cerebrovascular disease Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (greater than 35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes (33 to 35). In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk is also greater in older women (9). d. Dose-related risk of vascular disease from oral contraceptives A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (37 to 39). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (20 to 22). A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. e. Persistence of risk of vascular disease There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40 to 49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (40). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens. 2. Estimates of Mortality from Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970\u2019s but not reported until 1983 (41). However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling. Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4; and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective. TABLE III ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 No fertility control methods 7 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker** 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker** 2.2 3.4 6.6 13.5 51.1 117.2 IUD** 0.8 0.8 1 1 1.4 1.4 Condom* 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide* 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence* 2.5 1.6 1.6 1.7 2.9 3.6 *Deaths are birth related. **Deaths are method related. Adapted from H.W. Ory, Reference 41. 3. Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ). Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS , Postmarketing Experience ). Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women (42 to 45). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. 4. Hepatic Neoplasia Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (46). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (47, 48). Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (49 to 51) in long-term (greater than 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users. 5. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see CONTRAINDICATIONS ). Norethindrone acetate and ethinyl estradiol tablets can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. Oral Contraceptive Use Before and During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy (52 to 54). Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned (52, 53, 55, 56), when taken inadvertently during early pregnancy. The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed. 8. Gallbladder Disease Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (57, 58). More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal (59 to 61). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance (62). Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (23, 63). However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (64). Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives. A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a. and 1d. ), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking oral contraceptives (65) and this increase is more likely in older oral contraceptive users (66) and with continued use (65). Data from the Royal College of General Practitioners (18) and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal disease (67) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (66), and there is no difference in the occurrence of hypertension among ever and never users (65,67,68). 11. Headache The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause. 12. Bleeding Irregularities Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. 13. Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 14. Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets if depression recurs to a serious degree. table"
    ],
    "warnings_table": [
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"38%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"11%\"/><col width=\"10%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">15 to 19</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">20 to 24</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">25 to 29</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">30 to 34</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">35 to 39</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">40 to 44</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>No fertility control methods</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>9.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>14.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>25.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>28.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives non-smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>31.6</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>51.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>117.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>IUD**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Condom*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Diaphragm/spermicide*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.8</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Periodic abstinence*</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>3.6</paragraph></td></tr><tr><td colspan=\"7\" styleCode=\"Botrule \" valign=\"top\"><paragraph>*Deaths are birth related. **Deaths are method related.</paragraph></td></tr><tr><td colspan=\"7\" styleCode=\"Botrule \" valign=\"top\"><paragraph>Adapted from H.W. Ory, Reference 41.</paragraph></td></tr></tbody></table>"
    ],
    "precautions": [
      "PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections. 2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. 3. Lipid Disorders Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. 4. Liver Function If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function. 5. Fluid Retention Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. 6. Contact Lenses Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 7. Drug Interactions Effects of Other Drugs on Oral Contraceptives (69) Rifampin: Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants: Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Troglitazone: Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness. Antibiotics: Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. Concomitant Use with HCV Combination Therapy: Liver Enzyme Elevation Co-administeration of norethindrone acetate and ethinyl estradiol tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations (see WARNINGS , RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Co-administration of norethindrone acetate and ethinyl estradiol tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations. Other: Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Oral Contraceptives on Other Drugs Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. 8. Interactions with Laboratory Tests Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: a. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged. e. Triglycerides may be increased. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives. 9. Carcinogenesis See WARNINGS section. 10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS sections. 11. Lactation Small amounts of oral contraceptive steroids have been identified in human milk, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child. 12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."
    ],
    "spl_unclassified_section": [
      "PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (PATIENT PACKAGE INSERT BRIEF SUMMARY and DETAILED PATIENT PACKAGE INSERT). \u2022 Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs (see BOXED WARNINGS and CONTRAINDICATIONS ). \u2022 Counsel patients that the increased risk of venous thromboembolism compared to non-users of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or greater interruption in intake) the same or a different CHC (see WARNINGS ). \u2022 Counsel patients that this product does not protect against HIV-infection (AIDS) and other sexually transmitted infections. \u2022 Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs (see PRECAUTIONS ). \u2022 Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established (see PRECAUTIONS ). \u2022 Counsel any patient who starts norethindrone acetate and ethinyl estradiol tablets postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a white to off-white tablet for 7 consecutive days (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients that amenorrhea may occur. Pregnancy should be considered in the event of amenorrhea, and should be ruled out if amenorrhea is associated with symptoms of pregnancy, such as morning sickness or unusual breast tenderness (see WARNINGS). \u2022 Counsel patients with a history of depression that depression may reoccur. Women should contact their healthcare provider if depression occurs (see WARNINGS)",
      "NON-CONTRACEPTIVE HEALTH BENEFITS The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (76 to 81). Effects on menses: \u2022 Increased menstrual cycle regularity \u2022 Decreased blood loss and decreased incidence of iron deficiency anemia \u2022 Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation: \u2022 Decreased incidence of functional ovarian cysts \u2022 Decreased incidence of ectopic pregnancies Effects from long-term use: \u2022 Decreased incidence of fibroadenomas and fibrocystic disease of the breast \u2022 Decreased incidence of acute pelvic inflammatory disease \u2022 Decreased incidence of endometrial cancer \u2022 Decreased incidence of ovarian cancer",
      "BRIEF SUMMARY PATIENT PACKAGE INSERT This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Oral contraceptives, also known as \"birth control pills\" or \"the pill,\" are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you: \u2022 Smoke \u2022 Have high blood pressure, diabetes, high cholesterol \u2022 Have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast, jaundice, or malignant or benign liver tumors. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea, vomiting, and breakthrough bleeding may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill: 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack or angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences. 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. There may be slight increases in the risk of breast cancer among current users of hormonal birth control pills with longer duration of use of 8 years or more. Some studies have found an increase in the risk of developing cancer of the cervix in women taking the pill, but this finding may be related to differences in sexual behavior or other factors not related to use of the pill. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis.",
      "INSTRUCTIONS TO PATIENT TABLET DISPENSER The norethindrone acetate and ethinyl estradiol tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each with the days of the week appearing above the first row of tablets. Each white to off-white tablet contains 1 mg norethindrone acetate, USP and 0.02 mg ethinyl estradiol, USP. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet dispenser. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1 TO 3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK. IT HAS 21 PILLS: The 21-pill pack has 21 \"active\" white to off-white pills (with hormones) to take for 3 weeks, followed by 1week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following pictures: 4) the day label strips, if your period starts on a day other than Sunday 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the tablet blister over the area that has the days of the week (starting with Sunday) imprinted in the plastic. Norethindrone acetate and ethinyl estradiol tablets will contain: ALL WHITE TO OFF-WHITE PILLS 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first \"active\" white to off-white pill of the first pack during the first 24 hours of your period . 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \"active\" white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: 21 pills: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \"active\" pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \"active\" pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 2 white to off-white \"active\" pills in a row in THE 3rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 3 OR MORE white to off-white \"active\" pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \"ACTIVE\" PILL EACH DAY until you can reach your doctor or clinic. Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. Keep this and all drugs out of the reach of children. Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture. blister1"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): \u2022 Thrombophlebitis \u2022 Arterial thromboembolism \u2022 Pulmonary embolism \u2022 Myocardial infarction \u2022 Cerebral hemorrhage \u2022 Cerebral thrombosis \u2022 Hypertension \u2022 Gallbladder disease \u2022 Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 1) (70-74). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1) (70, 73, 75). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 to 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8 to 10 years of COC use. FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: \u2022 Mesenteric thrombosis \u2022 Retinal thrombosis The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related: \u2022 Nausea \u2022 Vomiting \u2022 Gastrointestinal symptoms (such as abdominal cramps and bloating) \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Temporary infertility after discontinuation of treatment \u2022 Edema \u2022 Melasma which may persist \u2022 Breast changes: tenderness, enlargement, secretion \u2022 Change in weight (increase or decrease) \u2022 Change in cervical erosion and secretion \u2022 Diminution in lactation when given immediately postpartum \u2022 Cholestatic jaundice \u2022 Migraine \u2022 Rash (allergic) \u2022 Depression \u2022 Reduced tolerance to carbohydrates \u2022 Vaginal candidiasis \u2022 Change in corneal curvature (steepening) \u2022 Intolerance to contact lenses The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted: \u2022 Pre-menstrual syndrome \u2022 Cataracts \u2022 Changes in appetite \u2022 Cystitis-like syndrome \u2022 Headache \u2022 Nervousness \u2022 Dizziness \u2022 Hirsutism \u2022 Loss of scalp hair \u2022 Erythema multiforme \u2022 Erythema nodosum \u2022 Hemorrhagic eruption \u2022 Vaginitis \u2022 Porphyria \u2022 Impaired renal function \u2022 Hemolytic uremic syndrome \u2022 Budd-Chiari syndrome \u2022 Acne \u2022 Changes in libido \u2022 Colitis figure1"
    ],
    "overdosage": [
      "OVERDOSAGE Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females."
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION The tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing on the tablet dispenser above the first row of tablets. Note: Each tablet dispenser has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days. Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen. The possibility of ovulation and conception prior to initiation of use should be considered. Dosage and Administration for 21-Day Dosage Regimen To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets must be taken exactly as directed and at intervals not exceeding 24 hours. Norethindrone acetate and ethinyl estradiol tablets provides the patient with a convenient tablet schedule of \u201c3 weeks on-1 week off\u201d. Two dosage regimens are described, one of which may be more convenient or suitable than the other for an individual patient. For the initial cycle of therapy, the patient begins her tablets according to the Day-1 Start or Sunday-Start regimen. With either regimen, the patient takes one tablet daily for 21 consecutive days followed by one week of no tablets. A. Sunday-Start Regimen: The patient begins taking tablets from the top row on the first Sunday after menstrual flow begins. When menstrual flow begins on Sunday, the first tablet is taken on the same day. The last tablet in the dispenser will then be taken on a Saturday, followed by no tablets for a week (7 days). For all subsequent cycles, the patient then begins a new 21-tablet regimen on the eighth day, Sunday, after taking her last tablet. Following this regimen, of 21 days on -7 days off, the patient will start all subsequent cycles on a Sunday. B. Day-1 Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the tablet dispenser. She starts taking one tablet daily, beginning with the first tablet in the top row. The patient completes her 21-tablet regimen when she has taken the last tablet in the tablet dispenser. She will then take no tablets for a week (7 days). For all subsequent cycles, the patient begins a new 21-tablet regimen on the eighth day after taking her last tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the tablet dispenser. Following this regimen of 21 days on-7 days off, the patient will start all subsequent cycles on the same day of the week as the first course. Likewise, the interval of no tablets will always start on the same day of the week. Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule. Special Notes on Administration Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after discontinuing medication. If spotting occurs while on the usual regimen of one tablet daily, the patient should continue medication without interruption. If the patient forgets to take one or more tablets, the following is suggested: One tablet is missed \u2022 take tablet as soon as remembered \u2022 take next tablet at the regular time Two consecutive tablets are missed (week 1 or week 2) \u2022 take two tablets as soon as remembered \u2022 take two tablets the next day \u2022 use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (week 3) Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets The possibility of ovulation occurring increases with each successive day that scheduled tablets are missed. While there is little likelihood of ovulation occurring if only one tablet is missed, the possibility of spotting or bleeding is increased. This is particularly likely to occur if two or more consecutive tablets are missed. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet dispenser on the next Sunday or the first day (Day 1), depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered. Use of Oral Contraceptives in the Event of a Missed Menstrual Period 1. If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out. 2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are available in dispensers each containing 21 white to off-white tablets. Each tablet contains 1 mg of norethindrone acetate, USP and 0.02 mg of ethinyl estradiol, USP. The tablets are white to off-white, uncoated, round, flat-faced beveled-edge, debossed with \u201816\u2019 on one side and \u2018G\u2019 on other side. 1 carton (NDC 68462-132-81) containing 3 blister cards (NDC 68462-132-79) of 21 tablets Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture."
    ],
    "references": [
      "REFERENCES 1. Back DJ, Breckenridge AM, Crawford FE, McIver M, Orme ML\u2019E, Rowe PH and Smith E: Kinetics of norethindrone in women II. Single-dose kinetics. Clin Pharmacol Ther 1978; 24:448-453. 2. H\u00fcmpel M, Nieuweboer B, Wendt H and Speck U: Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception 1979; 19:421-432. 3. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML\u2019E, Rowe PH and Watts MJ. An investigation of the pharmacokinetics of ethynyl estradiol in women using radioimmunoassay. Contraception 1979; 20:263-273. 4. Hammond GL, L\u00e4hteenm\u00e4ki PLA, L\u00e4hteenm\u00e4ki P and Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steriod Biochem 1982; 17:375-380. 5. Fotherby K. Pharmacokinetics and metabolism of progestins in humans, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994; 99-126. 6. Goldzieher JW. Pharmacokinetics and metabolism of ethynyl estrogens, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press Ltd., New York, 1994; 127-151. 7. Hatcher RA, et al. 1998. Contraceptive Technology, Seventeenth Edition. New York: Irvington Publishers. 8. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 1). New England Journal of Medicine, 305:612-618, 1981. 9. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 2). New England Journal of Medicine , 305:672-677, 1981. 10. Adam, S.A., and M. Thorogood: Oral contraception and myocardial infarction revisited: The effects of new preparations and prescribing patterns. Brit. J. Obstet. and Gynec., 88:838-845, 1981. 11. Mann, J.I., and W.H. Inman: Oral contraceptives and death from myocardial infarction. Brit. Med. J., 2(5965): 245-248, 1975. 12. Mann, J.I., M.P. Vessey, M. Thorogood, and R. Doll: Myocardial infarction in young women with special reference to oral contraceptive practice. Brit. Med. J., 2(5956):241-245, 1975. 13. Royal College of General Practitioners\u2019 Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet, 1:541-546, 1981. 14. Slone, D., S. Shapiro, D.W. Kaufman, L. Rosenberg, O.S. Miettinen, and P.D. Stolley: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N.E.J.M., 305: 420-424, 1981. 15. Vessey, M.P.: Female hormones and vascular disease: An epidemiological overview. Brit. J. Fam. Plann., 6:1-12, 1980. 16. Russell-Briefel, R.G., T.M. Ezzati, R. Fulwood, J.A. Perlman, and R.S. Murphy: Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Preventive Medicine, 15:352-362, 1986. 17. Goldbaum, G.M., J.S. Kendrick, G.C. Hogelin, and E.M. Gentry: The relative impact of smoking and oral contraceptive use on women in the United States. J.A.M.A., 258:1339-1342, 1987. 18. Layde, P.M., and V. Beral: Further analyses of mortality in oral contraceptive users: Royal College General Practitioners\u2019 Oral Contraception Study. (Table 5) Lancet, 1:541-546, 1981. 19. Knopp, R.H.: Arteriosclerosis risk: The roles of oral contraceptives and postmenopausal estrogens. J. of Reprod. Med. , 31(9)(Supplement): 913-921, 1986. 20. Krauss, R.M., S. Roy, D.R. Mishell, J. Casagrande, and M.C. Pike: Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am. J. Obstet. Gyn., 145:446-452, 1983. 21. Wahl, P., C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss, and B. Rifkind: Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N.E.J.M., 308:862-867, 1983. 22. Wynn, V., and R. Niththyananthan: The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am. J. Obstet. and Gyn., 142:766-771, 1982. 23. Wynn, V., and I. Godsland: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Medicine, 31 (9)(Supplement): 892-897, 1986. 24. LaRosa, J.C.: Atherosclerotic risk factors in cardiovascular disease. J. Reprod. Med., 31(9) (Supplement): 906-912, 1986. 25. Inman, W.H., and M.P. Vessey: Investigations of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Brit. Med. J., 2(5599): 193-199, 1968. 26. Maguire, M.G., J. Tonascia, P.E. Sartwell, P.D. Stolley, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives: A further report. Am. J. Epidemiology, 110(2): 188-195, 1979. 27. Pettiti, D.B., J. Wingerd, F. Pellegrin, and S. Ramacharan: Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J.A.M.A., 242:1150-1154, 1979. 28. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit. Med. J., 2(5599): 199-205, 1968. 29. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease: A further report. Brit. Med. J., 2(5658): 651-657, 1969. 30. Porter, J.B., J.R. Hunter, D.A. Danielson, H. Jick, and A. Stergachis: Oral contraceptives and non-fatal vascular disease: Recent experience. Obstet. and Gyn., 59(3):299-302, 1982. 31. Vessey, M., R. Doll, R. Peto, B. Johnson, and P. Wiggins: A long-term follow-up study of women using different methods of contraception: An interim report. J . Biosocial. Sci., 8:375-427, 1976. 32. Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J. of Royal College of General Practitioners, 28:393-399, 1978. 33. Collaborative Group for the study of stroke in young women: Oral contraception and increased risk of cerebral ischemia or thrombosis. N.E.J.M., 288:871-878, 1973. 34. Petitti, D.B., and J. Wingerd: Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet, 2:234-236, 1978. 35. Inman, W.H.: Oral contraceptives and fatal subarachnoid hemorrhage. Brit. Med. J. , 2(6203): 1468-70, 1979. 36. Collaborative Group for the study of stroke in young women: Oral contraceptives and stroke in young women: Associated risk factors. J.A.M.A. , 231:718-722, 1975. 37. Inman, W.H., M.P. Vessey, B. Westerholm, and A. Engelund: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Brit. Med. J., 2:203-209, 1970. 38. Meade, T.W., G. Greenberg, and S.G. Thompson: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Brit. Med. J., 280(6224): 1157-1161, 1980. 39. Kay, C.R.: Progestogens and arterial disease: Evidence from the Royal College of General Practitioners\u2019 study. Amer. J. Obstet. Gyn. , 142:762-765, 1982. 40. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J. Coll. Gen. Pract. , 33:75-82, 1983. 41. Ory, H.W: Mortality associated with fertility and fertility control: 1983. Family PlanningPerspectives, 15:50-56, 1983. 42. Ory, H., Z. Naib, S.B. Conger, R.A. Hatcher, and C.W. Tyler: Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Am. J. Obstet. Gynec. , 124:573-577, 1976. 43. Vessey, M.P., M. Lawless, K. McPherson, D. Yeates: Neoplasia of the cervix uteri and contraception: A possible adverse effect of the pill. Lancet , 2:930, 1983. 44. Brinton, L.A., G.R. Huggins, H.F. Lehman, K. Malli, D.A. Savitz, E. Trapido, J. Rosenthal, and R. Hoover: Long-term use of oral contraceptives and risk of invasive cervical cancer. Int. J. Cancer , 38:339-344, 1986. 45. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Brit. Med. J ., 290:961-965, 1985. 46. Rooks, J.B., H.W. Ory, K.G. Ishak, L.T. Strauss, J.R. Greenspan, A.P. Hill, and C.W. Tyler: Epidemiology of hepatocellular adenoma: The role of oral contraceptive use. J.A.M.A. , 242:644-648, 1979. 47. Bein, N.N., and H.S. Goldsmith: Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Brit. J. Surg ., 64:433-435, 1977. 48. Klatskin, G.: Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology , 73:386-394, 1977. 49. Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike: Hepatocellular carcinoma and oral contraceptives. Brit. J. Cancer , 48:437-440, 1983. 50. Neuberger, J., D. Forman, R. Doll, and R. Williams: Oral contraceptives and hepatocellular carcinoma. Brit. Med. J. , 292:1355-1357, 1986. 51. Forman, D., T.J. Vincent, and R. Doll: Cancer of the liver and oral contraceptives. Brit. Med. J ., 292: 1357-1361, 1986. 52. Harlap, S., and J. Eldor: Births following oral contraceptive failures. Obstet. Gynec ., 55:447-452, 1980. 53. Savolainen, E., E. Saksela, and L. Saxen: Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Amer. J. Obstet. Gynec. , 140:521-524, 1981. 54. Janerich, D.T., J.M. Piper, and D.M. Glebatis: Oral contraceptives and birth defects. Am. J. Epidemiology , 112:73-79, 1980. 55. Ferencz, C., G.M. Matanoski, P.D. Wilson, J.D. Rubin, C.A. Neill, and R. Gutberlet: Maternal hormone therapy and congenital heart disease. Teratology , 21:225-239, 1980. 56. Rothman, K.J., D.C. Fyler, A. Goldbatt, and M.B. Kreidberg: Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiology , 109:433-439, 1979. 57. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet , 1:1399-1404, 1973. 58. Royal College of General Practitioners: Oral Contraceptives and Health . New York, Pittman, 1974, 100p. 59. Layde, P.M., M.P. Vessey, and D. Yeates: Risk of gallbladder disease: A cohort study of young women attending family planning clinics. J. of Epidemiol. and Comm. Health , 36: 274-278, 1982. 60. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am. J. Epidemiol ., 119:796-805, 1984. 61. Strom, B.L., R.T. Tamragouri, M.L. Morse, E.L. Lazar, S.L. West, P. D. Stolley, and J.K. Jones: Oral contraceptives and other risk factors for gallbladder disease. Clin. Pharmacol. Ther. , 39:335-341, 1986. 62. Wynn, V., P.W. Adams, I.F. Godsland, J. Melrose, R. Niththyananthan, N.W. Oakley, and A. Seedj: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet , 1:1045-1049, 1979. 63. Wynn, V.: Effect of progesterone and progestins on carbohydrate metabolism. In Progesterone and Progestin. Edited by C.W. Bardin, E. Milgrom, P. Mauvis-Jarvis. New York, Raven Press , pp. 395-410, 1983. 64. Perlman, J.A., R. G. Roussell-Briefel, T.M. Ezzati, and G. Lieberknecht: Oral glucose tolerance and the potency of oral contraceptive progestogens. J. Chronic Dis. , 38:857- 864, 1985. 65. Royal College of General Practitioners\u2019 Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet , 1:624, 1977. 66. Fisch, I.R., and J. Frank: Oral contraceptives and blood pressure. J.A.M.A. , 237:2499- 2503, 1977. 67. Laragh, A.J.: Oral contraceptive induced hypertension: Nine years later. Amer. J. Obstet. Gynecol ., 126:141-147, 1976. 68. Ramcharan, S., E. Peritz, F.A. Pellegrin, and W.T. Williams: Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort. In Pharmacology of Steroid Contraceptive Drugs. Edited by S. Garattini and H.W. Berendes. New York, Raven Press , pp. 277-288, 1977. (Monographs of the Mario Negri Institute for Pharmacological Research, Milan.) 69. Back DJ, Orme ML\u2019E. Drug interactions, in Pharmacology of the contraceptive steroids. Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994, 407-425. 70. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med . 2002;346(26):2025-2032. 71. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control . 2005;16(5):537-544. 72. Dorjgochoo T, Shu XO, Li HL, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer . 2009;124(10):2442-2449. 73. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology . 2010;19(10):2496-2502. 74. Vessey M, Yeates D. Oral contraceptive use and cancer. Final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-683. 75. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med . 2017;377(23):2228-2239. 76. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. J.A.M.A. , 249:1596-1599, 1983. 77. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. J.A.M.A. , 257:796-800, 1987. 78. Ory, H.W.: Functional ovarian cysts and oral contraceptives: Negative association confirmed surgically. J.A.M.A. , 228:68-69, 1974. 79. Ory, H.W., P. Cole, B. Macmahon, and R. Hoover: Oral contraceptives and reduced risk of benign breast disease. N.E.J.M. , 294:41-422, 1976. 80. Ory, H.W.: The noncontraceptive health benefits from oral contraceptive use. Fam . Plann. Perspectives , 14:182-184, 1982. 81. Ory, H.W., J.D. Forrest, and R. Lincoln: Making Choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, p.1, 1983. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com May 2025 logo"
    ],
    "spl_unclassified_section_table": [
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>"
    ],
    "spl_patient_package_insert": [
      "DETAILED PATIENT PACKAGE INSERT Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. What You Should Know About Oral Contraceptives Any woman who considers using oral contraceptives (the \"birth control pill\" or \"the pill\") should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider's advice with regard to regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES Oral contraceptives or \"birth control pills'' or \"the pill\" are used to prevent pregnancy and are more effective than other non-surgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 3% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: Implant: <1% Male sterilization: <1% Injection: <1% Cervical Cap: 20 to 40% IUD: <1 to 2% Condom alone (male): 14% Diaphragm with spermicides: 20% Condom alone (female): 21% Spermicides alone: 26% Periodic abstinence: 25% Vaginal Sponge: 20 to 40% Withdrawal: 19% Female sterilization: <1% No method: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions: \u2022 A history of heart attack or stroke \u2022 Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), or eyes \u2022 A history of blood clots in the deep veins of your legs \u2022 Chest pain (angina pectoris) \u2022 Known or suspected breast cancer \u2022 Unexplained vaginal bleeding (until a diagnosis is reached by your doctor) \u2022 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill \u2022 Liver tumor (benign or cancerous) \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend a safer method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your healthcare provider if you have: \u2022 Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram \u2022 Diabetes \u2022 Elevated cholesterol or triglycerides \u2022 High blood pressure \u2022 Migraine or other headaches or epilepsy \u2022 Depression \u2022 Gallbladder, heart, or kidney disease \u2022 History of scanty or irregular menstrual periods Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. RISKS OF TAKING ORAL CONTRACEPTIVES 1. Risk of Developing Blood Clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives; in particular, a clot in the legs can cause thrombophlebitis, and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in GENERAL PRECAUTIONS .) 2. Heart Attacks and Strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder Disease Oral contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver Tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Risk of Cancer It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 No fertility control methods* 7 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smoker** 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker** 2.2 3.4 6.6 13.5 51.1 117.2 IUD** 0.8 0.8 1 1 1.4 1.4 Condom* 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide* 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence* 2.5 1.6 1.6 1.7 2.9 3.6 *Deaths are birth related. **Deaths are method related. In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7 to 26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: \u2022 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung) \u2022 Pain in the calf (indicating a possible clot in the leg) \u2022 Crushing chest pain or heaviness in the chest (indicating a possible heart attack) \u2022 Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) \u2022 Sudden partial or complete loss of vision (indicating a possible clot in the eye) \u2022 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts) \u2022 Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor) \u2022 Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression) \u2022 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark colored urine, or light colored bowel movements (indicating possible liver problems) SIDE EFFECTS OF ORAL CONTRACEPTIVES 1. Vaginal Bleeding Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider. 2. Contact Lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider. 3. Fluid Retention Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or healthcare provider. 4. Melasma A spotty darkening of the skin is possible, particularly of the face. 5. Other Side Effects Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections. If any of these side effects bother you, call your doctor or healthcare provider. GENERAL PRECAUTIONS 1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception. There is no conclusive evidence that oral contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy. 2. While Breastfeeding If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely. 3. Laboratory Tests If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills. 4. Drug Interactions Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin \u00ae is one brand of this drug); troglitazone; phenylbutazone; and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective. Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications. 5. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis. INSTRUCTIONS TO PATIENT TABLET DISPENSER The norethindrone acetate and ethinyl estradiol tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing above the first row of tablets. Each white to off-white tablet contains 1 mg norethindrone acetate, USP and 0.02 mg ethinyl estradiol, USP. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet dispenser. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1 TO 3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK IT HAS 21 PILLS: The 21-pill pack has 21 \"active\" white to off-white pills (with hormones) to take for 3 weeks, followed by 1week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following pictures: 4) the day label strips, if your period starts on a day other than Sunday 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the tablet blister over the area that has the days of the week (starting with Sunday) imprinted in the plastic. Norethindrone acetate and ethinyl estradiol tablets will contain: ALL WHITE TO OFF-WHITE PILLS 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first \"active\" white to off-white pill of the first pack during the first 24 hours of your period . 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \"active\" white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: 21 pills: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \"active\" pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \"active\" pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 2 white to off-white \"active\" pills in a row in THE 3rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 3 OR MORE white to off-white \"active\" pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \"ACTIVE\" PILL EACH DAY until you can reach your doctor or clinic. PREGNANCY DUE TO PILL FAILURE The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 3%. If failure does occur, the risk to the fetus is minimal. PREGNANCY AFTER STOPPING THE PILL There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. OVERDOSAGE Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. OTHER INFORMATION Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: \u2022 Menstrual cycles may become more regular \u2022 Blood flow during menstruation may be lighter and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur \u2022 Pain or other symptoms during menstruation may be encountered less frequently \u2022 Ectopic (tubal) pregnancy may occur less frequently \u2022 Noncancerous cysts or lumps in the breast may occur less frequently \u2022 Acute pelvic inflammatory disease may occur less frequently \u2022 Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the \"Physician Insert,\" which you may wish to read. Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection. MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS At times there may be no menstrual period after a cycle of pills. Therefore, if you miss one menstrual period but have taken the pills exactly as you were supposed to , continue as usual into the next cycle. If you have not taken the pills correctly and miss a menstrual period, you may be pregnant and should stop taking oral contraceptives until your doctor or healthcare provider determines whether or not you are pregnant. Until you can get to your doctor or healthcare provider, use another form of contraception. If two consecutive menstrual periods are missed, you should stop taking pills until it is determined whether or not you are pregnant. Although there does not appear to be any increase in birth defects in newborn babies if you become pregnant while using oral contraceptives, you should discuss the situation with your doctor or healthcare provider. Periodic Examination Your doctor or healthcare provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaou smear, i.e., test for cancer). Keep this and all drugs out of the reach of children. Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture. Trademarks are the property of their respective owners. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com May 2025 blister2 logo1"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"39%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><tbody><tr><td align=\"center\" colspan=\"7\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</content></paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and outcome</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">15 to 19</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">20 to 24</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">25 to 29</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">30 to 34</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">35 to 39</content></paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">40 to 44</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>No fertility control methods*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>9.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>14.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>25.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>28.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives non-smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>31.6</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Oral contraceptives smoker**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>51.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>117.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>IUD**</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Condom*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Diaphragm/spermicide*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.8</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Periodic abstinence*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.6</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/></tr><tr><td colspan=\"7\" styleCode=\"Botrule \" valign=\"top\"><paragraph>*Deaths are birth related.</paragraph><paragraph>**Deaths are method related.</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "Package/Label Display Panel - Pouch NDC 68462-132-79 Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1 mg/0.02 mg pouch",
      "Package/Label Display Panel - Carton NDC 68462-132-81 Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg carton"
    ],
    "set_id": "5a44f7a2-45f1-4d28-b9fb-61d9f2456422",
    "id": "0f4e690d-1b9a-4c51-ac0a-8aa783056a00",
    "effective_time": "20260129",
    "version": "7",
    "openfda": {
      "application_number": [
        "ANDA206969"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "Glenmark Pharmaceuticals Inc., USA"
      ],
      "product_ndc": [
        "68462-132"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ETHINYL ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1358762",
        "1358776"
      ],
      "spl_id": [
        "0f4e690d-1b9a-4c51-ac0a-8aa783056a00"
      ],
      "spl_set_id": [
        "5a44f7a2-45f1-4d28-b9fb-61d9f2456422"
      ],
      "package_ndc": [
        "68462-132-79",
        "68462-132-81"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0368462132814",
        "0368462132791"
      ],
      "nui": [
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "423D2T571U",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate Norethindrone NORETHINDRONE ACETATE NORETHINDRONE LACTOSE, UNSPECIFIED FORM MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE off-white AN;475"
    ],
    "description": [
      "DESCRIPTION Norethindrone acetate tablets, USP - 5 mg oral tablets. Norethindrone acetate, USP (17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone, USP. It is a white, or creamy white, crystalline powder. Norethindrone acetate tablets, USP contain the following inactive ingredients: lactose, magnesium stearate, and microcrystalline cellulose. 898a98a2-figure-01"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone. Pharmacokinetics Absorption Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1.Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation AUC (0-inf) (ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Effect of Food The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. Special Populations Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted. 898a98a2-figure-02"
    ],
    "clinical_pharmacology_table": [
      "<table><caption> Table 1.Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women </caption><col/><col/><thead><tr><th align=\"center\" valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\" colspan=\"2\"> Norethindrone Acetate (n=29) Arithmetic Mean &#xB1; SD </th></tr><tr><th valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\" colspan=\"2\"> Norethindrone (NET)</th></tr></thead><tfoot><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> AUC = area under the curve, </td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> C<sub>max</sub> = maximum plasma concentration, </td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> t<sub>max</sub> = time at maximum plasma concentration, </td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> t<sub>1/2</sub> = half-life, </td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> SD = standard deviation </td></tr></tfoot><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"> AUC <sub>(0-inf)</sub>(ng/ml*h)</td><td styleCode=\" Botrule Toprule Lrule Rrule\"> 166.90 &#xB1; 56.28</td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"> C<sub>max</sub> (ng/ml)</td><td styleCode=\" Botrule Toprule Lrule Rrule\"> 26.19 &#xB1; 6.19</td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"> t<sub>max</sub> (h)</td><td styleCode=\" Botrule Toprule Lrule Rrule\"> 1.83 &#xB1; 0.58</td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"> t<sub>1/2</sub> (h)</td><td styleCode=\" Botrule Toprule Lrule Rrule\"> 8.51 &#xB1; 2.19</td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate tablets, USP is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."
    ],
    "contraindications": [
      "CONTRAINDICATIONS Known or suspected pregnancy. There is no indication for norethindrone acetate, USP in pregnancy. (See PRECAUTIONS .) Undiagnosed vaginal bleeding Known, suspected or history of cancer of the breast Active deep vein thrombosis, pulmonary embolism or history of these conditions Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) Impaired liver function or liver disease As a diagnostic test for pregnancy Hypersensitivity to any of the drug components"
    ],
    "warnings": [
      "WARNINGS 1. Cardiovascular disorders Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. 2. Visual abnormalities Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued."
    ],
    "precautions": [
      "PRECAUTIONS General Precautions Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation. In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated. Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree. Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy. The pathologist should be advised of progestin therapy when relevant specimens are submitted. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate. Drug/Laboratory Test Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test. Carcinogenesis, Mutagenesis, Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established. Pregnancy Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See WARNINGS and PRECAUTIONS . The following adverse reactions have been observed in women taking progestins: Breakthrough bleeding Spotting Change in menstrual flow Amenorrhea Edema Changes in weight (decreases, increases) Changes in the cervical squamo-columnar junction and cervical secretions Cholestatic jaundice Rash (allergic) with and without pruritus Melasma or chloasma Clinical depression Acne Breast enlargement/tenderness Headache/migraine Urticaria Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) Decreased HDL cholesterol and increased LDL/HDL ratio Mood swings Nausea Insomnia Anaphylactic/anaphylactoid reactions Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) Optic neuritis (which may lead to partial or complete loss of vision)"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Therapy with norethindrone acetate tablets, USP must be adapted to the specific indications and therapeutic response of the individual patient. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg norethindrone acetate, USP may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate, USP therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate tablets, USP. Endometriosis: Initial daily dosage of 5 mg norethindrone acetate, USP for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate, USP is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone acetate tablets, USP, 5 mg, are supplied as white to off-white oval, biconvex tablets debossed with \u201cAN\u201d bisect \u201c475\u201d on one side and plain on the other side. They are available as follows: Bottles of 50: NDC 65162-475-05 Bottles of 90: NDC 65162-475-09 Bottles of 500: NDC 65162-475-50 Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [See USP Controlled Room Temperature]. Distributed by: Amneal Pharmaceuticals Bridgewater, NJ 08807 Rev. 08-2023-01"
    ],
    "spl_medguide": [
      "PATIENT INFORMATION Norethindrone Acetate Tablets Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition. What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets? Do not use norethindrone acetate if you are pregnant, breastfeeding or are trying to conceive. Do not use norethindrone acetate if you have had a previous blood clot, stroke, or heart attack. Do not use norethindrone acetate if you are postmenopausal. What is norethindrone acetate? Norethindrone acetate is similar to the progesterone hormones naturally produced by the body. What are norethindrone acetate tablets used for? Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. Who should not take norethindrone acetate tablets? You should not take norethindrone acetate tablets if you are postmenopausal, pregnant or breast-feeding. You should not take norethindrone acetate tablets if you have the following conditions: Known or suspected pregnancy . Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate and later find out you were pregnant, talk with your healthcare provider right away. History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions Liver impairment or disease Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate. Undiagnosed vaginal bleeding Hypersensitivity to norethindrone acetate tablets. See the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets. What are the risks associated with norethindrone acetate tablets? Risk to the Fetus Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. You should avoid using norethindrone acetate tablets during pregnancy. If you take norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. Abnormal Blood Clotting Use of progestational drugs, such as norethindrone acetate, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug. Eye Abnormalities Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. These are some of the warning signs of serious side effects with progestin therapy Breast lumps Dizziness and faintness Changes in speech Severe headaches Chest pain Shortness of breath Pains in your legs Changes in vision Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. Common side effects include Headache Breast pain Irregular vaginal bleeding or spotting Stomach/abdominal cramps/bloating Nausea and vomiting Hair loss Other side effects include High blood pressure Liver problems High blood sugar Fluid retention Enlargements of benign tumors of the uterus (\u201cfibroids\u201d) Vaginal yeast infections Mental depression These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist. What can I do to lower my chances of getting a serious side effect with norethindrone acetate? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate. Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks. General information about the safe and effective use of norethindrone acetate tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. Keep norethindrone acetate tablets out of the reach of children. This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate that is written for health professionals. What are the ingredients in norethindrone acetate tablets? Norethindrone acetate tablets contain the following inactive ingredients: lactose, magnesium stearate, and microcrystalline cellulose. Distributed by: Amneal Pharmaceuticals Bridgewater, NJ 08807 Rev. 08-2023-01 Dispense with Patient Information available at: documents.amneal.com/mg/ppi-norethindrone-tab.pdf"
    ],
    "spl_medguide_table": [
      "<table width=\"100%\"><col width=\"17px\"/><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Norethindrone Acetate Tablets</content></paragraph><paragraph>Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition.</paragraph><paragraph><content styleCode=\"bold\">What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets?</content></paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item><content styleCode=\"bold\">Do not use norethindrone acetate if you are pregnant, breastfeeding or are trying to conceive.</content></item><item><content styleCode=\"bold\">Do not use norethindrone acetate if you have had a previous blood clot, stroke, or heart attack.</content></item><item><content styleCode=\"bold\">Do not use norethindrone acetate if you are postmenopausal.</content></item></list><paragraph><content styleCode=\"bold\">What is norethindrone acetate?</content></paragraph><paragraph>Norethindrone acetate is similar to the progesterone hormones naturally produced by the body.</paragraph><paragraph><content styleCode=\"bold\">What are norethindrone acetate tablets used for?</content></paragraph><paragraph>Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance.</paragraph><paragraph><content styleCode=\"bold\">Who should not take norethindrone acetate tablets?</content></paragraph><paragraph><content styleCode=\"bold\">You should not take norethindrone acetate tablets if you are postmenopausal, pregnant or breast-feeding.</content></paragraph><paragraph>You should not take norethindrone acetate tablets if you have the following conditions:</paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item><content styleCode=\"bold\">Known or suspected pregnancy</content>. Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate and later find out you were pregnant, talk with your healthcare provider right away.</item><item><content styleCode=\"bold\">History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions</content></item><item><content styleCode=\"bold\">Liver impairment or disease</content></item><item><content styleCode=\"bold\">Known or suspected cancer of the breast.</content> If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate.</item><item><content styleCode=\"bold\">Undiagnosed vaginal bleeding</content></item><item><content styleCode=\"bold\">Hypersensitivity to norethindrone acetate tablets.</content> See the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets.</item></list><paragraph><content styleCode=\"bold\">What are the risks associated with norethindrone acetate tablets?</content></paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item><content styleCode=\"bold\">Risk to the Fetus</content><paragraph>Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy.</paragraph><paragraph>You should avoid using norethindrone acetate tablets during pregnancy. If you take norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible.</paragraph></item><item><content styleCode=\"bold\">Abnormal Blood Clotting</content><paragraph>Use of progestational drugs, such as norethindrone acetate, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug.</paragraph></item><item><content styleCode=\"bold\">Eye Abnormalities</content><paragraph>Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine.</paragraph><paragraph><content styleCode=\"bold\">These are some of the warning signs of serious side effects with progestin therapy</content></paragraph></item><item>Breast lumps</item><item>Dizziness and faintness</item><item>Changes in speech</item><item>Severe headaches</item><item>Chest pain</item><item>Shortness of breath</item><item>Pains in your legs</item><item>Changes in vision</item></list><paragraph>Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.</paragraph><paragraph><content styleCode=\"bold\">Common side effects include</content></paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item>Headache</item><item>Breast pain</item><item>Irregular vaginal bleeding or spotting</item><item>Stomach/abdominal cramps/bloating</item><item>Nausea and vomiting</item><item>Hair loss</item></list><paragraph><content styleCode=\"bold\">Other side effects include</content></paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item>High blood pressure</item><item>Liver problems</item><item>High blood sugar</item><item>Fluid retention</item><item>Enlargements of benign tumors of the uterus (&#x201C;fibroids&#x201D;)</item><item>Vaginal yeast infections</item><item>Mental depression</item></list><paragraph>These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist.</paragraph><paragraph><content styleCode=\"bold\">What can I do to lower my chances of getting a serious side effect with norethindrone acetate?</content><content styleCode=\"bold\"> </content></paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item>Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate.</item><item>Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.</item><item>If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks.</item></list><paragraph><content styleCode=\"bold\">General information about the safe and effective use of norethindrone acetate tablets</content></paragraph><paragraph>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them.</paragraph><paragraph><content styleCode=\"bold\">Keep norethindrone acetate tablets out of the reach of children.</content></paragraph><paragraph>This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate that is written for health professionals.</paragraph><paragraph><content styleCode=\"bold\">What are the ingredients in norethindrone acetate tablets?</content></paragraph><paragraph>Norethindrone acetate tablets contain the following inactive ingredients: lactose, magnesium stearate, and microcrystalline cellulose.</paragraph><paragraph>Distributed by: <content styleCode=\"bold\">Amneal Pharmaceuticals </content>Bridgewater, NJ 08807</paragraph><paragraph>Rev. 08-2023-01</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL kj"
    ],
    "set_id": "64cb920c-36e8-4d62-9d08-3ddf3989d313",
    "id": "764f6075-288a-4435-b148-35589e5e5835",
    "effective_time": "20241030",
    "version": "18",
    "openfda": {
      "application_number": [
        "ANDA200275"
      ],
      "brand_name": [
        "Norethindrone Acetate"
      ],
      "generic_name": [
        "NORETHINDRONE"
      ],
      "manufacturer_name": [
        "Amneal Pharmaceuticals LLC"
      ],
      "product_ndc": [
        "65162-475"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1000405"
      ],
      "spl_id": [
        "764f6075-288a-4435-b148-35589e5e5835"
      ],
      "spl_set_id": [
        "64cb920c-36e8-4d62-9d08-3ddf3989d313"
      ],
      "package_ndc": [
        "65162-475-03",
        "65162-475-05",
        "65162-475-09",
        "65162-475-50"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0365162475098"
      ],
      "unii": [
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate Norethindrone LACTOSE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE NORETHINDRONE ACETATE NORETHINDRONE off-white AN;475"
    ],
    "description": [
      "DESCRIPTION Norethindrone acetate tablets, USP - 5 mg oral tablets. Norethindrone acetate, USP (17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone, USP. It is a white, or creamy white, crystalline powder. Norethindrone acetate tablets, USP contain the following inactive ingredients: lactose, magnesium stearate, and microcrystalline cellulose. cd236b39-figure-01"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone. Pharmacokinetics Absorption Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1.Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation AUC (0-inf) (ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Effect of Food The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. Special Populations Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted. cd236b39-figure-02"
    ],
    "clinical_pharmacology_table": [
      "<table frame=\"void\" width=\"638\"><caption> Table 1.Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women </caption><thead><tr><td align=\"center\" colspan=\"2\" styleCode=\"BotruleLruleRruleToprule\" valign=\"top\"> Norethindrone Acetate (n=29) Arithmetic Mean &#xB1; SD </td></tr><tr><td align=\"left\" colspan=\"2\" styleCode=\"BotruleLruleRruleToprule\" valign=\"top\"> Norethindrone (NET)</td></tr></thead><tfoot><tr><td align=\"left\" colspan=\"2\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\"> AUC = area under the curve, </td></tr><tr><td align=\"left\" colspan=\"2\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\"> C <sub>max</sub> = maximum plasma concentration, </td></tr><tr><td align=\"left\" colspan=\"2\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\"> t <sub>max</sub> = time at maximum plasma concentration, </td></tr><tr><td align=\"left\" colspan=\"2\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\"> t <sub>1/2</sub> = half-life, </td></tr><tr><td align=\"left\" colspan=\"2\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\"> SD = standard deviation </td></tr></tfoot><tbody><tr><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">AUC <sub>(0-inf)</sub>(ng/ml*h) </td><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">166.90 &#xB1; 56.28</td></tr><tr><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">C <sub>max</sub> (ng/ml) </td><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">26.19 &#xB1; 6.19</td></tr><tr><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">t <sub>max</sub> (h) </td><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">1.83 &#xB1; 0.58</td></tr><tr><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">t <sub>1/2</sub> (h) </td><td align=\"left\" styleCode=\"BotruleLruleRruleToprule\" valign=\"middle\">8.51 &#xB1; 2.19</td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate tablets, USP is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."
    ],
    "contraindications": [
      "CONTRAINDICATIONS Known or suspected pregnancy. There is no indication for norethindrone acetate, USP in pregnancy. (See PRECAUTIONS .) Undiagnosed vaginal bleeding Known, suspected or history of cancer of the breast Active deep vein thrombosis, pulmonary embolism or history of these conditions Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) Impaired liver function or liver disease As a diagnostic test for pregnancy Hypersensitivity to any of the drug components"
    ],
    "warnings": [
      "WARNINGS 1. Cardiovascular disorders Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. 2. Visual abnormalities Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued."
    ],
    "precautions": [
      "PRECAUTIONS General Precautions Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation. In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated. Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree. Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy. The pathologist should be advised of progestin therapy when relevant specimens are submitted. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate. Drug/Laboratory Test Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test. Carcinogenesis, Mutagenesis, Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established. Pregnancy Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See WARNINGS and PRECAUTIONS . The following adverse reactions have been observed in women taking progestins: Breakthrough bleeding Spotting Change in menstrual flow Amenorrhea Edema Changes in weight (decreases, increases) Changes in the cervical squamo-columnar junction and cervical secretions Cholestatic jaundice Rash (allergic) with and without pruritus Melasma or chloasma Clinical depression Acne Breast enlargement/tenderness Headache/migraine Urticaria Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) Decreased HDL cholesterol and increased LDL/HDL ratio Mood swings Nausea Insomnia Anaphylactic/anaphylactoid reactions Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) Optic neuritis (which may lead to partial or complete loss of vision) To report SUSPECTED ADVERSE REACTIONS contact AvKARE at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Therapy with norethindrone acetate tablets, USP must be adapted to the specific indications and therapeutic response of the individual patient. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg norethindrone acetate, USP may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate, USP therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate tablets, USP. Endometriosis: Initial daily dosage of 5 mg norethindrone acetate, USP for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate, USP is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone acetate tablets, USP, 5 mg, are supplied as white to off-white oval, biconvex tablets debossed with \u201cAN\u201d bisect \u201c475\u201d on one side and plain on the other side. They are available as follows: Bottles of 90: NDC 42291-650-90 Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [See USP Controlled Room Temperature]. All registered trademarks in this document are the property of their respective owners."
    ],
    "spl_unclassified_section": [
      "Manufactured for: AvKARE Pulaski, TN 38478 Mfg. Rev. 08-2023-01 AV Rev. 11/24 (A)",
      "Manufactured for: AvKARE Pulaski, TN 38478 Mfg. Rev. 08-2023-01 AV Rev. 11/24 (A)"
    ],
    "spl_medguide": [
      "PATIENT INFORMATION Norethindrone Acetate Tablets Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition. What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets? Do not use norethindrone acetate if you are pregnant, breastfeeding or are trying to conceive. Do not use norethindrone acetate if you have had a previous blood clot, stroke, or heart attack. Do not use norethindrone acetate if you are postmenopausal. What is norethindrone acetate? Norethindrone acetate is similar to the progesterone hormones naturally produced by the body. What are norethindrone acetate tablets used for? Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. Who should not take norethindrone acetate tablets? You should not take norethindrone acetate tablets if you are postmenopausal, pregnant or breast-feeding. You should not take norethindrone acetate tablets if you have the following conditions: Known or suspected pregnancy . Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate and later find out you were pregnant, talk with your healthcare provider right away. History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions Liver impairment or disease Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate. Undiagnosed vaginal bleeding Hypersensitivity to norethindrone acetate tablets. See the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets. What are the risks associated with norethindrone acetate tablets? Risk to the Fetus Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. You should avoid using norethindrone acetate tablets during pregnancy. If you take norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. Abnormal Blood Clotting Use of progestational drugs, such as norethindrone acetate, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug. Eye Abnormalities Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. These are some of the warning signs of serious side effects with progestin therapy Breast lumps Dizziness and faintness Changes in speech Severe headaches Chest pain Shortness of breath Pains in your legs Changes in vision Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. Common side effects include Headache Breast pain Irregular vaginal bleeding or spotting Stomach/abdominal cramps/bloating Nausea and vomiting Hair loss Other side effects include High blood pressure Liver problems High blood sugar Fluid retention Enlargements of benign tumors of the uterus (\u201cfibroids\u201d) Vaginal yeast infections Mental depression These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist. What can I do to lower my chances of getting a serious side effect with norethindrone acetate? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate. Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks. General information about the safe and effective use of norethindrone acetate tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. Keep norethindrone acetate tablets out of the reach of children. This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate that is written for health professionals. What are the ingredients in norethindrone acetate tablets? Norethindrone acetate tablets contain the following inactive ingredients: lactose, magnesium stearate, and microcrystalline cellulose."
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 1"
    ],
    "set_id": "827c7ef1-a8b7-d0c4-b062-c5154b331a35",
    "id": "3f07bf1f-a9bc-c5ad-e063-6394a90a7545",
    "effective_time": "20250917",
    "version": "10",
    "openfda": {
      "application_number": [
        "ANDA200275"
      ],
      "brand_name": [
        "Norethindrone Acetate"
      ],
      "generic_name": [
        "NORETHINDRONE"
      ],
      "manufacturer_name": [
        "AvKARE"
      ],
      "product_ndc": [
        "42291-650"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1000405"
      ],
      "spl_id": [
        "3f07bf1f-a9bc-c5ad-e063-6394a90a7545"
      ],
      "spl_set_id": [
        "827c7ef1-a8b7-d0c4-b062-c5154b331a35"
      ],
      "package_ndc": [
        "42291-650-90"
      ],
      "original_packager_product_ndc": [
        "65162-475"
      ],
      "unii": [
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "CombiPatch (estradiol/norethindrone acetate transdermal system) estradiol/norethindrone acetate transdermal system DIPROPYLENE GLYCOL OLEIC ACID POVIDONE K30 ESTRADIOL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE CombiPatch (estradiol/norethindrone acetate transdermal system) estradiol/norethindrone acetate transdermal system DIPROPYLENE GLYCOL OLEIC ACID POVIDONE K30 ESTRADIOL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE"
    ],
    "boxed_warning": [
      "WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER, AND PROBABLE DEMENTIA Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders and Probable Dementia ). The Women\u2019s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders ). The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS , Probable Dementia and PRECAUTIONS , Geriatric Use ). Breast Cancer The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer. (See CLINICAL STUDIES and WARNINGS , Malignant Neoplasms , Breast Cancer ). In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. (See WARNINGS , Malignant Neoplasms , Endometrial Cancer ). Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders and Probable Dementia ). The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo. (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders ). The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS , Probable Dementia and PRECAUTIONS , Geriatric Use ). In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman."
    ],
    "description": [
      "DESCRIPTION CombiPatch \u00ae (estradiol/norethindrone acetate transdermal system) is an adhesive-based matrix transdermal patch designed to release both estradiol, an estrogen, and norethindrone acetate (NETA), a progestational agent, continuously upon application to intact skin. Two systems are available, providing the following in vivo delivery rates of estradiol and NETA. 1 NETA=norethindrone acetate. 2 Based on in vivo/in vitro flux data, delivery of both components per day via skin of average permeability (interindividual variation in skin permeability is approximately 20 percent). System Size Estradiol (mg) NETA 1 (mg) Nominal Delivery Rate 2 (mg per day) Estradiol / NETA 9 cm 2 round 0.62 2.7 0.05/0.14 16 cm 2 round 0.51 4.8 0.05/0.25 Estradiol USP (estradiol) is a white to creamy white, odorless, crystalline powder, chemically described as estra-1,3,5(10)-triene-3,17 \u03b2 -diol. The molecular weight of estradiol is 272.39 and the molecular formula is C 18 H 24 O 2 . NETA USP is a white to creamy white, odorless, crystalline powder, chemically described as 17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate. The molecular weight of NETA is 340.47 and the molecular formula is C 22 H 28 O 3 . The structural formulas for estradiol and NETA are: CombiPatch is comprised of 3 layers. Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a translucent polyolefin film backing, (2) an adhesive layer containing estradiol, NETA, acrylic adhesive, silicone adhesive, oleic acid NF, povidone USP and dipropylene glycol, and (3) a polyester release protective liner, which is attached to the adhesive surface and must be removed before the system can be used. The active components of the system are estradiol USP and NETA USP. The remaining components of the system are pharmacologically inactive. Chemical Structure Layer"
    ],
    "description_table": [
      "<table width=\"700\"><colgroup><col width=\"25%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"45%\"/></colgroup><tfoot><tr styleCode=\"First Last\"><td colspan=\"4\"><sup>1</sup>NETA=norethindrone acetate.  <sup>2</sup>Based on <content styleCode=\"italics\">in vivo/in vitro</content> flux data, delivery of both components per day via skin of average permeability (interindividual variation in skin permeability is approximately 20 percent).</td></tr></tfoot><tbody><tr styleCode=\"Botrule First\"><th styleCode=\"Toprule\" align=\"left\"> System Size</th><th styleCode=\"Toprule\" align=\"center\">Estradiol  (mg)</th><th styleCode=\"Toprule\" align=\"center\">NETA <sup>1</sup> (mg)</th><th styleCode=\"Toprule\" align=\"center\">Nominal Delivery Rate <sup>2</sup> (mg per day)  Estradiol / NETA</th></tr><tr styleCode=\"Botrule\"><td> 9 cm <sup>2</sup> round</td><td align=\"center\">0.62</td><td align=\"center\">2.7</td><td align=\"center\">0.05/0.14</td></tr><tr styleCode=\"Botrule Last\"><td> 16 cm <sup>2</sup> round</td><td align=\"center\">0.51</td><td align=\"center\">4.8</td><td align=\"center\">0.05/0.25</td></tr></tbody></table>"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, 2 estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Pharmacokinetics Absorption Estradiol: Estrogens used in hormone therapy are well absorbed through the skin, mucous membranes, and gastrointestinal tract. Administration of CombiPatch every 3 to 4 days in postmenopausal women produces average steady-state estradiol serum concentrations of 45 to 50 pg/mL, which are equivalent to the normal ranges observed at the early follicular phase in premenopausal women. These concentrations are achieved within 12 to 24 hours following CombiPatch application. Minimal fluctuations in serum estradiol concentrations are observed following CombiPatch application, indicating consistent hormone delivery over the application interval. In 1 study, serum concentrations of estradiol were measured in 40 healthy, postmenopausal women throughout 3 consecutive CombiPatch applications to the abdomen (each dose was applied for three 3.5-day periods). The corresponding pharmacokinetic parameters are summarized in Table 1. Table 1. Mean (SD) Serum Estradiol and Estrone Concentrations (pg/mL) at Steady-State (Uncorrected for Baseline Levels) Estradiol System Size Dose Estradiol/NETA (mg per day) C max C min C avg 9 cm 2 0.05/0.14 71 (32) 27 (17) 45 (21) 16 cm 2 0.05/0.25 71 (30) 37 (17) 50 (21) Estrone 9 cm 2 0.05/0.14 72 (23) 49 (19) 54 (19) 16 cm 2 0.05/0.25 78 (22) 58 (22) 60 (18) Norethindrone: Progestins used in hormone therapy are well absorbed through the skin, mucous membranes, and gastrointestinal tract. Norethindrone steady-state concentrations are attained within 24 hours of application of the CombiPatch transdermal delivery systems. Minimal fluctuations in serum norethindrone concentrations are observed following CombiPatch treatment, indicating consistent hormone delivery over the application interval. Serum concentrations of norethindrone increase linearly with increasing doses of NETA. In 1 study, serum concentrations of norethindrone were measured in 40 healthy, postmenopausal women throughout 3 consecutive CombiPatch applications to the abdomen (each dose was applied for three 3.5-day periods). The corresponding pharmacokinetic parameters are summarized in Table 2. Table 2. Mean (SD) Serum Norethindrone Concentrations (pg/mL) at Steady-State System Size Dose Estradiol/NETA (mg per day) C max C min C avg 9 cm 2 0.05/0.14 617 (341) 386 (137) 489 (244) 16 cm 2 0.05/0.25 1060 (543) 686 (306) 840 (414) Distribution Estradiol: The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone: In plasma, norethindrone is bound approximately 90 percent to SHBG and albumin. Metabolism Estradiol: Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone: NETA is hydrolyzed to the active moiety, norethindrone, in most tissues including skin and blood. Norethindrone is primarily metabolized in the liver. Excretion Estradiol: Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Estradiol has a short elimination half-life of approximately 2 to 3 hours; therefore, a rapid decline in serum levels is observed after the CombiPatch estradiol/NETA transdermal system is removed. Within 4 to 8 hours serum estradiol concentrations return to untreated, postmenopausal levels (less than 20 pg/mL). Concentration data from clinical trials indicate that the pharmacokinetics of estradiol did not change over time, suggesting no evidence of the accumulation of estradiol following extended patch wear periods (up to 1 year). Norethindrone: The elimination half-life of norethindrone is reported to be 6 to 8 hours. Norethindrone serum concentrations diminish rapidly and are less than 50 pg/mL within 48 hours after removal of the CombiPatch transdermal delivery system. Concentration data from clinical trials indicate that the pharmacokinetics of norethindrone did not change over time, suggesting no evidence of the accumulation of norethindrone following extended patch wear periods (up to 1 year). Special Populations No pharmacokinetic studies were conducted in special populations, including patients with renal or hepatic impairment."
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"table1\" width=\"750\"><caption>Table 1. Mean (SD) Serum Estradiol and Estrone Concentrations (pg/mL) at Steady-State (Uncorrected for Baseline Levels) </caption><colgroup><col width=\"25%\"/><col width=\"30%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/></colgroup><tbody><tr styleCode=\"Botrule First\"><th styleCode=\"Toprule\" colspan=\"5\">Estradiol</th></tr><tr styleCode=\"Botrule\" valign=\"top\"><th align=\"center\">System Size</th><th align=\"center\">Dose  Estradiol/NETA  (mg per day)</th><th align=\"center\">C <sub>max</sub></th><th align=\"center\">C <sub>min</sub></th><th align=\"center\">C <sub>avg</sub></th></tr><tr styleCode=\"Botrule\"><td align=\"center\">9 cm <sup>2</sup></td><td align=\"center\">0.05/0.14</td><td align=\"center\">71 (32)</td><td align=\"center\">27 (17)</td><td align=\"center\">45 (21)</td></tr><tr styleCode=\"Botrule\"><td align=\"center\">16 cm <sup>2</sup></td><td align=\"center\">0.05/0.25</td><td align=\"center\">71 (30)</td><td align=\"center\">37 (17)</td><td align=\"center\">50 (21)</td></tr><tr styleCode=\"Botrule\"><td colspan=\"5\" align=\"center\"><content styleCode=\"bold\">Estrone</content></td></tr><tr styleCode=\"Botrule\"><td align=\"center\">9 cm <sup>2</sup></td><td align=\"center\">0.05/0.14</td><td align=\"center\">72 (23)</td><td align=\"center\">49 (19)</td><td align=\"center\">54 (19)</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\">16 cm <sup>2</sup></td><td align=\"center\">0.05/0.25</td><td align=\"center\">78 (22)</td><td align=\"center\">58 (22)</td><td align=\"center\">60 (18)</td></tr></tbody></table>",
      "<table ID=\"table2\" width=\"750\"><caption>Table 2. Mean (SD) Serum Norethindrone Concentrations (pg/mL) at Steady-State </caption><colgroup><col width=\"25%\"/><col width=\"30%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/></colgroup><tbody><tr styleCode=\"Botrule First\" valign=\"top\"><th styleCode=\"Toprule\" align=\"center\">System Size</th><th styleCode=\"Toprule\" align=\"center\">Dose Estradiol/NETA  (mg per day)</th><th styleCode=\"Toprule\" align=\"center\">C <sub>max</sub></th><th styleCode=\"Toprule\" align=\"center\">C <sub>min</sub></th><th styleCode=\"Toprule\" align=\"center\">C <sub>avg</sub></th></tr><tr styleCode=\"Botrule\"><td align=\"center\">9 cm <sup>2</sup></td><td align=\"center\">0.05/0.14</td><td align=\"center\">617 (341)</td><td align=\"center\">386 (137)</td><td align=\"center\">489 (244)</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\">16 cm <sup>2</sup></td><td align=\"center\">0.05/0.25</td><td align=\"center\">1060 (543)</td><td align=\"center\">686 (306)</td><td align=\"center\">840 (414)</td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "Pharmacokinetics Absorption Estradiol: Estrogens used in hormone therapy are well absorbed through the skin, mucous membranes, and gastrointestinal tract. Administration of CombiPatch every 3 to 4 days in postmenopausal women produces average steady-state estradiol serum concentrations of 45 to 50 pg/mL, which are equivalent to the normal ranges observed at the early follicular phase in premenopausal women. These concentrations are achieved within 12 to 24 hours following CombiPatch application. Minimal fluctuations in serum estradiol concentrations are observed following CombiPatch application, indicating consistent hormone delivery over the application interval. In 1 study, serum concentrations of estradiol were measured in 40 healthy, postmenopausal women throughout 3 consecutive CombiPatch applications to the abdomen (each dose was applied for three 3.5-day periods). The corresponding pharmacokinetic parameters are summarized in Table 1. Table 1. Mean (SD) Serum Estradiol and Estrone Concentrations (pg/mL) at Steady-State (Uncorrected for Baseline Levels) Estradiol System Size Dose Estradiol/NETA (mg per day) C max C min C avg 9 cm 2 0.05/0.14 71 (32) 27 (17) 45 (21) 16 cm 2 0.05/0.25 71 (30) 37 (17) 50 (21) Estrone 9 cm 2 0.05/0.14 72 (23) 49 (19) 54 (19) 16 cm 2 0.05/0.25 78 (22) 58 (22) 60 (18) Norethindrone: Progestins used in hormone therapy are well absorbed through the skin, mucous membranes, and gastrointestinal tract. Norethindrone steady-state concentrations are attained within 24 hours of application of the CombiPatch transdermal delivery systems. Minimal fluctuations in serum norethindrone concentrations are observed following CombiPatch treatment, indicating consistent hormone delivery over the application interval. Serum concentrations of norethindrone increase linearly with increasing doses of NETA. In 1 study, serum concentrations of norethindrone were measured in 40 healthy, postmenopausal women throughout 3 consecutive CombiPatch applications to the abdomen (each dose was applied for three 3.5-day periods). The corresponding pharmacokinetic parameters are summarized in Table 2. Table 2. Mean (SD) Serum Norethindrone Concentrations (pg/mL) at Steady-State System Size Dose Estradiol/NETA (mg per day) C max C min C avg 9 cm 2 0.05/0.14 617 (341) 386 (137) 489 (244) 16 cm 2 0.05/0.25 1060 (543) 686 (306) 840 (414) Distribution Estradiol: The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone: In plasma, norethindrone is bound approximately 90 percent to SHBG and albumin. Metabolism Estradiol: Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone: NETA is hydrolyzed to the active moiety, norethindrone, in most tissues including skin and blood. Norethindrone is primarily metabolized in the liver. Excretion Estradiol: Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Estradiol has a short elimination half-life of approximately 2 to 3 hours; therefore, a rapid decline in serum levels is observed after the CombiPatch estradiol/NETA transdermal system is removed. Within 4 to 8 hours serum estradiol concentrations return to untreated, postmenopausal levels (less than 20 pg/mL). Concentration data from clinical trials indicate that the pharmacokinetics of estradiol did not change over time, suggesting no evidence of the accumulation of estradiol following extended patch wear periods (up to 1 year). Norethindrone: The elimination half-life of norethindrone is reported to be 6 to 8 hours. Norethindrone serum concentrations diminish rapidly and are less than 50 pg/mL within 48 hours after removal of the CombiPatch transdermal delivery system. Concentration data from clinical trials indicate that the pharmacokinetics of norethindrone did not change over time, suggesting no evidence of the accumulation of norethindrone following extended patch wear periods (up to 1 year). Special Populations No pharmacokinetic studies were conducted in special populations, including patients with renal or hepatic impairment."
    ],
    "pharmacokinetics_table": [
      "<table ID=\"table1\" width=\"750\"><caption>Table 1. Mean (SD) Serum Estradiol and Estrone Concentrations (pg/mL) at Steady-State (Uncorrected for Baseline Levels) </caption><colgroup><col width=\"25%\"/><col width=\"30%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/></colgroup><tbody><tr styleCode=\"Botrule First\"><th styleCode=\"Toprule\" colspan=\"5\">Estradiol</th></tr><tr styleCode=\"Botrule\" valign=\"top\"><th align=\"center\">System Size</th><th align=\"center\">Dose  Estradiol/NETA  (mg per day)</th><th align=\"center\">C <sub>max</sub></th><th align=\"center\">C <sub>min</sub></th><th align=\"center\">C <sub>avg</sub></th></tr><tr styleCode=\"Botrule\"><td align=\"center\">9 cm <sup>2</sup></td><td align=\"center\">0.05/0.14</td><td align=\"center\">71 (32)</td><td align=\"center\">27 (17)</td><td align=\"center\">45 (21)</td></tr><tr styleCode=\"Botrule\"><td align=\"center\">16 cm <sup>2</sup></td><td align=\"center\">0.05/0.25</td><td align=\"center\">71 (30)</td><td align=\"center\">37 (17)</td><td align=\"center\">50 (21)</td></tr><tr styleCode=\"Botrule\"><td colspan=\"5\" align=\"center\"><content styleCode=\"bold\">Estrone</content></td></tr><tr styleCode=\"Botrule\"><td align=\"center\">9 cm <sup>2</sup></td><td align=\"center\">0.05/0.14</td><td align=\"center\">72 (23)</td><td align=\"center\">49 (19)</td><td align=\"center\">54 (19)</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\">16 cm <sup>2</sup></td><td align=\"center\">0.05/0.25</td><td align=\"center\">78 (22)</td><td align=\"center\">58 (22)</td><td align=\"center\">60 (18)</td></tr></tbody></table>",
      "<table ID=\"table2\" width=\"750\"><caption>Table 2. Mean (SD) Serum Norethindrone Concentrations (pg/mL) at Steady-State </caption><colgroup><col width=\"25%\"/><col width=\"30%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/></colgroup><tbody><tr styleCode=\"Botrule First\" valign=\"top\"><th styleCode=\"Toprule\" align=\"center\">System Size</th><th styleCode=\"Toprule\" align=\"center\">Dose Estradiol/NETA  (mg per day)</th><th styleCode=\"Toprule\" align=\"center\">C <sub>max</sub></th><th styleCode=\"Toprule\" align=\"center\">C <sub>min</sub></th><th styleCode=\"Toprule\" align=\"center\">C <sub>avg</sub></th></tr><tr styleCode=\"Botrule\"><td align=\"center\">9 cm <sup>2</sup></td><td align=\"center\">0.05/0.14</td><td align=\"center\">617 (341)</td><td align=\"center\">386 (137)</td><td align=\"center\">489 (244)</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\">16 cm <sup>2</sup></td><td align=\"center\">0.05/0.25</td><td align=\"center\">1060 (543)</td><td align=\"center\">686 (306)</td><td align=\"center\">840 (414)</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "Drug Interactions No drug interaction studies have been conducted with CombiPatch. In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John\u2019s wort ( Hypericum perforatum ) preparations, anticonvulsants (e.g., phenobarbital, phenytoin and carbamazepine), phenylbutazone, and anti-infectives (e.g., rifampin, rifabutin, nevirapine and efavirenz) may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, nelfinavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects. Adhesion Averaging across 6 clinical trials lasting 3 months to 1 year, of 1,287 patients treated, CombiPatch transdermal systems completely adhered to the skin nearly 90 percent of the time over the 3- to 4-day wear period. Less than 2 percent of the patients required reapplication or replacement of systems due to lifting or detachment. Two patients (0.2 percent) discontinued therapy during clinical trials due to adhesion failure."
    ],
    "clinical_studies": [
      "CLINICAL STUDIES Effects on Vasomotor Symptoms In 2 clinical trials designed to assess the degree of relief of moderate to severe vasomotor symptoms in postmenopausal women (n=332), CombiPatch was administered for 3 28-day cycles in Continuous Combined or Continuous Sequential treatment regimens versus placebo. In the Continuous Combined regimen, CombiPatch was applied throughout the 3 cycles, replacing the system twice weekly. In the Continuous Sequential regimen, an estradiol-only transdermal system (Vivelle \u00ae 0.05 mg) was applied twice weekly during the first 14 days of a 28-day cycle; CombiPatch was applied for the remaining 14 days of the cycle and replaced twice weekly, as well. The mean number of hot flushes at baseline were 10 to 11 per day and 11 to 12 per day in the Continuous Combined and Continuous Sequential regimen trials, respectively. The mean number and intensity of daily hot flushes (intent-to-treat population) was significantly reduced from baseline to endpoint with either the Continuous Combined or Continuous Sequential administration of CombiPatch at all doses as compared to placebo (intent-to-treat population). (See Tables 3 and 4 ) Table 3. Adjusted Mean Change in the Number of Hot Flushes and Daily Intensity of Hot Flushes per Day in CombiPatch Continuous Combined Transdermal Therapy 1 Means were adjusted for imbalance among treatment groups and investigators (least squares mean from ANOVA). 2 Represents the milligrams of estradiol/NETA delivered daily by each system. 3 Population represents those patients who had baseline and endpoint observations. 4 The intensity of hot flushes was evaluated on a scale of 0 to 9 (none=0, mild=1-3, moderate= 4-6, severe=7-9). 5 P-value versus placebo = <0.001. 6 Total number of patients with available data is 56. 7 Total number of patients with available data is 50. CombiPatch Continuous Combined Placebo Adjusted Mean Change from Baseline 1 0.05/0.14 mg per day 2 n=57 0.05/0.25 mg per day 2 n=52 n=51 Number of Hot Flushes 3 -9.3 5 -8.9 5 -6.2 Daily Intensity of Hot Flushes 3,4 -4.6 5,6 -5.0 5 -2.8 7 Table 4. Adjusted Mean Change in the Number of Hot Flushes and Daily Intensity of Hot Flushes per Day in CombiPatch Continuous Sequential Transdermal Therapy 1 Means were adjusted for imbalance among treatment groups and investigators (least squares mean from ANOVA). 2 Represents the milligrams of estradiol/NETA delivered daily by each system. 3 Population represents those patients who had baseline and endpoint observations. 4 The intensity of hot flushes was evaluated on a scale of 0 to 9 (none=0, mild=1-3, moderate= 4-6, severe=7-9). 5 P-value versus placebo = <0.001. CombiPatch \u00ae Continuous Combined Placebo Adjusted Mean Change from Baseline 1 0.05/0.14 mg per day 2 n=54 0.05/0.25 mg per day 2 n=59 n=53 Number of Hot Flushes 3 -9.3 5 -9.5 5 -5.5 Daily Intensity of Hot Flushes 3,4 -4.4 5 -4.5 5 -2.1 Effects on the Endometrium The use of unopposed estrogen therapy has been associated with an increased risk of endometrial hyperplasia, a possible precursor of endometrial adenocarcinoma. Progestins counter the estrogenic effects by decreasing the number of nuclear estradiol receptors and suppressing epithelial DNA synthesis in endometrial tissue. Clinical studies indicate that the addition of a progestin to an estrogen regimen at least 12 days per cycle reduces the incidence of endometrial hyperplasia and the potential risk of adenocarcinoma in women with intact uteri. The addition of a progestin to an estrogen regimen has not been shown to interfere with the efficacy of estrogen therapy for its approved indications. CombiPatch was effective in reducing the incidence of estrogen-induced endometrial hyperplasia after 1 year of therapy in two clinical trials. Nine hundred fifty-five (955) postmenopausal women (with intact uteri) were treated with (i) a continuous regimen of CombiPatch alone ( Continuous Combined regimen), (ii) a sequential regimen with an estradiol-only (Vivelle 0.05 mg) transdermal system followed by a CombiPatch transdermal system ( Continuous Sequential regimen), or (iii) continuous regimen with an estradiol-only transdermal system (Vivelle 0.05 mg). The incidence of endometrial hyperplasia (primary endpoint) was significantly less after 1 year of therapy with either CombiPatch regimen than with the estradiol-only transdermal system. Tables 5 and 6 summarize these results (intent-to-treat populations). Table 5. Incidence of Endometrial Hyperplasia in a Continuous Combined CombiPatch Regimen 1 Represents milligrams of estradiol/NETA delivered daily by each system. 2 Biopsy after 12 cycles of treatment or hyperplasia before cycle 12. 3 Comparison of continuous combined regimen versus estradiol-only patch was significant (p <0.001). 4 This patient had hyperplasia at baseline. 5 One of 39 patients had hyperplasia in an endometrial polyp. CombiPatch Continuous Combined Vivelle Continuous 0.05/0.14 mg per day 1 0.05/0.25 mg per day 1 0.05 mg per day Number of Patients with Biopsies 2 123 98 103 Number (%) of Patients with Hyperplasia 1 (<1%) 3 1 (1%) 3,4 39 (38%) 5 Table 6. Incidence of Endometrial Hyperplasia in a Continuous Sequential CombiPatch Regimen 1 Represents milligrams of estradiol/NETA delivered daily by each system. 2 Biopsy after 12 cycles of treatment or hyperplasia before cycle 12. 3 Comparison of continuous sequential regimen versus estradiol-only patch was significant (p <0.001). 4 This patient had hyperplasia at baseline. 5 This patient had hyperplasia in an endometrial polyp. CombiPatch Continuous Sequential Vivelle Continuous 0.05/0.14 mg per day 1 0.05/0.25 mg per day 1 0.05 mg per day Number of Patients with Biopsies 2 117 114 115 Number (%) of Patients with Hyperplasia 1 (<1%) 3,4 1 (<1%) 3,5 23 (20%) Effects on Uterine Bleeding or Spotting With the Continuous Combined regimen, of the women treated with CombiPatch and who completed the 1-year study, the incidence of cumulative amenorrhea (the absence of bleeding or spotting during a 28-day cycle and sustained to the end of the study) increased over time. The incidence of amenorrhea from cycle 10 through 12 was 53 percent and 39 percent for the CombiPatch 0.05/0.14 mg per day and CombiPatch 0.05/0.25 mg per day treatment groups, respectively. Women who experienced bleeding usually characterized it as light (intensity of 1.3 on a scale of 1 to 4) with a duration of 4 and 6 days for the CombiPatch 0.05/0.14 mg per day and CombiPatch 0.05/0.25 mg per day treatment groups, respectively. (See Figure 1 ) Figure 1. Incidence of Cumulative Amenorrhea* in CombiPatch Continuous Combined Transdermal Therapy by Cycle Over a 1-Year Period (Intent-to-Treat Population) *Cumulative amenorrhea is defined as the absence of bleeding for the duration of a 28-day cycle and sustained to the end of the study. Women\u2019s Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) [defined as nonfatal MI, silent MI and CHD death], with invasive breast cancer as the primary adverse outcome. A \u201cglobal index\u201d included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other cause. These substudies did not evaluate the effects of CE plus MPA or CE-alone on menopausal symptoms. WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the \u201cglobal index.\u201d The absolute excess risk of events included in the \u201cglobal index\u201d was 19 per 10,000 women-years. For those outcomes included in the WHI \u201cglobal index\u201d that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. Results of the estrogen plus progestin substudy, which included 16,608 women (average 63 years of age, range 50 to 79 years; 83.9 percent white, 6.8 percent black, 5.4 percent Hispanic, 3.9 percent Other), are presented in Table 7 . These results reflect centrally adjudicated data after an average follow-up of 5.6 years. Table 7. Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years a,b a Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi. b Results are based on centrally adjudicated data. c Nominal confidence intervals (CI) unadjusted for multiple looks and multiple comparisons. d Not included in \u201cglobal index\u201d. e Includes metastatic and non-metastatic breast cancer, with the exception of in situ breast cancer. f All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. g A subset of the events was combined in a \u201cglobal index\u201d, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. Event Relative Risk CE/MPA vs. Placebo (95% nCI c ) CE/MPA n=8,506 Placebo n=8,102 Absolute Risk per 10,000 Women-Years CHD events 1.23 (0.99\u20131.53) 41 34 Nonfatal MI 1.28 (1.00\u20131.63) 31 25 CHD death 1.10 (0.70\u20131.75) 8 8 All strokes 1.31 (1.03\u20131.68) 33 25 Ischemic stroke 1.44 (1.09\u20131.90) 26 18 Deep vein thrombosis d 1.95 (1.43\u20132.67) 26 13 Pulmonary embolism 2.13 (1.45\u20133.11) 18 8 Invasive breast cancer e 1.24 (1.01\u20131.54) 41 33 Colorectal cancer 0.61 (0.42\u20130.87) 10 16 Endometrial cancer d 0.81 (0.48\u20131.36) 6 7 Cervical cancer d 1.44 (0.47\u20134.42) 2 1 Hip fracture 0.67 (0.47\u20130.96) 11 16 Vertebral fractures d 0.65 (0.46\u20130.92) 11 17 Lower arm/wrist fractures d 0.71 (0.59\u20130.85) 44 62 Total fractures d 0.76 (0.69\u20130.83) 152 199 Overall mortality f 1.00 (0.83\u20131.19) 52 52 Global Index g 1.13 (1.02\u20131.25) 184 165 Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age a nonsignificant trend toward reduced risk for overall mortality [hazard ratio (HR) 0.69 (95 percent CI 0.44 to 1.07)]. WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79 years; 75.3 percent white, 15.1 percent black, 6.1 percent Hispanic, 3.6 percent Other) after an average follow-up of 7.1 years, are presented in Table 8 . Table 8. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI a a Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi . b Nominal CI unadjusted for multiple looks and multiple comparisons. c Results are based on centrally adjudicated data for an average follow-up of 7.1 years. d Not included in \u201cglobal index\u201d. e Results are based on an average follow-up of 6.8 years. f All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. g A subset of the events was combined in a \u201cglobal index\u201d, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. Event Relative Risk CE vs. Placebo (95% nCI b ) CE n=5,310 Placebo n=5,429 Absolute Risk per 10,000 Women-Years CHD events c 0.95 (0.78\u20131.16) 54 57 Nonfatal MI c 0.91 (0.73\u20131.14) 40 43 CHD death c 1.01 (0.71\u20131.43) 16 16 All strokes c 1.33 (1.05\u20131.68) 45 33 Ischemic stroke c 1.55 (1.19\u20132.01) 38 25 Deep vein thrombosis c,d 1.47 (1.06\u20132.06) 23 15 Pulmonary embolism c 1.37 (0.90\u20132.07) 14 10 Invasive breast cancer c 0.80 (0.62\u20131.04) 28 34 Colorectal cancer e 1.08 (0.75\u20131.55) 17 16 Hip fracture c 0.65 (0.45\u20130.94) 12 19 Vertebral fractures c,d 0.64 (0.44\u20130.93) 11 18 Lower arm/wrist fractures c,d 0.58 (0.47\u20130.72) 35 59 Total fractures c,d 0.71 (0.64\u20130.80) 144 197 Death due to other causes e,f 1.08 (0.88\u20131.32) 53 50 Overall mortality c,d 1.04 (0.88\u20131.22) 79 75 Global Index g 1.02 (0.92\u20131.13) 206 201 For those outcomes included in the WHI \u201cglobal index\u201d that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. 9 The absolute excess risk of events included in the \u201cglobal index\u201d was a nonsignificant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years (see Table 8 ). Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for ischemic stroke, and this excess was present in all subgroups of women examined. 10 (see Table 8 ). Timing of the initiation of estrogen therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age showed in women 50 to 59 years of age, a nonsignificant trend toward reduced risk for CHD [HR 0.63 (95 percent, CI 0.36 to 1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46 to 1.11)]. Women\u2019s Health Initiative Memory Study The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age; 35 percent were 70 to 74 years of age; 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21 to 3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. Probable dementia as defined in this study included Alzheimer disease (AD), vascular dementia (VaD) and mixed type (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women. (See WARNINGS , Probable Dementia and PRECAUTIONS , Geriatric Use ) The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83 to 2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included AD, VaD and mixed type (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women. (See WARNINGS , Probable Dementia and PRECAUTIONS , Geriatric Use ) When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19 to 2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women. (See WARNINGS , Probable Dementia and PRECAUTIONS , Geriatric Use ) Chart"
    ],
    "clinical_studies_table": [
      "<table ID=\"table3\" width=\"750\"><caption>Table 3. Adjusted Mean Change in the Number of Hot Flushes and Daily Intensity of Hot Flushes per Day in CombiPatch Continuous Combined Transdermal Therapy </caption><colgroup><col width=\"40%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/></colgroup><tfoot><tr styleCode=\"First Last\"><td colspan=\"4\"><sup>1</sup>Means were adjusted for imbalance among treatment groups and investigators (least squares mean from ANOVA).  <sup>2</sup>Represents the milligrams of estradiol/NETA delivered daily by each system.  <sup>3</sup>Population represents those patients who had baseline and endpoint observations.  <sup>4</sup>The intensity of hot flushes was evaluated on a scale of 0 to 9 (none=0, mild=1-3, moderate= 4-6, severe=7-9).  <sup>5</sup>P-value versus placebo = &lt;0.001.  <sup>6</sup>Total number of patients with available data is 56.  <sup>7</sup>Total number of patients with available data is 50.</td></tr></tfoot><tbody><tr valign=\"top\"><th styleCode=\"Toprule\"/><th styleCode=\"Toprule\" colspan=\"2\" align=\"center\"><content styleCode=\"underline\">CombiPatch</content>  Continuous Combined</th><th styleCode=\"Toprule Underline\" colspan=\"1\">Placebo</th></tr><tr styleCode=\"Botrule\" valign=\"top\"><th align=\"center\">Adjusted Mean Change  from Baseline<sup>1</sup></th><th align=\"center\">0.05/0.14  mg per day<sup>2</sup> n=57</th><th align=\"center\">0.05/0.25  mg per day<sup>2</sup> n=52</th><th align=\"center\">n=51</th></tr><tr><td align=\"center\"><content styleCode=\"bold\">Number of Hot Flushes</content><content styleCode=\"bold\"><sup>3</sup></content></td><td align=\"center\">-9.3<sup>5</sup></td><td align=\"center\">-8.9<sup>5</sup></td><td align=\"center\">-6.2</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\"><content styleCode=\"bold\">Daily Intensity of Hot Flushes</content><content styleCode=\"bold\"><sup>3,4</sup></content></td><td align=\"center\">-4.6<sup>5,6</sup></td><td align=\"center\">-5.0<sup>5</sup></td><td align=\"center\">-2.8<sup>7</sup></td></tr></tbody></table>",
      "<table ID=\"table4\" width=\"750\"><caption>Table 4. Adjusted Mean Change in the Number of Hot Flushes and Daily Intensity of Hot Flushes per Day in CombiPatch Continuous Sequential Transdermal Therapy </caption><colgroup><col width=\"40%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/></colgroup><tfoot><tr styleCode=\"First Last\"><td colspan=\"4\"><sup>1</sup>Means were adjusted for imbalance among treatment groups and investigators (least squares mean from ANOVA).  <sup>2</sup>Represents the milligrams of estradiol/NETA delivered daily by each system.  <sup>3</sup>Population represents those patients who had baseline and endpoint observations.  <sup>4</sup>The intensity of hot flushes was evaluated on a scale of 0 to 9 (none=0, mild=1-3, moderate= 4-6, severe=7-9).  <sup>5</sup>P-value versus placebo = &lt;0.001.</td></tr></tfoot><tbody><tr valign=\"top\"><th styleCode=\"Toprule\"/><th styleCode=\"Toprule\" colspan=\"2\" align=\"center\"><content styleCode=\"underline\">CombiPatch</content>&#xAE;   Continuous Combined</th><th styleCode=\"Toprule Underline\" colspan=\"1\">Placebo</th></tr><tr styleCode=\"Botrule\" valign=\"top\"><th align=\"center\">Adjusted Mean Change  from Baseline<sup>1</sup></th><th align=\"center\">0.05/0.14  mg per day<sup>2</sup> n=54</th><th align=\"center\">0.05/0.25  mg per day<sup>2</sup> n=59</th><th align=\"center\">n=53</th></tr><tr><td align=\"center\">Number of Hot Flushes<sup>3</sup></td><td align=\"center\">-9.3<sup>5</sup></td><td align=\"center\">-9.5<sup>5</sup></td><td align=\"center\">-5.5</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\">Daily Intensity of Hot Flushes<sup>3,4</sup></td><td align=\"center\">-4.4<sup>5</sup></td><td align=\"center\">-4.5<sup>5</sup></td><td align=\"center\">-2.1</td></tr></tbody></table>",
      "<table ID=\"table5\" width=\"750\"><caption>Table 5. Incidence of Endometrial Hyperplasia in a Continuous Combined CombiPatch Regimen </caption><colgroup><col width=\"40%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/></colgroup><tfoot><tr styleCode=\"First Last\"><td colspan=\"4\"><sup>1</sup>Represents milligrams of estradiol/NETA delivered daily by each system.  <sup>2</sup>Biopsy after 12 cycles of treatment or hyperplasia before cycle 12.  <sup>3</sup>Comparison of continuous combined regimen versus estradiol-only patch was significant (p &lt;0.001).  <sup>4</sup>This patient had hyperplasia at baseline.  <sup>5</sup>One of 39 patients had hyperplasia in an endometrial polyp.</td></tr></tfoot><tbody><tr valign=\"top\"><th styleCode=\"Toprule\"/><th styleCode=\"Toprule\" colspan=\"2\" align=\"center\"><content styleCode=\"underline\">CombiPatch</content>  Continuous Combined</th><th styleCode=\"Toprule\" colspan=\"1\"><content styleCode=\"underline\">Vivelle</content> Continuous</th></tr><tr styleCode=\"Botrule\" valign=\"top\"><th/><th align=\"center\">0.05/0.14  mg per day<sup>1</sup></th><th align=\"center\">0.05/0.25  mg per day<sup>1</sup></th><th align=\"center\">0.05  mg per day</th></tr><tr styleCode=\"Botrule\"><td align=\"center\"><content styleCode=\"bold\">Number of Patients with Biopsies</content><sup>2</sup></td><td align=\"center\">123</td><td align=\"center\">98</td><td align=\"center\">103</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\"><content styleCode=\"bold\">Number (%) of Patients with Hyperplasia</content></td><td align=\"center\">1 (&lt;1%)<sup>3</sup></td><td align=\"center\">1 (1%)<sup>3,4</sup></td><td align=\"center\">39 (38%)<sup>5</sup></td></tr></tbody></table>",
      "<table ID=\"table6\" width=\"750\"><caption>Table 6. Incidence of Endometrial Hyperplasia in a Continuous Sequential CombiPatch Regimen </caption><colgroup><col width=\"40%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/></colgroup><tfoot><tr styleCode=\"First Last\"><td colspan=\"4\"><sup>1</sup>Represents milligrams of estradiol/NETA delivered daily by each system.  <sup>2</sup>Biopsy after 12 cycles of treatment or hyperplasia before cycle 12.  <sup>3</sup>Comparison of continuous sequential regimen versus estradiol-only patch was significant (p &lt;0.001).  <sup>4</sup>This patient had hyperplasia at baseline.  <sup>5</sup>This patient had hyperplasia in an endometrial polyp.</td></tr></tfoot><tbody><tr valign=\"top\"><th styleCode=\"Toprule\"/><th styleCode=\"Toprule\" colspan=\"2\" align=\"center\"><content styleCode=\"underline\">CombiPatch</content>  Continuous Sequential</th><th styleCode=\"Toprule\" colspan=\"1\"><content styleCode=\"underline\">Vivelle</content> Continuous</th></tr><tr styleCode=\"Botrule\" valign=\"top\"><th/><th align=\"center\">0.05/0.14  mg per day<sup>1</sup></th><th align=\"center\">0.05/0.25  mg per day<sup>1</sup></th><th align=\"center\">0.05  mg per day</th></tr><tr styleCode=\"Botrule\"><td align=\"center\"><content styleCode=\"bold\">Number of Patients with Biopsies</content><sup>2</sup></td><td align=\"center\">117</td><td align=\"center\">114</td><td align=\"center\">115</td></tr><tr styleCode=\"Botrule Last\"><td align=\"center\"><content styleCode=\"bold\">Number (%) of Patients with Hyperplasia</content></td><td align=\"center\">1 (&lt;1%)<content styleCode=\"bold\"><sup>3,4</sup></content></td><td align=\"center\">1 (&lt;1%)<sup>3,5</sup></td><td align=\"center\">23 (20%)</td></tr></tbody></table>",
      "<table ID=\"table7\" width=\"750\"><caption>Table 7. Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years<sup>a,b</sup></caption><colgroup><col width=\"28%\"/><col width=\"24%\"/><col width=\"24%\"/><col width=\"24%\"/></colgroup><tfoot><tr styleCode=\"First Last Toprule\"><td colspan=\"4\" align=\"left\"><content styleCode=\"bold\"><sup>a</sup></content>Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.  <content styleCode=\"bold\"><sup>b</sup></content>Results are based on centrally adjudicated data.  <content styleCode=\"bold\"><sup>c</sup></content>Nominal confidence intervals (CI) unadjusted for multiple looks and multiple comparisons.  <content styleCode=\"bold\"><sup>d</sup></content>Not included in &#x201C;global index&#x201D;.  <content styleCode=\"bold\"><sup>e</sup></content>Includes metastatic and non-metastatic breast cancer, with the exception of in situ breast cancer.  <content styleCode=\"bold\"><sup>f</sup></content>All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.  <content styleCode=\"bold\"><sup>g</sup></content>A subset of the events was combined in a &#x201C;global index&#x201D;, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</td></tr></tfoot><tbody><tr styleCode=\"First Toprule\" valign=\"top\"><td styleCode=\"Bold Botrule Toprule\" align=\"center\">Event</td><td styleCode=\"Bold Botrule Toprule\" align=\"center\">Relative Risk  CE/MPA vs. Placebo  (95% nCI<sup>c</sup>)</td><td styleCode=\"Bold Toprule\" align=\"center\">CE/MPA  n=8,506</td><td styleCode=\"Bold Toprule\" align=\"center\">Placebo  n=8,102</td></tr><tr styleCode=\"Botrule\" valign=\"top\"><td align=\"left\"/><td align=\"center\"/><td colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Absolute Risk per 10,000 Women-Years</content></td></tr><tr styleCode=\"Norule\"><td align=\"left\">CHD events</td><td align=\"center\">1.23 (0.99&#x2013;1.53)</td><td align=\"center\">41</td><td align=\"center\">34</td></tr><tr styleCode=\"Norule\"><td align=\"left\"><content styleCode=\"italics\">Nonfatal MI</content></td><td align=\"center\">1.28 (1.00&#x2013;1.63)</td><td align=\"center\">31</td><td align=\"center\">25</td></tr><tr styleCode=\"Norule\"><td align=\"left\"><content styleCode=\"italics\">CHD death</content></td><td align=\"center\">1.10 (0.70&#x2013;1.75)</td><td align=\"center\">8</td><td align=\"center\">8</td></tr><tr styleCode=\"Norule\"><td align=\"left\">All strokes</td><td align=\"center\">1.31 (1.03&#x2013;1.68)</td><td align=\"center\">33</td><td align=\"center\">25</td></tr><tr styleCode=\"Norule\"><td align=\"left\"><content styleCode=\"italics\">Ischemic stroke</content></td><td align=\"center\">1.44 (1.09&#x2013;1.90)</td><td align=\"center\">26</td><td align=\"center\">18</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Deep vein thrombosis<content styleCode=\"bold\"><sup>d</sup></content></td><td align=\"center\">1.95 (1.43&#x2013;2.67)</td><td align=\"center\">26</td><td align=\"center\">13</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Pulmonary embolism</td><td align=\"center\">2.13 (1.45&#x2013;3.11)</td><td align=\"center\">18</td><td align=\"center\">8</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Invasive breast cancer<content styleCode=\"bold\"><sup>e</sup></content></td><td align=\"center\">1.24 (1.01&#x2013;1.54)</td><td align=\"center\">41</td><td align=\"center\">33</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Colorectal cancer</td><td align=\"center\">0.61 (0.42&#x2013;0.87)</td><td align=\"center\">10</td><td align=\"center\">16</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Endometrial cancer<content styleCode=\"bold\"><sup>d</sup></content></td><td align=\"center\">0.81 (0.48&#x2013;1.36)</td><td align=\"center\">6</td><td align=\"center\">7</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Cervical cancer<content styleCode=\"bold\"><sup>d</sup></content></td><td align=\"center\">1.44 (0.47&#x2013;4.42)</td><td align=\"center\">2</td><td align=\"center\">1</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Hip fracture</td><td align=\"center\">0.67 (0.47&#x2013;0.96)</td><td align=\"center\">11</td><td align=\"center\">16</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Vertebral fractures<content styleCode=\"bold\"><sup>d</sup></content></td><td align=\"center\">0.65 (0.46&#x2013;0.92)</td><td align=\"center\">11</td><td align=\"center\">17</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Lower arm/wrist fractures<content styleCode=\"bold\"><sup>d</sup></content></td><td align=\"center\">0.71 (0.59&#x2013;0.85)</td><td align=\"center\">44</td><td align=\"center\">62</td></tr><tr styleCode=\"Botrule\"><td align=\"left\">Total fractures<content styleCode=\"bold\"><sup>d</sup></content></td><td align=\"center\">0.76 (0.69&#x2013;0.83)</td><td align=\"center\">152</td><td align=\"center\">199</td></tr><tr styleCode=\"Botrule Toprule\"><td align=\"left\">Overall mortality<content styleCode=\"bold\"><sup>f</sup></content></td><td align=\"center\">1.00 (0.83&#x2013;1.19)</td><td align=\"center\">52</td><td align=\"center\">52</td></tr><tr styleCode=\"Botrule Last Toprule\"><td align=\"left\">Global Index<content styleCode=\"bold\"><sup>g</sup></content></td><td align=\"center\">1.13 (1.02&#x2013;1.25)</td><td align=\"center\">184</td><td align=\"center\">165</td></tr></tbody></table>",
      "<table ID=\"table8\" width=\"750\"><caption>Table 8. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI <sup>a</sup></caption><colgroup><col width=\"34%\"/><col width=\"22%\"/><col width=\"22%\"/><col width=\"22%\"/></colgroup><tfoot><tr styleCode=\"First Last Toprule\"><td colspan=\"4\" align=\"left\"><content styleCode=\"bold\"><sup>a</sup></content>Adapted from numerous WHI publications. WHI publications can be viewed at <content styleCode=\"underline\">www.nhlbi.nih.gov/whi</content>.  <content styleCode=\"bold\"><sup>b</sup></content>Nominal CI unadjusted for multiple looks and multiple comparisons.  <content styleCode=\"bold\"><sup>c</sup></content>Results are based on centrally adjudicated data for an average follow-up of 7.1 years.  <content styleCode=\"bold\"><sup>d</sup></content>Not included in &#x201C;global index&#x201D;.  <content styleCode=\"bold\"><sup>e</sup></content>Results are based on an average follow-up of 6.8 years.  <content styleCode=\"bold\"><sup>f</sup></content>All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.  <content styleCode=\"bold\"><sup>g</sup></content>A subset of the events was combined in a &#x201C;global index&#x201D;, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</td></tr></tfoot><tbody><tr styleCode=\"First Toprule\" valign=\"top\"><td styleCode=\"Bold Botrule Toprule\" align=\"center\">Event</td><td styleCode=\"Bold Botrule Toprule\" align=\"center\">Relative Risk  CE vs. Placebo  (95% nCI <sup>b</sup>)</td><td styleCode=\"Bold Toprule\" align=\"center\">CE  <content styleCode=\"underline\">n=5,310</content></td><td styleCode=\"Bold Toprule\" align=\"center\">Placebo  <content styleCode=\"underline\">n=5,429</content></td></tr><tr styleCode=\"Botrule\" valign=\"top\"><td align=\"left\"/><td align=\"center\"/><td colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Absolute Risk per 10,000 Women-Years</content></td></tr><tr styleCode=\"Norule\"><td align=\"left\"><content styleCode=\"bold\">CHD events <sup>c</sup></content></td><td align=\"center\">0.95 (0.78&#x2013;1.16)</td><td align=\"center\">54</td><td align=\"center\">57</td></tr><tr styleCode=\"Norule\"><td align=\"left\"><content styleCode=\"italics\">Nonfatal MI</content><content styleCode=\"bold\"><sup>c</sup></content></td><td align=\"center\">0.91 (0.73&#x2013;1.14)</td><td align=\"center\">40</td><td align=\"center\">43</td></tr><tr styleCode=\"Norule\"><td align=\"left\"><content styleCode=\"italics\">CHD death</content><content styleCode=\"bold\"><sup>c</sup></content></td><td align=\"center\">1.01 (0.71&#x2013;1.43)</td><td align=\"center\">16</td><td align=\"center\">16</td></tr><tr styleCode=\"Norule\"><td align=\"left\">All strokes<content styleCode=\"bold\"><sup>c</sup></content></td><td align=\"center\">1.33 (1.05&#x2013;1.68)</td><td align=\"center\">45</td><td align=\"center\">33</td></tr><tr styleCode=\"Norule\"><td align=\"left\"><content styleCode=\"italics\">Ischemic stroke</content><content styleCode=\"bold\"><sup>c</sup></content></td><td align=\"center\">1.55 (1.19&#x2013;2.01)</td><td align=\"center\">38</td><td align=\"center\">25</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Deep vein thrombosis<content styleCode=\"bold\"><sup>c,d</sup></content></td><td align=\"center\">1.47 (1.06&#x2013;2.06)</td><td align=\"center\">23</td><td align=\"center\">15</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Pulmonary embolism<content styleCode=\"bold\"><sup>c</sup></content></td><td align=\"center\">1.37 (0.90&#x2013;2.07)</td><td align=\"center\">14</td><td align=\"center\">10</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Invasive breast cancer<content styleCode=\"bold\"><sup>c</sup></content></td><td align=\"center\">0.80 (0.62&#x2013;1.04)</td><td align=\"center\">28</td><td align=\"center\">34</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Colorectal cancer<content styleCode=\"bold\"><sup>e</sup></content></td><td align=\"center\">1.08 (0.75&#x2013;1.55)</td><td align=\"center\">17</td><td align=\"center\">16</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Hip fracture<content styleCode=\"bold\"><sup>c</sup></content></td><td align=\"center\">0.65 (0.45&#x2013;0.94)</td><td align=\"center\">12</td><td align=\"center\">19</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Vertebral fractures<content styleCode=\"bold\"><sup>c,d</sup></content></td><td align=\"center\">0.64 (0.44&#x2013;0.93)</td><td align=\"center\">11</td><td align=\"center\">18</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Lower arm/wrist fractures<content styleCode=\"bold\"><sup>c,d</sup></content></td><td align=\"center\">0.58 (0.47&#x2013;0.72)</td><td align=\"center\">35</td><td align=\"center\">59</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Total fractures<content styleCode=\"bold\"><sup>c,d</sup></content></td><td align=\"center\">0.71 (0.64&#x2013;0.80)</td><td align=\"center\">144</td><td align=\"center\">197</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Death due to other causes<content styleCode=\"bold\"><sup>e,f</sup></content></td><td align=\"center\">1.08 (0.88&#x2013;1.32)</td><td align=\"center\">53</td><td align=\"center\">50</td></tr><tr styleCode=\"Norule\"><td align=\"left\">Overall mortality<content styleCode=\"bold\"><sup>c,d</sup></content></td><td align=\"center\">1.04 (0.88&#x2013;1.22)</td><td align=\"center\">79</td><td align=\"center\">75</td></tr><tr styleCode=\"Botrule Last\"><td align=\"left\">Global Index<content styleCode=\"bold\"><sup>g</sup></content></td><td align=\"center\">1.02 (0.92&#x2013;1.13)</td><td align=\"center\">206</td><td align=\"center\">201</td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure."
    ],
    "contraindications": [
      "CONTRAINDICATIONS CombiPatch is contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding. Known, suspected, or history of breast cancer. Known or suspected estrogen-dependent neoplasia. Active DVT, PE, or history of these conditions. Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions. Known anaphylactic reaction or angioedema or hypersensitivity with CombiPatch. Known liver impairment or disease. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders. Known or suspected pregnancy."
    ],
    "warnings": [
      "WARNINGS See BOXED WARNING . 1. Cardiovascular Disorders An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. An increased risk of stroke and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately. Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. Stroke In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years). (See CLINICAL STUDIES ) The increase in risk was demonstrated after the first year and persisted. 1 Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). (See CLINICAL STUDIES ) The increase in risk was demonstrated in year 1 and persisted. Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately. Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 b. Coronary Heart Disease In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events (defined as nonfatal MI, silent MI, or CHD death) reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women years). 1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 (See CLINICAL STUDIES ). In the WHI estrogen-alone substudy, no overall effect on CHD events was reported in women receiving estrogen-alone compared to placebo. 2 (See CLINICAL STUDIES ) Subgroup analyses of women 50 to 59 years of age suggest a statistically nonsignificant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women less than 10 years since menopause (8 versus 16 per 10,000 women-years). 1 In postmenopausal women with documented heart disease (n=2,763, average 66.7 years of age), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred twenty-one (2,321) women from the original HERS trial agreed to participate in an open-label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in the HERS, the HERS II, and overall. c. Venous Thromboembolism In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE (DVT and PE) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted. 3 (See CLINICAL STUDIES ) Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. In the WHI estrogen-alone substudy, the risk of VTE was reported to be increased for women receiving daily CE (0.625 mg)-alone compared to women receiving placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women years). The increase in VTE risk was demonstrated during the first 2 years. 4 (See CLINICAL STUDIES ) Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately. If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. 2. Malignant Neoplasms a. Breast Cancer The WHI substudy of daily CE (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80) 5 [see CLINICAL STUDIES ]. After a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA compared to placebo. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups [see CLINICAL STUDIES ]. Consistent with the WHI clinical trial, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to >10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. b. Endometrial Cancer An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among users of unopposed estrogen is about 2 to 12 times greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with the use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use with increased risks of 15- to 24-fold for 5 to 10 years or more and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. c. Ovarian Cancer The WHI estrogen plus progestin substudy reported a statistically nonsignificant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI 0.77 to 3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. 7 A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years]vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. 3. Probable Dementia In the WHIMS estrogen plus progestin ancillary substudy of WHI, a population of 4,532 generally healthy postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21 to 3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. 8 (See CLINICAL STUDIES and PRECAUTIONS , Geriatric Use ) In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83 to 2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. 8 (See CLINICAL STUDIES and PRECAUTIONS , Geriatric Use ) When data from the 2 populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19 to 2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women. 8 (See PRECAUTIONS , Geriatric Use ) 4. Gallbladder Disease A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. 5. Hypercalcemia Estrogen administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level. 6. Visual Abnormalities Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued. 7. Angioedema Angioedema involving eye/eyelid, face, larynx, pharynx, tongue and extremity (hands, legs, ankles, and fingers) with or without urticaria requiring medical intervention has occurred in the postmarketing experience of using CombiPatch. If angioedema involves the tongue, glottis, or larynx, airway obstruction may occur. Women who develop angioedema anytime during the course of treatment with CombiPatch should not receive it again. Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. 8. Severe Anaphylactic/Anaphylactoid Reactions Cases of anaphylactic/anaphylactoid reactions, which developed anytime during the course of CombiPatch treatment and required emergency medical management, have been reported in the postmarketing setting. Involvement of skin (hives, pruritus, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) has been noted."
    ],
    "precautions": [
      "PRECAUTIONS A. General 1. Addition of a Progestin when a Woman has not had a Hysterectomy Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. 2. Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen. 3. Hypertriglyceridemia In women with preexisting hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Consider discontinuation of treatment if pancreatitis occurs. 4. Hepatic Impairment and/or Past History of Cholestatic Jaundice Although transdermally administered estrogen therapy avoids first-pass hepatic metabolism, estrogens may be poorly metabolized in women with impaired liver function. For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued. 5. Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T 4 and T 3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range. 6. Fluid Retention Estrogens plus progestins may cause some degree of fluid retention. Women with conditions which might be influenced by this factor, such as cardiac or renal impairment warrant careful observation when estrogens plus progestins are prescribed. 7. Hypocalcemia Estrogen therapy should be used with caution in women with hypoparathyroidism as estrogen-induced hypocalcemia may occur. 8. Exacerbation of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual endometriosis post-hysterectomy, the addition of progestin should be considered. 9. Exacerbation of Other Conditions Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine or porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions. B. Patient Information Physicians are advised to discuss the content of the PATIENT INFORMATION leaflet and INSTRUCTIONS FOR USE with patients for whom they prescribe CombiPatch. C. Laboratory Tests Serum FSH and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy. Laboratory parameters may be useful in guiding dosage for the treatment of hypoestrogenism due to hypogonadism, castration and primary ovarian failure. D. Drug-Laboratory Test Interactions 1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex; and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III; decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. 2. Increased TBG leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. 3. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin [CBG], SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). 4. Increased plasma high density lipoprotein (HDL) and HDL-2 subfraction concentrations, reduced low density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels. 5. Impaired glucose tolerance. E. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver. NETA was not mutagenic in a battery of in vitro or in vivo genetic toxicity assays. F. Pregnancy CombiPatch should not be used during pregnancy. (See CONTRAINDICATIONS .) There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. G. Nursing Mothers CombiPatch should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogens and progestins have been identified in the breast milk of women receiving these drugs. Caution should be exercised when CombiPatch is administered to a nursing woman. H. Pediatric Use CombiPatch is not indicated in children. Clinical studies have not been conducted in the pediatric population. I. Geriatric Use There have not been sufficient numbers of geriatric women involved in studies utilizing CombiPatch to determine whether those over 65 years of age differ from younger subjects in their response to CombiPatch. The Women\u2019s Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age. (See CLINICAL STUDIES . ) In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age. (See CLINICAL STUDIES . ) The Women\u2019s Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. (See CLINICAL STUDIES and WARNINGS , Probable Dementia . ) Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS , Probable Dementia . )"
    ],
    "information_for_patients": [
      "B. Patient Information Physicians are advised to discuss the content of the PATIENT INFORMATION leaflet and INSTRUCTIONS FOR USE with patients for whom they prescribe CombiPatch.",
      "Patient Information CombiPatch (k\u00e4m-b\u0113 `pach) (estradiol/norethindrone acetate transdermal system) Read this Patient Information before you start using CombiPatch and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. What is the most important information I should know about CombiPatch (a combination of estrogen and progestin hormones)? Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes, or dementia (decline of brain function). Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots. Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older. Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia. Using estrogen-alone may increase your chances of getting cancer of the uterus (womb). Using estrogen-alone may increase your chance of getting stroke or blood clots. Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older. You and your healthcare provider should talk regularly about whether you still need treatment with CombiPatch. What is CombiPatch? CombiPatch is a prescription medicine patch (Transdermal System) that contains 2 kinds of hormones, estrogen and progestin. What is CombiPatch used for? CombiPatch is used after menopause to: Reduce moderate to severe hot flashes Estrogens are hormones made by a woman\u2019s ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the \u201cchange of life\u201d or menopause (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes \u201csurgical menopause.\u201d When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest or sudden strong feelings of heat and sweating (\u201chot flashes\u201d or \u201chot flushes\u201d). In some women, the symptoms are mild, and they will not need to use estrogens. In other women, symptoms can be more severe. Treat moderate to severe menopausal changes in and around your vagina You and your healthcare provider should talk regularly about whether you still need treatment with CombiPatch to control these problems. If you use CombiPatch only to treat menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you. Treat certain conditions in women before menopause if their ovaries do not make enough estrogens naturally. You and your healthcare provider should talk regularly about whether you still need treatment with CombiPatch. Who should not use CombiPatch? Do not use CombiPatch if you have had your uterus (womb) removed (hysterectomy). CombiPatch contains a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not use CombiPatch. Do not start using CombiPatch if you: have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. currently have or have had certain cancers Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your health care provider about whether you should use CombiPatch. had a stroke or heart attack currently have or have had blood clots currently have or have had liver problems have been diagnosed with a bleeding disorder are allergic to CombiPatch or any of its ingredients See the list of ingredients in CombiPatch at the end of this leaflet. think you may be pregnant CombiPatch is not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results. Do not use CombiPatch if the test result is positive and talk to your healthcare provider. What should I tell my healthcare provider before I use CombiPatch? Before you use CombiPatch, tell your healthcare provider if you: have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. have any other medical conditions Your healthcare provider may need to check you more carefully if you have certain conditions such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop using CombiPatch. are breastfeeding The hormones in CombiPatch can pass into your breast milk. Tell your healthcare provider about all the medicines you take , including prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how CombiPatch works. CombiPatch may also affect how other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get new medicine. How should I use CombiPatch? For detailed instructions, see the step-by-step instructions for using CombiPatch at the end of this Patient Information. Use CombiPatch exactly as your healthcare provider tells you to use it. CombiPatch is for skin use only. Change your CombiPatch 2 times each week or every 3 to 4 days. Apply your CombiPatch to a clean, dry area on your lower abdomen. This area must be clean, dry, and free of powder, oil or lotion for your CombiPatch to stick to your skin. Apply your CombiPatch to a different area of your lower abdomen each time. Do not use the same application site 2 times in the same week. Do not apply CombiPatch to or near your breasts. If you forget to apply a new CombiPatch, you should apply a new CombiPatch as soon as possible. Once in place, the transdermal system should not be exposed to the sun for prolonged periods of time. You and your healthcare provider should talk regularly (every 3 to 6 months) about your dose and whether you still need treatment with CombiPatch. How do I change CombiPatch? When changing CombiPatch, slowly peel away the used CombiPatch from your skin. After you remove CombiPatch, you may have a small amount of stickiness (adhesive) left on your skin. If you have any adhesive left on your skin after you remove CombiPatch, allow the area to dry for 15 minutes. Gently rub the sticky area of your skin with oil or lotion to remove the adhesive. The new CombiPatch must be applied to a different area of your lower abdomen. This area must be clean, dry, cool and free of powder, oil or lotion. The same site should not be used again for at least 1 week after removal of CombiPatch. What are the possible side effects of CombiPatch? Side effects are grouped by how serious they are and how often they happen when you are treated. Serious, but less common side effects include: heart attack stroke blood clots dementia breast cancer cancer of the lining of the uterus (womb) cancer of the ovary high blood pressure high blood sugar gallbladder disease liver problems changes in your thyroid hormone levels enlargement of benign tumors of the uterus (\u201cfibroids\u201d) depression Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: new breast lumps unusual vaginal bleeding changes in vision or speech sudden new severe headaches severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Less serious, but common side effects include: headache breast pain irregular vaginal bleeding or spotting stomach or abdominal cramps, bloating nausea and vomiting hair loss fluid retention vaginal yeast infection redness or irritation at patch placement site These are not all the possible side effects of CombiPatch. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or does not go away. You may report side effects to Noven at 1-800-455-8070 or to FDA at 1-800-FDA-1088. What can I do to lower my chances of getting a serious side effect with CombiPatch? Talk with your healthcare provider regularly about whether you should continue using CombiPatch. See your healthcare provider right away if you get vaginal bleeding while using CombiPatch. Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances for getting heart disease. How should I store and throw away used CombiPatch? Store CombiPatch in the refrigerator at 36\u2109 to 46\u2109 (2\u2103 to 8\u2103). Allow patch to reach room temperature before application. Do not store CombiPatch outside of its pouch. Used patches still contain estrogen and progestin. To throw away the patch, fold the sticky side of the patch together, place in a sturdy child-proof container, and place this container in the trash. Used patches should not be flushed in the toilet. Keep CombiPatch and all medicines out of the reach of children. General information about the safe and effective use of CombiPatch. Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use CombiPatch for conditions for which it was not prescribed. Do not give CombiPatch to other people, even if they have the same symptoms you have. It may harm them. This leaflet provides a summary of the most important information about CombiPatch. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about CombiPatch that is written for health professionals. You can get more information by calling 1-800-455-8070 What are the ingredients in CombiPatch? Active Ingredients: estradiol and norethindrone acetate Inactive Ingredients: acrylic adhesive, silicone adhesive, oleic acid NF, povidone USP, dipropylene glycol, polyester release protective liner 102538-5"
    ],
    "drug_and_or_laboratory_test_interactions": [
      "D. Drug-Laboratory Test Interactions 1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex; and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III; decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. 2. Increased TBG leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. 3. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin [CBG], SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). 4. Increased plasma high density lipoprotein (HDL) and HDL-2 subfraction concentrations, reduced low density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels. 5. Impaired glucose tolerance."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "E. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver. NETA was not mutagenic in a battery of in vitro or in vivo genetic toxicity assays."
    ],
    "pregnancy": [
      "F. Pregnancy CombiPatch should not be used during pregnancy. (See CONTRAINDICATIONS .) There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy."
    ],
    "nursing_mothers": [
      "G. Nursing Mothers CombiPatch should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogens and progestins have been identified in the breast milk of women receiving these drugs. Caution should be exercised when CombiPatch is administered to a nursing woman."
    ],
    "pediatric_use": [
      "H. Pediatric Use CombiPatch is not indicated in children. Clinical studies have not been conducted in the pediatric population."
    ],
    "geriatric_use": [
      "I. Geriatric Use There have not been sufficient numbers of geriatric women involved in studies utilizing CombiPatch to determine whether those over 65 years of age differ from younger subjects in their response to CombiPatch. The Women\u2019s Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age. (See CLINICAL STUDIES . ) In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age. (See CLINICAL STUDIES . ) The Women\u2019s Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. (See CLINICAL STUDIES and WARNINGS , Probable Dementia . ) Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS , Probable Dementia . )"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See BOXED WARNING , WARNINGS , and PRECAUTIONS . Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Table 9. All Adverse Reactions Regardless of Relationship Reported at a Frequency of Greater than or Equal to 5 percent with CombiPatch VASOMOTOR SYMPTOM STUDIES CombiPatch 0.05/0.14 mg per day\u2020 CombiPatch 0.05/0.25 mg per day\u2020 Placebo n=113 n=112 n=107 Body as a Whole 46% 48% 41% Abdominal Pain 7% 6% 4% Accidental Injury 4% 5% 8% Asthenia 8% 12% 4% Back Pain 11% 9% 5% Flu Syndrome 9% 5% 7% Headache 18% 20% 20% Pain 6% 4% 9% Digestive 19% 23% 24% Diarrhea 4% 5% 7% Dyspepsia 1% 5% 5% Flatulence 4% 5% 4% Nausea 11% 8% 7% Nervous 16% 28% 28% Depression 3% 5% 9% Insomnia 3% 6% 7% Nervousness 3% 5% 1% Respiratory 24% 38% 26% Pharyngitis 4% 10% 2% Respiratory Disorder 7% 12% 7% Rhinitis 7% 13% 9% Sinusitis 4% 9% 9% Skin and Appendages 8% 17% 16% Application Site Reaction* 2% 6% 4% Urogenital 54% 63% 28% Breast Pain 25% 31% 7% Dysmenorrhea 20% 21% 5% Leukorrhea 5% 5% 3% Menstrual Disorder 6% 12% 2% Papanicolaou Smear Suspicious 8% 4% 5% Vaginitis 6% 13% 5% \u2020Represents milligrams of estradiol/NETA delivered daily by each system. *Application site reactions includes localized bleeding, bruising, burning, discomfort, dryness, eczema, edema, erythema, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, skin discoloration, skin pigmentation, swelling, urticaria, and vesicles. Table 10. All Adverse Reactions Regardless of Relationship Reported at a Frequency of Greater than or Equal to 5 percent with CombiPatch ENDOMETRIAL HYPERPLASIA STUDIES CombiPatch 0.05/0.14 mg per day\u2020 n=325 CombiPatch 0.05/0.25 mg per day\u2020 n=312 Vivelle 0.05 mg per day n=318 Body as a Whole 61% 60% 59% Abdominal Pain 12% 14% 16% Accidental Injury 10% 11% 8% Asthenia 10% 13% 11% Back Pain 15% 14% 13% Flu Syndrome 14% 10% 7% Headache 25% 17% 21% Infection 5% 3% 3% Pain 19% 15% 13% Digestive 42% 32% 31% Constipation 2% 5% 3% Diarrhea 14% 9% 7% Dyspepsia 8% 6% 5% Flatulence 7% 5% 6% Nausea 8% 12% 11% Tooth Disorder 6% 4% 1% Metabolic and Nutritional Disorders 12% 13% 11% Peripheral Edema 6% 6% 5% Musculoskeletal 17% 17% 15% Arthralgia 6% 6% 5% Nervous 33% 30% 28% Depression 8% 9% 8% Dizziness 6% 7% 5% Insomnia 8% 6% 4% Nervousness 5% 6% 3% Respiratory 45% 43% 40% Bronchitis 5% 3% 4% Pharyngitis 9% 9% 8% Respiratory Disorder 13% 9% 13% Rhinitis 19% 22% 17% Sinusitis 10% 12% 12% Skin and Appendages 38% 37% 31% Acne 4% 5% 4% Application Site Reaction* 20% 23% 17% Rash 6% 5% 3% Urogenital 71% 79% 74% Breast Enlargement 2% 7% 2% Breast Pain 34% 48% 40% Dysmenorrhea 30% 31% 19% Leukorrhea 10% 8% 9% Menorrhagia 2% 5% 9% Menstrual Disorder 17% 19% 14% Vaginal Hemorrhage 3% 6% 12% Vaginitis 9% 13% 13% \u2020Represents milligrams of estradiol/NETA delivered daily by each system. *Application site reactions includes localized bleeding, bruising, burning, discomfort, dryness, eczema, edema, erythema, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, skin discoloration, skin pigmentation, swelling, urticaria, and vesicles. Postmarketing Experience The following additional adverse reactions have been identified during post-approval use of CombiPatch. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System Endometrial hyperplasia, endocervical polyp, uterine leiomyomata, fallopian tube cyst, uterine spasms. Breast Breast cancer. Cardiovascular Hypertension, varicose veins. Gastrointestinal Jaundice cholestatic, cholelithiasis, gall bladder disorder, transaminases increased. Skin Skin discoloration. Central Nervous System Affect lability, libido disorder, migraine, vertigo, paresthesia. Miscellaneous Angioedema, hypersensitivity, weight increased."
    ],
    "adverse_reactions_table": [
      "<table width=\"750\" ID=\"table9\" styleCode=\"Noautorules\"><caption>Table 9. All Adverse Reactions Regardless of Relationship Reported at a Frequency of Greater than or Equal to 5 percent with CombiPatch</caption><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Toprule\"/><td colspan=\"2\" align=\"center\" styleCode=\"Toprule underline bold\">VASOMOTOR SYMPTOM STUDIES</td><td styleCode=\"Toprule\"/></tr><tr><td/><td align=\"center\" styleCode=\"bold\"><content styleCode=\"underline\">CombiPatch</content> 0.05/0.14  mg per day&#x2020; </td><td align=\"center\" styleCode=\"bold\"><content styleCode=\"underline\">CombiPatch</content> 0.05/0.25  mg per day&#x2020; </td><td align=\"center\" styleCode=\"bold\" valign=\"top\"><content styleCode=\"underline\">Placebo</content></td></tr><tr><td align=\"center\" styleCode=\"bold\"/><td align=\"center\" styleCode=\"bold\">n=113</td><td align=\"center\" styleCode=\"bold\">n=112</td><td align=\"center\" styleCode=\"bold\">n=107</td></tr><tr styleCode=\"Toprule\"><td align=\"left\" styleCode=\"Toprule italics\">Body as a Whole</td><td align=\"center\" styleCode=\"Toprule\">46%</td><td align=\"center\" styleCode=\"Toprule\">48%</td><td align=\"center\" styleCode=\"Toprule\">41%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Abdominal Pain</td><td align=\"center\">7%</td><td align=\"center\">6%</td><td align=\"center\">4%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Accidental Injury</td><td align=\"center\">4%</td><td align=\"center\">5%</td><td align=\"center\">8%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Asthenia</td><td align=\"center\">8%</td><td align=\"center\">12%</td><td align=\"center\">4%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Back Pain</td><td align=\"center\">11%</td><td align=\"center\">9%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Flu Syndrome</td><td align=\"center\">9%</td><td align=\"center\">5%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Headache</td><td align=\"center\">18%</td><td align=\"center\">20%</td><td align=\"center\">20%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Pain</td><td align=\"center\">6%</td><td align=\"center\">4%</td><td align=\"center\">9%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Digestive</td><td align=\"center\">19%</td><td align=\"center\">23%</td><td align=\"center\">24%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Diarrhea</td><td align=\"center\">4%</td><td align=\"center\">5%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Dyspepsia</td><td align=\"center\">1%</td><td align=\"center\">5%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Flatulence</td><td align=\"center\">4%</td><td align=\"center\">5%</td><td align=\"center\">4%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Nausea</td><td align=\"center\">11%</td><td align=\"center\">8%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Nervous</td><td align=\"center\">16%</td><td align=\"center\">28%</td><td align=\"center\">28%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Depression</td><td align=\"center\">3%</td><td align=\"center\">5%</td><td align=\"center\">9%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Insomnia</td><td align=\"center\">3%</td><td align=\"center\">6%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Nervousness</td><td align=\"center\">3%</td><td align=\"center\">5%</td><td align=\"center\">1%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Respiratory</td><td align=\"center\">24%</td><td align=\"center\">38%</td><td align=\"center\">26%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Pharyngitis</td><td align=\"center\">4%</td><td align=\"center\">10%</td><td align=\"center\">2%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Respiratory Disorder</td><td align=\"center\">7%</td><td align=\"center\">12%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Rhinitis</td><td align=\"center\">7%</td><td align=\"center\">13%</td><td align=\"center\">9%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Sinusitis</td><td align=\"center\">4%</td><td align=\"center\">9%</td><td align=\"center\">9%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Skin and Appendages</td><td align=\"center\">8%</td><td align=\"center\">17%</td><td align=\"center\">16%</td></tr><tr styleCode=\"Norule\"><td colspan=\"1\" align=\"left\"> Application Site Reaction*</td><td align=\"center\">2%</td><td align=\"center\">6%</td><td align=\"center\">4%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Urogenital</td><td align=\"center\">54%</td><td align=\"center\">63%</td><td align=\"center\">28%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Breast Pain</td><td align=\"center\">25%</td><td align=\"center\">31%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Dysmenorrhea</td><td align=\"center\">20%</td><td align=\"center\">21%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Leukorrhea</td><td align=\"center\">5%</td><td align=\"center\">5%</td><td align=\"center\">3%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Menstrual Disorder</td><td align=\"center\">6%</td><td align=\"center\">12%</td><td align=\"center\">2%</td></tr><tr styleCode=\"Norule\"><td colspan=\"1\" align=\"left\"> Papanicolaou Smear Suspicious</td><td align=\"center\">8%</td><td align=\"center\">4%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Botrule\"><td align=\"left\"> Vaginitis</td><td align=\"center\">6%</td><td align=\"center\">13%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td colspan=\"4\" align=\"left\">&#x2020;Represents milligrams of estradiol/NETA delivered daily by each system.</td></tr><tr styleCode=\"Norule\"><td colspan=\"4\" align=\"left\">*Application site reactions includes localized bleeding, bruising, burning, discomfort, dryness, eczema, edema, erythema, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, skin discoloration, skin pigmentation, swelling, urticaria, and vesicles.</td></tr></tbody></table>",
      "<table width=\"750\" ID=\"table10\" styleCode=\"Noautorules\"><caption>Table 10. All Adverse Reactions Regardless of Relationship Reported at a Frequency of Greater than or Equal to 5 percent with CombiPatch</caption><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Toprule\"/><td colspan=\"2\" align=\"center\" styleCode=\"Toprule underline bold\">ENDOMETRIAL HYPERPLASIA STUDIES</td><td styleCode=\"Toprule\"/></tr><tr><td/><td align=\"center\" styleCode=\"bold\"><content styleCode=\"underline\">CombiPatch</content> 0.05/0.14  mg per day&#x2020;  n=325 </td><td align=\"center\" styleCode=\"bold\"><content styleCode=\"underline\">CombiPatch</content> 0.05/0.25  mg per day&#x2020;  n=312 </td><td align=\"center\" styleCode=\"bold\"><content styleCode=\"underline\">Vivelle</content> 0.05  mg per day  n=318 </td></tr><tr styleCode=\"Toprule\"><td align=\"left\" styleCode=\"Toprule italics\">Body as a Whole</td><td align=\"center\" styleCode=\"Toprule\">61%</td><td align=\"center\" styleCode=\"Toprule\">60%</td><td align=\"center\" styleCode=\"Toprule\">59%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Abdominal Pain</td><td align=\"center\">12%</td><td align=\"center\">14%</td><td align=\"center\">16%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Accidental Injury</td><td align=\"center\">10%</td><td align=\"center\">11%</td><td align=\"center\">8%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Asthenia</td><td align=\"center\">10%</td><td align=\"center\">13%</td><td align=\"center\">11%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Back Pain</td><td align=\"center\">15%</td><td align=\"center\">14%</td><td align=\"center\">13%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Flu Syndrome</td><td align=\"center\">14%</td><td align=\"center\">10%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Headache</td><td align=\"center\">25%</td><td align=\"center\">17%</td><td align=\"center\">21%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Infection </td><td align=\"center\">5%</td><td align=\"center\">3%</td><td align=\"center\">3%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Pain</td><td align=\"center\">19%</td><td align=\"center\">15%</td><td align=\"center\">13%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Digestive</td><td align=\"center\">42%</td><td align=\"center\">32%</td><td align=\"center\">31%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Constipation</td><td align=\"center\">2%</td><td align=\"center\">5%</td><td align=\"center\">3%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Diarrhea</td><td align=\"center\">14%</td><td align=\"center\">9%</td><td align=\"center\">7%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Dyspepsia</td><td align=\"center\">8%</td><td align=\"center\">6%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Flatulence</td><td align=\"center\">7%</td><td align=\"center\">5%</td><td align=\"center\">6%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Nausea</td><td align=\"center\">8%</td><td align=\"center\">12%</td><td align=\"center\">11%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Tooth Disorder</td><td align=\"center\">6%</td><td align=\"center\">4%</td><td align=\"center\">1%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Metabolic and Nutritional Disorders</td><td align=\"center\">12%</td><td align=\"center\">13%</td><td align=\"center\">11%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Peripheral Edema</td><td align=\"center\">6%</td><td align=\"center\">6%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Musculoskeletal</td><td align=\"center\">17%</td><td align=\"center\">17%</td><td align=\"center\">15%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Arthralgia</td><td align=\"center\">6%</td><td align=\"center\">6%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Nervous</td><td align=\"center\">33%</td><td align=\"center\">30%</td><td align=\"center\">28%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Depression</td><td align=\"center\">8%</td><td align=\"center\">9%</td><td align=\"center\">8%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Dizziness</td><td align=\"center\">6%</td><td align=\"center\">7%</td><td align=\"center\">5%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Insomnia</td><td align=\"center\">8%</td><td align=\"center\">6%</td><td align=\"center\">4%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Nervousness</td><td align=\"center\">5%</td><td align=\"center\">6%</td><td align=\"center\">3%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Respiratory</td><td align=\"center\">45%</td><td align=\"center\">43%</td><td align=\"center\">40%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Bronchitis</td><td align=\"center\">5%</td><td align=\"center\">3%</td><td align=\"center\">4%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Pharyngitis</td><td align=\"center\">9%</td><td align=\"center\">9%</td><td align=\"center\">8%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Respiratory Disorder</td><td align=\"center\">13%</td><td align=\"center\">9%</td><td align=\"center\">13%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Rhinitis</td><td align=\"center\">19%</td><td align=\"center\">22%</td><td align=\"center\">17%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Sinusitis</td><td align=\"center\">10%</td><td align=\"center\">12%</td><td align=\"center\">12%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Skin and Appendages</td><td align=\"center\">38%</td><td align=\"center\">37%</td><td align=\"center\">31%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Acne</td><td align=\"center\">4%</td><td align=\"center\">5%</td><td align=\"center\">4%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Application Site Reaction*</td><td align=\"center\">20%</td><td align=\"center\">23%</td><td align=\"center\">17%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Rash</td><td align=\"center\">6%</td><td align=\"center\">5%</td><td align=\"center\">3%</td></tr><tr styleCode=\"Norule\"><td align=\"left\" styleCode=\"italics\">Urogenital</td><td align=\"center\">71%</td><td align=\"center\">79%</td><td align=\"center\">74%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Breast Enlargement</td><td align=\"center\">2%</td><td align=\"center\">7%</td><td align=\"center\">2%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Breast Pain</td><td align=\"center\">34%</td><td align=\"center\">48%</td><td align=\"center\">40%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Dysmenorrhea</td><td align=\"center\">30%</td><td align=\"center\">31%</td><td align=\"center\">19%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Leukorrhea</td><td align=\"center\">10%</td><td align=\"center\">8%</td><td align=\"center\">9%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Menorrhagia</td><td align=\"center\">2%</td><td align=\"center\">5%</td><td align=\"center\">9%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Menstrual Disorder</td><td align=\"center\">17%</td><td align=\"center\">19%</td><td align=\"center\">14%</td></tr><tr styleCode=\"Norule\"><td align=\"left\"> Vaginal Hemorrhage</td><td align=\"center\">3%</td><td align=\"center\">6%</td><td align=\"center\">12%</td></tr><tr styleCode=\"Botrule\"><td align=\"left\"> Vaginitis</td><td align=\"center\">9%</td><td align=\"center\">13%</td><td align=\"center\">13%</td></tr><tr styleCode=\"Norule\"><td colspan=\"4\" align=\"left\">&#x2020;Represents milligrams of estradiol/NETA delivered daily by each system.</td></tr><tr styleCode=\"Norule\"><td colspan=\"4\" align=\"left\">*Application site reactions includes localized bleeding, bruising, burning, discomfort, dryness, eczema, edema, erythema, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, skin discoloration, skin pigmentation, swelling, urticaria, and vesicles.</td></tr></tbody></table>"
    ],
    "overdosage": [
      "OVERDOSAGE Overdosage of estrogen or estrogen plus progestin may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of CombiPatch therapy with institution of appropriate symptomatic care."
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Generally, when estrogen therapy is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer. A woman without a uterus generally does not need a progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin. Use of estrogen-alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine whether treatment is still necessary. Adequate diagnostic measures, such as directed or random endometrial sampling, when indicated, should be undertaken to rule out malignancy in a postmenopausal woman with a uterus with undiagnosed persistent or recurring abnormal genital bleeding. Initiation of Therapy Patients should be started at the lowest dose. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. The lowest effective dose of CombiPatch has not been determined in clinical trials. Women not currently using continuous estrogen or combination estrogen plus progestin therapy may start therapy with CombiPatch at any time. However, women currently using continuous estrogen or combination estrogen plus progestin therapy should complete the current cycle of therapy, before initiating CombiPatch therapy. Women often experience withdrawal bleeding at the completion of the cycle. The first day of this bleeding would be an appropriate time to begin CombiPatch therapy. Therapeutic Regimens Combination estrogen plus progestin regimens are indicated for women with an intact uterus. Two CombiPatch (estradiol/NETA) transdermal delivery systems are available: 0.05 mg estradiol with 0.14 mg NETA per day (9 cm 2 ) and 0.05 mg estradiol with 0.25 mg NETA per day (16 cm 2 ). The lowest effective dose should be used. For all regimens, women should be reevaluated at 3- to 6-month intervals to determine if changes in hormone therapy or if continued hormone therapy is appropriate. Continuous Combined Regimen CombiPatch 0.05 mg estradiol/0.14 mg NETA per day (9 cm 2 ) matrix transdermal system is used for continuous uninterrupted treatment applied twice weekly on the lower abdomen. A new system should be applied to the skin every 3 to 4 days (twice weekly) during a 28-day cycle. Additionally, a dose of 0.05 mg estradiol/0.25 mg NETA (16 cm 2 system) is available if a greater progestin dose is desired. Irregular bleeding may occur particularly in the first six months, but generally decreases with time, and often to an amenorrheic state. Continuous Sequential Regimen CombiPatch can be applied as a sequential regimen in combination with an estradiol-only transdermal delivery system. In this treatment regimen, a 0.05 mg per day (nominal delivery rate) estradiol transdermal system (Vivelle-Dot \u00ae ) is worn for the first 14 days of a 28-day cycle, replacing the system every 3 to 4 days (twice weekly) according to product directions. For the remaining 14 days of the 28-day cycle, CombiPatch 0.05 mg estradiol/0.14 mg NETA per day (9 cm 2 ) transdermal system should be worn continuously on the lower abdomen. The CombiPatch system should be replaced every 3 to 4 days (twice weekly) during this 14-day period in the 28-day cycle. Additionally, a dose of 0.05 mg estradiol/0.25 mg NETA (16 cm 2 system) is available if a greater progestin dose is desired. Women should be advised that monthly withdrawal bleeding often occurs. Application of the System Site Selection CombiPatch should be placed on a smooth (fold-free), clean, dry area of the skin on the lower abdomen. CombiPatch should not be applied to or near the breasts. The area selected should not be oily (which can impair adherence of the system), damaged, or irritated. The waistline should be avoided, since tight clothing may rub the system off or modify drug delivery. The sites of application must be rotated, with an interval of at least one week allowed between applications to the same site. Application After opening the pouch, remove 1 side of the protective liner, taking care not to touch the adhesive part of the transdermal delivery system with the fingers. Immediately apply the transdermal delivery system to a smooth (fold-free) area of skin on the lower abdomen. Remove the second side of the protective liner and press the system firmly in place with the hand for at least 10 seconds, making sure there is good contact, especially around the edges. Care should be taken that the system does not become dislodged during bathing and other activities. If a system should fall off, the same system may be reapplied to another area of the lower abdomen. If necessary, a new transdermal system may be applied, in which case, the original treatment schedule should be continued. Only 1 system should be worn at any 1 time during the 3- to 4-day dosing interval. Once in place, the transdermal system should not be exposed to the sun for prolonged periods of time. Removal of the System Removal of the system should be done carefully and slowly to avoid irritation of the skin. Should any adhesive remain on the skin after removal of the system, allow the area to dry for 15 minutes. Then gently rub the area with an oil-based cream or lotion to remove the adhesive residue."
    ],
    "how_supplied": [
      "HOW SUPPLIED CombiPatch estradiol/NETA transdermal delivery system is available in: System Nominal Delivery Rate * Size Estradiol/NETA Presentation NDC Markings 9 cm 2 0.05/0.14 mg per day 8 systems per carton 68968-0514-8 CombiPatch 0.05/0.14 mg per day 16 cm 2 0.05/0.25 mg per day 8 systems per carton 68968-0525-8 CombiPatch 0.05/0.25 mg per day * Nominal delivery rate described. See DESCRIPTION for more details regarding drug delivery. Storage Conditions Store CombiPatch in the refrigerator at 36\u2109 to 46\u2109 (2\u2103 to 8\u2103). Store the systems in the sealed foil pouch. Do not store the system in areas where extreme temperatures can occur. Keep this and all medicines out of the reach of children. Vivelle\u00ae is a registered trademark of Novartis Corporation. & Vivelle-Dot \u00ae is a registered trademark of Novartis AG."
    ],
    "how_supplied_table": [
      "<table width=\"750\" styleCode=\"Noautorules\"><col width=\"15%\"/><col width=\"25%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><tbody><tr valign=\"top\"><td align=\"left\" styleCode=\"bold Toprule\">System</td><td colspan=\"4\" align=\"left\" styleCode=\"bold Toprule\">Nominal Delivery Rate <sup>*</sup></td></tr><tr valign=\"top\"><td align=\"left\" styleCode=\"bold underline\">Size</td><td align=\"left\" styleCode=\"bold underline\">Estradiol/NETA</td><td align=\"left\" styleCode=\"bold underline\">Presentation</td><td align=\"left\" styleCode=\"bold underline\">NDC</td><td align=\"left\" styleCode=\"bold underline\">Markings</td></tr><tr styleCode=\"Norule\" valign=\"top\"><td styleCode=\"Botrule\" align=\"left\">9 cm <sup>2</sup></td><td styleCode=\"Botrule\" align=\"left\">0.05/0.14 mg per day</td><td styleCode=\"Botrule\" align=\"left\">8 systems per carton</td><td styleCode=\"Botrule\" align=\"left\">68968-0514-8</td><td styleCode=\"Botrule\" align=\"left\">CombiPatch  0.05/0.14 mg per day </td></tr><tr valign=\"top\"><td styleCode=\"Botrule\" align=\"left\">16 cm <sup>2</sup></td><td styleCode=\"Botrule\" align=\"left\">0.05/0.25 mg per day</td><td styleCode=\"Botrule\" align=\"left\">8 systems per carton</td><td styleCode=\"Botrule\" align=\"left\">68968-0525-8 </td><td styleCode=\"Botrule\" align=\"left\">CombiPatch  0.05/0.25 mg per day </td></tr><tr styleCode=\"Toprule\"><td colspan=\"5\" align=\"left\"><sup>*</sup>Nominal delivery rate described. See <linkHtml href=\"#DESCRIPTION\">DESCRIPTION</linkHtml> for more details regarding drug delivery. </td></tr></tbody></table>"
    ],
    "references": [
      "REFERENCES Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA. 2007;297:1465-1477. Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365. Cushman M, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2004;292:1573-1580. Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med. 2006;166:772-780. Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA. 2003;289:3234-3253. Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA. 2006;295:1647-1657. Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. JAMA. 2003;290:1739-1748. Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA. 2004;291:2947-2958. Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. J Bone Miner Res. 2006;21:817-828. Hendrix SL, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434. CombiPatch \u00ae is a registered trademark of Noven Pharmaceuticals, Inc. Manufactured by: Noven Pharmaceuticals Inc. Miami, FL 33186 Distributed by: Noven Therapeutics, LLC Miami, FL 33186 \u00a9 2024 Noven Pharmaceuticals, Inc. For more information call 1-800-455-8070 or visit www.combipatch.com. 102538-5"
    ],
    "information_for_patients_table": [
      "<table width=\"800\"><tbody><tr styleCode=\"First Last\"><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about CombiPatch (a combination of estrogen and progestin hormones)?</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes, or dementia (decline of brain function).</item><item>Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.</item><item>Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.</item><item>Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia.</item><item>Using estrogen-alone may increase your chances of getting cancer of the uterus (womb).</item><item>Using estrogen-alone may increase your chance of getting stroke or blood clots.</item><item>Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.</item><item>You and your healthcare provider should talk regularly about whether you still need treatment with CombiPatch.</item></list></td></tr></tbody></table>"
    ],
    "instructions_for_use": [
      "Instructions for Use CombiPatch (k\u00e4m-b\u0113 `pach) (estradiol/norethindrone acetate transdermal system) Step 1. Pick the days you will change your CombiPatch. You will need to change your patch every 3 to 4 days (twice weekly). Step 2. Remove CombiPatch from the pouch. Tear open the protective pouch at the slit (do not use scissors) and remove the patch. See Figure A. The pouch should not be opened until you are ready to put the patch on. Step 3. Remove the adhesive liner. Peel off one side of the protective liner. See Figure B. Do not touch the sticky part of the patch with your fingers. See Figure B. Step 4. Placing the CombiPatch on your skin. Put the sticky side of the patch on the lower abdomen (below the panty line). See Figure C. Peel off the second side of the protective liner. See Figure C. Press the patch firmly in place with your hand for about 10 seconds. See Figure D. Note: Avoid the waistline, since clothing and belts may cause the CombiPatch to be rubbed off. Do not apply the CombiPatch to or near your breasts. Only apply the CombiPatch to skin that is clean, dry, and free of any powder, oil, or lotion. You should not apply the CombiPatch to injured, burned, or irritated skin, or areas with skin conditions (such as birth marks, tattoos, or that is very hairy). Step 5. Press the CombiPatch firmly onto your skin. Rub the edges of the CombiPatch with your fingers to make sure that it will stick to your skin. See Figure E. Note: Bathing, swimming, or showering will not affect the CombiPatch. Once in place, the patch should not be exposed to the sun for prolonged periods of time. If your CombiPatch falls off reapply it. If you cannot reapply the CombiPatch, apply a new CombiPatch to another area (See Figures C , D and E ) and continue to follow your original placement schedule. If you stop using your CombiPatch or forget to apply a new CombiPatch as scheduled you may have spotting, or bleeding, and your symptoms may come back. Step 6. Throwing away your used CombiPatch. When it is time to change your CombiPatch, remove the old CombiPatch before you apply a new one. To throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash. Used patches should not be flushed in the toilet. This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration. Manufactured by: Noven Pharmaceuticals Inc. Miami, FL 33186 Distributed by: Noven Therapeutics, LLC Miami, FL 33186 For more information call 1-800-455-8070 or visit www.combipatch.com. \u00a9 2024 Noven Pharmaceuticals, Inc. 102538-5 02/2024 Figure A Figure B Figure C,D Figure E"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - NDC - 68968-0514-8 CombiPatch Count - 50/140 NDC 68968-0514-8 Includes 8 Systems See New Storage Requirements Combipatch \u00ae 50/140 (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day Noven www.combipatch.com Twice-Weekly Rx Only Combipatch \u00ae 50/140 (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day Twice-Weekly Rx Only Contains 0.62 mg estradiol USP and 2.7 mg norethindrone acetate (NETA) USP to provide 0.05/0.14 mg of estradiol/NETA per day. Inactive components : a silicone and acrylic-based multi-polymeric adhesive, povidone USP, oleic acid NF, polyolefin laminate backing, polyester release liner and dipropylene glycol. Dosage and Administration: For transdermal use only. See package insert. Allow patch to reach room temperature before application. DO NOT STORE UNPOUCHED. Keep out of the reach of children. Store Combipatch \u00ae refrigerated at 36\u00b0F to 46\u00b0F (2\u00b0C to 8\u00b0C) See side panel for lot number and expiration date. www.combipatch.com N3 68968-0514-8 0 302391-4 Noven PLEASE READ THIS BEFORE APPLYING PATCH. Allow patch to reach room temperature before application. See reverse side for patient instructions. pull To open here LOT/EXP GTIN 00368968051480 969864 Mfd. By: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By Noven Therapeutics, LLC Miami, Florida 33186 Combi patch Count - 50/140",
      "PRINCIPAL DISPLAY PANEL - NDC - 68968-0525-8 CombiPatch Count - 50/250 NDC 68968-0525-8 Includes 8 Systems See New Storage Requirements Combipatch \u00ae 50/250 (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day Noven www.combipatch.com Twice-Weekly Rx Only Combipatch \u00ae 50/250 (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day Twice-Weekly Rx Only Contains 0.51 mg estradiol USP and 4.8 mg norethindrone acetate (NETA) USP to provide 0.05/0.25 mg of estradiol/NETA per day. Inactive components : a silicone and acrylic-based multi-polymeric adhesive, povidone USP, oleic acid NF, polyolefin laminate backing, polyester release liner and dipropylene glycol. Dosage and Administration: For transdermal use only. See package insert. Allow patch to reach room temperature before application. DO NOT STORE UNPOUCHED. Keep out of the reach of children. Store Combipatch \u00ae refrigerated at 36\u00b0F to 46\u00b0F (2\u00b0C to 8\u00b0C) See side panel for lot number and expiration date. www.combipatch.com N3 68968-0525-8 0 302390-4 Noven PLEASE READ THIS BEFORE APPLYING PATCH. Allow patch to reach room temperature before application. See reverse side for patient instructions. pull To open here LOT/EXP GTIN 00368968052586 969864 Mfd. By: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By Noven Therapeutics, LLC Miami, Florida 33186 Combi patch Count - 50/250"
    ],
    "set_id": "83198ef1-11c4-11e4-9191-0800200c9a66",
    "id": "a8dddb67-4c56-4d1d-a4ce-83dc426d33f6",
    "effective_time": "20240221",
    "version": "14",
    "openfda": {
      "application_number": [
        "NDA020870"
      ],
      "brand_name": [
        "CombiPatch (estradiol/norethindrone acetate transdermal system)"
      ],
      "generic_name": [
        "ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM"
      ],
      "manufacturer_name": [
        "Noven Therapeutics, LLC"
      ],
      "product_ndc": [
        "68968-0514",
        "68968-0525"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "TRANSDERMAL"
      ],
      "substance_name": [
        "ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1251493",
        "1251495",
        "1251499",
        "1251501"
      ],
      "spl_id": [
        "a8dddb67-4c56-4d1d-a4ce-83dc426d33f6"
      ],
      "spl_set_id": [
        "83198ef1-11c4-11e4-9191-0800200c9a66"
      ],
      "package_ndc": [
        "68968-0514-8",
        "68968-0525-8"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "M0447348",
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_cs": [
        "Estradiol Congeners [CS]"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "4TI98Z838E",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL norethindrone acetate and ethinyl estradiol ETHINYL ESTRADIOL ETHINYL ESTRADIOL NORETHINDRONE ACETATE NORETHINDRONE .ALPHA.-TOCOPHEROL, DL- ANHYDROUS LACTOSE CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K25 SODIUM LAURYL SULFATE SUCROSE white to off-white 239"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including norethindrone acetate and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS )."
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are a progestogen-estrogen combination. Each white to off-white tablet contains norethindrone acetate (19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1) ), 1 mg; ethinyl estradiol (19-Norpregna-1,3,5(10)-trien-20-yne-3, 17-diol, (17\u03b1)-) , 0.02 mg. Also contains lactose anhydrous, dl -\u03b1-tocopherol, compressible sugar, croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K-25, sodium lauryl sulphate. The structural formulas are as follows: Ethinyl Estradiol and Norethindrone Acetate Structural Formulas"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1-3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1-3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3). Special Population Race The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function. Drug-Drug Interactions Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions."
    ],
    "pharmacokinetics": [
      "Pharmacokinetics The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature. Absorption Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1-3). Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1-3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4). Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6). Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5, 6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3)."
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD Adapted from RA Hatcher et al, Reference 7. % Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use Method Lowest Expected The authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. Typical This term represents \"typical\" couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (No contraception) (85) (85) Oral contraceptives 3 Combined 0.1 N/A N/A - Data not available. progestin only 0.5 N/A Diaphragm with spermicidal cream or jelly 6 20 Spermicides alone (foam, creams, gels, vaginal suppositories and vaginal film) 6 26 Vaginal Sponge nulliparous 9 20 parous 20 40 Implant 0.05 0.05 Injection: depot medroxyprogesterone acetate 0.3 0.3 IUD progesterone T 1.5 2.0 copper T 380A 0.6 0.8 LNg 20 0.1 0.1 Condom without spermicides female 5 21 male 3 14 Cervical Cap with spermicidal cream or jelly nulliparous 9 20 parous 26 40 Periodic abstinence (all methods) 1-9 25 Withdrawal 4 19 Female sterilization 0.5 0.5 Male sterilization 0.10 0.15"
    ],
    "indications_and_usage_table": [
      "<table ID=\"_RefID21\" styleCode=\"Noautorules\" width=\"100%\"><caption>TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD</caption><col width=\"65%\"/><col width=\"22%\"/><col width=\"12%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Adapted from RA Hatcher et al, Reference 7.</td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">% Of Women Experiencing an Unintended Pregnancy</content> <content styleCode=\"bold\">in the First Year of Continuous Use</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Lowest Expected</content><footnote ID=\"_Ref126832944\">The authors&apos; best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Typical</content><footnote ID=\"_Ref126833075\">This term represents &quot;typical&quot; couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>(No contraception) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>(85)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>(85)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> Combined </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>N/A <footnote ID=\"_Ref126833083\">N/A - Data not available.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progestin only </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>N/A <footnoteRef IDREF=\"_Ref126833083\"/></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicidal cream or jelly </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone (foam, creams, gels, vaginal   suppositories and vaginal film) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>26 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Implant </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.05</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.05</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: depot medroxyprogesterone acetate </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> progesterone T </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>2.0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> copper T 380A </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> LNg 20 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom without spermicides</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> female </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>21</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> male </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>14</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Cervical Cap with spermicidal cream or jelly</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> nulliparous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph> parous </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>40</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Periodic abstinence (all methods) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1-9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>25</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Withdrawal </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>19</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Female sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Male sterilization </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>0.10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>0.15</paragraph></td></tr></tbody></table>"
    ],
    "contraindications": [
      "CONTRAINDICATIONS \u2022 Oral contraceptives are contraindicated in women who currently have the following conditions: \u2022 Thrombophlebitis or thromboembolic disorders \u2022 A past history of deep vein thrombophlebitis or thromboembolic disorders \u2022 Cerebral vascular or coronary artery disease \u2022 Current diagnosis of, or history of, breast cancer, which may be hormone sensitive \u2022 Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \u2022 Undiagnosed abnormal genital bleeding \u2022 Cholestatic jaundice of pregnancy or jaundice with prior pill use \u2022 Hepatic adenomas or carcinomas \u2022 Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT )."
    ],
    "warnings": [
      "WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author's permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial Infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10-16). The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases (17). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives. TABLE II: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity (19). In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism (20-24). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS ). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. TABLE II: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE b. Thromboembolism An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (9, 10, 25-30). Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8). A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives (15,32). The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions (15,32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. c. Cerebrovascular Disease Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (greater than 35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes (33-35). In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk is also greater in older women (9). d. Dose-related Risk of Vascular Disease from Oral Contraceptives A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (37-39). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (20-22). A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. e. Persistence of Risk of Vascular Disease There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40-49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (40). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens. 2. Estimates of Mortality from Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970's but not reported until 1983 (41). However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling. Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4; and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective. TABLE III ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15 -19 20-24 25-29 30-34 35-39 40-44 No fertility control methods 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non- smoker Deaths are birth related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom Deaths are method related. 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 Adapted from H.W. Ory, Reference 41. 3. Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ). Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS, Postmarketing Experience ). Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women (42-45). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. 4. Hepatic Neoplasia Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (46). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (47,48). Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (49- 51) in long-term (greater than 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users. 5. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see Contraindications (4) ). Norethindrone acetate and ethinyl estradiol tablets can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. Oral Contraceptive Use Before and During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy (52-54). Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned (52, 53, 55, 56), when taken inadvertently during early pregnancy. The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed. 8. Gallbladder Disease Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (57, 58). More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal (59-61). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance (62). Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (23, 63). However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (64). Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives. A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1a . and 1d .), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking oral contraceptives (65) and this increase is more likely in older oral contraceptive users (66) and with continued use (65). Data from the Royal College of General Practitioners (18) and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal disease (67) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (66), and there is no difference in the occurrence of hypertension among ever and never users (65,67,68). 11. Headache The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause. 12. Bleeding Irregularities Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Nonhormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. 13. Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 14. Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets if depression recurs to a serious degree."
    ],
    "warnings_table": [
      "<table ID=\"_RefID34\" styleCode=\"Noautorules\" width=\"100%\"><caption>TABLE III ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"33%\"/><col width=\"12%\"/><col width=\"10%\"/><col width=\"11%\"/><col width=\"12%\"/><col width=\"11%\"/><col width=\"9%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Method of control and  outcome</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">15 -19</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">20-24</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">25-29</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">30-34</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">35-39</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">40-44</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>No fertility control methods</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>7.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>7.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>9.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>14.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>25.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>28.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives non- smoker<footnote ID=\"_Ref126835060\">Deaths are birth related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>13.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>31.6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Oral contraceptives  smoker<footnoteRef IDREF=\"_Ref126835060\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>13.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>51.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>117.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD<footnoteRef IDREF=\"_Ref126835060\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Condom<footnote ID=\"_Ref126835031\">Deaths are method related.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm/spermicide<footnoteRef IDREF=\"_Ref126835031\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>2.8</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref126835031\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>1.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>3.6</paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Adapted from H.W. Ory, Reference 41.</paragraph></td></tr></tbody></table>"
    ],
    "precautions": [
      "PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections. 2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. 3. Lipid Disorders Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. 4. Liver Function If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function. 5. Fluid Retention Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention. 6. Contact Lenses Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 7. Drug Interactions Effects of Other Drugs on Oral Contraceptives (69) Rifampin Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Anticonvulsants Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness. Troglitazone Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness. Antibiotics Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids. Atorvastatin Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively. Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation: Co-administration of norethindrone acetate and ethinyl estradiol tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations (see Warnings, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT ). Co-administration of norethindrone acetate and ethinyl estradiol tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations. Other Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Effects of Oral Contraceptives on Other Drugs Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. 8. Interactions with Laboratory Tests Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: a. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T 4 by column or by radioimmunoassay. Free T 3 resin uptake is decreased, reflecting the elevated TBG; free T 4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged. e. Triglycerides may be increased. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives. 9. Carcinogenesis See WARNINGS section. 10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS section. 11. Lactation Small amounts of oral contraceptive steroids have been identified in human milk, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child. 12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."
    ],
    "pregnancy": [
      "10. Pregnancy Discontinue norethindrone acetate and ethinyl estradiol tablets if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS section."
    ],
    "nursing_mothers": [
      "11. Lactation Small amounts of oral contraceptive steroids have been identified in human milk, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child."
    ],
    "pediatric_use": [
      "12. Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."
    ],
    "spl_unclassified_section": [
      "PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (PATIENT PACKAGE INSERT BRIEF SUMMARY and DETAILED PATIENT PACKAGE INSERT). \u2022 Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs (see BOXED WARNING and CONTRAINDICATIONS ). \u2022 Counsel patients that the increased risk of venous thromboembolism compared to non-users of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or greater interruption in intake) the same or a different CHC (see WARNINGS ). \u2022 Counsel patients that this product does not protect against HIV-infection (AIDS) and other sexually transmitted infections. \u2022 Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs (see PRECAUTIONS ). \u2022 Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established (see PRECAUTIONS ). \u2022 Counsel any patient who starts norethindrone acetate and ethinyl estradiol tablets postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a white to off-white tablet for 7 consecutive days (see DOSAGE AND ADMINISTRATION ). \u2022 Counsel patients that amenorrhea may occur. Pregnancy should be considered in the event of amenorrhea, and should be ruled out if amenorrhea is associated with symptoms of pregnancy, such as morning sickness or unusual breast tenderness (see WARNINGS ). \u2022 Counsel patients with a history of depression that depression may reoccur. Women should contact their healthcare provider if depression occurs (see WARNINGS ).",
      "INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet, blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each with the days of the week appearing on the tablet blister pack above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 white to off-white tablets Norethindrone Acetate and Ethinyl Estradiol Tablets, 1 mg/0.02 mg Each white to off-white tablet contains 1 mg norethindrone acetate and 0.02 mg ethinyl estradiol. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 21 PILLS: The 21-pill pack has 21 \"active\" white to off-white pills (with hormones) to take for 3 weeks, followed by 1 week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone acetate and ethinyl estradiol tablets, 1 mg/0.02 mg will contain: ALL WHITE TO OFF-WHITE PILLS. 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. AN EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \"active\" white to off-white pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \"active\" white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \"active\" pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \"active\" pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 2 white to off-white \"active\" pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 3 OR MORE white to off-white \"active\" pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic. PREGNANCY DUE TO PILL FAILURE The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 3%. If failure does occur, the risk to the fetus is minimal. PREGNANCY AFTER STOPPING THE PILL There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. OVERDOSAGE Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. OTHER INFORMATION Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: \u2022 Menstrual cycles may become more regular \u2022 Blood flow during menstruation may be lighter and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur \u2022 Pain or other symptoms during menstruation may be encountered less frequently \u2022 Ectopic (tubal) pregnancy may occur less frequently \u2022 Noncancerous cysts or lumps in the breast may occur less frequently. \u2022 Acute pelvic inflammatory disease may occur less frequently \u2022 Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the \"Physician Insert\", which you may wish to read. Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection. MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS At times there may be no menstrual period after a cycle of pills. Therefore, if you miss one menstrual period but have taken the pills exactly as you were supposed to, continue as usual into the next cycle. If you have not taken the pills correctly and miss a menstrual period, you may be pregnant and should stop taking oral contraceptives until your doctor or healthcare provider determines whether or not you are pregnant. Until you can get to your doctor or healthcare provider, use another form of contraception. If two consecutive menstrual periods are missed, you should stop taking pills until it is determined whether or not you are pregnant. Although there does not appear to be any increase in birth defects in newborn babies if you become pregnant while using oral contraceptives, you should discuss the situation with your doctor or healthcare provider. Periodic Examination Your doctor or healthcare provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaou smear, i.e., test for cancer). Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited Ahmedabad - 382 213, India Code No.: GUJ-DRUGS/G/28/1297 75101282 Revised: 1/2024 FC:OT:7280:R6 Instructions for Use Figure 3 Instructions for Use Figure 4"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): \u2022 Thrombophlebitis \u2022 Arterial thromboembolism \u2022 Pulmonary embolism \u2022 Myocardial infarction \u2022 Cerebral hemorrhage \u2022 Cerebral thrombosis \u2022 Hypertension \u2022 Gallbladder disease \u2022 Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1) (70-74). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1) (70,73,75). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use. FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: \u2022 Mesenteric thrombosis \u2022 Retinal thrombosis The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related: \u2022 Nausea \u2022 Vomiting \u2022 Gastrointestinal symptoms (such as abdominal cramps and bloating) \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Temporary infertility after discontinuation of treatment \u2022 Edema \u2022 Melasma which may persist \u2022 Breast changes: tenderness, enlargement, secretion \u2022 Change in weight (increase or decrease) \u2022 Change in cervical erosion and secretion \u2022 Diminution in lactation when given immediately postpartum \u2022 Cholestatic jaundice \u2022 Migraine \u2022 Rash (allergic) \u2022 Depression \u2022 Reduced tolerance to carbohydrates \u2022 Vaginal candidiasis \u2022 Change in corneal curvature (steepening) \u2022 Intolerance to contact lenses The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted: \u2022 Pre-menstrual syndrome \u2022 Cataracts \u2022 Changes in appetite \u2022 Cystitis-like syndrome \u2022 Headache \u2022 Nervousness \u2022 Dizziness \u2022 Hirsutism \u2022 Loss of scalp hair \u2022 Erythema multiforme \u2022 Erythema nodosum \u2022 Hemorrhagic eruption \u2022 Vaginitis \u2022 Porphyria \u2022 Impaired renal function \u2022 Hemolytic uremic syndrome \u2022 Budd-Chiari syndrome \u2022 Acne \u2022 Changes in libido \u2022 Colitis FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES"
    ],
    "overdosage": [
      "OVERDOSAGE Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females. NON-CONTRACEPTIVE HEALTH BENEFITS The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (76-81). Effects on menses: \u2022 Increased menstrual cycle regularity \u2022 Decreased blood loss and decreased incidence of iron deficiency anemia \u2022 Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation: \u2022 Decreased incidence of functional ovarian cysts \u2022 Decreased incidence of ectopic pregnancies Effects from long-term use: \u2022 Decreased incidence of fibroadenomas and fibrocystic disease of the breast \u2022 Decreased incidence of acute pelvic inflammatory disease \u2022 Decreased incidence of endometrial cancer \u2022 Decreased incidence of ovarian cancer"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION The tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing on the tablet blister above the first row of tablets. Note: Each blister card has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days. Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen. The possibility of ovulation and conception prior to initiation of use should be considered. Dosage and Administration for 21-Day Dosage Regimen To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets must be taken exactly as directed and at intervals not exceeding 24 hours. Norethindrone acetate and ethinyl estradiol tablets provide the patient with a convenient tablet schedule of \u201c3 weeks on - 1 week off.\u201d Two dosage regimens are described, one of which may be more convenient or suitable than the other for an individual patient. For the initial cycle of therapy, the patient begins her tablets according to the Day-1 Start or Sunday-Start regimen. With either regimen, the patient takes one tablet daily for 21 consecutive days followed by one week of no tablets. A. Sunday-Start Regimen: The patient begins taking tablets from the top row on the first Sunday after menstrual flow begins. When menstrual flow begins on Sunday, the first tablet is taken on the same day. The last tablet in the blister pack will then be taken on a Saturday, followed by no tablets for a week (7 days). For all subsequent cycles, the patient then begins a new 21-tablet regimen on the eighth day, Sunday, after taking her last tablet. Following this regimen, of 21 days on \u2013 7 days off, the patient will start all subsequent cycles on a Sunday. B. Day-1 Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the blister pack. She starts taking one tablet daily, beginning with the first tablet in the top row. The patient completes her 21-tablet regimen when she has taken the last tablet in the blister pack. She will then take no tablets for a week (7 days). For all subsequent cycles, the patient begins a new 21-tablet regimen on the eighth day after taking her last tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the blister pack. Following this regimen of 21 days on \u2013 7 days off, the patient will start all subsequent cycles on the same day of the week as the first course. Likewise, the interval of no tablets will always start on the same day of the week. Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule. Special Notes on Administration Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after discontinuing medication. If spotting occurs while on the usual regimen of one tablet daily, the patient should continue medication without interruption. If the patient forgets to take one or more tablets, the following is suggested: One tablet is missed \u2022 take tablet as soon as remembered \u2022 take next tablet at the regular time Two consecutive tablets are missed (week 1 or week 2) \u2022 take two tablets as soon as remembered \u2022 take two tablets the next day \u2022 use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (week 3) Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed Sunday-Start Regimen: \u2022 take one tablet daily until Sunday \u2022 discard remaining tablets \u2022 start new pack of tablets immediately (Sunday) \u2022 use another birth control method for seven days following the missed tablets Day-1 Start Regimen: \u2022 discard remaining tablets \u2022 start new pack of tablets that same day \u2022 use another birth control method for seven days following the missed tablets The possibility of ovulation occurring increases with each successive day that scheduled tablets are missed. While there is little likelihood of ovulation occurring if only one tablet is missed, the possibility of spotting or bleeding is increased. This is particularly likely to occur if two or more consecutive tablets are missed. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new blister pack on the next Sunday or the first day (Day 1), depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered. Use of Oral Contraceptives in the Event of a Missed Menstrual Period 1. If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out. 2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg are packaged in a carton of three pouches (NDC 0378-7280-53) and a carton of five pouches (NDC 0378-7280-98); each pouch contains a blister pack of 21 tablets. Each blister pack contains 21 white to off-white , round, flat-faced, unscored tablet debossed with 239 on one side and plain on the other side. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]"
    ],
    "references": [
      "REFERENCES 1. Back DJ, Breckenridge AM, Crawford FE, Mclver M, Orme ML'E, Rowe PH and Smith E: Kinetics of norethindrone in women II. Single-dose kinetics. Clin Pharmacol Ther 1978; 24:448-453. 2. Humpel M, Nieuweboer B, Wendt H and Speck U: Investigations of pharmacokinetics of ethinyl estradiol to specific consideration of a possible first-pass effect in women. Contraception 1979;19:421-432. 3. Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML'E, Rowe PH and Watts MJ. An investigation of the pharmacokinetics of ethinyl estradiol in women using radioimmunoassay. Contraception 1979;20:263-273. 4. Hammond GL, Lahteenmaki PLA, Lahteenmaki P and Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steriod Biochem 1982;17:375-380. 5. Fotherby K. Pharmacokinetics and metabolism of progestins in humans, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994;99-126. 6. Goldzieher JW. Pharmacokinetics and metabolism of ethynyl estrogens, in Pharmacology of the contraceptive steroids, Goldzieher JW, Fotherby K (eds), Raven Press Ltd., New York, 1994;127-151. 7. Hatcher RA, et al. 1998. Contraceptive Technology, Seventeenth Edition. New York: Irvington Publishers. 8. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 1). New England Journal of Medicine, 305:612-618, 1981. 9. Stadel, B.V.: Oral contraceptives and cardiovascular disease. (Pt. 2). New England Journal of Medicine, 305:672-677, 1981. 10. Adam, S.A., and M. Thorogood: Oral contraception and myocardial infarction revisited: The effects of new preparations and prescribing patterns. Brit. J. Obstet. and Gynec., 88:838-845, 1981. 11. Mann, J.I., and W.H. Inman: Oral contraceptives and death from myocardial infarction. Brit. Med. J., 2(5965): 245-248, 1975. 12. Mann, J.I., M.P. Vessey, M. Thorogood, and R. Doll: Myocardial infarction in young women with special reference to oral contraceptive practice. Brit. Med. J., 2(5956):241-245, 1975. 13. Royal College of General Practitioners' Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet, 1:541-546, 1981. 14. Slone, D., S. Shapiro, D.W. Kaufman, L. Rosenberg, O.S. Miettinen, and P.D. Stolley: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N.E.J.M., 305:420-424, 1981. 15. Vessey, M.P.: Female hormones and vascular disease: An epidemiological overview. Brit. J. Fam. Plann., 6:1-12, 1980. 16. Russell-Briefel, R.G., T.M. Ezzati, R. Fulwood, J.A. Perlman, and R.S. Murphy: Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Preventive Medicine , 15:352-362, 1986. 17. Goldbaum, G.M., J.S. Kendrick, G.C. Hogelin, and E.M. Gentry: The relative impact of smoking and oral contraceptive use on women in the United States. J.A.M.A., 258:1339-1342, 1987. 18. Layde, P.M., and V. Beral: Further analyses of mortality in oral contraceptive users: Royal College General Practitioners' Oral Contraception Study. (Table 5) Lancet, 1:541-546, 1981. 19. Knopp, R.H.: Arteriosclerosis risk: The roles of oral contraceptives and postmenopausal estrogens. J. of Reprod. Med., 31(9)(Supplement): 913-921, 1986. 20. Krauss, R.M., S. Roy, D.R. Mishell, J. Casagrande, and M.C. Pike: Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am. J. Obstet. Gyn., 145:446-452, 1983. 21. Wahl, P., C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss, and B. Rifkind: Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N.E.J.M., 308:862-867, 1983. 22. Wynn, V., and R. Niththyananthan: The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am. J. Obstet. and Gyn., 142:766-771, 1982. 23. Wynn, V., and I. Godsland: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Medicine, 31 (9)(Supplement): 892-897, 1986. 24. LaRosa, J.C.: Atherosclerotic risk factors in cardiovascular disease. J. Reprod. Med., 31(9)(Supplement): 906-912, 1986. 25. Inman, W.H., and M.P. Vessey: Investigations of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Brit. Med. J., 2(5599): 193-199, 1968. 26. Maguire, M.G., J. Tonascia, P.E. Sartwell, P.D. Stolley, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives: A further report. Am. J. Epidemiology, 110(2): 188-195, 1979. 27. Pettiti, D.B., J. Wingerd, F. Pellegrin, and S. Ramacharan: Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J.A.M.A., 242:1150-1154, 1979. 28. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit. Med. J., 2(5599): 199-205, 1968. 29. Vessey, M.P., and R. Doll: Investigation of relation between use of oral contraceptives and thromboembolic disease: A further report. Brit. Med. J., 2(5658): 651-657, 1969. 30. Porter, J.B., J.R. Hunter, D.A. Danielson, H. Jick, and A. Stergachis: Oral contraceptives and non-fatal vascular disease: Recent experience. Obstet. and Gyn., 59(3):299-302, 1982. 31. Vessey, M., R. Doll, R. Peto, B. Johnson, and P. Wiggins: A long-term follow-up study of women using different methods of contraception: An interim report. J.Biosocial. Sci., 8:375-427, 1976. 32. Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J. of Royal College of General Practitioners, 28:393-399, 1978. 33. Collaborative Group for the study of stroke in young women: Oral contraception and increased risk of cerebral ischemia or thrombosis. N.E.J.M., 288:871-878, 1973. 34. Petitti, D.B., and J.Wingerd: Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet, 2:234-236, 1978. 35. Inman, W.H.: Oral contraceptives and fatal subarachnoid hemorrhage. Brit. Med. J., 2(6203): 1468-70, 1979. 36. Collaborative Group for the study of stroke in young women: Oral contraceptives and stroke in young women: Associated risk factors. J.A.M.A., 231:718-722, 1975. 37. Inman, W.H., M.P. Vessey, B. Westerholm, and A. Engelund: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Brit. Med. J., 2:203-209, 1970. 38. Meade, T.W., G. Greenberg, and S.G. Thompson: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Brit. Med. J., 280(6224): 1157-1161, 1980. 39. Kay, C.R.: Progestogens and arterial disease: Evidence from the Royal College of General Practitioners' study. Amer. J. Obstet. Gyn., 142:762-765, 1982. 40. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J. Coll. Gen. Pract., 33:75-82, 1983. 41. Ory, H.W: Mortality associated with fertility and fertility control: 1983. Family Planning Perspectives, 15:50-56, 1983. 42. Ory, H., Z. Naib, S.B. Conger, R.A. Hatcher, and C.W. Tyler: Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Am. J. Obstet. Gynec., 124:573-577, 1976. 43. Vessey, M.P., M. Lawless, K. McPherson, D. Yeates: Neoplasia of the cervix uteri and contraception: A possible adverse effect of the pill. Lancet, 2:930, 1983. 44. Brinton, L.A., G.R. Huggins, H.F. Lehman, K. Malli, D.A. Savitz, E. Trapido, J. Rosenthal, and R. Hoover: Long-term use of oral contraceptives and risk of invasive cervical cancer. Int. J. Cancer, 38:339-344, 1986. 45. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Brit. Med. J., 290:961-965, 1985. 46. Rooks, J.B., H.W. Ory, K.G. Ishak, L.T. Strauss, J.R. Greenspan, A.P. Hill, and C.W. Tyler: Epidemiology of hepatocellular adenoma: The role of oral contraceptive use. J.A.M.A., 242:644-648, 1979. 47. Bein, N.N., and H.S. Goldsmith: Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Brit. J. Surg., 64:433-435, 1977. 48. Klatskin, G.: Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology, 73:386-394, 1977. 49. Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike: Hepatocellular carcinoma and oral contraceptives. Brit. J. Cancer, 48:437-440, 1983. 50. Neuberger, J., D. Forman, R. Doll, and R. Williams: Oral contraceptives and hepatocellular carcinoma. Brit. Med. J., 292:1355-1357, 1986. 51. Forman, D., T.J. Vincent, and R. Doll: Cancer of the liver and oral contraceptives. Brit. Med. J., 292:1357-1361, 1986. 52. Harlap, S., and J. Eldor: Births following oral contraceptive failures. Obstet. Gynec., 55:447-452, 1980. 53. Savolainen, E., E. Saksela, and L. Saxen: Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Amer. J. Obstet. Gynec., 140:521-524, 1981. 54. Janerich, D.T., J.M. Piper, and D.M. Glebatis: Oral contraceptives and birth defects. Am. J. Epidemiology, 112:73-79, 1980. 55. Ferencz, C., G.M. Matanoski, P.D. Wilson, J.D. Rubin, C.A. Neill, and R. Gutberlet: Maternal hormone therapy and congenital heart disease. Teratology, 21:225-239, 1980. 56. Rothman, K.J., D.C. Fyler, A. Goldbatt, and M.B. Kreidberg: Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiology, 109:433-439, 1979. 57. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet, 1:1399-1404, 1973. 58. Royal College of General Practitioners: Oral Contraceptives and Health. New York, Pittman, 1974, 100p. 59. Layde, P.M., M.P. Vessey, and D. Yeates: Risk of gallbladder disease: A cohort study of young women attending family planning clinics. J. of Epidemiol. and Comm. Health, 36:274-278, 1982. 60. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am. J. Epidemiol., 119:796-805, 1984. 61. Strom, B.L., R.T. Tamragouri, M.L. Morse, E.L. Lazar, S.L. West, P.D. Stolley, and J.K. Jones: Oral contraceptives and other risk factors for gallbladder disease. Clin. Pharmacol. Ther., 39:335-341, 1986. 62. Wynn, V., P.W. Adams, I.F. Godsland, J. Melrose, R. Niththyananthan, N.W. Oakley, and A. Seedj: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet, 1:1045-1049, 1979. 63. Wynn, V.: Effect of progesterone and progestins on carbohydrate metabolism. In Progesterone and Progestin. Edited by C.W. Bardin, E. Milgrom, P. Mauvis-Jarvis. New York, Raven Press, pp. 395-410, 1983. 64. Perlman, J.A., R. G. Roussell-Briefel, T.M. Ezzati, and G. Lieberknecht: Oral glucose tolerance and the potency of oral contraceptive progestogens. J. Chronic Dis., 38:857-864, 1985. 65. Royal College of General Practitioners' Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet, 1:624, 1977. 66. Fisch, I.R., and J. Frank: Oral contraceptives and blood pressure. J.A.M.A., 237:2499-2503, 1977. 67. Laragh, A.J.: Oral contraceptive induced hypertension: Nine years later. Amer. J. Obstet. Gynecol., 126:141-147, 1976. 68. Ramcharan, S., E. Peritz, F.A. Pellegrin, and W.T. Williams: Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort. In Pharmacology of Steroid Contraceptive Drugs. Edited by S. Garattini and H.W. Berendes. New York, Raven Press , pp. 277-288, 1977. (Monographs of the Mario Negri Institute for Pharmacological Research, Milan.) 69. Back DJ, Orme ML'E. Drug interactions, in Pharmacology of the contraceptive steroids. Goldzieher JW, Fotherby K (eds), Raven Press, Ltd., New York, 1994, 407-425. 70. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med . 2002;346(26):2025-2032. 71. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control . 2005;16(5):537-544. 72. Dorjgochoo T, Shu XO, Li HL, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer . 2009;124(10):2442-2449. 73. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(10):2496-2502. 74. Vessey M, Yeates D. Oral contraceptive use and cancer. Final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-683. 75. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med . 2017;377(23):2228-2239. 76. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. J.A.M.A., 249:1596-1599, 1983. 77. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. J.A.M.A., 257:796-800, 1987. 78. Ory, H.W.: Functional ovarian cysts and oral contraceptives: Negative association confirmed surgically. J.A.M.A., 228:68-69, 1974. 79. Ory, H.W., P. Cole, B. Macmahon, and R. Hoover: Oral contraceptives and reduced risk of benign breast disease. N.E.J.M., 294:41-422, 1976. 80. Ory, H.W.: The noncontraceptive health benefits from oral contraceptive use. Fam. Plann. Perspectives, 14:182-184, 1982. 81. Ory, H.W., J.D. Forrest, and R. Lincoln: Making Choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, p.1, 1983."
    ],
    "information_for_patients": [
      "BRIEF SUMMARY PATIENT PACKAGE INSERT This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Oral contraceptives, also known as \"birth control pills\" or \"the pill\", are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you: \u2022 Smoke \u2022 Have high blood pressure, diabetes, high cholesterol \u2022 Have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast, jaundice, or malignant or benign liver tumors. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea, vomiting, and breakthrough bleeding may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill: 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack or angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences. 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. There may be slight increases in the risk of breast cancer among current users of hormonal birth control pills with longer duration of use of 8 years or more. Some studies have found an increase in the risk of developing cancer of the cervix in women taking the pill, but this finding may be related to differences in sexual behavior or other factors not related to use of the pill. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis."
    ],
    "information_for_patients_table": [
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>"
    ],
    "instructions_for_use": [
      "INSTRUCTIONS TO PATIENT TABLET BLISTER PACK The norethindrone acetate and ethinyl estradiol tablet blister pack has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in three rows of seven tablets each, with the days of the week appearing above the first row of tablets. If your TABLET BLISTER PACK contains: You are taking: 21 white to off-white tablets Norethindrone acetate and ethinyl estradiol tablets, 1 mg/0.02 mg Each white to off-white tablet contains 1 mg norethindrone acetate and 0.02 mg ethinyl estradiol. DIRECTIONS To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet blister. Do not press with your thumbnail, fingernail, or any other sharp object. HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS: Before you start taking your pills. Anytime you are not sure what to do. 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant. 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH, DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day. 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 21 PILLS: The 21-Day pill pack has 21 \"active\" white to off-white pills (with hormones) to take for 3 weeks, followed by 1 week without pills. 3. ALSO FIND: 1) where on the pack to start taking pills, 2) in what order to take the pills (follow the arrows), and 3) the week numbers as shown in the following picture: Norethindrone acetate and ethinyl estradiol tablets, 1 mg/0.02 mg contain: ALL WHITE TO OFF-WHITE PILLS. 4. BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. An EXTRA, FULL PILL PACK. WHEN TO START THE FIRST PACK OF PILLS You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember. DAY-1 START: 1. Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.) 2. Place this day label strip on the tablet blister card over the area that has the days of the week (starting with Sunday) printed on the blister card. 3. Take the first \"active\" white to off-white pill of the first pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period. SUNDAY START: 1. Take the first \"active\" white to off-white pill of the first pack on the Sunday after your period starts , even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control. WHAT TO DO DURING THE MONTH 1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. WHAT TO DO IF YOU MISS PILLS If you MISS 1 white to off-white \"active\" pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you have sex. If you MISS 2 white to off-white \"active\" pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 2 white to off-white \"active\" pills in a row in THE 3 rd WEEK : 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. If you MISS 3 OR MORE white to off-white \"active\" pills in a row (during the first 3 weeks): 1. If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. 2. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You COULD GET PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a white to off-white \"active\" pill every day for 7 days. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE \u201cACTIVE\u201d PILL EACH DAY until you can reach your doctor or clinic. Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. Keep this and all drugs out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Instructions for Use Figure 1 Instructions for Use Figure 2"
    ],
    "instructions_for_use_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"54%\"/><col width=\"44%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains: </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking: </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>21 white to off-white tablets </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Norethindrone acetate and ethinyl estradiol tablets, 1 mg/0.02 mg </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</content></paragraph></td></tr></tbody></table>"
    ],
    "spl_patient_package_insert": [
      "DETAILED PATIENT PACKAGE INSERT Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections. What You Should Know About Oral Contraceptives Any woman who considers using oral contraceptives (the \"birth control pill\" or \"the pill\") should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider's advice with regard to regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES Oral contraceptives or \"birth control pills\" or \"the pill\" are used to prevent pregnancy and are more effective than other non-surgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 3% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: Implant: < 1% Male sterilization: < 1% Injection: < 1% Cervical Cap: 20 to 40% IUD: < 1% to 2% Condom alone (male): 14% Diaphragm with spermicides: 20% Condom alone (female): 21% Spermicides alone: 26% Periodic abstinence: 25% Vaginal Sponge: 20 to 40% Withdrawal: 19% Female sterilization: < 1% No method: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions: \u2022 A history of heart attack or stroke \u2022 Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), or eyes \u2022 A history of blood clots in the deep veins of your legs \u2022 Chest pain (angina pectoris) \u2022 Known or suspected breast cancer \u2022 Unexplained vaginal bleeding (until a diagnosis is reached by your doctor) \u2022 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill \u2022 Liver tumor (benign or cancerous) \u2022 Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend a safer method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your healthcare provider if you have: \u2022 Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram \u2022 Diabetes \u2022 Elevated cholesterol or triglycerides \u2022 High blood pressure \u2022 Migraine or other headaches or epilepsy \u2022 Depression \u2022 Gallbladder, heart, or kidney disease \u2022 History of scanty or irregular menstrual periods Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. RISKS OF TAKING ORAL CONTRACEPTIVES 1. Risk of Developing Blood Clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives; in particular, a clot in the legs can cause thrombophlebitis, and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in GENERAL PRECAUTIONS .) 2. Heart Attacks and Strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder Disease Oral contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver Tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Risk of Cancer It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Method of control and outcome 15-19 20-24 25-29 30-34 35-39 40-44 No fertility control methods Deaths are birth related. 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non- smoker Deaths are method related. 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/ spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6 In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7-26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: \u2022 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung) \u2022 Pain in the calf (indicating a possible clot in the leg) \u2022 Crushing chest pain or heaviness in the chest (indicating a possible heart attack) \u2022 Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) \u2022 Sudden partial or complete loss of vision (indicating a possible clot in the eye) \u2022 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts) \u2022 Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor) \u2022 Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression) \u2022 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark colored urine, or light-colored bowel movements (indicating possible liver problems) SIDE EFFECTS OF ORAL CONTRACEPTIVES 1. Vaginal Bleeding Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider. 2. Contact Lenses If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider. 3. Fluid Retention Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or healthcare provider. 4. Melasma A spotty darkening of the skin is possible, particularly of the face. 5. Other Side Effects Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections. If any of these side effects bother you, call your doctor or healthcare provider. GENERAL PRECAUTIONS 1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception. There is no conclusive evidence that oral contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy. 2. While Breastfeeding If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely. 3. Laboratory Tests If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills. 4. Drug Interactions Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin \u00ae is one brand of this drug); troglitazone; phenylbutazone; and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective. Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications. 5. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis."
    ],
    "spl_patient_package_insert_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"47%\"/><col width=\"51%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Implant: &lt; 1% </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Male sterilization: &lt; 1% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Injection: &lt; 1% </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Cervical Cap: 20 to 40% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>IUD: &lt; 1% to 2% </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Condom alone (male): 14% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Diaphragm with spermicides: 20% </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Condom alone (female): 21% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Spermicides alone: 26% </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Periodic abstinence: 25% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"top\"><paragraph>Vaginal Sponge: 20 to 40% </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"top\"><paragraph>Withdrawal: 19% </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Female sterilization: &lt; 1% </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>No method: 85% </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</content></paragraph></td></tr></tbody></table>",
      "<table styleCode=\"Noautorules\" width=\"100%\"><caption>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE</caption><col width=\"34%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><col width=\"11%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Method of control and  outcome</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">15-19</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">20-24</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">25-29</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">30-34</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">35-39</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">40-44</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>No fertility control methods<footnote ID=\"_Ref156537455\">Deaths are birth related.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>7.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>7.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>9.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>14.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>25.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>28.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Oral contraceptives non- smoker<footnote ID=\"_Ref156537471\">Deaths are method related.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>13.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>31.6 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Oral contraceptives smoker<footnoteRef IDREF=\"_Ref156537471\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>3.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>6.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>13.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>51.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>117.2 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>IUD<footnoteRef IDREF=\"_Ref156537471\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.8 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.0 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Condom<footnoteRef IDREF=\"_Ref156537455\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.1 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>0.4 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule\" valign=\"middle\"><paragraph>Diaphragm/ spermicide<footnoteRef IDREF=\"_Ref156537455\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>1.3 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>2.2 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule\" valign=\"middle\"><paragraph>2.8 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph>Periodic abstinence<footnoteRef IDREF=\"_Ref156537455\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph>2.5 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph>1.6 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph>1.7 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph>2.9 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"middle\"><paragraph>3.6 </paragraph></td></tr></tbody></table>"
    ],
    "spl_unclassified_section_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"54%\"/><col width=\"44%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>If your TABLET BLISTER PACK contains: </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>You are taking: </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>21 white to off-white tablets </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule\" valign=\"top\"><paragraph>Norethindrone Acetate and Ethinyl Estradiol Tablets, 1 mg/0.02 mg </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">IMPORTANT POINTS TO REMEMBER</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">BEFORE </content>YOU START TAKING YOUR PILLS</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHEN TO START THE <content styleCode=\"underline\">FIRST </content>PACK OF PILLS</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO DURING THE MONTH</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">WHAT TO DO IF YOU MISS PILLS</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"98%\"/><tbody><tr><td styleCode=\"Botrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</content> Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE WHITE TO OFF-WHITE &#x201C;ACTIVE&#x201D; PILL EACH DAY until you can reach your doctor or clinic.</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 1 mg/0.02 mg NDC 0378-7280-53 Rx only Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1 mg/0.02 mg This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. An Oral Contraceptive 3 pouches, each pouch contains one blister pack of 21 tablets Each white to off-white tablet contains norethindrone acetate 1 mg and ethinyl estradiol 0.02 mg. Each blister pack contains 21 tablets white to off-white tablets. DOSAGE: One tablet daily as prescribed. See prescribing information. IMPORTANT: The \u201cPatient Instructions\u201d which are packaged inside each pouch provides important instructions to the patient. Please supply these instructions and the carrier sleeve to the patient when dispensing. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Made in India Code No.: GUJ-DRUGS/G/28/1297 Mylan.com FC:7280:3C:R2 Norethindrone Acetate and Ethinyl Estradiol Tablets Label"
    ],
    "set_id": "89948751-bd6e-4e9c-b87c-8782706c1097",
    "id": "e450353d-021c-b48d-d1ea-0787a1561ae2",
    "effective_time": "20240115",
    "version": "10",
    "openfda": {
      "application_number": [
        "ANDA202771"
      ],
      "brand_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "Mylan Pharmaceuticals Inc."
      ],
      "product_ndc": [
        "0378-7280"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ETHINYL ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1358762",
        "1358776"
      ],
      "spl_id": [
        "e450353d-021c-b48d-d1ea-0787a1561ae2"
      ],
      "spl_set_id": [
        "89948751-bd6e-4e9c-b87c-8782706c1097"
      ],
      "package_ndc": [
        "0378-7280-85",
        "0378-7280-53"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "423D2T571U",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate Norethindrone Ethinyl Estradiol Ethinyl Estradiol Lactose Monohydrate Mannitol Cellulose, Microcrystalline Povidone K30 Sodium Starch Glycolate Type A Potato Peppermint Magnesium Stearate .Alpha.-Tocopherol Sucralose XI;T4 Ferrous Fumarate Ferrous Fumarate Ferrous Fumarate Lactose Monohydrate Mannitol Povidone K30 Cellulose, Microcrystalline Sodium Starch Glycolate Type A Potato Magnesium Stearate Sucralose Peppermint XI;12 Structural Formula - Ethinyl Estradiol Structural Formula - Norethindrone Acetate Pregnancy Risk nor-ee-ff-carton-new.jpg"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4) ] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Women over 35 years old who smoke should not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (4) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use ( 4 )"
    ],
    "recent_major_changes": [
      "RECENT MAJOR CHANGES SECTION Warning and Precautions ( 5.11 ) 04/2022"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is indicated for use by females of reproductive age to prevent pregnancy [see Clinical Studies ( 14 )] The efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is an estrogen/progestin COC indicated for use by women to prevent pregnancy ( 1 ) The efficacy in women with a body mass index of more than 35 kg/m 2 has not been evaluated ( 1 , 8.8 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One tablet daily chewed and swallowed taken at the same time of day. Follow with 8 ounces of water ( 2.1 ) Take one table by mouth at the same time every day for 28 days ( 2.1 ) Take tablets in the order directed on the blister pack (2.1 ) Tablets may be administered without regard to meals ( 12.3 ) 2.1 How to Take Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets must be taken exactly as directed. Instruct patients to take one tablet by mouth at the same time every day. The Tablet may be chewed and swallowed or swallowed as whole. The patient should drink a full glass (8 ounces) of water immediately after the white tablets are chewed or swallowed whole. Tablets must be taken in the order directed on the blister pack. Tablets should not be skipped or taken at intervals exceeding 24 hours. For patient instructions for missed tablets, [see FDA-approved patient labeling] . Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals [see Clinical Pharmacology ( 12.3 )] . 2.2 How to Start Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Instruct the patient to begin taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start). Day 1 Start During the first cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets use, instruct the patient to take one white norethindrone acetate and ethinyl estradiol tablet daily, beginning on Day one (1 ) of her menstrual cycle (the first day of menstruation is Day one). She should take one white norethindrone acetate and ethinyl estradiol tablet daily for 24 consecutive days, followed by one brown ferrous fumarate tablet daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken in the order directed on the package at the same time each day. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days if she starts taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on a day other than the first day of her menstrual cycle. The possibility of ovulation and conception prior to initiation of medication should be considered. Sunday Start During the first cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets use, instruct the patient to take one white norethindrone acetate and ethinyl estradiol tablet daily, beginning on the first Sunday after the onset of her menstrual period. She should take one white norethindrone acetate and ethinyl estradiol tablet daily for 24 consecutive days, followed by one brown ferrous fumarate tablet daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken in the order directed on the package at the same time each day. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should begin her next and all subsequent 28-day regimens of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the same day of the week that she began her first regimen, following the same schedule. She should begin taking her white norethindrone acetate and ethinyl estradiol tablets on the next day after ingestion of the last brown ferrous fumarate tablet, regardless of whether or not a menstrual period has occurred or is still in progress. Anytime a subsequent cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is started later than the day following administration of the last brown ferrous fumarate tablet, the patient should use another method of contraception until she has taken a white norethindrone acetate and ethinyl estradiol tablet daily for 7 consecutive days. For postpartum women who do not breastfeed or after a second trimester abortion, start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets no earlier than 4 weeks postpartum due to the increased risk of thromboembolism. If the patient starts on norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets for 7 consecutive days. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be initiated immediately after a first-trimester abortion or miscarriage; if the patient starts norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets immediately, additional contraceptive measures are not needed. 2.3 Switching from another Hormonal Method of Contraception If the patient is switching from a combination hormonal method such as: - Another pill - Vaginal ring - Patch Instruct her to take the first white norethindrone acetate and ethinyl estradiol tablet on the day she would have taken her next COC pill. She should not continue taking the tablets from her previous birth control pack, and should not skip any days between packs. If she does not have a withdrawal bleed, rule out pregnancy before starting norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. If she previously used a vaginal ring or transdermal patch, she should start using norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the day she would have resumed the previous product. If the patient is switching from a progestin-only method such as a: - Progestin-only pill - Implant - Intrauterine system - Injection She may switch any day from a progestin-only pill; instruct her to take the first white norethindrone acetate and ethinyl estradiol tablet on the day she would have taken her next progestin-only pill. She should use a non-hormonal method of contraception for 7 consecutive days. If switching from an implant or injection, start the first white norethindrone acetate and ethinyl estradiol tablet on the day her next injection would have been due or on the day of removal of her implant. If switching from an IUD, depending on the timing of removal, back-up contraception may be needed. 2.4 Advice in Case of Gastrointestinal Disturbances If the patient vomits or has diarrhea (within 3 to 4 hours after she takes a white norethindrone acetate and ethinyl estradiol tablet), she should follow the instructions in the \u201cWhat to Do if You Miss Tablets\u201d section [see FDA-approved patient labeling] ."
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, 1 mg/20 mcg is available in blister packs. Each blister pack contains 28 tablets in the following order: 24 white, round, (active) chewable tablets imprinted with \u201cXI\u201d on one side and \u201cT4\u201d on the other side, and each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. 4 brown, round (non-hormonal placebo) tablets imprinted with \u201cXI\u201d on one side and \u201c12\u201d on the other side, and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose. Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, 1 mg/20 mcg consists of 28 tablets in the following order ( 3 ): 24 white chewable tablets (active), each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol 4 brown tablets (non-hormonal placebo), each containing 75 mg ferrous fumarate, which do not serve any therapeutic purpose"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, are contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ( 5.1 )] Have cerebrovascular disease [see Warnings and Precautions ( 5.1 )] Have coronary artery disease [see Warnings and Precautions ( 5.1 )] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ( 5.1 )] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ( 5.1 )] Have uncontrolled hypertension [see Warnings and Precautions ( 5.4 )] Have diabetes mellitus with vascular disease [see Warnings and Precautions ( 5.5 )] Have headaches with focal neurological symptoms or have migraine headaches with aura All women over age 35 with migraine headache [see Warnings and Precautions ( 5.6 )] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions ( 5.2 )] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.7 )] Pregnancy, because there is no reason to use COCs during pregnancy [see Warnings and Precautions ( 5.8 ) and Use in Specific Populations ( 8.1 )] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions ( 5.11 )] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [ see Warnings and Precautions ( 5.3 )] A high risk of arterial or venous thrombotic diseases (4) Breast cancer or other estrogen- or progestin-sensitive cancer ( 4 ) Liver tumors or liver disease ( 4 ) Undiagnosed abnormal uterine bleeding ( 4 ) Pregnancy ( 4 ) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Vascular risks: Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding ( 5.1 ) Liver disease: Discontinue if jaundice occurs ( 5.2 ) High blood pressure: Do not prescribe for women with uncontrolled hypertension or hypertension with vascular disease ( 5.3 ) Carbohydrate and lipid metabolic effects: monitor prediabetic and diabetic women taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia ( 5.5 ) Headache: Evaluate significant changes in headaches and discontinue if indicated ( 5.6 ) Uterine bleeding: Evaluate irregular bleeding or amenorrhea ( 5.7 ) 5.1 Thromboembolic Disorders and Other Vascular Problems Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if an arterial or deep venous thrombotic event (VTE) occurs. Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. If feasible, stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE. Start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 womanyears. The risk of VTE is highest during the first year of use of a COC. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest in older (greater than 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with underlying risk factors. Use COCs with caution in women with cardiovascular disease risk factors. 5.2 Liver Disease Impaired Liver Function Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications ( 4) ] . Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if jaundice develops. Liver Tumors Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is contraindicated in women with benign and malignant liver tumors [see Contraindications ( 4 )] . Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (greater than 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users. 5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [ see Contraindications ( 4 )]. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen. 5.4 High Blood Pressure Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease [ see Contraindications ( 4 )] . For women with well-controlled hypertension, monitor blood pressure and stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if blood pressure rises significantly. An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin. 5.5 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may also worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC-related cholestasis. 5.6 Carbohydrate and Lipid Metabolic Effects Carefully monitor prediabetic and diabetic women who are taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. COCs may decrease glucose tolerance in a dose-related fashion. Consider alternative contraception for women with uncontrolled dyslipidemias. A small proportion of women will have adverse lipid changes while on COCs. Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. 5.7 Headache If a woman taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if indicated. Consider discontinuation of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) [see Contraindications ( 4 )] . 5.8 Bleeding Irregularities and Amenorrhea Unscheduled Bleeding and Spotting Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC. Based on patient diaries from a clinical trial evaluating the safety and efficacy of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets, 24-35% of women experienced unscheduled bleeding per cycle. A total of 10 subjects out of 743 (1.3%) discontinued due to bleeding or spotting. Amenorrhea and Oligomenorrhea Women who are not pregnant and use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may experience amenorrhea. In the clinical trial with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets and ferrous fumarate tablets, 22 to 36% of the women using norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets and ferrous fumarate tablets experienced amenorrhea in at least one of 6 cycles of use. Some women may experience post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. 5.9 COC Use before or during Early Pregnancy Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when oral contraceptives are taken inadvertently during early pregnancy. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if pregnancy is confirmed. Administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy [see Use in Specific Populations ( 8.1 )] . 5.10 Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if depression recurs to a serious degree. 5.11 Malignant Neoplasms Breast Cancer Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive [see Contraindications ( 4 )]. Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use [see Adverse Reactions ( 6.2 )]. Cervical Cancer Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors. 5.12 Effect on Binding Globulins The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormones or cortisol therapy may need to be increased. 5.13 Monitoring A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare. 5.14 Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 5.15 Chloasma Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ( 5.1 )] Vascular events [see Warnings and Precautions ( 5.1 )] Liver disease [see Warnings and Precautions ( 5.2 )] Adverse reactions commonly reported by COC users are: Irregular uterine bleeding Nausea Breast Tenderness Headache The most common adverse reactions in clinical trials (greater than or equal to 2%) were: headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Xiromed at 1-844-XIROMED (1-844-947-6633) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data presented in Section 6.1 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. Common Adverse Reactions (Greater Than or Equal to 2% of all Treated Subjects) : The most common adverse reactions reported by at least 2% of the 743 women using norethindrone acetate/ethinyl estradiol tablets were the following, in order of decreasing incidence: headache (6.3%), vaginal candidiasis (6.1%), nausea (4.6%), menstrual cramps (4.4%), breast tenderness (3.4%), bacterial vaginitis (3.1%), abnormal cervical smear (3.1%), acne (2.7%), mood swings (2.2%), and weight gain (2.0%). Adverse Reactions Leading to Study Discontinuation : Among the 743 women using norethindrone acetate/ethinyl estradiol tablets, 46 women (6.2%) withdrew because of an adverse event. Adverse events occurring in 3 or more subjects leading to discontinuation of treatment were, in decreasing order: abnormal or irregular bleeding (1.3%), nausea (0.8%), menstrual cramps (0.5%), and increased blood pressure (0.4%). 6.2 Postmarketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use. Figure 1. RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. The following adverse reactions have been identified during post approval use of a 24- day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Adverse reactions are grouped into System Organ Classes. Vascular disorders: thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein). Hepatobiliary disorders: cholelithiasis, cholecystitis, hepatic adenoma, hemangioma of liver. Immune system disorders: hypersensitivity reaction. Skin and subcutaneous disorders: alopecia, rash (generalized and allergic), pruritus, skin discoloration. GI disorders: nausea, vomiting, abdominal pain. Musculoskeletal and connective tissue disorders: myalgia. Eye disorders: blurred vision, visual impairment, corneal thinning, change in corneal curvature (steepening). Infections and infestations: fungal infection, vaginal infection. Investigations: change in weight or appetite (increase or decrease), fatigue, malaise, peripheral edema, blood pressure increased. Nervous system disorders: headache, dizziness, migraine, loss of consciousness. Psychiatric disorders: mood swings, depression, insomnia, anxiety, suicidal ideation, panic attack, changes in libido. Renal and urinary disorders: cystitis-like syndrome. Reproductive system and breast disorders: breast changes (tenderness, pain, enlargement, and secretion), premenstrual syndrome, dysmenorrhea. Cardiovascular: chest pain, palpitations, tachycardia, myocardial infarction. image description"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations. No drug-drug interaction studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate and products containing St. John\u2019s wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin and certain COCs containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone concentrations. Human immunodeficiency virus (HIV)/ Hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors: Significant changes (increase or decrease) in the plasma concentrations of the estrogen and progestin have been noted in some cases of co-administration of HIV/HCV protease inhibitors or of non-nucleoside reverse transcriptase inhibitors. Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids. 7.2 Effects of Combined Oral Contraceptives on Other Drugs COCs containing ethinyl estradiol may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs. 7.3 Concomitant Use with HCV Combination Therapy \u2013 Liver Enzyme Elevation Do not co-administer norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with HCV drug combinations containing ombitasvir/ paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [ see Warnings and Precautions ( 5.3) ]. 7.4 Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Nursing mothers: Not recommended; can decrease milk production ( 8.3 ) 8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. 8.2 Lactation 8.2 Lactation Risk Summary Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see Dosage and Administration (2.2) ]. The developmental and health benefits of breast-feeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and any potential adverse effects on the breast-fed child from norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets or from the underlying maternal condition. 8.3 Nursing Mothers When possible, advise the nursing mother to use other forms of contraception until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk. 8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated. 8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in postmenopausal women and is not indicated in this population. 8.6 Renal Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in subjects with renal impairment. 8.7 Hepatic Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in subjects with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded [see Contraindications ( 4 ) and Warnings and Precautions ( 5.2 )] . 8.8 Body Mass Index The safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with a body mass index (BMI) greater than 35 kg/m 2 has not been evaluated [see Clinical Studies ( 14 )] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.",
      "8.2 Lactation 8.2 Lactation Risk Summary Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see Dosage and Administration (2.2) ]. The developmental and health benefits of breast-feeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and any potential adverse effects on the breast-fed child from norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets or from the underlying maternal condition."
    ],
    "nursing_mothers": [
      "8.3 Nursing Mothers When possible, advise the nursing mother to use other forms of contraception until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in postmenopausal women and is not indicated in this population."
    ],
    "overdosage": [
      "10 OVERDOSAGE There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea."
    ],
    "description": [
      "11 DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, 1 mg/20 mcg provides an oral contraceptive regimen consisting of 24 white active chewable tablets that contain the active ingredients, followed by 4 brown non-hormonal placebo tablets as specified below: 24 white, round tablets each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. 4 brown, round tablets each containing 75 mg ferrous fumarate Each white active chewable tablet also contains the following inactive ingredients: lactose monohydrate, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, peppermint flavor, magnesium stearate, alpha tocopherol, and sucralose. Each brown placebo tablet contains ferrous fumarate, lactose monohydrate, mannitol, povidone, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sucralose and peppermint flavor. The ferrous fumarate tablets do not serve any therapeutic purpose. The empirical formula of ethinyl estradiol is C 20 H 24 O 2 and the structural formula is: The chemical name of ethinyl estradiol is [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17\u03b1)-]. The molecular weight of ethinyl estradiol is 296.40. The empirical formula of norethindrone acetate is C 22 H 28 O 3 and the structural formula is: The chemical name of norethindrone acetate is [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)-]. The molecular weight of norethindrone acetate is 340.46."
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation. 12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. 12.3 Pharmacokinetics Absorption In a single-dose, two-way, crossover clinical study conducted in 35 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol tablet chewed and swallowed was bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablet (24-day regimen tablets) swallowed whole based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are absorbed from norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed), with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring at 1.0 hr (range: 0.7 to 2.5 hrs) and 1.3 hr (range: 1 to 2.5 hrs) post-dose, respectively. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single-dose administrations of norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed) in 35 healthy female subjects are provided in Figures 2 and 3, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets (swallowed whole) in 17 healthy female subjects, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean (\u00b1 Standard Deviation) Plasma Norethindrone Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed to Healthy Female Volunteers under Fasting Conditions (n = 35) Figure 3. Mean (\u00b1 Standard Deviation) Plasma Ethinyl Estradiol Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers Under Fasting Conditions (n = 35) Analyte Arithmetic Mean (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max AUC (0+tldc) (pg/mL\u2022h) AUC (0+inf) (pg/mL\u2022h) t 1/2 (hr) NE 10200 (36) 1.03 (0.67\u20132.50) 48620 (40) 49250 (40) 8.58 EE 84.7 (24) 1.33 (1.00\u20132.50) 677.5 (33) 741.6 (33) 9.68 C max = Maximum plasma concentration t max = Time of C max AUC (0-tldc) = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC (0-inf) = Area under the plasma concentration versus time curve from time 0 to infinity t \u00bd = Terminal phase half-life % CV = Coefficient of Variation * The harmonic mean (0.693/mean terminal phase rate constant) is reported for t \u00bd , and the median (range) is reported for t max Food Effect Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals. A single-dose administration of norethindrone acetate/ethinyl estradiol tablets with food decreased the maximum concentration of norethindrone by 51% and increased the extent of absorption by 15% and decreased the maximum concentration of ethinyl estradiol by 51% but not the extent of absorption. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. image description image description"
    ],
    "clinical_pharmacology_table": [
      "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"80%\"><tbody><tr styleCode=\"Botrule Toprule Lrule Rrule\"><td align=\"center\" rowspan=\"2\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>Analyte</paragraph></td><td align=\"center\" colspan=\"5\" styleCode=\"Lrule Rrule\"><paragraph>Arithmetic Mean (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr styleCode=\"Botrule Toprule Lrule Rrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>C<sub>max</sub></paragraph><paragraph>(pg/mL)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>t<sub>max</sub></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>AUC<sub>(0+tldc)</sub></paragraph><paragraph>(pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>AUC<sub>(0+inf) </sub></paragraph><paragraph>(pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>t<sub>1/2</sub></paragraph><paragraph>(hr)</paragraph></td></tr><tr align=\"center\" styleCode=\"Botrule Toprule Lrule Rrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>NE</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>10200</paragraph><paragraph>(36)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1.03</paragraph><paragraph>(0.67&#x2013;2.50)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>48620</paragraph><paragraph>(40)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>49250</paragraph><paragraph>(40)</paragraph></td><td styleCode=\"Lrule Rrule\"><paragraph>8.58</paragraph></td></tr><tr align=\"center\" styleCode=\"Botrule Toprule Lrule Rrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>EE</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>84.7</paragraph><paragraph>(24)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1.33</paragraph><paragraph>(1.00&#x2013;2.50)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>677.5</paragraph><paragraph>(33)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>741.6</paragraph><paragraph>(33)</paragraph></td><td styleCode=\"Lrule Rrule\"><paragraph>9.68</paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption In a single-dose, two-way, crossover clinical study conducted in 35 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol tablet chewed and swallowed was bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablet (24-day regimen tablets) swallowed whole based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are absorbed from norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed), with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring at 1.0 hr (range: 0.7 to 2.5 hrs) and 1.3 hr (range: 1 to 2.5 hrs) post-dose, respectively. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single-dose administrations of norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed) in 35 healthy female subjects are provided in Figures 2 and 3, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets (swallowed whole) in 17 healthy female subjects, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean (\u00b1 Standard Deviation) Plasma Norethindrone Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed to Healthy Female Volunteers under Fasting Conditions (n = 35) Figure 3. Mean (\u00b1 Standard Deviation) Plasma Ethinyl Estradiol Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers Under Fasting Conditions (n = 35) Analyte Arithmetic Mean (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max AUC (0+tldc) (pg/mL\u2022h) AUC (0+inf) (pg/mL\u2022h) t 1/2 (hr) NE 10200 (36) 1.03 (0.67\u20132.50) 48620 (40) 49250 (40) 8.58 EE 84.7 (24) 1.33 (1.00\u20132.50) 677.5 (33) 741.6 (33) 9.68 C max = Maximum plasma concentration t max = Time of C max AUC (0-tldc) = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC (0-inf) = Area under the plasma concentration versus time curve from time 0 to infinity t \u00bd = Terminal phase half-life % CV = Coefficient of Variation * The harmonic mean (0.693/mean terminal phase rate constant) is reported for t \u00bd , and the median (range) is reported for t max Food Effect Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals. A single-dose administration of norethindrone acetate/ethinyl estradiol tablets with food decreased the maximum concentration of norethindrone by 51% and increased the extent of absorption by 15% and decreased the maximum concentration of ethinyl estradiol by 51% but not the extent of absorption. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. image description image description"
    ],
    "pharmacokinetics_table": [
      "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"80%\"><tbody><tr styleCode=\"Botrule Toprule Lrule Rrule\"><td align=\"center\" rowspan=\"2\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>Analyte</paragraph></td><td align=\"center\" colspan=\"5\" styleCode=\"Lrule Rrule\"><paragraph>Arithmetic Mean (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr styleCode=\"Botrule Toprule Lrule Rrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>C<sub>max</sub></paragraph><paragraph>(pg/mL)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>t<sub>max</sub></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>AUC<sub>(0+tldc)</sub></paragraph><paragraph>(pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>AUC<sub>(0+inf) </sub></paragraph><paragraph>(pg/mL&#x2022;h)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>t<sub>1/2</sub></paragraph><paragraph>(hr)</paragraph></td></tr><tr align=\"center\" styleCode=\"Botrule Toprule Lrule Rrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>NE</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>10200</paragraph><paragraph>(36)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1.03</paragraph><paragraph>(0.67&#x2013;2.50)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>48620</paragraph><paragraph>(40)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>49250</paragraph><paragraph>(40)</paragraph></td><td styleCode=\"Lrule Rrule\"><paragraph>8.58</paragraph></td></tr><tr align=\"center\" styleCode=\"Botrule Toprule Lrule Rrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>EE</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>84.7</paragraph><paragraph>(24)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1.33</paragraph><paragraph>(1.00&#x2013;2.50)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>677.5</paragraph><paragraph>(33)</paragraph></td><td styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>741.6</paragraph><paragraph>(33)</paragraph></td><td styleCode=\"Lrule Rrule\"><paragraph>9.68</paragraph></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [See Warnings and Precautions ( 5.2 , 5.10 ) and Use in Specific Populations ( 8.1 ).]"
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [See Warnings and Precautions ( 5.2 , 5.10 ) and Use in Specific Populations ( 8.1 ).]"
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES The data presented in Section 14 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. In a clinical study, 743 women 18 to 45 years of age were studied to assess the efficacy of norethindrone acetate/ethinyl estradiol tablets, for up to six 28-day cycles providing a total of 3,823 treatment-cycles of exposure. The racial demographic of all enrolled women was: 70% Caucasian, 16% African-American, 10% Hispanic, 2% Asian and 2% Other. Women with body mass index (BMI) greater than 35 kg/m were excluded from the study. The weight range for those women treated was 90 to 260 pounds, with a mean weight of 147 pounds. Among the women in the study, about 40% had not used hormonal contraception immediately prior to enrolling in this study. A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies in 3,565 treatment cycles during which no backup contraception was used. The Pearl Index for norethindrone acetate and ethinyl estradiol tablets was 1.82 (95% confidence interval 0.59 - 4.25)."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, 1 mg/20 mcg is available in blister cards (dispensers) containing 28 tablets: NDC 70700-101-85, Carton containing 3 blister cards. Each blister card contains 28 tablets in the following order: 24 white, round (active) tablets imprinted with \u201cXI\u201d on one side and \u201cT4\u201d on the other side, and each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. 4 brown, round (non-hormonal placebo) tablets imprinted with \u201cXI\u201d on one side and \u201c12\u201d on the other side, and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose. 16.2 Storage Conditions Store at 20\u00ba to 25\u00ba C (68\u00ba to 77\u00baF); excursions permitted to 15\u00ba to 30\u00baC (59 to 86\u00ba F) [see USP Controlled Room Temperature]. Keep this drug and all drugs out of the reach of children."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) Counsel patients on the following information: Cigarette smoking increases the risk of serious cardiovascular events from COC use, and women who are over 35 years old and smoke should not use COCs. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets does not protect against HIV infection (AIDS) and other sexually transmitted infections. The Warnings and Precautions associated with COCs. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is not to be used during pregnancy; if pregnancy occurs during use of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, instruct the patient to stop further intake. Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event tablets are missed. See \u201cWhat to Do if You Miss Tablets\u201d section in FDA-approved patient labeling. Use a back-up or alternative method of contraception when enzyme inducers are used with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established. Women who start COCs postpartum, and who have not yet had a period, should use an additional method of contraception until they have taken a white tablet for 7 consecutive days. Amenorrhea may occur. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles. Manufactured by Laboratorios Leon Farma S.A., Spain for Xiromed LLC, Florham Park, NJ 07932 Product of Spain PI-101-04 Rev. 07/2023"
    ],
    "patient_medication_information": [
      "FDA Approved Patient Labeling Guide FDA-Approved Patient Labeling Guide for Using Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets WARNING TO WOMEN WHO SMOKE Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. Birth control pills help to lower the chances of becoming pregnant when taken as directed. They do not protect against HIV infection (AIDS) and other sexually transmitted infections. What are Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets? Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets is a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate. How well do Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets work? Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant. Based on the results of one clinical study of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg tablets lasting six months, about 1 to 4 out of 100 women may get pregnant during the first year they use Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets. Women with a BMI above 35 kg/m 2 were not studied in the clinical trial, so it is not known how well Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets protects against pregnancy in such women. If you are overweight, discuss with your healthcare provider whether Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets is the best choice for you. The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant. How do I take Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets? 1. Be sure to read these directions before you start taking your tablets or anytime you are not sure what to do. 2. The tablets may be chewed and swallowed or swallowed whole. You should drink a full glass (8 ounces) of water immediately after chewing or swallowing. 3. The right way to take the tablet is to take one tablet every day at the same time in the order directed on the package. Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets can be taken without regard to meals. If you miss tablets you could get pregnant. This includes starting the pack late. The more tablets you miss, the more likely you are to get pregnant. See \"What to Do if You Miss Tablets\u201d below. 4. Many women have spotting or light bleeding at unexpected times, or may feel sick to their stomach during the first 1 to 3 packs of tablets. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the tablets. The problem will usually go away. If it does not go away, check with your healthcare provider. 5. Missing tablets can also cause spotting or light bleeding, even when you make up these missed tablets. On the days you take two tablets, to make up for missed tablets, you could also feel a little sick to your stomach. 6. If you have vomiting (within 3 to 4 hours after you take your tablet), you should follow the instructions for \"What to Do if You Miss Tablets\". If you have diarrhea or if you take certain medicines, including some antibiotics and some herbal products such as St. John's wort, your tablets may not work as well. Use a back-up method (such as condoms and spermicides) until you check with your healthcare provider. 7. If you have trouble remembering to take Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, talk to your healthcare provider about how to make tablet-taking easier or about using another method of birth control. 8. If you have any questions or are unsure about the information in this leaflet, call your healthcare provider. Before You Start Taking Your Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets 1. Decide What Time of Day You Want to Take Your Tablet. It is important to take Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets in the order directed on the package at the same time every day. Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets can be taken without regard to meals. 2. Look at Your Tablet Pack \u2013 It has 28 Tablets The Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets pack has 24 \"active\" white tablets (with hormones) to be taken for 24 days, followed by 4 \"reminder\" brown tablets (without hormones) to be taken for the next four days. 3. Also look for: a) Where on the pack to start taking tablets, b) In what order to take the tablets (follow the arrows shown in the picture above) c) The week numbers as shown in the picture above. 4. Be sure you have ready at all times a) another kind of birth control (such as a condoms and spermicide) to use as a back-up in case you miss tablets, and b) an extra, full tablet pack. When to Start the First Pack of Tablets You have a choice for which day to start taking your first pack of tablets. Decide with your healthcare provider which is the best day for you. Pick a time of day which will be easy to remember. Day 1 Start: 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first white tablet of the pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the tablet at the beginning of your period. However, if you start Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets later than the first day of your period, you should use another method of birth control (such as a condom and spermicide) as a back-up method until you have taken 7 white tablets. Sunday Start: 1. Take the first white tablet of the pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control (such as a condom and spermicide) as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). This also applies if you start Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets after having been pregnant, and you have not had a period since your pregnancy. When You Switch From a Different Birth Control Tablet or Capsule When switching from another birth control pill, finish all the tablets or capsules, then Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets should be started on the same day that a new pack of the previous birth control tablet or capsule would have been started. When You Switch From Another Type of Birth Control Method When switching from a transdermal patch or vaginal ring, finish the 21 days of use, wait 7 days, then Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets should be started when the next application would have been due. When switching from an injection, Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets should be started when the next injection would have been due. When switching from an intrauterine device or an implant, Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets should be started on the day of removal. What to Do During the Month 1. Take one tablet at the same time every day until the pack is empty. Do not skip tablets even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). 2. Do not skip tablets even if you do not have sex very often. When you finish a pack of tablets, start the next pack on the day after your last brown tablet. Do not wait any days between packs. What to Do if You Miss Tablets Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets may not be as effective if you miss any white tablets, especially if you miss the first few or the last few white tablets in a pack. If you miss 1 white tablet: 1. Take the tablet as soon as you remember. Take the next tablet at your regular time. This means you may take two tablets in one day. 2. You do not need to use a back-up birth control method if you have sex. If you miss 2 white tablets in a row in week 1 OR week 2 of your pack: 1. Take two tablets on the day you remember and two tablets the next day. 2. Then take one tablet a day until you finish the pack. 3. You could become pregnant if you have sex in the 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. If you miss 2 white tablets in a row in week 3 or week 4 of your pack: 1. If you are a Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. If you are a Sunday Starter: Keep taking one tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. 2. You could become pregnant if you have sex in the 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a backup for those 7 days. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss 3 or more white tablets in a row during any week: 1. If you are a Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. 2. You could become pregnant if you have sex on the days when you missed tablets or during the first 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up the next time you have sex and for the first 7 days after you restart your tablets. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss any of the 4 brown tablets in Week 4: 1. Throw away the tablets you missed. 2. Keep taking one tablet each day until the pack is empty. 3. You do not need a back-up method. 4. Start the next pack of Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets as scheduled. Finally, if you are still not sure what to do about the tablets you have missed: 1. Use a back-up method (such as a condom and spermicide) anytime you have sex. 2. Contact your healthcare provider and continue taking one active white tablet each day until otherwise directed. Who should not take Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets? Your healthcare provider will not give you Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets if you have: Ever had blood clots in your arms, legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis) Ever had a stroke Ever had a heart attack Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart An inherited problem with your blood that makes it clot more than normal High blood pressure that medicine cannot control Diabetes with kidney, eye, nerve, or blood vessel damage Ever had certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or have any migraine headache if you are over age 35. Ever had breast cancer or any cancer that is sensitive to female hormones Liver disease, including liver tumors Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood Also, do not take birth control pills if you: Smoke and are over 35 years old Are or suspect you are pregnant Have any unexplained bleeding from the vagina Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy, also called cholestasis of pregnancy. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). What else should I know about taking Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets? Birth control pills do not protect you against any sexually transmitted infection, including HIV, the virus that causes AIDS. Do not skip any tablets, even if you do not have sex often. If you miss a period, you could be pregnant. However, some women miss periods or have light periods on birth control pills, even when they are not pregnant. Contact your healthcare provider for advice if you: Think you are pregnant Miss one period and have not taken your birth control pills every day Miss two periods in a row Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects. You should stop Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets at least four weeks before you have surgery and not restart it until at least two weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, may decrease the amount of milk you make. A small amount of the pill's hormones passes into breast milk. Tell your healthcare provider about all medicines and herbal products that you take. Some medicines and herbal products may make birth control pills less effective, including: barbiturates bosentan carbamazepine felbamate griseofulvin oxcarbazepine phenytoin rifampin St. John\u2019s wort topiramate Use a back-up or alternative birth control method when you take medicines that may make birth control pills less effective. Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your healthcare provider may need to adjust the dose of lamotrigine. If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like a condom and spermicide, until you check with your healthcare provider. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone. If you are scheduled for any laboratory tests, tell your healthcare provider that you are taking birth control pills. Certain blood tests may be affected by birth control pills. What are the most serious risks of taking Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets? Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke. Some examples of serious blood clots are blood clots in the: Legs (deep vein thrombosis) Lungs (pulmonary embolus) Eyes (loss of eyesight) Heart (heart attack) Brain (stroke) Women who take birth control pills may get: High blood pressure Gallbladder problems Rare cancerous or noncancerous liver tumors All of these events are uncommon in healthy women. Call your healthcare provider right away if you have: Persistent leg pain Sudden shortness of breath Sudden blindness, partial or complete Severe pain or pressure in your chest Sudden, severe headache unlike your usual headaches Weakness or numbness in an arm or leg, or trouble speaking Yellowing of the skin or eyeballs What are the common side effects of birth control pills? The most common side effects of birth control pills are: Spotting or bleeding between menstrual periods Nausea Breast tenderness Headache These side effects are usually mild and usually disappear with time. Less common side effects are: Acne Less sexual desire Bloating or fluid retention Blotchy darkening of the skin, especially on the face High blood sugar, especially in women who already have diabetes High fat (cholesterol, triglyceride) levels in the blood Depression, especially if you have had depression in the past. Call your healthcare provider immediately if you have any thoughts of harming yourself Problems tolerating contact lenses Weight gain This is not a complete list of possible side effects. Talk to your healthcare provider if you develop any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088. No serious problems have been reported from a birth control pill overdose, even when accidentally taken by children. Do birth control pills cause cancer? It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners. What should I know about my period when taking Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets? Irregular vaginal bleeding or spotting may occur while you are taking Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding, which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your tablets on schedule. If the bleeding occurs in more than one cycle, is unusually heavy, or lasts for more than a few days, call your healthcare provider. Some women may not have a menstrual period but this should not be cause for alarm as long as you have taken the tablets according to direction. What if I miss my scheduled period when taking Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets? It is not uncommon to miss your period. However, if you go two or more months in a row without a period, or you miss your period after a month where you did not take all your tablets correctly, call your healthcare provider because you may be pregnant. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. Stop taking Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets if you are pregnant. What if I want to become pregnant? You may stop taking the tablets whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the tablets. General Advice about Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Your healthcare provider prescribed Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets for you. Please do not share Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets with anyone else. Keep Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets out of the reach of children. If you have concerns or questions, ask your healthcare provider. You may also ask your pharmacist for a more detailed label written for healthcare professionals. Manufactured by Laboratorios Leon Farma S.A., Spain For Xiromed LLC, Florham Park, NJ 07932 Product of Spain PIL-101-04 Rev. 07/2023 nor-acetate-ethinyl-estradiol-blister-label.jpg"
    ],
    "patient_medication_information_table": [
      "<table><tbody><tr align=\"center\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">WARNING TO WOMEN WHO SMOKE</content></td></tr><tr><td/></tr><tr align=\"center\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</content></td></tr></tbody></table>"
    ],
    "spl_patient_package_insert": [
      ""
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION Norethindrone Acetate and Ethinyl Estradiol Tablets, 1 mg/20 mcg and Ferrous Fumarate Tablets NDC 70700-101-85"
    ],
    "set_id": "b4bc4302-9484-465a-090d-47e1e0360b73",
    "id": "0b7a2fac-2281-4c64-29aa-5e0d05d49236",
    "effective_time": "20230712",
    "version": "9",
    "openfda": {
      "application_number": [
        "ANDA209609"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS AND FERROUS FUMARATE TABLETS"
      ],
      "manufacturer_name": [
        "Xiromed, LLC"
      ],
      "product_ndc": [
        "70700-101"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "rxcui": [
        "259176",
        "1426288",
        "1426600"
      ],
      "spl_id": [
        "0b7a2fac-2281-4c64-29aa-5e0d05d49236"
      ],
      "spl_set_id": [
        "b4bc4302-9484-465a-090d-47e1e0360b73"
      ],
      "package_ndc": [
        "70700-101-85"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL CALCIUM STEARATE STARCH, CORN ISOPROPYL ALCOHOL LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE POVIDONE K30 .ALPHA.-TOCOPHEROL D&C RED NO. 30 TALC light pink to pink uncoated, flat-faced, beveled-edge D5 Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL CALCIUM STEARATE STARCH, CORN ISOPROPYL ALCOHOL LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE POVIDONE K30 .ALPHA.-TOCOPHEROL TALC white to off-white uncoated, flat-faced, beveled-edge D6"
    ],
    "boxed_warning": [
      "WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women\u2019s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions ( 5.1 ), and Clinical Studies ( 14.5 )] . The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )]. Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions ( 5.1 , 5.3 ), and Clinical Studies ( 14.5 , 14.6 )]. Breast Cancer The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.5 )]. Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions ( 5.2 )] . Cardiovascular Disorders and Probable Dementia The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions ( 5.1 ) and Clinical Studies ( 14.5 )]. The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.5 ) and Clinical Studies ( 14.6 )]. Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions ( 5.1 , 5.3 ), and Clinical Studies ( 14.5 , 14.6 )]. Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER See full prescribing information for complete boxed warning. Estrogen Plus Progestin Therapy \u2022 The Women\u2019s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, and myocardial infarction (MI) ( 5.1 ) \u2022 The WHI estrogen plus progestin substudy reported increased risk of invasive breast cancer ( 5.2 ) \u2022 The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) \u2022 Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease of dementia ( 5.1 , 5.3 ) Estrogen-Alone Therapy \u2022 There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 ) \u2022 The WHI estrogen-alone substudy reported increased risks of stroke and DVT ( 5.1 ) \u2022 The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) \u2022 Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 )"
    ],
    "recent_major_changes": [
      "Boxed Warning 5/2023 Warnings and Precautions, Malignant Neoplasms ( 5.2 ) 11/2023"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets are a combination of an estrogen and progestin indicated in a woman with a uterus for: \u2022 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) \u2022 Prevention of Postmenopausal Osteoporosis ( 1.2 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Use estrogen, alone or in combination with a progestogen, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Re-evaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary. \u2022 One tablet orally once daily ( 2.1 , 2.2 ) 2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Take a single norethindrone acetate and ethinyl estradiol tablet, orally once daily. 2.2 Prevention of Postmenopausal Osteoporosis Take a single norethindrone acetate and ethinyl estradiol tablet, orally once daily"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS The following two strengths of Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are available: Norethindrone Acetate and Ethinyl Estradiol Tablets, USP (0.5 mg/2.5 mcg): Each light pink to pink, round, flat-faced beveled edge, uncoated tablet contains 0.5 mg norethindrone acetate, USP and 2.5 mcg ethinyl estradiol, USP; debossed with \u2018D5\u2019 on one side and plain on the other side. Norethindrone Acetate and Ethinyl Estradiol Tablets, USP (1 mg/5 mcg): Each white to off-white, round, flat-faced beveled edge, uncoated tablet contains 1 mg norethindrone acetate, USP and 5 mcg ethinyl estradiol, USP; debossed with \u2018D6\u2019 on one side and plain on the other side. \u2022 Round, light pink to light tablet contains 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol ( 3 ) \u2022 Round, white to off-white tablet contains 1 mg norethindrone acetate and 5 mcg ethinyl estradiol ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Norethindrone acetate and ethinyl estradiol tablets are contraindicated in women with any of the following conditions: \u2022 Undiagnosed abnormal genital bleeding [see Warnings and Precautions ( 5.2 )]. \u2022 Breast cancer or a history of breast cancer [see Warnings and Precautions ( 5.2 )]. \u2022 Estrogen-dependent neoplasia [see Warnings and Precautions ( 5.2 )]. \u2022 Active DVT, PE or a history of these conditions [see Warnings and Precautions ( 5.1 )]. \u2022 Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions [see Warnings and Precautions ( 5.1 )]. \u2022 Known anaphylactic reaction, angioedema, or hypersensitivity to norethindrone acetate and ethinyl estradiol tablets . \u2022 Hepatic impairment or disease. \u2022 Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders. \u2022 Undiagnosed abnormal genital bleeding ( 4 , 5.2 ) \u2022 Breast cancer or a history of breast cancer ( 4 , 5.2 ) \u2022 Estrogen-dependent neoplasia ( 4 , 5.2 ) \u2022 Active DVT, PE, or history of these conditions ( 4 , 5.1 ) \u2022 Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions ( 4 , 5.1 ) \u2022 Known anaphylactic reaction, angioedema or hypersensitivity to norethindrone acetate and ethinyl estradiol tablets ( 4 ) \u2022 Hepatic impairment or disease ( 4 , 5.10 ) \u2022 Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS \u2022 Estrogens increase the risk of gallbladder disease ( 5.4 ) \u2022 Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs ( 5.5 , 5.6 , 5.9 , 5.10 ) \u2022 Monitor thyroid function in women on thyroid replacement therapy ( 5.11 , 5.18) 5.1 Cardiovascular Disorders Increased risk of PE, DVT, stroke, and MI are reported with estrogen plus progestin therapy. Increased risks of stroke and DVT are reported with estrogen-alone therapy. Immediately discontinue estrogen with or without progestogen therapy if any of these occur or are suspected. Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). Stroke The WHI estrogen plus progestin substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 strokes per 10,000 women- years) [ see Clinical Studies ( 14.5 ) ]. The increase in risk was demonstrated after the first year and persisted. 1 Immediately discontinue estrogen with or without progestogen therapy if a stroke occurs or is suspected. The WHI estrogen-alone substudy, reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily conjugated estrogens CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted [ see Clinical Studies ( 14.5 ) ] . Immediately discontinue estrogen-alone therapy if a stroke occurs or is suspected. Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 Coronary Heart Disease The WHI estrogen plus progestin substudy reported an increased risk (not statistically significant) of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) in those women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). 1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies ( 14.5 ) ] . The WHI estrogen-alone substudy reported no overall effect on CHD events in women receiving estrogen-alone compared to placebo 2 [see Clinical Studies ( 14.5 )] . Subgroup analyses of women 50 to 59 years of age, who were less than 10 years since menopause, suggest a reduction (not statistically significant) of CHD events in those women receiving CE (0.625 mg)-alone compared to placebo (8 versus 16 per 10,000 woman-years). 1 In postmenopausal women with documented heart disease (n = 2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall. Venous Thromboembolism The WHI estrogen plus progestin substudy reported a statistically significant 2-fold greater rate of VTE (DVT and PE) in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted 3 [see Clinical Studies ( 14.5 )] . Immediately discontinue estrogen plus progestogen therapy if a VTE occurs or is suspected. In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years 4 [see Clinical Studies ( 14.5 )] . Immediately discontinue estrogen-alone therapy if a VTE occurs or is suspected. If feasible, discontinue estrogens at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism or during periods of prolonged immobilization. 5.2 Malignant Neoplasms Breast Cancer After a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA compared to placebo. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years for CE plus MPA compared with placebo [see Clinical Studies ( 14.5 )] . Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86 and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups 5 [see Clinical Studies ( 14.5 )]. The WHI substudy of daily CE (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. In the WHI estrogen-alone substudy, after an average follow up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80 compared to placebo 6 [see Clinical Studies ( 14.5 )] . Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to >10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. These studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors and prior mammogram results. Endometrial Cancer Endometrial hyperplasia (a possible precursor of endometrial cancer) has been reported to occur at a rate of approximately 1 percent or less with norethindrone acetate and ethinyl estradiol tablets. An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. Clinical surveillance of all women using estrogen-alone or estrogen plus progestogen therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestogen to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Ovarian Cancer The CE plus MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77 to 3.24), but it was not statistically significant. The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. 7 A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27 to 1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. 5.3 Probable Dementia In the WHI Memory Study (WHIMS) estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21 to 3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )] . In the WHIMS estrogen-alone ancillary study, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83 to 2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )] . When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19 to 2.6). Since both ancillary substudies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )] . 5.4 Gallbladder Disease A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. 5.5 Hypercalcemia Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. Discontinue estrogens, including norethindrone acetate and ethinyl estradiol tablets, if hypercalcemia occurs, and take appropriate measures to reduce the serum calcium level. 5.6 Visual Abnormalities Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue norethindrone acetate and ethinyl estradiol tablets pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. Permanently discontinue estrogens, including norethindrone acetate and ethinyl estradiol tablets , if examination reveals papilledema or retinal vascular lesions. 5.7 Addition of a Progestogen When a Woman Has Not Had a Hysterectomy Studies of the addition of a progestogen for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestogens with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. 5.8 Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen. 5.9 Exacerbation of Hypertriglyceridemia In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Discontinue norethindrone acetate and ethinyl estradiol tablets if pancreatitis occurs. 5.10 Hepatic Impairment and/or a Past History of Cholestatic Jaundice Estrogens may be poorly metabolized in women with hepatic impairment. Exercise caution in any women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy. In the case of recurrence of cholestatic jaundice, discontinue norethindrone acetate and ethinyl estradiol tablets. 5.11 Exacerbation of Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T 4 and T 3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy. Monitor thyroid function in these women during treatment with norethindrone acetate and ethinyl estradiol tablets to maintain their free thyroid hormone levels in an acceptable range. 5.12 Fluid Retention Estrogens plus progestogens may cause some degree of fluid retention. Monitor any women with condition(s) that might predispose her to fluid retention, such as cardiac or renal impairment. Discontinue estrogen plus progestogen therapy, including norethindrone acetate and ethinyl estradiol tablets, with evidence of medically concerning fluid retention. 5.13 Hypocalcemia Estrogen-induced hypocalcemia may occur in women with hypoparathyroidism. Consider whether the benefits of estrogen therapy, including norethindrone acetate and ethinyl estradiol tablets, outweigh the risks in such women. 5.14 Exacerbation of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. 5.15 Hereditary Angioedema Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. Consider whether the benefits of estrogen therapy, including norethindrone acetate and ethinyl estradiol tablets, outweigh the risks in such women. 5.16 Exacerbation of Other Conditions Estrogen therapy, including norethindrone acetate and ethinyl estradiol tablets, may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus and hepatic hemangiomas. Consider whether the benefits of estrogen therapy outweigh the risks in women with such conditions. 5.17 Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of postmenopausal women with moderate to severe vasomotor symptoms. 5.18 Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased TBG levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Norethindrone acetate and ethinyl estradiol tablets 1/5 was associated with an SHBG increase of 22 percent. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels. Impaired glucose tolerance."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: \u2022 Cardiovascular Disorders [see Boxed Warning, Warnings and Precautions ( 5.1 )] . \u2022 Malignant Neoplasms [see Boxed Warning, Warnings and Precautions ( 5.2 )] . Most common adverse reactions with norethindrone acetate and ethinyl estradiol tablets (incidence greater than or equal to 5 percent) are: headache, abdominal pain, breast pain, and edema (generalized). (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported by \u22655 percent of women in controlled clinical studies of norethindrone acetate and ethinyl estradiol tablets are shown in Table 1. Table 1. Associated Adverse Reactions Reported by \u22655 Percent of Women by Body System * BODY SYSTEM/ Adverse Reaction Number (Percent) of Subjects Placebo Norethindrone Acetate and Ethinyl Estradiol Tablets 0.5/2.5 Norethindrone Acetate and Ethinyl Estradiol Tablets 1/5 N = 247 N = 244 N = 258 BODY AS A WHOLE 23 (12.8) 30 (16.9) 30 (15.7) Edema - Generalized 10 (4) 12 (4.9) 11 (4.3) Headache 12 (4.9) 14 (5.7) 16 (6.2) DIGESTIVE SYSTEM 8 (4.4) 17 (9.6) 25 (13.1) Abdominal Pain 3 (1.2) 13 (5.3) 14 (6.8) UROGENITAL SYSTEM 20 (11.1) 34 (19.2) 45 (23.6) Breast Pain 9 (3.6) 22 (9) 20 (7.8) *The total number of women for each body system may be less than the number of women with AEs in that body system because a women may have had more than one AE per body system 6.2 Postmarketing Experience The following additional adverse reactions have been identified during post-approval use of norethindrone acetate and ethinyl estradiol tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; increase in size of uterine leiomyomata, vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer; uterine cancer; vaginal hemorrhage; ovarian cyst; irregular menstruation; metrorrhagia; menorrhagia; dysmenorrhea; uterine enlargement. Breasts Tenderness, enlargement, breast pain, nipple pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer; breast disorder; breast mass; breast enlargement. Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; thrombosis; chest pain; myocardial infarction; cerebrovascular accident (stroke); transient ischemic attack; hemiparesis; increase in blood pressure; irregular heart rate; palpitations; dyspnea. Gastrointestinal Nausea, vomiting; cholestatic jaundice; pancreatitis, enlargement of hepatic hemangiomas; bloating, abdominal cramps; abdominal pain; increased incidence of gallbladder disease; cholecystitis; cholelithiasis. Skin Chloasma or melasma that may persist when drug is discontinued; generalized erythema; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; rash, pruritus. Eyes Retinal vascular thrombosis; visual impairment; intolerance to contact lenses. Central Nervous System (CNS) Headache; migraine; dizziness; depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy, dementia; paresthesia; insomnia. Miscellaneous Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthralgias; leg cramps; back pain; changes in libido; urticaria, angioedema, anaphylactoid/anaphylactic reactions; hypocalcemia; exacerbation of asthma; increased triglycerides; blood glucose abnormal; fatigue; myalgia; hypersensitivity."
    ],
    "adverse_reactions_table": [
      "<table cellpadding=\"0pt\" width=\"91.06%\"><col width=\"27%\"/><col width=\"27%\"/><col width=\"24%\"/><col width=\"22%\"/><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>BODY SYSTEM/</item><item><caption> </caption>Adverse Reaction</item></list></td><td colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Number (Percent) of Subjects</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Placebo</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Norethindrone Acetate and Ethinyl Estradiol Tablets  0.5/2.5</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Norethindrone Acetate and Ethinyl Estradiol Tablets  1/5</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>N = 247</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>N = 244</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>N = 258</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>BODY AS A WHOLE</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>23 (12.8)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>30 (16.9)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>30 (15.7)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Edema - Generalized</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>10 (4)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>12 (4.9)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>11 (4.3)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Headache</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>12 (4.9)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>14 (5.7)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>16 (6.2)</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>DIGESTIVE SYSTEM</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>8 (4.4)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>17 (9.6)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>25 (13.1)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Abdominal Pain</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>3 (1.2)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>13 (5.3)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>14 (6.8)</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>UROGENITAL SYSTEM</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>20 (11.1)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>34 (19.2)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>45 (23.6)</item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Breast Pain</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>9 (3.6)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>22 (9)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>20 (7.8)</item></list></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen and progestin drug metabolism. Inducers of CYP3A4 such as St. John\u2019s wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine and rifampin may decrease the plasma concentration of estrogens and progestins, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase the plasma concentration of the estrogen or the progestin or both and may result in adverse reactions. Co-administration of atorvastatin and certain hormonal products containing ethinyl estradiol increase AUC values for ethinyl estradiol approximately 20 percent. Ascorbic acid and acetaminophen may increase the plasma ethinyl estradiol concentration, possibly by inhibition of conjugation. Combination hormonal products have been shown to significantly decrease the plasma concentration of lamotrigine likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. (7.1)"
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Norethindrone acetate and ethinyl estradiol tablets are not indicated for use in pregnancy. There are no data with the use of norethindrone acetate and ethinyl estradiol tablets in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined (estrogens and progestins) product before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary Estrogens plus progestogens are present in human milk and can reduce milk production in breast-feeding women. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. The development and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol tablets and any potential adverse effects on the breastfed child from norethindrone acetate and ethinyl estradiol tablets or from the underlying maternal condition. 8.4 Pediatric Use Norethindrone acetate and ethinyl estradiol tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population. 8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing norethindrone acetate and ethinyl estradiol tablets to determine whether those over 65 years of age differ from younger subjects in their response to norethindrone acetate and ethinyl estradiol tablets. The Women\u2019s Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . The Women\u2019s Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Norethindrone acetate and ethinyl estradiol tablets are not indicated for use in pregnancy. There are no data with the use of norethindrone acetate and ethinyl estradiol tablets in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined (estrogens and progestins) product before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Norethindrone acetate and ethinyl estradiol tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing norethindrone acetate and ethinyl estradiol tablets to determine whether those over 65 years of age differ from younger subjects in their response to norethindrone acetate and ethinyl estradiol tablets. The Women\u2019s Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . The Women\u2019s Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE Overdosage of estrogen plus progestogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of norethindrone acetate and ethinyl estradiol tablets therapy with institution of appropriate symptomatic care."
    ],
    "description": [
      "11 DESCRIPTION Norethindrone Acetate and Ethinyl Estradiol Tablets, USP is a continuous dosage regimen of a progestin-estrogen combination for oral administration. The following two strengths of Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are available as: Norethindrone Acetate and Ethinyl Estradiol Tablets USP (0.5 mg/2.5 mcg): Each light pink to pink, round, flat-faced beveled edge, uncoated tablet contains 0.5 mg norethindrone acetate, USP and 2.5 mcg ethinyl estradiol, USP. Norethindrone Acetate and Ethinyl Estradiol Tablets USP (1 mg/5 mcg): Each white to off-white, round, flat-faced beveled edge, uncoated tablet contains 1 mg norethindrone acetate, USP and 5 mcg ethinyl estradiol, USP. Each tablet also contains the following inactive ingredients: calcium stearate, cornstarch, lactose monohydrate, microcrystalline cellulose, povidone and vitamin E and talc. The 0.5 mg/2.5 mcg light pink to pink tablet also contains D&C red no. 30. The structural formulas are as follows Ethinyl Estradiol, USP [19-Nor-17\u03b1-pregna-1,3,5(10)-trien-20-yne-3,17-diol] Molecular Weight: 296.40 Molecular Formula: C 20 H 24 O 2 Norethindrone Acetate USP [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 \u03b1)] Molecular Weight: 340.46 Molecular Formula: C 22 H 28 O 3 eestructure noreestructure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. The pharmacologic effects of ethinyl estradiol are similar to those of endogenous estrogens. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, bone, skeletal tissue and central nervous system. Progestins produce similar endometrial changes to those of the naturally occurring hormone progesterone. 12.2 Pharmacodynamics Generally, a serum estrogen concentration does not predict an individual woman\u2019s therapeutic response to norethindrone acetate and ethinyl estradiol tablets nor her risk for adverse outcomes. Likewise, exposure comparisons across different estrogen products to infer efficacy or safety for the individual woman may not be valid. 12.3 Pharmacokinetics Absorption Norethindrone acetate (NA) is completely deacetylated to norethindrone after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol (EE) are absorbed from norethindrone acetate and ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol generally occurring 1 to 2 hours postdose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64 percent for norethindrone and 55 percent for ethinyl estradiol. Bioavailability of norethindrone acetate and ethinyl estradiol tablets is similar to that from solution for norethindrone and slightly less for ethinyl estradiol. Administration of norethindrone acetate and ethinyl estradiol tablets with a high fat meal decreases rate but not extent of ethinyl estradiol absorption. The extent of norethindrone absorption is increased by 27 percent following administration of norethindrone acetate and ethinyl estradiol tablets with food. The full pharmacokinetic profile of norethindrone acetate and ethinyl estradiol tablets was not characterized due to assay sensitivity limitations. However, the multiple-dose pharmacokinetics were studied at a dose of 1 mg NA/10 mcg EE in 18 post-menopausal women. Mean plasma concentrations are shown below (Figure 1) and pharmacokinetic parameters are found in Table 2. Based on a population pharmacokinetic analysis, mean steady-state concentrations of norethindrone for 1 mg NA/5 mcg EE and 1/10 are slightly more than proportional to dose when compared to 0.5 mg NA/2.5 mcg EE tablets. It can be explained by higher SHBG concentrations. Mean steady-state plasma concentrations of ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 0.5 /2.5 tablets and norethindrone acetate and ethinyl estradiol 1 /5 tablets are proportional to dose, but there is a less than proportional increase in steady-state concentrations for the NA/EE 1 /10 tablet. Figure 1. Mean Steady-State (Day 87) Plasma Norethindrone and Ethinyl Estradiol Concentrations Following Continuous Oral Administration of 1 mg NA/10 mcg EE Tablets Table 2. Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters\u2020 Following Administration of 1 mg NA/10 mcg EE Tablets C max t max AUC (0 to 24) CL/F t 1/2 NORETHINDRONE ng/mL hr ng\u2022hr/mL mL/min hr Day 1 6 (3.3) 1.8 (0.8) 29.7 (16.5) 588 (416) 10.3 (3.7) Day 87 10.7 (3.6) 1.8 (0.8) 81.8 (36.7) 226 (139) 13.3 (4.5) ETHINYL ESTRADIOL pg/mL hr pg\u2022hr/mL mL/min hr Day 1 33.5 (13.7) 2.2 (1) 339 (113) ND \u2021 ND \u2021 Day 87 38.3 (11.9) 1.8 (0.7) 471 (132) 383 (119) 23.9 (7.1) \u2020 C max = Maximum plasma concentration; t max = time of C max ; AUC (0 to 24) = Area under the plasma concentration-time curve over the dosing interval; and CL/F = Apparent oral clearance; t \u00bd = Elimination half-life \u2021 ND = Not determined Based on a population pharmacokinetic analysis, average steady-state concentrations (Css) of norethindrone and ethinyl estradiol for norethindrone acetate and ethinyl estradiol 1/5 tablets are estimated to be 2.6 ng/mL and 11.4 pg/mL, respectively. Css values of norethindrone and ethinyl estradiol for norethindrone acetate and ethinyl estradiol 0.5/2.5 tablets are estimated to be 1.1 ng/mL and 5.4 ng/mL, respectively. The pharmacokinetics of ethinyl estradiol and norethindrone acetate were not affected by age, (age range 40 to 62 years), in the postmenopausal population studied. Distribution The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin. Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95 percent); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol, such that exposure to ethinyl estradiol following administration of 1 mg of norethindrone acetate is equivalent to oral administration of 2.8 mcg ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of 1 mg NA/10 mcg EE tablets are approximately 13 hours and 24 hours, respectively. fig1"
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"_Refid1351\" cellpadding=\"0pt\" width=\"99.4%\"><caption>Table 2. Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters&#x2020; Following Administration of 1 mg NA/10 mcg EE Tablets </caption><col width=\"28%\"/><col width=\"17%\"/><col width=\"13%\"/><col width=\"16%\"/><col width=\"15%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>C<sub>max</sub></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>t<sub>max</sub></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>AUC (0 to 24)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>CL/F</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>t<sub>1/2</sub></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"bold\">NORETHINDRONE</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ng/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ng&#x2022;hr/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>mL/min</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 1</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>6 (3.3)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>1.8 (0.8)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>29.7 (16.5)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>588 (416)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>10.3 (3.7)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 87</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>10.7 (3.6)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>1.8 (0.8)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>81.8 (36.7)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>226 (139)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>13.3 (4.5)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"bold\">ETHINYL ESTRADIOL</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>pg/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>pg&#x2022;hr/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>mL/min</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 1</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>33.5 (13.7)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>2.2 (1)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>339 (113)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ND<sup>&#x2021;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ND<sup>&#x2021;</sup></item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 87</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>38.3 (11.9)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>1.8 (0.7)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>471 (132)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>383 (119)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>23.9 (7.1)</item></list></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. The pharmacologic effects of ethinyl estradiol are similar to those of endogenous estrogens. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, bone, skeletal tissue and central nervous system. Progestins produce similar endometrial changes to those of the naturally occurring hormone progesterone."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Generally, a serum estrogen concentration does not predict an individual woman\u2019s therapeutic response to norethindrone acetate and ethinyl estradiol tablets nor her risk for adverse outcomes. Likewise, exposure comparisons across different estrogen products to infer efficacy or safety for the individual woman may not be valid."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption Norethindrone acetate (NA) is completely deacetylated to norethindrone after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol (EE) are absorbed from norethindrone acetate and ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol generally occurring 1 to 2 hours postdose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64 percent for norethindrone and 55 percent for ethinyl estradiol. Bioavailability of norethindrone acetate and ethinyl estradiol tablets is similar to that from solution for norethindrone and slightly less for ethinyl estradiol. Administration of norethindrone acetate and ethinyl estradiol tablets with a high fat meal decreases rate but not extent of ethinyl estradiol absorption. The extent of norethindrone absorption is increased by 27 percent following administration of norethindrone acetate and ethinyl estradiol tablets with food. The full pharmacokinetic profile of norethindrone acetate and ethinyl estradiol tablets was not characterized due to assay sensitivity limitations. However, the multiple-dose pharmacokinetics were studied at a dose of 1 mg NA/10 mcg EE in 18 post-menopausal women. Mean plasma concentrations are shown below (Figure 1) and pharmacokinetic parameters are found in Table 2. Based on a population pharmacokinetic analysis, mean steady-state concentrations of norethindrone for 1 mg NA/5 mcg EE and 1/10 are slightly more than proportional to dose when compared to 0.5 mg NA/2.5 mcg EE tablets. It can be explained by higher SHBG concentrations. Mean steady-state plasma concentrations of ethinyl estradiol for the norethindrone acetate and ethinyl estradiol 0.5 /2.5 tablets and norethindrone acetate and ethinyl estradiol 1 /5 tablets are proportional to dose, but there is a less than proportional increase in steady-state concentrations for the NA/EE 1 /10 tablet. Figure 1. Mean Steady-State (Day 87) Plasma Norethindrone and Ethinyl Estradiol Concentrations Following Continuous Oral Administration of 1 mg NA/10 mcg EE Tablets Table 2. Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters\u2020 Following Administration of 1 mg NA/10 mcg EE Tablets C max t max AUC (0 to 24) CL/F t 1/2 NORETHINDRONE ng/mL hr ng\u2022hr/mL mL/min hr Day 1 6 (3.3) 1.8 (0.8) 29.7 (16.5) 588 (416) 10.3 (3.7) Day 87 10.7 (3.6) 1.8 (0.8) 81.8 (36.7) 226 (139) 13.3 (4.5) ETHINYL ESTRADIOL pg/mL hr pg\u2022hr/mL mL/min hr Day 1 33.5 (13.7) 2.2 (1) 339 (113) ND \u2021 ND \u2021 Day 87 38.3 (11.9) 1.8 (0.7) 471 (132) 383 (119) 23.9 (7.1) \u2020 C max = Maximum plasma concentration; t max = time of C max ; AUC (0 to 24) = Area under the plasma concentration-time curve over the dosing interval; and CL/F = Apparent oral clearance; t \u00bd = Elimination half-life \u2021 ND = Not determined Based on a population pharmacokinetic analysis, average steady-state concentrations (Css) of norethindrone and ethinyl estradiol for norethindrone acetate and ethinyl estradiol 1/5 tablets are estimated to be 2.6 ng/mL and 11.4 pg/mL, respectively. Css values of norethindrone and ethinyl estradiol for norethindrone acetate and ethinyl estradiol 0.5/2.5 tablets are estimated to be 1.1 ng/mL and 5.4 ng/mL, respectively. The pharmacokinetics of ethinyl estradiol and norethindrone acetate were not affected by age, (age range 40 to 62 years), in the postmenopausal population studied. Distribution The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin. Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95 percent); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol, such that exposure to ethinyl estradiol following administration of 1 mg of norethindrone acetate is equivalent to oral administration of 2.8 mcg ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of 1 mg NA/10 mcg EE tablets are approximately 13 hours and 24 hours, respectively. fig1"
    ],
    "pharmacokinetics_table": [
      "<table ID=\"_Refid1351\" cellpadding=\"0pt\" width=\"99.4%\"><caption>Table 2. Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters&#x2020; Following Administration of 1 mg NA/10 mcg EE Tablets </caption><col width=\"28%\"/><col width=\"17%\"/><col width=\"13%\"/><col width=\"16%\"/><col width=\"15%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>C<sub>max</sub></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>t<sub>max</sub></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>AUC (0 to 24)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>CL/F</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>t<sub>1/2</sub></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"bold\">NORETHINDRONE</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ng/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ng&#x2022;hr/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>mL/min</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 1</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>6 (3.3)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>1.8 (0.8)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>29.7 (16.5)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>588 (416)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>10.3 (3.7)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 87</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>10.7 (3.6)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>1.8 (0.8)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>81.8 (36.7)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>226 (139)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>13.3 (4.5)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"bold\">ETHINYL ESTRADIOL</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>pg/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>pg&#x2022;hr/mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>mL/min</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>hr</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 1</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>33.5 (13.7)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>2.2 (1)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>339 (113)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ND<sup>&#x2021;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>ND<sup>&#x2021;</sup></item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Day 87</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>38.3 (11.9)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>1.8 (0.7)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>471 (132)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>383 (119)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>23.9 (7.1)</item></list></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Effects on Vasomotor Symptoms in Postmenopausal Women A 12-week placebo-controlled, multicenter, randomized clinical trial was conducted in 266 symptomatic women who had at least 56 moderate to severe hot flushes during the week prior to randomization. On average, women had 12 hot flushes per day upon study entry. A total of 66 women were randomized to receive norethindrone acetate and ethinyl estradiol tablets 1/5 and 66 women were randomized to the placebo group. Norethindrone acetate and ethinyl estradiol tablets 1/5 was shown to be statistically better than placebo at weeks 4, and 12 for relief of the frequency of moderate to severe vasomotor symptoms (see Table 3). In Table 4, norethindrone acetate and ethinyl estradiol tablets 1 /5 was shown to be statistically better than placebo at weeks 4 and 12 for relief of the severity of moderate to severe vasomotor symptoms. Table 3. Mean Change from Baseline in the Number of Moderate to Severe Vasomotor Symptoms per Week -ITT Population, LOCF Visit Placebo (N = 66) Norethindrone Acetate and Ethinyl Estradiol Tablets 0.5 /2.5 (N = 67) Norethindrone Acetate and Ethinyl Estradiol Tablets 1 /5 (N = 66) Baseline [1] Mean (SD) 76.5 (21.4) 77.6 (26.5) 70 (16.6) Week 4 Mean (SD) 39.4 (27.6) 30.2 (26.1) 20.4 (22.7) Mean Change From Baseline (SD) -37 (26.6) -47.4 \u00e8 (26.1) -49.6 \u00e8 (22.1) p-Value vs. Placebo (95 percent CI) [2] 0.041 (-20, -1) <0.001 (-22, -6) Week 12 Mean (SD) 31.1 (27) 13.8 (20.4) 11.3 (18.9) Mean Change from Baseline (SD) -45.3 (30.2) -63.8 \u00e8 (27.5) -58.7 \u00e8 (23.1) p-Value vs. Placebo (95 percent CI) [2] <0.001 (-27, -7) <0.001 (-25, -5) \u00e8 Denotes statistical significance at the 0.05 level [1] The baseline number of moderate to severe vasomotor symptoms (MSVS) is the weekly average number of MSVS during the two week pre-randomization observation period. [2] ANCOVA -Analysis of Covariance model where the observation variable is change from baseline; independent variables include treatment, center and baseline as covariate. The 95 percent CI -Mann-Whitney confidence interval for the difference between means (not stratified by center). ITT = intent to treat; LOCF last observation carried forward; CI = confidence interval 2 randomized subjects (1 in Placebo and 1 in norethindrone acetate and ethinyl estradiol tablets) did not return diaries. Table 4. Mean Change from Baseline in the Daily Severity Score of Moderate to Severe Vasomotor Symptoms per Week - ITT Population, LOCF Visit Placebo (N = 66) Norethindrone Acetate and Ethinyl Estradiol Tablets 0.5 /2.5 (N = 67) Norethindrone Acetate and Ethinyl Estradiol Tablets 1 /5 (N = 66) Baseline [1] Mean (SD) 2.49 (0.26) 2.48 (0.22) 2.47 (0.23) Week 4 Mean (SD) 2.13 (0.74) 1.88 (0.89) 1.45 (1.03) Mean Change from Baseline (SD) -0.36 (0.68) -0.59 (0.83) -1.02 \u00a5 (1.06) p-Value vs Placebo (95 percent CI) [2] - 0.130 (-0.3, 0) <0.001 (-0.9, -0.2) Week 5 Mean (SD) 2.06 (0.79) 1.68 (0.99) 1.23 (1.03) Mean Change from Baseline (SD) -0.44 (0.74) -0.8 \u00a5 (0.94) -1.24 \u00a5 (1.07) p-Value vs Placebo (95 percent CI) [2] - 0.041 (-0.4, -0) <0.001 (-1.2, -0.3) Week 12 Mean (SD) 1.82 (1.03) 1.22 (1.11) 1.02 (1.16) Mean Change from Baseline (SD) -0.67 (1.02) -1.26 \u00a5 (1.08) -1.45 \u00a5 (1.19) p-Value vs Placebo (95 percent CI) [2] - 0.002 (-0.9, -0.2) <0.001 (-1.4, -0.3) \u00a5 Denotes statistical significance at the 0.05 level [1] The baseline severity of moderate to severe vasomotor symptoms (MSVS) is the daily severity score of MSVS during the two week pre-randomization observation period. [2] ANCOVA - Analysis of Covariance model where the observation variable is change from baseline; independent variables include treatment, center and baseline as covariate. The 95 percent CI - Mann-Whitney confidence interval for the difference between means (not stratified by center). ITT = intent to treat; LOCF = last observation carried forward; CI = confidence interval 2 randomized women (1 in Placebo and 1 in norethindrone acetate and ethinyl estradiol tablets) did not return diaries. 14.2 Effects on the Endometrium A 2-year, placebo-controlled, multicenter, randomized clinical trial was conducted to determine the safety and efficacy of norethindrone acetate and ethinyl estradiol tablets on maintaining bone mineral density, protecting the endometrium, and to determine effects on lipids. A total of 1,265 women were enrolled and randomized to either placebo, 0.2 mg NA/1 mcg ethinyl estradiol (NA/EE 0.2 /1), 0.5 mg NA/2.5 mcg EE (NA/EE 0.5 /2.5), norethindrone acetate and ethinyl estradiol tablets 1/5 and 1 mg NA/10 mcg EE (NA/EE 1/10) or matching unopposed EE doses (1, 2.5, 5, or 10 mcg) for a total of 9 treatment groups. All participants received 1000 mg of calcium supplementation daily. Of the 1,265 women randomized to the various treatment arms of this study, 137 were randomized to placebo, 146 to norethindrone acetate and ethinyl estradiol tablets 1/5, 136 to NA/EE 0.5/2.5 and 141 to EE 5 mcg and 137 to EE 2.5 mcg. Of these, 134 placebo, 143 norethindrone acetate and ethinyl estradiol tablets 1/5, 136 NA/EE 0.5/2.5, 139 EE 5 mcg and 137 EE 2.5 mcg had a baseline endometrial result. Baseline biopsies were classified as normal (in approximately 95 percent of subjects), or insufficient tissue (in approximately 5 percent of subjects). Follow-up biopsies were obtained in approximately 70 to 80 percent of patients in each arm after 12 and 24 months of therapy. Results for norethindrone acetate and ethinyl estradiol tablets 1/5 and appropriate comparators are shown in Table 5. Table 5. Endometrial Biopsy Results After 12 and 24 Months of Treatment (CHART Study, 376-359) Endometrial Status Placebo Norethindrone Acetate and Ethinyl Estradiol Tablets EE Alone 0.5/2.5 1/5 2.5 mcg 5 mcg Number of Patients Biopsied at Baseline N = 134 N = 136 N = 143 N = 137 N = 139 MONTH 12 (Percent Patients) Patients Biopsied (percent) 113 (84) 103 (74) 110 (77) 100 (73) 114 (82) Insufficient Tissue 30 34 45 20 20 Atrophic Tissue 60 41 41 15 2 Proliferative Tissue 23 28 24 65 91 Endometrial Hyperplasia * 0 0 0 0 1 MONTH 24 (Percent Patients) Patients Biopsied (percent) 94 (70) 99 (73) 102 (71) 89 (65) 107 (77) Insufficient Tissue 35 42 37 23 17 Atrophic Tissue 38 30 33 6 2 Proliferative Tissue 20 27 32 60 86 Endometrial Hyperplasia * 1 0 0 0 2 * All patients with endometrial hyperplasia were carried forward for all time points. 14.3 Effects on Uterine Bleeding or Spotting in Postmenopausal Women The cumulative incidence of amenorrhea, defined as no bleeding or spotting obtained from participant recall, was evaluated over 12 months for norethindrone acetate and ethinyl estradiol tablets 1/5 and placebo arms. Results are shown in Figure 2. Figure 2. Participants with Cumulative Amenorrhea Over Time: Intent-to-Treat Population, Last Observation Carried Forward fig2 14.4 Effect on Bone Mineral Density in Postmenopausal Women In the 2 year study, trabecular BMD was assessed at lumbar spine using quantitative computed tomography. A total of 419 postmenopausal primarily Caucasian women, 40 to 64 years of age, with intact uteri and non-osteoporotic bone mineral densities were randomized (1:1:1) to norethindrone acetate and ethinyl estradiol tablets 1/5, NA/EE 0.5/2.5 or placebo. Approximately 75 percent of the women in each group completed the two-year study. All women received 1000 mg calcium in divided doses. Vitamin D was not supplemented. As shown in Figure 3, women treated with norethindrone acetate and ethinyl estradiol tablets 1/5 had an average increase of 3.1 percent in lumbar spine BMD from baseline to Month 24. Women treated with placebo had average decreases of \u20136.3 percent in spinal BMD from baseline to Month 24. The differences in the changes from baseline to Month 24 in the norethindrone acetate and ethinyl estradiol tablets 1/5 group compared with the placebo group was statistically significant. Figure 3. Mean Percent Change (+ SE) From Baseline in Volumetric Bone Mineral Density* at Lumbar Spine Measured by Quantitative Computed Tomography after 12 and 24 Months of Treatment (Intent-to-Treat Population) *It should be noted that when measured by QCT, BMD gains and losses are greater than when measured by dual X-ray absorptiometry (DXA). Therefore, the differences in the changes in BMD between the placebo and active drug treated groups will be larger when measured by QCT compared with DXA. Changes in BMD measured by DXA should not be compared with changes in BMD measured by QCT. fig3 14.5 Women's Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome. A \u201cglobal index\u201d included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other cause. The study did not evaluate the effects of CE plus MPA or CE-alone on menopausal symptoms. WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the \u201cglobal index\u201d. The absolute excess risk of events included in the \u201cglobal index\u201d was 19 per 10,000 women-years. For those outcomes included in the WHI \u201cglobal index\u201d that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 6. These results reflect centrally adjudicated data after an average follow-up of 5.6 years. Table 6. Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years \u00b6 #\u03f7 Event Relative Risk CE/MPA vs. Placebo (95 percent nCI \u00df ) CE/MPA n = 8,506 Placebo n = 8,102 Absolute Risk per 10,000 Women-Years CHD events 1.23 (0.99 to 1.53) 41 34 Non-fatal MI 1.28 (1 to 1.63) 31 25 CHD death 1.10 (0.7 to 1.75) 8 8 All strokes 1.31 (1.03 to 1.68) 33 25 Ischemic stroke 1.44 (1.09 to 1.9) 26 18 Deep vein thrombosis \u00e0 1.95 (1.43 to 2.67) 26 13 Pulmonary embolism 2.13 (1.45 to 3.11) 18 8 Invasive breast cancer \u1ebb 1.24 (1.01 to 1.54) 41 33 Colorectal cancer 0.61 (0.42 to 0.87) 10 16 Endometrial cancer \u00e0 0.81 (0.48 to 1.36) 6 7 Cervical cancer \u00e0 1.44 (0.47 to 4.42) 2 1 Hip fracture 0.67 (0.47 to 0.96) 11 16 Vertebral fractures \u00e0 0.65 (0.46 to 0.92) 11 17 Lower arm/wrist fractures \u00e0 0.71 (0.59 to 0.85) 44 62 Total fractures \u00e0 0.76 (0.69 to 0.83) 152 199 Overall Mortality \u00df \u00f0 1 (0.83 to 1.19) 52 52 Global Index \u00f8 1.13 (1.02 to 1.25) 184 165 \u00b6 Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi. #\u03f7 Results are based on centrally adjudicated data. \u00df Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. \u00e0 Not included in \"global index\". \u1ebb Includes metastic and non-metastic breast cancer with the exception of in situ cancer. \u00f0 All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. \u00f8 A subset of the events was combined in a \"global index\" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age, a non-significant trend toward reduced risk for overall mortality [( hazard ratio (HR) 0.69 (95 percent CI, 0.44 to 1.07) ]. WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was also stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years, are presented in Table 7. Table 7. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI \u00a5 Event Relative Risk CE vs. Placebo (95 percent nCI CE CE N = 5,310 Placebo n = 5,429 Absolute Risk per 10,000 Women-Years CHD events ce 0.95 (0.78 to 1.16) 54 57 Non-fatal MI ce 0.91 (0.73 to1.14) 40 42 CHD death ce 1.01 (0.71 to1.43) 16 16 All strokes ce 1.33 (1.05 to 1.68) 45 33 Ischemic stroke ce 1.55 (1.19 to 2.01) 38 25 Deep vein thrombosis ce \u0110 1.47 (1.06 to 2.06) 23 15 Pulmonary embolism ce 1.37 (0.90 to 2.07) 14 10 Invasive breast cancer ce 0.80 (0.62 to 1.04) 28 34 Colorectal cancer* 1.08 (0.75 to 1.55) 17 16 Hip fracture ce 0.65 (0.45 to 0.94) 12 19 Vertebral fractures ce \u0110 0.64 (0.44 to 0.93) 11 18 Lower arm/wrist fractures ce \u0110 0.58 (0.47 to 0.72) 35 59 Total fractures ce \u0110 0.71 (0.64 to 0.8) 144 197 Deaths due to other causes* \u2020 1.08 (0.88 to 1.32) 53 50 Overall Mortality ce \u0110 1.04 (0.88 to 1.22) 79 75 Global Index \u2021 1.02(0.92 to 1.13) 206 201 \u00a5 Adapted from numerous WHI publications. WHI publications can be viewed at www.nblbi.nih.gov/whi . CE Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. ce Results are based on centrally adjudicated data for an average follow-up of 7.1 years. \u0110 Not included in \"global index\". * Results are based on an average follow-up of 6.8 years. \u2020 All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. \u2021 A subset of the events was combined in a \"global index\" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. For those outcomes included in the WHI \u201cglobal index\u201d that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone were 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. 9 The absolute excess risk of events included in the \u201cglobal index\u201d was a non- significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years (see Table 7). Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone therapy increased the risk of ischemic stroke, and this excess was present in all subgroups of women examined 10 (see Table 7). Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [ HR 0.63 (95 percent CI, 0.36 to 1.09) ] and overall mortality [HR 0.71 ( 95 percent CI, 0.46 to 1.11 )]. 14.6 Women's Health Initiative Memory Study The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, and 18 percent were 75 years of age and older) to evaluate the effects of CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21 to 3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 per 10,000 women-years. Probable dementia as defined in this study included Alzheimer\u2019s disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [ see Warnings and Precautions ( 5.3 ) , and Use in Specific Populations ( 8.5 ) ]. The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age and older (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83 to 2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions ( 5.3 ) , and Use in Specific Populations ( 8.5 )]. When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19 to 2.6). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women [ see Warnings and Precautions ( 5.3 ) , and Use in Specific Populations ( 8.5 )] ."
    ],
    "clinical_studies_table": [
      "<table width=\"90.36%\"><col width=\"27%\"/><col width=\"18%\"/><col width=\"27%\"/><col width=\"29%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Visit</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo </content> <content styleCode=\"bold\">(N = 66)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Norethindrone Acetate and Ethinyl Estradiol Tablets</content></paragraph><paragraph><content styleCode=\"bold\">0.5 /2.5 </content> <content styleCode=\"bold\">(N = 67)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Norethindrone Acetate and Ethinyl Estradiol Tablets</content> <content styleCode=\"bold\">1 /5 </content> <content styleCode=\"bold\">(N = 66)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Baseline [1]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean (SD) </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>76.5 (21.4) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>77.6 (26.5) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>70 (16.6) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Week 4</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean (SD) </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>39.4 (27.6) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30.2 (26.1) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20.4 (22.7) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean Change From Baseline (SD)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-37 (26.6) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-47.4<sup>&#xE8;</sup> (26.1) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-49.6<sup>&#xE8;</sup> (22.1) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>p-Value vs. Placebo  (95 percent CI) [2]</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.041 (-20, -1) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt;0.001 (-22, -6) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Week 12</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean (SD)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>31.1 (27)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13.8 (20.4) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11.3 (18.9) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean Change from Baseline (SD)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-45.3 (30.2) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-63.8<sup>&#xE8;</sup> (27.5) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-58.7<sup>&#xE8;</sup> (23.1) </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>p-Value vs. Placebo  (95 percent CI) [2]</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>&lt;0.001 (-27, -7) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>&lt;0.001 (-25, -5) </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"32%\"/><col width=\"16%\"/><col width=\"26%\"/><col width=\"26%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Visit</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo </content> <content styleCode=\"bold\">(N = 66)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Norethindrone Acetate and Ethinyl Estradiol Tablets</content> <content styleCode=\"bold\">0.5 /2.5</content></paragraph><paragraph><content styleCode=\"bold\">(N = 67)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Norethindrone Acetate and Ethinyl Estradiol Tablets</content> <content styleCode=\"bold\">1 /5 </content> <content styleCode=\"bold\">(N = 66)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Baseline [1]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean (SD)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.49 (0.26)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.48 (0.22)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.47 (0.23)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Week 4</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean (SD)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.13 (0.74)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.88 (0.89)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.45 (1.03)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean Change from Baseline (SD)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-0.36 (0.68)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-0.59 (0.83)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-1.02<sup>&#xA5;</sup> (1.06)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>p-Value vs Placebo (95 percent CI) [2]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>0.130 (-0.3, 0)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>&lt;0.001 (-0.9, -0.2)</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Week 5</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean (SD)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.06 (0.79)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.68 (0.99)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.23 (1.03)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean Change from Baseline (SD)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-0.44 (0.74)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-0.8<sup>&#xA5; </sup>(0.94)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-1.24<sup>&#xA5; </sup>(1.07)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>p-Value vs Placebo (95 percent CI) [2]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.041 (-0.4, -0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.001 (-1.2, -0.3)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Week 12</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean (SD)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1.82 (1.03)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1.22 (1.11)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1.02 (1.16)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Mean Change from Baseline (SD)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-0.67 (1.02)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-1.26<sup>&#xA5;</sup> (1.08)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-1.45<sup>&#xA5;</sup> (1.19)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>p-Value vs Placebo (95 percent CI) [2]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0.002 (-0.9, -0.2)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>&lt;0.001 (-1.4, -0.3)</paragraph></td></tr></tbody></table>",
      "<table width=\"95.14%\"><col width=\"28%\"/><col width=\"14%\"/><col width=\"19%\"/><col width=\"16%\"/><col width=\"12%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Endometrial Status</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Norethindrone Acetate and Ethinyl Estradiol Tablets</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">EE Alone</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.5/2.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1/5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.5 mcg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5 mcg</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Number of Patients Biopsied at Baseline</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>N = 134</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>N = 136</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>N = 143</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>N = 137</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>N = 139</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">MONTH 12 (Percent Patients)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Patients Biopsied (percent)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>113 (84)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>103 (74)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>110 (77)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>100 (73)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>114 (82)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Insufficient Tissue </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Atrophic Tissue </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Proliferative Tissue </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>91</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Endometrial Hyperplasia <sup>*</sup></item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">MONTH 24 (Percent Patients)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Patients Biopsied (percent) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>94 (70)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>99 (73)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>102 (71)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>89 (65)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>107 (77)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Insufficient Tissue </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Atrophic Tissue </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Proliferative Tissue </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>86</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Endometrial Hyperplasia <sup>*</sup></item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"26%\"/><col width=\"27%\"/><col width=\"21%\"/><col width=\"25%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Event</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Relative Risk  CE/MPA vs. Placebo (95 percent nCI<sup>&#xDF;</sup>)</item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>CE/MPA</paragraph><paragraph>n = 8,506</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Placebo n = 8,102</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>Absolute Risk per 10,000 Women-Years</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>CHD events</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1.23 (0.99 to 1.53)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>41</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>34</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">Non-fatal MI</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">1.28 (1 </content>to<content styleCode=\"italics\"> 1.63)</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">31</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">25</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">CHD death</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">1.10 (0.7 </content>to<content styleCode=\"italics\"> 1.75)</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">8</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">8</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>All strokes</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1.31 (1.03 to 1.68)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>33</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>25</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">Ischemic stroke</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">1.44 (1.09 </content>to<content styleCode=\"italics\"> 1.9)</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">26</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"italics\">18</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Deep vein thrombosis <sup>&#xE0;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1.95 (1.43 to 2.67)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>26</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>13</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Pulmonary embolism</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>2.13 (1.45 to 3.11)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>18</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>8</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Invasive breast cancer <sup>&#x1EBB;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1.24 (1.01 to 1.54)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>41</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>33</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Colorectal cancer</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>0.61 (0.42 to 0.87)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>10</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>16</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Endometrial cancer<sup> &#xE0;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>0.81 (0.48 to 1.36)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>6</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>7</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Cervical cancer <sup>&#xE0;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1.44 (0.47 to 4.42)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>2</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Hip fracture</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>0.67 (0.47 to 0.96)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>11</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>16</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Vertebral fractures <sup>&#xE0;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>0.65 (0.46 to 0.92)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>11</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>17</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Lower arm/wrist fractures <sup>&#xE0;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>0.71 (0.59 to 0.85)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>44</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>62</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Total fractures <sup>&#xE0;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>0.76 (0.69 to 0.83)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>152</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>199</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Overall Mortality <sup>&#xDF; &#xF0;</sup></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1 (0.83 to 1.19)</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>52</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>52</item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>Global Index <sup>&#xF8;</sup></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>1.13 (1.02 to 1.25)</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>184</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>165</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"37%\"/><col width=\"30%\"/><col width=\"17%\"/><col width=\"17%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Event </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph> Relative Risk CE vs. Placebo (95 percent nCI<sup>CE</sup></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph> CE N = 5,310</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph> Placebo n = 5,429</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> </paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> Absolute Risk per 10,000 Women-Years</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> CHD events<sup>ce</sup> </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 0.95 (0.78 to 1.16)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 54</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 57</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> <content styleCode=\"italics\">Non-fatal MI<sup>ce</sup> </content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> <content styleCode=\"italics\">0.91 (0.73 to1.14)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 40</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 42</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> <content styleCode=\"italics\">CHD death</content><sup>ce</sup></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 1.01 (0.71 to1.43)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 16</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 16</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> All strokes<sup>ce</sup> </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 1.33 (1.05 to 1.68)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 45</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 33</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> <content styleCode=\"italics\">Ischemic stroke</content><sup>ce</sup><content styleCode=\"italics\"> </content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 1.55 (1.19 to 2.01)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 38</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> 25</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Deep vein thrombosis<sup>ce</sup> <sup>&#x110;</sup> </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 1.47 (1.06 to 2.06)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 23</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 15</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Pulmonary embolism<sup>ce</sup> </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 1.37 (0.90 to 2.07)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 14</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 10</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Invasive breast cancer<sup>ce</sup> </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 0.80 (0.62 to 1.04)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 28</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 34</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Colorectal cancer* </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 1.08 (0.75 to 1.55)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 17</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 16</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Hip fracture<sup>ce</sup> </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 0.65 (0.45 to 0.94)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 12</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 19</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Vertebral fractures<sup>ce</sup> <sup>&#x110;</sup></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 0.64 (0.44 to 0.93)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 11</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 18</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Lower arm/wrist fractures<sup> ce</sup> <sup>&#x110;</sup></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 0.58 (0.47 to 0.72)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 35</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 59</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Total fractures<sup> ce</sup> <sup>&#x110;</sup></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 0.71 (0.64 to 0.8)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 144</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 197</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Deaths due to other causes* <sup>&#x2020;</sup></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 1.08 (0.88 to 1.32)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 53</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 50</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> Overall Mortality<sup> ce</sup> <sup>&#x110;</sup></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 1.04 (0.88 to 1.22)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 79</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 75</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph> Global Index<sup>&#x2021;</sup></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph> 1.02(0.92 to 1.13)</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph> 206</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph> 201</paragraph></td></tr></tbody></table>"
    ],
    "references": [
      "15 REFERENCES 1. Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA . 2007;297:1465-1477. 2. Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365. 3. Cushman M, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA . 2004;292:1573-1580. 4. Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med . 2006;166:772-780. 5. Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA . 2003;289:3234-3253. 6. Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA. 2006;295:1647-1657. 7. Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. JAMA. 2003;290:1739-1748. 8. Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA. 2004;291:2947-2958. 9. Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women\u2019s Health Initiative Randomized Trial. J Bone Miner Res . 2006;21:817-828. 10. Hendrix SL, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women\u2019s Health Initiative. Circulation . 2006;113:2425-2434."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Norethindrone Acetate and Ethinyl Estradiol Tablets, USP are available in the following strengths and package sizes: Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 0.5 mg/2.5 mcg, are light pink to pink, round, flat-faced, beveled edge, uncoated, tablets debossed with \u201cD5\u201d on one side and plain on the other side. Each tablet contains 0.5 mg norethindrone acetate, USP and 2.5 mcg ethinyl estradiol, USP and are available as: NDC 68462-656-90 Bottle of 90 Tablets NDC 68462-656-29 1 carton containing 3 individual foil pouches (68462-656-84). Each pouch contains 1 blister of 28 tablets (68462-656-84) Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1 mg/5 mcg are white to off-white, round, flat-faced, beveled edge, uncoated tablets debossed with \u201cD6\u201d on one side plain on the other side. Each tablet contains 1 mg norethindrone acetate, USP and 5 mcg ethinyl estradiol, USP and are available as: NDC 68462-657-90 Bottle of 90 Tablets NDC 68462-657-29 1 carton containing 3 individual foil pouches (68462-657-84). Each pouch contains 1 blister of 28 tablets (68462-657-84). 16.2 Storage and Handling Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature]. Keep norethindrone acetate and ethinyl estradiol tablets out of the reach of children."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise women to read the FDA-approved patient labeling ( Patient Information ) Vaginal Bleeding Inform postmenopausal women to report any vaginal bleeding to their healthcare provider as soon as possible [see Warnings and Precautions ( 5.2 )] . Possible Serious Adverse Reactions with Estrogen Plus Progestogen Therapy Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestogen therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 )] . Possible Common Adverse Reactions with Estrogen Plus Progestogen Therapy Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progetogen therapy such as headache, breast pain and tenderness, nausea and vomiting. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com May 2025 logo1"
    ],
    "spl_patient_package_insert": [
      "PATIENT INFORMATION Norethindrone Acetate and Ethinyl Estradiol (nor-eth-IN-drone ASS-uh-TATE and ETH in il es tra DYE ole) Tablets, USP 0.5 mg/2.5 mcg and 1 mg/5 mcg Read this Patient Information before you start using norethindrone acetate and ethinyl estradiol tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. What is the most important information I should know about norethindrone acetate and ethinyl estradiol tablets (a combination of estrogen and progestogen)? \u2022 Do not use estrogens with or without progestogens to prevent heart disease, heart attacks, strokes or dementia (decline of brain function). \u2022 Using estrogens with progestogens may increase your chances of getting heart attack, strokes, breast cancer, or blood clots. \u2022 Using estrogens with progestogens may increase your chance of getting dementia, based on a study of women 65 years of age and older. \u2022 Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). \u2022 Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline of brain function). \u2022 Using estrogen-alone may increase your chances of getting strokes or blood clots. \u2022 Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age and older. \u2022 Only one estrogen with progestogen product and dose have been shown to increase your chances of getting heart attacks, strokes, breast cancer, blood clots, and dementia. Only one estrogen-alone product and dose have been shown to increase your chances of getting strokes, blood clots, and dementia. Because other products and doses have not been studied in the same way, it is not known how the use of norethindrone acetate and ethinyl estradiol tablets will affect your chances of these conditions. You and your healthcare provider should talk regularly about whether you still need treatment with norethindrone acetate and ethinyl estradiol tablets. What are norethindrone acetate and ethinyl estradiol tablets? Norethindrone acetate and ethinyl estradiol tablets are a prescription medicine that contains two kinds of hormones, an estrogen and a progestogen. What are norethindrone acetate and ethinyl estradiol tablets used for? Norethindrone acetate and ethinyl estradiol tablets are used after menopause to: \u2022 Reduce moderate to severe hot flushes Estrogens are hormones made by a woman\u2019s ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the \u201cchange of life\u201d or menopause, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes \u201csurgical menopause\u201d. When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden intense episodes of heat and sweating (\u201chot flashes\u201d or \u201chot flushes\u201d). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. \u2022 Help reduce your chances of getting osteoporosis (thin weak bones) If you use norethindrone acetate and ethinyl estradiol tablets only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you still need treatment with norethindrone acetate and ethinyl estradiol tablets. Who should not use norethindrone acetate and ethinyl estradiol tablets? Do not use norethindrone acetate and ethinyl estradiol tablets if you have had your uterus (womb) removed (hysterectomy). Norethindrone acetate and ethinyl estradiol tablets contain a progestogen to decrease the chance of getting cancer of the uterus (womb). If you do not have a uterus, you do not need a progestogen and you should not take norethindrone acetate and ethinyl estradiol tablets. Do not start using norethindrone acetate and ethinyl estradiol tablets if you: \u2022 have any unusual vaginal bleeding. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. \u2022 have been diagnosed with a bleeding disorder. \u2022 currently have or have had certain cancers. Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus (womb). If you have or have had cancer, talk with your healthcare provider about whether you should take norethindrone acetate and ethinyl estradiol tablets. \u2022 had a stroke or heart attack \u2022 currently have or have had blood clots \u2022 currently have or have had liver problems \u2022 are allergic to norethindrone acetate and ethinyl estradiol tablets or any of its ingredients. See the list of ingredients in norethindrone acetate and ethinyl estradiol tablets at the end of this leaflet. Before you use norethindrone acetate and ethinyl estradiol tablets, tell your healthcare provider about all of your medical conditions, including if you: \u2022 have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. \u2022 have any other medical conditions that may become worse while you are using norethindrone acetate and ethinyl estradiol tablets. Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. \u2022 are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop using norethindrone acetate and ethinyl estradiol tablets. \u2022 are pregnant or think you may be pregnant. Norethindrone acetate and ethinyl estradiol tablets is not for pregnant women. \u2022 are breastfeeding The hormones in norethindrone acetate and ethinyl estradiol tablets can pass into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how norethindrone acetate and ethinyl estradiol tablets works. Some other medicines and food products may increase or decrease the concentrations of the hormones in norethindrone acetate and ethinyl estradiol tablets in the blood. Norethindrone acetate and ethinyl estradiol tablets may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. How should I use norethindrone acetate and ethinyl estradiol tablets? \u2022 Take norethindrone acetate and ethinyl estradiol tablets exactly as your healthcare provider tells you to take it. \u2022 Take 1 norethindrone acetate and ethinyl estradiol tablet at the same time each day. \u2022 You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether or not you still need treatment with norethindrone acetate and ethinyl estradiol tablets. What are the possible side effects of norethindrone acetate and ethinyl estradiol tablets? Side effects are grouped by how serious they are and how often they happen when you are treated. Serious, but less common side effects include: \u2022 Heart attack \u2022 Stroke \u2022 Blood clots \u2022 Breast cancer \u2022 Cancer of the lining of the uterus (womb) \u2022 Cancer of the ovary \u2022 Dementia \u2022 Gallbladder disease \u2022 High or low blood calcium levels \u2022 Changes in vision \u2022 High blood pressure \u2022 High levels of fat in your blood \u2022 Liver problems \u2022 Changes in your thyroid hormone levels \u2022 Swelling or fluid retention \u2022 Cancer changes of endometriosis \u2022 Enlargement of benign tumors of the uterus (\u201cfibroids\u201d) \u2022 Worsening swelling of face or tongue (angioedema) in women who have a history of angioedema \u2022 Changes in laboratory test results such as bleeding time and high blood sugar levels Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: \u2022 new breast lumps \u2022 unusual vaginal bleeding \u2022 changes in vision or speech \u2022 sudden new severe headaches \u2022 severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Common side effects of norethindrone acetate and ethinyl estradiol tablets include: \u2022 headache \u2022 breast pain \u2022 irregular vaginal bleeding or spotting \u2022 stomach or abdominal cramps, bloating \u2022 hair loss \u2022 fluid retention \u2022 vaginal yeast infection These are not all the possible side effects of norethindrone acetate and ethinyl estradiol tablets. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or does not go away. You may report side effects to Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088. What can I do to lower my chances of a serious side effect with norethindrone acetate and ethinyl estradiol tablets? \u2022 Talk with your healthcare provider regularly about whether you should continue using norethindrone acetate and ethinyl estradiol tablets. \u2022 If you have a uterus, talk with your healthcare provider about whether norethindrone acetate and ethinyl estradiol tablet is right for you. \u2022 In general, the addition of a progestogen is recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). \u2022 See your healthcare provider right away if you get vaginal bleeding while using norethindrone acetate and ethinyl estradiol tablets. \u2022 Have a pelvic exam, breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. \u2022 If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram (breast x-ray), you may need to have breast exams more often. \u2022 If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or use tobacco, you may have a higher chance for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart disease. How should I store norethindrone acetate and ethinyl estradiol tablets? Store norethindrone acetate and ethinyl estradiol tablets at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F). Keep norethindrone acetate and ethinyl estradiol tablets out of the reach of children. General information about the safe and effective use of norethindrone acetate and ethinyl estradiol tablets. Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use norethindrone acetate and ethinyl estradiol tablets for conditions for which it was not prescribed. Do not give norethindrone acetate and ethinyl estradiol tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about norethindrone acetate and ethinyl estradiol tablets that is written for health professionals. For more information about norethindrone acetate and ethinyl estradiol tablets, call Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115. What are the ingredients in norethindrone acetate and ethinyl estradiol tablets? Active Ingredients: norethindrone acetate, USP and ethinyl estradiol, USP Inactive Ingredients: calcium stearate, cornstarch, lactose monohydrate, microcrystalline cellulose, povidone and vitamin E and talc. The 0.5 mg/2.5 mcg light pink to pink tablets also contain D&C red no. 30 . This Patient Information has been approved by the U.S Food and Drug Administration. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com May 2025 logo"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about norethindrone acetate and ethinyl estradiol tablets (a combination of estrogen and progestogen)?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Do not use estrogens with or without progestogens to prevent heart disease, heart attacks, strokes or dementia (decline of brain function).</item><item><caption>&#x2022;</caption>Using estrogens with progestogens may increase your chances of getting heart attack, strokes, breast cancer, or blood clots.</item><item><caption>&#x2022;</caption>Using estrogens with progestogens may increase your chance of getting dementia, based on a study of women 65 years of age and older.</item><item><caption>&#x2022;</caption>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).</item><item><caption>&#x2022;</caption>Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline of brain function). </item><item><caption>&#x2022;</caption>Using estrogen-alone may increase your chances of getting strokes or blood clots.</item><item><caption>&#x2022;</caption>Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age and older.</item><item><caption>&#x2022;</caption>Only one estrogen with progestogen product and dose have been shown to increase your chances of getting heart attacks, strokes, breast cancer, blood clots, and dementia. Only one estrogen-alone product and dose have been shown to increase your chances of getting strokes, blood clots, and dementia. Because other products and doses have not been studied in the same way, it is not known how the use of norethindrone acetate and ethinyl estradiol tablets will affect your chances of these conditions. You and your healthcare provider should talk regularly about whether you still need treatment with norethindrone acetate and ethinyl estradiol tablets. </item></list></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL carton-1mg-5mcg",
      "PRINCIPAL DISPLAY PANEL carton-0-5mg-2-5mcg"
    ],
    "set_id": "cf549b5a-2707-4020-9f94-dab1260e1664",
    "id": "bc4774d0-9902-4678-af65-69d6a70d9983",
    "effective_time": "20260129",
    "version": "6",
    "openfda": {
      "application_number": [
        "ANDA203038"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"
      ],
      "manufacturer_name": [
        "Glenmark Pharmaceuticals Inc., USA"
      ],
      "product_ndc": [
        "68462-656",
        "68462-657"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ETHINYL ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1090992",
        "1251323",
        "1251334",
        "1251336"
      ],
      "spl_id": [
        "bc4774d0-9902-4678-af65-69d6a70d9983"
      ],
      "spl_set_id": [
        "cf549b5a-2707-4020-9f94-dab1260e1664"
      ],
      "package_ndc": [
        "68462-656-90",
        "68462-656-29",
        "68462-657-90",
        "68462-657-29"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0368462657294",
        "0368462656297"
      ],
      "nui": [
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "423D2T571U",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate Norethindrone Acetate NORETHINDRONE ACETATE NORETHINDRONE SILICON DIOXIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE TALC to off-white flat faced beveled edged G;304"
    ],
    "description": [
      "DESCRIPTION Norethindrone acetate tablets USP - 5 mg oral tablets. Norethindrone acetate USP, (17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white, or creamy white, crystalline powder. Norethindrone acetate tablets USP, 5 mg contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and talc. structure"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone. PHARMACOKINETICS Absorption: Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf) (ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions figure1 Effect of Food: The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution: Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism: Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion: Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. SPECIAL POPULATIONS Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In pre-menopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in pre-menopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted."
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"_RefIDCD5EBF156DFB444086DB8DD624D60FB4\" width=\"100%\"><caption>Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women </caption><col width=\"59%\"/><col width=\"39%\"/><tbody><tr><td colspan=\"2\" styleCode=\"Toprule \" valign=\"top\"><paragraph>Norethindrone Acetate (n=29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>Norethindrone (NET)</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>AUC (0-inf) (ng/ml*h)</paragraph></td><td valign=\"top\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>C<sub>max</sub> (ng/ml)</paragraph></td><td valign=\"top\"><paragraph>26.19 &#xB1; 6.19</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>t<sub>max</sub> (h)</paragraph></td><td valign=\"top\"><paragraph>1.83 &#xB1; 0.58</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>t<sub>1/2</sub> (h)</paragraph></td><td valign=\"top\"><paragraph>8.51 &#xB1; 2.19</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>AUC = area under the curve,</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>C<sub>max</sub> = maximum plasma concentration,</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>t<sub>max</sub> = time at maximum plasma concentration,</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>t<sub>1/2</sub> = half-life,</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule \" valign=\"top\"><paragraph>SD = standard deviation</paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "PHARMACOKINETICS Absorption: Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf) (ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions figure1 Effect of Food: The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution: Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism: Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion: Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. SPECIAL POPULATIONS Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In pre-menopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in pre-menopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted."
    ],
    "pharmacokinetics_table": [
      "<table ID=\"_RefIDCD5EBF156DFB444086DB8DD624D60FB4\" width=\"100%\"><caption>Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women </caption><col width=\"59%\"/><col width=\"39%\"/><tbody><tr><td colspan=\"2\" styleCode=\"Toprule \" valign=\"top\"><paragraph>Norethindrone Acetate (n=29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>Norethindrone (NET)</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>AUC (0-inf) (ng/ml*h)</paragraph></td><td valign=\"top\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>C<sub>max</sub> (ng/ml)</paragraph></td><td valign=\"top\"><paragraph>26.19 &#xB1; 6.19</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>t<sub>max</sub> (h)</paragraph></td><td valign=\"top\"><paragraph>1.83 &#xB1; 0.58</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>t<sub>1/2</sub> (h)</paragraph></td><td valign=\"top\"><paragraph>8.51 &#xB1; 2.19</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>AUC = area under the curve,</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>C<sub>max</sub> = maximum plasma concentration,</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>t<sub>max</sub> = time at maximum plasma concentration,</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph>t<sub>1/2</sub> = half-life,</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule \" valign=\"top\"><paragraph>SD = standard deviation</paragraph></td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."
    ],
    "contraindications": [
      "CONTRAINDICATIONS \u2022 Known or suspected pregnancy. There is no indication for norethindrone acetate in pregnancy. (See PRECAUTIONS ). \u2022 Undiagnosed vaginal bleeding \u2022 Known, suspected or history of cancer of the breast \u2022 Active deep vein thrombosis, pulmonary embolism or history of these conditions \u2022 Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) \u2022 Impaired liver function or liver disease \u2022 As a diagnostic test for pregnancy \u2022 Hypersensitivity to any of the drug components"
    ],
    "warnings": [
      "WARNINGS 1. Cardiovascular disorders Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. 2. Visual abnormalities Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued."
    ],
    "precautions": [
      "PRECAUTIONS 1. General Precautions \u2022 Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation \u2022 In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated \u2022 Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree \u2022 Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy \u2022 The pathologist should be advised of progestin therapy when relevant specimens are submitted 2. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate. 3. Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: \u2022 Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. \u2022 Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radio immunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. \u2022 Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). \u2022 Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. \u2022 Impaired glucose metabolism. \u2022 Reduced response to metyrapone test. 4. Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established. 5. Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses. 6. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman. 7. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "general_precautions": [
      "1. General Precautions \u2022 Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation \u2022 In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated \u2022 Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree \u2022 Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy \u2022 The pathologist should be advised of progestin therapy when relevant specimens are submitted"
    ],
    "information_for_patients": [
      "2. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate."
    ],
    "drug_and_or_laboratory_test_interactions": [
      "3. Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: \u2022 Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. \u2022 Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radio immunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. \u2022 Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). \u2022 Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. \u2022 Impaired glucose metabolism. \u2022 Reduced response to metyrapone test."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "4. Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established."
    ],
    "pregnancy": [
      "5. Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses."
    ],
    "nursing_mothers": [
      "6. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman."
    ],
    "pediatric_use": [
      "7. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See WARNINGS and PRECAUTIONS . The following adverse reactions have been observed in women taking progestins: \u2022 Breakthrough bleeding \u2022 Spotting \u2022 Change in menstrual flow \u2022 Amenorrhea \u2022 Edema \u2022 Changes in weight (decreases, increases) \u2022 Changes in the cervical squamo-columnar junction and cervical secretions \u2022 Cholestatic jaundice \u2022 Rash (allergic) with and without pruritus \u2022 Melasma or chloasma \u2022 Clinical depression \u2022 Acne \u2022 Breast enlargement/tenderness \u2022 Headache/migraine \u2022 Urticaria \u2022 Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) \u2022 Decreased HDL cholesterol and increased LDL/HDL ratio \u2022 Mood swings \u2022 Nausea \u2022 Insomnia \u2022 Anaphylactic/anaphylactoid reactions \u2022 Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) \u2022 Optic neuritis (which may lead to partial or complete loss of vision)"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Therapy with norethindrone acetate must be adapted to the specific indications and therapeutic response of the individual patient. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg norethindrone acetate may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate. Endometriosis: Initial daily dosage of 5 mg norethindrone acetate for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone acetate tablets USP are available as: 5 mg: White to off-white oval, flat faced beveled edged, uncoated tablets debossed with \u2018G with breakline\u2019 on one side and 304 on other side. Available as follows: Bottles of 50 NDC 68462-304-50 Bottles of 500 NDC 68462-304-05"
    ],
    "storage_and_handling": [
      "Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature]. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888)721-7115 www.glenmarkpharma-us.com August 2025 glenmarklogo1"
    ],
    "spl_patient_package_insert": [
      "PATIENT INFORMATION Norethindrone acetate tablets USP, 5 mg Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition. What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets? \u2022 Do not use norethindrone acetate if you are pregnant, breastfeeding or are trying to conceive. \u2022 Do not use northindrone acetate if you have had a previous blood clot, stroke, or heart attack. \u2022 Do not use norethindrone acetate if you are postmenopausal. What is norethindrone acetate? Norethindrone acetate is similar to the progesterone hormones naturally produced by the body. Your healthcare provider may provide norethindrone acetate as individual tablets. What are norethindrone acetate tablets used for? Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. Who should not take norethindrone acetate tablets? You should not take norethindrone acetate tablets if you are postmenopausal, pregnant or breastfeeding. You should not take norethindrone acetate tablets if you have the following conditions: \u2022 Known or suspected pregnancy. Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate and later find out you were pregnant, talk with your healthcare provider right away \u2022 History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions \u2022 Liver impairment or disease \u2022 Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate \u2022 Undiagnosed vaginal bleeding \u2022 Hypersensitivity to norethindrone acetate tablets. See the end of this leaflet for a list of all of the ingredients in norethindrone acetate What are the risks associated with norethindrone acetate tablets? \u2022 Risk to the Fetus: Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. You should avoid using norethindrone acetate tablets during pregnancy. If you take norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. \u2022 Abnormal Blood Clotting: Use of progestational drugs, such as norethindrone acetate, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug. \u2022 Eye Abnormalities: Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. These are some of the warning signs of serious side effects with progestin therapy: \u2022 Breast lumps \u2022 Dizziness and faintness \u2022 Changes in speech \u2022 Severe headaches \u2022 Chest pain \u2022 Shortness of breath \u2022 Pain in your legs \u2022 Changes in vision Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. Common side effects include: \u2022 Headache \u2022 Breast pain \u2022 Irregular vaginal bleeding or spotting \u2022 Stomach/abdominal cramps/bloating \u2022 Nausea and vomiting \u2022 Hair loss Other side effects include: \u2022 High blood pressure \u2022 Liver problems \u2022 High blood sugar \u2022 Fluid retention \u2022 Enlargements of benign tumors of the uterus (\"fibroids\") \u2022 Vaginal yeast infections \u2022 Mental depression These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist. What can I do to lower my chances of getting a serious side effect with norethindrone acetate? \u2022 Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate \u2022 Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often \u2022 If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks General information about the safe and effective use of norethindrone acetate tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. Keep norethindrone acetate tablets out of the reach of children. This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate that is written for health professionals. What are the ingredients in norethindrone acetate tablets? Norethindrone acetate tablets contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and talc. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888)721-7115 www.glenmarkpharma-us.com Revised: August 2025 glenmarklogo2"
    ],
    "package_label_principal_display_panel": [
      "Principal Display Panel NDC 68462-304-50 Norethindrone Acetate Tablets USP Bottle Label 5 mg 50 tablets label5mg"
    ],
    "set_id": "d0a94321-eb60-4aa6-a429-f0156f9f8e01",
    "id": "61f08f82-c9ec-45cf-ab8b-18afabde75e2",
    "effective_time": "20260129",
    "version": "10",
    "openfda": {
      "application_number": [
        "ANDA091090"
      ],
      "brand_name": [
        "Norethindrone Acetate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "Glenmark Pharmaceuticals Inc., USA"
      ],
      "product_ndc": [
        "68462-304"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1000405"
      ],
      "spl_id": [
        "61f08f82-c9ec-45cf-ab8b-18afabde75e2"
      ],
      "spl_set_id": [
        "d0a94321-eb60-4aa6-a429-f0156f9f8e01"
      ],
      "package_ndc": [
        "68462-304-50",
        "68462-304-05"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0368462304501"
      ],
      "unii": [
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL ACACIA SUGARCANE LACTOSE MONOHYDRATE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE TALC white to off-white AN;30 Inert Inert FERROUS FUMARATE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL CELLULOSE, MICROCRYSTALLINE POVIDONE SUCRALOSE AN;364"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Women over 35 years old who smoke should not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets (4) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use (4)"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for use by females of reproductive age to prevent pregnancy [see Clinical Studies (14) ] . The efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy (1) The efficacy in females of reproductive potential with a body mass index of more than 35 kg/m 2 has not been evaluated (1, 8.8)"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One tablet daily chewed and swallowed or swallowed whole taken at the same time of day. Follow with 8 ounces of water (2.1) Take one tablet by mouth at the same time every day for 28 days (2.1) Take tablets in the order directed on the blister pack (2.1) Tablets may be administered without regard to meals (12.3) 2.1 How to Take Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets must be taken exactly as directed. Instruct patients to take one tablet by mouth at the same time every day. The tablet may be chewed and swallowed or swallowed whole. The patient should drink a full glass (8 ounces) of water immediately after the white tablets are chewed or swallowed whole. Tablets must be taken in the order directed on the blister pack. Tablets should not be skipped or taken at intervals exceeding 24 hours. For patient instructions for missed tablets. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals [see Clinical Pharmacology (12.3) ] . 2.2 How to Start Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Instruct the patient to begin taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start). Day 1 Start During the first cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets use, instruct the patient to take one white norethindrone acetate and ethinyl estradiol tablet daily, beginning on Day one (1) of her menstrual cycle (the first day of menstruation is Day one). She should take one white norethindrone acetate and ethinyl estradiol tablet daily for 24 consecutive days, followed by one brown ferrous fumarate tablet daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken in the order directed on the package at the same time each day. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days if she starts taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on a day other than the first day of her menstrual cycle. The possibility of ovulation and conception prior to initiation of medication should be considered. Sunday Start During the first cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets use, instruct the patient to take one white norethindrone acetate and ethinyl estradiol tablet daily, beginning on the first Sunday after the onset of her menstrual period. She should take one white norethindrone acetate and ethinyl estradiol tablet daily for 24 consecutive days, followed by one brown ferrous fumarate tablet daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be taken in the order directed on the package at the same time each day. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should begin her next and all subsequent 28-day regimens of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the same day of the week that she began her first regimen, following the same schedule. She should begin taking her white norethindrone acetate and ethinyl estradiol tablets on the next day after ingestion of the last brown tablet, regardless of whether or not a menstrual period has occurred or is still in progress. Anytime a subsequent cycle of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is started later than the day following administration of the last brown ferrous fumarate tablet, the patient should use another method of contraception until she has taken a white norethindrone acetate and ethinyl estradiol tablet daily for 7 consecutive days. For postpartum women who do not breastfeed or after a second trimester abortion, start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets no earlier than 4 weeks postpartum due to the increased risk of thromboembolism. If the patient starts on norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets for 7 consecutive days. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be initiated immediately after a first-trimester abortion or miscarriage; if the patient starts norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets immediately, additional contraceptive measures are not needed. Switching from another Hormonal Method of Contraception If the patient is switching from a combination hormonal method such as: Another pill Vaginal ring Patch Instruct her to take the first white norethindrone acetate and ethinyl estradiol tablet on the day she would have taken her next COC pill. She should not continue taking the tablets from her previous birth control pack, and should not skip any days between packs. If she does not have a withdrawal bleed, rule out pregnancy before starting norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. If she previously used a vaginal ring or transdermal patch, she should start using norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets on the day she would have resumed the previous product. If the patient is switching from a progestin-only method such as a: Progestin-only pill Implant Intrauterine system Injection She may switch any day from a progestin-only pill; instruct her to take the first white norethindrone acetate and ethinyl estradiol tablet on the day she would have taken her next progestin-only pill. She should use a non-hormonal method of contraception for 7 consecutive days. If switching from an implant or injection, start the first white norethindrone acetate and ethinyl estradiol tablet on the day her next injection would have been due or on the day of removal of her implant. If switching from an IUD, depending on the timing of removal, back-up contraception may be needed. 2.3 Missed Doses Table 1. Instructions for Missed Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets If one white tablet is missed Take the missed tablet as soon as possible. Take the next tablet at the regular time. Continue taking one tablet a day until the pack is finished. Additional nonhormonal contraception (such as condoms) is not needed. If two white tablets in a row are missed in Week 1 or Week 2 of the tablet pack Take the two missed tablets as soon as possible, and the next two tablets the next day. Continue taking one tablet a day until the pack is finished. Use additional nonhormonal contraception (such as condoms) until hormonal tablets have been taken for 7 days after missing tablets. If two white tablets are missed in Week 3 or Week 4 of the tablet pack Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. Sunday Starter: Keep taking one tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. Use additional nonhormonal contraception (such as condoms) until hormonal tablets have been taken for 7 days after missing tablets. If three or more white tablets in a row are missed Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. Sunday Starter: Keep taking one tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. Bleeding may occur during the week following the missed tablets. Use additional nonhormonal contraception (such as condoms) until hormonal tablets have been taken for 7 days after missing tablets. If any of the four brown tablets are missed Throw away the missed tablets. Continue taking the remaining tablets until the pack is finished. Additional nonhormonal contraception (such as condoms) is not needed. 2.4 Advice in Case of Gastrointestinal Disturbances If the patient vomits or has diarrhea (within 3 to 4 hours after she takes a white norethindrone acetate and ethinyl estradiol tablet), she should follow the instructions in the \u201c What to Do if You Miss Tablets \u201d section [see 2.3 Missed Doses ] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"17px\"/><col/><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If one white tablet is missed</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Take the missed tablet as soon as possible. Take the next tablet at the regular time. Continue taking one tablet a day until the pack is finished.</paragraph><paragraph>Additional nonhormonal contraception (such as condoms) is not needed.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If two white tablets in a row are missed in</paragraph><paragraph>Week 1 or Week 2 of the tablet pack</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Take the two missed tablets as soon as possible, and the next two tablets the next day. Continue taking one tablet a day until the pack is finished.</paragraph><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal tablets have been taken for 7 days after missing tablets.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If two white tablets are missed in Week 3 or</paragraph><paragraph>Week 4 of the tablet pack</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Day 1 Starter:</content></paragraph><paragraph>Throw out the rest of the tablet pack and start a new pack that same day.</paragraph><paragraph><content styleCode=\"bold\">Sunday Starter:</content></paragraph><paragraph>Keep taking one tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day.</paragraph><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal tablets have been taken for 7 days after missing tablets.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If three or more white tablets in a row are missed</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Day 1 Starter: </content></paragraph><paragraph>Throw out the rest of the tablet pack and start a new pack that same day. </paragraph><paragraph><content styleCode=\"bold\">Sunday Starter:</content></paragraph><paragraph>Keep taking one tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. </paragraph><paragraph>Bleeding may occur during the week following the missed tablets. </paragraph><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal tablets have been taken for 7 days after missing tablets.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If any of the four brown tablets are missed</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Throw away the missed tablets. Continue taking the remaining tablets until the pack is finished. </paragraph><paragraph>Additional nonhormonal contraception (such as condoms) is not needed.</paragraph></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets are available in blister packs. Each blister pack contains 28 tablets in the following order: 24 white, round, (active) chewable tablets debossed with \u201cAN\u201d on one side and \u201c30\u201d on the other side, and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. 4 brown, round (non-hormonal placebo) tablets debossed with \u201cAN\u201d on one side and \u201c364\u201d on the other side, and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose. Norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets consists of 28 tablets in the following order (3) : 24 white chewable tablets (active), each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol 4 brown tablets (non-hormonal placebo), each containing 75 mg ferrous fumarate, which do not serve any therapeutic purpose"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1) ] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4 ) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.5) ] Have headaches with focal neurological symptoms or have migraine headaches with aura All women over age 35 with migraine headache [see Warnings and Precautions (5.6) ] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.7) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions (5.10) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ] A high risk of arterial or venous thrombotic diseases (4) Breast cancer (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (4)"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Vascular risks: Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding (5.1) Liver disease: Discontinue if jaundice occurs (5.2) High blood pressure: Do not prescribe for women with uncontrolled hypertension or hypertension with vascular disease (5.4) Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia (5.6) Headache: Evaluate significant change in headaches and discontinue if indicated (5.7) Uterine bleeding: Evaluate irregular bleeding or amenorrhea (5.8) 5.1 Thromboembolic Disorders and Other Vascular Problems Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if an arterial or deep venous thrombotic event (VTE) occurs. Stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. If feasible, stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE. Start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use of a COC. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued. Use of COCs also increases the risk of arterial thrombosis such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest in older (greater than 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with underlying risk factors. Use COCs with caution in women with cardiovascular disease risk factors. 5.2 Liver Disease Impaired Liver Function Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4) ] . Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if jaundice develops. Liver Tumors Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in women with benign and malignant liver tumors [see Contraindications (4) ] . Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (greater than 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users. 5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [see Contraindications (4) ] . Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen. 5.4 High Blood Pressure Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in women with uncontrolled hypertension or hypertension with vascular disease [see Contraindications (4) ] . For women with well-controlled hypertension, monitor blood pressure and stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if blood pressure rises significantly. An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin. 5.5 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may also worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC-related cholestasis. 5.6 Carbohydrate and Lipid Metabolic Effects Carefully monitor prediabetic and diabetic women who are taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. COCs may decrease glucose tolerance in a dose-related fashion. Consider alternative contraception for women with uncontrolled dyslipidemias. A small proportion of women will have adverse lipid changes while on COCs. Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. 5.7 Headache If a woman taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if indicated. Consider discontinuation of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) [see Contraindications (4) ] . 5.8 Bleeding Irregularities and Amenorrhea Unscheduled Bleeding and Spotting Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC. Based on patient diaries from a clinical trial evaluating the safety and efficacy of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets, 24% to 35% of women experienced unscheduled bleeding per cycle. A total of 10 subjects out of 743 (1.3%) discontinued due to bleeding or spotting. Amenorrhea and Oligomenorrhea Women who are not pregnant and use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may experience amenorrhea. In the clinical trial with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets and ferrous fumarate tablets, 22% to 36% of the women using norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets and ferrous fumarate tablets experienced amenorrhea in at least one of 6 cycles of use. Some women may experience post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. 5.9 COC Use before or during Early Pregnancy Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when oral contraceptives are taken inadvertently during early pregnancy. Discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if pregnancy is confirmed. Administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy [see Use in Specific Populations (8.1) ] . 5.10 Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if depression recurs to a serious degree. 5.11 Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally-sensitive [see Contraindications (4) ] . Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use [see Adverse Reactions (6.2) ] . Cervical Cancer Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors. 5.12 Effect on Binding Globulins The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormones or cortisol therapy may need to be increased. 5.13 Monitoring A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare. 5.14 Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 5.15 Chloasma Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions (5.1) ] Vascular events [see Warnings and Precautions (5.1) ] Liver disease [see Warnings and Precautions (5.2) ] Adverse reactions commonly reported by COC users are: Irregular uterine bleeding Nausea Breast tenderness Headache The most common adverse reactions in clinical trials (greater than or equal to 2%) were: headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data presented in Section 6.1 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. Common Adverse Reactions (Greater Than or Equal to 2% of all Treated Subjects) : The most common adverse reactions reported by at least 2% of the 743 women using norethindrone acetate/ethinyl estradiol tablets were the following, in order of decreasing incidence: headache (6.3%), vaginal candidiasis (6.1%), nausea (4.6%), menstrual cramps (4.4%), breast tenderness (3.4%), bacterial vaginitis (3.1%), abnormal cervical smear (3.1%), acne (2.7%), mood swings (2.2%), and weight gain (2%). Adverse Reactions Leading to Study Discontinuation : Among the 743 women using norethindrone acetate/ethinyl estradiol tablets, 46 women (6.2%) withdrew because of an adverse event. Adverse events occurring in 3 or more subjects leading to discontinuation of treatment were, in decreasing order: abnormal or irregular bleeding (1.3%), nausea (0.8%), menstrual cramps (0.5%), and increased blood pressure (0.4%). 6.2 Post-marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 1). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 to 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8 to 10 years of COC use. Figure 1. RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. The following adverse reactions have been identified during post approval use of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Adverse reactions are grouped into System Organ Classes. Vascular disorders: thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein). Hepatobiliary disorders: cholelithiasis, cholecystitis, hepatic adenoma, hemangioma of liver. Immune system disorders: hypersensitivity reaction. Skin and subcutaneous disorders: alopecia, rash (generalized and allergic), pruritus, skin discoloration. GI disorders: nausea, vomiting, abdominal pain. Musculoskeletal and connective tissue disorders: myalgia. Eye disorders: blurred vision, visual impairment, corneal thinning, change in corneal curvature (steepening). Infections and infestations: fungal infection, vaginal infection. Investigations: change in weight or appetite (increase or decrease), fatigue, malaise, peripheral edema, blood pressure increased. Nervous system disorders: headache, dizziness, migraine, loss of consciousness. Psychiatric disorders: mood swings, depression, insomnia, anxiety, suicidal ideation, panic attack, changes in libido. Renal and urinary disorders: cystitis-like syndrome. Reproductive system and breast disorders: breast changes (tenderness, pain, enlargement, and secretion), premenstrual syndrome, dysmenorrhea. Cardiovascular: chest pain, palpitations, tachycardia, myocardial infarction. 1"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations. No drug-drug interaction studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs (7.1) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate and products containing St. John\u2019s wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin and certain COCs containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone concentrations. Human immunodeficiency virus (HIV)/ Hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors: Significant changes (increase or decrease) in the plasma concentrations of the estrogen and progestin have been noted in some cases of co-administration of HIV/HCV protease inhibitors or of non-nucleoside reverse transcriptase inhibitors. Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids. 7.2 Effects of Combined Oral Contraceptives on Other Drugs COCs containing ethinyl estradiol may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs. 7.3 Concomitant Use with HCV Combination Therapy \u2013 Liver Enzyme Elevation Do not co-administer norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with HCV drug combinations containing ombitasvir/ paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions (5.3) ] . 7.4 Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation: Not recommended; can decrease milk production (8.2) 8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. 8.2 Lactation Risk Summary Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see Dosage and Administration (2.2)]. The developmental and health benefits of breast-feeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and any potential adverse effects on the breast-fed child from norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets or from the underlying maternal condition. 8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated. 8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have not been studied in postmenopausal women and is not indicated in this population. 8.6 Renal Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in subjects with renal impairment. 8.7 Hepatic Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets has not been studied in subjects with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded [see Contraindications (4) and Warnings and Precautions (5.2) ] . 8.8 Body Mass Index The safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with a body mass index (BMI) greater than 35 kg/m 2 has not been evaluated [see Clinical Studies (14) ] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively."
    ],
    "nursing_mothers": [
      "8.2 Lactation Risk Summary Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see Dosage and Administration (2.2)]. The developmental and health benefits of breast-feeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets and any potential adverse effects on the breast-fed child from norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets or from the underlying maternal condition."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets have not been studied in postmenopausal women and is not indicated in this population."
    ],
    "overdosage": [
      "10 OVERDOSAGE There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea."
    ],
    "description": [
      "11 DESCRIPTION Norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets provide an oral contraceptive regimen consisting of 24 white active chewable tablets that contain the active ingredients, followed by 4 brown non-hormonal placebo tablets as specified below: 24 white, round tablets each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. 4 brown, round tablets each containing 75 mg ferrous fumarate. Each white active chewable tablet also contains the following inactive ingredients: acacia, confectioner\u2019s sugar, lactose monohydrate, magnesium stearate, microcrystalline cellulose and talc. Each brown placebo tablet contains ferrous fumarate, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, povidone, spearmint flavor and sucralose. The ferrous fumarate tablets do not serve any therapeutic purpose. The molecular formula of ethinyl estradiol, USP is C 20 H 24 O 2 and the structural formula is: The chemical name of ethinyl estradiol, USP is [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17\u03b1)-]. The molecular weight of ethinyl estradiol, USP is 296.40. The molecular formula of norethindrone acetate, USP is C 22 H 28 O 3 and the structural formula is: The chemical name of norethindrone acetate, USP is [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)-]. The molecular weight of norethindrone acetate, USP is 340.46. chem structure chem structure 2"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action CHCs lower the risk of becoming pregnant primarily by suppressing ovulation. 12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. 12.3 Pharmacokinetics Absorption In a single-dose, two-way, crossover clinical study conducted in 35 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol tablet chewed and swallowed was bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablet (24-day regimen tablets) swallowed whole based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are absorbed from norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed), with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring at 1 hr (range: 0.7 to 2.5 hrs) and 1.3 hr (range: 1 to 2.5 hrs) post-dose, respectively. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single-dose administrations of norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed) in 35 healthy female subjects are provided in Figures 2 and 3, and Table 2. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets (swallowed whole) in 17 healthy female subjects, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean (\u00b1 Standard Deviation) Plasma Norethindrone Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Figure 3. Mean (\u00b1 Standard Deviation) Plasma Ethinyl Estradiol Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Table 2. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers Under Fasting Conditions (n = 35) Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC (0\u00b1tldc) (pg/mL\u2022h) AUC (0\u00b1inf) (pg/mL\u2022h) t 1/2 (hr) NE 10,200 (36) 1.03 (0.67 to 2.50) 48,620 (40) 49,250 (40) 8.58 EE 84.7 (24) 1.33 (1 to 2.50) 677.5 (33) 741.6 (33) 9.68 C max = Maximum plasma concentration t max = Time of C max AUC (0\u00b1tldc) = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC (0\u00b1inf) = Area under the plasma concentration versus time curve from time 0 to infinity t 1/2 = Terminal phase half-life % CV = Coefficient of Variation (%) a The harmonic mean (0.693/mean terminal phase rate constant) is reported for t 1/2 , and the median (range) is reported for t max Food Effect Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals. A single-dose administration of norethindrone acetate/ethinyl estradiol tablets with food decreased the maximum concentration of norethindrone by 51% and increased the extent of absorption by 15% and decreased the maximum concentration of ethinyl estradiol by 51% but not the extent of absorption. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. figure 1 figure 2"
    ],
    "clinical_pharmacology_table": [
      "<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"12.48%\"/><col width=\"87.52%\"/><col/><col/><col/><col/><tbody><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Analyte </paragraph></td><td colspan=\"5\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Arithmetic Mean<sup>a</sup> (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub>  (pg/mL)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub>  (hr)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#xB1;tldc)</sub>  (pg/mL&#x2022;h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#xB1;inf)</sub>  (pg/mL&#x2022;h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>1/2</sub>  (hr)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>10,200   (36)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.03   (0.67 to 2.50)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>48,620   (40)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>49,250  (40)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8.58</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>EE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>84.7   (24)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.33   (1 to 2.50)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>677.5   (33)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>741.6  (33)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>9.68</paragraph></td></tr><tr><td colspan=\"6\" styleCode=\" Botrule Toprule Lrule Rrule\">C<sub>max</sub> = Maximum plasma concentration <paragraph>t<sub>max</sub> = Time of C<sub>max</sub></paragraph><paragraph>AUC<sub>(0&#xB1;tldc)</sub> = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration</paragraph><paragraph>AUC<sub>(0&#xB1;inf)</sub> = Area under the plasma concentration versus time curve from time 0 to infinity</paragraph><paragraph>t<sub>1/2</sub> = Terminal phase half-life</paragraph><paragraph>% CV = Coefficient of Variation (%)</paragraph><paragraph><sup>a</sup> The harmonic mean (0.693/mean terminal phase rate constant) is reported for t<sub>1/2</sub>, and the median (range) is reported for t<sub>max</sub></paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action CHCs lower the risk of becoming pregnant primarily by suppressing ovulation."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption In a single-dose, two-way, crossover clinical study conducted in 35 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol tablet chewed and swallowed was bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablet (24-day regimen tablets) swallowed whole based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are absorbed from norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed), with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring at 1 hr (range: 0.7 to 2.5 hrs) and 1.3 hr (range: 1 to 2.5 hrs) post-dose, respectively. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single-dose administrations of norethindrone acetate and ethinyl estradiol tablets (chewed and swallowed) in 35 healthy female subjects are provided in Figures 2 and 3, and Table 2. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets (swallowed whole) in 17 healthy female subjects, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean (\u00b1 Standard Deviation) Plasma Norethindrone Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Figure 3. Mean (\u00b1 Standard Deviation) Plasma Ethinyl Estradiol Concentration-Time Profile Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers under Fasting Conditions (n = 35) Table 2. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single-Dose Oral Administration of Norethindrone Acetate and Ethinyl Estradiol Tablets (chewed and swallowed) to Healthy Female Volunteers Under Fasting Conditions (n = 35) Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC (0\u00b1tldc) (pg/mL\u2022h) AUC (0\u00b1inf) (pg/mL\u2022h) t 1/2 (hr) NE 10,200 (36) 1.03 (0.67 to 2.50) 48,620 (40) 49,250 (40) 8.58 EE 84.7 (24) 1.33 (1 to 2.50) 677.5 (33) 741.6 (33) 9.68 C max = Maximum plasma concentration t max = Time of C max AUC (0\u00b1tldc) = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration AUC (0\u00b1inf) = Area under the plasma concentration versus time curve from time 0 to infinity t 1/2 = Terminal phase half-life % CV = Coefficient of Variation (%) a The harmonic mean (0.693/mean terminal phase rate constant) is reported for t 1/2 , and the median (range) is reported for t max Food Effect Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may be administered without regard to meals. A single-dose administration of norethindrone acetate/ethinyl estradiol tablets with food decreased the maximum concentration of norethindrone by 51% and increased the extent of absorption by 15% and decreased the maximum concentration of ethinyl estradiol by 51% but not the extent of absorption. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. figure 1 figure 2"
    ],
    "pharmacokinetics_table": [
      "<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"12.48%\"/><col width=\"87.52%\"/><col/><col/><col/><col/><tbody><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Analyte </paragraph></td><td colspan=\"5\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Arithmetic Mean<sup>a</sup> (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub>  (pg/mL)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub>  (hr)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#xB1;tldc)</sub>  (pg/mL&#x2022;h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#xB1;inf)</sub>  (pg/mL&#x2022;h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>1/2</sub>  (hr)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>10,200   (36)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.03   (0.67 to 2.50)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>48,620   (40)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>49,250  (40)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8.58</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>EE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>84.7   (24)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.33   (1 to 2.50)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>677.5   (33)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>741.6  (33)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>9.68</paragraph></td></tr><tr><td colspan=\"6\" styleCode=\" Botrule Toprule Lrule Rrule\">C<sub>max</sub> = Maximum plasma concentration <paragraph>t<sub>max</sub> = Time of C<sub>max</sub></paragraph><paragraph>AUC<sub>(0&#xB1;tldc)</sub> = Area under plasma concentration versus time curve from 0 to tldc, the time of last determinable concentration</paragraph><paragraph>AUC<sub>(0&#xB1;inf)</sub> = Area under the plasma concentration versus time curve from time 0 to infinity</paragraph><paragraph>t<sub>1/2</sub> = Terminal phase half-life</paragraph><paragraph>% CV = Coefficient of Variation (%)</paragraph><paragraph><sup>a</sup> The harmonic mean (0.693/mean terminal phase rate constant) is reported for t<sub>1/2</sub>, and the median (range) is reported for t<sub>max</sub></paragraph></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [see Warnings and Precautions (5.2 , 5.11) ]."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [see Warnings and Precautions (5.2 , 5.11) ]."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES The data presented in Section 14 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. In a clinical study, 743 women 18 to 45 years of age were studied to assess the efficacy of norethindrone acetate/ethinyl estradiol tablets, for up to six 28-day cycles providing a total of 3,823 treatment-cycles of exposure. The racial demographic of all enrolled women was: 70% Caucasian, 16% African-American, 10% Hispanic, 2% Asian and 2% Other. Women with body mass index (BMI) greater than 35 kg/m 2 were excluded from the study. The weight range for those women treated was 90 to 260 pounds, with a mean weight of 147 pounds. Among the women in the study, about 40% had not used hormonal contraception immediately prior to enrolling in this study. A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies in 3,565 treatment cycles during which no backup contraception was used. The Pearl Index for norethindrone acetate and ethinyl estradiol tablets was 1.82 (95% confidence interval 0.59 to 4.25)."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Norethindrone acetate and ethinyl estradiol tablets, USP 1 mg/20 mcg and ferrous fumarate tablets, 75 mg are available in blister cards (dispensers) containing 28 tablets (NDC 60219-1031-6): Cartons of 3 blister cards (dispensers) NDC 60219-1031-7 Each blister card contains 28 tablets in the following order: 24 white to off-white, round, uncoated, unscored, flat-faced beveled edge (active) tablets debossed with \u201cAN\u201d on one side and \u201c30\u201d on the other side, and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. 4 brown, round, uncoated, unscored, flat-faced, beveled edge (non-hormonal placebo) tablets debossed with \u201cAN\u201d on one side and \u201c364\u201d on the other side, and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose. 16.2 Storage Conditions Store at 20\u00b0 to 25\u00b0 C (68\u00b0 to 77\u00b0 F); excursions permitted between 15\u00b0 to 30\u00b0 C (59\u00b0 to 86\u00b0 F) [see USP Controlled Room Temperature]. Keep this drug and all drugs out of the reach of children.",
      "16.1 How Supplied Norethindrone acetate and ethinyl estradiol tablets, USP 1 mg/20 mcg and ferrous fumarate tablets, 75 mg are available in blister cards (dispensers) containing 28 tablets (NDC 60219-1031-6): Cartons of 3 blister cards (dispensers) NDC 60219-1031-7 Each blister card contains 28 tablets in the following order: 24 white to off-white, round, uncoated, unscored, flat-faced beveled edge (active) tablets debossed with \u201cAN\u201d on one side and \u201c30\u201d on the other side, and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. 4 brown, round, uncoated, unscored, flat-faced, beveled edge (non-hormonal placebo) tablets debossed with \u201cAN\u201d on one side and \u201c364\u201d on the other side, and each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose."
    ],
    "storage_and_handling": [
      "16.2 Storage Conditions Store at 20\u00b0 to 25\u00b0 C (68\u00b0 to 77\u00b0 F); excursions permitted between 15\u00b0 to 30\u00b0 C (59\u00b0 to 86\u00b0 F) [see USP Controlled Room Temperature]. Keep this drug and all drugs out of the reach of children."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) Counsel patients on the following information: Cigarette smoking increases the risk of serious cardiovascular events from COC use, and women who are over 35 years old and smoke should not use COCs. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets do not protect against HIV infection (AIDS) and other sexually transmitted infections. The Warnings and Precautions associated with COCs. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are not to be used during pregnancy; if pregnancy occurs during use of Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, instruct the patient to stop further intake. Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event tablets are missed. See \u201c What to Do if You Miss Tablets \u201d section in FDA-approved patient labeling . Use a back-up or alternative method of contraception when enzyme inducers are used with norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established. Women who start COCs postpartum, and who have not yet had a period, should use an additional method of contraception until they have taken a white tablet for 7 consecutive days. Amenorrhea may occur. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles. Distributed by: Amneal Pharmaceuticals of New York, LLC Brookhaven, NY 11719 Rev. 07-2023-07"
    ],
    "spl_patient_package_insert": [
      "FDA-Approved Patient Labeling Guide for Using Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets WARNING TO WOMEN WHO SMOKE Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. Birth control pills help to lower the chances of becoming pregnant when taken as directed. They do not protect against HIV infection (AIDS) and other sexually transmitted infections. What are norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate. How well do norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets work? Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant. Based on the results of one clinical study of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets lasting six months, about 1 to 4 out of 100 women may get pregnant during the first year they use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Women with a BMI above 35 kg/m 2 were not studied in the clinical trial, so it is not known how well norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets protect against pregnancy in such women. If you are overweight, discuss with your healthcare provider whether norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets is the best choice for you. The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant. How do I take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Be sure to read these directions before you start taking your tablets or anytime you are not sure what to do. The tablets may be chewed and swallowed or swallowed whole. You should drink a full glass (8 ounces) of water immediately after chewing or swallowing. The right way to take the tablet is to take one tablet every day at the same time in the order directed on the package. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be taken without regard to meals. If you miss tablets you could get pregnant. This includes starting the pack late. The more tablets you miss, the more likely you are to get pregnant. See \"What to Do if You Miss Tablets\u201d below. Many women have spotting or light bleeding at unexpected times, or may feel sick to their stomach during the first 1 to 3 packs of tablets. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the tablets. The problem will usually go away. If it does not go away, check with your healthcare provider. 5. Missing tablets can also cause spotting or light bleeding, even when you make up these missed tablets. On the days you take two tablets, to make up for missed tablets, you could also feel a little sick to your stomach. 6. If you have vomiting (within 3 to 4 hours after you take your tablet), you should follow the instructions for \"What to Do if You Miss Tablets\". If you have diarrhea or if you take certain medicines, including some antibiotics and some herbal products such as St. John's Wort, your tablets may not work as well. Use a back-up method (such as condoms and spermicides) until you check with your healthcare provider. 7. If you have trouble remembering to take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, talk to your healthcare provider about how to make tablet-taking easier or about using another method of birth control. 8. If you have any questions or are unsure about the information in this leaflet, call your healthcare provider. Before You Start Taking Your Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets 1. Decide What Time of Day You Want to Take Your Tablet. It is important to take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in the order directed on the package at the same time every day. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets can be taken without regard to meals. 2. Look at Your Tablet Pack \u2013 It has 28 Tablets The norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets pack has 24 \"active\" white tablets (with hormones) to be taken for 24 days, followed by 4 \"reminder\" brown tablets (without hormones) to be taken for the next four days. 3. Also look for: a) Where on the pack to start taking tablets, b) In what order to take the tablets (follow the arrows shown in the picture above) c) The week numbers as shown in the picture above. 4. Be sure you have ready at all times a) another kind of birth control (such as a condoms and spermicide) to use as a back-up in case you miss tablets, and b) an extra, full tablet pack. When to Start the First Pack of Tablets You have a choice for which day to start taking your first pack of tablets. Decide with your healthcare provider which is the best day for you. Pick a time of day which will be easy to remember. Day 1 Start: 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). 2. Place this day label strip on the tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. 3. Take the first white tablet of the pack during the first 24 hours of your period. 4. You will not need to use a back-up method of birth control, since you are starting the tablet at the beginning of your period. However, if you start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets later than the first day of your period, you should use another method of birth control (such as a condom and spermicide) as a back-up method until you have taken 7 white tablets. Sunday Start: 1. Take the first white tablet of the pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 2. Use another method of birth control (such as a condom and spermicide) as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). This also applies if you start norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets after having been pregnant, and you have not had a period since your pregnancy. When You Switch From a Different Birth Control Tablet or Capsule When switching from another birth control pill, finish all the tablets or capsules, then norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started on the same day that a new pack of the previous birth control tablet or capsule would have been started. When You Switch From Another Type of Birth Control Method When switching from a transdermal patch or vaginal ring, finish the 21 days of use, wait 7 days, then norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started when the next application would have been due. When switching from an injection, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started when the next injection would have been due. When switching from an intrauterine device or an implant, norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be started on the day of removal. What to Do During the Month 1. Take one tablet at the same time every day until the pack is empty. Do not skip tablets even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). 2. Do not skip tablets even if you do not have sex very often. When you finish a pack of tablets, start the next pack on the day after your last brown tablet. Do not wait any days between packs. What to Do if You Miss Tablets Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets may not be as effective if you miss any white tablets, especially if you miss the first few or the last few white tablets in a pack. If you miss 1 white tablet: 1. Take the tablet as soon as you remember. Take the next tablet at your regular time. This means you may take two tablets in one day. 2. You do not need to use a back-up birth control method if you have sex. If you miss 2 white tablets in a row in week 1 OR week 2 of your pack: 1. Take two tablets on the day you remember and two tablets the next day. 2. Then take one tablet a day until you finish the pack. 3. You could become pregnant if you have sex in the 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. If you miss 2 white tablets in a row in week 3 or week 4 of your pack: 1. If you are a Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. If you are a Sunday Starter: Keep taking one tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. 2. You could become pregnant if you have sex in the 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss 3 or more white tablets in a row during any week: 1. If you are a Day 1 Starter: Throw out the rest of the tablet pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 tablet every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of tablets that same day. 2. You could become pregnant if you have sex on the days when you missed tablets or during the first 7 days after you restart your tablets. You must use another birth control method (such as a condom and spermicide) as a back-up the next time you have sex and for the first 7 days after you restart your tablets. 3. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss any of the 4 brown tablets in Week 4: 1. Throw away the tablets you missed. 2. Keep taking one tablet each day until the pack is empty. 3. You do not need a back-up method. 4. Start the next pack of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets as scheduled. Finally, if you are still not sure what to do about the tablets you have missed: 1. Use a back-up method (such as a condom and spermicide) anytime you have sex. 2. Contact your healthcare provider and continue taking one active white tablet each day until otherwise directed. Who should not take norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Your healthcare provider will not give you norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you have: Ever had blood clots in your arms, legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis) Ever had a stroke Ever had a heart attack Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart An inherited problem with your blood that makes it clot more than normal High blood pressure that medicine cannot control Diabetes with kidney, eye, nerve, or blood vessel damage Ever had certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or have any migraine headache if you are over age 35. Ever had breast cancer, which may be sensitive to female hormones Liver disease, including liver tumors Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood Also, do not take birth control pills if you: Smoke and are over 35 years old Are or suspect you are pregnant Have any unexplained bleeding from the vagina Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy, also called cholestasis of pregnancy. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). What else should I know about taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Birth control pills do not protect you against any sexually transmitted infection, including HIV, the virus that causes AIDS. Do not skip any tablets, even if you do not have sex often. If you miss a period, you could be pregnant. However, some women miss periods or have light periods on birth control pills, even when they are not pregnant. Contact your healthcare provider for advice if you: Think you are pregnant Miss one period and have not taken your birth control pills every day Miss two periods in a row Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects. You should stop norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets at least four weeks before you have surgery and not restart it until at least two weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, may decrease the amount of milk you make. A small amount of the pill's hormones passes into breast milk. Tell your healthcare provider about all medicines and herbal products that you take. Some medicines and herbal products may make birth control pills less effective, including: barbiturates bosentan carbamazepine felbamate griseofulvin oxcarbazepine phenytoin rifampin St. John\u2019s wort topiramate Use a back-up or alternative birth control method when you take medicines that may make birth control pills less effective. Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your healthcare provider may need to adjust the dose of lamotrigine. If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like a condom and spermicide, until you check with your healthcare provider. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone. If you are scheduled for any laboratory tests, tell your healthcare provider that you are taking birth control pills. Certain blood tests may be affected by birth control pills. What are the most serious risks of taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke. Some examples of serious blood clots are blood clots in the: Legs (deep vein thrombosis) Lungs (pulmonary embolus) Eyes (loss of eyesight) Heart (heart attack) Brain (stroke) Women who take birth control pills may get: High blood pressure Gallbladder problems Rare cancerous or noncancerous liver tumors All of these events are uncommon in healthy women. Call your healthcare provider right away if you have: Persistent leg pain Sudden shortness of breath Sudden blindness, partial or complete Severe pain or pressure in your chest Sudden, severe headache unlike your usual headaches Weakness or numbness in an arm or leg, or trouble speaking Yellowing of the skin or eyeballs What are the common side effects of birth control pills? The most common side effects of birth control pills are: Spotting or bleeding between menstrual periods Nausea Breast tenderness Headache These side effects are usually mild and usually disappear with time. Less common side effects are: Acne Less sexual desire Bloating or fluid retention Blotchy darkening of the skin, especially on the face High blood sugar, especially in women who already have diabetes High fat (cholesterol, triglyceride) levels in the blood Depression, especially if you have had depression in the past. Call your healthcare provider immediately if you have any thoughts of harming yourself Problems tolerating contact lenses Weight gain This is not a complete list of possible side effects. Talk to your healthcare provider if you develop any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088. No serious problems have been reported from a birth control pill overdose, even when accidentally taken by children. Do birth control pills cause cancer? It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners. What should I know about my period when taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? Irregular vaginal bleeding or spotting may occur while you are taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding, which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your tablets on schedule. If the bleeding occurs in more than one cycle, is unusually heavy, or lasts for more than a few days, call your healthcare provider. Some women may not have a menstrual period but this should not be cause for alarm as long as you have taken the tablets according to direction. What if I miss my scheduled period when taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets? It is not uncommon to miss your period. However, if you go two or more months in a row without a period, or you miss your period after a month where you did not take all your tablets correctly, call your healthcare provider because you may be pregnant. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. Stop taking norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets if you are pregnant. What if I want to become pregnant? You may stop taking the tablets whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the tablets. General Advice about Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets Your healthcare provider prescribed norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets for you. Please do not share norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets with anyone else. Keep norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets out of the reach of children. If you have concerns or questions, ask your healthcare provider. You may also ask your pharmacist for a more detailed label written for healthcare professionals. For all medical inquiries contact Amneal Pharmaceuticals at 1-877-835-5472. Distributed by: Amneal Pharmaceuticals of New York, LLC Brookhaven, NY 11719 Rev. 07-2023-05 figure 1 ppi 2"
    ],
    "spl_patient_package_insert_table": [
      "<table><col/><tbody><tr><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph><content styleCode=\"bold\">WARNING TO WOMEN WHO SMOKE</content></paragraph><paragraph><content styleCode=\"bold\">Do not use norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets </content><content styleCode=\"bold\">if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. </content></paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL NDC 60219-1031-6 Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1 mg/ 20 mcg Rx only Face card and Pouch Labels Amneal Pharmaceuticals LLC NDC 60219-1031-7 Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1 mg/ 20 mcg Rx only Carton Label Amneal Pharmaceuticals LLC Day of Week Stickers 2 1 4 5"
    ],
    "set_id": "d4fa03d8-0ae0-497f-ba4e-76f03fd7a3ab",
    "id": "ae13db8f-27e2-420a-b909-99d0347e6286",
    "effective_time": "20230718",
    "version": "13",
    "openfda": {
      "application_number": [
        "ANDA207514"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"
      ],
      "manufacturer_name": [
        "Amneal Pharmaceuticals NY LLC"
      ],
      "product_ndc": [
        "60219-1031"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "259176",
        "1358762",
        "1359117",
        "1426288"
      ],
      "spl_id": [
        "ae13db8f-27e2-420a-b909-99d0347e6286"
      ],
      "spl_set_id": [
        "d4fa03d8-0ae0-497f-ba4e-76f03fd7a3ab"
      ],
      "package_ndc": [
        "60219-1031-6",
        "60219-1031-7"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate and Ethinyl Estradiol, and Ferrous Fumarate Norethindrone Acetate and Ethinyl Estradiol, and Ferrous Fumarate Ferrous Fumarate Ferrous Fumarate FERROUS FUMARATE SOYBEAN OIL YELLOW WAX LECITHIN, SOYBEAN GELATIN SORBITOL SORBITAN GLYCERIN FD&C BLUE NO. 1 FD&C RED NO. 40 TITANIUM DIOXIDE WATER maroon A9 Norethindrone Acetate and Ethinyl Estradiol Norethindrone Acetate and Ethinyl Estradiol NORETHINDRONE ACETATE NORETHINDRONE ETHINYL ESTRADIOL ETHINYL ESTRADIOL SESAME OIL ALPHA-TOCOPHEROL ALCOHOL GELATIN SORBITOL SORBITAN GLYCERIN FD&C RED NO. 40 TITANIUM DIOXIDE WATER CORN OIL PEG-6 ESTERS pale pink A3"
    ],
    "boxed_warning": [
      "WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See Full Prescribing Information for complete boxed warning. Women over 35 years old who smoke should not use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. (4) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. (4)"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are indicated for use by females of reproductive age to prevent pregnancy [see Clinical Studies (14) ] . The efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. -------------INDICATIONS AND USAGE------------- Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy (1) Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy (1, 8.8)"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Take one capsule by mouth at the same time every day (2.1) Take capsules in the order directed on the blister pack (2.1) Capsules may be administered without regard to meals (2.1) 2.1 How to Take Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules To achieve maximum contraceptive effectiveness, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules must be taken exactly as directed. Instruct patients to take one capsule by mouth at the same time every day. Capsules must be taken in the order directed on the blister pack. Capsules should not be skipped or taken at intervals exceeding 24 hours. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be administered without regard to meals [see Clinical Pharmacology (12.3) ] . 2.2 How to Start Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules Instruct the patient to begin taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start). Day 1 Start During the first cycle of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules use, instruct the patient to take one pink capsule daily, beginning on Day one (1) of her menstrual cycle (the first day of menstruation is Day one). She should take one pink capsule daily for 24 consecutive days, followed by one maroon capsule daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be taken in the order directed on the package at the same time each day. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days if she starts taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules on a day other than the first day of her menstrual cycle. The possibility of ovulation and conception prior to initiation of medication should be considered. Sunday Start During the first cycle of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules use, instruct the patient to take one pink capsule daily, beginning on the first Sunday after the onset of her menstrual period. She should take one pink capsule daily for 24 consecutive days, followed by one maroon capsule daily on days 25 through 28. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be taken in the order directed on the package at the same time each day. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should begin her next and all subsequent 28-day regimens of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules on the same day of the week that she began her first regimen, following the same schedule. She should begin taking her pink capsules on the next day after ingestion of the last maroon capsule, regardless of whether or not a menstrual period has occurred or is still in progress. Anytime a subsequent cycle of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules is started later than the day following administration of the last maroon capsule, the patient should use another method of contraception until she has taken a pink capsule daily for 7 consecutive days. For postpartum women who do not breastfeed or after a second trimester abortion, start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules no earlier than 4 weeks postpartum due to the increased risk of thromboembolism. If the patient starts norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules for 7 consecutive days. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be initiated immediately after a first-trimester abortion or miscarriage; if the patient starts norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules immediately, additional contraceptive measures are not needed. Switching from another Hormonal Method of Contraception If the patient is switching from a combination hormonal method such as: Another pill Vaginal ring Patch Instruct her to take the first pink capsule on the day she would have taken her next COC pill. She should not continue taking the tablet from her previous birth control pack, and should not skip any days between packs. If she does not have a withdrawal bleed, rule out pregnancy before starting norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. If she previously used a vaginal ring or transdermal patch, she should start using norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules on the day she would have resumed the previous product. If the patient is switching from a progestin-only method such as a: Progestin-only pill Implant Intrauterine system Injection She may switch any day from a progestin-only pill; instruct her to take the first pink capsule on the day she would have taken her next progestin-only pill. She should use a non-hormonal method of contraception for 7 consecutive days. If switching from an implant or injection, start the first pink capsule on the day her next injection would have been due or on the day of removal of her implant. If switching from an IUD, depending on the timing of removal, back-up contraception may be needed. 2.3 Missed Doses Table 1. Instructions for Missed Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules If one pink capsule is missed Take the missed capsule as soon as possible. Take the next capsule at the regular time. Continue taking one capsule a day until the pack is finished. Additional nonhormonal contraception (such as condoms) is not needed. If two pink capsules in a row are missed in Week 1 or Week 2 of the capsule pack Take the two missed capsules as soon as possible, and the next two capsules the next day. Continue taking one capsule a day until the pack is finished. Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules. If two pink capsules in a row are missed in Week 3 or Week 4 of the capsule pack Day 1 Starter: Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day. Sunday Starter: Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules. If three or more pink capsules in a row are missed Day 1 Starter: Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day. Sunday Starter: Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. Bleeding may occur during the week following the missed capsules. Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules. If any of the four maroon capsules are missed Throw away the missed capsules. Continue taking the remaining capsules until the pack is finished. Additional nonhormonal contraception (such as condoms) is not needed. 2.4 Advice in Case of Gastrointestinal Disturbances If the patient vomits or has diarrhea (within 3 to 4 hours after she takes a pink capsule), she should follow the instructions in the \u201cWhat to Do if You Miss Capsules\u201d section [see Dosage and Administration (2.3) ] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"17pt\"/><col width=\"275.4pt\"/><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If one pink capsule is missed</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Take the missed capsule as soon as possible. Take the next capsule at the regular time. Continue taking one capsule a day until the pack is finished. </paragraph><paragraph>Additional nonhormonal contraception (such as condoms) is not needed.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If two pink capsules in a row are missed in Week 1 or Week 2 of the capsule pack</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Take the two missed capsules as soon as possible, and the next two capsules the next day. Continue taking one capsule a day until the pack is finished.</paragraph><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If two pink capsules in a row are missed in Week 3 or Week 4 of the capsule pack</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Day 1 Starter:</content></paragraph><paragraph>Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day.</paragraph><paragraph><content styleCode=\"bold\">Sunday Starter:</content></paragraph><paragraph>Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. </paragraph><paragraph>Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If three or more pink capsules in a row are missed</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Day 1 Starter:</content></paragraph><paragraph>Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day. </paragraph><paragraph><content styleCode=\"bold\">Sunday Starter:</content></paragraph><paragraph>Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. </paragraph><paragraph>Bleeding may occur during the week following the missed capsules. Use additional nonhormonal contraception (such as condoms) until hormonal capsules have been taken for 7 days after missing capsules.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>If any of the four maroon capsules are missed</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Throw away the missed capsules. Continue taking the remaining capsules until the pack is finished. </paragraph><paragraph>Additional nonhormonal contraception (such as condoms) is not needed.</paragraph></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are available in blister packs. Each blister pack contains 28 soft gelatin capsules in the following order: 24 oval, opaque, pale pink (active) soft gelatin capsules, printed with \u201cA3\u201d and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. 4 oval, opaque, maroon, (non-hormonal placebo) soft gelatin capsules, printed with \u201cA9\u201d and each containing 75 mg ferrous fumarate, USP. The ferrous fumarate capsules do not serve any therapeutic purpose. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules consists of 28 soft gelatin capsules in the following order (3) : 24 pink capsules (active), each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP 4 maroon capsules (non-hormonal placebo) each containing 75 mg ferrous fumarate, USP which does not serve any therapeutic purpose"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1) ] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.6) ] Have headaches with focal neurological symptoms or have migraine headaches with aura Women over age 35 with any migraine headaches [see Warnings and Precautions (5.7) ] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions (5.11) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ] A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (4)"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Vascular risks: Stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding ( 5.1 ) Liver disease: Discontinue if jaundice occurs ( 5.2 ) High blood pressure: Do not prescribe norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules for women with uncontrolled hypertension or hypertension with vascular disease ( 5.4 ) Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia ( 5.6 ) Headache: Evaluate significant change in headaches and discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if indicated ( 7 ) Uterine bleeding: Evaluate irregular bleeding or amenorrhea ( 5.8 ) 5.1 Thromboembolic Disorders and Other Vascular Problems Stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if an arterial or deep venous thrombotic event (VTE) occurs. Stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. If feasible, stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE. Start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use of a COC. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest in older (> 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with underlying risk factors. Use COCs with caution in women with cardiovascular disease risk factors. 5.2 Liver Disease Impaired Liver Function Do not use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in women with acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4) ] . Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if jaundice develops. Liver Tumors Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are contraindicated in women with benign and malignant liver tumors [see Contraindications (4) ] . Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users. 5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [see Contraindications (4) ] . Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen. 5.4 High Blood Pressure Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are contraindicated in women with uncontrolled hypertension or hypertension with vascular disease [see Contraindications (4) ] . For women with well-controlled hypertension, monitor blood pressure and stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if blood pressure rises significantly. An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin. 5.5 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may also worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC-related cholestasis. 5.6 Carbohydrate and Lipid Metabolic Effects Carefully monitor prediabetic and diabetic women who are taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. COCs may decrease glucose tolerance in a dose-related fashion. Consider alternative contraception for women with uncontrolled dyslipidemias. A small proportion of women will have adverse lipid changes while on COCs. Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. 5.7 Headache If a woman taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if indicated. Consider discontinuation of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) [see Contraindications (4) ] . 5.8 Bleeding Irregularities and Amenorrhea Unscheduled Bleeding and Spotting Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC. Based on patient diaries from a clinical trial evaluating the safety and efficacy of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets, 24% to 35% of women experienced unscheduled bleeding per cycle. A total of 10 subjects out of 743 (1.3%) discontinued due to bleeding or spotting. Amenorrhea and Oligomenorrhea Women who are not pregnant and use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may experience amenorrhea. In the clinical trial with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets, 22% to 36% of the women using norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets experienced amenorrhea in at least one of 6 cycles of use. Some women may experience post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent. If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active capsules or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. 5.9 COC Use before or during Early Pregnancy Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when oral contraceptives are taken inadvertently during early pregnancy. Discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if pregnancy is confirmed. Administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy [see Use in Specific Populations (8.1) ] . 5.10 Depression Carefully observe women with a history of depression and discontinue norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if depression recurs to a serious degree. 5.11 Malignant Neoplasms Breast Cancer Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally-sensitive [see Contraindications (4) ] . Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use [see Adverse Reactions (6.2) ]. Cervical Cancer Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors. 5.12 Effect on Binding Globulins The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased. 5.13 Monitoring A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare. 5.14 Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. 5.15 Chloasma Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions (5.1) ] Vascular events [see Warnings and Precautions (5.1) ] Liver disease [see Warnings and Precautions (5.2) ] Adverse reactions commonly reported by COC users are: Irregular uterine bleeding Nausea Breast tenderness Headache The most common adverse reactions in clinical trials (\u2265 2%) are headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data presented in Section 6.1 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. Common Adverse Reactions (\u2265 2% of all Treated Subjects): The most common adverse reactions reported by at least 2% of the 743 women using norethindrone acetate/ethinyl estradiol tablets were the following, in order of decreasing incidence: headache (6.3%), vaginal candidiasis (6.1%), nausea (4.6%), menstrual cramps (4.4%), breast tenderness (3.4%), bacterial vaginitis (3.1%), abnormal cervical smear (3.1%), acne (2.7%), mood swings (2.2%), and weight gain (2.0%). Adverse Reactions Leading to Study Discontinuation: Among the 743 women using norethindrone acetate/ethinyl estradiol tablets, 46 women (6.2%) withdrew because of an adverse event. Adverse events occurring in 3 or more subjects leading to discontinuation of treatment were, in decreasing order: abnormal or irregular bleeding (1.3%), nausea (0.8%), menstrual cramps (0.5%), and increased blood pressure (0.4%). 6.2 Postmarketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 1). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 to 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8 to 10 years of COC use. Figure 1. RR = relative risk; OR = odds ratio; HR = hazard ratio. \u201cever COC\u201d are females with current or past COC use; \u201cnever COC use\u201d are females that never used COCs. The following adverse reactions have been identified during post approval use of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Vascular disorders: thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein). Hepatobiliary disorders: cholelithiasis, cholecystitis, hepatic adenoma, hemangioma of liver. Immune system disorders: hypersensitivity reaction. Skin and subcutaneous disorders: alopecia, rash (generalized and allergic), pruritus, skin discoloration. GI disorders: nausea, vomiting, abdominal pain. Musculoskeletal and connective tissue disorders: myalgia. Eye disorders: blurred vision, visual impairment, corneal thinning, change in corneal curvature (steepening). Infections and infestations: fungal infection, vaginal infection. Investigations: change in weight or appetite (increase or decrease), fatigue, malaise, peripheral edema, blood pressure increased. Nervous system disorders: headache, dizziness, migraine, loss of consciousness. Psychiatric disorders: mood swings, depression, insomnia, anxiety, suicidal ideation, panic attack, changes in libido. Renal and urinary disorders: cystitis-like syndrome. Reproductive system and breast disorders: breast changes (tenderness, pain, enlargement, and secretion), premenstrual syndrome, dysmenorrhea. Cardiovascular: chest pain, palpitations, tachycardia, myocardial infarction. 1"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations. Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs (7.1) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate and products containing St. John\u2019s wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin and certain COCs containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone concentrations. Human immunodeficiency virus (HIV)/ Hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors: Significant changes (increase or decrease) in the plasma concentrations of estrogen and progestin have been noted in some cases of co-administration with HIV/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors. Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids. 7.2 Effects of Combined Oral Contraceptives on Other Drugs COCs containing ethinyl estradiol may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs. 7.3 Concomitant Use with HCV Combination Therapy \u2013 Liver Enzyme Elevation Do not co-administer norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with HCV drug combinations containing ombitasvir/ paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions (5.3) ] . 7.4 Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation: Not recommended; Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can decrease milk production (8.2) 8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. 8.2 Lactation Risk Summary Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see Dosage and Administration (2.2) ] . The developmental and health benefits of breast-feeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules and any potential adverse effects on the breast-fed child from norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules or from the underlying maternal condition. 8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated. 8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in postmenopausal women and is not indicated in this population. 8.6 Renal Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in subjects with renal impairment [see Clinical Pharmacology (12.3) ] . 8.7 Hepatic Impairment The pharmacokinetics of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in subjects with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded [see Contraindications (4) and Warnings and Precautions (5.2) ] . 8.8 Body Mass Index The safety and efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in women with a body mass index (BMI) > 35 kg/m 2 has not been evaluated [see Clinical Studies (14) ] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively."
    ],
    "nursing_mothers": [
      "8.2 Lactation Risk Summary Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see Dosage and Administration (2.2) ] . The developmental and health benefits of breast-feeding should be considered along with the mother\u2019s clinical need for norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules and any potential adverse effects on the breast-fed child from norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules or from the underlying maternal condition."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules has not been studied in postmenopausal women and is not indicated in this population."
    ],
    "overdosage": [
      "10 OVERDOSAGE There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea."
    ],
    "description": [
      "11 DESCRIPTION Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules contain norethindrone acetate USP, a progestin, and ethinyl estradiol USP, an estrogen. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules provides an oral contraceptive regimen consisting of 24 pink active soft gelatin capsules that contain the active ingredients, followed by 4 maroon non-hormonal placebo soft gelatin capsules as specified below: 24 oval, opaque, pale pink soft gelatin capsules each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. 4 oval, opaque, maroon, soft gelatin capsules each containing 75 mg ferrous fumarate, USP Each pink active capsule also contains the following inactive ingredients: sesame oil, linoleoyl polyoxylglycerides, DL-\u03b1-tocopherol, dehydrated alcohol, gelatin, sorbitol sorbitan solution, glycerin, FD&C Red #40, titanium dioxide and purified water. Each maroon non-hormonal placebo capsule contains ferrous fumarate USP, soybean oil, yellow beeswax, soy lecithin gelatin, sorbitol sorbitan solution, glycerin, FD&C Blue #1, FD&C Red #40, titanium dioxide and purified water. The ferrous fumarate capsules do not serve any therapeutic purpose. The chemical name of ethinyl estradiol, USP is [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17\u03b1)-]. The molecular formula of ethinyl estradiol, USP is C 20 H 24 O 2 and the structural formula is: The chemical name of norethindrone acetate, USP is [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17\u03b1)-]. The molecular formula of norethindrone acetate, USP is C 22 H 28 O 3 and the structural formula is: Ethinyl Estradiol Structural Formula Norethindrone Acetate Structural Formula"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action CHCs lower the risk of becoming pregnant primarily by suppressing ovulation. 12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. 12.3 Pharmacokinetics Absorption In a single-dose, crossover clinical study conducted in 39 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules were bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets (24-day regimen tablets) based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed from norethindrone acetate/ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring 1 to 4 hours post-dose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single- and multiple-dose administrations of norethindrone acetate/ethinyl estradiol tablets in 17 healthy female volunteers are provided in Figures 2 and 3, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean Plasma Norethindrone Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers under Fasting Condition (n = 17) Figure 3. Mean Plasma Ethinyl Estradiol Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Regimen Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC (0\u221224) (pg/mL\u2022h) C min (pg/mL) t \u00bd (hr) C avg (pg/mL) Day 1 (Single Dose) NE 8,420 (31) 1.0 (0.7 to 4.0) 33,390 (40) -- -- -- EE 64.5 (27) 1.3 (0.7 to 4.0) 465.4 (26) -- -- -- SHBG -- -- -- 57.5 (37) b -- -- Day 24 (Multiple Dose) NE 16,400 (26) 1.3 (0.7 to 4.0) 88,160 (30) 880 (51) 8.4 3,670 (30) EE 81.9 (24) 1.7 (1.0 to 2.0) 701.3 (28) 11.4 (43) 14.5 29.2 (28) SHBG -- -- -- 144 (24) -- -- C max = Maximum plasma concentration t max = Time of C max C min = minimum plasma concentration at steady-state AUC (0\u221224) = Area under plasma concentration versus time curve from 0 to 24 hours t \u00bd = Apparent first-order terminal elimination half-life C avg = Average plasma concentration = AUC (0\u201324)/24 % CV = Coefficient of Variation (%) SHBG = Sex Hormone Binding Globulin (nmol/L) a The harmonic mean (0.693/mean apparent elimination rate constant) is reported for t \u00bd , and the median (range) is reported for t max . b The SHBG concentration reported here is the pre-dose concentration. Food Effect Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be administered without regard to meals. A single-dose administration of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with food in 38 healthy, non-smoking premenopausal women decreased the maximum concentration of norethindrone and ethinyl estradiol by 38% and 33%, respectively. Food intake did not affect the extent of ethinyl estradiol absorption, but increased the extent of norethindrone absorption by 19%. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (>95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. Drug Interactions No drug-drug interaction studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Figure 1 Figure 2"
    ],
    "clinical_pharmacology_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"7.65in\"/><col/><col/><col/><col/><col/><col/><col/><tbody><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17)</content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Regimen </paragraph></td><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Analyte </paragraph></td><td colspan=\"6\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Arithmetic Mean<sup>a</sup> (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub>  (pg/mL)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub>  (hr)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#x2212;24)</sub>  (pg/mL&#x2022;h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>min</sub>  (pg/mL)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>&#xBD;</sub>  (hr)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>avg</sub>  (pg/mL)</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Day 1   (Single Dose) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8,420   (31)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.0   (0.7 to 4.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>33,390   (40)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>EE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>64.5   (27)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.3   (0.7 to 4.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>465.4   (26)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>SHBG </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>57.5   (37)<sup>b</sup></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Day 24   (Multiple Dose) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>16,400   (26)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.3   (0.7 to 4.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>88,160   (30)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>880   (51)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8.4</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>3,670   (30)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>EE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>81.9   (24)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.7   (1.0 to 2.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>701.3   (28)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>11.4   (43)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>14.5</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>29.2   (28)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>SHBG </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>144   (24)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub> = Maximum plasma concentration </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub> = Time of C<sub>max</sub></paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>min</sub> = minimum plasma concentration at steady-state </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#x2212;24)</sub> = Area under plasma concentration versus time curve from 0 to 24 hours </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>&#xBD;</sub> = Apparent first-order terminal elimination half-life </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>avg</sub> = Average plasma concentration = AUC<sub>(0&#x2013;24)/24</sub></paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>% CV = Coefficient of Variation (%) </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>SHBG = Sex Hormone Binding Globulin (nmol/L) </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><sup>a</sup>The harmonic mean (0.693/mean apparent elimination rate constant) is reported for t<sub>&#xBD;</sub>, and the median (range) is reported for t<sub>max</sub>. </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><sup>b</sup>The SHBG concentration reported here is the pre-dose concentration. </paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action CHCs lower the risk of becoming pregnant primarily by suppressing ovulation."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics No specific pharmacodynamic studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption In a single-dose, crossover clinical study conducted in 39 healthy, non-smoking premenopausal women under fasting condition, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules were bioequivalent to norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets (24-day regimen tablets) based on the exposure (AUC) and peak concentration (C max ) of norethindrone and ethinyl estradiol. Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed from norethindrone acetate/ethinyl estradiol tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring 1 to 4 hours post-dose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol. The plasma norethindrone and ethinyl estradiol pharmacokinetics following single- and multiple-dose administrations of norethindrone acetate/ethinyl estradiol tablets in 17 healthy female volunteers are provided in Figures 2 and 3, and Table 1. Following multiple-dose administration of norethindrone acetate/ethinyl estradiol tablets, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of norethindrone acetate/ethinyl estradiol tablets. Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13. Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state. Figure 2. Mean Plasma Norethindrone Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers under Fasting Condition (n = 17) Figure 3. Mean Plasma Ethinyl Estradiol Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17) Regimen Analyte Arithmetic Mean a (% CV) by Pharmacokinetic Parameter C max (pg/mL) t max (hr) AUC (0\u221224) (pg/mL\u2022h) C min (pg/mL) t \u00bd (hr) C avg (pg/mL) Day 1 (Single Dose) NE 8,420 (31) 1.0 (0.7 to 4.0) 33,390 (40) -- -- -- EE 64.5 (27) 1.3 (0.7 to 4.0) 465.4 (26) -- -- -- SHBG -- -- -- 57.5 (37) b -- -- Day 24 (Multiple Dose) NE 16,400 (26) 1.3 (0.7 to 4.0) 88,160 (30) 880 (51) 8.4 3,670 (30) EE 81.9 (24) 1.7 (1.0 to 2.0) 701.3 (28) 11.4 (43) 14.5 29.2 (28) SHBG -- -- -- 144 (24) -- -- C max = Maximum plasma concentration t max = Time of C max C min = minimum plasma concentration at steady-state AUC (0\u221224) = Area under plasma concentration versus time curve from 0 to 24 hours t \u00bd = Apparent first-order terminal elimination half-life C avg = Average plasma concentration = AUC (0\u201324)/24 % CV = Coefficient of Variation (%) SHBG = Sex Hormone Binding Globulin (nmol/L) a The harmonic mean (0.693/mean apparent elimination rate constant) is reported for t \u00bd , and the median (range) is reported for t max . b The SHBG concentration reported here is the pre-dose concentration. Food Effect Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may be administered without regard to meals. A single-dose administration of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with food in 38 healthy, non-smoking premenopausal women decreased the maximum concentration of norethindrone and ethinyl estradiol by 38% and 33%, respectively. Food intake did not affect the extent of ethinyl estradiol absorption, but increased the extent of norethindrone absorption by 19%. Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (>95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation. Excretion Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of norethindrone acetate/ethinyl estradiol tablets are approximately 8 hours and 14 hours, respectively. Drug Interactions No drug-drug interaction studies were conducted with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Figure 1 Figure 2"
    ],
    "pharmacokinetics_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"7.65in\"/><col/><col/><col/><col/><col/><col/><col/><tbody><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Norethindrone Acetate/Ethinyl Estradiol Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17)</content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Regimen </paragraph></td><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Analyte </paragraph></td><td colspan=\"6\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Arithmetic Mean<sup>a</sup> (% CV) by Pharmacokinetic Parameter</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub>  (pg/mL)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub>  (hr)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#x2212;24)</sub>  (pg/mL&#x2022;h)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>min</sub>  (pg/mL)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>&#xBD;</sub>  (hr)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>avg</sub>  (pg/mL)</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Day 1   (Single Dose) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8,420   (31)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.0   (0.7 to 4.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>33,390   (40)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>EE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>64.5   (27)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.3   (0.7 to 4.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>465.4   (26)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>SHBG </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>57.5   (37)<sup>b</sup></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Day 24   (Multiple Dose) </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>16,400   (26)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.3   (0.7 to 4.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>88,160   (30)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>880   (51)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8.4</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>3,670   (30)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>EE </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>81.9   (24)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.7   (1.0 to 2.0)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>701.3   (28)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>11.4   (43)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>14.5</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>29.2   (28)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>SHBG </paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>144   (24)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>--</paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub> = Maximum plasma concentration </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub> = Time of C<sub>max</sub></paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>min</sub> = minimum plasma concentration at steady-state </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC<sub>(0&#x2212;24)</sub> = Area under plasma concentration versus time curve from 0 to 24 hours </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>&#xBD;</sub> = Apparent first-order terminal elimination half-life </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>avg</sub> = Average plasma concentration = AUC<sub>(0&#x2013;24)/24</sub></paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>% CV = Coefficient of Variation (%) </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>SHBG = Sex Hormone Binding Globulin (nmol/L) </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><sup>a</sup>The harmonic mean (0.693/mean apparent elimination rate constant) is reported for t<sub>&#xBD;</sub>, and the median (range) is reported for t<sub>max</sub>. </paragraph></td></tr><tr><td colspan=\"8\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><sup>b</sup>The SHBG concentration reported here is the pre-dose concentration. </paragraph></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [see Warnings and Precautions (5.2, 5.11) ]."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility [see Warnings and Precautions (5.2, 5.11) ]."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES The data presented in Section 14 are from a clinical trial conducted with a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are bioequivalent to these norethindrone acetate/ethinyl estradiol tablets. In a clinical study, 743 women 18 to 45 years of age were studied to assess the efficacy of norethindrone acetate/ethinyl estradiol tablets, for up to six 28-day cycles providing a total of 3,823 treatment-cycles of exposure. The racial demographic of all enrolled women was: 70% Caucasian, 16% African-American, 10% Hispanic, 2% Asian and 2% Other. Women with body mass index (BMI) greater than 35 mg/m 2 were excluded from the study. The weight range for those women treated was 90 to 260 pounds, with a mean weight of 147 pounds. Among the women in the study, about 40% had not used hormonal contraception immediately prior to enrolling in this study. A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies in 3,565 treatment cycles during which no backup contraception was used. The Pearl Index for norethindrone acetate/ethinyl estradiol tablets was 1.82 (95% confidence interval 0.59 to 4.25)."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Norethindrone acetate and ethinyl estradiol capsules, 1 mg/20 mcg and ferrous fumarate capsules, 75 mg are available in blister cards (dispensers) containing 28 soft gelatin capsules: Each blister card contains 28 capsules in the following order: 24 oval, opaque, pale pink (active) soft gelatin capsules, printed with \u2018A3\u2019 and each containing 1 mg norethindrone acetate, USP and 20 mcg ethinyl estradiol, USP. 4 oval, opaque, maroon, (non-hormonal placebo) soft gelatin capsules, printed with \u201cA9\u201d and each containing 75 mg ferrous fumarate, USP. The ferrous fumarate capsules do not serve any therapeutic purpose. Each blister card is packed in a carton (NDC 69238-1686-6). Cartons of 5 blister cards packed individually in 5 cartons are provided for dispensing (NDC 69238-1686-3). 5 cartons - each carton contains 1 blister card (28): NDC 69238-1686-6 16.2 Storage Conditions Store at 20\u00b0 to 25\u00ba C (68\u00b0 to 77\u00ba F); excursions permitted between 15\u00b0 to 30\u00ba C (59\u00b0 to 86\u00ba F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) . Counsel patients on the following information: Cigarette smoking increases the risk of serious cardiovascular events from COC use, and women who are over 35 years old and smoke should not use COCs. Increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules do not protect against HIV infection (AIDS) and other sexually transmitted infections. The Warnings and Precautions associated with COCs. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are not to be used during pregnancy; if pregnancy occurs during use of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, instruct the patient to stop further intake. Take one capsule daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed. See \u201c What to Do if You Miss Capsules \u201d section in FDA-approved patient labeling . Use a back-up or alternative method of contraception when enzyme inducers are used with norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established. Women who start COCs postpartum, and who have not yet had a period, should use an additional method of contraception until they have taken a pink capsule for 7 consecutive days. Amenorrhea may occur. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 07-2023-02"
    ],
    "spl_patient_package_insert": [
      "FDA-Approved Patient Labeling Guide for Using Norethindrone Acetate (nor eth \u02b9 in drone as \u02b9 e tate) and Ethinyl Estradiol (eth \u02b9 i nil es \u02ba tra dye \u02b9 ol) Capsules and Ferrous Fumarate (fer \u02b9 us fue \u02b9 ma rate) Capsules WARNING TO WOMEN WHO SMOKE Do not use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. Birth control pills help to lower the chances of becoming pregnant when taken as directed. They do not protect against HIV infection (AIDS) and other sexually transmitted infections. What are norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules? Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate. How well does norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules work? Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant. Based on the results of one clinical study of a 24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 0.020 mg tablets lasting six months, about 1 to 4 out of 100 women may get pregnant during the first year they use norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Women with a BMI above 35 kg/m 2 were not studied in the clinical trial, so it is not known how well norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules protects against pregnancy in such women. If you are overweight, discuss with your healthcare provider whether norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are the best choice for you. The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant. How do I take norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules? Be sure to read these directions before you start taking your capsules or anytime you are not sure what to do. The right way to take the capsule is to take one capsule every day at the same time in the order directed on the package. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can be taken without regard to meals. If you miss capsules you could get pregnant. This includes starting the pack late. The more capsules you miss, the more likely you are to get pregnant. See \"WHAT TO DO IF YOU MISS CAPSULES\u201d below. Many women have spotting or light bleeding at unexpected times, or may feel sick to their stomach during the first 1 to 3 packs of capsules. If you do have spotting or light bleeding or feel sick to your stomach, do not stop taking the capsules. The problem will usually go away. If it does not go away, check with your healthcare provider. Missing capsules can also cause spotting or light bleeding, even when you make up these missed capsules. On the days you take two capsules, to make up for missed capsules, you could also feel a little sick to your stomach. If you have vomiting (within 3 to 4 hours after you take your capsule), you should follow the instructions for \"WHAT TO DO IF YOU MISS CAPSULES.\" If you have diarrhea or if you take certain medicines, including some antibiotics and some herbal products such as St. John's Wort, your capsules may not work as well. Use a back-up method (such as condoms and spermicides) until you check with your healthcare provider. If you have trouble remembering to take norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, talk to your healthcare provider about how to make capsule-taking easier or about using another method of birth control. If you have any questions or are unsure about the information in this leaflet, call your healthcare provider. Before You Start Taking Your Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules Decide What Time of Day You Want to Take Your Capsule. It is important to take norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in the order directed on the package at the same time every day. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules can be taken without regard to meals. Look at Your Capsule Pack \u2013 It has 28 Capsules The norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules-pill pack has 24 \"active\" pink capsules (with hormones) to be taken for 24 days, followed by 4 \"reminder\" maroon capsules (without hormones) to be taken for the next four days. Also look for: a) Where on the pack to start taking capsules, b) In what order to take the capsules (follow the arrows shown in the picture above) c) The week numbers as shown in the picture above. Be sure you have ready at all times a) another kind of birth control (such as a condoms and spermicide) to use as a back-up in case you miss capsules, and b) an extra, full pill pack. When to Start the First Pack of Capsules You have a choice for which day to start taking your first pack of capsules. Decide with your healthcare provider which is the best day for you. Pick a time of day which will be easy to remember. Day 1 Start: Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins). Place this day label strip on the capsule dispenser over the area that has the days of the week (starting with Sunday) printed on the plastic. Take the first pink pill of the pack during the first 24 hours of your period. You will not need to use a back-up method of birth control, since you are starting the capsule at the beginning of your period. However, if you start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules later than the first day of your period, you should use another method of birth control (such as a condom and spermicide) as a back-up method until you have taken 7 pink capsules. Sunday Start: Take the first pink capsule of the pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day. Use another method of birth control (such as a condom and spermicide) as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). This also applies if you start norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules after having been pregnant, and you have not had a period since your pregnancy. When You Switch From a Different Birth Control Tablet When switching from another birth control pill, finish all the tablets, then norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started on the same day that a new pack of the previous birth control tablet would have been started. When You Switch From Another Type of Birth Control Method When switching from a transdermal patch or vaginal ring, finish the 21 days of use, wait 7 days, then norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started when the next application would have been due. When switching from an injection, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started when the next injection would have been due. When switching from an intrauterine device or an implant, norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules should be started on the day of removal. What to Do During the Month Take one capsule at the same time every day until the pack is empty. Do not skip capsules even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip capsules even if you do not have sex very often. When you finish a pack of capsules, start the next pack on the day after your last maroon capsule. Do not wait any days between packs. What to Do if You Miss Capsules Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules may not be as effective if you miss any pink capsules, especially if you miss the first few or the last few pink capsules in a pack. If you miss 1 pink capsule: Take the capsule as soon as you remember. Take the next capsule at your regular time. This means you may take two capsules in one day. You do not need to use a back-up birth control method if you have sex. If you miss 2 pink capsules in a row in week 1 OR week 2 of your pack: Take two capsules on the day you remember and two capsules the next day. Then take one capsule a day until you finish the pack. You could become pregnant if you have sex in the 7 days after you restart your capsules. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. If you miss 2 pink capsules in a row in week 3 or week 4 of your pack: If you are a Day 1 Starter: Throw out the rest of the norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules pack and start a new pack that same day. If you are a Sunday Starter: Keep taking one capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. You could become pregnant if you have sex in the 7 days after you restart your capsules. You must use another birth control method (such as a condom and spermicide) as a back-up for those 7 days. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss 3 or more pink capsules in a row during any week: If you are a Day 1 Starter: Throw out the rest of the capsule pack and start a new pack that same day. If you are a Sunday Starter: Keep taking 1 capsule every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of capsules that same day. You could become pregnant if you have sex on the days when you missed capsules or during the first 7 days after you restart your capsules. You must use another birth control method (such as a condom and spermicide) as a back-up the next time you have sex and for the first 7 days after you restart your capsules. You may not have your period this month but this is expected. However, if you miss your period two months in a row, call your healthcare provider because you might be pregnant. If you miss any of the 4 maroon capsules in Week 4: Throw away the capsules you missed. Keep taking one capsule each day until the pack is empty. You do not need a back-up method. Start the next pack of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules as scheduled. Finally, if you are still not sure what to do about the capsules you have missed: Use a back-up method (such as a condom and spermicide) anytime you have sex. Contact your healthcare provider and continue taking one active pink capsule each day until otherwise directed. Who should not take norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules? Your healthcare provider will not give you norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if you have: Ever had blood clots in your arms, legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis) Ever had a stroke Ever had a heart attack Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart An inherited problem with your blood that makes it clot more than normal High blood pressure that medicine cannot control Diabetes with kidney, eye, nerve, or blood vessel damage Ever had certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or have any migraine headaches if you are over age 35 Ever had breast cancer, which may be sensitive to female hormones Liver disease, including liver tumors Take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme \u201calanine aminotransferase\u201d (ALT) in the blood. Also, do not take birth control pills if you: Smoke and are over 35 years old Are or suspect you are pregnant Have any unexplained bleeding from the vagina Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy, also called cholestasis of pregnancy. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). What else should I know about taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules? Birth control pills do not protect you against any sexually transmitted infection, including HIV, the virus that causes AIDS. Do not skip any pills, even if you do not have sex often. If you miss a period, you could be pregnant. However, some women miss periods or have light periods on birth control pills, even when they are not pregnant. Contact your healthcare provider for advice if you: Think you are pregnant Miss one period and have not taken your birth control pills every day Miss two periods in a row Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects. You should stop norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules at least four weeks before you have surgery and not restart it until at least two weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, may decrease the amount of milk you make. A small amount of the pill's hormones pass into breast milk. Tell your healthcare provider about all medicines and herbal products that you take. Some medicines and herbal products may make birth control pills less effective, including: barbiturates bosentan carbamazepine felbamate griseofulvin oxcarbazepine phenytoin rifampin St. John\u2019s wort topiramate Use a back-up or alternative birth control method when you take medicines that may make birth control pills less effective. Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your healthcare provider may need to adjust the dose of lamotrigine. If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like a condom and spermicide, until you check with your healthcare provider. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone. If you are scheduled for any laboratory tests, tell your healthcare provider that you are taking birth control pills. Certain blood tests may be affected by birth control pills. What are the most serious risks of taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules? Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke. Some examples of serious blood clots are blood clots in the: * Legs (deep vein thrombosis) * Lungs (pulmonary embolus) * Eyes (loss of eyesight) * Heart (heart attack) * Brain (stroke) Women who take birth control pills may get: * High blood pressure * Gallbladder problems * Rare cancerous or noncancerous liver tumors All of these events are uncommon in healthy women. Call your healthcare provider right away if you have: * Persistent leg pain * Sudden shortness of breath * Sudden blindness, partial or complete * Severe pain or pressure in your chest * Sudden, severe headache unlike your usual headaches * Weakness or numbness in an arm or leg, or trouble speaking * Yellowing of the skin or eyeballs What are the common side effects of birth control pills? The most common side effects of birth control pills are: Spotting or bleeding between menstrual periods Nausea Breast tenderness Headache These side effects are usually mild and usually disappear with time. Less common side effects are: * Acne * Less sexual desire * Bloating or fluid retention * Blotchy darkening of the skin, especially on the face * High blood sugar, especially in women who already have diabetes * High fat (cholesterol, triglyceride) levels in the blood * Depression, especially if you have had depression in the past. Call your healthcare provider immediately if you have any thoughts of harming yourself * Problems tolerating contact lenses * Weight gain This is not a complete list of possible side effects. Talk to your healthcare provider if you develop any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088. No serious problems have been reported from a birth control pill overdose, even when accidentally taken by children. Do birth control pills cause cancer? It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners. What should I know about my period when taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules? Irregular vaginal bleeding or spotting may occur while you are taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding, which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle, is unusually heavy, or lasts for more than a few days, call your healthcare provider. Some women may not have a menstrual period but this should not be cause for alarm as long has you have taken the pills according to direction. What if I miss my scheduled period when taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules? It is not uncommon to miss your period. However, if you go two or more months in a row without a period, or you miss your period after a month where you did not take all your pills correctly, call your healthcare provider because you may be pregnant. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. Stop taking norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if you are pregnant. What if I want to become pregnant? You may stop taking the capsule whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the capsule. General Advice about norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules Your healthcare provider prescribed norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules for you. Please do not share norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules with anyone else. Keep norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules out of the reach of children. If you have concerns or questions, ask your healthcare provider. You may also ask your pharmacist for a more detailed label written for healthcare professionals. This Patient Information has been approved by the U.S. Food and Drug Administration. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 07-2023-03 Chart Pill Pack"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"1pt\"/><tbody><tr><td><paragraph><content styleCode=\"bold\">Do not use </content><content styleCode=\"bold\">norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</content></paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL Carton"
    ],
    "set_id": "e145ebc7-b6c0-474b-a712-c6f3b2342998",
    "id": "eaacb828-e8db-45c4-882b-a6ddf46bf7f0",
    "effective_time": "20230808",
    "version": "12",
    "openfda": {
      "application_number": [
        "ANDA214292"
      ],
      "brand_name": [
        "Norethindrone Acetate and Ethinyl Estradiol, and Ferrous Fumarate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE"
      ],
      "manufacturer_name": [
        "Amneal Pharmaceuticals NY LLC"
      ],
      "product_ndc": [
        "69238-1686"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "rxcui": [
        "1421459",
        "1421460",
        "1421461"
      ],
      "spl_id": [
        "eaacb828-e8db-45c4-882b-a6ddf46bf7f0"
      ],
      "spl_set_id": [
        "e145ebc7-b6c0-474b-a712-c6f3b2342998"
      ],
      "package_ndc": [
        "69238-1686-6",
        "69238-1686-3"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0369238168631"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate Norethindrone Acetate SILICON DIOXIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE TALC NORETHINDRONE ACETATE NORETHINDRONE to off-white flat faced beveled edged G;304"
    ],
    "description": [
      "DESCRIPTION Norethindrone acetate tablets USP - 5 mg oral tablets Norethindrone acetate USP, (17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white, or creamy white, crystalline powder. Norethindrone acetate tablets USP, 5 mg contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and talc. norethindrone-acetate-structure"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone. PHARMACOKINETICS Absorption: Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf) (ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Figure 1 Effect of Food: The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution: Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism: Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion: Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half- life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. SPECIAL POPULATIONS Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In pre-menopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in pre-menopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"100%\" ID=\"_RefIDCD5EBF156DFB444086DB8DD624D60FB4\"><caption>Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women</caption><colgroup><col width=\"49%\"/><col width=\"49%\"/></colgroup><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Norethindrone Acetate (n=29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Norethindrone (NET)</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>AUC (0-inf) (ng/ml*h)</paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>C <sub>max</sub>(ng/ml) </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>26.19 &#xB1; 6.19</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>t <sub>max</sub>(h) </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>1.83 &#xB1; 0.58</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>t <sub>1/2</sub>(h) </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>8.51 &#xB1; 2.19</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph>AUC = area under the curve,</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>C <sub>max</sub>= maximum plasma concentration, </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>t <sub>max</sub>= time at maximum plasma concentration, </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>t <sub>1/2</sub>= half-life, </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>SD = standard deviation</paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "PHARMACOKINETICS Absorption: Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n=29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf) (ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Figure 1 Effect of Food: The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution: Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism: Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion: Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half- life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. SPECIAL POPULATIONS Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In pre-menopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in pre-menopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted."
    ],
    "pharmacokinetics_table": [
      "<table width=\"100%\" ID=\"_RefIDCD5EBF156DFB444086DB8DD624D60FB4\"><caption>Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women</caption><colgroup><col width=\"49%\"/><col width=\"49%\"/></colgroup><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Norethindrone Acetate (n=29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Norethindrone (NET)</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>AUC (0-inf) (ng/ml*h)</paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>C <sub>max</sub>(ng/ml) </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>26.19 &#xB1; 6.19</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>t <sub>max</sub>(h) </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>1.83 &#xB1; 0.58</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>t <sub>1/2</sub>(h) </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>8.51 &#xB1; 2.19</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph>AUC = area under the curve,</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>C <sub>max</sub>= maximum plasma concentration, </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>t <sub>max</sub>= time at maximum plasma concentration, </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>t <sub>1/2</sub>= half-life, </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>SD = standard deviation</paragraph></td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone acetate is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."
    ],
    "contraindications": [
      "CONTRAINDICATIONS Known or suspected pregnancy. There is no indication for norethindrone acetate in pregnancy. (See PRECAUTIONS ). Undiagnosed vaginal bleeding Known, suspected or history of cancer of the breast Active deep vein thrombosis, pulmonary embolism or history of these conditions Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) Impaired liver function or liver disease As a diagnostic test for pregnancy Hypersensitivity to any of the drug components"
    ],
    "warnings": [
      "WARNINGS 1. Cardiovascular disorders Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. 2. Visual abnormalities Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued."
    ],
    "precautions": [
      "PRECAUTIONS 1. General Precautions Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy The pathologist should be advised of progestin therapy when relevant specimens are submitted 2. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate. 3. Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radio immunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentratios are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test. 4. Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established. 5. Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses. 6. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman. 7. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "general_precautions": [
      "1. General Precautions Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy The pathologist should be advised of progestin therapy when relevant specimens are submitted"
    ],
    "information_for_patients": [
      "2. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate."
    ],
    "drug_and_or_laboratory_test_interactions": [
      "3. Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radio immunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentratios are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "4. Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established."
    ],
    "pregnancy": [
      "5. Pregnancy Category X Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses."
    ],
    "nursing_mothers": [
      "6. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman."
    ],
    "pediatric_use": [
      "7. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See WARNINGS and PRECAUTIONS The following adverse reactions have been observed in women taking progestins: Breakthrough bleeding Spotting Change in menstrual flow Amenorrhea Edema Changes in weight (decreases, increases) Changes in the cervical squamo-columnar junction and cervical secretions Cholestatic jaundice Rash (allergic) with and without pruritus Melasma or chloasma Clinical depression Ace Breast enlargement/tenderness Headache/migraine Urticaria Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) Decreased HDL cholesterol and increased LDL/HDL ratio Mood swings Nausea Insomnia Anaphylactic/anaphylactoid reactions Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) Optic neuritis (which may lead to partial or complete loss of vision)"
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Therapy with norethindrone acetate must be adapted to the specific indications and therapeutic response of the individual patient. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg norethindrone acetate may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate. Endometriosis: Initial daily dosage of 5 mg norethindrone acetate for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone acetate tablets USP are available as: 5 mg : White to off-white oval, flat faced beveled edged, uncoated tablets debossed with \u2018G with breakline\u2019 on one side and 304 on other side. Available as follows: Unit dose packages of 30 (3 x 10) NDC 60687-921-21"
    ],
    "storage_and_handling": [
      "Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken. PACKAGING INFORMATION American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Glenmark Pharmaceuticals Inc., USA as follows: (5 mg / 30 UD) NDC 60687-921-21 packaged from NDC 68462-304 For questions about the drug product, call Glenmark Pharmaceuticals Inc., USA at 1 (888)721-7115 or visit www.glenmarkpharma.com/usa . For questions about the packaging and labeling, call American Health Packaging at 1-800-707-4621 Distributed by: American Health Packaging Columbus, OH 43217 8492121/0625F"
    ],
    "spl_patient_package_insert": [
      "PATIENT INFORMATION 8492121/0625F Norethindrone acetate tablets USP Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition. What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets? Do not use norethindrone acetate if you are pregnant, breast-feeding or are trying to conceive. Do not use northindrone acetate if you have had a previous blood clot, stroke, or heart attack. Do not use norethindrone acetate if you are postmenopausal. What is norethindrone acetate? Norethindrone acetate is similar to the progesterone hormones naturally produced by the body. Your healthcare provider may provide norethindrone acetate as individual tablets. What are norethindrone acetate tablets used for? Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. Who should not take norethindrone acetate tablets? You should not tke norethindrone acetate tablets if you are postmenopausal, pregnant or breast-feeding. You should not take norethindrone acetate tablets if you have the following conditions: Known or suspected pregnancy. Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate and later find out you were pregnant, talk with your healthcare provider right away History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions Liver impairment or disease Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate Undiagnosed vaginal bleeding Hypersensitivity to norethindrone acetate tablets. See the end of this leaflet for a list of all of the ingredients in norethindrone acetate What are the risks associated with norethindrone acetate tablets? Risk to the Fetus: Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. You should avoid using norethindrone acetate tablets during pregnancy. If you take norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. Abnormal Blood Clotting: Use of progestational drugs, such as norethindrone acetate, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug. Eye Abnormalities: Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. These are some of the warning signs of serious side effects with progestin therapy: Breast lumps Dizziness and faintness Changes in speech Severe headaches Chest pain Shortness of breath Pain in your legs Changes in vision Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. Common side effects include: Headache Breast pain Irregular vaginal bleeding or spotting Stomach/abdominal cramps/bloating Nausea and vomiting Hair loss Other side effects include: High blood pressure Liver problems High blood sugar Fluid retention Enlargements of benign tumors of the uterus (\"fibroids\") Vaginal yeast infections Mental depression These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist. What can I do to lower my chances of getting a serious side effect with norethindrone acetate? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks General information about the safe and effective use of norethindrone acetate tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. Keep norethindrone acetate tablets out of the reach of children. This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate that is written for health professionals. What are the ingredients in norethindrone acetate tablets? Norethindrone acetate tablets contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and talc. For questions about the drug product, call Glenmark Pharmaceuticals Inc., USA at 1 (888)721-7115 or visit www.glenmarkpharma.com/usa . For questions about the packaging and labeling, call American Health Packaging at 1-800-707-4621 Distributed by: American Health Packaging Columbus, OH 43217 8492121/0625F"
    ],
    "package_label_principal_display_panel": [
      "Package/Label Display Panel \u2013 Carton \u2013 5 mg NDC 60687- 921 -21 Norethindrone Acetate Tablets USP 5 mg 30 Tablets (3 x 10) Rx Only PHARMACIST: Dispense with Patient Information to each patient. ORALLY ACTIVE PROGESTIN Each Tablet Contains: Norethindrone acetate USP......................................................5 mg Usual Dosage: See full prescribing information. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 68462-304, Glenmark Pharmaceuticals Inc., USA. Distributed by: American Health Packaging, Columbus, Ohio 43217 792121 0492121/0625 5 mg Norethindrone Tablets Carton.jpg",
      "Package/Label Display Panel \u2013 Blister \u2013 5 mg Norethindrone Acetate Tablet USP 5 mg 5 mg Norethindrone Tablet Blister.jpg"
    ],
    "set_id": "eb0b80e0-5b69-4efa-ae8a-62e718a62dc3",
    "id": "485ceb49-adae-1b29-e063-6294a90aded8",
    "effective_time": "20260114",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA091090"
      ],
      "brand_name": [
        "Norethindrone Acetate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "American Health Packaging"
      ],
      "product_ndc": [
        "60687-921"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1000405"
      ],
      "spl_id": [
        "485ceb49-adae-1b29-e063-6294a90aded8"
      ],
      "spl_set_id": [
        "eb0b80e0-5b69-4efa-ae8a-62e718a62dc3"
      ],
      "package_ndc": [
        "60687-921-11",
        "60687-921-21"
      ],
      "original_packager_product_ndc": [
        "68462-304"
      ],
      "unii": [
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "ESTRADIOL AND NORETHINDRONE ACETATE estradiol and norethindrone acetate STARCH, CORN COPOVIDONE K25-31 POLYSORBATE 80 LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TALC TRIACETIN NORETHINDRONE ACETATE NORETHINDRONE ESTRADIOL ESTRADIOL EX1"
    ],
    "recent_major_changes": [
      "Warnings and Precautions, Malignant Neoplasms (5.2) 11/2023"
    ],
    "boxed_warning": [
      "WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER See full prescribing information for complete boxed warning Estrogen Plus Progestin Therapy The Women\u2019s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) ( 5.1 ) The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer ( 5.2 ) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) Estrogen-Alone Therapy There is an increased risk of endometrial cancer in a woman with a uterus who use unopposed estrogens ( 5.2 ) The WHI estrogen-alone substudy reported increased risks of stroke and DVT ( 5.1 ) The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia ( 5.2 , 5.3 ) Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women\u2019s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions ( 5.1 ), and Clinical Studies ( 14.5 )] . The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )] . Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions ( 5.1 , 5.3 ), and Clinical Studies ( 14.5 , 14.6 )] . Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.5 )] . Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions ( 5.2 )] . Cardiovascular Disorders and Probable Dementia The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions ( 5.1 ), and Clinical Studies ( 14.5 )]. The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )]. Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions ( 5.1 , 5.3 ), and Clinical Studies ( 14.5 , 14.6 )] . Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.",
      "What is the most important information I should know about estradiol and norethindrone acetate tablets (a combination of estrogen and progestogen)? Do not use estrogens with or without progestogens to prevent heart disease, heart attacks, strokes, or dementia (decline of brain function). Using estrogens with progestogens may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots. Using estrogens with progestogens may increase your chance of getting dementia, based on a study of women 65 years of age and older. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Do not use estrogen-alone to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function). Using estrogen-alone may increase your chances of getting strokes or blood clots. Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age and older. Only one estrogen with progestogen product and dose have been shown to increase your chances of getting heart attacks, strokes, breast cancer, blood clots, and dementia. Only one estrogen-alone product and dose have been shown to increase your chances of getting strokes, blood clots, and dementia. Because other products and doses have not been studied in the same way, it is not known how the use of estradiol and norethindrone acetate tablets will affect your chances of these conditions. You and your healthcare provider should talk regularly about whether you still need treatment with estradiol and norethindrone acetate tablets."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Estradiol and Norethindrone acetate tablets is indicated for: Estradiol and Norethindrone acetate tablet is an estrogen and progestin combination indicated in a woman with a uterus for: \u2022 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause (1.1) \u2022 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause (1.2) Limitations of Use: When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. \u2022 Prevention of Postmenopausal Osteoporosis (1.3) Limitations of Use: When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION \u2022 Take a single Estradiol and Norethindrone acetate tablets orally once daily for the Treatment of Moderate to severe Vasomotor Symptoms due to Menopause and for the Prevention of Postmenopausal Osteoporosis (2.1, 2.3) \u2022Estradiol and norethindrone acetate tablets are taken orally once daily for the Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause (2.2) Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Reevaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary. 2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Take a single Estradiol and Norethindrone acetate tablet orally once daily for the treatment of moderate to severe vasomotor symptoms due to menopause. \u2022Estradiol and Norethindrone acetate tablets 1 mg/0.5 mg 2.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Take a single Estradiol and Norethindrone acetate tablet orally once daily for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. \u2022Estradiol and Norethindrone acetate tablets 1 mg/0.5 mg 2.3 Prevention of Postmenopausal Osteoporosis Take a single Estradiol and Norethindrone acetate tablet orally once daily for the prevention of postmenopausal osteoporosis. \u2022Estradiol and Norethindrone acetate tablets 1 mg/0.5 mg"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS \u2022 Estradiol and norethindrone acetate 1 mg/0.5 mg tablet (3) Estradiol and Norethindrone acetate tablets, USP 1 mg/0.5 mg are available as follows: \u2022 Each Estradiol and Norethindrone acetate tablet, USP contains 1 mg of estradiol and 0.5 mg of norethindrone acetate. The tablets are white to off-white, round, biconvex, film coated tablets, debossed with \"EX1\" on one side and plain on other side."
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS \u2022 Undiagnosed abnormal genital bleeding (4) \u2022 Breast cancer or a history of breast cancer (4, 5.2) \u2022 Estrogen-dependent neoplasia (4, 5.2) \u2022 Active DVT, PE, or history of these conditions (4, 5.1) \u2022 Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions (4, 5.1) \u2022 Known anaphylactic reaction, angioedema, or hypersensitivity to Estradiol and Norethindrone acetate tablets (4) \u2022 Hepatic impairment or disease (4, 5.10) \u2022 Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders (4) Estradiol and Norethindrone acetate tablets is contraindicated in women with any of the following conditions: \u2022 Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.2)] \u2022 Breast cancer or history of breast cancer [see Warnings and Precautions (5.2)] \u2022 Estrogen-dependent neoplasia [see Warnings and Precautions (5.2)] \u2022 Active DVT, PE, or history of these conditions [see Warnings and Precautions (5.1)] \u2022 Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions [see Warnings and Precautions (5.1)] \u2022 Known anaphylactic reaction, angioedema, or hypersensitivity to Estradiol and Norethindrone acetate tablets \u2022 Hepatic impairment or disease \u2022 Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Estrogens increase the risk of gall bladder disease ( 5.4 ) Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs ( 5.5 , 5.6 , 5.9 , 5.10 ) Monitor thyroid function in women on thyroid replacement therapy ( 5.11 , 5.18 ) 5.1 Cardiovascular Disorders Increased risks of PE, DVT, stroke and MI are reported with estrogen plus progestin therapy. Increased risks of stroke and DVT are reported with estrogen-alone therapy. Immediately discontinue estrogen with or without progestogen therapy if any of these occur or is suspected. Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). Stroke The WHI estrogen plus progestin substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 strokes per 10,000 women-years) [see Clinical Studies ( 14.5 )] . The increase in risk was demonstrated after the first year and persisted.1 Immediately discontinue estrogen with or without progestogen therapy if a stroke occurs or is suspected. The WHI estrogen-alone substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 strokes per 10,000 women-years, respectively). The increase in risk was demonstrated in year 1 and persisted [see Clinical Studies ( 14.5 )] . Immediately discontinue estrogen-alone therapy if a stroke occurs or is suspected. Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 Coronary Heart Disease The WHI estrogen plus progestin substudy reported an increased risk (not statistically significant) of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) in those women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). 1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies ( 14.5 )]. The WHI estrogen-alone substudy reported no overall effect on CHD events in women receiving estrogen-alone compared to placebo 2 [see Clinical Studies ( 14.5 )]. Subgroup analyses of women 50 to 59 years of age, who were less than 10 years since menopause, suggest a reduction (not statistically significant) in CHD events in those women receiving daily CE (0.625 mg)-alone compared to placebo (8 versus 16 per 10,000 women-years). 1 In postmenopausal women with documented heart disease (n=2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall. Venous Thromboembolism The WHI estrogen plus progestin substudy reported a statistically significant 2-fold greater rate of VTE (DVT and PE) in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted 3 [see Clinical Studies ( 14.5 )] . Immediately discontinue estrogen plus progestogen therapy if a VTE occurs or is suspected. In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years 4 [see Clinical Studies ( 14.5 )] . Immediately discontinue estrogen-alone therapy if a VTE occurs or is suspected. If feasible, discontinue estrogens at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. 5.2 Malignant Neoplasms Breast Cancer After a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA compared to placebo. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years, for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups 5 [see Clinical Studies ( 14.5 )] . The WHI substudy of daily CE (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80] compared to placebo 6 [see Clinical Studies ( 14.5 )] . Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer with estrogen plus progestin therapy, and a smaller increase in the risk for breast cancer with estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to >10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI Trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. These studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. The use of estrogen-alone and estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation. In a one-year trial among 1,176 women who received either unopposed 1 mg estradiol or a combination of 1 mg estradiol plus one of three different doses of NETA (0.1, 0.25, 0.5 mg), seven new cases of breast cancer were diagnosed, two of which occurred among the group of 295 women treated with Estradiol and Norethindrone acetate tablets 1 mg/0.5 mg and two of which occurred among the group of 294 women treated with 1 mg estradiol/0.1 mg NETA. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. Endometrial Cancer An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2-to 12-fold greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears to be associated with prolonged use, with increased risks of 15-to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. Clinical surveillance of all women using estrogen-alone or estrogen plus progestogen therapy is important. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding with unknown etiology. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestogen to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Endometrial hyperplasia occured at a rate of approximately 1 percent or less with Estradiol and Norethindrone acetate tablets in a clinical trial. Ovarian Cancer The CE plus MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent confidence interval [CI], 0.77-3.24), but it was not statistically significant. The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years 7 A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% CI 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. 5.3 Probable Dementia In the WHI Memory Study (WHIMS) estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for the CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )] . In the WHIMS estrogen-alone ancillary study, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )]. When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk of probable dementia was 1.76 (95 percent CI, 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Use in Specific Populations ( 8.5 ), and Clinical Studies ( 14.6 )] . 5.4 Gallbladder Disease A 2-to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. 5.5 Hypercalcemia Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. Discontinue estrogens, including Estradiol and Norethindrone acetate tablets if hypercalcemia occurs, and take appropriate measures to reduce the serum calcium level. 5.6 Vision Abnormalities Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue Estradiol and Norethindrone acetate tablet pending examination if there is a sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. Permanently discontinue estrogens, including Estradiol and Norethindrone acetate tablet, if examination reveals papilledema or retinal vascular lesions 5.7 Addition of a Progestogen When a Woman Has Not Had a Hysterectomy Studies of the addition of a progestogen for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestogens with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. 5.8 Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen. 5.9 Exacerbation of Hypertriglyceridemia In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Discontinue Estradiol and Norethindrone acetate tablet if pancreatitis occurs. 5.10 Hepatic Impairment and/or Past History of Cholestatic Jaundice Estrogens may be poorly metabolized in women with hepatic impairment. Exercise caution in any woman with a history of cholestatic jaundice associated with past estrogen use or with pregnancy. In the case of recurrence of cholestatic jaundice, discontinue Estradiol and Norethindrone acetate tablet. 5.11 Exacerbation of Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy. Monitor thyroid function in these women during treatment with Estradiol and Norethindrone acetate tablet to maintain their free thyroid hormone levels in an acceptable range. 5.12 Fluid Retention Estrogens plus progestogens may cause some degree of fluid retention. Monitor any woman with a condition(s) that might predispose her to fluid retention, such as a cardiac or renal impairment. Discontinue estrogen plus progestogen therapy, including Estradiol and Norethindrone acetate tablets, with evidence of medically concerning fluid retention. 5.13 Hypocalcemia Estrogen-induced hypocalcemia may occur in women with hypoparathyroidism. Consider whether the benefits of estrogen therapy, including Estradiol and Norethindrone acetate tablets, outweigh the risks in such women. 5.14 Exacerbation of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. 5.15 Hereditary Angioedema Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. Consider whether the benefits of estrogen therapy, including estradiol and norethindrone acetate tablets, outweigh the risks in such women. 5.16 Exacerbation of Other Conditions Estrogen therapy, including estradiol and norethindrone acetate tablets, may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas. Consider whether the benefits of estrogen therapy outweigh the risks in such women. 5.17 Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy. 5.18 Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/rennin substrate, alpha-1 antitrypsin, ceruloplasmin). Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentration, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglyceride levels. Impaired glucose tolerance."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions (incidence \u2265 5 percent) with Estradiol and Norethindrone acetate tablets are: back pain, headache, pain in the extremity, nausea, diarrhea, gastroenteritis, insomnia, emotional lability, upper respiratory tract infection, sinusitis, nasopharyngitis, weight increase, breast pain, post-menopausal bleeding, uterine fibroid vaginal hemorrhage, ovarian cyst, endometrial thickening, viral infection, moniliasis genital, and accidental injury. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following serious adverse reactions are discussed elsewhere in the labeling: \u2022 Cardiovascular Disorders [see Boxed Warning, Warnings and Precautions ( 5.1 )] \u2022 Malignant Neoplasms [see Boxed Warning, Warnings and Precautions ( 5.2 )] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported with estradiol and norethindrone acetate tablets 1 mg/0.5 mg by investigators during clinical trials regardless of causality assessment are shown in Table 1. Table 1: All Treatment-Emergent Adverse Reactions Regardless of Relationship Reported at a Frequency of \u2265 5 Percent with Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg Endometrial Hyperplasia Study (12-Months) Vasomotor Symptoms Study (3-Months) Osteoporosis Study (2-Years) Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (n=295) 1 mg E 2 (n=296) Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (n=29) Placebo (n=34) Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (n=47) Placebo (n=48) Body as a Whole Back Pain 6% 5% 3% 3% 6% 4% Headache 16% 16% 17% 18% 11% 6% Digestive System Nausea 3% 5% 10% 0% 11% 0% Gastroenteritis 2% 2% 0% 0% 6% 4% Nervous System Insomnia 6% 4% 3% 3% 0% 8% Emotional Lability 1% 1% 0% 0% 6% 0% Respiratory System Upper Respiratory Tract Infection 18% 15% 10% 6% 15% 19% Sinusitis 7% 11% 7% 0% 15% 10% Metabolic and Nutritional Weight Increase 0% 0% 0% 0% 9% 6% Urogenital System Breast Pain 24% 10% 21% 0% 17% 8% Post-Menopausal Bleeding 5% 15% 10% 3% 11% 0% Uterine Fibroid 5% 4% 0% 0% 4% 8% Ovarian Cyst 3% 2% 7% 0% 0% 8% Resistance Mechanism Infection Viral 4% 6% 0% 3% 6% 6% Moniliasis Genital 4% 7% 0% 0% 6% 0% Secondary Terms Injury Accidental 4% 3% 3% 0% 17% including one upper extremity fracture in each group 4% Other Events 2% 3% 3% 0% 6% 4% Adverse reactions reported with estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg by investigators during clinical trials regardless of causality assessment are shown in Table 2. Table 2: All Treatment-Emergent Adverse Reactions Regardless of Relationship Reported at a Frequency of \u2265 5 Percent with Estradiol and Norethindrone Acetate Tablets 0.5 mg/0.1 mg Estradiol and Norethindrone Acetate Tablets 0.5 mg/0.1 mg (n=194) Placebo (n=200) Body as a Whole Back Pain 10% 4% Headache 22% 19% Pain in extremity 5% 4% Digestive System Nausea 5% 4% Diarrhea 6% 6% Respiratory System Nasopharyngitis 21% 18% Urogenital System Endometrial thickening 10% 4% Vaginal hemorrhage 26% 12% 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of estradiol and norethindrone acetate tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; pre-menstrual-like syndrome; cystitis-like syndrome; ovarian cancer; endometrial hyperplasia; endometrial cancer. Breast Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer. Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction, stroke; increase in blood pressure. Gastrointestinal Nausea, vomiting; changes in appetite; cholestatic jaundice; abdominal pain/cramps, flatulence, bloating; increased incidence of gallbladder disease and pancreatitis. Skin Chloasma or melasma that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; seborrhea; hirsutism; itching; skin rash; pruritus. Eyes Retinal vascular thrombosis, intolerance to contact lenses. Central Nervous System Headache; migraine; dizziness; mental depression; chorea; insomnia; nervousness; mood disturbances; irritability; exacerbation of epilepsy; dementia. Miscellaneous Increase or decrease in weight; edema; leg cramps; changes in libido; fatigue; exacerbation of asthma; increased triglycerides; hypersensitivity; anaphylactoid/anaphylactic reactions."
    ],
    "adverse_reactions_table": [
      "<table width=\"99%\"><col width=\"13%\"/><col width=\"22%\"/><col width=\"9%\"/><col width=\"22%\"/><col width=\"5%\"/><col width=\"22%\"/><col width=\"5%\"/><tbody><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"/><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Endometrial Hyperplasia Study</content> <content styleCode=\"bold\">(12-Months)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Vasomotor Symptoms Study</content> <content styleCode=\"bold\">(3-Months)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Osteoporosis Study</content> <content styleCode=\"bold\">(2-Years)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol and Norethindrone Acetate Tablets</content> <content styleCode=\"bold\">1 mg/0.5 mg</content> <content styleCode=\"bold\">(n=295)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 mg E <sub>2</sub>(n=296) </content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol and Norethindrone Acetate Tablets</content> <content styleCode=\"bold\">1 mg/0.5 mg</content> <content styleCode=\"bold\">(n=29)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=34)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol and Norethindrone Acetate Tablets</content> <content styleCode=\"bold\">1 mg/0.5 mg</content> <content styleCode=\"bold\">(n=47)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=48)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Body as a Whole</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"><paragraph> Back Pain</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>5%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>16%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>16%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>17%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>18%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Digestive System</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Nausea </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>5%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>10%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Gastroenteritis</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>2%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>2%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Nervous System</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>8%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> Emotional Lability</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>1%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>1%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Respiratory System</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> Upper Respiratory   Tract Infection </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>18%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>15%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>10%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>15%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>19%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> Sinusitis</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>7%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>7%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>15%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>10%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Metabolic and Nutritional</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> Weight Increase</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>9%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Urogenital System</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Breast Pain</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>24%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>10%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>21%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>17%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>8%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Post-Menopausal Bleeding</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>5%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>15%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>10%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Uterine Fibroid</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>5%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>8%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Ovarian Cyst</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>2%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>7%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>8%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Resistance Mechanism</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> Infection Viral</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> Moniliasis Genital</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>7%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Secondary Terms</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"><paragraph> Injury Accidental</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>17% <footnote ID=\"_RefID11_1\">including one upper extremity fracture in each group</footnote></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4% <footnoteRef IDREF=\"_RefID11_1\"/></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"><paragraph> Other Events</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>2%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4%</paragraph></td></tr></tbody></table>",
      "<table width=\"101%\"><col width=\"30%\"/><col width=\"41%\"/><col width=\"29%\"/><tbody><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Estradiol and Norethindrone Acetate Tablets </content> <content styleCode=\"bold\">0.5 mg/0.1 mg </content> <content styleCode=\"bold\">(n=194)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=200)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Body as a Whole</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Back Pain</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>10%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>4%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>22%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>19%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Pain in extremity</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>5%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>4%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Digestive System</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>5%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>4%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>6%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>6%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Respiratory System</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Nasopharyngitis</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>21%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>18%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"italics\">Urogenital System</content></content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Endometrial thickening</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>10%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>4%</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph> Vaginal hemorrhage</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>26%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>12%</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. (7) Co-administration of estradiol with norethindrone acetate did not elicit any apparent influence on the pharmacokinetics of norethindrone acetate. Similarly, no relevant interaction of norethindrone acetate on the pharmacokinetics of estradiol was found within the NETA dose range investigated in a single dose study. Estradiol In-vitro and in-vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John\u2019s wort ( Hypericum perforatum ) preparations, phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and result in adverse reactions. Norethindrone Acetate Drugs or herbal products that induce or inhibit cytochrome P-450 enzymes, including CYP3A4, may decrease or increase the serum concentrations of norethindrone."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Estradiol and norethindrone acetate tablets are not indicated for use in pregnancy. There are no data with the use of estradiol and norethindrone acetate tablets in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalities and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary Estrogens plus progestogens are present in human milk and can reduce milk production in breast-feeding women. This reduction can occur at any time but is less likely to occur once breast-feeding is well established. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for estradiol and norethindrone acetate tablets and any potential adverse effects on the breastfed child from estradiol and norethindrone acetate tablets or from the underlying maternal condition. 8.4 Pediatric Use Estradiol and norethindrone acetate tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population. 8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing estradiol and norethindrone acetate tablets to determine whether those over 65 years of age differ from younger subjects in their response to estradiol and norethindrone acetate tablets. The Women\u2019s Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . The Women\u2019s Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] .",
      "8.2 Lactation Risk Summary Estrogens plus progestogens are present in human milk and can reduce milk production in breast-feeding women. This reduction can occur at any time but is less likely to occur once breast-feeding is well established. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for estradiol and norethindrone acetate tablets and any potential adverse effects on the breastfed child from estradiol and norethindrone acetate tablets or from the underlying maternal condition."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Estradiol and norethindrone acetate tablets are not indicated for use in pregnancy. There are no data with the use of estradiol and norethindrone acetate tablets in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalities and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Estradiol and norethindrone acetate tablets are not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing estradiol and norethindrone acetate tablets to determine whether those over 65 years of age differ from younger subjects in their response to estradiol and norethindrone acetate tablets. The Women\u2019s Health Initiative Studies In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies ( 14.5 )] . The Women\u2019s Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] . Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see Warnings and Precautions ( 5.3 ), and Clinical Studies ( 14.6 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE Overdosage of estrogen plus progestogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of estradiol and norethindrone acetate tablets therapy with institution of appropriate symptomatic care."
    ],
    "description": [
      "11 DESCRIPTION Estradiol and norethindrone acetate tablets USP, 1 mg/0.5 mg are a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, polysorbate 80, magnesium stearate, hypromellose, talc and triacetin. Estradiol (E 2 ), is a white or almost white crystalline powder. Its chemical name is estra-1, 3, 5 (10)-triene-3, 17\u03b2-diol hemihydrate with the empirical formula of C 18 H 24 O 2 , \u00bd H 2 O and a molecular weight of 281.4. The structural formula of E 2 is as follows: Estradiol Norethindrone acetate (NETA), is a white or yellowish-white crystalline powder. Its chemical name is 17\u03b2 -acetoxy-19-nor-17\u03b1 -pregn-4-en-20-yn-3-one with the empirical formula of C 22 H 28 O 3 and molecular weight of 340.5. The structural formula of NETA is as follows: Norethindrone Acetate image description image description"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system. 12.2 Pharmacodynamics Generally, a serum estrogen concentration does not predict an individual woman\u2019s therapeutic response to estradiol and norethindrone acetate tablets nor her risk for adverse outcomes. Likewise, exposure comparisions across different estrogen products to infer efficacy or safety for the individual woman may not be valid. 12.3 Pharmacokinetics Absorption Estradiol Estradiol is absorbed through the gastrointestinal tract. Following oral administration of estradiol and norethindrone acetate tablets, peak plasma estradiol concentrations are reached within 5 to 8 hours. The oral bioavailability of estradiol following administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg when compared to a combination oral solution is 53%. Administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg with food did not modify the bioavailability of estradiol. Norethindrone Acetate After oral administration, norethindrone acetate is absorbed and transformed to norethindrone. Norethindrone reaches a peak plasma concentration within 0.5 to 1.5 hours after the administration of estradiol and norethindrone acetate tablets. The oral bioavailability of norethindrone following administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg when compared to a combination oral solution is 100%. Administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg with food increases norethindrone AUC 0-72 by 19% and decreases C max by 36%. The pharmacokinetic parameters of estradiol (E 2 ), estrone (E 1 ), and norethindrone (NET) following oral administration of 1 estradiol and norethindrone acetate tablet 1 mg/0.5 mg or 2 estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg tablet(s) to healthy postmenopausal women are summarized in Table 3. Table 3: Pharmacokinetic Parameters After Administration of 1 Tablet of Estradiol and Norethindrone Acetate 1 mg/0.5 mg or 2 Tablets of Estradiol and Norethindrone Acetate 0.5 mg/0.1 mg to Healthy Postmenopausal Women 1 x Estradiol and Norethindrone Acetate Tablets 2 x Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg 0.5 mg/0.1 mg (n=24) (n=24) Mean (%CV) Mean (%CV) Estradiol (E 2 ) AUC 0-t (pg/mL*h) 766.5 (48) 697.3 (53) C max (pg/mL) 26.8 (36) 26.5 (37) t max (h): median (range) 6.0 (0.5-16.0) 6.5 (0.5-16.0) t 1/2 (h) 14.0 (29) 14.5 (27) Estrone (E 1 ) AUC 0-t (pg/mL*h) 4469.1 (48) 4506.4 (44) C max (pg/mL) 195.5 (37) 199.5 (30) t max (h): median (range) 6.0 (1.0-9.0) 6.0 (2.0-9.0) t 1/2 (h) 10.7 (44) 11.8 (25) Norethindrone (NET) AUC 0-t (pg/mL*h) 21043 (41) 8407.2 (43) C max (pg/mL) 5249.5 (47) 2375.4 (41) t max (h) : median (range) 0.7 (0.7-1.25) 0.8 (0.7-1.3) t 1/2 (h) 9.8 (32) 11.4 (36) AUC = area under the curve, 0 - last quantifiable sample C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, Following continuous dosing with once-daily administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg, serum concentrations of estradiol, estrone, and norethindrone reached steady-state within two weeks with an accumulation of 33 to 47% above concentrations following single dose administration. Unadjusted circulating concentrations of E 2 , E 1 , and NET during estradiol and norethindrone acetate tablets 1 mg/0.5 mg treatment at steady-state (dosing at time 0) are provided in Figures 1a and 1b. Figure 1a: Mean Baseline-Uncorrected Estradiol and Estrone Serum Concentration-Time Profiles Following Multiple Doses of Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Figure 1b: Mean Baseline-Uncorrected Norethindrone Serum Concentration-Time Profile Following Multiple Doses of Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Distribution Estradiol The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estradiol circulates in the blood bound to SHBG (37%) and to albumin (61%), while only approximately 1 to 2% is unbound. Norethindrone Acetate Norethindrone also binds to a similar extent to SHBG (36%) and to albumin (61%). Metabolism Estradiol Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone Acetate The most important metabolites of norethindrone are isomers of 5\u03b1-dihydro-norethindrone and tetrahydro-norethindrone, which are excreted mainly in the urine as sulfate or glucuronide conjugates. Excretion Estradiol Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. The half-life of estradiol following single dose administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg is 12 to 14 hours. Norethindrone Acetate The terminal half-life of norethindrone is about 8 to 11 hours. image description image description"
    ],
    "clinical_pharmacology_table": [
      "<table width=\"101%\"><colgroup><col width=\"21%\"/><col width=\"39%\"/><col width=\"39%\"/></colgroup><tbody><tr><td styleCode=\"Lrule Rrule Toprule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 x Estradiol and Norethindrone Acetate Tablets</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">2 x Estradiol and Norethindrone Acetate Tablets</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 mg/0.5 mg</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">0.5 mg/0.1 mg</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=24)</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=24)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Mean</content><footnote ID=\"_RefID15_1\"/><content styleCode=\"bold\"> (%CV)</content><footnote ID=\"_RefID15_2\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Mean</content><footnoteRef IDREF=\"_RefID15_1\"/><content styleCode=\"bold\"> (%CV)</content><footnoteRef IDREF=\"_RefID15_2\"/></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol</content><footnote ID=\"_RefID15_5\"/><content styleCode=\"bold\"> (E <sub>2</sub>) </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> AUC <sub>0-t</sub> (pg/mL*h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>766.5 (48)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>697.3 (53)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> C <sub>max</sub> (pg/mL) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>26.8 (36)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>26.5 (37)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>max</sub> (h): median (range) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.0 (0.5-16.0)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.5 (0.5-16.0)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>1/2</sub> (h) <footnote ID=\"_RefID15_6\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>14.0 <footnote ID=\"_RefID15_7\"/> (29) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>14.5 <footnote ID=\"_RefID15_8\"/> (27) </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estrone</content><footnoteRef IDREF=\"_RefID15_5\"/><content styleCode=\"bold\"> (E <sub>1</sub>) </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> AUC <sub>0-t</sub> (pg/mL*h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4469.1 (48)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4506.4 (44)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> C <sub>max</sub> (pg/mL) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>195.5 (37)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>199.5 (30)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>max</sub> (h): median (range) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.0 (1.0-9.0)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.0 (2.0-9.0)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>1/2</sub> (h) <footnoteRef IDREF=\"_RefID15_6\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>10.7 (44) <footnote ID=\"_RefID15_11\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11.8 (25) <footnoteRef IDREF=\"_RefID15_11\"/></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Norethindrone (NET) </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> AUC <sub>0-t</sub> (pg/mL*h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>21043 (41)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>8407.2 (43)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> C <sub>max</sub> (pg/mL) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>5249.5 (47)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>2375.4 (41)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>max</sub> (h) : median (range) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0.7 (0.7-1.25)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0.8 (0.7-1.3)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>1/2</sub> (h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>9.8 (32) <footnote ID=\"_RefID15_13\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11.4 (36) <footnote ID=\"_RefID15_14\"/></paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Absorption Estradiol Estradiol is absorbed through the gastrointestinal tract. Following oral administration of estradiol and norethindrone acetate tablets, peak plasma estradiol concentrations are reached within 5 to 8 hours. The oral bioavailability of estradiol following administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg when compared to a combination oral solution is 53%. Administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg with food did not modify the bioavailability of estradiol. Norethindrone Acetate After oral administration, norethindrone acetate is absorbed and transformed to norethindrone. Norethindrone reaches a peak plasma concentration within 0.5 to 1.5 hours after the administration of estradiol and norethindrone acetate tablets. The oral bioavailability of norethindrone following administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg when compared to a combination oral solution is 100%. Administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg with food increases norethindrone AUC 0-72 by 19% and decreases C max by 36%. The pharmacokinetic parameters of estradiol (E 2 ), estrone (E 1 ), and norethindrone (NET) following oral administration of 1 estradiol and norethindrone acetate tablet 1 mg/0.5 mg or 2 estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg tablet(s) to healthy postmenopausal women are summarized in Table 3. Table 3: Pharmacokinetic Parameters After Administration of 1 Tablet of Estradiol and Norethindrone Acetate 1 mg/0.5 mg or 2 Tablets of Estradiol and Norethindrone Acetate 0.5 mg/0.1 mg to Healthy Postmenopausal Women 1 x Estradiol and Norethindrone Acetate Tablets 2 x Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg 0.5 mg/0.1 mg (n=24) (n=24) Mean (%CV) Mean (%CV) Estradiol (E 2 ) AUC 0-t (pg/mL*h) 766.5 (48) 697.3 (53) C max (pg/mL) 26.8 (36) 26.5 (37) t max (h): median (range) 6.0 (0.5-16.0) 6.5 (0.5-16.0) t 1/2 (h) 14.0 (29) 14.5 (27) Estrone (E 1 ) AUC 0-t (pg/mL*h) 4469.1 (48) 4506.4 (44) C max (pg/mL) 195.5 (37) 199.5 (30) t max (h): median (range) 6.0 (1.0-9.0) 6.0 (2.0-9.0) t 1/2 (h) 10.7 (44) 11.8 (25) Norethindrone (NET) AUC 0-t (pg/mL*h) 21043 (41) 8407.2 (43) C max (pg/mL) 5249.5 (47) 2375.4 (41) t max (h) : median (range) 0.7 (0.7-1.25) 0.8 (0.7-1.3) t 1/2 (h) 9.8 (32) 11.4 (36) AUC = area under the curve, 0 - last quantifiable sample C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, Following continuous dosing with once-daily administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg, serum concentrations of estradiol, estrone, and norethindrone reached steady-state within two weeks with an accumulation of 33 to 47% above concentrations following single dose administration. Unadjusted circulating concentrations of E 2 , E 1 , and NET during estradiol and norethindrone acetate tablets 1 mg/0.5 mg treatment at steady-state (dosing at time 0) are provided in Figures 1a and 1b. Figure 1a: Mean Baseline-Uncorrected Estradiol and Estrone Serum Concentration-Time Profiles Following Multiple Doses of Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Figure 1b: Mean Baseline-Uncorrected Norethindrone Serum Concentration-Time Profile Following Multiple Doses of Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (N=24) Distribution Estradiol The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estradiol circulates in the blood bound to SHBG (37%) and to albumin (61%), while only approximately 1 to 2% is unbound. Norethindrone Acetate Norethindrone also binds to a similar extent to SHBG (36%) and to albumin (61%). Metabolism Estradiol Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Norethindrone Acetate The most important metabolites of norethindrone are isomers of 5\u03b1-dihydro-norethindrone and tetrahydro-norethindrone, which are excreted mainly in the urine as sulfate or glucuronide conjugates. Excretion Estradiol Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. The half-life of estradiol following single dose administration of estradiol and norethindrone acetate tablets 1 mg/0.5 mg is 12 to 14 hours. Norethindrone Acetate The terminal half-life of norethindrone is about 8 to 11 hours. image description image description"
    ],
    "pharmacokinetics_table": [
      "<table width=\"101%\"><colgroup><col width=\"21%\"/><col width=\"39%\"/><col width=\"39%\"/></colgroup><tbody><tr><td styleCode=\"Lrule Rrule Toprule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 x Estradiol and Norethindrone Acetate Tablets</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">2 x Estradiol and Norethindrone Acetate Tablets</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 mg/0.5 mg</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">0.5 mg/0.1 mg</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=24)</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=24)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Mean</content><footnote ID=\"_RefID15_1\"/><content styleCode=\"bold\"> (%CV)</content><footnote ID=\"_RefID15_2\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Mean</content><footnoteRef IDREF=\"_RefID15_1\"/><content styleCode=\"bold\"> (%CV)</content><footnoteRef IDREF=\"_RefID15_2\"/></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol</content><footnote ID=\"_RefID15_5\"/><content styleCode=\"bold\"> (E <sub>2</sub>) </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> AUC <sub>0-t</sub> (pg/mL*h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>766.5 (48)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>697.3 (53)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> C <sub>max</sub> (pg/mL) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>26.8 (36)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>26.5 (37)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>max</sub> (h): median (range) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.0 (0.5-16.0)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.5 (0.5-16.0)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>1/2</sub> (h) <footnote ID=\"_RefID15_6\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>14.0 <footnote ID=\"_RefID15_7\"/> (29) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>14.5 <footnote ID=\"_RefID15_8\"/> (27) </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estrone</content><footnoteRef IDREF=\"_RefID15_5\"/><content styleCode=\"bold\"> (E <sub>1</sub>) </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> AUC <sub>0-t</sub> (pg/mL*h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4469.1 (48)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>4506.4 (44)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> C <sub>max</sub> (pg/mL) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>195.5 (37)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>199.5 (30)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>max</sub> (h): median (range) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.0 (1.0-9.0)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.0 (2.0-9.0)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>1/2</sub> (h) <footnoteRef IDREF=\"_RefID15_6\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>10.7 (44) <footnote ID=\"_RefID15_11\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11.8 (25) <footnoteRef IDREF=\"_RefID15_11\"/></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Norethindrone (NET) </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> AUC <sub>0-t</sub> (pg/mL*h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>21043 (41)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>8407.2 (43)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> C <sub>max</sub> (pg/mL) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>5249.5 (47)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>2375.4 (41)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>max</sub> (h) : median (range) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0.7 (0.7-1.25)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0.8 (0.7-1.3)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph> t <sub>1/2</sub> (h) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>9.8 (32) <footnote ID=\"_RefID15_13\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>11.4 (36) <footnote ID=\"_RefID15_14\"/></paragraph></td></tr></tbody></table>"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Effects on Vasomotor Symptoms in Postmenopausal Women In a 12-week randomized clinical trial involving 92 subjects, estradiol and norethindrone acetate tablets 1 mg/0.5 mg were compared to 1 mg of estradiol and to placebo. The mean number and intensity of hot flushes were significantly reduced from baseline to week 4 and 12 in both the estradiol and norethindrone acetate tablets 1 mg/0.5 mg and the 1 mg estradiol group compared to placebo (see Figure 2). Figure 2: Mean Weekly Number of Moderate and Severe Hot Flushes in a 12-Week Study In a study conducted in Europe a total of 577 postmenopausal women were randomly assigned to either estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg, 0.5 mg E 2 /0.25 mg NETA, or placebo for 24 weeks of treatment. The mean number and severity of hot flushes were significantly reduced at week 4 and week 12 in the estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg (see Figure 3) and 0.5 mg E 2 /0.25 mg NETA groups compared to placebo. Figure 3: Mean Number of Moderate to Severe Hot Flushes for Weeks 0 Through 12 image description image description 14.2 Effects on the Endometrium in Postmenopausal Women Estradiol and norethindrone acetate tablets 1 mg/0.5 mg reduced the incidence of estrogen-induced endometrial hyperplasia at 1 year in a randomized, controlled clinical trial. This trial enrolled 1,176 postmenopausal women who were randomized to one of 4 arms: 1 mg estradiol unopposed (n=296), 1 mg E 2 + 0.1 mg NETA (n=294), 1 mg E 2 + 0.25 mg NETA (n=291), and estradiol and norethindrone acetate tablets 1 mg/0.5 mg (n=295). At the end of the study, endometrial biopsy results were available for 988 women. The results of the 1 mg estradiol unopposed arm compared to estradiol and norethindrone acetate tablets 1 mg/0.5 mg are shown in Table 4. Table 4: Incidence of Endometrial Hyperplasia with Unopposed Estradiol and Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg in a 12-Month Study Estradiol and Norethindrone Acetate Tablets 1 mg E 2 1 mg E 2 /0.5 mg NETA 1 mg E 2 /0.25 mg NETA 1 mg E 2 /0.1 mg NETA (n=296) (n=295) (n=291) (n=294 ) No. of subjects with histological evaluation at the end of the study 247 241 251 249 No. (%) of subjects with endometrial hyperplasia at the end of the study 36 (14.6%) 1 (0.4%) 1 (0.4%) 2 (0.8%) 14.3 Effects on Uterine Bleeding or Spotting in Postmenopausal Women During the initial months of therapy, irregular bleeding or spotting occurred with estradiol and norethindrone acetate tablets 1 mg/0.5 mg treatment. However, bleeding tended to decrease over time, and after 12 months of treatment with estradiol and norethindrone acetate tablets 1 mg/0.5 mg, about 86 percent of women were amenorrheic (see Figure 4). Figure 4: Patients Treated with Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg with Cumulative Amenorrhea over Time Percentage of Women with no Bleeding or Spotting at any Cycle Through Cycle 13 Intent to Treat Population, LOCF Note: the percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown. If data were missing, the bleeding value from the last reported day was carried forward (LOCF). In the clinical trial with estradiol and norethindrone acetate tablets 0.5 mg/0.1 mg, 88 percent of women were amenorrheic after 6 months of treatment (See Figure 5). Figure 5: Patients Treated with Estradiol and Norethindrone Acetate Tablets 0.5 mg/0.1 mg with Cumulative Amenorrhea over Time Percentage of Women with no Bleeding or Spotting at any Cycle Through Cycle 6, Intent to Treat Population, LOCF image description image description 14.4 Effects on Bone Mineral Density in Postmenopausal Women The results of two randomized, multicenter, calcium-supplemented (500 to 1,000 mg per day), placebo-controlled, 2 year clinical trials have shown that estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg are effective in preventing bone loss in postmenopausal women. A total of 462 postmenopausal women with intact uteri and baseline BMD values for lumbar spine within 2 standard deviations of the mean in healthy young women (T-score > -2.0) were enrolled. In a US trial, 327 postmenopausal women (mean time from menopause 2.5 to 3.1 years) with a mean age of 53 years were randomized to 7 groups (0.25 mg, 0.5 mg, and 1 mg of estradiol alone, 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and 2 mg estradiol with 1 mg norethindrone acetate, and placebo). In a European trial (EU trial), 135 postmenopausal women (mean time from menopause 8.4 to 9.3 years) with a mean age of 58 years were randomized to 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and placebo. Approximately 58 percent and 67 percent of the randomized subjects in the two clinical trials, respectively, completed the two clinical trials. BMD was measured using dual-energy x-ray absorptiometry (DXA). A summary of the results comparing estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg to placebo from the two prevention trials is shown in Table 5. Table 5: Percentage Change (Mean \u00b1 SD) in Bone Mineral Density (BMD) for Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg and 0.5 mg E 2 (Intent to Treat Analysis, Last Observation Carried Forward) US Trial EU Trial Placebo 0.5 mg E 2 Estradiol and Norethindrone Acetate Tablets 1mg/0.5 mg Placebo Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg (n=37) (n=31) (n=37) (n=40) (n=38) Lumbar spine -2.1 \u00b1 2.9 2.3 \u00b1 2.8 3.8 \u00b1 3.0 -0.9 \u00b1 4.0 5.4 \u00b1 4.8 Femoral neck -2.3 \u00b1 3.4 0.3 \u00b1 2.9 1.8 \u00b1 4.1 -1.0 \u00b1 4.6 0.7 \u00b1 6.1 Femoral trochanter -2.0 \u00b1 4.3 1.7 \u00b1 4.1 3.7 \u00b1 4.3 0.8 \u00b1 6.9 6.3 \u00b1 7.6 US= United States, EU = European The overall difference in mean percentage change in BMD at the lumbar spine in the US trial (1000 mg per day calcium) between estradiol and norethindrone acetate tablets 1 mg/0.5 mg and placebo was 5.9 percent and between estradiol 0.5 mg and placebo was 4.4 percent. In the European trial (500 mg per day calcium), the overall difference in mean percentage change in BMD at the lumbar spine was 6.3 percent. Estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg also increased BMD at the femoral neck and femoral trochanter compared to placebo. The increase in lumbar spine BMD in the US and European clinical trials for estradiol and norethindrone acetate tablets 1 mg/0.5 mg and estradiol 0.5 mg is displayed in Figure 6. Figure 6: Percentage Change in Bone Mineral Density (BMD) \u00b1 SEM of the Lumbar Spine (L1-L4) for Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg and Estradiol 0.5 mg (Intent to Treat Analysis with Last Observation Carried Forward) image description 14.5 Women\u2019s Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome. A \u201cglobal index\u201d included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other cause. These substudies did not evaluate the effects of CE plus MPA or CE-alone on menopausal symptoms. WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the \u201cglobal index.\u201d The absolute excess risk of events included in the \u201cglobal index\u201d was 19 per 10,000 women-years. For those outcomes included in the WHI \u201cglobal index,\u201d that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 6. These results reflect centrally adjudicated data after an average follow-up of 5.6 years. Table 6: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi. , Results are based on centrally adjudicated data. Event Relative Risk CE/MPA versus Placebo (95 percent nCI Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. ) CE/MPA n = 8,506 Placebo n = 8,102 Absolute Risk per 10,000 Women-Years CHD events 1.23 (0.99-1.53) 41 34 Non-fatal MI 1.28 (1.00-1.63) 31 25 CHD death 1.10 (0.70-1.75) 8 8 All strokes 1.31 (1.03-1.68) 33 25 Ischemic stroke 1.44 (1.09-1.90) 26 18 Deep vein thrombosis Not included in \u201cglobal index\u201d. 1.95 (1.43-2.67) 26 13 Pulmonary embolism 2.13 (1.45-3.11) 18 8 Invasive breast cancer Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. 1.24 (1.01-1.54) 41 33 Colorectal cancer 0.61 (0.42-0.87) 10 16 Endometrial cancer 0.81 (0.48-1.36) 6 7 Cervical cancer 1.44 (0.47-4.42) 2 1 Hip fracture 0.67 (0.47-0.96) 11 16 Vertebral fractures 0.65 (0.46-0.92) 11 17 Lower arm/wrist fractures 0.71 (0.59-0.85) 44 62 Total fractures 0.76 (0.69-0.83) 152 199 Overall Mortality , All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. 1.00 (0.83-1.19) 52 52 Global Index A subset of the events was combined in a \u201cglobal index\u201d defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. 1.13 (1.02-1.25) 184 165 Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [hazard ratio (HR) 0.69 (95 percent CI, 0.44-1.07)] . WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years, are presented in Table 7. Table 7. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi. Event Relative Risk CE versus Placebo (95 percent nCI Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. ) CE n = 5,310 Placebo n = 5,429 Absolute Risk per 10,000 Women-Years CHD events Results are based on centrally adjudicated data for an average follow-up of 7.1 years. 0.95 (0.78-1.16) 54 57 Non-fatal MI 0.91 (0.73-1.14) 40 43 CHD death 1.01 (0.71-1.43) 16 16 All strokes 1.33 (1.05-1.68) 45 33 Ischemic stroke 1.55 (1.19-2.01) 38 25 Deep vein thrombosis , Not included in \u201cglobal index\u201d. 1.47 (1.06-2.06) 23 15 Pulmonary embolism 1.37 (0.90-2.07) 14 10 Invasive breast cancer 0.80 (0.62-1.04) 28 34 Colorectal cancer Results are based on an average follow-up of 6.8 years. 1.08 (0.75-1.55) 17 16 Hip fracture 0.65 (0.45-0.94) 12 19 Vertebral fractures , 0.64 (0.44-0.93) 11 18 Lower arm/wrist fractures , 0.58 (0.47-0.72) 35 59 Total fractures , 0.71 (0.64-0.80) 144 197 Death due to other causes , All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease. 1.08 (0.88-1.32) 53 50 Overall mortality , 1.04 (0.88-1.22) 79 75 Global Index A subset of the events was combined in a \u201cglobal index\u201d defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. 1.02 (0.92-1.13) 206 201 For those outcomes included in the WHI \u201cglobal index\u201d that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. 9 The absolute excess risk of events included in the \u201cglobal index\u201d was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years. Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow up of 7.1 years, reported no significant difference in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for ischemic stroke, and this excess risk was present in all subgroups of women examined. 10 Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [HR 0.63 (95 percent CI, 0.36-1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46-1.11)] . 14.6 Women\u2019s Health Initiative Memory Study The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. Probable dementia as defined in this study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Use in Specific Populations ( 8.5 )] . The WHIMS estrogen-alone ancillary study of WHI study enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age, 36 percent were 70 to 74 years of age, 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo. After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Use in Specific Populations ( 8.5 )] . When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women [see Warnings and Precautions ( 5.3 ), and Use in Specific Populations ( 8.5 )] ."
    ],
    "clinical_studies_table": [
      "<table width=\"101%\"><col width=\"44%\"/><col width=\"8%\"/><col width=\"16%\"/><col width=\"16%\"/><col width=\"16%\"/><tbody><tr><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol and Norethindrone Acetate Tablets</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 mg E <sub>2</sub></content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 mg E <sub>2</sub>/0.5 mg NETA </content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 mg E <sub>2</sub>/0.25 mg NETA </content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">1 mg E <sub>2</sub>/0.1 mg NETA </content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=296)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=295)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=291)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=294 )</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>No. of subjects with histological evaluation at the end of the study  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>247  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>241  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>251  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>249  </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>No. (%) of subjects with endometrial hyperplasia at the end of the study  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>36 (14.6%)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1 (0.4%)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1 (0.4%)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>2 (0.8%)  </paragraph></td></tr></tbody></table>",
      "<table width=\"101%\" ID=\"_RefID23\"><caption>Table 5: Percentage Change (Mean &#xB1; SD) in Bone Mineral Density (BMD) for Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg and 0.5 mg E <sub>2</sub><footnote ID=\"_RefID23_1\"/> (Intent to Treat Analysis, Last Observation Carried Forward) </caption><colgroup><col width=\"14%\"/><col width=\"7%\"/><col width=\"9%\"/><col width=\"32%\"/><col width=\"7%\"/><col width=\"32%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"/><td align=\"center\" colspan=\"3\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">US Trial</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">EU Trial</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"bottom\"/><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo </content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">0.5 mg E <sub>2</sub></content><footnoteRef IDREF=\"_RefID23_1\"/></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol and Norethindrone Acetate Tablets </content>  <content styleCode=\"bold\">1mg/0.5 mg</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo </content></paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">Estradiol and Norethindrone Acetate Tablets </content>  <content styleCode=\"bold\">1 mg/0.5 mg</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=37)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=31)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=37)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=40)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph><content styleCode=\"bold\">(n=38)</content></paragraph></td></tr><tr><td colspan=\"6\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>Lumbar spine </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>-2.1 &#xB1; 2.9</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>2.3 &#xB1; 2.8 <footnote ID=\"_RefID23_3\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3.8 &#xB1; 3.0 <footnoteRef IDREF=\"_RefID23_3\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>-0.9 &#xB1; 4.0</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>5.4 &#xB1; 4.8 <footnoteRef IDREF=\"_RefID23_3\"/></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>Femoral neck </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>-2.3 &#xB1; 3.4</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0.3 &#xB1; 2.9 <footnote ID=\"_RefID23_6\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>1.8 &#xB1; 4.1 <footnoteRef IDREF=\"_RefID23_3\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>-1.0 &#xB1; 4.6</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0.7 &#xB1; 6.1</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>Femoral trochanter </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>-2.0 &#xB1; 4.3</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>1.7 &#xB1; 4.1 <footnote ID=\"_RefID23_8\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>3.7 &#xB1; 4.3 <footnoteRef IDREF=\"_RefID23_3\"/></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>0.8 &#xB1; 6.9</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>6.3 &#xB1; 7.6 <footnoteRef IDREF=\"_RefID23_3\"/></paragraph></td></tr><tr><td colspan=\"6\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\"><paragraph>US= United States, EU = European</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID323\" width=\"101%\"><caption>Table 6: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years <footnote ID=\"_RefID323_1\">Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.</footnote><sup>,</sup><footnote ID=\"_RefID323_2\">Results are based on centrally adjudicated data.</footnote></caption><col width=\"32%\"/><col width=\"27%\"/><col width=\"21%\"/><col width=\"21%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Event</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Relative Risk</content> <content styleCode=\"bold\">CE/MPA versus Placebo</content> <content styleCode=\"bold\">(95 percent </content>nCI <footnote ID=\"_RefID323_3\">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote><content styleCode=\"bold\">)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">CE/MPA</content> <content styleCode=\"bold\">n = 8,506</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n = 8,102</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Absolute Risk per 10,000 Women-Years</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>CHD events  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.23 (0.99-1.53)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>41  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>34  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> Non-fatal MI </content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">1.28 (1.00-1.63)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">31</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">25</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> CHD death </content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">1.10 (0.70-1.75)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">8</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">8</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>All strokes  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.31 (1.03-1.68)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>33  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>25  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> Ischemic stroke </content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">1.44 (1.09-1.90)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">26</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">18</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Deep vein thrombosis <footnote ID=\"_RefID323_4\">Not included in &#x201C;global index&#x201D;.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.95 (1.43-2.67)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">26</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">13</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Pulmonary embolism  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2.13 (1.45-3.11)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>18  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>8  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Invasive breast cancer <footnote ID=\"_RefID323_5\">Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. </footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.24 (1.01-1.54)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>41  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>33  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Colorectal cancer  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.61 (0.42-0.87)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>16  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Endometrial cancer <footnoteRef IDREF=\"_RefID323_4\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.81 (0.48-1.36)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>6  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>7  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Cervical cancer <footnoteRef IDREF=\"_RefID323_4\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.44 (0.47-4.42)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hip fracture  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.67 (0.47-0.96)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>16  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Vertebral fractures <footnoteRef IDREF=\"_RefID323_4\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.65 (0.46-0.92)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>17  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Lower arm/wrist fractures <footnoteRef IDREF=\"_RefID323_4\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.71 (0.59-0.85)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>44  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>62  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Total fractures <footnoteRef IDREF=\"_RefID323_4\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.76 (0.69-0.83)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>152  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>199  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Overall Mortality <footnoteRef IDREF=\"_RefID323_3\"/><sup>,</sup><footnote ID=\"_RefID323_12\">All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.00 (0.83-1.19)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>52  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>52  </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Global Index <footnote ID=\"_RefID323_13\">A subset of the events was combined in a &#x201C;global index&#x201D; defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1.13 (1.02-1.25)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>184  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>165  </paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID324\" width=\"101%\"><caption>Table 7. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI <footnote ID=\"_RefID324_1\">Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.</footnote></caption><col width=\"32%\"/><col width=\"29%\"/><col width=\"20%\"/><col width=\"20%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Event</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Relative Risk</content> <content styleCode=\"bold\">CE versus Placebo</content> <content styleCode=\"bold\">(95 percent nCI</content><footnote ID=\"_RefID324_2\">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote><content styleCode=\"bold\">)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">CE</content> <content styleCode=\"bold\">n = 5,310</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n = 5,429</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Absolute Risk per 10,000 Women-Years</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>CHD events <footnote ID=\"_RefID324_3\">Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.95 (0.78-1.16)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>54  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>57  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> Non-fatal </content>MI <footnoteRef IDREF=\"_RefID324_3\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">0.91 (0.73-1.14)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">40</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">43</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> CHD death</content><footnoteRef IDREF=\"_RefID324_3\"/><content styleCode=\"italics\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">1.01 (0.71-1.43)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">16</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">16</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>All strokes <footnoteRef IDREF=\"_RefID324_3\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.33 (1.05-1.68)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>45  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>33  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"> Ischemic stroke</content><footnoteRef IDREF=\"_RefID324_3\"/><content styleCode=\"italics\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">1.55 (1.19-2.01)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">38</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">25</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Deep vein thrombosis <footnoteRef IDREF=\"_RefID324_3\"/><sup>,</sup><footnote ID=\"_RefID324_9\">Not included in &#x201C;global index&#x201D;.</footnote><sup/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.47 (1.06-2.06)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>23  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>15  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Pulmonary embolism <footnoteRef IDREF=\"_RefID324_3\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.37 (0.90-2.07)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>14  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Invasive breast cancer <footnoteRef IDREF=\"_RefID324_3\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.80 (0.62-1.04)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>28  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>34  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Colorectal cancer <footnote ID=\"_RefID324_12\">Results are based on an average follow-up of 6.8 years.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.08 (0.75-1.55)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>17  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>16  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hip fracture <footnoteRef IDREF=\"_RefID324_3\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.65 (0.45-0.94)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>12  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>19  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Vertebral fractures <footnoteRef IDREF=\"_RefID324_3\"/><sup>,</sup><footnoteRef IDREF=\"_RefID324_9\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.64 (0.44-0.93)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>18  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Lower arm/wrist fractures <footnoteRef IDREF=\"_RefID324_3\"/><sup>,</sup><footnoteRef IDREF=\"_RefID324_9\"/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.58 (0.47-0.72)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>35  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>59  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Total fractures <footnoteRef IDREF=\"_RefID324_3\"/><sup>,</sup><footnoteRef IDREF=\"_RefID324_9\"/><sup/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.71 (0.64-0.80)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>144  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>197  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Death due to other causes <footnoteRef IDREF=\"_RefID324_12\"/><sup>,</sup><footnote ID=\"_RefID324_21\">All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote><sup/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.08 (0.88-1.32)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>53  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>50  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Overall mortality <footnoteRef IDREF=\"_RefID324_3\"/><sup>,</sup><footnoteRef IDREF=\"_RefID324_9\"/><sup/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1.04 (0.88-1.22)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>79  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>75  </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Global Index <footnote ID=\"_RefID324_24\">A subset of the events was combined in a &#x201C;global index&#x201D; defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</footnote><sup/> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1.02 (0.92-1.13)  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>206  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>201  </paragraph></td></tr></tbody></table>"
    ],
    "references": [
      "15 REFERENCES 1.Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA . 2007;297:1465-1477. 2.Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med . 2006;166:357-365. 3.Cushman M, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA . 2004;292:1573-1580. 4.Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med . 2006;166:772-780. 5.Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA . 2003;289:3234-3253. 6.Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA . 2006;295:1647-1657. 7.Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. JAMA . 2003;290:1739-1748. 8.Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA . 2004;291:2947-2958. 9.Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women\u2019s Health Initiative Randomized Trial. J Bone Miner Res . 2006;21:817-828. 10.Hendrix SL, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women\u2019s Health Initiative. Circulation . 2006;113:2425-2434."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Estradiol and norethindrone acetate tablets, USP 1 mg/0.5 mg are white to off-white, round, biconvex, film coated tablets, debossed with \"EX1\" on one side and plain on other side. The blister packs are available in box (NDC 79929-012-07) containing 3 pouch and each pouch contain 1 blister pack of 28 tablets 16.2 Storage and Handling Store in dry place protected from light. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]"
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise women to read the FDA-approved patient labeling (Patient Information Vaginal Bleeding Inform postmenopausal women to report any vaginal bleeding to their healthcare provider as soon as possible [see Warnings and Precautions (5.2)] . Possible Serious Adverse Reactions with Estrogen Plus Progestogen Therapy Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestogen therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia [see Warnings and Precautions (5.1, 5.2, 5.3)] . Possible Common Adverse Reactions with Estrogen Plus Progestogen Therapy Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestogen therapy such as headache, breast pain and tenderness, nausea and vomiting. Rx Only Manufactured For: Naari Pte Limited 36 Robinson Road, #13-06 City House, Singapore 068877 Issued March 2024 Patient Information Estradiol and Norethindrone Acetate Tablets (es-truh-dahy-awl and nawr-eth-in-deohnl) Read this Patient Information before you start using estradiol and norethindrone acetate tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. What is the most important information I should know about estradiol and norethindrone acetate tablets (a combination of estrogen and progestogen)? Do not use estrogens with or without progestogens to prevent heart disease, heart attacks, strokes, or dementia (decline of brain function). Using estrogens with progestogens may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots. Using estrogens with progestogens may increase your chance of getting dementia, based on a study of women 65 years of age and older. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Do not use estrogen-alone to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function). Using estrogen-alone may increase your chances of getting strokes or blood clots. Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age and older. Only one estrogen with progestogen product and dose have been shown to increase your chances of getting heart attacks, strokes, breast cancer, blood clots, and dementia. Only one estrogen-alone product and dose have been shown to increase your chances of getting strokes, blood clots, and dementia. Because other products and doses have not been studied in the same way, it is not known how the use of estradiol and norethindrone acetate tablets will affect your chances of these conditions. You and your healthcare provider should talk regularly about whether you still need treatment with estradiol and norethindrone acetate tablets. What is Estradiol and Norethindrone acetate tablets? Estradiol and Norethindrone acetate tablet is a prescription medicine that contains two kinds of hormones, an estrogen and a progestin. What are Estradiol and Norethindrone acetate tablets used for? Estradiol and Norethindrone acetate tablets are used after menopause to: \u2022 Reduce moderate to severe hot flushes Estrogens are hormones made by a woman\u2019s ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 yrs old. This drop in body estrogen levels causes the \u201cchange of life\u201d or menopause, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes \u201csurgical menopause.\u201d When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden, intense feelings of heat and sweating (\u201chot flashes\u201d or \u201chot flushes\u201d). In some women, the symptoms are mild, and they will not need to use estrogens. In other women, symptoms can be more severe. \u2022 Treat moderate to severe menopausal changes in and around the vagina You and your healthcare provider should talk regularly about whether you still need treatment with Estradiol and Norethindrone acetate tablets 1 mg/0.5 mg to treat these problems. If you use Estradiol and Norethindrone acetate tablets 1 mg/0.5 mg only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you. \u2022 Help reduce your chances of getting osteoporosis (thin weak bones) Osteoporosis from menopause is a thinning of the bones that makes them weaker and easier to break. If you use Estradiol and Norethindrone acetate tablets to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you still need treatment with Estradiol and Norethindrone acetate tablets. Who should not use Estradiol and Norethindrone acetate tablets? Do not use Estradiol and Norethindrone acetate tablets if you have had your uterus (womb) removed (hysterectomy). Estradiol and norethindrone acetate tablets contain a progestogen to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestogen and you should not use Estradiol and Norethindrone acetate tablets. Do not start using Estradiol and Norethindrone acetate tablets if you: \u2022 have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. \u2022 have been diagnosed with a bleeding disorder \u2022 currently have or have had certain cancers Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus (womb). If you have or have had cancer, talk with your healthcare provider about whether you should use Estradiol and Norethindrone acetate tablets. \u2022 had a stroke or heart attack \u2022 currently have or have had blood clots \u2022 currently have or have had liver problems \u2022 are allergic to Estradiol and Norethindrone acetate tablets or any of the ingredients in it. See the list of ingredients in Estradiol and Norethindrone acetate tablets at the end of this leaflet. Before you use Estradiol and Norethindrone acetate tablets, tell your healthcare provider about all of your medical conditions, including if you: \u2022 have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. \u2022 have any other medical conditions that may become worse while you are using Estradiol and Norethindrone acetate tablets Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. \u2022 are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop using Estradiol and Norethindrone acetate tablets. \u2022 are pregnant or think you may be pregnant. Estradiol and Norethindrone acetate tablets are not for pregnant women. \u2022 are breast feeding The hormones in Estradiol and Norethindrone acetate tablets can pass into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how Estradiol and Norethindrone acetate tablets work. Estradiol and norethindrone acetate tablets may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get new medicine. How should I use Estradiol and Norethindrone acetate tablets? \u2022Use Estradiol and Norethindrone acetate tablets exactly as your healthcare provider tells you to use it. \u2022Take 1 tablet at the same time each day. \u2022You and your healthcare provider should talk regularly (every 3 to 6 months) about your dose and whether you still need treatment with Estradiol and Norethindrone acetate tablets. What are the possible side effects of Estradiol and Norethindrone acetate tablets? Side effects are grouped by how serious they are and how often they happen when you are treated. Serious, but less common side effects include: \u2022heart attack\u2022stroke\u2022blood clots\u2022breast cancer\u2022cancer of the lining of the uterus (womb)\u2022cancer of the ovary\u2022dementia\u2022high or low blood calcium levels\u2022gallbladder disease\u2022visual abnormalities\u2022high blood pressure\u2022high levels of fat (triglycerides) in your blood\u2022liver problems\u2022changes in your thyroid hormone levels\u2022fluid retention\u2022cancer changes of endometriosis\u2022enlargement of benign tumors of the uterus (\u201cfibroids\u201d)\u2022worsening swelling of face and tongue (angioedema) in women who have a history of angioedema\u2022changes in laboratory tests results such as bleeding times and high blood sugar levels Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: \u2022new breast lumps \u2022unusual vaginal bleeding\u2022changes in vision or speech \u2022sudden new severe headaches \u2022severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Common side effects of Estradiol and Norethindrone acetate tablets include: \u2022irregular vaginal bleeding or spotting \u2022nausea \u2022stomach or abdominal cramps, bloating \u2022headache \u2022vomiting \u2022back pain \u2022breast pain \u2022diarrhea \u2022fluid retention \u2022vaginal yeast infection These are not all the possible side effects of Estradiol and Norethindrone acetate tablets. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or do not go away. You may report side effects to FDA at 1-800-FDA-1088. What can I do to lower my chances of a serious side effect with Estradiol and norethindrone acetate tablets? \u2022Talk with your healthcare provider regularly about whether you should continue using Estradiol and Norethindrone acetate tablets. \u2022If you have a uterus, talk with your healthcare provider about whether Estradiol and Norethindrone acetate tablets are right for you. \u2022In general, the addition of a progestogen is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). \u2022See your healthcare provider right away if you get vaginal bleeding while using Estradiol and Norethindrone acetate tablets .\u2022Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else .\u2022If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram (breast x-ray), you may need to have breast exams more often. \u2022If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. \u2022Ask your healthcare provider for ways to lower your chances for getting heart disease. How should I store Estradiol and Norethindrone acetate tablets? Store Estradiol and Norethindrone acetate tablets at room temperature between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Store Estradiol and Norethindrone acetate tablets in a dry place protected from light. Keep Estradiol and Norethindrone acetate tablets and all medicines out of the reach of children. General information about the safe and effective use of Estradiol and Norethindrone acetate tablets. Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use Estradiol and Norethindrone acetate tablets for conditions for which they were not prescribed. Do not give estradiol and norethindrone acetate tablets to other people, even if they have the same symptoms you have. They may harm them. You can ask your healthcare provider or pharmacist for information about estradiol and norethindrone acetate tablets that is written for health professionals. For more information, call x-xxx-xxx-xxxx. What are the ingredients in Estradiol and Norethindrone acetate tablets? Active ingredients: E stradiol and Norethindrone acetate Inactive Ingredients: lactose monohydrate, starch (corn), copovidone, polysorbate 80, magnesium stearate, hypromellose, talc and triacetin. This Patient Information has been approved by the U.S. Food and Drug Administration. Manufactured for: Naari Pte Limited 36 Robinson Road, #13-06 City House, Singapore 068877 Issued March 2024 image description"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 79929-012-07 Rx only Estradiol and Norethindrone Acetate Tablets, USP 1 mg/0.5 mg 3 pouches, each pouch contains one blister pack of 28 tablets image description"
    ],
    "set_id": "f70185fe-9fcf-655f-e053-6394a90a20dc",
    "id": "1a990fcf-1731-8ca1-e063-6294a90ac9c8",
    "effective_time": "20240611",
    "version": "5",
    "openfda": {
      "application_number": [
        "ANDA210233"
      ],
      "brand_name": [
        "ESTRADIOL AND NORETHINDRONE ACETATE"
      ],
      "generic_name": [
        "ESTRADIOL AND NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "Naari Pte. Limited"
      ],
      "product_ndc": [
        "79929-012"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ESTRADIOL",
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1359126",
        "1359127"
      ],
      "spl_id": [
        "1a990fcf-1731-8ca1-e063-6294a90ac9c8"
      ],
      "spl_set_id": [
        "f70185fe-9fcf-655f-e053-6394a90a20dc"
      ],
      "package_ndc": [
        "79929-012-07"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0379929012075"
      ],
      "nui": [
        "M0447348",
        "N0000175825",
        "N0000000100"
      ],
      "pharm_class_cs": [
        "Estradiol Congeners [CS]"
      ],
      "pharm_class_epc": [
        "Estrogen [EPC]"
      ],
      "pharm_class_moa": [
        "Estrogen Receptor Agonists [MoA]"
      ],
      "unii": [
        "4TI98Z838E",
        "9S44LIC7OJ"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Norethindrone Acetate Norethindrone Acetate NORETHINDRONE ACETATE NORETHINDRONE ANHYDROUS LACTOSE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE b;211;5"
    ],
    "description": [
      "DESCRIPTION Norethindrone Acetate Tablets, USP (17-hydroxy-19-nor-17\u03b1-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white, or creamy white, crystalline powder. The structural formula is as follows: C 22 H 28 O 3 M.W. 340.46 Each Norethindrone Acetate Tablet, USP for oral administration, contains norethindrone acetate, USP 5 mg. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose. Norethindrone Acetate structural formula"
    ],
    "clinical_pharmacology": [
      "CLINICAL PHARMACOLOGY Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone. Pharmacokinetics Absorption Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n = 29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf)(ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Figure 1 Effect of Food The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours. Special Populations Geriatrics The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated. Race The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. Renal Insufficiency The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function. Hepatic Insufficiency The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease. Drug Interactions No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted."
    ],
    "clinical_pharmacology_table": [
      "<table><col/><col/><tbody><tr><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Table 1</content></paragraph><paragraph>Pharmacokinetic Parameters after a Single Dose of  Norethindrone Acetate in Healthy Women</paragraph></td></tr><tr><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Norethindrone Acetate (n = 29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td valign=\"top\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Norethindrone (NET) </paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC (0-inf)(ng/ml*h)</paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub> (ng/ml) </paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>26.19 &#xB1; 6.19 </paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub> (h) </paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.83 &#xB1; 0.58 </paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>1/2</sub> (h) </paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8.51 &#xB1; 2.19 </paragraph></td></tr><tr><td valign=\"top\" colspan=\"2\" styleCode=\" Toprule\"><paragraph>AUC = area under the curve,  C<sub>max </sub>= maximum plasma concentration,  t<sub>max </sub>= time at maximum plasma concentration,  t<sub>1/2 </sub>= half-life,  SD = standard deviation </paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "Pharmacokinetics Absorption Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1. Table 1 Pharmacokinetic Parameters after a Single Dose of Norethindrone Acetate in Healthy Women Norethindrone Acetate (n = 29) Arithmetic Mean \u00b1 SD Norethindrone (NET) AUC (0-inf)(ng/ml*h) 166.90 \u00b1 56.28 C max (ng/ml) 26.19 \u00b1 6.19 t max (h) 1.83 \u00b1 0.58 t 1/2 (h) 8.51 \u00b1 2.19 AUC = area under the curve, C max = maximum plasma concentration, t max = time at maximum plasma concentration, t 1/2 = half-life, SD = standard deviation Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions Figure 1 Effect of Food The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied. Distribution Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg. Metabolism Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. Excretion Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours."
    ],
    "pharmacokinetics_table": [
      "<table><col/><col/><tbody><tr><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Table 1</content></paragraph><paragraph>Pharmacokinetic Parameters after a Single Dose of  Norethindrone Acetate in Healthy Women</paragraph></td></tr><tr><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Norethindrone Acetate (n = 29) Arithmetic Mean &#xB1; SD</paragraph></td></tr><tr><td valign=\"top\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Norethindrone (NET) </paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>AUC (0-inf)(ng/ml*h)</paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>166.90 &#xB1; 56.28</paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>C<sub>max</sub> (ng/ml) </paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>26.19 &#xB1; 6.19 </paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>max</sub> (h) </paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.83 &#xB1; 0.58 </paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>t<sub>1/2</sub> (h) </paragraph></td><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>8.51 &#xB1; 2.19 </paragraph></td></tr><tr><td valign=\"top\" colspan=\"2\" styleCode=\" Toprule\"><paragraph>AUC = area under the curve,  C<sub>max </sub>= maximum plasma concentration,  t<sub>max </sub>= time at maximum plasma concentration,  t<sub>1/2 </sub>= half-life,  SD = standard deviation </paragraph></td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "INDICATIONS AND USAGE Norethindrone Acetate Tablets, USP are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone Acetate Tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."
    ],
    "contraindications": [
      "CONTRAINDICATIONS Known or suspected pregnancy. There is no indication for norethindrone acetate in pregnancy. (See PRECAUTIONS .) Undiagnosed vaginal bleeding Known, suspected or history of cancer of the breast Active deep vein thrombosis, pulmonary embolism or history of these conditions Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) Impaired liver function or liver disease As a diagnostic test for pregnancy Hypersensitivity to any of the drug components"
    ],
    "warnings": [
      "WARNINGS Cardiovascular Disorders Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. Visual Abnormalities Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued."
    ],
    "precautions": [
      "PRECAUTIONS General Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation. In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated. Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree. Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy. The pathologist should be advised of progestin therapy when relevant specimens are submitted. Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate tablets. Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test. Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established. Pregnancy Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses. Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman. Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "general_precautions": [
      "General Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation. In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated. Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree. Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy. The pathologist should be advised of progestin therapy when relevant specimens are submitted."
    ],
    "information_for_patients": [
      "Information for the Patient Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe norethindrone acetate tablets."
    ],
    "drug_and_or_laboratory_test_interactions": [
      "Drug/Laboratory Tests Interactions The following laboratory test results may be altered by the use of estrogen/progestin combination drugs: Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X a and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay. T 3 resin uptake is decreased, reflecting the elevated TBG. Free T 4 and free T 3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). Increased plasma HDL and HDL 2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels. Impaired glucose metabolism. Reduced response to metyrapone test."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "Carcinogenesis, Mutagenesis, and Impairment of Fertility Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established."
    ],
    "pregnancy": [
      "Pregnancy Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses."
    ],
    "nursing_mothers": [
      "Nursing Mothers Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman."
    ],
    "pediatric_use": [
      "Pediatric Use Norethindrone acetate tablets are not indicated in children."
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See WARNINGS and PRECAUTIONS . The following adverse reactions have been observed in women taking progestins: Breakthrough bleeding Spotting Change in menstrual flow Amenorrhea Edema Changes in weight (decreases, increases) Changes in the cervical squamo-columnar junction and cervical secretions Cholestatic jaundice Rash (allergic) with and without pruritus Melasma or chloasma Clinical depression Acne Breast enlargement/tenderness Headache/migraine Urticaria Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) Decreased HDL cholesterol and increased LDL/HDL ratio Mood swings Nausea Insomnia Anaphylactic/anaphylactoid reactions Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) Optic neuritis (which may lead to partial or complete loss of vision) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch."
    ],
    "dosage_and_administration": [
      "DOSAGE AND ADMINISTRATION Therapy with norethindrone acetate tablets must be adapted to the specific indications and therapeutic response of the individual patient. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology 2.5 to 10 mg norethindrone acetate tablets may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate tablets therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate tablets. Endometriosis Initial daily dosage of 5 mg norethindrone acetate tablets for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate tablets is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination."
    ],
    "how_supplied": [
      "HOW SUPPLIED Norethindrone Acetate Tablets, USP are available as: 5 mg: White, oval, flat-faced, beveled-edge, scored tablet. Debossed with stylized b on one side and 211/5 on the scored side. Available in bottles of 50 tablets (NDC 0555-0211-10). Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [See USP Controlled Room Temperature]. Keep this and all medications out of the reach of children. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. B 11/2022"
    ],
    "how_supplied_table": [
      "<table><col width=\"9%\"/><col width=\"91%\"/><tbody><tr><td valign=\"top\" styleCode=\" Toprule\"><paragraph>5 mg:</paragraph></td><td valign=\"top\" styleCode=\" Toprule\"><paragraph>White, oval, flat-faced, beveled-edge, scored tablet. Debossed with stylized b on one side and 211/5 on the scored side. Available in bottles of 50 tablets (NDC 0555-0211-10).</paragraph></td></tr></tbody></table>"
    ],
    "spl_patient_package_insert": [
      "PATIENT INFORMATION Norethindrone Acetate (nor eth\u2032 in drone as\u2032 e tate) Tablets, USP Read this PATIENT INFORMATION before you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition. What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets? Do not use norethindrone acetate tablets if you are pregnant, breastfeeding or are trying to conceive. Do not use norethindrone acetate tablets if you have had a previous blood clot, stroke, or heart attack. Do not use norethindrone acetate tablets if you are postmenopausal. What are norethindrone acetate tablets? Norethindrone acetate tablets are similar to the progesterone hormones naturally produced by the body. Your healthcare provider may provide norethindrone acetate tablets as individual tablets. What are norethindrone acetate tablets used for? Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance. Who should not take norethindrone acetate tablets? You should not take norethindrone acetate tablets if you are postmenopausal, pregnant, or breastfeeding. You should not take norethindrone acetate tablets if you have the following conditions: Known or suspected pregnancy . Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate tablets during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate tablets and later find out you were pregnant, talk with your healthcare provider right away. History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions Liver impairment or disease Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate tablets. Undiagnosed vaginal bleeding Hypersensitivity to norethindrone acetate tablets . See the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets. What are the risks associated with norethindrone acetate tablets? Risk to the Fetus Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy. You should avoid using norethindrone acetate tablets during pregnancy. If you take Norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible. Abnormal Blood Clotting Use of progestational drugs, such as norethindrone acetate tablets, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug. Eye Abnormalities Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine. These are some of the warning signs of serious side effects with progestin therapy Breast lumps Dizziness and faintness Changes in speech Severe headaches Chest pain Shortness of breath Pains in your legs Changes in vision Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you. Common side effects include Headache Breast pain Irregular vaginal bleeding or spotting Stomach/abdominal cramps/bloating Nausea and vomiting Hair loss Other side effects include High blood pressure Liver problems High blood sugar Fluid retention Enlargements of benign tumors of the uterus (\u201cfibroids\u201d) Vaginal yeast infections Mental depression These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist. What can I do to lower my chances of getting a serious side effect with norethindrone acetate tablets? Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate tablets. Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks. General information about the safe and effective use of norethindrone acetate tablets Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them. Keep norethindrone acetate tablets out of the reach of children. This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate tablets that is written for health professionals. What are the ingredients in norethindrone acetate tablets? Norethindrone acetate tablets contain the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. B 11/2022"
    ],
    "package_label_principal_display_panel": [
      "Package/Label Display Panel NDC 0555-0211-10 Norethindrone Acetate Tablets, USP 5 mg ORALLY ACTIVE PROGESTIN PHARMACIST: Dispense the accompanying Patient Information Leaflet to each patient. Rx only 50 TABLETS 1"
    ],
    "set_id": "f73f9807-4af6-4faa-ba9a-656a47a4c5e0",
    "id": "953441f0-0a24-40ba-a433-1de55da3ebaa",
    "effective_time": "20221130",
    "version": "9",
    "openfda": {
      "application_number": [
        "ANDA075951"
      ],
      "brand_name": [
        "Norethindrone Acetate"
      ],
      "generic_name": [
        "NORETHINDRONE ACETATE"
      ],
      "manufacturer_name": [
        "Teva Pharmaceuticals USA, Inc."
      ],
      "product_ndc": [
        "0555-0211"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "NORETHINDRONE ACETATE"
      ],
      "rxcui": [
        "1000405"
      ],
      "spl_id": [
        "953441f0-0a24-40ba-a433-1de55da3ebaa"
      ],
      "spl_set_id": [
        "f73f9807-4af6-4faa-ba9a-656a47a4c5e0"
      ],
      "package_ndc": [
        "0555-0211-10"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "9S44LIC7OJ"
      ]
    }
  }
]